<SEC-DOCUMENT>0000950123-20-009633.txt : 20200918
<SEC-HEADER>0000950123-20-009633.hdr.sgml : 20200918
<ACCEPTANCE-DATETIME>20200910172737
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-20-009633
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		33
FILED AS OF DATE:		20200910
<PUBLIC-REL-DATE>20200918
DATE AS OF CHANGE:		20200910

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shattuck Labs, Inc.
		CENTRAL INDEX KEY:			0001680367
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				812575858
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-03389
		FILM NUMBER:		201169363

	BUSINESS ADDRESS:	
		STREET 1:		1018 W. 11TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78703
		BUSINESS PHONE:		919-864-2700

	MAIL ADDRESS:	
		STREET 1:		1018 W. 11TH STREET
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on September 10,
2020 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>This Amendment No. 1 to the draft registration statement has not been filed publicly with the Securities and Exchange
Commission, and all information herein remains strictly confidential. </B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF 1933 </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Shattuck Labs, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>81-2575858</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Primary Standard Industrial</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Classification Code Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1018 W. 11th Street, Suite 100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX 78703 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(919) <FONT
STYLE="white-space:nowrap">864-2700</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Taylor Schreiber, M.D., Ph.D. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Chief Executive Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shattuck Labs, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1018
W. 11th Street, Suite 100 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX 78703 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(919) <FONT STYLE="white-space:nowrap">864-2700</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>area code, of agent for service) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>With copies to:
</I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Ryan A. Murr<BR>Branden C. Berns</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Gibson, Dunn&nbsp;&amp; Crutcher LLP</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>555 Mission Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94105-0921</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">393-8373</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Erin Ator Thomson</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>General Counsel</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Shattuck
Labs, Inc.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>1018 W. 11th Street, Suite 100</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Austin, TX 78703</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(919) <FONT
STYLE="white-space:nowrap">864-2700</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>B. Shayne Kennedy</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Nathan Ajiashvili</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Latham
&amp; Watkins LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>885 Third Avenue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New York, NY 10022</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">906-1200</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective. </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box.&nbsp;&nbsp;&#9744;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744;</P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If
this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;&#9744;</P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT
STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company,&#148;
and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. (Check one): </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9744; </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities to be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Proposed&nbsp;Maximum<BR>Aggregate Offering<BR>Price<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registration Fee</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common Stock, par value $0.0001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes the aggregate offering price of additional shares that the underwriters have the option to purchase from the registrant. See &#147;Underwriting.&#148; </TD></TR></TABLE>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration
statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to such Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#eb0029"><B>The information in this preliminary prospectus is not complete and may be changed. These
securities may not be sold until the registration statement filed with the Securities and Exchange Commission is declared effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#eb0029"><B>Subject to Completion, dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g03i25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>  <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is the
initial public offering of our shares of common stock. We are selling&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. We currently expect the initial public offering price to
be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. Currently, no
public market for our common stock exists. We have applied to list our common stock on The Nasdaq Global Market under the symbol &#147;STTK.&#148; </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted the underwriters an option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
&#147;emerging growth company&#148; as defined under the federal securities laws and, as such, may elect to comply with certain reduced public company reporting requirements in future reports after the closing of this offering. See
&#147;Business&#151;Implications of Being an Emerging Growth Company.&#148; </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our common stock involves risks. See &#147;<A HREF="#toc69956_2">Risk Factors</A>&#148; beginning on page&nbsp;12 of this prospectus. </B></P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither the Securities and Exchange Commission nor any other regulatory body have approved or disapproved these securities, or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; beginning on page 185 for additional information regarding underwriting compensation. </TD></TR></TABLE>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters expect to deliver the shares of common stock to purchasers on our
about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 through the book entry facilities of The Depository Trust Company. </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:20pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:20pt">
<TD VALIGN="top"><B>Citigroup</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore ISI</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-size:14pt"><B>Needham&nbsp;&amp;&nbsp;Company</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>  <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2020 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_4">Industry and Market Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_6">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_7">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_8">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_9">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_10">Management&#146;s Discussion and Analysis of Financial Condition and Results of
 Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_11">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_12">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_13">Executive Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_14">Principal Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_15">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_16">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_17">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_18">Material U.S. Federal Income Tax Consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_20">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_22">Where You Can Find Additional Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc69956_23">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not, and the underwriters have not, authorized anyone to provide you with information other than in this prospectus or in any free
writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for and cannot provide any assurance as to the reliability of any other information others may give you. We are not, and the underwriters are
not, making an offer to sell shares of our common stock in any jurisdiction where the offer or sale is not permitted. The information in this prospectus or any free writing prospectus is accurate only as of its date, regardless of its time of
delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations, and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering, or
possession or distribution of this prospectus, in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves
about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus includes our trademarks, including the Shattuck logo, ARC<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and
GADLEN<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, which are our property and are protected under applicable intellectual property laws. This prospectus also includes trademarks and trade names that are the property of other
organizations. Solely for convenience, trademarks and trade names referred to in this prospectus appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols,
but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use
or display of other companies&#146; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information
that you should consider before deciding to invest in our common stock. You should read the entire prospectus carefully, including &#147;Risk Factors</I>,<I>&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations,&#148; and our financial statements and notes to those financial statements, before making an investment decision. Some of the statements in this summary constitute forward-looking statements, see &#147;Special Note Regarding
Forward-Looking Statements.&#148; In this prospectus, unless the context requires otherwise, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Shattuck Labs,&#148; &#147;Shattuck,&#148; or the &#147;company&#148; refer to Shattuck
Labs, Inc. Additionally, references to our &#147;Board&#148; refer to the board of directors of Shattuck Labs, Inc. </I> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of
biologic medicine. We believe our approach has the potential to fundamentally transform the therapeutic modulation of the immune system. We have created a novel approach to immune-modulation by designing biologics with structural characteristics
that are not achievable by existing therapeutic modalities. Compounds derived from our proprietary Agonist Redirected Checkpoint, or ARC<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, platform simultaneously inhibit checkpoint molecules
and activate costimulatory molecules within a single therapeutic. Our initial product candidates are designed to be differentiated therapeutics addressing molecular targets that are well characterized and scientifically validated in immuno-oncology
but are underexploited by current treatment modalities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead, wholly owned product candidate,
<FONT STYLE="white-space:nowrap">SL-172154,</FONT> has been rationally designed to simultaneously inhibit the CD47/SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> checkpoint interaction to restore an anti-tumor immune response and to activate the
CD40 costimulatory receptor to bolster an immune response. We are currently conducting a Phase 1 clinical trial evaluating SL-172154 in patients with ovarian cancer, and we expect to announce initial data from the dose-escalation portion of this
trial in the second half of 2021. We plan to initiate a second Phase 1 trial evaluating the SL-172154 in patients with cutaneous squamous cell carcinoma, or CSCC, or head and neck squamous cell carcinoma, or HNSCC, and we expect to announce data
from the dose-escalation portion of this trial in the second half of 2022. Our second product candidate, <FONT STYLE="white-space:nowrap">SL-279252,</FONT> which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been
rationally designed to simultaneously inhibit the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> interaction and activate the OX40 receptor. We are evaluating
<FONT STYLE="white-space:nowrap">SL-279252</FONT> in a Phase 1 clinical trial in patients with advanced solid tumors and lymphoma, and we expect to announce data from the dose-escalation portion of this trial in the second half of 2021. In addition
to our clinical-stage ARC product candidates, we possess a deep pipeline of preclinical immuno-oncology product candidates. Longer-term, we are pursuing additional disease areas, including autoimmune diseases, where our dual-sided fusion protein
platforms may provide advantages over current treatment modalities. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer is characterized by the uncontrolled proliferation of
abnormal cells. The immune system typically recognizes and eliminates abnormal cells. However, cancer cells have the ability to evade the immune system through the expression of checkpoint molecules, which ward off an anti-tumor immune response that
would otherwise lead to elimination of cancer cells. In an effort to leverage the immune system to promote an anti-tumor response, researchers have developed checkpoint inhibitor therapies, including
<FONT STYLE="white-space:nowrap">anti-CTLA-4,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1,</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT>
antibodies, which have represented a revolutionary milestone in the treatment of cancer. These therapies generate deep and durable responses, translating into meaningful clinical benefit and have become the cornerstone of treatment paradigms for
many cancers. However, the clinical benefit is limited to a minority of patients. This limitation highlights the need for novel modalities that may benefit a greater number of patients, such as a compound that simultaneously inhibits checkpoint
molecules while activating costimulatory molecules to generate a beneficial immune response. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Driven by an increasing understanding of tumor biology, it is now well-established that the
activation of costimulatory molecules can generate a more effective immune response where current checkpoint inhibitors have failed. To date, there has been limited clinical success in combining the inhibition of checkpoints with the activation of
trimeric costimulatory molecules. We believe these efforts have had limited success due to the structural mismatch between existing bivalent antibodies and the trimeric costimulatory receptors of the tumor necrosis factor, or TNF, receptor
superfamily, such as CD40 and OX40. TNF activation and downstream signaling require the assembly of three receptor molecules, or trimerization. Existing bivalent antibodies can only bind to two TNF receptors and are thus unable to trimerize TNF
receptors, leading to weak signaling. Additionally, administration of two separate antibodies, which distribute in the body independent of one another, does not guarantee colocalization of their mechanisms of activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary ARC platform is designed to overcome the limitations of existing bivalent antibodies. ARC compounds consolidate checkpoint
blockade and immune costimulation within a single therapeutic. Additionally, ARC compounds possess a structure that matches the native structure of the target receptors and colocalizes both mechanisms of activity within the immune synapse to promote
a coordinated immune response. As shown in Figure&nbsp;1 below, one end of the ARC compound consists of a checkpoint receptor domain and the opposite end consists of a TNF ligand domain, connected by a scaffold such as an Fc domain. We design ARC
compounds to self-assemble into a hexameric structure, as shown in Figure&nbsp;1 below, comprising six distinct checkpoint receptor domains and six distinct TNF ligand domains, which form two trimerized costimulatory ligand domains. The hexameric
structure of an ARC compound facilitates clusters of binding domains thus leveraging the strength of multiple individual binding interactions, known as affinity, into a greater collective strength of all binding interactions, known as avidity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 1&#151;Structural Properties of ARC Compounds </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g38l06.jpg" ALT="LOGO">
 </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unique dual-sided structure of our ARC compounds allows us to simultaneously and
effectively target a wide array of pathways for the creation of a deep and differentiated product pipeline. We utilize our understanding of disease pathology and immune dysfunction to identify pairings of optimal domains. Initially, our efforts are
concentrated on three broad target families including immune checkpoints, the TNF superfamily, and cytokines. While therapeutic inhibition of immune checkpoints has been shown to improve overall survival in a minority of cancer patients, combining
immune checkpoint blockade with activation of TNF superfamily receptors or modulation of cytokines may deepen responses and increase the number of cancer patients that benefit from immunotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the following features represent the key advantages offered by compounds developed with the ARC platform: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Matching Native Structure of TNF Receptors.</I></B> TNF receptors and ligands require trimerization, or
assembly into groups of three, for efficient signaling. A hexameric ARC compound contains two trimerized TNF ligand domains, which directly activate trimeric TNF receptors, thus overcoming the structural limitations of bivalent antibodies.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Target Specificity, High Affinity, and High Avidity.</I></B> ARC compounds incorporate twelve distinct
binding domains, six for each of the two targets, enabling high-avidity and durable binding to specific cell surface targets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Replacing Tumor Immune Evasion with Potent Immune Stimulation. </I></B>ARC compounds are designed to
simultaneously reverse a tumor&#146;s immune evasion and amplify anti-tumor immune responses locally within the tumor microenvironment. In preclinical models, the ability of our ARC compounds to colocalize checkpoint inhibition and costimulation
demonstrated superior anti-tumor response as compared to the administration of separate antibody therapies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Versatility.</I></B> Modularity of the ARC platform enables production of thousands of potential
therapeutic candidates across oncology, autoimmune diseases, and other disease areas. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Speed from Concept to Compound to Clinic.</I></B> The ARC platform allows for a significantly compressed
development timeline from &#147;Concept to Compound to Clinic,&#148; which has enabled us to generate over 300 unique, dual-sided fusion proteins and two clinical-stage assets in less than four years. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Accelerated Lead Selection Process.</I></B> We are able to identify and select optimal therapeutic
constructs during the design and discovery phase of product candidate development through the rational pairing of optimized domains, enabling the efficient transition from discovery to the clinic. The rapid development path of ARC compounds permits
systematic and simultaneous comparison of multiple ARC compound variants prior to lead selection. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe these
collective advantages create the potential for the capital-efficient identification and pursuit of differentiated product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also leveraging our expertise and intellectual property to build novel platforms beyond our ARC platform, where dual-sided fusion
proteins may provide advantages over existing therapeutic antibodies. One such platform is our Gamma Delta T Cell Engager platform, known as GADLEN<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>. A majority of T cells in the human body
bear an alpha beta T cell receptor, which recognizes tumor antigens via major histocompatibility complex, or MHC, molecules. Some cancer cells reduce the expression of MHC molecules, rendering those cancer cells invisible to most alpha beta T cells.
Gamma delta T cells represent approximately 2% to 5% of the total T cell population and, unlike alpha beta T cells, are not dependent on MHC molecules to recognize and kill tumor cells. The therapeutic utilization of gamma delta T cells represents a
novel approach for the treatment of cancer. This approach may be particularly beneficial in targeting tumors that are not addressable by alpha beta T cells. Additionally,&nbsp;as immunotherapies that stimulate alpha beta T cell-dependent immune
responses are </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increasingly utilized across cancer treatment paradigms, the proportion of patients who may become refractory to alpha beta T cell-mediated therapies will also increase over time, creating an
absence of effective treatment options that may be addressed by the utilization of gamma delta T cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we believe compounds
developed with our ARC and GADLEN platform may provide significant key advantages, we are in an early stage of development using novel technologies and cannot assure you that our approach will lead to the development of marketable products. For
example, SL-279252 is in Phase 1 development and although data as of September 9, 2020 has shown it has been well tolerated, with no <FONT STYLE="white-space:nowrap">dose-limiting</FONT> toxicities observed, additional data from any of our
dual-sided fusion protein product candidates may result in unanticipated safety and efficacy outcomes or unexpected biological interactions that could delay or prevent their development. Moreover, we are aware that others have experienced limited
clinical success when attempting to combine the inhibition of checkpoint molecules with the activation of trimeric costimulatory molecules. We believe this limited success is attributable to a structural mismatch between the bivalent antibodies and
trimeric costimulatory receptors, which we have attempted to address in the design of our ARC platform compounds. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are leveraging our proprietary ARC and GADLEN platforms to discover and develop dual-sided,
<FONT STYLE="white-space:nowrap">bi-functional</FONT> fusion protein product candidates. We own or have exclusively licensed the intellectual property rights to our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table highlights our two clinical-stage assets that have been derived from our ARC platform:&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g14c21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <FONT STYLE="white-space:nowrap">SL-172154,</FONT> simultaneously inhibits CD47
and activates the CD40 receptor. We believe <FONT STYLE="white-space:nowrap">SL-172154</FONT> has the potential to offer a differentiated approach to targeting CD47. Other approaches solely focus on activating the innate immune system by blocking
the CD47 macrophage &#147;don&#146;t eat me&#148; signal. In addition to inhibiting CD47, <FONT STYLE="white-space:nowrap">SL-172154</FONT> is designed to bridge the innate and adaptive immune response by subsequently activating CD40 signaling to
upregulate antigen presentation machinery. In preclinical studies of <FONT STYLE="white-space:nowrap">SL-172154,</FONT> we observed superior tumor rejection as compared to CD47 and CD40 antibodies, a durable receptor occupancy, a dose-dependent
lymphocyte migration into lymphoid tissues and no occurrence of anemia. We have initiated a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">SL-172154</FONT> administered by intravenous injection in patients with ovarian, fallopian tube,
and peritoneal cancers, referred to collectively as ovarian cancer, and expect to announce initial data from the dose-escalation portion of this trial in the second half of 2021. We plan to initiate a second Phase 1
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trial of <FONT STYLE="white-space:nowrap">SL-172154</FONT> administered by intratumoral injection in patients with CSCC or HNSCC and expect to announce data from the dose-escalation
portion of this trial in the second half of 2022. These tumors were selected due to their particularly high expression of CD47, a high presence of macrophages in the tumor microenvironment, and a lack of effective treatment options for these
indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second product candidate, <FONT STYLE="white-space:nowrap">SL-279252,</FONT> being developed in collaboration with
Takeda, simultaneously inhibits <FONT STYLE="white-space:nowrap">PD-1</FONT> and activates the OX40 receptor. We believe <FONT STYLE="white-space:nowrap">SL-279252</FONT> has the potential to offer a differentiated approach to targeting <FONT
STYLE="white-space:nowrap">PD-1</FONT> and OX40, as compared to existing antibody therapies, either as individual monotherapies or in combination. Antibodies targeting OX40 have not demonstrated sufficient efficacy in clinical trials, a result that
we believe is due to a structural mismatch between bivalent antibodies and trimeric OX40 receptors. The unique hexameric structure of <FONT STYLE="white-space:nowrap">SL-279252</FONT> is designed to more effectively bind to and activate OX40
receptors, leading to optimized signaling and resulting in T cell activation and proliferation. Together, these properties are intended to replace <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-mediated</FONT></FONT> immune
inhibition with OX40 costimulation to synergistically enhance anti-tumor response. In preclinical models, compared to the combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and OX40-agonist
antibodies, <FONT STYLE="white-space:nowrap">SL-279252</FONT> demonstrated superior tumor reduction. In nonhuman primates treated with SL-279252, we observed dose-dependent lymphocyte expansion followed by post-dose lymphocyte migration into tissue.
Our ongoing Phase 1 trial is evaluating <FONT STYLE="white-space:nowrap">SL-279252</FONT> in patients with advanced solid tumors and lymphoma. We expect to announce dose-escalation data in the second half of 2021. Takeda has an option to exercise a
license of <FONT STYLE="white-space:nowrap">SL-279252</FONT> prior to initiation of a Phase 2 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our lead
product candidates, we have an extensive discovery pipeline consisting of over 300 unique fusion proteins that we have manufactured and characterized in both <I>in vitro </I>and<I> in vivo</I> studies. We intend to nominate additional lead
candidates in oncology, as well as autoimmune disease, to further broaden our pipeline. In accordance with our prioritization strategy, we intend to develop these compounds as data emerge that clinically validate the targets. We anticipate
submitting additional Investigational New Drug Applications, or INDs, for compounds derived from our ARC or GADLEN platforms in both the second half of 2021 and the first half of 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team and Board
possess decades of experience in cancer immunotherapy, autoimmune disease, targeted therapeutics, protein engineering, biologics manufacturing, clinical development, regulatory strategy, and commercialization. Members of our team were involved with,
or led, drug development programs leading to the approval of drugs including Votrient, Tafinlar, Mekinist, Enbrel, Nucala, Valtrex, Arranon, Tykerb, Avastin, Revlimid, Pomalyst, and others. Our team members have held senior leadership positions at
leading companies including GlaxoSmithKline, Celgene, Pfizer, Novartis, Takeda, Alexion, Medarex, Amgen, Merck KGaA, OSI Pharmaceuticals, and Reata Pharmaceuticals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our founding in 2016, we have raised approximately $239.1&nbsp;million through redeemable convertible preferred stock financings and <FONT
STYLE="white-space:nowrap">non-dilutive</FONT> partnership funds. Our key investors include Redmile Group, Fidelity Management and Research Company, Janus Henderson, EcoR1 Capital, Partner Fund Management, Avidity Partners, Hatteras Venture
Partners, Emerson Collective, Piper Sandler&nbsp;&amp; Co., JSR Corporation, and Takeda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become the world leader in the discovery, development, and commercialization of dual-sided,
<FONT STYLE="white-space:nowrap">bi-functional</FONT> fusion proteins for the treatment of cancer and autoimmune diseases. We plan to achieve this by utilizing our proprietary ARC and GADLEN platforms to create novel therapeutics to treat patients
who lack effective treatment options. Key elements of our strategy include: </P>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Rapidly advancing our clinical-stage ARC product candidates, <FONT STYLE="white-space:nowrap">SL-172154</FONT>
and <FONT STYLE="white-space:nowrap">SL-279252,</FONT> through clinical development and marketing approval. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leveraging our ARC and GADLEN platforms to rapidly advance additional product candidates into clinical
development. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Continuing to augment our fusion protein manufacturing capabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Collaborating with leading biopharmaceutical companies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Deepening our intellectual property portfolio to continue to protect our platform technologies and product
candidates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Building on our culture of R&amp;D excellence and continuing to
<FONT STYLE="white-space:nowrap">out-innovate</FONT> ourselves. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our common stock involves significant risks. You should carefully consider the risks described in &#147;Risk Factors&#148; before
making a decision to invest in our common stock. If we are unable to successfully address these risks and challenges, our business, financial condition, results of operations, or prospects could be materially and adversely affected. In such case,
the trading price of our common stock would likely decline, and you may lose all or part of your investment. Below is a summary of some of the risks we face. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have a limited operating history and have incurred significant losses since our inception, we expect to incur
losses for the foreseeable future, and we may never achieve profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">All of our product candidates are in preclinical or early-stage clinical development and clinical drug
development is a lengthy and expensive process with uncertain timelines and outcomes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Results of preclinical studies of our product candidates may not be predictive of the results of future
preclinical studies or clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties
that may delay or prevent marketing approval. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical
studies and clinical trials, business, financial condition, and results of operations. For example, we have experienced delays in our clinical trial of SL-279252 as a result of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic,
including delays with certain third-party vendors supporting this trial. As &#147;shelter in place&#148; orders and other public health guidance measures are reinstated in the locations of our clinical trial sites, we expect that some patients may
also choose to forego one or more doses in our clinical trials due to challenges faced by such patients in travelling to our clinical trial sites, which may negatively affect the study results. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We depend on the enrollment of patients in our clinical trials for our product candidates and if we experience
delays or difficulties in the enrollment of patients in clinical trials, including as a result of competition for patients or the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may be unable to complete these trials on a
timely basis, if at all. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The development and commercialization of biopharmaceutical products is subject to extensive regulation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We operate in highly competitive and rapidly changing industries, which may result in others discovering,
developing, or commercializing competing products before or more successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on patents and other intellectual property rights to protect our technology, including product candidates
and our ARC and GADLEN platforms, the prosecution, enforcement, defense, and maintenance of which may be challenging and costly. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Even if this offering is successful, we will require substantial additional funding, which may not be available
to us on acceptable terms, or at all. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company, as defined in Section&nbsp;2(a) of the Securities Act of 1933, as amended, or the Securities Act, as
modified by the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies,
including relief from the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, less extensive disclosure obligations regarding executive compensation in our registration statements, periodic reports,
and proxy statements, exemptions from </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the requirements to hold a nonbinding advisory vote on executive compensation, and exemptions from stockholder
approval of any golden parachute payments not previously approved. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation-related information that
would be required if we were not an emerging growth company. As a result, our stockholders may not have access to certain information that they may deem important. We could be an emerging growth company for up to five years, although circumstances
could cause us to lose that status earlier, including if our total annual gross revenues exceed $1.07&nbsp;billion, if we issue more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during any three-year period,
or if the market value of our common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of June&nbsp;30 of any year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the JOBS Act also provides that an emerging growth company may take advantage of the extended transition period provided in the
Securities Act for complying with new or revised accounting standards. An emerging growth company may therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to
avail ourselves of this exemption and, as a result, will not be subject to the same implementation timing for new or revised accounting standards as are required of other public companies that are not emerging growth companies, which may make
comparison of our financial information to those of other public companies more difficult. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in the State of Delaware on May&nbsp;9, 2016. Our corporate offices are located at 1018 W. 11th Street, Suite 100, Austin,
Texas 78703 and 21 Parmer Way, Suite 200, Durham, North Carolina 27709 and our telephone number is (919) <FONT STYLE="white-space:nowrap">864-2700.</FONT> Our website is<I> www.shattucklabs.com</I>. The information on, or that can be accessed
through, our website is not part of this prospectus and is not incorporated by reference herein. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares of common stock </P></TD>
<TD>The underwriters have a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise in
full their option to purchase the additional shares of our common stock). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We expect that our net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million (or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise in full their option to purchase additional shares of our common stock), at an assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover of this prospectus, after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. We intend to use the net proceeds of this offering: to advance SL-172154 through the completion of our ongoing and planned Phase 1 clinical trials and to commence a Phase 2 clinical program;
to advance SL-279252 through the completion of our ongoing Phase 1 clinical trial; and to develop and advance additional product candidates derived from our platforms through IND-enabling studies and to commence Phase 1 clinical trials. See
&#147;Use of Proceeds&#148; for additional information. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Directed share program </P></TD>
<TD>At our request, the underwriters have reserved up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock offered by this prospectus, for sale, at the initial public offering price, to certain of our directors,
officers, employees, or persons otherwise associated with us through a directed share program. The number of shares of common stock available for sale to the general public will be reduced to the extent these parties purchase any of such reserved
shares. Any reserved shares of common stock that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares offered by this prospectus. See &#147;Underwriting&#148; for additional
information. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>You should carefully read and consider the information set forth in the section entitled &#147;Risk Factors&#148; beginning on page 12, together with all of the other information set forth in this prospectus, before deciding whether to invest in
our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Proposed Nasdaq Global Market trading symbol </P></TD>
<TD>&#147;STTK.&#148; </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding after this offering (i)&nbsp;is
based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock (including shares of our redeemable convertible preferred stock outstanding on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis) outstanding as of June&nbsp;30, 2020 and (ii)&nbsp;excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2020 under our 2016 Stock Incentive Plan, or 2016 Plan, at a weighted average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock issuable upon the exercise of stock options granted subsequent to June&nbsp;30, 2020 under the 2016 Plan, at a weighted-average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock issuable upon the settlement of restricted stock units outstanding as of June&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock issuable upon the settlement of restricted stock units granted subsequent to June&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock reserved for future issuance pursuant to future awards under our 2020 Stock Incentive Plan, or 2020 Plan, which will become effective upon consummation of the offering and replace the 2016 Plan, as well as any automatic increase in the
number of shares of common stock reserved for future issuance under the 2020 Plan; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock to be reserved for future issuance under our 2020 Employee Stock Purchase Plan, or ESPP, which will become effective immediately prior to the completion of this offering, as well as any automatic increase in the number of shares of
common stock reserved for future issuance under the ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise noted, we have presented the information
in this prospectus based on the following assumptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the conversion, in accordance with our existing amended and restated certificate of incorporation, of all shares
of our redeemable convertible preferred stock outstanding as of the date hereof into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-for-one</FONT></FONT> stock split of our common stock and a proportional adjustment to the conversion ratio of
our redeemable convertible preferred stock to be effected prior to the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise by the underwriters of their option to purchase additional shares of our common stock in this
offering; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">no exercise of outstanding stock options or vesting of restricted stock units after June&nbsp;30, 2020; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our second amended and restated certificate of incorporation with the Secretary
of State of the State of Delaware, which will be in effect immediately after the completion of this offering </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth a summary of our historical financial data as of and for the periods ended on the dates indicated. The summary
statements of operations data presented below for the years ended December&nbsp;31, 2018 and 2019 are derived from our audited financial statements included elsewhere in this prospectus. The summary statements of operations data for the six months
ended June&nbsp;30, 2019 and 2020 and our summary balance sheet data as of June&nbsp;30, 2020 are derived from our unaudited interim financial statements included elsewhere in this prospectus. Our unaudited interim financial statements have been
prepared in accordance with generally accepted accounting principles in the United States, or GAAP, on the same basis as our audited annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal,
recurring adjustments, necessary for the fair presentation of those unaudited interim financial statements. The following summary financial data should be read in conjunction with &#147;Selected Financial Data,&#148; &#147;Management&#146;s
Discussion and Analysis of Financial Condition and Results of Operations,&#148; and our financial statements and related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands, except share and per share amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,442</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,887</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,282</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,157</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,807</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,218</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,502</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,892</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,783</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,736</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,696</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,346</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on the extinguishment of notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic
and<BR>diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding&#151;basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,081,936</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103,190</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,099,148</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114,399</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share&#151;basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares outstanding&#151;basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,196,209</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,785,497</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 2 to our audited financial statements and Note 2 to our unaudited financial statements included elsewhere in this prospectus for a description of how we compute net loss per share&#151;basic and diluted, pro
forma net loss per common share&#151;basic and diluted, and the weighted-average shares outstanding&#151;basic and diluted, in each case, used in the computation of these per share amounts. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%">
<div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,534</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,534</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,282</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,282</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,544</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,544</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,464</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,464</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,109</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,080</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reflects the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock upon the closing of this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reflects the pro forma adjustments described in footnote (1)&nbsp;and the sale by us of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this
offering at the assumed initial public offering price of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Pro forma as adjusted information is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. Each $1.00 increase or decrease in the
assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would
increase or decrease pro forma as adjusted cash and cash equivalents and short-term investments, working capital, total assets, and total stockholders&#146; equity by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. A share increase or decrease in the number of shares offered by us would increase or decrease pro forma as adjusted cash and cash equivalents and
short-term investments, working capital, total assets, and total stockholders&#146; equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the assumed initial
price to public remains the same, and after deducting estimated underwriting discounts and commissions payable by us. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. See our audited and unaudited financial statements and accompanying notes included elsewhere in this prospectus for further details regarding our
current assets and our current liabilities. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in shares of our common stock involves a high degree of risk. You should carefully consider the following risks and
uncertainties, together with all of the other information contained in this prospectus, including our financial statements and related notes included elsewhere in this prospectus, before making an investment decision. The risks described below are
not the only ones facing us. Many of the following risks and uncertainties are, and will be, exacerbated by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and any worsening of the global business and economic environment as a result.
The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could materially and adversely affect our business, financial condition, reputation, or
results of operations. In such case, the trading price of shares of our common stock could decline, and you may lose all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an early
clinical-stage biotechnology company and have incurred significant losses since our inception and we expect to incur losses for the foreseeable future. We have no products approved for commercial sale and may never achieve or maintain profitability.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biotechnology company with a limited operating history. Biotechnology product development is a highly
speculative undertaking and involves a substantial degree of risk. We have incurred significant operating losses since inception. For the years ended December&nbsp;31, 2018 and 2019 and for the six months ended June&nbsp;30, 2020, we reported a net
loss of $7.4 million, $24.0 million, and $12.8 million, respectively. As of June&nbsp;30, 2020, we have an accumulated deficit of $48.3 million. Our losses have resulted principally from expenses incurred in the research and development of our
product candidates and from management and administrative costs and other expenses that we have incurred while building our business infrastructure. We expect to continue to incur significant operating losses for the foreseeable future as we
continue our research and development efforts and seek to obtain regulatory approval and commercialization of our product candidates. We anticipate that our expenses will increase substantially as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to advance the preclinical and clinical development of our lead product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate preclinical studies and clinical trials for additional product candidates that we may identify in the
future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our operational, financial, and management systems and increase personnel, including personnel to support
our clinical development, manufacturing, and commercialization efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to develop, perfect, and defend our intellectual property portfolio; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting, or other expenses in operating our business, including the additional costs
associated with operating as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have financed our operations to date primarily through private
financings and payments received under a collaboration agreement. We have devoted a significant portion of our financial resources and efforts to developing our ARC platform, identifying potential product candidates, conducting preclinical studies
of a variety of product candidates, and preparing for and conducting clinical trials of product candidates. We are in the early stages of development of our product candidates, and we have not completed development and commercialization of any
product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate
significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering and developing additional product candidates,
obtaining regulatory approval for any product candidates that successfully complete clinical trials, accessing manufacturing capacity, establishing marketing capabilities, and ultimately selling any products for which we may obtain regulatory
approval. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is sufficient to achieve profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with pharmaceutical products and
biological development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the U.S. Food and Drug Administration, or FDA, or other regulatory
authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials or the development of any of our product candidates, our expenses could increase and commercial revenue could
be further delayed and more uncertain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our limited operating history may make it difficult for you to evaluate the success of our business to date
and to assess our future viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in 2016, we have devoted a significant portion of our resources to
developing our product candidates, our other research and development efforts, building our intellectual property portfolio, raising capital, and providing general and administrative support for these operations. While we are evaluating <FONT
STYLE="white-space:nowrap">SL-172154</FONT> in two ongoing Phase 1 clinical trials and are also evaluating <FONT STYLE="white-space:nowrap">SL-279252</FONT> in a Phase 1 clinical trial, we have not completed a clinical trial for any product
candidate. We have not yet demonstrated our ability to successfully complete clinical trials (including Phase 3 or other pivotal clinical trials), obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do
so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Additionally, we expect our financial condition and operating results to continue to fluctuate significantly from period to period due to
a variety of factors, many of which are beyond our control. Consequently, any predictions you may make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require additional funding in order to complete development of our product candidates and commercialize our products, if approved. This
additional financing may not be available on acceptable terms, or at all. If we are unable to raise capital when needed, we could be forced to delay, reduce, or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have funded our operations primarily through private financings and payments received under a collaboration agreement. We expect
our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing clinical trials of <FONT STYLE="white-space:nowrap">SL-172154</FONT> and <FONT STYLE="white-space:nowrap">SL-279252,</FONT> initiate
additional clinical trials, and continue to research, develop, and conduct preclinical studies of our other product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales, and distribution. Furthermore, upon the closing of this
offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when
needed or on attractive terms, we could be forced to delay, reduce, or eliminate our research and development programs or any future commercialization efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current business plans, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents
and short-term investments, will enable us to fund our operating expenses through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong,
and we could use our capital resources sooner than we currently expect, requiring us to seek additional funds sooner than planned, through public or private equity or debt financings or other sources, such as strategic collaborations. In addition,
we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management
from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop our product candidates. Our future capital requirements will depend on many factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, timing, progress, costs, and results of discovery, preclinical development, laboratory testing, and
clinical trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs, timing, and outcome of regulatory review of any of our product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of manufacturing clinical supplies of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and
distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing and amount of any milestone, royalty, or other payments we are required to make pursuant to any
current or future collaboration or license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the progress of our collaboration with Takeda to develop product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and timing of preparing, filing, and prosecuting patent applications, maintaining and enforcing our
intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain existing, and establish new, strategic collaborations, licensing, or other arrangements
and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty, or other payments due under any such agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the cost of building a sales force in anticipation of product commercialization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of competing technological and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we acquire or invest in business, products, and technologies, including our collaboration
with Takeda and any other licensing or collaboration arrangements for any of our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to
raise additional funds will depend on financial, economic, and market conditions and other factors, over which we may have no or limited control. Market volatility resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other
factors could also adversely impact our ability to access capital as and when needed. Additional funds may not be available when we need them, on terms that are acceptable to us or at all. If adequate funds are not available to us on a timely basis,
we could be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay, limit, reduce, or terminate preclinical studies, clinical trials, or other research and development
activities, or eliminate one or more of our development programs altogether; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delay, limit, reduce, or terminate our efforts to access manufacturing capacity, establish sales and marketing
capabilities or other activities that may be necessary to commercialize our product candidates, or reduce our flexibility in developing or maintaining our sales and marketing strategy. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our operations
with our existing cash and cash equivalents and short-term investments, the net proceeds from this offering, equity or debt financings, and upfront and milestone and royalties payments, if any, received under our collaboration with Takeda and any
other future licenses or collaborations. If we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other
preferences that adversely affect your rights as a holder of our common stock. In addition, the possibility of such issuance may cause the market price of our common stock to decline. Debt financing, if available, may result in increased fixed
payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends, or acquiring, selling, or licensing
intellectual property rights, which could adversely impact our ability to conduct our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through
collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technologies, future revenue streams, or product candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek funds through arrangements with
collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results, and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Public health crises such as pandemics or similar outbreaks could materially and adversely affect our preclinical and clinical trials, business,
financial condition, and results of operations. </I></B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2020, the World Health Organization declared <FONT
STYLE="white-space:nowrap">COVID-19</FONT> a global pandemic and the United States declared a national emergency with respect to <FONT STYLE="white-space:nowrap">COVID-19.</FONT> In response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, &#147;shelter in place&#148; orders and other public health guidance measures have been implemented across much of the United States, including in the locations of our offices, clinical trial sites, key vendors, and partners. We have
experienced delays in our clinical trial of <FONT STYLE="white-space:nowrap">SL-279252</FONT> as a result of the ongoing pandemic, including delays with certain third-party vendors supporting this trial. We temporarily paused enrollment of patients
for our clinical trial of SL-279252 between March and May 2020 and we resumed enrollment in June 2020. As &#147;shelter in place&#148; orders and other public health guidance measures are reinstated in the locations of our clinical trial sites, we
expect that some patients may also choose to forego one or more doses in our clinical trials, due to challenges faced by such patients in travelling to our clinical trial sites, which may negatively affect the study results. We expect that our
clinical development program timelines may continue to be negatively affected by <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which could materially and adversely affect our business, financial condition, and results of operations. Further, due
to &#147;shelter in place&#148; orders and other public health guidance measures, we may be required to implement a work-from-home policy for all staff members excluding those necessary to maintain minimum basic operations. In such an instance, our
increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our
personnel to be in our laboratories may be delayed. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, or
similar pandemics, and related &#147;shelter in place&#148; orders and other public health guidance measures, we have and may in the future experience disruptions that could materially and adversely impact our clinical trials, business, financial
condition, and results of operations. Potential disruptions include but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in enrolling patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or difficulties in initiating or expanding clinical trials, including delays or difficulties with clinical
site initiation and recruiting clinical site investigators and clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting <FONT
STYLE="white-space:nowrap">COVID-19</FONT> or other health conditions or being forced to quarantine; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site data monitoring and efficacy, safety
and translational data collection, processing and analyses, due to limitations on travel imposed or recommended by federal, state, or local governments, employers and others or interruption of clinical trial subject visits, which may impact the
collection and integrity of subject data and clinical study endpoints; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals
serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays or disruptions in preclinical experiments and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies
due to restrictions of <FONT STYLE="white-space:nowrap">on-site</FONT> staff and unforeseen circumstances at contract research organizations, or CROs, and vendors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption or delays in the operations of the FDA and comparable foreign regulatory agencies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing
organizations due to staffing shortages, production slowdowns, or stoppages and disruptions in delivery systems; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limitations on employee or other resources that would otherwise be focused on the conduct of our clinical trials
and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> work, including because of sickness of employees or their families, the desire of employees to avoid travel or contact with large groups of people, an increased reliance on working from home,
school closures, or mass transit disruptions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulations as part of a response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors
due to limitations in employee resources or forced furlough of government or contractor personnel; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic continues to rapidly evolve. The extent to which
the outbreak may affect our clinical trials, business, financial condition, and results of operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, such as the ultimate geographic spread of the
disease, the duration of the outbreak, travel restrictions, and actions to contain the outbreak or treat its impact, such as social distancing and quarantines or lock-downs in the United States and other countries, business closures, or business
disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Future developments in these and other areas present material uncertainty and risk with respect to our clinical trials,
business, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or our collaborators are unable to successfully develop and commercialize our
product candidates, or experience significant delays in doing so, our business, financial condition, and results of operations will be materially adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to generate product and royalty revenues, which we do not expect will occur for at least the next several years, if ever, will
depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a
marketable product. Each of our product candidates and any future product candidates we develop will require significant clinical development; management of clinical, preclinical, and manufacturing activities; regulatory approval in multiple
jurisdictions; establishing manufacturing supply, including commercial manufacturing supply; and require us to build a commercial organization and make substantial investment and significant marketing efforts before we generate any revenue from
product sales. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our
product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successful development of our product candidates will depend on several factors, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">successful and timely completion of clinical trials and preclinical studies for which the FDA, or any comparable
foreign regulatory authority agree with the design, endpoints, or implementation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receiving regulatory approvals or authorizations for conducting our planned clinical trials or future clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiation and successful patient enrollment in, and completion of, additional clinical trials on a timely basis;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the
applicable product candidate is safe and effective as a treatment for our targeted indications or, in the case of an applicable product candidates which is regulated as a biological product, that the applicable product is safe, pure, and potent for
our targeted indications; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to demonstrate to the satisfaction of the FDA or any comparable foreign regulatory authority that the
applicable product candidate&#146;s risk-benefit ratio for its proposed indication is acceptable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">timely receipt of marketing approvals for our product candidates from applicable regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishing and scaling up, either alone or with third-party manufacturers, manufacturing capabilities of
clinical supply for our clinical trials and commercial manufacturing, if any of our product candidates are approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully develop and commercialize our product candidates, which would materially adversely affect our
business, financial condition, and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ARC platform is based on novel technologies that are unproven and may not result in
approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to use and
expand our technology platforms, including ARC and GADLEN, to build a pipeline of product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing a pipeline
of product candidates using our proprietary ARC platform. We have not received regulatory approval for any of ARC product candidates. The scientific research that forms the basis of our efforts to develop product candidates with our ARC platform is
still ongoing. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our ARC platform is both preliminary and limited. Given the novelty of our technologies, we intend to work closely with the FDA
and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. The validation process takes time and resources, may require independent
third-party analyses, and may not be accepted by the FDA and other regulatory authorities. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies. Our
approach combines two binding domains to create fusion proteins that potentially restore and enhance immune system function in a single construct, which approach is unproven and may not be successful. To our knowledge, our dual-sided fusion protein
product candidates have not been tested before in humans and may have properties that negatively impact safety and efficacy, such as greater immunogenicity when compared to existing antibody therapeutics. Moreover, the dual-sided nature of our
product candidates may have unexpected biological interactions when administered <I>in vivo</I>. For example, it may be necessary to either implement a loading dose strategy or delay enrollment of patients recently treated with anti-PD-1 antibodies
to mitigate interactions between anti-PD-1 antibodies and SL-279252. Finally, the FDA or other regulatory agencies may lack experience in evaluating the safety and efficacy of our ARC platform, which could result in a longer than expected regulatory
review process, increase our expected development costs, and delay or prevent commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally,
a key element of our strategy is to use and expand our technology platforms, including ARC and GADLEN, to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of a variety of
different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at various cancers and autoimmune diseases, we may not be able to develop product candidates that are safe
and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other
characteristics </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize
product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our share price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to continue to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth,
which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, we had 45 full-time employees. We expect to experience continued
growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs and, ultimately, sales and marketing. To manage our anticipated future growth, we must continue to implement and
improve our managerial, operational, and financial systems; expand our facilities; and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing
a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our
management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, future growth imposes significant added responsibilities on members of management, including: identifying, recruiting,
integrating, maintaining, and motivating additional employees; managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to
contractors and other third parties; and improving our operational, financial and management controls, reporting systems, and procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on certain independent organizations, advisors, and consultants to provide certain services, including strategic, financial,
business development services, as well as certain aspects of regulatory approval, clinical management, manufacturing, and preparation for a potential commercial launch. There can be no assurance that the services of independent organizations,
advisors, and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of
the services provided by consultants or contract manufacturing organizations is compromised for any reason, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval of our product candidates
or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends upon the continued contributions of our key management, scientific, and technical personnel, many of whom have been
instrumental for us and have substantial experience with our product candidates and related technologies. The loss of key managers and senior scientists could delay our research and development activities. Despite our efforts to retain valuable
employees, members of our management, scientific, and development teams may terminate their employment with us on short notice. Although we have employment agreements with certain of our key employees, these employment agreements provide for <FONT
STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could leave our employment at any time, with or without notice. In addition, the competition for qualified personnel in the biotechnology and pharmaceutical
industries is intense, and our future success depends upon our ability to attract, retain, and motivate highly-skilled scientific, technical, and managerial employees. We face competition for personnel from other companies, universities, public and
private research institutions, and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement our business strategy, which could have a material adverse effect on our
business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Development and Clinical Testing of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates or any future product candidates,
which would prevent or delay or limit the scope of regulatory approval and commercialization. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain the requisite regulatory
approvals to market and sell any of our product candidates and any other future product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our investigational drug products are safe and effective for use
in each targeted indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin
clinical trials are never approved by regulatory authorities for commercialization. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful, and a clinical trial can fail at any
stage of testing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the process of obtaining regulatory approval is expensive, often takes many years following the commencement
of clinical trials, and can vary substantially based upon the type, complexity, and novelty of the product candidates involved, as well as the target indications, patient population, and regulatory agency. Prior to obtaining approval to
commercialize our product candidates and any future product candidates in the United States or abroad, we, our collaborators or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical
trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials that we conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product
candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols,
differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols, and the rate of dropout among clinical trial participants. If the results of our ongoing or future clinical trials are
inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be
delayed in obtaining marketing approval, if at all. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and
other indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and
analyses, and we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. We cannot guarantee that the FDA
or comparable foreign regulatory authorities will view our product candidates as having efficacy even if positive results are observed in clinical trials. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate
by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing
application, approval of our product candidates and any future product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in
support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial
potential. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interim, topline or preliminary data from our clinical trials that we announce or publish from time to
time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose preliminary or topline or data from our preclinical studies and clinical trials, which is based on
a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions,
estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results
of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final
data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that
we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data
could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or
analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product, and our company in general. If the
interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may
be harmed, which could harm our business, operating results, prospects, or financial condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of preclinical studies of our product
candidates may not be predictive of the results of future preclinical studies or clinical trials. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain the requisite
regulatory approvals to market and sell any of our product candidates, we or any collaborator for such candidates must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe, pure, and potent in
humans. Before an IND can be submitted to the FDA and become effective, which is a perquisite for conducting clinical trials on human subjects, a product candidate must successfully progress through extensive preclinical studies, which include
preclinical laboratory testing, animal studies, and formulation studies in accordance with Good Laboratory Practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Success in
preclinical studies does not ensure that later preclinical studies or clinical trials will be successful. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after
positive results in earlier preclinical studies. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously
unreported adverse events. The design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. In
addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Notwithstanding any potential promising results in earlier studies, we cannot be certain that we will not face similar setbacks. In addition, the
results of our preclinical animal studies, including our <FONT STYLE="white-space:nowrap">non-human</FONT> primate studies, may not be predictive of the results of outcomes in subsequent clinical trials on human subjects. Product candidates in
clinical trials may fail to show the desired pharmacological properties or safety and efficacy traits despite having progressed through preclinical studies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to receive positive results in preclinical studies or clinical trials of our
product candidates, the development timeline and regulatory approval and commercialization prospects for our most advanced product candidates, and, correspondingly, our business and financial prospects would be negatively impacted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>All of our product candidates are in preclinical or early-stage clinical development. Clinical drug development is a lengthy and expensive process with
uncertain timelines and uncertain outcomes. If clinical trials of our product candidates are prolonged or delayed, we or any collaborators may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product
candidates on a timely basis or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical testing is expensive and can take many years to complete, and its outcome is
inherently uncertain. Failure can occur at any time during the clinical trial process. Product candidates in later stages of clinical trials may fail to produce the same results or to show the desired safety and efficacy traits despite having
progressed through preclinical studies and initial clinical trials. Our future clinical trial results may not be successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, some of our trials, including our ongoing Phase 1 trials evaluating <FONT STYLE="white-space:nowrap">SL-279252</FONT> and Phase
1 trial evaluating <FONT STYLE="white-space:nowrap">SL-172154,</FONT> are open-label trials in which both the patient and investigator know whether the patient is receiving the investigational product candidate or an existing approved therapy.
Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect, as patients in open-label clinical trials are aware when they are receiving treatment. In addition, open-label clinical trials may be subject
to an &#147;investigator bias&#148; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given
this knowledge. Therefore, it is possible that positive results observed in open-label trials will not be replicated in later placebo-controlled trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have not completed any clinical trials required for the approval of our product candidates. We may experience delays in our
ongoing clinical trials, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time, or be completed on schedule, if at all. Clinical trials can be delayed, suspended, or terminated for a
variety of reasons, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to obtain regulatory authorization to commence a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to obtain institutional review board, or IRB, approval at each site; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to reach agreement on acceptable terms with prospective contract research organizations, or
CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">difficulty in recruiting clinical trial investigators of appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in establishing the appropriate dosage levels in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays in or failure to recruit and enroll suitable patients to participate in a trial, particularly considering
study inclusion and exclusion criteria and patients&#146; prior lines of therapy and treatment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the difficulty in certain countries in identifying the <FONT STYLE="white-space:nowrap">sub-populations</FONT>
that we are trying to treat in a particular trial, which may delay enrollment and reduce the power of a clinical trial to detect statistically significant results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">lower than anticipated retention rates of patients in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to have patients complete a trial or return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays adding new investigators or clinical trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">safety or tolerability concerns could cause us or our collaborators or governmental authorities, as applicable,
to suspend or terminate a trial if it is found that the participants are being exposed to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
unacceptable health risks, undesirable side effects, or other unfavorable characteristics of the product candidate, or if such undesirable effects or risks are found to be caused by a chemically
or mechanistically similar therapeutic or therapeutic candidate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our third-party research contractors failing to comply with regulatory requirements or meet their contractual
obligations to us in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in regulatory requirements, policies, and guidelines; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing sufficient quantities of a product candidate for use in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the quality or stability of a product candidate falling below acceptable standards; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the treatment landscape for our target indications that may make our product candidates no longer
relevant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third-party actions claiming infringement by our product candidates in clinical trials outside the United States
and obtaining injunctions interfering with our progress; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including
war and terrorism, natural disasters including earthquakes, typhoons, floods, and fires, or disease, including the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase the likelihood that we encounter
such difficulties or delays in initiating, enrolling, conducting, or completing our planned and ongoing clinical trials. Moreover, while we plan to submit additional INDs for other drug candidates, we may not be able to file such INDs on the
timeline we expect. For example, we may experience manufacturing delays or other delays with <FONT STYLE="white-space:nowrap">IND-enabling</FONT> preclinical studies. Moreover, we cannot be sure that submission of an IND will result in the FDA
allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in
an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials must be conducted in accordance with the FDA and other applicable regulatory authorities&#146; legal requirements, regulations
or guidelines, and are subject to oversight by these governmental agencies and Ethics Committees or IRBs at the medical institutions where the clinical trials are conducted. We could encounter delays if a clinical trial is suspended or terminated by
us, by the IRBs or Ethics Committees of the institutions in which such trials are being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA, or other regulatory authorities. Such authorities may
impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by
the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative
actions, or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed,
and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process,
and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right
to commercialize our product candidates and impair our ability to commercialize our product candidates and may harm our business and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, clinical trials must be conducted with supplies of our product candidates produced under current good manufacturing practices, or
cGMP, requirements and other regulations. Furthermore, we rely on CROs and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual
performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants
for our clinical trials, fail to conduct the study in accordance with GCP, or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays, or both, which
may harm our business. In addition, clinical trials that are conducted in countries outside the United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements, and the
engagement of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA, and different standards of diagnosis, screening, and medical care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may have serious adverse, undesirable, or unacceptable side effects or other properties that may delay or prevent marketing
approval. If such side effects are identified following approval, if any, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Undesirable side effects that may be caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or halt
clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. While we believe that the targeted nature of our dual-sided fusion proteins may carry a
lower risk of overstimulating the immune system and causing a cytokine storm (a side effect associated with certain other antibody therapies), we do not have enough clinical data and experience with these molecules in humans to fully anticipate side
effects. Accordingly, we may experience unexpected side effects and/or higher levels of known side effects in clinical trials, such as cytokine storms associated with immune checkpoint inhibitors or red blood cell lysis associated with SIRP<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results of our clinical trials could reveal a high and unacceptable severity and
prevalence of these or other side effects. In such an event, our clinical trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product
candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result in potential product liability claims. Any of these
occurrences may harm our business, financial condition, and prospects significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, clinical trials by their nature utilize a
sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to
the product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that any of our product candidates receives marketing approval and we or others later identify
undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may withdraw or limit approvals of such products and require us to take our approved
product off the market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or
field alerts to physicians and pharmacies, or issue other communications containing warnings or other safety information about the product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution
to patients, or that we implement a risk evaluation and mitigation strategy, or REMS, plan to ensure that the benefits of the product outweigh its risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to change the dose or the way the product is administered, conduct additional clinical trials,
or change the labeling of the product; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to limitations on how we may promote or manufacture the product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of the product may decrease significantly; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be subject to litigation or product liability claims; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us, our collaborators, or our potential future partners from achieving or maintaining market acceptance of
the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of any products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The manufacture of our product candidates is complex. Our third-party manufacturers may encounter difficulties in production, which could delay or
entirely halt their ability to supply our product candidates for clinical trials or, if approved, for commercial sale. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product
candidates are considered to be biologics and the process of manufacturing biologics is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. We do not
own or operate any cGMP manufacturing facilities. We rely, and expect to continue to rely, on third-party contract development and manufacturing organizations for the manufacture of our product candidates for preclinical and clinical testing. To
date, we and our contract manufacturers have limited experience in the manufacturing of cGMP batches of our product candidates. Our contract manufacturers must comply with cGMPs, regulations, and guidelines for the manufacturing of biologics used in
clinical trials and, if approved, marketed products. To date, we and our contract manufacturers have only produced smaller cGMP batches of our product candidates and have not scaled up the manufacturing process for later-stage clinical trials and
commercialization. Larger scale manufacturing will require the development of new processes, including for the removal of impurities that are a normal byproduct of the manufacturing process. The nature of our dual-sided fusion proteins requires the
development of novel manufacturing and purification processes, which could cause delays in the <FONT STYLE="white-space:nowrap">scale-up</FONT> of manufacturing, as well as greater costs that could negatively impact the financial viability of our
product candidates. Moreover, the nature of our dual-sided fusion proteins creates challenges for the stability of the drug substance, which has the potential to cause delays in completing clinical studies and potentially limiting clinical trial
site locations based on applicable regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of manufacturing our biologic product candidates is extremely susceptible to
product loss due to contamination, oxidation, equipment failure, or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics, and difficulties in scaling the
production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product
candidates or in the manufacturing facilities in which our product candidates are made, this could lead to withdrawal of our products from the market, and such manufacturing facilities may need to be closed for an extended period of time to
investigate and remedy the contamination. Moreover, if the FDA determines that our third-party manufacturers are not in compliance with FDA laws and regulations, including those governing cGMPs, the FDA may deny BLA approval until the deficiencies
are corrected or we replace the manufacturer in our BLA with a manufacturer that is in compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any adverse developments affecting
manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to
take inventory write-offs and incur other charges and expenses for products that fail to meet specifications as a result of defects or storage over an extended period of time, undertake costly remediation efforts, or seek more costly manufacturing
alternatives. As part of our process development efforts, we also may make changes to our manufacturing processes at various points during development, for various reasons, such as controlling costs, achieving scale, decreasing processing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time, increasing manufacturing success rate, or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product
candidates to perform differently and affect the results of our ongoing clinical trials or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform <I>ex vivo</I> comparability studies and to
collect additional data from patients prior to undertaking more advanced clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on enrollment of patients in our clinical
trials for our product candidates. If we experience delays or difficulties enrolling in our clinical trials, our research and development efforts and business, financial condition, and results of operations could be materially adversely affected.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patient candidates. These
trials and other trials we conduct may be subject to delays for a variety of reasons, including as a result of patient enrollment taking longer than anticipated, patient withdrawal, or adverse events. For example, we have experienced delays in our
clinical trial of <FONT STYLE="white-space:nowrap">SL-279252</FONT> as a result of the ongoing pandemic. These types of developments could cause us to delay the trial or halt further development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical trials will compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this
competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Moreover, enrolling patients in
clinical trials for cancer therapies is challenging, as cancer patients will first receive the applicable standard of care. Many patients who respond positively to the standard of care antibody therapy, such as PD-1 checkpoint inhibitors, (and thus
do not enroll in clinical trials) are believed to have tumor types that may have responded well to our product candidates. This may limit the number of eligible patients able to enroll in our clinical trials who have the potential to benefit from
our drug candidates and could extend development timelines or increase costs for these programs. Patients who fail to respond positively to the standard of care treatment will be eligible for clinical trials of unapproved drug candidates. However,
these patients may have either compromised immune function from prior administration of chemotherapy or an enhanced immune response from the prior administration of checkpoint inhibitors. Either of these prior treatment regimens may render our
therapies less effective in clinical trials. We may seek to mitigate these effects in the future through modification of enrollment eligibility criteria, including patients with tumor types that are not typically responsive to anti-PD-1 antibodies,
or pursuing combination regimens early in clinical development to enable access to anti-PD-1 native patients. Additionally, patients who have failed approved therapies will typically have more advanced cancer and a poorer long-term prognosis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials
at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment depends on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the severity of the disease under investigation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eligibility criteria for the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the proximity of patients to clinical sites; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the design of the clinical protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before the administration of our
product candidates or trial completion; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of competing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of new drugs approved for the indication the clinical trial is investigating; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in
relation to other available therapies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These factors may make it difficult for us to enroll enough patients to complete
our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process, and delay or potentially
jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory
approval of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become exposed to costly and damaging liability claims, either when testing our product candidates in
the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing, and use of pharmaceutical products. While we currently have no products that have been approved for
commercial sale, the current and future use of product candidates by us and our partners in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the
product, healthcare providers, pharmaceutical companies, our partners, or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for
our product candidates or any prospects for commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the clinical trial process is designed
to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or
after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even successful defense against product liability claims would require significant financial and management resources. Regardless of the
merits or eventual outcome, liability claims may result in: decreased demand for our product candidates; injury to our reputation; withdrawal of clinical trial participants; initiation of investigations by regulators; costs to defend the related
litigation; a diversion of management&#146;s time and our resources; substantial monetary awards to trial participants or patients; product recalls, withdrawals or labeling, marketing or promotional restrictions; loss of revenue; exhaustion of any
available insurance and our capital resources; the inability to commercialize any product candidate; and a decline in our share price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we maintain adequate product liability insurance for our product candidates, it is possible that our liabilities could exceed our
insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing approval for any of our product candidates. However, we may be unable to maintain insurance coverage at a reasonable
cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our
assets may not be sufficient to cover such claims, and our business operations could be impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Regulatory Environment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The development and commercialization of biopharmaceutical products is subject to extensive regulation, and the regulatory approval processes of the FDA
and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates on a timely basis if at all, our business will be substantially
harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical development, manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export,
import, marketing, distribution, adverse event reporting, including the submission of safety and other post-marketing information and reports, and other possible activities relating to our product candidates are subject to extensive regulation. In
the United States, marketing approval of biologics requires the submission of a Biologics License Application, or BLA, to the FDA, and we are not permitted to market any product candidate in the United States until we obtain approval from the FDA of
the BLA for that product candidate. A BLA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing, and controls. Outside the United States, many comparable
foreign regulatory authorities employ similar approval processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not previously submitted a BLA to the FDA or similar regulatory
approval filings to comparable foreign authorities, for any product candidate, and we cannot be certain that any of our product candidates will receive regulatory approval. We are not permitted to market our product candidates in the United States
or in other countries until we receive approval of a BLA from the FDA or marketing approval from applicable regulatory authorities outside the United States. Obtaining approval of a BLA can be a lengthy, expensive, and uncertain process, and as a
company we have no experience with the preparation of a BLA submission or any other application for marketing approval. In addition, the FDA has the authority to require a risk evaluation and mitigation strategies, or REMS, plan as part of a BLA or
after approval, which may impose further requirements or restrictions on the distribution or use of an approved biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting
treatment to patients who meet certain <FONT STYLE="white-space:nowrap">safe-use</FONT> criteria and requiring treated patients to enroll in a registry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates could fail to receive regulatory approval for many reasons, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that
a product candidate is safe and effective for its proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or
comparable foreign regulatory authorities for approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety
risks; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from
preclinical studies or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission
of a BLA or other submission or to obtain regulatory approval in the United States or elsewhere, or regulatory authorities may not accept a submission due to, among other reasons, the content or formatting of the submission; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or
facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly
change in a manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This lengthy approval process, as well as the unpredictability of future clinical trial
results, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects. The FDA and other regulatory authorities have substantial
discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. For example, regulatory authorities in various jurisdictions have in the past had, and may in the future
have, differing requirements for, interpretations of and opinions on our preclinical and clinical data. As a result, we may be required to conduct additional preclinical studies, alter our proposed clinical trial designs, or conduct additional
clinical trials to satisfy the regulatory authorities in each of the jurisdictions in which we hope to conduct clinical trials and develop and market our products, if approved. Further, even if we believe the data collected from clinical trials of
our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited
indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not
include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review, which may result
in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or
experience unanticipated problems with our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the FDA or a comparable foreign regulatory authority approves any of our
product candidates, the manufacturing processes, labeling, packaging, distribution, import, export, adverse event reporting, storage, advertising, promotion, and recordkeeping for the product will be subject to extensive and ongoing regulatory
requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval, all of which
may result in significant expense and limit our ability to commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the
product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturers and manufacturers&#146; facilities are required to comply with extensive FDA and comparable foreign regulatory authority
requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and
adherence to commitments made in any approved marketing application. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality
control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or
our manufacture of a product, or if we or one of our distributors, licensees or <FONT STYLE="white-space:nowrap">co-marketers</FONT> fails to comply with regulatory requirements, the regulators could take various actions. These include issuing
warning letters or untitled letters, imposing fines on us, imposing restrictions on the product or its manufacture, and requiring us to recall or remove the product from the market. The regulators could also suspend or withdraw our marketing
authorizations, requiring us to conduct additional clinical trials, change our product labeling, or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such product may be impaired, and we
may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition, and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we have any product candidate approved, our product labeling, advertising,
and promotion will be subject to regulatory requirements and continuing regulatory review. In the United States, the FDA and the Federal Trade Commission, or FTC, strictly regulate the promotional claims that may be made about pharmaceutical
products to ensure that any claims about such products are consistent with regulatory approvals, not misleading or false in any particular, and adequately substantiated by clinical data. The promotion of a drug product in a manner that is false,
misleading, unsubstantiated, or for unapproved (or <FONT STYLE="white-space:nowrap">off-label)</FONT> uses may result in enforcement letters, inquiries and investigations, and civil and criminal sanctions by the FDA or the FTC. In particular, a
product may not be promoted for uses that are not approved by the FDA as reflected in the product&#146;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a
manner that is inconsistent with the approved label. If we are found to have promoted such <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws
and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant
sanctions and may result in false claims litigation under federal and state statutes, which can lead to consent decrees, civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid,
and other federal and state healthcare programs. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in
<FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or
problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product
from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue warning letters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, or require us to issue, safety-related communications, such as safety alerts, field alerts, &#147;Dear
Doctor&#148; letters to healthcare professionals, or import alerts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose civil or criminal penalties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend, limit, or withdraw regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspend any of our preclinical studies and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refuse to approve pending applications or supplements to approved applications submitted by us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impose restrictions on our operations, including closing our contract manufacturers&#146; facilities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">seize or detain products, refuse to permit the import or export of products, or require us to conduct a product
recall. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any government investigation of alleged violations of law could require us to expend significant time and
resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products, if approved. If
regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that
could prevent, limit, or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, either in the
United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders,
that could impose </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and
review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its regulatory authority. If these executive actions impose
restrictions on the FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. In addition, if we are slow or unable to adapt to changes in existing requirements or the
adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain,
or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved, or commercialized in a timely manner or at all, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding
levels, statutory, regulatory, and policy changes, the FDA&#146;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#146;s ability to perform routine functions. Average
review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and
unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics or modifications to licensed biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our
business. For example, over the last several years, including for 35 days beginning on December&nbsp;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA
employees and stop critical activities.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on
March&nbsp;10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March&nbsp;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities.
Subsequently, on July&nbsp;10, 2020, the FDA announced its intention to resume certain <FONT STYLE="white-space:nowrap">on-site</FONT> inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to
use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities.&nbsp;Regulatory authorities
outside the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to
prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our
regulatory submissions, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our research and development activities could be affected or
delayed as a result of possible restrictions on animal testing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain laws and regulations require us to test our product
candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop
animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development
activities may be interrupted, delayed, or become more expensive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business operations and current and future relationships with healthcare professionals, principal
investigators, consultants, vendors, customers, and third-party payors in the United States and elsewhere are subject to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, and other healthcare laws and
regulations, which could expose us to substantial penalties, contractual damages, reputation harm, administrative burdens, and diminished profits. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, healthcare facilities and institutions, physicians, and third-party payors in the United States and elsewhere will play a
primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, healthcare facilities and institutions, principal investigators,
consultants, customers, and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, that may constrain the
business or financial arrangements and relationships through which we research, sell, market, and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and
regulation by the federal government and by the states and foreign jurisdictions in which we conduct our business. The applicable federal, state, and foreign healthcare laws that affect our ability to operate include, but are not limited to, the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and
willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral
of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. The term
&#147;remuneration&#148; has been broadly interpreted to include anything of value, including stock options. The federal Anti-Kickback Statute has also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand
and prescribers, purchasers and formulary managers on the other the other hand. Any arrangements with prescribers must be for <I>bona fide</I> services and compensated at fair market value. A person or entity does not need to have actual knowledge
of the statute or specific intent to violate it in order to have committed a violation. In addition, on July 24, 2020, President Trump issued an Executive Order directing the Department of Health and Human Services, or HHS, to engage in rulemaking
to eliminate the safe harbor protections under the Anti-Kickback Statute that cover rebates for health plan sponsors and pharmacy benefit managers, and instead protect the application of discounts at the patients&#146; point of sale, in an effort to
ensure that discounts on prescription drugs are passed directly to patients; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. federal civil and criminal false claims and civil monetary penalties laws, including the civil False
Claims Act, which prohibit, among other things, including through civil whistleblower or qui tam actions, individuals or entities from knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval
that are false or fraudulent, knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease, or conceal an obligation to pay
money to the U.S. federal government. Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government by, among other things, engaging in impermissible marketing practices, such as the <FONT
STYLE="white-space:nowrap">off-label</FONT> promotion of a product for an indication for which it has not received FDA approval. In addition, the government may assert that a claim including items and services resulting from a violation of the
federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and
civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing, or covering up a material fact or making any
materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items, or services. Similar to the federal Anti-Kickback </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate it in order to have committed a violation.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Federal Food, Drug, and Cosmetic Act, or the FDCA, which prohibits, among other things, the adulteration
or misbranding of drugs, biologics, and medical devices; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate
commerce of a biological product unless a biologics license is in effect for that product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the U.S. Physician Payments Sunshine Act and its implementing regulations, which requires, among other things,
certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare and
Medicaid Services, or CMS, information related to certain payments and other transfers of value to physicians, as defined by statute, and teaching hospitals, as well as ownership and investment interests held by such physicians and their immediate
family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous year to certain other healthcare professionals, including physician assistants, nurse practitioners, clinical nurse
specialists, certified nurse anesthetists, and certified nurse-midwives; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply
to our business practices, including but not limited to, research, distribution, sales and marketing arrangements, and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that
require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to
healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of
value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">similar healthcare laws and regulations in foreign jurisdictions, including reporting requirements detailing
interactions with and payments to healthcare providers. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ensuring that our internal operations and future business
arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to
detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such
laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. We have entered into consulting and scientific advisory board arrangements with physicians and other
healthcare providers, including some who could influence the use of our product candidates, if approved. Compensation under some of these arrangements includes the provision of stock or stock options in addition to cash consideration. Because of the
complex and <FONT STYLE="white-space:nowrap">far-reaching</FONT> nature of these laws, it is possible that governmental authorities could conclude that our payments to physicians may not be fair market value for <I>bona fide</I> services or that our
business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the
laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, exclusion from government-funded
healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of noncompliance, disgorgement, individual imprisonment, contractual
damages, reputational harm, diminished profits, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable
laws, they may be subject to criminal, civil or administrative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions
can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees, independent contractors, principal investigators, consultants, commercial partners, and vendors may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee
fraud or other misconduct. We cannot ensure that our compliance controls, policies, and procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or
regulations of the jurisdictions in which we operate, including, without limitation, employment, foreign corrupt practices, trade restrictions and sanctions, environmental, competition, and patient privacy and other privacy laws and regulations.
Misconduct by employees could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and
regulations, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to
prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, labeling, marketing and promotion, sales commission, customer incentive programs, and
other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible
to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions
or lawsuits stemming from a failure to be in compliance with such laws or regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any such actions are instituted against us, and
we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant civil,
criminal and administrative penalties, damages, monetary fines, individual imprisonment, disgorgement of profits, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational
harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of noncompliance with the law, and curtailment or
restructuring of our operations, any of which could adversely affect our ability to operate our business and pursue our strategy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Current and
future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory
changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare
costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which substantially
changed the way healthcare is financed by both governmental and private payors. Among the provisions of the ACA of importance to the pharmaceutical and biotechnology industries, which includes biologics, are the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturers and importers of certain branded prescription drugs, including certain biologics, with annual sales
of more than $5&nbsp;million made to or covered by specified federal healthcare programs are required to pay an annual, nondeductible fee according to their market share of all such sales; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to
23.1% of the average manufacturer price for most branded drugs, biologics, and biosimilars and to 13.0% for generic drug, and cap of the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted, or injected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are
enrolled in Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid
coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expansion of the entities eligible for discounts under the Public Health program, commonly referred to as the
&#147;340B Program;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians, also
known as the &#147;Physicians Payment Sunshine Act;&#148; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models
to lower Medicare and Medicaid spending, potentially including prescription drug spending; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect
there will be additional challenges and amendments to the ACA in the future. For example, the Tax Cuts and Jobs Act of 2017, repealed the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the ACA on certain
individuals who fail to maintain qualifying health coverage that is commonly referred to as the &#147;individual mandate.&#148; In December 2019, a U.S. District Court upheld a ruling that the ACA is unconstitutional in its entirety because the
&#147;individual mandate&#148; was repealed by Congress. In March 2020, the Supreme Court of the United States agreed to hear the appeal of this decision. It is unclear how this and other efforts to challenge, repeal, or replace the ACA will impact
the ACA or our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was
enacted which, among other things, have reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers. These new laws or any other similar laws introduced in the future, as well as regulatory actions that
may be taken by CMS, may result in additional reductions in Medicare and other healthcare funding, which could negatively affect our customers and accordingly, our financial operations. Moreover, payment methodologies may be subject to changes in
healthcare legislation and regulatory initiatives. Additionally, individual states in the United States have passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing and costs. Similar
developments have occurred outside of the United States, including in the European Union where healthcare budgetary constraints have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. To
obtain reimbursement or pricing approval in some European Union member states, we may be required to conduct studies that compare the cost-effectiveness of our product candidates to other therapies that are considered the local standard of care.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative
action in the United States or any other jurisdiction. If we or any third parties we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory
compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we are able to commercialize any product candidate, coverage and adequate reimbursement may not be available or such product candidate may
become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The regulations that govern regulatory approvals, pricing, and reimbursement for drug products vary widely from country to country. Some
countries require approval of the sale price of a drug product before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription drug product pricing remains
subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of
the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more
product candidates, even if our product candidates obtain regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to commercialize any products successfully
also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, such as government authorities, private health insurers, and other
organizations. Even if we succeed in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive
basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of coverage and reimbursement. Increasingly, the third-party payors who reimburse
patients or healthcare providers are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for drug products. If the price we are able to
charge for any products we develop, or the coverage and reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could be affected adversely. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be significant delays in obtaining reimbursement for newly-approved drug products, and coverage may be more limited than the
purposes for which the drug product is approved by the FDA or similar foreign regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drugs product will be reimbursed in all cases or at a rate that covers our costs,
including research, development, manufacture, sale, and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interim reimbursement levels for new drug products, if applicable,
may also be insufficient to cover our costs and may not be made permanent. Reimbursement rates may be based on payments allowed for lower cost drug products that are already reimbursed, may be incorporated into existing payments for other services
and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drug products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict
imports of drug products from countries where they may be sold at lower prices than in the United States. Obtaining coverage and adequate reimbursement for our product candidates may be particularly difficult because of the higher prices often
associated with drugs administered under the supervision of a physician. Similarly, because our product candidates are physician-administered injectables, separate reimbursement for the product itself may or may not be available. Instead, the
administering physician may or may not be reimbursed for providing the treatment or procedure in which our product is used. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, no
uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can differ significantly from payor to payor. Third-party payors often follow Medicare coverage policy and payment limitations in setting their
own reimbursement rates, but also have their own methods and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
approval process apart from Medicare determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and
clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Decisions regarding the extent of coverage
and amount of reimbursement to be provided for any product candidates that we develop will be made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">payor-by-payor</FONT></FONT> basis. One payor&#146;s determination to provide
coverage for a drug does not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payor&#146;s decision to provide coverage for a therapy does not imply that an adequate
reimbursement rate will be approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be, legislative and regulatory proposals at the
foreign, federal, and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future, including repeal, replacement, or
significant revisions to the Affordable Care Act. The continuing efforts of the government, insurance companies, managed care organizations, and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price
controls may adversely affect: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the demand for our product candidates, if we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to set a price that we believe is fair for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain coverage and reimbursement approval for a product; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of taxes that we are required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we may develop companion diagnostic tests for use with our product candidates. If we develop such a companion diagnostic test,
we, or our collaborators, may also seek to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our product candidates, if approved. While we have not yet developed any companion
diagnostic test for our product candidates, if we do, there is significant uncertainty regarding our ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates. Our inability to promptly obtain
coverage and adequate reimbursement from both third-party payors for the product candidates and any companion diagnostic tests that we may develop and for which we obtain regulatory approval could have a material and adverse effect on our business,
financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We face potential liability related to the privacy of health information we obtain from
clinical trials sponsored by us or our collaborators, from research institutions and our collaborators, and directly from individuals. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our partners and vendors are subject to various federal, state, and foreign data protection laws and regulations (i.e., laws and
regulations that address data privacy and security). If we fail to comply with these laws and regulations we may be subject to litigation, regulatory investigations, enforcement notices, enforcement actions, fines, and criminal or civil penalties,
as well as negative publicity and a potential loss of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, numerous federal and state laws and regulations,
including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations that govern the collection, use, disclosure, and protection of health-related and other personal
information could apply to our operations or the operations of our partners. For example, most healthcare providers, including research institutions from which we or our collaborators obtain patient health information, are subject to privacy and
security regulations promulgated under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH. Under HIPAA, we could potentially face substantial criminal or civil penalties if we knowingly
receive individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#146;s requirements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for disclosure of individually identifiable health information, or otherwise violate applicable HIPAA requirements related to the protection of such information. Even when HIPAA does not apply,
failing to take appropriate steps to keep consumers&#146; personal information secure may constitute a violation of the Federal Trade Commission Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the
clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of
affected individuals and state regulators in the event of a breach of personal information. These state laws include the recently enacted California Consumer Privacy Act, which establishes additional data privacy rights for residents of the State of
California. Similar laws have been proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our clinical trial programs and research collaborations outside the United States may implicate international data protection laws, including,
in Europe, the General Data Protection Regulation, or GDPR, which became effective in 2018. The GDPR imposes stringent operational requirements for processors and controllers of personal data. Among other things, the GDPR requires detailed notices
for clinical trial subjects and investigators, as well as requirements regarding the security of personal data and notification of data processing obligations or security incidents to appropriate data protection authorities or data subjects. If our
privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices, and/or enforcement actions requiring us to change the way we use personal data and/or
fines. In addition to statutory enforcement, a personal data breach can lead to negative publicity and a potential loss of business. Further, following the United Kingdom&#146;s withdrawal from the E.U. effective as of December&nbsp;31, 2020, we
will have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, which may have differing requirements. If we fail to comply with United Kingdom data protection laws we may be subject to litigation, regulatory
investigations, enforcement notices, and/or enforcement actions, as well as negative publicity and a potential loss of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
also subject to evolving EEA laws on data export, as we may transfer personal data from the EEA to other jurisdictions. Recent legal developments in Europe have created complexity and uncertainty regarding transfers of personal data from the EEA to
the United States. For example, on July&nbsp;16, 2020, the Court of Justice of the European Union, or CJEU, invalidated the <FONT STYLE="white-space:nowrap">EU-US</FONT> Privacy Shield Framework, or Privacy Shield, under which personal data could be
transferred from the EEA to United States entities who had self-certified under the Privacy Shield scheme. Moreover, it is uncertain whether the standard contractual clauses will also be invalidated by the European courts or legislature. As
government authorities issue further guidance on personal data export mechanisms and/or start taking enforcement action, we could suffer additional costs, complaints, and/or regulatory investigations or fines, and/or if we are otherwise unable to
transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely
affect our financial results. These laws and regulations may apply, not only to us, but also to vendors that store or otherwise process data on our behalf, such as information technology vendors. If such a vendor misuses data we have provided to it,
or fails to safeguard such data, we may be subject to litigation, regulatory investigations, enforcement notices, and/or enforcement actions, as well as negative publicity and a potential loss of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are likely to be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data
security laws. Claims that we have violated individuals&#146; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend, and could result in adverse publicity that could
harm our business. Moreover, even if we take all necessary action to comply with regulatory requirements, we could be subject to a hack or data breach, which could subject us to fines and penalties, as well as reputational damage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or any collaborators fail to comply with applicable federal, state, or local
regulatory requirements, we could be subject to a range of regulatory actions that could affect our or any collaborators&#146; ability to seek to commercialize our clinical candidates. Any threatened or actual government enforcement action could
also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Commercialization of Our Product Candidates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We operate in highly competitive and rapidly changing industries, which may result in
others discovering, developing or commercializing competing products before or more successfully than we do. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biotechnology and
pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new and innovative products on a
cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large pharmaceutical and biotechnology companies, academic institutions, government
agencies and other public and private research organizations. These organizations may have significantly greater resources than we do and conduct similar research, seek patent protection and establish collaborative arrangements for research,
development, manufacturing, and marketing of products that compete with our product candidates. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors.
Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With the proliferation of new oncology drugs and therapies, we expect to face increasingly intense competition as new technologies become
available. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may
become available in the future. The highly competitive nature of and rapid technological changes in the biotechnology and pharmaceutical industries could render our product candidates or our technology obsolete, less competitive or uneconomical. Our
competitors may, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have significantly greater financial, manufacturing, marketing, drug development, technical, and human resources
than we do; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">develop and commercialize products that are safer, more effective, less expensive, more convenient or easier to
administer, or have fewer or less severe side effects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain quicker regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish superior proprietary positions covering our products and technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">implement more effective approaches to sales and marketing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">form more advantageous strategic alliances. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these factors occur, our business, financial condition, and results of operations could be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any collaborators may decide to market and sell products that compete with the product candidates that we have agreed to license
to them, and any competition by our collaborators could also have a material adverse effect on our future business, financial condition, and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with
large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If the market opportunity for any product candidate that we or our strategic partners develop is
smaller than we believe, our revenue may be adversely affected and our business may suffer. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to initially focus our
product candidate development on treatments for various oncology indications. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our estimates. These estimates, which have been
derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, and market research, may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers.
Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter
the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we or our strategic partners develop could be significantly diminished and have an adverse material impact on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be
small. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer therapies are sometimes characterized by line of therapy (first, second, third, fourth, etc.), and the FDA often
initially approves new therapies only for use in a particular line or lines of therapy. When cancer is detected early enough, first line therapy is sometimes adequate to provide a cure or prolong life without a cure. Whenever first line therapy
(typically chemotherapy, hormone therapy, surgery, or a combination of these) proves unsuccessful, second line therapy (typically more chemotherapy, radiation, antibody drugs, tumor targeted small molecules, or a combination of these) may be
administered. Third or fourth line therapies can include bone marrow transplantation, antibody and small molecule targeted therapies, more invasive forms of surgery, and new technologies. We may initially seek approval of our product candidates as a
third line therapy for patients who have failed other approved treatments. Subsequently, for product candidates that prove to be sufficiently beneficial, if any, we would expect to seek approval as a second and first line therapy. However, there is
no guarantee that our product candidates, even if initially approved, would be subsequently approved as a second or first line therapy. In addition, we may have to conduct additional clinical trials prior to gaining approval as a second or first
line therapy. Because the potentially addressable patient target population for our product candidates may be limited to patients who are ineligible for or have failed prior treatments, even if we obtain significant market share for our product
candidates, we may never achieve profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail
to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial and managerial resources, we focus on research programs, therapeutic platforms, and product candidates that
we identify for specific indications. Additionally, we have contractual commitments under our collaboration agreements to use commercially reasonable efforts to develop certain programs and thus, do not have unilateral discretion to vary from such
agreed to efforts. In addition, we have contractual commitments to conduct certain development plans, and thus may not have discretion to modify such development plans, including clinical trial designs, without agreement from our collaboration
partners. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause
us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms, and product candidates for specific indications may not yield any
commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, or other
royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if approved, our products may not gain market acceptance, in which case we may not be able to
generate product revenues, which will materially adversely affect our business, financial condition, and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA or any other regulatory authority approves the marketing of any product candidates that we develop on our own or with a
collaborator, physicians, healthcare providers, patients, or the medical community may not accept or use them. Additionally, the product candidates that we are developing are based on our proprietary ARC platform, which is a new technology. If these
products do not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of any of our product candidates will depend on a variety of factors,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of market introduction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any approvals and the countries in which approvals are obtained; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number and clinical profile of competing products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to provide acceptable evidence of safety and efficacy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the prevalence and severity of any side effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">relative convenience and ease of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cost-effectiveness; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">patient diagnostics and screening infrastructure in each market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse publicity about our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">availability of coverage, adequate reimbursement and sufficient payment from health maintenance organizations and
other insurers, both public and private, for our product candidates, or the procedures utilizing our product candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the willingness of patients to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of coverage by third-party payors and government authorities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other potential advantages over alternative treatment methods. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates fail to gain market acceptance, this will have a material adverse impact on our ability to generate revenues to
provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may prove not to be large enough to allow us to generate significant revenues. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no marketing, sales, or distribution infrastructure and we intend to either establish a sales and marketing infrastructure or
outsource this function to a third party. Either of these commercialization strategies carries substantial risks to us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
currently have no marketing, sales, and distribution capabilities because all of our product candidates are still in clinical or preclinical development. If any of our product candidates are approved, we intend to either establish a sales and
marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in a legally compliant manner, or to outsource this function to a third party. There are risks involved if we decide to
establish our own sales and marketing capabilities or enter into arrangements with third parties to perform these services. To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product
revenue may be lower than if we directly marketed or sold any approved products. Such collaborative arrangements with partners may place the commercialization of our products outside of our control and would make us subject to a number of risks
including that we may not be able to control the amount or timing of resources that our collaborative partner </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
devotes to our products or that our collaborator&#146;s willingness or ability to complete its obligations, and our obligations under our arrangements may be adversely affected by business
combinations or significant changes in our collaborator&#146;s business strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to enter into these arrangements on
acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our
future product revenue will suffer and we may incur significant additional losses, which would have a material adverse effect on our business, financial condition, and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval
pathway for biological products that are biosimilar to or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a highly similar or &#147;biosimilar&#148;
product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date
on which the reference product was first approved. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for
the competing product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. The law is complex and is still being interpreted
and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that any
of our product candidates approved as a biological product under a BLA should qualify for the <FONT STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to
congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA,
some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar
to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Jurisdictions in addition to the United States have established abbreviated pathways for regulatory approval of biological products that are
biosimilar to earlier approved reference products. For example, the European Union has had an established regulatory pathway for biosimilars since 2004. However, biosimilars can only be authorized once the period of data exclusivity on the reference
biological medicine has expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increased likelihood of biosimilar competition has increased the risk of loss of innovators&#146;
market exclusivity. Due to this risk, and uncertainties regarding patent protection, if our clinical candidates are approved for marketing, it is not possible to predict the length of market exclusivity for any particular product with certainty
based solely on the expiration of the relevant patent(s) or the current forms of regulatory exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. The loss
of market exclusivity for a product would likely materially and negatively affect revenues and we may not generate adequate or sufficient revenues from them or be able to reach or sustain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third-parties to manufacture our product candidates. Any failure by a third-party manufacturer to produce acceptable drug substance for us or
to obtain authorization from the FDA or comparable regulatory authorities may delay or impair our ability to initiate or complete our clinical trials, obtain regulatory approvals or commercialize approved products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently own or operate any GMP manufacturing facilities nor do we have any <FONT STYLE="white-space:nowrap">in-house</FONT> GMP
manufacturing capabilities. We rely on our strategic partners to manufacture product candidates licensed to them or work with multiple third-party contract manufacturers to produce sufficient quantities of materials required for the manufacture of
our product candidates for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards, and intend to do so for the commercial manufacture of our products, if approved. If we are unable to arrange for such
third-party manufacturing sources, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of product candidate or we may be delayed in doing so. Such failure or substantial delay could
materially harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on third parties for biological materials that are used in our discovery and development programs.
These materials can be difficult to produce and occasionally have variability from the product specifications. Any disruption in the supply of these biological materials consistent with our product specifications could materially adversely affect
our business. Although we have control processes and screening procedures, biological materials are susceptible to damage and contamination and may contain active pathogens. We may also have lower yields in manufacturing batches, which can increase
our costs and slow our development timelines. Improper storage of these materials, by us or any third-party suppliers, may require us to destroy some of our biological raw materials or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves,
including reliance on the third party for regulatory compliance and quality control and assurance, volume production, the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control (including a
failure to synthesize and manufacture our product candidates in accordance with our product specifications) and the possibility of termination or nonrenewal of the agreement by the third party at a time that is costly or damaging to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA and other regulatory authorities require that our product candidates be manufactured according to cGMPs and similar
foreign standards relating to methods, facilities, and controls used in the manufacturing, processing, and packing of the product, which are intended to ensure that biological products are safe and that they consistently meet applicable requirements
and specifications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical manufacturers are required to register their facilities and products manufactured at the time of
submission of the marketing application and then annually thereafter with the FDA and certain state and foreign agencies. If the FDA or a comparable foreign regulatory authority does not approve our proposed contract manufacturer&#146;s facilities
for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for, or
market our product candidates, if approved. Any discovery of problems with a product, or a manufacturing or laboratory facility used by us or our strategic partners, may result in restrictions on the product or on the manufacturing or laboratory
facility, including marketed product recall, suspension of manufacturing, product seizure, or a voluntary withdrawal of the drug from the market. We may have little to no control regarding the occurrence of third-party manufacturer incidents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were unable to find an adequate replacement or another acceptable solution in time, our clinical trials could be delayed, or our
commercial activities could be harmed. In addition, the fact that we are dependent on our collaborators, our suppliers, and other third parties for the manufacture, filling, storage, and distribution of our product candidates means that we are
subject to the risk that the products may have manufacturing defects that we have limited ability to prevent or control. The sale of products containing such defects could adversely </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affect our business, financial condition, and results of operations. Any failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any
failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical manufacturers are also subject to extensive post-marketing oversight by the FDA and comparable regulatory authorities in the
jurisdictions where the product is marketed, which include periodic unannounced and announced inspections by the FDA to assess compliance with cGMP requirements. If an FDA inspection of a manufacturer&#146;s facilities reveals conditions that the
FDA determines not to comply with applicable regulatory requirements, the FDA may issue observations through a Notice of Inspectional Observations, commonly referred to as a &#147;Form FDA 483&#148; report. If observations in the Form FDA 483 report
are not addressed in a timely manner and to the FDA&#146;s satisfaction, the FDA may issue a Warning Letter or proceed directly to other forms of enforcement action. Any failure by one of our contract manufacturers to comply with cGMP or to provide
adequate and timely corrective actions in response to deficiencies identified in a regulatory inspection could result in further enforcement action that could lead to a shortage of products and harm our business, including withdrawal of approvals
previously granted, seizure, injunction or other civil or criminal penalties. The failure of a manufacturer to address any concerns raised by the FDA or foreign regulators could also lead to plant shutdown or the delay or withholding of product
approval by the FDA in additional indications, or by foreign regulators in any indication. Certain countries may impose additional requirements on the manufacturing of drug products or drug substances, and on manufacturers, as part of the regulatory
approval process for products in such countries. The failure by our third-party manufacturers to satisfy such requirements could impact our ability to obtain or maintain approval of our products in such countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct our preclinical studies and
clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements, or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our
product candidates and our business could be substantially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely upon third
parties, including independent clinical investigators and third-party CROs, to conduct our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for
execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable
protocol, legal, regulatory, and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which
are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors,
principal investigators, and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require
us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP
regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of
resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is
substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may require us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have
an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our
creditors, or if we are liquidated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a limited number of third-party service providers that specialize or have the expertise
required to achieve our business objectives. If any of our relationships with these third-party laboratories, CROs or clinical investigators terminate, we may not be able to enter into arrangements with alternative laboratories, CROs, or
investigators or to do so in a timely manner or on commercially reasonable terms. If laboratories, CROs, or clinical investigators do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be
replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our preclinical or clinical protocols, regulatory requirements or for other reasons, our preclinical or clinical trials may be
extended, delayed, or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be
harmed, our costs could increase, and our ability to generate revenues could be delayed. Switching or adding additional laboratories or CROs (or investigators) involves additional cost and requires management time and focus. In addition, there is a
natural transition period when a new laboratory or CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher
workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our contracted laboratories and CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or
that these delays or challenges will not have a material adverse impact on our business, financial condition, and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition,
clinical investigators may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or
actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the preclinical study or clinical trial, the integrity of the data generated at the applicable preclinical study or clinical
trial site may be questioned and the utility of the preclinical study or clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA. Any such delay or rejection could prevent us from commercializing our
clinical-stage product candidate or any future product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not realize the benefits of any existing or future collaborative or
licensing arrangement, and if we fail to enter into new strategic relationships our business, financial condition, commercialization prospects, and results of operations may be materially adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund
expenses. Therefore, for some of our product candidates, we may decide to enter into new collaborations with pharmaceutical or biopharmaceutical companies for the development and potential commercialization of those product candidates. For instance,
we have a discovery collaboration with Takeda pursuant to which we are collaborating on the development of certain product candidates, we are obligated to conduct certain development activities, and pursuant to which Takeda has an option to acquire
a commercial license to these product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Collaborations
are complex and time-consuming to negotiate and document. We may also be restricted under existing and future collaboration agreements from entering into agreements on certain terms with other potential collaborators. We may not be able to negotiate
collaborations on acceptable terms, or at all. If our strategic collaborations do not result in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
successful development and commercialization of product candidates, or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or
royalty payments under the collaboration. Moreover, our estimates of the potential revenue we are eligible to receive under our strategic collaborations may include potential payments related to therapeutic programs for which our collaborators have
discontinued development or may discontinue development in the future. If that were to occur, we may have to curtail the development of a particular product candidate, reduce or delay its development program or one or more of our other development
programs, delay its potential commercialization or reduce the scope of our sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our
expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring
our product candidates to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In instances where we do enter into collaborations, we could be subject to
the following risks, each of which may materially harm our business, commercialization prospects, and financial condition: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not be able to control the amount and timing of resources that is required of us to complete our
development obligations or that the collaboration partner devotes to the product development or marketing programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the collaboration partner may experience financial difficulties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a
clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be required to relinquish important rights such as marketing, distribution, and intellectual property
rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary
information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation
and potential liability; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a collaborator could move forward with a competing product developed either independently or in collaboration
with third parties, including our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and our collaboration partner may disagree regarding the development plan for product candidates on which we
are collaborating (for example, we may disagree with a collaboration partner regarding target indications, inclusion or exclusion criteria for a clinical trial, or the decision to seek front line therapy approval versus second, third, or fourth line
therapy approval); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes may arise between the collaborators and us that result in the delay or termination of the research,
development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">business combinations or significant changes in a collaborator&#146;s business strategy may adversely affect our
willingness to complete our obligations under any arrangement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue
further development or commercialization of the applicable product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we license products or businesses, we
may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve
the results, revenue, or specific net income that justifies such transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>To date, we have relied on one single-source supplier for bulk drug substance. The loss of this
supplier or its failure to supply us with BDS on a timely basis could cause our ability to develop our product candidates and adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We depend on one single-source supplier for bulk drug substance, or BDS. Although we believe that we have a substantial reserve of BDS to
support our current clinical trial programs, there can be no assurance that our supply of BDS will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. Additionally, we do not have any control
over the process or timing of the acquisition or manufacture of materials by our supplier, and cannot ensure that it will deliver to us the BDS we order on time, or at all. The loss of BDS provided by this supplier could require us to change the
design of our product candidate development process based on the functions, limitations, features, and specifications of the replacement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting
demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources, or reduced manufacturing yields, any of which would negatively impact our operating
results. Our reliance on this single-source supplier exposes us to certain risks, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our supplier may cease or reduce production or deliveries, raise prices, or renegotiate terms;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may be unable to locate a suitable replacement on acceptable terms or on a timely basis, if at all;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if there is a disruption to our single-source supplier&#146;s operations, and if we are unable to enter into
arrangements with alternative suppliers, we may need to halt our clinical trial programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays caused by supply issues may harm our reputation, frustrate our customers, and cause them to turn to our
competitors for future projects; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop our product candidates could be materially and adversely impacted if the single-source
supplier upon which we rely were to experience a significant business challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality compliance issues, or
other financial, legal, regulatory, or reputational issues. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, to meet anticipated demand, our single-source
supplier may need to increase manufacturing capacity, which could involve significant challenges. This may require us and our supplier to invest substantial additional funds and hire and retain the technical personnel who have the necessary
experience. Neither we nor our supplier may successfully complete any required increase to existing manufacturing capacity in a timely manner, or at all. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain sufficient raw and intermediate materials on a timely basis or if we experience other manufacturing or supply difficulties,
our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacture of certain of our product candidates requires the timely delivery of
sufficient amounts of raw and intermediate materials. We work closely with our suppliers to ensure the continuity of supply, but cannot guarantee these efforts will always be successful. Further, while efforts are made to diversify our sources of
raw and intermediate materials, in certain instances we acquire raw and intermediate materials from a sole supplier. While we believe that alternative sources of supply exist where we rely on sole supplier relationships, there can be no assurance
that we will be able to quickly establish additional or replacement sources for some materials. A reduction or interruption in supply, and an inability to develop alternative sources for such supply, could adversely affect our ability to manufacture
our product candidates in a timely or cost-effective manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Supply sources could be interrupted from time to time and, if interrupted, there is no
guarantee that supplies could be resumed within a reasonable time frame and at an acceptable cost or at all. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on our
manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials. There are a limited number of suppliers for raw materials that we use to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacture our drugs and there may be a need to assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for
our clinical trials, and if approved, ultimately for commercial sale. We do not have any control over the process or timing of the acquisition of these raw materials by our manufacturers. Moreover, we currently do not have any agreements for the
commercial production of these raw materials. We cannot be sure that these suppliers will remain in business, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these
materials for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event a new supplier must be used. The time and effort to
qualify a new supplier could result in additional costs, diversion of resources, or reduced manufacturing yields, any of which would negatively impact our operating results. Although we generally do not begin a clinical trial unless we believe we
have a sufficient supply of a product candidate to complete the clinical trial, any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a
third-party manufacturer could considerably delay completion of our clinical trials, product testing, and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase these raw materials after regulatory
approval has been obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product
candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property and Information Technology </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We rely on patents and other intellectual property rights to protect our technology, including product candidates and our ARC and GADLEN platforms, the
prosecution, enforcement, defense, and maintenance of which may be challenging and costly. Failure to protect or enforce these rights adequately could harm our ability to compete and impair our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on obtaining and maintaining patents and other forms of intellectual property rights for technology
related to our product candidates, including, but not limited to, our ARC and GADLEN platforms, product candidates, methods used to manufacture those product candidates, formulations thereof, and the methods for treating patients using those product
candidates. Given that the development of our technology and product candidates is at an early stage, our intellectual property portfolio with respect to certain aspects of our technology and product candidates is also at an early stage. We seek to
protect our proprietary position by filing patent applications in the United States and abroad related to our novel platform technologies and product candidates that are important to our business. The patent prosecution process is expensive and
time-consuming, and we may not be able to prepare, file, and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, during the patent prosecution process, we may receive rejections. Although
we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance, scope,
validity, enforceability, and commercial value of our current or future patent rights are highly uncertain. It is possible that we will fail to identify patentable aspects of inventions made in the course of development and commercialization
activities before it is too late to obtain patent protection on them. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively
prevent others from commercializing competitive technologies and product candidates. The patent examination process may require us to narrow the scope of the claims of our pending and future patent applications, which may limit the scope of patent
protection that may be obtained. Further, even if we obtain patents with sufficient scope to protect our technology or product candidates in their present forms, future technical changes to our technology or product candidates may render the patent
coverage inadequate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that all of the potentially relevant prior art relating to our patents and patent applications
has been found. If such prior art exists, it can invalidate or narrow the scope of a patent or prevent a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may initiate opposition,
interference, <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, <I>inter partes</I> review, nullification, or derivation actions in court or before patent offices, or similar proceedings challenging the validity, ownership,
enforceability, or scope of such patents, which may result in the patent claims being narrowed, invalidated, or held unenforceable or circumvented. Because patent applications in the United States and other jurisdictions are confidential for a
period of time after filing, and some remain so until issued, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file any patent applications related
to such inventions. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications, and then only to the extent the issued claims cover
the technology. Furthermore, even where we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention where the other party can show that they used the invention in commerce before our filing date or the
other party benefits from a compulsory license. Additionally, our competitors or other third parties may be able to evade our patent rights by developing new antibodies, biosimilar antibodies, or alternative technologies or products in a <FONT
STYLE="white-space:nowrap">non-infringing</FONT> manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, given the amount of time required for the development, testing and
regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude
others from commercializing products similar or identical to ours. Moreover, some of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may in the future be,
<FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain an exclusive license to any such third-party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent applications,
such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we or our licensors may
need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents in order to enforce such patents against third parties, and such cooperation may not be
provided to us or our licensors. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other
provisions during the patent application process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO, foreign patent offices and patent courts or other authorities in granting patents and ruling on
claim scope and validity are not always applied uniformly or predictably. Patent positions of life sciences companies can be uncertain and involve complex factual, scientific, and legal questions. Changes in either the patent laws or their
interpretation in any jurisdiction that we seek patent protection may diminish our ability to protect our inventions, maintain and enforce our intellectual property rights; and, more generally, may affect the value of our intellectual property,
including the narrowing of the scope of our patents and any that we may license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to protect or to obtain, maintain or extend
adequate patent and other intellectual property rights could materially adversely affect our ability to develop and market our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our issued patents relating to one or more of our product candidates or our proprietary
platforms, including our ARC and GADLEN platforms, which could ultimately render our patents invalid or unenforceable and adversely affect our competitive position. Intellectual property litigation or other legal proceedings could cause us to spend
substantial resources and distract our personnel from their normal responsibilities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or other
intellectual property that relate to our ARC and GADLEN platforms and product candidates, their respective methods of use, manufacture, and formulations thereof. To protect our competitive position and counter infringement or unauthorized use, we
may from time to time need to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resort to litigation to enforce or defend any patents or other intellectual property rights owned or licensed by us by filing infringement claims. As enforcement of intellectual property rights
is difficult, unpredictable, time-consuming, and expensive, we may fail in enforcing our rights, in which case our competitors may be permitted to use our technology without being required to pay us any license fees. In addition, litigation
involving our patents carries the risk that one or more of our patents will be held invalid (in whole or in part, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">claim-by-claim</FONT></FONT> basis) or held unenforceable. Such
an adverse court ruling could allow third parties to commercialize our product candidates or methods, or our ARC or GADLEN platform, and then compete directly with us, without payment to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if resolved in our favor, such litigation and other legal proceedings may cause us to incur significant expenses and would be likely to
divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities, and may impact our reputation. In addition, there could be public announcements of the results of
hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings
could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors
may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
proceedings could have a material adverse effect on our ability to compete in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were to initiate legal proceedings
against a third party to enforce a patent related to one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States or in certain jurisdictions in Europe,
defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, novelty,
<FONT STYLE="white-space:nowrap">non-obviousness,</FONT> written description or enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the
USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar invalidity and/or unenforceability claims before administrative bodies in the United States or abroad, even outside the context of litigation through
opposition, interference, <FONT STYLE="white-space:nowrap">re-examination,</FONT> post-grant review, <I>inter partes</I> review, nullification, or derivation actions or proceedings. The outcome following legal assertions of invalidity and
unenforceability during patent litigation or administrative proceedings is unpredictable. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent
protection on one or more of our technologies, product candidates, methods or certain aspects of our ARC or GADLEN platform. Such a loss of patent protection could have a material adverse impact on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is also a risk that, even if the validity of our patents is upheld, the court will construe our patent&#146;s claims narrowly or decide
that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover our own products or the other party&#146;s products. Even if we establish infringement, the court may decide
not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. Patents and other intellectual property rights also will not protect our technology if competitors design around our
protected technology without infringing our patents or other intellectual property rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may fail to identify relevant third-party patents or may incorrectly interpret the relevance,
scope, or expiration of a third-party patent which might adversely affect our ability to develop our ARC and GADLEN platforms and product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that our operations and activities do not, or will not in the future, infringe existing or future patents. We also cannot
guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each
and every third-party patent and pending application in the United States and abroad that is relevant to our ARC or GADLEN platform or necessary for the commercialization of our product candidates in any jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third parties. Our competitors in both
the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained or may in the future apply for and obtain,
patents that will prevent, limit, or otherwise interfere with our ability to make, use, and sell our product candidates. We do not always conduct independent reviews of pending patent applications of and patents issued to third parties. Patent
applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S.
applications that will not be filed outside the United States can remain confidential until patents are issued. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, and unintentionally
abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our product candidates, or the
use thereof. As such, there may be applications of third parties now pending or recently revived patents of which we are unaware. These applications may later result in issued patents, or the revival of previously abandoned patents, that will
prevent, limit, or otherwise interfere with our ability to make, use, or sell our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope of a patent claim is
determined by an interpretation of law and, among other considerations, the written disclosure in a patent and the patent&#146;s prosecution history. The claim scope sought in a patent application can be significantly reduced before the patent is
issued, and its scope can be reinterpreted or further altered even after patent issuance, including through interferences, post-grant proceedings, opposition proceedings, or other intellectual property proceedings to address issues or errors that
may render claims of the issued patent either wholly or partially invalid or unenforceable. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our
product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#146;s pending application will issue with claims of relevant scope. Our
determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. We cannot provide any assurances that
third-party patents do not exist which might be enforced against our current technology, including our platform technologies, product candidates and their respective methods of use, manufacture, and formulations thereof, and could result in either
an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual property rights of third parties could adversely affect our ability to develop or commercialize our product candidates, such that we could
be required to litigate or obtain licenses from third parties in order to develop or market our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial
success depends, in part, on our ability to develop, manufacture, market, and sell our product candidates without infringing, or otherwise violating the intellectual property and other proprietary rights of third parties. Our competitive position
may suffer if patents issued to third parties or other third-party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intellectual property rights cover our methods or product candidates or elements thereof, our manufacture or uses relevant to our development plans, our product candidates or other attributes of
our product candidates, or our ARC or GADLEN platform. In such cases, we may not be in a position to develop or commercialize product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property
right concerned, which can be expensive and time-consuming, or have to enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party
to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our product candidates. Parties making claims against us may seek and obtain injunctive or other equitable relief, which could
effectively block our ability to further develop and commercialize our product candidates. We will vigorously defend the claims asserted against us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are sued for patent infringement, we would need to demonstrate that our product candidates or platform technologies either do not
infringe the patent claims of a relevant patent or that the patent claims are invalid or unenforceable, and we may not be able to do this. Proving invalidity may be difficult. For example, in the United States, proving invalidity in court requires a
showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. We may not have sufficient resources to bring these actions to a successful conclusion. If we are unable to successfully settle future claims
on terms acceptable to us, we may be required to engage or continue costly, unpredictable, and time-consuming litigation and may be prevented from or experience substantial delays in marketing our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our involvement in litigation, and in any interferences, post-grant proceedings, opposition proceedings, or other intellectual property
proceedings inside and outside of the United States may divert management from focusing on business operations, and even if we are successful in these proceedings, we may incur substantial costs and the time and attention of our management and
scientific personnel could be diverted in pursuing these proceedings, which could have a material adverse effect on our business and operations. In addition, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any current and potential intellectual property litigation also could force us to do one or more of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">stop marketing, selling, incorporating, manufacturing, or using our product candidates or any products, if
approved, in the United States and/or other jurisdictions that use the subject intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obtain from a third party asserting its intellectual property rights, a license to sell or use the relevant
technology, including the obligation to pay royalties, which license may not be available on reasonable terms, or at all, or may be <FONT STYLE="white-space:nowrap">non-exclusive</FONT> thereby giving our competitors access to the same technologies
licensed to us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redesign those products or processes that use any allegedly infringing or misappropriated technology, which may
result in significant cost or delay to us, or which redesign could be impossible or technically infeasible; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay damages, including the possibility of treble damages and attorneys&#146; fees in a patent case if a court
finds us to have willfully infringed certain intellectual property rights. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may need to obtain additional licenses of
third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own and are pursuing rights to the intellectual property, including patent applications relating to our ARC platform and our product
candidates. From time to time, we may be required to license technologies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
relating to our therapeutic research programs from additional third parties to further develop or commercialize our platform technologies and product candidates. The targets of our product
candidates have also been the subject of research by many companies that have filed patent applications or have patents related to such targets and therapeutic methods relating to those targets. There can be no assurance any such patents will not be
asserted against us or that we will not need to seek licenses from such third parties. We may not be able to secure such licenses on acceptable terms, if at all, and any such litigation would be costly and time-consuming. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should we be required to obtain licenses to any third-party technology, including any such patents required to manufacture, use, or sell our
product candidates, the growth of our business will likely depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> maintain, or use these proprietary rights. The inability to obtain any third-party license
required to develop or commercialize any of our product candidates could cause us to abandon any related efforts, which could seriously harm our business and operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations
may be held by others. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary
for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual
property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to
license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
thereby giving our competitors access to the same technologies licensed to us. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of a product candidate or program, we may have
to abandon development of that product candidate or program and our business and financial condition could suffer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We depend on intellectual
property licensed from third parties and if we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing
and protecting our product candidates or we could lose certain rights to grant sublicenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current licenses impose, and any
future licenses we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and/or other obligations on us. If we breach any of
these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop,
manufacture, and sell any future products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors may own or control intellectual property that has not been licensed to us
and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#146;s rights. In addition, while we cannot determine currently the amount of the royalty obligations we would be
required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and
commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the
licensor that is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the sublicensing of patent and other rights under our collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from
the joint creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain
provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property
or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.
Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the
affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may rely on third parties from whom we license proprietary technology to file and prosecute patent applications and maintain patents and
otherwise protect the intellectual property rights we license from them. We may have limited control over these activities or any other intellectual property rights that may be related to our <FONT STYLE="white-space:nowrap">in-licensed</FONT>
intellectual property rights. For example, we cannot be certain that such activities by these licensors will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual
property rights. Therefore, these patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We may have limited control over the manner in which our licensors initiate an
infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property rights that may be licensed to us. It is possible that the licensors&#146; infringement proceeding or defense
activities may be less vigorous than if we conduct them ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks and trade names are not adequately protected, then we may not
be able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our registered or
unregistered trademarks or trade names may be challenged, infringed, circumvented, or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to
build name recognition by potential collaborators, partners, or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete
effectively and our business may be adversely affected. If other entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our use of our current trademarks throughout the world. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those
rejections, we may be unable to overcome such rejections. In addition, in both the USPTO and comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel
registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to
compete effectively and our business may be adversely affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may license our trademarks and trade names to third parties, such as distributors. Though
these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill
associated with our trademarks and trade names. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidates for an
adequate amount of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the
natural expiration of a patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is
limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including biosimilar medications. In addition, although upon issuance
in the United States a patent&#146;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have
sufficient patent life to protect our product candidates and any products, if approved, our business and results of operations will be adversely affected. Given the amount of time required for the development, testing, and regulatory review of new
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing
products similar or identical to ours. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain protection under the Hatch-Waxman Amendments and similar
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration, and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be
eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a
patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining
term of a patent beyond a total of 14 years from the date of product approval, and only claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. However, we may not receive an extension if
we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents, or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to
obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products
sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We enjoy only limited geographical protection with
respect to certain patents and may not be able to protect our intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents are of
national or regional effect. While we will endeavor to try to protect our technologies, products and product candidates with intellectual property rights such as patents throughout the world, as appropriate, the process of obtaining patents is
time-consuming, expensive, and sometimes unpredictable in other countries. We may not be able to file, prosecute, maintain, enforce, or license all necessary or desirable patent rights at a commercially reasonable cost or in a timely manner. In
addition, we may not pursue or obtain patent protection in all markets. As such, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using
our inventions in and into the United States or other jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">International applications under the Patent Cooperation Treaty, or PCT, are usually filed
within 12 months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in additional jurisdictions where we believe our product candidates may be marketed. We have not, and will not, file for
patent protection in all national and regional jurisdictions where such protection may be available. Filing, prosecuting, and defending patents on all of our research programs and product candidates in all countries throughout the world would be
prohibitively expensive, and, therefore, the scope and strength of our intellectual property rights will vary from jurisdiction to jurisdiction. In addition, we may decide to abandon national and regional patent applications before grant. Finally,
the grant proceeding of each national/regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. Further, the
standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. It is common that depending on the country, the scope of patent protection may vary for the same product candidate and/or
technology. As such, we do not know the degree of future protection that we will have on our technologies and product candidates in different jurisdictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may use our or our collaboration partners&#146; technologies in jurisdictions where we have not obtained patent protection to
develop their own products and, further, may export otherwise infringing products to territories where we or our collaboration partners have patent protection, but enforcement is not as strong as that in the United States. These products may compete
with our product candidates, and our or our collaboration partners&#146; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions, particularly certain developing countries, do not protect intellectual property rights, particularly those
relating to pharmaceuticals or biologics, to the same extent as laws in the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. Consequently, we may not be able
to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. If we encounter difficulties in
protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in
those jurisdictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our
efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We
may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain
significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some countries, including China and India,
have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries,
the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired
and our business and results of operations may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become subject to claims challenging the inventorship or ownership of
our patents and other intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally enter into confidentiality and intellectual property assignment
agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, those agreements may not be
honored </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes regarding
ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute
could be expensive and time consuming. If we were unsuccessful, we could lose valuable rights in intellectual property that we regard as our own. In addition, interferences, post-grant proceedings, opposition proceedings, derivation proceedings, or
other intellectual property proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship
disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting
obligations of third parties involved in developing our product candidates or as a result of questions regarding <FONT STYLE="white-space:nowrap">co-ownership</FONT> of potential joint inventions. Litigation may be necessary to resolve these and
other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we fail in defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in
defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellectual
property rights do not necessarily address all potential threats to our competitive advantage. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection
afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. Moreover, if a third party has
intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may be able to make product candidates similar to our product candidates but that are not covered by the
claims of the patents that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the patents of third parties may have an adverse effect on our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or any future strategic partners might not have been the first to conceive or reduce to practice the
inventions covered by the issued patent or pending patent application that we own or have exclusively licensed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we or any future strategic partners might not have been the first to file patent applications covering certain of
our inventions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing, misappropriating, or otherwise violating our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">it is possible that our pending patent applications will not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issued patents that we own or have exclusively licensed may not provide us with any competitive advantage, or may
be held invalid or unenforceable, as a result of legal challenges by our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we cannot predict the degree and range of protection any issued patents will afford us against competitors,
whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications, or whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">third parties performing manufacturing or testing for us using our product candidates or technologies could use
the intellectual property of others without obtaining a proper license; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may not develop additional technologies that are patentable. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these events occur, they could significantly harm our business, results of operations, and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Composition of matter patents for biological and pharmaceutical products such as our product candidates are generally considered to be the
strongest form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications covering composition of
matter of our product candidates will be considered patentable by the USPTO or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign
countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the
scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products <FONT STYLE="white-space:nowrap">&#147;off-label.&#148;</FONT> Although <FONT
STYLE="white-space:nowrap">off-label</FONT> prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product
candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property,
particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological complexity and legal complexity. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain
circumstances and weakened the rights of patent owners in certain situations. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming, and inherently uncertain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2011, the America Invents Act, or the AIA, was enacted in the United States, resulting in significant changes to the U.S. patent
system. An important change introduced by the AIA was a transition to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system for deciding which party should be granted a patent when two or
more patent applications are filed by different parties claiming the same invention, which went into effect on March&nbsp;16, 2013. Therefore, a third party that now files a patent application in the USPTO before we do could be awarded a patent
covering an invention of ours even if we created the invention before it was created by the third party. While we are cognizant of the time from invention to filing of a patent application, circumstances could prevent us from promptly filing patent
applications for our inventions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among some of the other changes introduced by the AIA were changes that limit where a patentee may file
a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary
standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to
invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a
defendant in a district court action. The AIA and its continued implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, and the patent applications of our collaborators, and the enforcement
or defense of our issued patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and
regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enforce our existing patents and patents that we might obtain in the future. For example, in the case, <I>Assoc. for Molecular Pathology v. Myriad Genetics, Inc.</I>, the U.S. Supreme Court held
that certain claims to DNA molecules are not patentable. While we do not believe that any of the patents owned or licensed by us will be found invalid based on this decision, we cannot predict how future decisions by the courts, the U.S. Congress or
the USPTO may impact the value of our patents. Similarly, there is complexity and uncertainty related to European patent laws. For example, European patent laws are stringent in the type of amendments that are allowed during prosecution, and the
complexity and uncertainty of European patent laws has also increased in recent years. These limitations and requirements could adversely affect our ability to obtain new patents in the future that may be important for our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may rely on trade secret and proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> which can be difficult to trace and enforce and, if we are
unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to
seeking patents for some of our technology and product candidates, we may rely on trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> to protect our technology, especially where patent protection is believed to be of
limited value, to maintain our competitive position with respect to our research programs and product candidates. Elements of our product candidates, including processes for their preparation and manufacture, may involve proprietary <FONT
STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> to be our primary intellectual
property. Any disclosure, either intentional or unintentional, by our employees or by other third parties of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus adversely
eroding our competitive position in our market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> can be
difficult to protect or maintain as confidential. To protect this type of information against disclosure or appropriation by competitors, we generally require our employees, consultants, contractors, collaborators, advisors, and other third parties
to enter into confidentiality agreements with us. Despite these efforts, any of these parties may unintentionally or willfully breach the agreements and disclose our confidential information, and confidentiality agreements may not provide an
adequate remedy in the event of unauthorized disclosure of confidential information. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be
effective. Enforcing a claim that a third party obtained illegally and is using trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how</FONT> is also expensive, time-consuming, and unpredictable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction. The laws of some foreign countries do not protect
proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. Furthermore,
if a competitor lawfully obtained or independently developed any of our trade secrets, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.
Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, some courts inside and outside the United States are
less willing or are unwilling to protect trade secrets or other proprietary information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trade secrets can over time be disseminated
within the industry through independent development, the publication of journal articles and the movement of personnel skilled in the art from company to company or academic to industry scientific positions. Though our agreements with third parties
typically restrict the ability of our employees, consultants, contractors, collaborators, advisors, and other third parties to publish data potentially relating to our trade secrets, our agreements may contain certain limited publication rights.
Because from time to time we expect to rely on third parties in the development, manufacture, and distribution of our product candidates and provision of our services, we must, at times, share trade secrets with them. Despite employing the
contractual and other security precautions described above, the need to share trade secrets increases the risk that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. If any of our trade
secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be
disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, our
competitors may independently develop substantially equivalent trade secrets, proprietary information, or <FONT STYLE="white-space:nowrap">know-how</FONT> and may even apply for patent protection in respect of the same. If successful in obtaining
such patent protection, our competitors could limit our use of our trade secrets and/or confidential <FONT STYLE="white-space:nowrap">know-how.</FONT> Under certain circumstances and to make it more likely that we have our freedom to operate, we may
also decide to publish some <FONT STYLE="white-space:nowrap">know-how</FONT> to make it difficult for others to obtain patent rights covering such <FONT STYLE="white-space:nowrap">know-how,</FONT> at the risk of potentially exposing our trade
secrets to our competitors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to third-party claims asserting that our employees, consultants, contractors, collaborators, or
advisors have misappropriated or wrongfully used or disseminated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our employees, including our senior management, were previously employed at universities or at other biopharmaceutical companies,
including our competitors or potential competitors. Some of these employees executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements in connection
with such previous employment. Similarly, we work with consultants, contractors, collaborators, advisors, or other third parties who have worked with, and do currently work with, other companies, including our competitors or potential competitors,
and have executed proprietary rights, <FONT STYLE="white-space:nowrap">non-disclosure,</FONT> and <FONT STYLE="white-space:nowrap">non-competition</FONT> agreements in connection with such other companies. Although we try to ensure that our
employees, consultants, contractors, collaborators, advisors, or other third parties do not use or disclose the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims
that we or these employees or individuals that we work with have used or disclosed confidential information or intellectual property of others, including trade secrets or other proprietary information, or that we caused an individual to breach the
terms of his or her <FONT STYLE="white-space:nowrap">non-competition</FONT> or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement with a current or former employer or competitor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Litigation may be necessary to defend against these claims and, even if we are successful, could result in substantial costs and could be a
distraction to management, our employees, and our routine business. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or sustain damages.
Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to develop or commercialize our technology or product candidates. Such a license may not be available on
commercially reasonable terms or at all. Moreover, any such litigation or the threat thereof may adversely affect our reputation and our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors
or hire employees or consultants, each of which would have an adverse effect on our business, results of operations, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over
the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent
lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in
partial or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to
official actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees, and failure to properly legalize and submit formal documents within prescribed time limits. If we fail to maintain the patents and patent
applications covering our product candidates or if we otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would have an adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our information technology systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches, which could
adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We collect and maintain information in digital form that is necessary to conduct our business, and
we are dependent on our information technology systems and those of third parties to operate our business. In the ordinary course of our business, we collect, store, and transmit large amounts of confidential information, including intellectual
property, proprietary business information, and personal information, and data to comply with cGMP and data integrity requirements. It is critical that we do so in a secure manner to maintain data security and data integrity of such information. We
have established physical, electronic, and organizational measures to safeguard and secure our systems to prevent a data compromise. We have also outsourced elements of our information technology infrastructure, and as a result a number of
third-party vendors may or could have access to our confidential information. Despite the implementation of security measures, our information technology systems and data and those of our current or future CROs or other contractors and consultants
are vulnerable to compromise or damage from computer hacking, malicious software, fraudulent activity, employee misconduct, human error, telecommunication and electrical failures, natural disasters, or other cybersecurity attacks or accidents.
Future acquisitions could expose us to additional cybersecurity risks and vulnerabilities from any newly acquired information technology infrastructure. Cybersecurity attacks are constantly increasing in sophistication and are made by groups and
individuals with a wide range of motives (including industrial espionage) and expertise, including by organized criminal groups, &#147;hacktivists,&#148; nation states, and others. As a company with an increasingly global presence, our systems are
subject to frequent attacks and have been targeted been foreign actors for purposes of economic espionage. Due to the nature of some of these attacks, there is a risk that an attack may remain undetected for a period of time. While we continue to
make investments to improve the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any cybersecurity incident could adversely affect our business, by leading to, for example, the loss of trade secrets or other intellectual
property, demands for ransom or other forms of blackmail, or the unauthorized disclosure of personal or other sensitive information of our employees, clinical trial patients, customers, and others. Although to our knowledge we have not experienced
any material cybersecurity incident to date, if such an event were to occur, it could seriously harm our development programs and our business operations. We could be subject to regulatory actions taken by governmental authorities, litigation under
laws that protect the privacy of personal information, or other forms of legal proceedings, which could result in significant liabilities or penalties. Further, a cybersecurity incident may disrupt our business or damage our reputation, which could
have a material adverse effect on our business, prospects, operating results, share price, stockholder value, and financial condition. We could also incur substantial remediation costs, including the costs of investigating the incident, repairing or
replacing damaged systems, restoring normal business operations, implementing increased cybersecurity protections, and paying increased insurance premiums. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Ownership of Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
stock price may be volatile or may decline regardless of our operating performance, resulting in substantial losses for investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our common stock may be highly volatile and may fluctuate substantially as a result of a variety of factors, some of which
are related in complex ways. The market price of our common stock may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fluctuate significantly in response to numerous factors, many of which are beyond our control, including the factors listed below and other factors describe in this &#147;Risk Factors&#148;
section: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commencement, enrollment, or results of current and future preclinical studies and clinical trials and trials
we may conduct, or changes in the development status of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse
development with respect to the applicable regulatory authority&#146;s review of such filings, including, without limitation, the issuance by the FDA of a &#147;refusal to file&#148; letter or a request for additional information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse results or delays in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our decision to initiate a preclinical study or clinical trial, not to initiate a preclinical study or clinical
trial or to terminate an existing preclinical study or clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">adverse actions taken by regulatory agencies with respect to our preclinical studies or clinical trials,
manufacturing supply chain or sales and marketing activities, including failure to receive regulatory approval of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in laws or regulations, including, but not limited to, preclinical study or clinical trial requirements
for approvals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any adverse changes to our relationship with manufacturers or suppliers; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing, supply or distribution shortages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions or departures of key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unanticipated serious safety concerns related to the use of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our
ability to obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our results of operations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our cash position; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to
the public; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publication of research reports about us or our industry, or immuno-oncology in particular, or positive or
negative recommendations or withdrawal of research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements made by us or our competitors of new product and service offerings, acquisitions, strategic
relationships, joint ventures, or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to establish collaborations, if needed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to effectively manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the size and growth of our initial cancer target markets; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to successfully treat additional types of cancers or at different stages; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">press reports, whether or not true, about our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales or perceived potential sales of our common stock by us or our stockholders in the future;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">overall fluctuations in the equity markets; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in accounting practices or principles; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes or developments in the global regulatory environment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">litigation involving us, our industry or both, or investigations by regulators into our operations or those of
our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general, and the Nasdaq Stock Market, or Nasdaq, and biopharmaceutical companies in particular, have
experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock,
regardless of our actual operating performance. If the market price of our common stock after this offering does not exceed the initial public offering price, you may not realize any return on, and may lose some or all of, your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We could be subject to securities class action litigation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price
of a company&#146;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#146;s attention and resources, which would harm our business, operating results, or financial condition.
Additionally, the dramatic increase in the cost of directors&#146; and officers&#146; liability insurance may cause us to opt for lower overall policy limits or to forgo insurance that we may otherwise rely on to cover significant defense costs,
settlements, and damages awarded to plaintiffs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders and management own a significant percentage of our stock and will be
able to exert significant control over matters subject to stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates owned
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding voting stock and, upon the closing of this offering, that same group will own
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding voting stock (assuming no exercise of the underwriters&#146; option to purchase additional shares). Therefore, even
after this offering these stockholders will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to
control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common
stock that you may feel are in your best interest as one of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of our common stock in the public market could cause our
common stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock price could decline as a result of sales of a large number of shares of common stock
after this offering or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem
appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this
offering,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock will be outstanding (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares if the underwriters exercise their option to purchase additional shares from us in full), based on the number of shares outstanding as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All shares of common stock expected to be sold in this offering will be freely tradable
without restriction or further registration under the Securities Act unless held by our &#147;affiliates&#148; as defined in Rule 144 under the Securities Act. The resale of the
remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares of common
stock following this offering, is currently prohibited or otherwise restricted as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our stockholders with the underwriters in connection with this offering. However, subject to applicable securities law restrictions, these shares will be able to be sold in
the public market beginning 181 days after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for
sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements and/or <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, as well as
Rules 144 and 701 under the Securities Act. For more information, see &#147;Shares Eligible for Future Sale.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of
this offering, the holders of approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of
our outstanding shares following this offering, of our common stock will have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements
that we may file for ourselves or our other stockholders. We also intend to register the offer and sale of all shares of common stock that we may issue under our equity compensation plans. Once we register the offer and sale of shares for the
holders of registration rights and shares that may be issued under our equity incentive plans, these shares will be able to be sold in the public market upon issuance, subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements
described under &#147;Underwriting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the future, we may issue additional shares of common stock, or other equity or
debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement, or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our
common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>There has been no prior public market for our common stock, and an active trading market may not develop or be sustained.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been no public market for our common stock prior to this offering. The initial public offering price for our common
stock was determined through negotiations among the underwriters and us and may vary from the market price of our common stock following this offering. An active or liquid market in our common stock may not develop upon closing of this offering or,
if it does develop, it may not be sustainable. The lack of an active market may impair the value of your shares, your ability to sell your shares at the time you wish to sell them and the prices that you may obtain for your shares. An inactive
market may also impair our ability to raise capital by selling our common stock and our ability to acquire other companies, products, or technologies by using our common stock as consideration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our management team has broad discretion to use the net proceeds from this offering and its investment of these proceeds may not yield a favorable
return. They may invest the net proceeds from this offering in ways with which investors disagree. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use a portion of
the net proceeds from this offering to advance SL-172154 through the completion of our ongoing and planned Phase 1 clinical trials and to commence a Phase 2 clinical program, to advance SL-279252 through the completion of our ongoing Phase 1
clinical trial, and to develop and advance additional product candidates derived from our platforms through IND-enabling studies and to commence Phase 1 clinical trials. See &#147;Use of Proceeds.&#148; However, within the scope of our plan, and in
light of the various risks to our business, including those discussed in this &#147;Risk Factors&#148; section and elsewhere in this prospectus, our management will have broad discretion over the use of net proceeds from this offering, and could
spend the net proceeds in ways our stockholders may not agree with or that do not yield a favorable return, if at all. If we do not invest or apply the net proceeds from this offering in ways that improve our operating results, we may fail to
achieve expected financial results, which could cause our stock price to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts either do not publish research about us or publish inaccurate or
unfavorable research about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the trading price or trading volume of our common stock could decline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will be influenced in part by the research and reports that securities or industry analysts may publish
about us, our business, our market, or our competitors. If one or more of these analysts initiate research with an unfavorable rating or downgrade our common stock, provide a more favorable recommendation about our competitors or publish inaccurate
or unfavorable research about our business, our common stock price would likely decline. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets,
which in turn could cause the trading price or trading volume of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase shares of our common stock in our
initial public offering, you will experience substantial and immediate dilution. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, is substantially higher than the net tangible book
value per share of our outstanding common stock immediately following the completion of this offering. If you purchase shares of common stock in this offering, you will experience substantial and immediate dilution in the pro forma net tangible book
value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share as of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . That is because the
price that you pay will be substantially greater than the pro forma net tangible book value per share of the common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than the
assumed initial public offering price when they purchased their shares of our capital stock. You will experience additional dilution when those holding stock options exercise their right to purchase common stock under our equity incentive plans or
when we otherwise issue additional shares of common stock. See &#147;Dilution.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company, and any decision on our
part to comply only with certain reduced reporting and disclosure requirements applicable to emerging growth companies could make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company&#148; as defined in the JOBS Act and, for as long as we continue to be an emerging growth company, we
may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging growth companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to have our independent registered public accounting firm audit our internal control over
financial reporting under Section&nbsp;404 of the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations regarding executive compensation in our periodic reports and annual report on Form
<FONT STYLE="white-space:nowrap">10-K;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements of holding <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on
executive compensation and stockholder approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could be
an emerging growth company for up to five years following the completion of our initial public offering. Our status as an emerging growth company will end as soon as any of the following takes place: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the fiscal year in which we have more than $1.07&nbsp;billion in annual revenue;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date we qualify as a &#147;large accelerated filer,&#148; with at least $700&nbsp;million of equity
securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which we have issued, in any three-year period, more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the last day of the fiscal year ending after the fifth anniversary of the completion of our initial public
offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict if investors will find our common stock less attractive if we choose to
rely on any of the exemptions afforded to emerging growth companies. If some investors find our common stock less attractive because we rely on any of these exemptions, there may be a less active trading market for our common stock and the market
price of our common stock may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised
accounting standards until such time as those standards apply to private companies. We elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private
companies until the earlier of the date that we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these financial statements
may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The
requirements of being a public company may strain our resources, result in more litigation, and divert management&#146;s attention. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street
Reform and Consumer Protection Act, or the Dodd-Frank Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial
compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our
business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our
internal control and procedures on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management
oversight may be required. As a result, management&#146;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may also need to hire additional employees or engage outside
consultants to comply with these requirements, which will increase our costs and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, changing laws, regulations, and
standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time consuming. These laws, regulations, and standards
are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in
continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations, and standards, and this
investment may result in increased general and administrative expenses and a diversion of management&#146;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations, and
standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely
affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These new rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in
the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our Board, particularly to serve on
our audit committee and compensation committee, and qualified executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By disclosing information in this prospectus and in
future filings required of a public company, our business and financial condition will become more visible, which we believe may result in threatened or actual litigation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our
favor, the time and resources needed to resolve them could divert our management&#146;s resources and seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to
maintain proper and effective internal controls over financial reporting our ability to produce accurate and timely financial statements could be impaired. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;404 of the Sarbanes-Oxley Act, our management will be required to report upon the effectiveness of our internal
control over financial reporting beginning with the annual report for our fiscal year ending December&nbsp;31, 2021. When we lose our status as an &#147;emerging growth company&#148; and a &#147;smaller reporting company&#148; and become an
&#147;accelerated filer&#148; or a &#147;large accelerated filer,&#148; our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules governing the
standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under
the Securities Exchange Act of 1934, as amended, or the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting
in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash flows. If we are unable to conclude that our internal
control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence
in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material
weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We must design our
disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the
time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance
that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or
executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons,
by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not currently intend to pay dividends on our common stock and, consequently, our stockholders&#146; ability to achieve a return on their
investment will depend on appreciation of the value of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our
common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in
the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not certain. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our second amended and restated certificate of incorporation and our amended and
restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second amended and restated certificate of incorporation and our amended and restated bylaws, each to be in effect immediately prior to the
completion of this offering, will contain provisions that could depress the market price of our common stock by acting to discourage, delay, or prevent a change in control of our company or changes in our management that the stockholders of our
company may deem advantageous. These provisions, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish a staggered Board divided into three classes serving staggered three-year terms, such that not all
members of the Board will be elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">authorize our Board to issue new series of preferred stock without stockholder approval and create, subject to
applicable law, a series of preferred stock with preferential rights to dividends or our assets upon liquidation, or with superior voting rights to our existing common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eliminate the ability of our stockholders to call special meetings of stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">eliminate the ability of our stockholders to fill vacancies on our Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">establish advance notice requirements for nominations for election to our Board or for proposing matters that can
be acted upon by stockholders at our annual stockholder meetings; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">permit our Board to establish the number of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that our Board is expressly authorized to make, alter or repeal our amended bylaws;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that stockholders can remove directors only for cause and only upon the approval of not less than 66<SUP
STYLE="vertical-align:top">2</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB><SUB STYLE="font-size:85%; vertical-align:bottom"></SUB>&nbsp;of all outstanding shares of our voting stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">require the approval of not less than 66<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB
STYLE="font-size:85%; vertical-align:bottom">3</SUB>&nbsp;of all outstanding shares of our voting stock to amend our bylaws and specific provisions of our certificate of incorporation; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">limit the jurisdictions in which certain stockholder litigation may be brought. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a Delaware corporation, we will be subject to the anti-takeover provisions of Section&nbsp;203 of the Delaware General Corporation Law,
which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in which the person
first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at <FONT STYLE="white-space:nowrap">least&nbsp;two-thirds&nbsp;of</FONT> the outstanding
disinterested shares. The application of Section&nbsp;203 of the Delaware General Corporation Law could also have the effect of delaying or preventing a change of control of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our second amended and restated certificate of incorporation will provide that the Court of Chancery of the State of Delaware will be the exclusive
forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second amended and restated certificate of incorporation to be in effect upon the completion of this offering will provide that, unless we
consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (1)&nbsp;any derivative action or proceeding brought on our behalf, (2)&nbsp;any action asserting a breach of a
fiduciary duty owed by any director, officer or other employee to us or our stockholders, (3)&nbsp;any action asserting a claim against us or any director, officer, or other employee arising pursuant to the Delaware General Corporation Law,
(4)&nbsp;any action to interpret, apply, enforce, or determine the validity of our second amended and restated certificate of incorporation or amended and restated bylaws, or (5)&nbsp;any other action asserting a claim that is governed by the
internal affairs doctrine, shall be the Court of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Chancery of the State of Delaware (or another state court or the federal court located within the State of Delaware if the Court of Chancery does not have or declines to accept jurisdiction), in
all cases subject to the court&#146;s having jurisdiction over indispensable parties named as defendants. In addition, our second amended and restated certificate of incorporation will provide that the federal district courts of the United States
will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act but that the forum selection provision will not apply to claims brought to enforce a duty or liability created by the Exchange Act.
Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our
directors and officers. Alternatively, if a court were to find the choice of forum provision contained in our second amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs
associated with resolving such action in other jurisdictions, which could harm our business, financial condition, and operating results. For example, under the Securities Act, federal courts have concurrent jurisdiction over all suits brought to
enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in our
shares of capital stock shall be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use our net operating loss carryforwards and other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2019, we had U.S. federal and state net operating loss, or NOL, carryforwards of $14.0 million and $0.2 million,
respectively, which may be available to offset future taxable income. As of December&nbsp;31, 2019, we also had federal tax credits of $2.3 million, which may be used to offset future tax liabilities. These NOLs and tax credit carryforwards will
begin to expire in 2036. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Use of our NOL carryforwards and tax credit carryforwards depends on many factors, including having current or
future taxable income, which cannot be assured. Our U.S. NOL and tax credit carryforwards could expire unused and be unavailable to offset future taxable income or income tax liabilities because of their limited duration or because of restrictions
under U.S. tax law. In addition, for taxable years beginning after December 31, 2020, the deductibility of federal NOLs generated in taxable years beginning after December 31, 2017 is limited to 80% of our taxable income in such year (after taking
into account utilization of NOLs generated in taxable years beginning before January 1, 2018), where taxable income is determined without regard to such NOL deduction itself. In addition, under Sections 382 and 383 of the Internal Revenue Code of
1986, as amended, or the Code, and certain corresponding provisions of state law, a corporation that undergoes an &#147;ownership change&#148; is subject to limitations on its ability to utilize its pre-change NOL and tax credit carryforwards to
offset future taxable income or taxes. For these purposes, an ownership change generally occurs where the aggregate stock ownership of one or more stockholders (or groups of stockholders), each of whom owns at least 5% of a corporation&#146;s stock,
increases by more than 50 percentage points over its lowest ownership percentage within a specified testing period. We believe we have experienced ownership changes in the past, and we believe it is likely that we will experience an additional
ownership change in the future as a result of this offering or subsequent shifts in our stock ownership, some of which are outside our control. If finalized, Treasury Regulations currently proposed under Section 382 of the Code may further limit our
ability to utilize our pre-change NOL and tax credit carryforwards if we undergo an additional ownership change as a result of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we earn taxable income in the future, we expect that our ability to use existing NOL and tax credit carryforwards to offset such taxable
income will be materially limited as a result of these ownership changes. The application of such limitations may cause U.S. federal income taxes (and possibly state income taxes) to be paid by us earlier than they otherwise would be paid if such
limitations were not in effect and could cause such NOLs and tax credit carryforwards to expire unused, in each case reducing or eliminating the benefit of such NOLs and tax credit carryforwards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent we are not able to offset our future taxable income with our NOLs or offset
future taxes with our tax credit carryforwards, this would adversely affect our operating results and cash flows. These same risks can arise in the context of state income and franchise tax given many states conform to federal law and rely on
federal authority for determining state NOLs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains &#147;forward-looking statements&#148; within the meaning of the federal securities laws, which statements are
subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this prospectus, including statements concerning our plans, objectives, goals,
strategies, future events, future revenues or performance, financing needs, plans or intentions relating to products and markets, and business trends and other information referred to under the sections entitled &#147;Prospectus Summary,&#148;
&#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business,&#148; are forward-looking statements. In some cases, you can identify forward-looking statements by
terms such as &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;objective,&#148; &#147;intend,&#148; &#147;should,&#148; &#147;could,&#148; &#147;can,&#148; &#147;would,&#148; &#147;expect,&#148; &#147;believe,&#148; &#147;design,&#148;
&#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;plan,&#148; or the negative of these terms, and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts, and
reflect our current views with respect to future events. Given the significant uncertainties, you should not place undue reliance on these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are a number of risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking
statements expressed or implied in this prospectus. Such risks, uncertainties and other factors include, among others, the following risks, uncertainties and factors: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recent and ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and associated <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our use of the net proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of the initiation, progress, and expected results of our preclinical studies, our clinical trials and
our research and development programs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain the continued service of our key executives and to identify, hire, and retain additional
qualified professionals; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to advance product candidates into, and successfully complete, preclinical studies and clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing or likelihood of regulatory filings and approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials
and for commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pricing, coverage, and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the implementation of our business model, strategic plans for our business, and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our
technology platforms, including our ARC and GADLEN platforms, and our product candidates, including the projected terms of patent protection; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of
such arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding the market opportunity for our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, capital requirements, and needs for additional financing and our ability to
obtain additional capital; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry, including competing product candidates and therapies.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be other factors that may cause our actual results to differ materially from the
forward-looking statements expressed or implied in this prospectus, including factors disclosed in &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; You should
evaluate all forward-looking statements made in this prospectus in the context of these risks and uncertainties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We caution you that the
risks, uncertainties, and other factors referred to above and elsewhere in this prospectus may not contain all of the risks, uncertainties and other factors that may affect our future results and operations. Moreover, new risks will emerge from time
to time. It is not possible for our management to predict all risks. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result
in the consequences or affect us or our business in the way expected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All forward-looking statements in this prospectus apply only as of
the date made and are expressly qualified in their entirety by the cautionary statements included in this prospectus. Except as required by law, we disclaim any intent to publicly update or revise any forward-looking statements to reflect subsequent
events or circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_4"></A>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We obtained the industry, market, and competitive position data used throughout this prospectus from our own internal estimates and research,
as well as from industry and general publications, and research, surveys, and studies conducted by third parties. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal
research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of the industry and market, which we believe to be reasonable. In addition, while we believe the industry, market, and competitive
position data included in this prospectus is reliable and based on reasonable assumptions, we have not independently verified any third-party information, and all such data involve risks and uncertainties and are subject to change based on various
factors, including those discussed under the section entitled &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that we will receive net proceeds of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million (or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters&#146; option to purchase additional shares is exercised in full) from the sale of the shares of common stock offered by us in this offering, based on an assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase (decrease) in the assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares of common stock offered by us, as set forth on the cover of this prospectus, remains the same, and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1,000,000 shares in the number of shares of common stock offered by us, as set forth on the cover of this prospectus, would increase (decrease) our net
proceeds from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering
expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds of this offering, together with our existing cash and cash equivalents and
short-term investments, primarily as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to advance
<FONT STYLE="white-space:nowrap">SL-172154</FONT> through the completion of our ongoing and planned Phase 1 clinical trials and to commence a Phase 2 clinical program; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to advance SL-279252 through the
completion of our ongoing Phase 1 clinical trial; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to develop and advance additional product
candidates derived from our platforms through IND-enabling studies and to commence Phase 1 clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend
to use the remainder of the net proceeds for working capital and general corporate purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expected use of proceeds from this
offering represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the proceeds to be received upon the completion of this
offering or the amounts that we will actually spend on the uses set forth above. We may also use a portion of the proceeds to license, acquire, or invest in complementary businesses, technology, products, or assets. However, we have no current
commitments to do so. If we receive any additional proceeds from this offering, we expect to use such proceeds on a proportional basis to the categories described above. The amount and timing of our actual expenditures will depend on numerous
factors. As a result, our management will have broad discretion over the use of the proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our current
business plans, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents and short-term investments, will be sufficient to fund our planned operations through
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently. Such amount will not be
sufficient for us to fund our product candidates through regulatory approval and commercialization, and we will need to raise substantial additional capital in order to do so. To obtain the capital necessary to fund our product candidates through
regulatory approval and commercialization, we may need to enter into additional public or private equity offerings, debt financings, or collaborations and licensing arrangements, or seek out other capital sources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the use of the proceeds from this offering, we may invest the proceeds in a variety of capital preservation investments, including
interest-bearing, investment-grade securities, certificates of deposit, or government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and future earnings, if
any, to fund the operations and the further development and expansion of our business. We have no present intention to pay cash dividends on our common stock. Any determination to pay dividends to holders of our common stock will be at the
discretion of our Board and will depend on many factors, including our financial condition, results of operations, liquidity, earnings, projected capital and other cash requirements, legal requirements, restrictions in the agreements governing any
indebtedness we may enter into, our business prospects, and other factors that our Board deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_7"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and short-term investments and capitalization as of June&nbsp;30, 2020: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U></U><U></U><U></U><U></U>on an actual basis; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><U></U><U></U><U></U><U></U>on a pro forma basis to give effect to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an
aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock upon the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the filing and effectiveness of our second amended and restated certificate of incorporation, which will be in
effect immediately after the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a pro forma as adjusted basis to give effect to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the pro forma items described immediately above; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance and sale of shares of our common stock in this offering, at an assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses
payable by us. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">pro-forma</FONT> information below is illustrative only
and our capitalization following the completion of this offering will be adjusted based on the actual initial public offering price and other terms determined at pricing. You should read the following table in conjunction with the sections entitled
&#147;Use of Proceeds,&#148; &#147;Selected Financial Data,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; and our financial statements and related notes included in this prospectus.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;Per&nbsp;share&nbsp;amounts)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A redeemable convertible preferred stock, $0.0001 par value, 1,093,019 shares authorized,
1,093,019 shares issued and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma <FONT STYLE="white-space:nowrap">as-adjusted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B redeemable convertible preferred stock, $0.0001 par value, 550,571 shares authorized,
550,571 shares issued and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma <FONT STYLE="white-space:nowrap">as-adjusted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock, $0.0001
par value, 1,319,964 shares authorized, 1,319,964 shares issued and outstanding, actual; no shares authorized, issued and outstanding, pro forma and pro forma <FONT STYLE="white-space:nowrap">as-adjusted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, $0.0001 par value, no shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, no shares issued and outstanding, pro forma and pro forma as adjusted.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value, 4,950,000 shares authorized, 1,121,327 shares issued and
1,118,140 shares outstanding, actual; 4,950,000 shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma
<FONT STYLE="white-space:nowrap">as-adjusted</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">141,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease pro forma as adjusted cash and cash equivalents and short-term
investments, total stockholders&#146; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus,
remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share increase or decrease in the number
of shares offered by us would increase or decrease pro forma as adjusted cash and cash equivalents and short-term investments, total stockholders&#146; equity and total capitalization by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that the assumed initial price to public remains the same, and after deducting estimated underwriting discounts and commissions payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding share information in the table above is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock (including shares of our redeemable convertible preferred stock outstanding on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) outstanding as of June&nbsp;30, 2020 and (ii)&nbsp;excludes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon
the exercise of stock options outstanding as of June&nbsp;30, 2020 under the 2016 Plan, at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon
the exercise of stock options granted subsequent to June&nbsp;30, 2020 under the 2016 Plan, at a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon
the settlement of restricted stock units outstanding as of June&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon
the settlement of restricted stock units granted subsequent to June&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for
future issuance pursuant to future awards under our 2020 Plan, as well as any automatic increase in the number of shares of common stock reserved for future issuance under the 2020 Plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock to be reserved
for future issuance under the ESPP, which will become effective immediately prior to the completion of this offering, as well as any automatic increase in the number of shares of common stock reserved for future issuance under the ESPP.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in the shares of our common stock in this offering, your ownership interest will be immediately diluted. Dilution represents the
difference between the amount per share paid by investors in this offering and the <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value per share of our common stock immediately after this offering. The data in this section
are derived from our balance sheet as of June&nbsp;30, 2020. <FONT STYLE="white-space:nowrap">As-converted</FONT> net tangible book value per share is equal to our total tangible assets less the amount of our total liabilities, divided by the sum of
the number of shares of our common stock that will be outstanding immediately prior to the closing of this offering (assuming the conversion of all outstanding shares of our reedemable convertible preferred stock into shares of common stock). Our <FONT
STYLE="white-space:nowrap">as-converted</FONT> net tangible book value as of June&nbsp;30, 2020 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to our receipt of the estimated net proceeds from the sale of our common stock in this offering, based on an assumed
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and other
estimated offering expenses payable by us our net tangible book value, <FONT STYLE="white-space:nowrap">as-adjusted,</FONT> as of June&nbsp;30, 2020 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock. This represents an immediate increase in net tangible book value to our existing stockholders of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and an
immediate dilution to new investors in this offering of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. The following table illustrates this per share dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net tangible book value per share as of June&nbsp;30, 2020, after giving effect to the
conversion of all of our reedemable convertible preferred stock into shares of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in pro forma as adjusted net tangible book value per share attributable to new
investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A $1.00 increase (decrease) in the assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase (decrease) our <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, the <FONT
STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the dilution per share to new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly,
each increase (decrease) in the number of shares offered by us would increase (decrease) our <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, the <FONT
STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the dilution per share to new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if the underwriters exercise their option to purchase additional shares in full, assuming the assumed public offering price remains the same and after deducting the estimated underwriting
discounts and commissions and estimated offering expenses payable by us. If the underwriters fully exercise their option to purchase additional shares, <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value after this offering
would increase by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and there would be an immediate dilution of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents, on an <FONT STYLE="white-space:nowrap">as-adjusted</FONT>
basis, as described above, the differences between the existing stockholders and the purchasers of shares in this offering with respect to the number of shares purchased from us, the total consideration paid, and the average price paid per share at
an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share (the midpoint of the range set forth on the cover page of this prospectus): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Consideration</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price<BR>Per Share</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters were to fully exercise their option to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock from us, the percentage of shares of our common stock held by existing stockholders would
be&nbsp;&nbsp;&nbsp;&nbsp;%, and the percentage of shares of our common stock held by new investors would be&nbsp;&nbsp;&nbsp;&nbsp;%. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The outstanding share information in the table above is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of our common stock (including shares of our reedemable convertible preferred stock outstanding on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) outstanding as of June&nbsp;30, 2020, and (ii)&nbsp;excludes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon
the exercise of stock options outstanding as of June&nbsp;30, 2020 under the 2016 Plan, at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon
the exercise of stock options granted subsequent to June&nbsp;30, 2020 under the 2016 Plan, at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon
the settlement of restricted stock units outstanding as of June&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon
the settlement of restricted stock units granted subsequent to June&nbsp;30, 2020, at a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock reserved for
future issuance pursuant to future awards under our 2020 Plan, as well as any automatic increase in the number of shares of common stock reserved for future issuance under the 2020 Plan; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock to be reserved
for future issuance under the ESPP, which will become effective immediately prior to the completion of this offering, as well as any automatic increase in the number of shares of common stock reserved for future issuance under the ESPP.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_9"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables set forth our selected historical financial data as of and for the periods ended on the dates indicated. The selected
statements of operations data for the years ended December&nbsp;31, 2018 and 2019 and the selected balance sheet data as of December&nbsp;31, 2018 and 2019 are derived from our audited financial statements and accompanying notes included elsewhere
in this prospectus. The selected statements of operations data for the six months ended June&nbsp;30, 2019 and 2020 and the selected balance sheet data as of June&nbsp;30, 2020 have been derived from our unaudited interim financial statements and
accompanying notes included elsewhere in this prospectus. We have prepared the unaudited interim financial data in accordance with GAAP and on the same basis as the audited financial statements and the accompanying notes included elsewhere in this
prospectus, and we have included all adjustments, consisting only of normal recurring adjustments, that management considers necessary for a fair presentation of the information for the periods presented. Our historical results are not necessarily
indicative of the results that may be expected in the future, and the historical results for the six months ended June&nbsp;30, 2020 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2020, or for any
other period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the following selected historical financial data together with our audited and unaudited financial
statements and accompanying notes included elsewhere in this prospectus and the information under the caption &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; The selected historical financial
data included in this section are not intended to replace the audited and unaudited financial statements and the accompanying notes and are qualified in their entirety by our audited and unaudited financial statements and the accompanying notes
included elsewhere in this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,442</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,887</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,282</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,157</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,807</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,218</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,502</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,892</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,783</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,736</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,696</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,346</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on the extinguishment of notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,081,936</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103,190</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,099,148</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114,399</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share&#151;basic and
diluted<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares outstanding&#151;basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,196,209</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,785,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">See Note 2 to our audited financial statements and Note 2 to our unaudited financial statements included elsewhere
in this prospectus for a description of how we compute net loss per share&#151;basic and diluted, pro forma net loss per share&#151;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:9pt">
basic and diluted, and the weighted average shares outstanding&#151;basic and diluted, in each case, used in the computation of these per share amounts. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">60,376</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,087</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">147,534</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,782</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,458</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,282</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,161</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,969</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,544</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,178</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,453</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,464</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total redeemable convertible preferred
stock<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,109</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. See our audited and unaudited financial statements and accompanying notes included elsewhere in this prospectus for further details regarding our
current assets and our current liabilities. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Total redeemable convertible preferred stock is the sum of our Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series <FONT STYLE="white-space:nowrap">B-1</FONT>
redeemable convertible preferred stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our financial
statements and the related notes and other financial information included elsewhere in this prospectus. This discussion and analysis contain <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements based upon our current plans and
expectations that involve risks, uncertainties, and assumptions, such as statements regarding our plans, objectives, expectations, intentions, and beliefs. Our actual results and the timing of events could differ materially from those anticipated in
these forward-looking statements as a result of various factors, including those set forth under the section entitled &#147;Risk Factors&#148; and included elsewhere in this prospectus. You should carefully read the &#147;Special Note Regarding
Forward-Looking Statements&#148; and &#147;Risk Factors&#148; sections of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from the results described below. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative
clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We believe our approach has the potential to fundamentally transform the therapeutic modulation of the
immune system. We have created a novel approach to immune-modulation by designing biologics with structural characteristics that are not achievable by existing therapeutic modalities. Compounds derived from our proprietary Agonist Redirected
Checkpoint, or ARC<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Our initial product candidates are designed to be
differentiated therapeutics addressing molecular targets that are well characterized and scientifically validated in immuno-oncology but are underexploited by current treatment modalities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead, wholly owned product candidate, <FONT STYLE="white-space:nowrap">SL-172154,</FONT> has been rationally designed to simultaneously
inhibit the CD47/SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. We are currently conducting a Phase 1
clinical trial evaluating <FONT STYLE="white-space:nowrap">SL-172154</FONT> in patients with ovarian cancer, and we expect to announce initial data from the dose-escalation portion of this trial in the second half of 2021. We plan to initiate a
second Phase 1 trial evaluating the SL-172154 in patients with cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma, and we expect to announce data from the dose-escalation portion of this trial in the second half of 2022. Our
second product candidate, <FONT STYLE="white-space:nowrap">SL-279252,</FONT> which is being developed in collaboration with Takeda, has been rationally designed to simultaneously inhibit the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> interaction and activate the OX40 receptor. We are evaluating <FONT STYLE="white-space:nowrap">SL-279252</FONT> in a Phase 1 clinical trial in patients with advanced solid tumors and lymphoma, and
we expect to announce data from the dose-escalation portion of this trial in the second half of 2021. In addition to our clinical-stage ARC product candidates, we possess a deep pipeline of preclinical immuno-oncology product candidates.
Longer-term, we are pursuing additional disease areas, including autoimmune diseases, where our dual-sided fusion protein platforms may provide advantages over current treatment modalities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in 2016, we have devoted substantially all of our resources to developing and perfecting our intellectual property rights,
conducting research and development activities, including undertaking preclinical studies of our product candidates, conducting clinical trials of our most advanced product candidates, manufacturing our product candidates, organizing and staffing
our company, business planning, and raising capital. We do not have any products approved for sale and we have not generated any revenue from product sales. We continue to have related party revenue under a collaboration agreement with Takeda. We
have funded our operations to date through the sale of redeemable convertible preferred stock for approximately $152.9&nbsp;million, the issuance of convertible notes for approximately $10.5&nbsp;million and payments received pursuant to our
collaboration agreement with Takeda for approximately $75.7&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2018 and 2019, our net
loss was $7.4&nbsp;million and $24.0&nbsp;million, respectively. For the six months ended June&nbsp;30, 2019 and 2020, our net loss was $9.3&nbsp;million and $12.8&nbsp;million, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respectively. We have not been profitable since inception, and as of June&nbsp;30, 2020, we had an accumulated deficit of $48.3&nbsp;million and $147.5&nbsp;million in cash and cash equivalents
and short-term investments. We expect to continue to incur significant expenses and increasing operating losses in the near term. We expect our expenses will increase substantially in connection with our ongoing activities, as we: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to advance the preclinical and clinical development of our lead product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">initiate preclinical studies and clinical trials for additional product candidates that we may identify in the
future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expand our operational, financial, and management systems and increase personnel, including personnel to support
our clinical development, manufacturing, and commercialization efforts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">continue to develop, perfect, and defend our intellectual property portfolio; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">incur additional legal, accounting, or other expenses in operating our business, including the additional costs
associated with operating as a public company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to generate significant product revenue unless and
until we successfully complete development and obtain regulatory and marketing approval of, and begin to sell, one or more of our product candidates, which we expect will take several years. We expect to spend a significant amount in development and
marketing costs prior to such time. We may never succeed in achieving regulatory and marketing approval for our product candidates. We may obtain unexpected results from our preclinical and clinical trials. We may elect to discontinue, delay, or
modify preclinical and clinical trials of our product candidates. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the
development of that product candidate. Accordingly, until such time as we can generate significant product revenue, if ever, we expect to continue to seek private or public equity and debt financing to meet our capital requirements. There can be no
assurance that such funding may be available to us on acceptable terms, or at all, or that we will be able to commercialize our product candidates. In addition, we may not be profitable even if we commercialize any of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Coronavirus Pandemic </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
March&nbsp;10, 2020, the World Health Organization characterized the novel <FONT STYLE="white-space:nowrap">COVID-19</FONT> virus as a global pandemic. There is significant uncertainty as to the effects of this disease which may, among other things,
materially impact our business, including our ongoing and planned clinical trials.&nbsp;To date, we have experienced delays in our <FONT STYLE="white-space:nowrap">SL-279252</FONT> clinical trial as a result of the ongoing pandemic, including delays
with certain <FONT STYLE="white-space:nowrap">third-party</FONT> vendors supporting this trial. We temporarily paused enrollment of patients for our clinical trial of SL-279252 between March and May 2020 and we resumed enrollment in June 2020. As
&#147;shelter in place&#148; orders and other public health guidance measures are reinstated in the locations of our clinical trial sites, we expect that some patients may also choose to forego one or more doses in our clinical trials, due to
challenges faced by such patients in travelling to our clinical trial sites, which may negatively affect the study results. We expect that our clinical development program timelines will continue to be negatively affected by <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> although the degree of these delays is difficult to predict. Further, due to &#147;shelter in place&#148; orders and other public health guidance measures, we may be required to implement a work-from-home
policy for all staff members excluding those necessary to maintain minimum basic operations. In such an instance, our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely
impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories may be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and work-from-home policies and other operational
limitations mandated by federal, state, and local governments as a result of the pandemic, certain of our research and development activities, including the conduct of preclinical studies, have been delayed and may be further delayed and other
aspects of our business, such as the conduct of various corporate functions and the ability of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our Board and management to provide oversight and guidance may be adversely impacted until such operational limitations are lifted. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
or local outbreaks associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could result in difficulty manufacturing our product candidates, securing clinical trial site locations, CROs, and/or trial monitors and other critical
vendors and consultants supporting our clinical trials. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact our ability to enroll patients or to complete all scheduled physician visits for
currently enrolled patients. These situations, or others associated with <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, could cause delays in our clinical trial plans and could increase expected costs, all of which could have a material
adverse effect on our business and its financial condition.&nbsp;At the current time, we are unable to quantify the potential effects of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our future operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration and License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Agreement with Takeda </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
August 8, 2017, we entered into a Collaboration Agreement with Millennium Pharmaceuticals, Inc., or Takeda, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd., or the Collaboration Agreement. The Collaboration Agreement was
subsequently amended in April 2018, October 2018, and March 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Collaboration Agreement, we are required to use our
commercially reasonable efforts to conduct preclinical and Phase 1 clinical trials for two molecules, PD-1-Fc-OX40L and CSF1R-Fc-CD40L, and Takeda has an exclusive option to license one or both of these clinical-stage ARC compounds for a specified
amount of time up to and following the conclusion of each respective Phase 1 trial. While we are currently evaluating PD-1-Fc-OX40L in a Phase 1 clinical trial, we have not yet conducted a Phase 1 clinical trial for CSF1R-Fc-CD40L. During the
development phase of the Collaboration Agreement, we may not, by ourselves or through a third party, develop or commercialize a compound, molecule or product that targets both PD-1 and OX40L, or a compound, molecule or product that targets both
CSF1R and CD40L. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, pursuant to the Collaboration Agreement, we agreed to conduct certain preclinical studies on four additional
preclinical ARC molecules, and Takeda had an option to license up to two of the four preclinical molecules. We completed our research and development activities related to the four preclinical molecules and delivered a final report to Takeda. Takeda
elected to not exercise its option to enter into up to two licenses for such molecules, and Takeda&#146;s option period for such molecules has now lapsed. As a result, the Collaboration Agreement is terminated as to the four preclinical molecules
and Takeda does not have any rights to participate in the development or commercialization of such molecules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Collaboration
Agreement, Takeda is granted a right of first negotiation to enter into licenses for each molecule within a specified class of ARC molecules. To exercise its right of first negotiation, Takeda will be required to provide a notice within a specified
time, and if the parties do not conclude a license agreement within a set timeframe, we will be entitled to enter into licenses with third parties, subject to certain conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thus far under the Collaboration Agreement, we have received approximately $75.7 million in option payments, milestone payments, and expense
reimbursements from Takeda. If Takeda exercises its exclusive option to license one or both of the clinical-stage ARC compounds (PD-1-Fc-OX40L and CSF1R-Fc-CD40L), we will enter into a license agreement with Takeda with respect to such compound. Any
such license agreement would, among other things, require Takeda to use its commercially reasonable efforts to develop the licensed compound and seek approval for the compound. In addition, Takeda would be solely responsible, at its costs, for the
development, manufacture, and commercialization of the licensed ARC compounds. If both ARC compounds are licensed, we would be entitled to additional payments consisting of up to an aggregate of $78.75 million in license fee payments and up to an
aggregate of $450 million in clinical, regulatory, and sales milestone payments. In addition, we would be eligible for tiered royalty payments on net sales of licensed products at percentages ranging from the high single digits to sub-teens, subject
to specified reductions, during the royalty term. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Takeda exercises its option to enter into a license agreement, the royalty term with
respect to the licensed product would extend, on a country-by-country basis, from the period commencing on the first commercial sale of the product in such country and ending on the later of (i) the expiration of the last to expire of the valid
claims of the applicable licensed patent rights covering the product in such country or (ii) the tenth anniversary of the first commercial sale of the product in such country. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless sooner terminated, the Collaboration Agreement will continue until the later of (a)&nbsp;February 8, 2021, (b) the earlier of (i) the
90th day following delivery of a report detailing certain results of the PD-1-Fc-OX40L Phase 1 clinical trial and (ii) the exercise by Takeda of its right to an exclusive license with respect to PD-1-Fc-OX40L, and (c) the earlier of (i) the 90th day
following delivery of a report detailing certain results of the CSF1R-Fc-CD40L Phase 1 clinical trial and (ii) the exercise by Takeda of its right to an exclusive license with respect to CSF1R-Fc-CD40L. Either party may terminate the Collaboration
Agreement prior to expiration upon the insolvency or uncured material breach of the other party. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Heat License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, we entered into an Exclusive License Agreement, or the Heat License Agreement, with Heat Biologics Inc., or Heat. The Heat
License Agreement was subsequently amended in November 2016, December 2016, and March 2017. Pursuant to the Heat License Agreement, Heat granted to us a worldwide, sublicensable exclusive license to research, develop, manufacture, and commercialize
products under three provisional patent applications, including all patents issuing from such applications, or the Fusion Protein Patent Rights and a worldwide, sublicensable nonexclusive license to research, develop, manufacture, and commercialize
certain know how owned and controlled by Heat related to the Fusion Protein Patent Rights. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Heat License Agreement, Heat was
required to conduct certain research and development services under a mutually-agreed upon research and development plan and Heat was eligible to receive financial support from us for these efforts. Effective March 2017, Heat completed all research
and development services under the Heat License Agreement and assigned to us three patent applications and all data derived from the research and development activities, referred to collectively as the Research Services Inventions. Pursuant to the
terms of the Heat License Agreement, we are obligated to use commercially reasonable efforts to diligently research and develop at least one product covered by the Fusion Protein Patent Rights, including the obligation to file an IND application for
such product. Our development efforts, including the development of SL-279252 and certain other ARC compounds, to date satisfy these obligations. In addition, we are to provide annual reports to Heat on or before the anniversary of the effective
date of the Heat License Agreement to inform Heat of our progress. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless sooner terminated or extended, the term of the Heat
License Agreement continues until the later of 20 years following the effective date and the expiration of the last-to-expire royalty term. Either party may terminate the agreement due to a material breach by the other party (subject to a 90-day
cure period) or if the other party files for bankruptcy. In the event we terminate the Heat License Agreement due to a material breach by Heat, Heat must assign to us all right, title, and interest in the patent rights licensed under the Heat
License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to an upfront payment of $50,000, the Heat License Agreement requires us to make further payments to Heat
of up to $20.6 million in the aggregate, for the achievement of specified development, regulatory, and commercial sale milestones for certain licensed products. We are also required to pay Heat a percentage of certain upfront fees or other
non-royalty payments we receive that are not tied to milestone events under any sublicense of the Fusion Protein Patent Rights. We are also required to pay Heat a royalty on all worldwide net sales by us, our affiliates, and sublicenses of certain
licensed products in the low single digits. Royalties are payable, on a product-by-product and country-by-country basis, commencing on the first commercial sale of such product and continuing until the last-to-expire valid patent claim to the
licensed patent rights that cover such product in that country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Components of our Results of Operation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Revenue &#150; Related Party </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Collaboration Agreement, we are eligible to receive up to $33.8&nbsp;million if Takeda exercises options to enter into license
agreements for <FONT STYLE="white-space:nowrap">SL-279252</FONT> and $45.0 million if Takeda exercises options to enter into license agreements for <FONT STYLE="white-space:nowrap">SL-115154.</FONT> We are also entitled to receive reimbursements for
certain materials and costs incurred in conjunction with research and development activities. We are further eligible to receive up to $450.0&nbsp;million in additional fees if certain milestones are reached, and we are eligible to receive tiered
royalties from the high single digits to the sub teens percentages based on annual worldwide net sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the years ended
December&nbsp;31, 2018 and 2019 we received payments of $21.0&nbsp;million and $8.5&nbsp;million, respectively, and we received $11.3 million for the six months ended June&nbsp;30, 2020. We have recognized total revenue of $48.2&nbsp;million through
June&nbsp;30, 2020 under the Collaboration Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no products approved for commercial sale and we have not generated any
revenue from commercial product sales. Our total revenue to date has been generated solely from our collaboration agreement with Takeda. We expect to continue to recognize revenue under this agreement as development work is performed. We expect that
any collaboration revenue we generate from our collaboration agreement with Takeda and any future collaboration partners will fluctuate from period to period as a result of the timing and the amount of milestones and other payments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product
candidates. These expenses include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses incurred under agreements with contract research organizations, or CROs, as well as investigative sites
and consultants that conduct our preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing and development expenses and the costs of acquiring and manufacturing preclinical study and
clinical trial materials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">analysis of manufacturing processes for optimization; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">employee-related expenses, including salaries, benefits, and stock-based compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fees paid to consultants who assist with research and development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expenses relating to regulatory activities, including filing fees paid to regulatory agencies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">laboratory materials and supplies used to support our research activities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allocated expenses for facility-related costs. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses by product candidate: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SL-279252</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,209</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,901</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,468</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,701</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SL-172154</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,087</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,489</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,327</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,765</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other pipeline candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,436</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,632</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,445</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Internal costs, including personnel related benefits, facilities, and depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,075</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,421</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,075</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,981</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,807</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">29,218</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,502</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,892</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development activities are central to our business model. Product candidates in
later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of <FONT STYLE="white-space:nowrap">later-stage</FONT> clinical
trials. We expect our research and development expenses to increase significantly over the next several years as we conduct preclinical studies and clinical trials, including <FONT STYLE="white-space:nowrap">later-stage</FONT> clinical trials, for
our current and future product candidates and pursue regulatory approval of our product candidates, including preparing regulatory filings. As we expand our research and development activities, we will correspondingly incur an increase in personnel
costs, including salaries, employee benefits, and <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation, as discussed in greater detail below under &#147;General and Administrative Expenses.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of conducting the necessary preclinical and clinical research to obtain regulatory approval is costly and time consuming. The
actual probability of success for our product candidates may be affected by a variety of factors including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the safety and efficacy of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">early clinical data for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">investment in our clinical programs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of collaborators to successfully develop our licensed product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacturing capability; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">commercial viability. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we
are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates, if ever. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expense consists primarily of personnel expenses, including salaries, benefits, and
<FONT STYLE="white-space:nowrap">stock-based</FONT> compensation expense, for employees and consultants in executive, finance, accounting, legal, and human resource functions. General and administrative expense also includes corporate facility
costs, including rent, utilities, depreciation, and maintenance, not otherwise included in research and development expense, as well as legal fees related to intellectual property and corporate matters and fees for accounting and consulting
services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our general and administrative expense will increase in the future to support our continued research and
development activities and as a result of the increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants, lawyers, and
accountants, among other expenses. Additionally, we anticipate increased costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the SEC,
insurance, and investor relations costs. If any of our current or future product candidates obtains U.S. regulatory approval, we expect that we would incur significantly increased expenses associated with building a sales and marketing team. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Interest Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income consists of interest earned on our cash equivalents and short-term investments, which consists of amounts held in a money
market fund and at various times in short-term government obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have not recorded any income tax benefits for the net operating losses, or NOLs, we have incurred and for our research
and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our NOLs and tax credits will not be realized. As of December&nbsp;31, 2019, we had U.S. federal and state net
operating loss carryforwards of $14.0&nbsp;million, and $0.2&nbsp;million, respectively, which may be available to offset future taxable income. As of December&nbsp;31, 2019, we also had federal tax credits of $2.3&nbsp;million, which may be used to
offset future tax liabilities. These NOLs and tax credit carryforwards will begin to expire in 2036. We have recorded a full valuation allowance against our deferred tax assets at each balance sheet date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison
of the Six Months Ended June&nbsp;30, 2019 and 2020 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our results of operations for the six months
ended June&nbsp;30, 2019 and 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue &#150; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,282</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,157</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">875</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,502</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,892</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,390</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,696</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,346</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">650</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,165</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Revenue &#150; Related Party </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration revenue increased by $0.9&nbsp;million, or 16.6%, from $5.3&nbsp;million for the six months ended June&nbsp;30, 2019 to
$6.2&nbsp;million for the six months ended June&nbsp;30, 2020. The increase is driven by increased clinical and development work on <FONT STYLE="white-space:nowrap">SL-279252</FONT> associated with Amendment No. 3 to the Collaboration Agreement.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $3.4&nbsp;million, or 27.1%, from $12.5&nbsp;million for the six months ended June&nbsp;30, 2019
to $15.9&nbsp;million for the six months ended June&nbsp;30, 2020. The increase was primarily attributable to an increase of $4.2&nbsp;million in manufacturing and clinical costs incurred in connection with the Collaboration Agreement and an
increase in personnel cost of $0.9&nbsp;million offset by a decrease of $1.0&nbsp;million in nonclinical studies and laboratory costs and a $0.8&nbsp;million reduction in consulting costs due to bringing certain activities <FONT
STYLE="white-space:nowrap">in-house.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by $0.7&nbsp;million, or 24.1%, from $2.7&nbsp;million for the six months ended June&nbsp;30,
2019 to $3.3&nbsp;million for the six months ended June&nbsp;30, 2020. The increase was primarily due to a $0.7&nbsp;million increase in personnel-related costs driven by higher employee headcount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income decreased by $0.2&nbsp;million from $0.6&nbsp;million for the six months ended June&nbsp;30, 2019 to $0.4&nbsp;million for the
six months ended June&nbsp;30, 2020. The decrease was primarily due to a decrease in investments in corporate and government obligations in 2020 compared to 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the Years Ended December&nbsp;31, 2018 and 2019 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our results of operations for the years ended December&nbsp;31, 2018 and 2019. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue &#150; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,442</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,887</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,555</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55.9</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,807</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,218</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,411</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,783</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,736</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,953</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,631</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(100.0</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">258</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72.3</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,594</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Collaboration Revenue &#150; Related Party </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration revenue decreased by $12.6&nbsp;million, or 55.9%, from $22.4&nbsp;million for the year ended December&nbsp;31, 2018 to
$9.9&nbsp;million for the year ended December&nbsp;31, 2019. Pursuant to the Collaboration Agreement, in 2018 and the first quarter of 2019, we performed development and nonclinical studies on <FONT STYLE="white-space:nowrap">SL-279252</FONT> and <FONT
STYLE="white-space:nowrap">SL-115154.</FONT> We also conducted early research and development on the four preclinical molecules under the Collaboration Agreement. We completed the development plans for all four preclinical molecules in the first
quarter of 2019 and have recognized all revenue associated with those programs. Takeda declined to license any of the four preclinical molecules. We continue to advance <FONT STYLE="white-space:nowrap">SL-279252</FONT> and <FONT
STYLE="white-space:nowrap">SL-115154</FONT> through clinical and preclinical studies and will continue to recognize revenue as earned under the Collaboration Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Research and Development Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased by $4.4&nbsp;million, or 17.8%, from $24.8&nbsp;million for the year ended December&nbsp;31, 2018
to $29.2&nbsp;million for the year ended December&nbsp;31, 2019. The increase was primarily attributable to an increase of $9.4&nbsp;million and $2.1&nbsp;million in <FONT STYLE="white-space:nowrap">non-clinical</FONT> and manufacturing development
expense for <FONT STYLE="white-space:nowrap">SL-172154</FONT> and <FONT STYLE="white-space:nowrap">SL-115154,</FONT> respectively, as we prepared for SL-172154 to go into a Phase 1 clinical trial in the second half of 2020, and an increase in
personnel-related expense of $2.3&nbsp;million due to an increase in employee headcount. These increases were offset by a decrease in <FONT STYLE="white-space:nowrap">non-clinical</FONT> and manufacturing development expense for <FONT
STYLE="white-space:nowrap">SL-279252</FONT> as that program moved into a Phase 1 clinical trial in April 2019 and a decrease in other pipeline development costs as a result of completing work for the four preclinical molecules under the
Collaboration Agreement in March 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>General and Administrative Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses increased by $2.0&nbsp;million, or 51.6%, from $3.8&nbsp;million for the year ended December&nbsp;31, 2018
to $5.7&nbsp;million for the year ended December&nbsp;31, 2019. The increase was primarily due </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to a $1.0&nbsp;million increase in professional services expense related to accounting and audit fees related to the 2017 and 2018 fiscal year and tax services for the 2018 fiscal year, and a
$0.8&nbsp;million increase in personnel-related expense due to an increase in employee headcount. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Income </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income increased by $0.2&nbsp;million,&nbsp;or 22.6%, from $1.0&nbsp;million for the year ended December&nbsp;31, 2018 to
$1.2&nbsp;million for the year ended December&nbsp;31, 2019. The increase was primarily due to an increase in interest earned from funds held in money market accounts and debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Interest Expense </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense decreased by $2.6&nbsp;million or 100% from $2.6&nbsp;million for the year ended December&nbsp;31, 2018 to none for the year
ended December&nbsp;31, 2019. No interest expense was incurred in 2019 as all of our outstanding convertible notes were converted into shares of our Series A redeemable convertible preferred stock in 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Gain on Extinguishment of Notes Payable </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018, there was a $0.8&nbsp;million gain on the extinguishment of notes payable associated with the conversion of all the outstanding
convertible notes into shares of Series A redeemable convertible preferred stock. No similar gains were recognized in the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other expenses
decreased by $0.3&nbsp;million from $0.4&nbsp;million for the year ended December&nbsp;31, 2018 to $0.1&nbsp;million for the year ended December&nbsp;31, 2019. In 2018, we recorded a $0.4&nbsp;million expense to reflect the change in the fair value
of a derivative instrument. No such charge was incurred in 2019 as the derivative was settled in 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred losses since inception. As of June&nbsp;30, 2020, we had an accumulated deficit of $48.3&nbsp;million and $147.5&nbsp;million
of cash and cash equivalents and short-term investments. Historically, we have funded our operations to date primarily from private placements of preferred stock for approximately $152.9&nbsp;million, the issuance of convertible notes for
approximately $10.5&nbsp;million and payments received pursuant to a collaboration agreement with Takeda for approximately $75.7&nbsp;million. We anticipate incurring additional losses and negative cash flows from operations until such time, if
ever, that we can generate significant sales of our product candidates currently in development. We are highly dependent on our ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements,
and/or debt and equity financing. Our ability to fund planned clinical operations, research and development, and commercialization of product candidates is expected to depend on the amount and timing of cash receipts from these funding sources.
Adequate additional funding may not be available to the us on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on our financial condition and ability to pursue its business strategies.
Management believes that our cash and cash equivalents and short-term investments as of June&nbsp;30, 2020 are sufficient to fund the projected operations of the company through at
least&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Capital Resources and Funding Requirements
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of cash are to fund our operations, which consist primarily of research and development expenditures related to
our programs, product development costs, operating expenses, and working capital requirements. We believe that our cash and cash equivalents and short-term investments, together with the net proceeds from this offering, will enable us to fund our
operating expenses through&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We expect to incur </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantial additional expenditures in the near term to support our ongoing activities including clinical trials of several product candidates. Additionally, we expect to incur additional costs
as a result of operating as a public company. We expect to continue to incur net losses for the next several years, and we are highly dependent on our ability to find additional sources of funding in the form of debt,<B> </B>equity financing, or
additional partnerships. Our ability to fund our product development and clinical operations will depend on the amount and timing of cash received from planned financings. Our future capital requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the scope, timing, progress, and results of discovery, preclinical development, laboratory testing, and clinical
trials for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of manufacturing our product candidates for clinical trials and in preparation for marketing approval
and commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the extent to which we enter into collaborations or other arrangements with additional third parties in order to
further develop our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of preparing, filing, and prosecuting patent applications, maintaining, and enforcing our intellectual
property rights and defending other intellectual <FONT STYLE="white-space:nowrap">property-related</FONT> claims; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs and fees associated with the discovery, acquisition, or
<FONT STYLE="white-space:nowrap">in-license</FONT> of additional product candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish additional collaborations on favorable terms, if at all; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs required to scale up our clinical, regulatory, and manufacturing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing,
distribution, and storage capabilities, for any of our product candidates for which we receive marketing approval; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates
receive marketing approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we obtain regulatory approval to market our product candidates, if ever, we cannot
generate revenues from sales of our products. Even if we are able to sell our products, we may not generate a sufficient amount of product revenues to finance our cash requirements. Accordingly, we may seek to raise any necessary additional capital
through a combination of public or private equity offerings, debt financings, collaborations, licensing arrangements, and other marketing and distribution agreements. There can be no assurance that such funding may be available to us on acceptable
terms, or at all. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures
associated with our current and anticipated preclinical studies and clinical trials. The issuance of equity securities may result in dilution to stockholders. If we raise additional funds through the issuance of debt securities, these securities may
have rights, preferences and privileges senior to those of our common stock and the terms of the debt securities could impose significant restrictions on our operations. The failure to raise funds as and when needed could have a negative impact on
our financial condition and ability to pursue our business strategies. Additionally, if additional funding is not secured when required, we may need to delay or curtail our operations until such funding is received, which would have a material
adverse impact on our business prospects and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows a summary of our cash flows for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(unaudited) </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net (decrease) increase in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">124,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2019, net cash used in operating activities was $5.9&nbsp;million and primarily reflected our net
loss of $9.3&nbsp;million and a $3.1&nbsp;million net decrease in our operating assets and liabilities, partially offset by noncash charges $0.2&nbsp;million in <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation and $0.3&nbsp;million
in depreciation expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2020, net cash used in operating activities was $8.3&nbsp;million and
primarily reflected our net loss of $12.8&nbsp;million and a $3.9&nbsp;million net decrease in our operating assets and liabilities, partially offset by noncash charges $0.3&nbsp;million in <FONT STYLE="white-space:nowrap">stock-based</FONT>
compensation and $0.3&nbsp;million in depreciation expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash (Used in) Provided by Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2019, net cash used in investing activities was $2.8&nbsp;million of which $0.3&nbsp;million was used
to purchase property and equipment, $21.8&nbsp;million was used to purchase short-term investments, and $19.3&nbsp;million was received from the sale of short-term investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2020, net cash provided by investing activities was $15.2&nbsp;million of which $0.4&nbsp;million
was used to purchase property and equipment, $2.7&nbsp;million was used to purchase short-term investments, and $18.3&nbsp;million was received from the sale of short-term investments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Provided by Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2020, net cash provided by financing activities was $117.1&nbsp;million and was primarily from the
sale of our Series B and <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows a
summary of our cash flows for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,903</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, net cash used in operating activities was $6.9&nbsp;million and primarily reflected our net loss
of $7.4&nbsp;million, which net loss includes $2.6&nbsp;million of noncash interest expense and a $2.5&nbsp;million net decrease in our operating assets and liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019, net cash used in operating activities was $21.0&nbsp;million and primarily reflected our net
loss of $24.0&nbsp;million and a $2.2&nbsp;million net decrease in our operating assets and liabilities, partially offset by noncash charges $0.5&nbsp;million in <FONT STYLE="white-space:nowrap">stock-based</FONT> compensation and $0.5&nbsp;million
in depreciation expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash Used in Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2018, net cash used in investing activities was $29.9&nbsp;million, of which $1.2&nbsp;million was used
to purchase property and equipment and $28.7&nbsp;million was used to purchase short-term investments. No proceeds were received from the sale of short-term investments in 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019, net cash used in investing activities was $3.6&nbsp;million of which $0.5&nbsp;million was used
to purchase property and equipment, $44.3&nbsp;million was used to purchase short-term investments, and $41.1&nbsp;million was received from the sale of short-term investments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Net Cash (Used in) Provided by Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year end December&nbsp;31, 2018, net cash provided by financing activities was $35.1&nbsp;million from the sale of our Series A
redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2019, a nominal amount related to offering costs in
connection with the private placements of our preferred common stock was used for financing activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Other Commitments
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our contractual obligations and commitments at December&nbsp;31, 2019: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>(in thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1 year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to<BR>3&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3 to<BR>5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5 years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The operating lease is for office space leased in Durham, North Carolina. The lease for this office was amended on July 24, 2020 to include an expansion to the leased facility. This will result in incremental increases
to the existing lease obligations as follows: none in 2020, $0.8 million for 2021 and 2022, $0.9 million for 2023 and 2024, and $1.9 million thereafter for total incremental payments of $3.6 million. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commitment amounts in the table above are associated with contracts that are enforceable and legally binding and that specify all
significant terms, including fixed or minimum services to be used, fixed, minimum, or variable price provisions, and the approximate timing of the actions under the contracts. Payments due upon cancellation consisting only of payments for services
provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation are not included in the preceding table as the amount and timing of such payments are not known. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not included any potential contingent payments upon the achievement by us of specified regulatory and commercial events, as
applicable, or patent prosecution or royalty payments we may be required to make under the Heat License Agreement. We have excluded these potential payments in the contractual obligations table because the timing and likelihood of these contingent
payments are not currently known and would be difficult to predict or estimate. See &#147;Business&#151;Collaboration and License Agreements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contractual obligations represent future cash commitments and liabilities under agreements
with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company&#146;s contractual obligations result primarily from obligations for various contract manufacturing organizations and
clinical research organizations, which include potential payments the Company may be required to make under its agreements. The contracts also contain variable costs and milestones that are hard to predict as they are based on such things as
patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under contract manufacturing organization, or CMO, and CRO agreements may be different depending on the timing of receipt of goods or services or changes to
agreed-upon terms or amounts for some obligations. Also, those agreements are cancelable upon written notice by the Company and, therefore, not long-term liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the periods presented, we did not have, nor do we currently have, any relationships with unconsolidated entities or financial
partnerships, including entities sometimes referred to as structured finance or special purpose entities that were established for the purpose of facilitating <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements or other
contractually narrow or limited purposes. We do not engage in <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet financing arrangements. In addition, we do not engage in trading activities involving
<FONT STYLE="white-space:nowrap">non-exchange</FONT> traded contracts. We therefore believe that we are not materially exposed to any financing, liquidity, market, or credit risk that could arise if we had engaged in these relationships. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
management&#146;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments,
including those related to revenue recognition, the accrual for research and development expenses, and the valuation of stock-based awards. We base our estimates on historical experience, known trends and events, and various other factors that are
believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in
Note&nbsp;2 to our financial statements included elsewhere in this prospectus, we believe the following accounting policies are the most critical to the judgments and estimates used in the preparation of our financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have and may
continue to enter into collaboration agreements with other companies. Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply, and
participation on joint steering and patent committees. We evaluate the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or
service meets the criteria required of a performance obligation, we consider the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and
whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, we develop judgmental assumptions, which may include market
conditions, reimbursement rates for personnel costs, development timelines, and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we conclude that a contract should be accounted for as a combined performance
obligation and recognized over time, we then determine the period over which revenue should be recognized and the method by which to measure revenue. We generally recognize revenue using a cost-based input method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recognize collaboration revenue when our customer or collaborator obtains control of promised goods or services, in an amount that reflects
the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for such arrangements, we perform the following five steps: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">i. identify the contract(s) with a customer; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">ii. identify the performance obligations in the contract; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">iii. determine the transaction price; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">iv. allocate the transaction price to the performance obligations within the contract; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">v. recognize revenue when (or as) the entity satisfies a performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We only apply the five-step model to contracts when we determine that it is probable we will collect the consideration we are entitled to in
exchange for the goods or services we transfer to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At contract inception, we assess the goods or services promised within
the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the arrangement consist of a license to our intellectual property and research, development and manufacturing services. We
may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer.&nbsp;Performance obligations
are promises in a contract to transfer a distinct good or service to the customer that (i)&nbsp;the customer can benefit from on its own or together with other readily available resources, and (ii)&nbsp;is separately identifiable from other promises
in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We determine transaction price based on the amount of consideration we expect to receive for transferring the promised goods or services in
the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, we estimate the probability and extent of consideration we expect to receive under the contract
utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. We then consider any constraints on the variable consideration and include in the transaction price variable
consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We then allocate the transaction price to each performance obligation based on the relative standalone selling price and recognize revenue as
the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and
other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of
measuring progress. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such
consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts received prior to satisfying the revenue recognition criteria are recognized as
deferred revenue in our balance sheet.&nbsp;Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as
revenue within the 12 months following the balance sheet date are classified as noncurrent liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Expense </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. We expense
research and development costs as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We accrue an expense for preclinical studies and clinical trial activities performed by
vendors based upon estimates of the proportion of work completed. We determine the estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal personnel and external service providers as to the
progress or stage of completion of trials or services and the <FONT STYLE="white-space:nowrap">agreed-upon</FONT> fee to be paid for such services. However, actual costs and timing of clinical trials are highly uncertain, subject to risks and may
change depending upon a number of factors, including our clinical development plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make estimates of our prepaid and accrued expenses
as of each balance sheet date in our financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual
accordingly. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and
recognized as expense in the period that the related goods are consumed or services are performed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Stock-Based</FONT>
Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We measure compensation expense for all <FONT STYLE="white-space:nowrap">share-based</FONT> awards based on the estimated
fair value of the <FONT STYLE="white-space:nowrap">share-based</FONT> awards on the grant date. We use the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model to value our stock option awards. We recognize compensation expense
on a <FONT STYLE="white-space:nowrap">straight-line</FONT> basis over the requisite service period, which is generally the vesting period of the award. We have not issued awards for which vesting is subject to a market or performance conditions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> <FONT STYLE="white-space:nowrap">option-pricing</FONT> model requires the use
of subjective assumptions that include the expected stock price volatility and the fair value of the underlying common stock on the date of grant. See Note&nbsp;11 to our audited financial statements included elsewhere in this prospectus for
information concerning certain of the specific assumptions we used in applying the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model to determine the estimated fair value of our stock options granted during the year ended
December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes by grant date the number of shares of common stock subject to stock options
granted from January&nbsp;1, 2019, as well as the associated per share exercise price and the estimated fair value per share of our common stock as of the grant date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grant date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>options&nbsp;granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise&nbsp;price<BR>per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;fair<BR>value&nbsp;per&nbsp;share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 6, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,250</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.15</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.14</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May&nbsp;14, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.15</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.89</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;18, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;4, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;11, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January&nbsp;2, 2020 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">19,866</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">21.69</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12.83</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, the aggregate intrinsic value of vested and unvested stock options outstanding as of June&nbsp;30, 2020 was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Estimating the Fair Value of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are required to estimate the fair value of the common stock underlying our <FONT STYLE="white-space:nowrap">share-based</FONT> awards when
performing the fair value calculations using the <FONT STYLE="white-space:nowrap">Black-Scholes</FONT> option pricing model. Because our common stock is not currently publicly traded, the fair value of the common stock underlying our stock options
has been determined on each grant date by our Board, with input from management, considering our most recently available <FONT STYLE="white-space:nowrap">third-party</FONT> valuation of common stock. All options to purchase shares of our common
stock are intended to be granted with an exercise price per share no less than the estimated fair value per share of our common stock underlying those options on the date of grant, based on the information known to us on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">third-party</FONT> valuations of our common stock were performed using methodologies, approaches and
assumptions consistent with the American Institute of Certified Public Accountants, or AICPA, <I>Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as</I> <I>Compensation</I>, or the AICPA Practice
Guide. In addition, our Board considered various objective and subjective factors to estimate the estimated fair value of our common stock, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the estimated value of each security both outstanding and anticipated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated capital structure that will directly impact the value of the currently outstanding securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our results of operations and financial position; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the status of our research and development efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the composition of, and changes to, our management team and Board; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lack of liquidity of our common stock as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">external market conditions affecting the life sciences and biotechnology industry sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. and global economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public
offering, or IPO, or a sale of our company, given prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the market value and volatility of comparable companies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the closing of this offering, the fair value of our common stock will be the closing price of our common stock on The Nasdaq Global
Market as reported on the date of the grant. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 2 to our financial statements found elsewhere in this prospectus for a description of recent accounting pronouncements applicable to
our financial statements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Qualitative and Quantitative Disclosures About Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Interest Rate Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to market risk related to changes in interest rates. As of June&nbsp;30, 2020, we had cash and cash equivalents and short-term
investments of $147.5&nbsp;million consisting of bank deposits, monies in a money market fund and U.S. Treasury securities. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S.
interest rates, particularly because our investments are in marketable debt securities. Our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities are subject to interest rate risk and will fall
in value if market interest rates increase. Due to the short-term duration of our investment portfolio and the low risk profile </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio. We have the ability to hold our available-sale-securities
until maturity and therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effects of Inflation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inflation generally
affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JOBS Act Transition Period </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an
emerging growth company as defined in the JOBS Act. Under the JOBS Act, an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards and delay the adoption of certain
accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new
or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company
effective dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under
the JOBS Act. Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation exemptions to the requirements for (1)&nbsp;providing an auditor&#146;s attestation report on our
system of internal controls over financial reporting pursuant to Section&nbsp;404(b) of the <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act and (2)&nbsp;complying with any requirement that may be adopted by the Public Company Accounting
Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an
emerging growth company until the earlier to occur of (a)&nbsp;the last day of the fiscal year (i)&nbsp;following the fifth anniversary of the completion of this offering, (ii)&nbsp;in which we have total annual gross revenues of at least
$1.07&nbsp;billion or (iii)&nbsp;in which we are deemed to be a &#147;large accelerated filer&#148; under the rules of the SEC, which means the market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
exceeds $700.0&nbsp;million as of the prior June&nbsp;30th, or (b)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior
<FONT STYLE="white-space:nowrap">three-year</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; meaning that the market
value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue is less than
$100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT>
is less than $250.0&nbsp;million or (ii)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less
than $700.0&nbsp;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and, similar to emerging
growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_11"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an innovative
clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We believe our approach has the potential to fundamentally transform the therapeutic modulation of the
immune system. We have created a novel approach to immune-modulation by designing biologics with structural characteristics that are not achievable by existing therapeutic modalities. Compounds derived from our proprietary Agonist Redirected
Checkpoint, or ARC, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. Our initial product candidates are designed to be differentiated therapeutics addressing molecular targets
that are well characterized and scientifically validated in immuno-oncology but are underexploited by current treatment modalities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
lead, wholly owned product candidate, <FONT STYLE="white-space:nowrap">SL-172154,</FONT> has been rationally designed to simultaneously inhibit the CD47/SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> checkpoint interaction to restore an
anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. We are currently conducting a Phase 1 clinical trial evaluating SL-172154 in patients with ovarian cancer and we expect to announce initial
data from the dose-escalation portion of this trial in the second half of 2021. We plan to initiate a second Phase 1 trial evaluating <FONT STYLE="white-space:nowrap">SL-172154</FONT> in patients with cutaneous squamous cell carcinoma, or CSCC, or
head and neck squamous cell carcinoma, or HNSCC, and we expect to announce data from the does-escalation portion of this trial in the second half of 2022. Our second product candidate, <FONT STYLE="white-space:nowrap">SL-279252,</FONT> which is
being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> interaction and activate
the OX40 receptor. We are evaluating <FONT STYLE="white-space:nowrap">SL-279252</FONT> in a Phase 1 clinical trial in patients with advanced solid tumors and lymphoma, and we expect to announce data from the dose-escalation portion of the trial in
the second half of 2021. In addition to our clinical-stage ARC product candidates, we possess a deep pipeline of preclinical immuno-oncology product candidates. Longer-term, we are pursuing additional disease areas, including autoimmune diseases,
where our dual-sided fusion protein platforms may provide advantages over current treatment modalities. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cancer is characterized by
the uncontrolled proliferation of abnormal cells. The immune system typically recognizes and eliminates abnormal cells. However, cancer cells have the ability to evade the immune system through the expression of checkpoint molecules, which ward off
an anti-tumor immune response that would otherwise lead to elimination of cancer cells. In an effort to leverage the immune system to promote an anti-tumor response, researchers have developed checkpoint inhibitor therapies, including <FONT
STYLE="white-space:nowrap">anti-CTLA-4,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1,</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-L1</FONT></FONT> antibodies,
which have represented a revolutionary milestone in the treatment of cancer. These therapies generate deep and durable responses, translating into meaningful clinical benefit and have become the cornerstone of treatment paradigms for many cancers.
However, the clinical benefit is limited to a minority of patients. This limitation highlights the need for novel modalities that may benefit a greater number of patients, such as a compound that simultaneously inhibits checkpoint molecules while
activating costimulatory molecules to generate a beneficial immune response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Driven by an increasing understanding of tumor biology, it
is now well-established that the activation of costimulatory molecules can generate a more effective immune response where current checkpoint inhibitors have failed. To date, there has been limited clinical success in combining the inhibition of
checkpoints with the activation of trimeric costimulatory molecules. We believe these efforts have had limited success due to the structural mismatch between existing bivalent antibodies and the trimeric costimulatory receptors of the tumor necrosis
factor, or TNF, receptor superfamily, such as CD40 and OX40. TNF activation and downstream signaling require the assembly of three receptor molecules, or trimerization. Existing bivalent antibodies can only bind to two TNF receptors and are thus
unable to trimerize TNF receptors, leading to weak signaling. Additionally, administration of two separate antibodies, which distribute in the body independent of one another, does not guarantee colocalization of their mechanisms of activity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary ARC platform is designed to overcome the limitations of existing bivalent
antibodies. ARC compounds consolidate checkpoint blockade and immune costimulation within a single therapeutic. Additionally, ARC compounds possess a structure that matches the native structure of the target receptors and colocalizes both mechanisms
of activity within the immune synapse to promote a coordinated immune response. As shown in Figure 1 below, one end of the ARC compound consists of a checkpoint receptor domain and the opposite end consists of a TNF ligand domain, connected by a
scaffold such as an Fc domain. We design ARC compounds to self-assemble into a hexameric structure, as shown in Figure 1 below, comprising six distinct checkpoint receptor domains and six distinct TNF ligand domains, which form two trimerized
costimulatory ligand domains. The hexameric structure of an ARC compound facilitates clusters of binding domains thus leveraging the strength of multiple individual binding interactions, known as affinity, into a greater collective strength of all
binding interactions, known as avidity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 1&#151;Structural Properties of ARC Compounds </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g38l06.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unique dual-sided structure of our ARC compounds allows us to simultaneously and effectively
target a wide array of pathways for the creation of a deep and differentiated product pipeline. We utilize our understanding of disease pathology and immune dysfunction to identify pairings of optimal domains. Initially, our efforts are concentrated
on three broad target families: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Immune Checkpoints.</I></B> Immune checkpoints include a variety of receptor/ligand pairs that inhibit
immune responses and are utilized by many cancers as a defense against anti-tumor immune responses. The blockade of immune checkpoints, such as CD47/SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1,</FONT></FONT> and TIGIT/PVR, has the potential to restore anti-tumor immune responses and improve survival in cancer patients. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>TNF Superfamily.</I></B> The TNF superfamily consists of multiple structurally related receptors, such as
CD40, OX40, <FONT STYLE="white-space:nowrap">4-1BB,</FONT> DR5, CD30, LT&szlig;R, and HVEM, as well as ligands that orchestrate the induction, magnitude, quality, and duration of immune responses. Individual TNF receptor/ligand pairs exhibit
distinct expression patterns on immune cell subsets and can fine-tune both myeloid cell- and lymphocyte-mediated immunity. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Cytokines. </I></B>Cytokines, chemokines, and interleukins include a broad range of soluble molecules that
control a wide array of biological responses, including inflammation and immunity. We believe our platform&#146;s ability to block or activate these pathways, including <FONT STYLE="white-space:nowrap">CSF1R/CSF1/IL-34</FONT> and TGFBR2/ <FONT
STYLE="white-space:nowrap">TGF-&szlig;</FONT> and specific cytokines, expands our addressable target universe and potential therapeutic indications. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While therapeutic inhibition of immune checkpoints has been shown to improve overall survival in a minority of cancer patients, combining
immune checkpoint blockade with activation of TNF superfamily receptors, or modulation of cytokines may deepen responses and increase the number of cancer patients that benefit from immunotherapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that the following features represent the key advantages offered by compounds developed with the ARC platform: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Matching Native Structure of TNF Receptors.</I></B> TNF receptors and ligands require trimerization, or
assembly into groups of three, for efficient signaling. A hexameric ARC compound contains two trimerized TNF ligand domains, which directly activate trimeric TNF receptors, thus overcoming the structural limitations of bivalent antibodies.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Target Specificity, High Affinity, and High Avidity.</I></B> ARC compounds incorporate twelve distinct
binding domains, six for each of the two targets, enabling high-avidity and durable binding to specific cell surface targets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Replacing Tumor Immune Evasion with Potent Immune Stimulation. </I></B>ARC compounds are designed to
simultaneously reverse a tumor&#146;s immune evasion and amplify anti-tumor immune responses locally within the tumor microenvironment. In preclinical models, the ability of our ARC compounds to colocalize checkpoint inhibition and costimulation
demonstrated superior anti-tumor response as compared to the administration of separate antibody therapies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Versatility.</I></B> Modularity of the ARC platform enables production of thousands of potential
therapeutic candidates across oncology, autoimmune diseases, and other disease areas. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Speed from Concept to Compound to Clinic.</I></B> The ARC platform allows for a significantly compressed
development timeline from &#147;Concept to Compound to Clinic,&#148; which has enabled us to clinical trials and generate over 300 unique, dual-sided fusion proteins and two clinical-stage assets in less than four years. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Accelerated Lead Selection Process.</I></B> We are able to identify and select optimal therapeutic
constructs during the design and discovery phase of product candidate development through the rational pairing of optimized domains, enabling the efficient transition from discovery to the clinic. The rapid development path of ARC compounds permits
systematic and simultaneous comparison of multiple ARC compound variants prior to lead selection. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe these
collective advantages create the potential for the capital-efficient identification and pursuit of differentiated product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also leveraging our expertise and intellectual property to build novel platforms beyond our ARC platform, where dual-sided fusion
proteins may provide advantages over existing therapeutic antibodies. One such platform is our Gamma Delta T Cell Engager platform, known as GADLEN. A majority of T cells in the human body bear an alpha beta T cell receptor, which recognizes tumor
antigens via major histocompatibility complex, or MHC, molecules. Some cancer cells reduce the expression of MHC molecules, rendering those cancer cells invisible to most alpha beta T cells. Gamma delta T cells represent approximately 2% to 5% of
the total T cell population and, unlike alpha beta T cells, are not dependent on MHC molecules to recognize and kill tumor cells. The therapeutic utilization of gamma delta T cells represents a novel approach for the treatment of cancer. This
approach may be particularly beneficial in targeting tumors that are not addressable by alpha beta T cells. Additionally,&nbsp;as immunotherapies that stimulate alpha beta T cell-dependent immune responses are increasingly utilized across cancer
treatment paradigms, the proportion of patients who may become refractory to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
alpha beta T cell-mediated therapies will also increase over time, creating an absence of effective treatment options that may be addressed by the utilization of gamma delta T cells. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we believe compounds developed with our ARC and GADLEN platform may provide significant key advantages, we are in an early stage of
development using novel technologies and cannot assure you that our approach will lead to the development of marketable products. For example, SL-279252 is in Phase 1 development and although data as of September 9, 2020 has shown it has been well
tolerated, with no <FONT STYLE="white-space:nowrap">dose-limiting</FONT> toxicities observed, additional data from any of our dual-sided fusion protein product candidates may result in unanticipated safety and efficacy outcomes or unexpected
biological interactions that could delay or prevent their development. Moreover, we are aware that others have experienced limited clinical success when attempting to combine the inhibition of checkpoint molecules with the activation of trimeric
costimulatory molecules. We believe this limited success is attributable to a structural mismatch between the bivalent antibodies and trimeric costimulatory receptors, which we have attempted to address in the design of our ARC platform compounds.
</P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Pipeline </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are leveraging
our proprietary ARC and GADLEN platforms to discover and develop dual-sided, <FONT STYLE="white-space:nowrap">bi-functional</FONT> fusion protein product candidates. We own or have exclusively licensed the intellectual property rights to our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table highlights our two clinical-stage assets that have been derived from our ARC
platform:&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g14c21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <FONT STYLE="white-space:nowrap">SL-172154,</FONT> simultaneously inhibits CD47
and activates the CD40 receptor. We believe <FONT STYLE="white-space:nowrap">SL-172154</FONT> has the potential to offer a differentiated approach to targeting CD47. Other approaches solely focus on activating the innate immune system by blocking
the CD47 macrophage &#147;don&#146;t eat me&#148; signal. In addition to inhibiting CD47, <FONT STYLE="white-space:nowrap">SL-172154</FONT> is designed to bridge the innate and adaptive immune response by subsequently activating CD40 signaling to
upregulate antigen presentation machinery. In preclinical studies of <FONT STYLE="white-space:nowrap">SL-172154,</FONT> we observed superior tumor rejection as compared to CD47 and CD40 antibodies, a durable receptor occupancy, a dose-dependent
lymphocyte migration into lymphoid tissues and no occurrence of anemia. We have initiated a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">SL-172154</FONT> administered by intravenous injection in patients with ovarian, fallopian tube,
and peritoneal cancers, referred to collectively as ovarian cancer, and we expect to announce initial data from the dose-escalation portion of this trial in the second half of 2021. We plan to initiate a second Phase 1 clinical trial of <FONT
STYLE="white-space:nowrap">SL-172154</FONT> administered by intratumoral injection in patients with CSCC or HNSCC and we expect to announce data from the dose-escalation portion of this trial in the second half of 2022. These tumors were selected
due to their particularly high expression of CD47, a high presence of macrophages in the tumor microenvironment, and a lack of effective treatment options for these indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second product candidate, <FONT STYLE="white-space:nowrap">SL-279252,</FONT> being
developed in collaboration with Takeda, simultaneously inhibits <FONT STYLE="white-space:nowrap">PD-1</FONT> and activates the OX40 receptor. We believe <FONT STYLE="white-space:nowrap">SL-279252</FONT> has the potential to offer a differentiated
approach to targeting PD-1 and OX40, as compared to existing antibody therapies, either as individual monotherapies or in combination. Antibodies targeting OX40 have not demonstrated sufficient efficacy in clinical trials, a result that we believe
is due to a structural mismatch between bivalent antibodies and trimeric OX40 receptors. The unique hexameric structure of <FONT STYLE="white-space:nowrap">SL-279252</FONT> is designed to more effectively bind to and activate OX40 receptors, leading
to optimized signaling and resulting in T cell activation and proliferation. Together, these properties are intended to replace <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-mediated</FONT></FONT> immune inhibition with
OX40 costimulation to synergistically enhance anti-tumor response. In preclinical models, compared to the combination of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> and OX40-agonist antibodies, <FONT
STYLE="white-space:nowrap">SL-279252</FONT> demonstrated superior tumor reduction and lymphocyte proliferation and migration to tissues. Our ongoing Phase 1 trial is evaluating <FONT STYLE="white-space:nowrap">SL-279252</FONT> in patients with
advanced solid tumors and lymphoma. We expect to announce dose-escalation data in the second half of 2021. Takeda has an option to exercise a license of <FONT STYLE="white-space:nowrap">SL-279252</FONT> prior to initiation of a Phase 2 clinical
trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our lead product candidates, we have an extensive discovery pipeline consisting of over 300 unique fusion proteins
that we have manufactured and characterized in both <I>in vitro </I>and<I> in vivo</I> studies. We intend to nominate additional lead candidates in oncology, as well as autoimmune disease, to further broaden our pipeline. In accordance with our
prioritization strategy, we intend to develop these compounds as data emerge that clinically validate the targets. Our long-term plan also includes the development of product candidates for novel targets. We plan to nominate clinical product
candidates from our ARC or GADLEN platforms. We anticipate submitting additional Investigational New Drug Applications, or INDs, in both the second half of 2021 and in the first half of 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table highlights the preclinical programs from which we may select our next clinical candidates to be developed independently or
in collaboration with a partner: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g40j56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team and Board possess decades of experience in cancer immunotherapy, autoimmune disease, targeted therapeutics, protein
engineering, biologics manufacturing, clinical development, regulatory strategy, and commercialization. Members of our team were involved with, or led, drug development programs leading to the approval of drugs including Votrient, Tafinlar,
Mekinist, Enbrel, Nucala, Valtrex, Arranon, Tykerb, Avastin, Revlimid, Pomalyst, and others. Our team members have held senior leadership positions at leading companies including GlaxoSmithKline, Celgene, Pfizer, Novartis, Takeda, Alexion, Medarex,
Amgen, Merck KGaA, OSI Pharmaceuticals, and Reata Pharmaceuticals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our founding in 2016, we have raised approximately
$239.1&nbsp;million through redeemable convertible preferred stock financings and <FONT STYLE="white-space:nowrap">non-dilutive</FONT> partnership funds. Our key investors include Redmile Group, Fidelity
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Management and Research Company, Janus Henderson, EcoR1 Capital, Partner Fund Management, Avidity Partners, Hatteras Venture Partners, Emerson Collective, Piper Sandler&nbsp;&amp; Co., JSR
Corporation, and Takeda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become the world leader in the discovery, development, and commercialization of dual-sided,
<FONT STYLE="white-space:nowrap">bi-functional</FONT> fusion proteins for the treatment of cancer and autoimmune diseases. We plan to achieve this by utilizing our proprietary ARC and GADLEN platforms to create novel therapeutics to treat patients
who lack effective treatment options. Key elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Rapidly advancing</B> <B>our clinical-stage ARC product candidates,
<FONT STYLE="white-space:nowrap">SL-172154</FONT> and <FONT STYLE="white-space:nowrap">SL-279252,</FONT> through clinical development and marketing approval. </B><FONT STYLE="white-space:nowrap">SL-172154,</FONT> our lead wholly owned program, is
currently in a Phase 1 trial for the treatment of ovarian cancer, and we plan to initiate a second Phase 1 trial for the treatment of CSCC and HNSCC in the second half of 2020. We expect to announce initial data from the dose-escalation portion of
the SL-172154 trial in patients with ovarian cancer in the second half of 2021 and data from the dose-escalation portion of the SL-172154 trial in patients with CSCC or HNSCC in the second half of 2022. Further development may include other solid
tumors and hematological <FONT STYLE="white-space:nowrap">malignancies.&nbsp;SL-279252,</FONT> which we are developing in collaboration with Takeda, is also in a Phase 1 trial for the treatment of advanced solid tumors and lymphoma. We expect to
announce data from the dose-escalation portion of the SL-279252 trial in the second half of 2021. If the data obtained in these trials are highly compelling, accelerated registration paths and other regulatory designations will be discussed with
regulatory agencies. However, any such determination will be made in the sole discretion of such regulatory agencies and there can be no guarantee that any of our product candidates will be granted a differentiated regulatory path or designation.
</P></TD></TR></TABLE>  <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Leveraging our ARC and GADLEN platforms to rapidly advance additional product candidates into clinical
development. </B>Our platforms allow us to rapidly identify and develop pipeline product candidates.<B> </B>Since our inception in 2016, we have generated more than 300 unique, dual-sided fusion proteins. Our initial focus is on targets that are
well characterized and scientifically validated in immuno-oncology but are underexploited by current treatment modalities. Longer-term, we plan to pursue novel targets in immuno-oncology and also pursue additional diseases areas, including
autoimmune diseases, where our dual-sided fusion proteins may provide advantages as compared to current treatment modalities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continuing to augment our fusion protein manufacturing capabilities.</B> We are pioneers in the field of
therapeutic <FONT STYLE="white-space:nowrap">bi-functional</FONT> fusion proteins. Manufacturing these biologic drugs involves substantial internally-developed <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets. To date, we have
invested major resources in the development and optimization of our purification process, as well as other aspects of the manufacturing process. We intend to continue investing in our internal manufacturing capabilities so as to provide sufficient
supply for our clinical trials and eventually scale production up to meet commercial requirements. The continual improvement of our manufacturing capabilities will be important to driving efficiency, maintaining high standards of quality control,
and ensuring that investigators, physicians, and patients have adequate access to our approved products. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Collaborating with leading biopharmaceutical companies. </B>Similar to our collaboration agreement with
Takeda, we intend to broaden the global reach of our <FONT STYLE="white-space:nowrap">bi-functional</FONT> fusion protein platforms by selectively collaborating with leading biopharmaceutical companies.&nbsp;We intend to retain significant economic
and commercial rights to our programs in key geographic areas that are core to our long-term strategy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Deepening our intellectual property portfolio to continue to protect our platform technologies and product
candidates.</B> We have built a global intellectual property portfolio consisting of patents and patent applications, trade secrets, trademarks, and <FONT STYLE="white-space:nowrap">know-how</FONT> to protect the product candidates developed from
our <FONT STYLE="white-space:nowrap">bi-functional</FONT> fusion protein platforms. We plan to expand our intellectual property portfolio as we continue to advance and develop existing product candidates and platforms, as well as create novel
platform technologies. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Building on our culture of R&amp;D excellence and continuing to
<FONT STYLE="white-space:nowrap">out-innovate</FONT> ourselves</B><B>.</B> Our people, and the culture that we foster, have been instrumental to our success. We have assembled a world-class team of professionals whose track records include the
successful development of several commercial products at major biopharmaceutical companies. The expertise that we have assembled has enabled us to develop two novel platforms to date and will allow us to maintain our leadership position in the field
of <FONT STYLE="white-space:nowrap">bi-functional</FONT> fusion proteins. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview of Immuno-oncology Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past decade, a growing understanding of the molecular mechanisms that allow cancer cells to evade detection by the immune system has
led to the advent of immuno-oncology, a treatment paradigm that seeks to stimulate or supplement a person&#146;s own immune system to selectively attack cancer cells. Immune responses are initiated through antigen presentation by innate immune
cells, including macrophages, and dendritic cells. The ensuing adaptive immune response is mediated by T cells. Both innate and adaptive immune responses are governed by the balance of signals that inhibit the immune response, or checkpoint
pathways, and signals that accelerate the immune response, or costimulatory pathways. Checkpoint inhibition is focused on releasing the &#147;brakes&#148; on the immune system to allow T cells to recognize and eradicate tumors. In certain types of
tumors, checkpoint inhibitors have demonstrated higher response rates, improved overall survival, and a better safety profile as compared to other available treatments. One subset of checkpoint inhibitors,
<FONT STYLE="white-space:nowrap">PD-1</FONT> inhibitors, achieved $19.4&nbsp;billion in global sales in 2019 and are expected to garner over $36.0&nbsp;billion in global annual sales by 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Checkpoint inhibitors have demonstrated clinical benefit for a subset of cancer patients, but there remains room for improvement. It is
estimated that less than 13% of all cancer patients in the United States respond to checkpoint inhibitors. Approximately 44% of U.S. patients with cancer are eligible for checkpoint inhibitor therapies and only 28% of these patients respond to
therapy, underscoring the lack of effective treatment options. Multiple mechanisms contribute to preventing anti-tumor activity and, consequently, it is critical to simultaneously modulate several immune processes in order to circumvent the various
adaptations tumors employ to evade the immune system. One such approach has been to activate costimulatory molecules in combination with checkpoint inhibition. One prominent class of costimulatory molecules is the TNF superfamily, which includes
many receptors such as CD40 and OX40. The diversity of receptors within the TNF superfamily allows the immune system to fine-tune the magnitude, quality and duration of specific immune responses. This diversity can be leveraged to purposefully build
therapeutics to modulate the specific TNF pathways which are most relevant for the underlying disease biology. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While many TNF
receptor agonist antibodies have been developed and tested in human clinical trials, most have been discontinued after Phase 1 testing and only in a rare instance have they advanced to pivotal studies. Activation and downstream signaling require the
assembly of three receptor molecules, or trimerization. As shown in Panel A of Figure 2 below, there is a structural mismatch between bivalent antibody therapeutics and trimeric TNF receptors, such as OX40. Traditional bivalent antibodies can only
bind to two TNF receptors and are thus unable to individually trimerize a TNF receptor, leading to weak signaling of TNF pathways. As shown in Panel B of Figure 2, in order for TNF receptor agonist antibodies to trimerize a TNF receptor, multiple
antibodies must be cross-linked through Fc receptors located on accessory cells. As shown in Panel C of Figure 2, this mechanism becomes less effective at increasing antibody doses due to saturation of TNF receptors and Fc receptors independently of
each other. Consequently, there is no free Fc receptor available to cross-link the TNF receptor bound antibody. This effect manifests in clinical trials as an atypical dose-response relationship. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 2&#151;Antibody Therapies Lead to Inefficient TNF Pathway Activation </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g35x57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, expression levels of TNF superfamily receptors fluctuate throughout the course of a
patient&#146;s immune response and vary from patient to patient. For example, OX40 could be expressed in 2% of a patient&#146;s T cells prior to inducing an immune response, but could rise to 25% of T cells shortly following induction of an immune
response. Effective trimerization of a TNF receptor such as OX40 requires a <FONT STYLE="white-space:nowrap">sub-saturating</FONT> dose of an existing TNF receptor antibody in order to avoid ineffective signaling as shown in Panel C of Figure 2
above. However, an optimal <FONT STYLE="white-space:nowrap">sub-saturating</FONT> dose cannot be accurately determined given the fluctuation of TNF receptor expression throughout the course of a patient&#146;s immune response and the variation in
TNF receptor expression from patient to patient. The need remains for a molecule that does not require exogenous Fc receptor-mediated cross-linking in order to induce trimerization of TNF receptor targets and drive a costimulatory signal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our ARC Platform </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our proprietary Agonist
Redirected Checkpoint, or ARC, platform has the potential to create therapeutics that can dramatically change the way we treat cancer and other diseases. We developed the ARC platform to address the need for a single therapeutic that consolidates
multiple immune functions. Compounds developed from our ARC platform simultaneously block immune checkpoint receptors and activate costimulatory molecules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Structure of an ARC Compound </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We designed the ARC platform as a modular scaffold wherein three principal components are fused together, comprising a human Type 1
extracellular domain protein, an Fc domain, and a human Type 2 extracellular domain protein. A vector carrying a sequence of the dual-sided construct is then transfected into mammalian cells, which are used as the ARC production cell line. Once
purified, the proteins secreted by the cell then self-assemble via a step-wise process, first dimerizing via disulfide bonds in the Fc domain, followed by trimerization on the costimulatory factor ligand domains, as shown in Figure 3 below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 3&#151;Assembly Process for ARC Compounds </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g74a56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown on the left in Figure 4 below, these components form a compound with a unique hexameric structure,
incorporating six distinct binding domains for each of two targets, for a total of twelve binding sites. This property endows each ARC compound with the ability to bind multiple targets with higher affinity and avidity than is achievable by
antibody-based therapeutics. The image on the right in Figure 4 below provides a high-resolution electron micrograph representing a <FONT STYLE="white-space:nowrap">birds-eye</FONT> view of <FONT STYLE="white-space:nowrap">SL-279252,</FONT> with the
six white spots representing each of the six OX40L binding domains of the compound. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 4&#151;Structure of the ARC Compound
SL-279252 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g21s76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The functional domains of ARC compounds are derived from native human proteins, rather than antibody
binding domains. This enables the rapid generation of new constructs, given that the starting template for distinct ARC compounds is the human genome. Therefore, an ARC compound can be taken from the conception stage to a manufactured purified
protein in approximately six weeks, whereas it can take approximately six months to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reach the same stage for an antibody therapeutic candidate. This rapid reduction in discovery processing time, has allowed us to generate more than 300 unique, dual-sided fusion proteins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the strong scientific rationale for targeting the TNF receptor superfamily, clinical trials evaluating existing bivalent antibodies
have failed to demonstrate meaningful clinical benefit, which we believe is due to the structural mismatch between bivalent antibodies and the native trimeric structure of TNF receptors. As shown in Figure 4 above, the hexameric structure of our ARC
compounds uniquely allows for effective binding and activation of trimeric receptors without the need for Fc receptor-mediated cross-linking. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 5&#151;ARC Compounds Uniquely Facilitate Trimerization </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g57f62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond its unique ability to effectively activate the TNF receptor superfamily, we believe the ARC compound
possesses several additional advantages over existing antibody therapeutics. Unlike IgG and IgM antibodies, which can only bind to a single target, an ARC compound can bind to two distinct targets. While bispecific antibodies can also bind to two
unique targets, they do so in a monovalent fashion, whereas ARC compounds can do so in a multivalent fashion. The hexameric structure of an ARC compound represents a differentiated approach, including two sets of six binding domains, allowing for
high-avidity binding to two distinct targets. The ARC platform thus enables the synergistic colocalization of checkpoint blockade and costimulatory molecule activation, which has been shown <I>in vitro </I>and<I> in vivo</I> to be superior on
several measures to <FONT STYLE="white-space:nowrap">co-administration</FONT> of two separate bivalent antibodies or single-sided fusion proteins. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Figure 6 below compares our ARC compound with several antibody formats, including IgG
antibodies, bispecific antibodies, and IgM antibodies: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 6&#151;Comparative Attributes of Antibodies and ARC Compounds </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g14c33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Hexameric Structure and Checkpoint/Costimulatory Colocalization of ARC Compounds Provide Enhanced
Anti-Tumor Activity Compared to Existing Antibodies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ a rigorous preclinical framework to ensure that only the most
promising product candidates are selected for clinical development. Before advancing an ARC product candidate into clinical development, both human and mouse variants for each product candidate are generated and systematically evaluated in parallel
through a battery of analytical assays, comparing the anti-tumor activity of an ARC product candidate to antibodies targeting the same pathways in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> <I>in
vitro </I>and <I>in vivo </I>animal studies. For example, as shown in Figure 7 below, we evaluated the anti-tumor activity of murine SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><FONT STYLE="white-space:nowrap">-Fc-CD40L</FONT> in the left
panel, and murine <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1-Fc-OX40L</FONT></FONT></FONT> in the right panel, against antibodies targeting the same pathways. Individual mice with rapidly
growing tumors were treated with checkpoint blocking antibodies and costimulatory agonist antibodies, either alone or in combination, in comparison with the corresponding ARC compounds. The dosing regimen was fixed in these studies across all groups
to facilitate a controlled comparison of the efficacy of each treatment. These results demonstrate that ARC compounds were able to control tumor growth in mice to a greater degree than the corresponding existing antibodies, either alone or in
combination. The primary columns in Figure 7 below represents the number of mice that rejected the primary tumor. The <FONT STYLE="white-space:nowrap">re-challenge</FONT> columns in Figure 7 below represents the number of mice that rejected the
primary tumor and were also capable of rejecting a second tumor challenge without repeat treatment. For example, of the five mice that rejected their primary tumors after treatment with murine SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><FONT
STYLE="white-space:nowrap">-Fc-CD40L,</FONT> three had demonstrated a durable, adaptive immune response by rejecting a second tumor challenge without the administration of an additional dose. We believe the superior tumor control in mice treated
with ARC compounds is due to the colocalization of a trimerized TNF ligand to the site of checkpoint blockade and is a distinguishing characteristic that we expect will be observed across the platform. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 7&#151;ARC Compounds Show Significantly Enhanced Anti-Tumor Activity as Compared to
Antibody Controls </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g14d44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once we have established the anti-tumor activity of an ARC product candidate, the next phase of preclinical
development consists of additional <I>in vitro </I>studies further comparing the ARC product candidate against benchmark antibodies targeting the same pathways. For example, we used a standard potency assay previously used to support the approval of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies. This assay compared the amount of <FONT STYLE="white-space:nowrap">interleukin-2,</FONT> or <FONT STYLE="white-space:nowrap">IL-2,</FONT> secreted
by lymphocytes following treatment with <I>staphylococcal enterotoxin B</I>, or SEB, a bacterial toxin, in the presence of <FONT STYLE="white-space:nowrap">SL-279252</FONT> and other
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> or OX40 agonist antibodies. Secretion of <FONT STYLE="white-space:nowrap">IL-2</FONT> by human lymphocytes is an indicator of adaptive immune activation. As
shown in Figure 8 below, when primary human lymphocytes were exposed to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies nivolumab and pembrolizumab in the presence of SEB, both <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies stimulated a dose-dependent increase in the concentration of <FONT STYLE="white-space:nowrap">IL-2</FONT> in the cell cultures. In contrast,
tavolixizumab, an OX40 agonist antibody, did not stimulate an increase in the concentration of measured <FONT STYLE="white-space:nowrap">IL-2</FONT> in the cell cultures, and did not increase the quantity of
<FONT STYLE="white-space:nowrap">IL-2</FONT> secretion stimulated by nivolumab or pembrolizumab alone. We believe the lack of activity of tavolixizumab in this assay is due to the dependence of the antibody on Fc receptor mediated cross-linking for
activity. <FONT STYLE="white-space:nowrap">SL-279252</FONT> also stimulated dose-dependent increases in the concentration of <FONT STYLE="white-space:nowrap">IL-2</FONT> secreted by human lymphocytes in the cultures, and a higher concentration of <FONT
STYLE="white-space:nowrap">IL-2</FONT> was observed in cultures treated with <FONT STYLE="white-space:nowrap">SL-279252</FONT> than with nivolumab or pembrolizumab. These data indicate that <FONT STYLE="white-space:nowrap">SL-279252</FONT> is a more
potent stimulator of <FONT STYLE="white-space:nowrap">IL-2</FONT> secretion by human lymphocytes as compared to nivolumab or pembrolizumab. In addition to the two assay systems described above, we utilize a multitude of other criteria to further
assess preclinical safety and efficacy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 8&#151;</B><B><I>In Vitro</I></B><B> Potency Assay for PD-1 Biologics </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g14e45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Primary human peripheral blood mononuclear cells, or PBMC, were harvested and treated with SEB and <FONT
STYLE="white-space:nowrap">SL-279252</FONT> and benchmark antibody controls. Because antibodies contain two target binding domains, molar comparisons to ARC compounds were made on the basis of a matched number of ARC binding sites, using the
molecular weight of a dimeric ARC. </I></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once ARC product candidates demonstrate superior performance as compared to the relevant
antibody comparators in both mouse tumor models and human <I>in vitro </I>assays, we may advance our ARC product candidates to studies in <FONT STYLE="white-space:nowrap">non-human</FONT> primates, or NHP. We have evaluated eight different ARC
compounds in NHP to date and have observed unique <FONT STYLE="white-space:nowrap">on-target</FONT> activity between ARC compounds. As an example, NHP treated with <FONT STYLE="white-space:nowrap">SL-172154</FONT> were observed to have
dose-dependent migration of CD40+ lymphocytes from the peripheral blood into secondary lymphoid organs including the lymph nodes and spleen. We observed extensive expansion of lymphoid-rich cells in the spleen from a NHP treated with <FONT
STYLE="white-space:nowrap">SL-172154</FONT> as compared to a control from the same study. In contrast to <FONT STYLE="white-space:nowrap">SL-172154,</FONT> NHP treated with <FONT STYLE="white-space:nowrap">SL-279252</FONT> were observed to have
dose-dependent migration of lymphocytes to the liver, gastrointestinal tract, and lungs. In addition, we observed infiltration of both local lymph nodes and the areas surrounding blood vessels in the lung of a NHP treated with <FONT
STYLE="white-space:nowrap">SL-279252,</FONT> as compared to a control animal from the same study. To our knowledge, similar observations have not been reported in NHP studies utilizing <FONT STYLE="white-space:nowrap">TNF-agonist</FONT> antibodies.
We believe these observations, which were accompanied by serum cytokine changes, provide evidence of <FONT STYLE="white-space:nowrap">on-target</FONT> biology driven by ARC compound-mediated stimulation of CD40 or OX40. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that by systematically evaluating ARC compounds targeting clinically validated checkpoints through a series of preclinical studies
comparing ARC compounds to the relevant benchmark antibodies, we are able to prioritize ARC product candidates that are best positioned to provide a clinical benefit. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Versatility of the Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The modularity of our dual-sided fusion protein platforms, including our ARC platform, facilitates a vast repertoire of potential dual-sided
fusion proteins that can be synthesized and developed.<I> </I>In the human genome, there are more than 1,400 Type 1 membrane proteins, which are characterized by an extracellular amino terminal domain, and more than 450 Type 2 membrane proteins,
which are characterized by an extracellular carboxy terminal domain. ARC compounds are assembled from any combination of Type 1 and Type 2 membrane proteins and, therefore, have significant diversity, with more than 630,000 possible combinations.
Within this vast set of possible combinations, we have chosen to focus initially on three classes of targets that have already shown significant clinical relevance for the treatment of cancer comprising immune checkpoints, the TNF superfamily, and
cytokines. We utilize our understanding of disease pathology and immune dysfunction to identify pairings of optimal targets within a single therapeutic. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Examples of notable targets that we are currently utilizing, or may in future elect to
utilize, our ARC compounds are described in the table below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Potential Targets for ARC Compounds </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g77v34.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to targeting immune checkpoints and TNF superfamily receptors, we are also targeting cytokines,
which are largely responsible for promoting and regulating an immune response. Cytokines are proteins synthesized and secreted by immune cells and which mediate immune stimulation or suppression, thereby driving autoimmune diseases and participating
in immune evasion and progression of cancers. In cancer, cytokines such as <FONT STYLE="white-space:nowrap">IL-2</FONT> and interferons have been shown to stimulate antitumor immune response, whereas cytokines such as
<FONT STYLE="white-space:nowrap">TGF-&szlig;,</FONT> CSF1, and IL-34 have been shown to promote tumor progression. In autoimmune diseases, <FONT STYLE="white-space:nowrap">IL-6</FONT> and TNF<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> are highly
implicated in disease development and progression. We have leveraged the versatility of our ARC platform to construct ARC compounds that target cytokines implicated in cancer as well as cytokines implicated in autoimmune diseases. For example, <FONT
STYLE="white-space:nowrap">SL-115154</FONT> binds soluble CSF1 and <FONT STYLE="white-space:nowrap">IL-34</FONT> and simultaneously activates CD40 receptors. Some of our early stage product candidates bind
<FONT STYLE="white-space:nowrap">TGF-&szlig;</FONT> and simultaneously activate a variety of costimulatory receptors. Similar to our cancer product candidates, our autoimmune product candidates are designed to influence disease pathways by
simultaneously trapping inflammatory signals and promoting immunosuppressive functions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our GADLEN Platform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our expertise in engineering dual-sided, <FONT STYLE="white-space:nowrap">bi-functional</FONT> fusion proteins has enabled the development of
our Gamma Delta T Cell Engager, or GADLEN, platform to leverage gamma delta T cells for the treatment of cancer. We expect to nominate product candidates from our GADLEN platform in 2021 to support our clinical-stage pipeline in 2022 and beyond.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The therapeutic utilization of gamma delta T cells represents a novel approach for the treatment of cancer. This approach may be
particularly beneficial in targeting tumors that are not addressable by alpha beta T cells. Additionally, as immunotherapies that stimulate alpha beta T cell-dependent immune response are increasingly utilized across cancer treatment paradigms, we
expect the proportion of patients who will become refractory to alpha beta T cell-mediated therapies will also increase over time, creating an absence of effective treatment options that may be addressed by the utilization of gamma delta T cells.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A majority of T cells in the human body bear an alpha beta T cell receptor, which recognizes tumor antigens presented on major
histocompatibility complex, or MHC, molecules. Some cancer cells reduce the expression of MHC molecules or tumor antigens, rendering those cancer cells invisible to most alpha beta T cells. Gamma delta T cells represent approximately 2% to 5% of the
total T cell population and their presence within tumors is strongly correlated with increased survival in cancer patients. Unlike alpha beta T cells, gamma delta T cells are not dependent on MHC molecules, or a single antigen, to recognize and kill
tumor cells. Instead, the gamma delta </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
T cell receptor is activated by a newly-identified, tissue-specific complex of two heterodimerized butyrophilin proteins. Thus, biologic therapies comprising a heterodimer of butyrophilin
proteins may provide a tool to therapeutically modulate gamma delta T cells. Our GADLEN platform has the potential to expand the range of addressable indications for cancer immunotherapy and treat historically difficult to treat patients. We have
leveraged our expertise in engineering dual sided <FONT STYLE="white-space:nowrap">bi-functional</FONT> fusion proteins to develop a suite of heterodimerized butyrophilin proteins connected to antigen-targeted single chain antibody fragments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">GADLEN compounds are comprised of two distinct fusion protein chains, and an engineered Fc linker domain that facilitates heterodimerization
between the two chains. As shown in the left panel of Figure 9A below, the assembled GADLEN compound contains the extracellular domains of heterodimerized butyrophilin proteins on one side and is linked to tumor antigen specific single chain
antibody fragments on the opposite side. The gamma delta T cell receptors recognize and are activated by specific butyrophilin protein heterodimers. Thus, the GADLEN construct is designed to facilitate targeting of specific gamma delta T cells to
tumor cells expressing a defined antigen, as shown in the right panel of Figure 9A below. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 9A&#151;GADLEN Platform Overview
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g46y71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To demonstrate the feasibility of the GADLEN approach, a murine GADLEN construct was developed
incorporating a butyrophilin 1, or BTNL1, and butyrophilin 6, or BTNL 6, heterodimer and an scFv domain targeting the CD19 antigen. In both mice and humans, gamma delta T cells represent approximately 2% to 5% of the total T cell population, as
shown in Figure 9B in a murine model. Following treatment on Days 0 and 3 with the murine GADLEN, mBTNL1/6-Fc-CD19scFv, we observed dose-dependent expansion of the endogenous gamma delta T cell compartment to approximately 12% of all T cells 24
hours after the second treatment. Concurrent with expansion, mBTNL1/6-Fc-CD19scFv also caused activation of murine gamma delta T cells, as demonstrated by upregulation of the CD69 activation marker, shown in Figure 9B. Murine B cells express CD19,
and therefore were a potential target of gamma delta T cells following treatment with mBTNL1/6-Fc-CD19scFv. Accordingly, we observed depletion of the endogenous B cell compartment concurrent with gamma delta T cell expansion and activation following
treatment with mBTNL1/6-Fc-CD19scFv, as shown in Figure 9B. We believe these studies indicate that GADLEN compounds enable therapeutic modulation of gamma delta T cells <I>in vivo</I>, and that GADLEN compounds may be designed to activate
tissue-restricted populations of endogenous gamma delta T cells to target specific tumor antigens in both solid and liquid tumors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 9B&#151;Dose Dependent Gamma T Cell Expansion, Activation, and Killing Activity
Following Administration of the GADLEN Compound mBTNL1/6-Fc-CD19scFv </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g66q53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our ARC Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the collective advantages of our ARC platform and our internal capabilities allow for the capital-efficient identification and
pursuit of differentiated product candidates. Our lead product candidates, <FONT STYLE="white-space:nowrap">SL-172154</FONT> and <FONT STYLE="white-space:nowrap">SL-279252,</FONT> are designed to address molecular targets that are well-characterized
and clinically validated in immuno-oncology, but are under-exploited by current treatment modalities. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">SL-172154:</FONT> A Dual CD47/SIRP</I></B><B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><B></B><B></B><B><I> Blocking and CD40-Activating ARC Compound </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <FONT STYLE="white-space:nowrap">SL-172154,</FONT> simultaneously inhibits CD47 and activates the CD40 receptor.
In preclinical studies of <FONT STYLE="white-space:nowrap">SL-172154,</FONT> we have observed no occurrence of anemias, a durable receptor occupancy, and dose-dependent lymphocyte migration into lymphoid tissues. We have initiated a Phase 1 clinical
trial of <FONT STYLE="white-space:nowrap">SL-172154</FONT> administered by intravenous injection in patients with ovarian, fallopian tube, and peritoneal cancers, collectively referred to as ovarian cancer, and we plan to initiate a second Phase 1
clinical trial of <FONT STYLE="white-space:nowrap">SL-172154</FONT> administered by intratumoral injection in patients with CSCC or HNSCC in the second half of 2020. These tumors were selected due to their particularly high expression of CD47, a
high presence of macrophages in the tumor microenvironment, and a lack of effective treatment options for these indications. For the Phase 1 clinical trial evaluating SL-172154 in ovarian cancer patients, we expect to announce initial data from the
dose-escalation portion of the trial in the second half of 2021. We plan to announce data from the dose-escalation portion of the Phase 1 trial evaluating SL-172154 in CSCC and HNSCC patients in the second half of 2022. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Improving upon Existing Therapeutics Targeting CD47/SIRP</I><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><I></I><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order for CD47/SIRP<B></B><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><B></B><B></B> blockade to effectively inhibit tumor growth, the
CD47/SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> &#147;don&#146;t eat me&#148; signal must be blocked and an &#147;eat me&#148; signal must be present to stimulate macrophage-mediated phagocytosis. While CD47 and SIRP<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> therapeutics have demonstrated anti-tumor activity in a range of tumor types including diffuse large B-cell lymphoma, or DLBCL, myelodysplastic syndrome, acute myeloid leukemia, gastric cancer, and ovarian
cancer, we believe there are a number of factors that limit the potential of existing antibody therapeutics. For example, antibodies that block the CD47 &#147;don&#146;t eat me&#148; signal and provide an &#147;eat me&#148; signal via the Fc domain,
can result in toxicities including anemia and other cytopenias, which have been observed clinically with magrolimab, <FONT STYLE="white-space:nowrap">TTI-621,</FONT> and SRF231. In preclinical studies in NHP, administration of the CD47 blocking
antibody known as magrolimab, or 5F9-G4, caused blood hemoglobin concentrations to drop into the transfusion range for most animals that received a dose of 1 mg/kg or greater. We believe these observations were due to residual effector function in
the FC domain of magrolimab, which caused red blood cell destruction following binding of CD47 on red blood cells. This has limited development of these antibodies in the absence of the <FONT STYLE="white-space:nowrap">low-dose</FONT> priming
regimen developed for magrolimab. Other CD47 blocking agents, including the SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><FONT STYLE="white-space:nowrap">-Fc</FONT> fusion protein known as <FONT STYLE="white-space:nowrap">ALX-148,</FONT>
contain an Fc domain that does not bind Fc receptors, and therefore blocks CD47 without providing an &#147;eat me&#148; signal that leads to anemia or other cytopenias. While the avoidance of cytopenias is a major benefit of CD47 targeted therapies
that do not engage Fc receptors, in order for those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
agents to provide anti-tumor benefit they must be paired with a strategy that directs macrophages to specifically &#147;eat&#148; tumor cells. These tumor-targeted &#147;eat me&#148; signals can
be provided by ADCP-competent antibodies, such as rituximab, cetuximab, or trastuzumab, that bind to tumor antigens. Antibody-dependent cellular phagocytosis, or ADCP, is a highly regulated process in which an antibody binds to and marks a target,
in this case a tumor cell, for phagocytosis. In addition, natural &#147;eat me&#148; signals can be induced by certain chemotherapies that increase expression of calreticulin, a well-established &#147;eat me&#148; signal expressed on the surface of
cells marked for phagocytosis, on the surface of tumor cells. Preclinical studies have shown that the anti-tumor response to CD47/SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> blockade is completely dependent upon macrophage engagement of an
adaptive immune response following tumor cell phagocytosis, specifically following engagement and activation of CD8+ T cells. Thus, strategies that not only enhance innate immunity via CD47/SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>
blockade, but also enhance an adaptive immune response may be synergistic. To our knowledge, there are no other CD47/SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> targeted agents in clinical development that include a second functional domain
to stimulate an adaptive immune response. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Our Approach to Bridging Innate and Adaptive Immunity by Simultaneously Targeting CD47 and
CD40 </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While competing CD47 and SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> programs solely focus on activating the innate
immune system by inhibiting CD47, <FONT STYLE="white-space:nowrap">SL-172154</FONT> is designed to bridge the innate and adaptive immune response by simultaneously blocking the CD47 macrophage &#147;don&#146;t eat me&#148; signal and activating CD40
signaling. We believe that incorporating a CD40 agonist domain into a CD47 blocking therapeutic will stimulate macrophages not to just &#147;eat&#148; tumor cells, but will also drive those macrophages to more effectively present the tumor antigens
that they have consumed to T cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in Figure 10 below, when macrophages consume tumor cells in the setting of CD47/SIRP<FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> blockade, they must then digest and display tumor antigens on their surface to catalyze an adaptive, T cell-mediated immune response. Macrophage consumption of tumor cells is critical to the mechanism of
CD47/SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> blockade, but T cells are responsible for tumor shrinkage. Thus, strategies that enhance the processing and display of tumor antigens on the surface of macrophages and other antigen presenting
cells are likely to enhance the effectiveness of CD47/SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> blockade. CD40 is a TNF receptor expressed by antigen-presenting cells, including macrophages. Stimulation of CD40 substantially enhances
antigen presentation and subsequent T cell-activation by antigen-presenting cells. Accordingly, we have demonstrated in preclinical studies that the stimulation of CD40 in coordination with CD47/SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>
blockade using murine SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><FONT STYLE="white-space:nowrap">-Fc-CD40L</FONT> controls tumor growth and improves survival to a greater degree than either CD47- or CD40-targeted antibodies either alone or
in combination, and these effects were attributed to enhanced tumor cell killing by T cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 10&#151;Mechanism of Action of <FONT STYLE="white-space:nowrap">SL-172154</FONT>
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g92v31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently conducting a Phase 1 clinical trial evaluating the intravenous administration of
<FONT STYLE="white-space:nowrap">SL-172154</FONT> in patients with ovarian cancer and plan to initiate a second Phase 1 trial evaluating the intratumoral administration of <FONT STYLE="white-space:nowrap">SL-172154</FONT> in patients with CSCC or
HNSCC. The primary objective of each Phase 1 trial is to assess the safety and tolerability of <FONT STYLE="white-space:nowrap">SL-172154.</FONT> The secondary objectives include evaluation of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">pharmacokinetic and pharmacodynamic profiles as well as the anti-tumor activity of <FONT STYLE="white-space:nowrap">SL-172154.</FONT> We expect to identify the
recommended Phase 2 dose for <FONT STYLE="white-space:nowrap">SL-172154</FONT> as a monotherapy. We expect to provide initial data from the monotherapy dose-escalation portion of our intravenous and intratumoral Phase 1 trials in the second half of
2021 and the second half of 2022, respectively. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Phase 1 trial of <FONT STYLE="white-space:nowrap">SL-172154</FONT> administered
intravenously is being conducted in patients with advanced ovarian, fallopian tube, and primary peritoneal cancers, collectively referred to as ovarian cancer, patients who have failed and are ineligible for further platinum-based therapies. We
believe that ovarian cancer represents a first-in-class opportunity in an indication that lacks effective treatment options. Ovarian cancer expresses the highest levels of CD47 of any solid tumor and is a tumor type with a high presence of
macrophages, which express CD40. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Phase 1A dose-escalation portion of the trial, three or more patients will be enrolled through
each of five dose levels. Following the identification of a recommended Phase 2 dose, or RP2D, for monotherapy, we plan to evaluate <FONT STYLE="white-space:nowrap">SL-172154</FONT> in two Phase 1B expansion cohorts in ovarian cancer, including in
combination with cetuximab, an ADCP-competent antibody targeting EGFR, and in combination with doxorubicin. We conducted a study with an academic collaborator to investigate the expression of EGFR on tumor biopsies from ovarian cancer patients. From
a total of 594 biopsies analyzed, the majority were greater than 50% positive for EGFR Doxorubicin is the standard of care chemotherapy that stimulates upregulation of calreticulin on tumor cells.&nbsp;We anticipate enrolling a total of
approximately 70 patients across the dose-escalation and expansion portions of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
trial. As of September&nbsp;9, 2020, two patients have completed the first cycle of treatment with SL-172154 at the first dose level and tolerated the drug well. An overview of the initial
clinical development strategy for evaluating <FONT STYLE="white-space:nowrap">SL-172154</FONT> administered intravenously in patients with advanced ovarian cancer is below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 11 &#151;Initial Clinical Development Strategy of <FONT STYLE="white-space:nowrap">SL-172154</FONT> in Ovarian Cancer </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g33a91.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the second half of 2020, we
plan to initiate a Phase 1 trial of <FONT STYLE="white-space:nowrap">SL-172154</FONT> administered intratumorally in patients with locally advanced or metastatic CSCC and HNSCC not amenable to further treatment with surgery, radiation, or standard
systemic therapies. In the Phase 1A dose-escalation portion of the study, three or more patients will be enrolled through each of four dose levels. Following the identification of a monotherapy RP2D, we plan to evaluate <FONT
STYLE="white-space:nowrap">SL-172154</FONT> in one or more Phase 1B expansion cohorts in combination with cetuximab or one or more other combinations. We anticipate enrolling a total of approximately 45 patients across the dose-escalation and
expansion portions of the trial. An overview of the initial clinical development strategy for evaluating <FONT STYLE="white-space:nowrap">SL-172154</FONT> administered intratumorally in patients with locally advanced or metastatic CSCC and HNSCC is
below: </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 12&#151;Initial Clinical Development Strategy of <FONT STYLE="white-space:nowrap">SL-172154</FONT> in CSCC and HNSCC
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g27e95.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the completion of Phase 1 development, we plan to select one or more combination
regimens, routes of administration and tumor types to advance into Phase 2 development. In addition, we plan to also evaluate <FONT STYLE="white-space:nowrap">SL-172154</FONT> in patients with other solid tumors and hematologic malignancies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Preclinical Experience </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have conducted extensive preclinical studies of <FONT STYLE="white-space:nowrap">SL-172154</FONT> that have demonstrated the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A significant increase in macrophage-mediated phagocytosis of tumor cells </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The activation of antigen presenting cells by a CD40-induced type I interferon response </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dose-dependent increases in <FONT STYLE="white-space:nowrap">IL-2</FONT> by human lymphocytes
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dose-dependent activation of a CD8+ T cell response, which was responsible for tumor cell killing
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Taken together, these data demonstrate the potential ability of <FONT STYLE="white-space:nowrap">SL-172154</FONT> to
activate and bridge the adaptive and innate immune responses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In <I>in vitro</I> studies, murine
SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-Fc-CD40L</FONT></FONT> was shown to bind CD47 and CD40 with high, picomolar affinity. As predicted from the hexameric structure of
the compound, the CD40L domain stimulated CD40 signaling in the absence of Fc receptor cross-linking. In <I>in vivo</I> studies, administration of murine SIRP<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">-Fc-CD40L</FONT></FONT> resulted in dose-dependent activation of antigen presenting cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We performed
standard <I>in vitro </I>tumor cell phagocytosis assays to demonstrate whether <FONT STYLE="white-space:nowrap">SL-172154</FONT> enhanced macrophage-mediated phagocytosis of various tumor cell lines both alone and in combination with tumor-targeted
ADCP-competent antibodies. As shown in Figure 13 below, consistent with the mechanism of action of CD47 blocking agents, <FONT STYLE="white-space:nowrap">SL-172154</FONT> significantly enhanced the ability of macrophages to phagocytose tumor cells
in the presence of tumor-targeted ADCP-competent antibodies. Additionally, <FONT STYLE="white-space:nowrap">SL-172154</FONT> potentiated macrophage-mediated phagocytosis of tumor cells that expressed calreticulin, a well-established &#147;eat
me&#148; signal expressed on the surface of cells marked for phagocytosis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 13&#151;Tumor Phagocytosis Activity of
SIRP</B><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT><B></B><B><FONT STYLE="white-space:nowrap">-Fc-CD40L</FONT> with or without ADCP-competent Antibodies </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g00d01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Human monocyte derived macrophages were <FONT STYLE="white-space:nowrap">co-cultured</FONT> with HCC1954,
A431, HCC827, or <FONT STYLE="white-space:nowrap">Caov-3</FONT> cells in the presence of an IgG negative control, <FONT STYLE="white-space:nowrap">SL-172154,</FONT> an ADCP-competent tumor-targeted antibody, including Trastuzumab or Cetuximab, or
the combination of <FONT STYLE="white-space:nowrap">SL-172154</FONT> and the ADCP-competent tumor-targeted antibody. After two hours, the proportion of tumor cells phagocytosed by human macrophages was determined and reported as the phagocytosis
index. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CD40 is known to stimulate proliferation of B cells and CD4+ T cells from human PBMC in the presence of cross-linked anti-CD40
antibodies or CD40L. To evaluate this effect, CD8+ T cell-depleted PBMC were isolated from a total of 50 different human blood donors and cultured in the presence of a dose-titration of <FONT STYLE="white-space:nowrap">SL-172154.</FONT> As shown in
Figure 14 below, as compared to both positive and negative controls, soluble <FONT STYLE="white-space:nowrap">SL-172154</FONT> stimulated dose-dependent proliferation of human PBMC over seven days. In addition,
<FONT STYLE="white-space:nowrap">SL-172154</FONT> was observed to stimulate a dose-dependent increase in the number of <FONT STYLE="white-space:nowrap">IL-2</FONT> secreting PBMC on day eight, which is a downstream indicator of CD40 activation. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 14 &#151;</B><I></I><B></B><I></I><B><I>In Vitro</I></B><I></I><B></B><I></I><B>
Human PBMC Proliferation and Activation Assay </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g98y91.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">CD8-depleted</FONT> PBMC from 50 distinct human blood donors, each
indicated as a single spot in each figure, were cultured with media only, the positive control KLH, the <FONT STYLE="white-space:nowrap">non-activating</FONT> control Exenatide, or 0.3, 3, 30, or 300 nM of
<FONT STYLE="white-space:nowrap">SL-172154.</FONT> On Days 5, 6, and 7, proliferation was assessed via <SUP STYLE="font-size:85%; vertical-align:top">3</SUP>H-Thymidine incorporation as shown in the left panel, and on Day 8, <FONT
STYLE="white-space:nowrap">IL-2</FONT> positive cells were assessed by ELISpot as shown in the right panel. </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted
dose-range finding and repeat dose GLP toxicity studies in NHP to evaluate the safety and pharmacologic effects of <FONT STYLE="white-space:nowrap">SL-172154.</FONT> In these studies, <FONT STYLE="white-space:nowrap">SL-172154</FONT> was
administered as five once-weekly doses across a dose range of 0.1 mg/kg to 40 mg/kg, followed by a recovery period. Data from these studies indicated that <FONT STYLE="white-space:nowrap">SL-172154</FONT> induced a potent immune response in NHP.
Figure 15 below shows dose-dependent saturation of CD47 positive red blood cells, which was durable for greater than seven days. In addition, <FONT STYLE="white-space:nowrap">SL-172154</FONT> bound CD40-expressing B cells in the peripheral blood and
stimulated a dose-dependent migration of lymphocytes from the peripheral blood within 24 hours of treatment, as shown in Figure 16 below. We believe these data are supportive of either a once weekly or every other week dosing schedule. Histology
samples demonstrated that the post-dose decreases in peripheral blood lymphocytes were accompanied by accumulation of proliferating lymphocytes in lymph nodes and spleen. Administration of <FONT STYLE="white-space:nowrap">SL-172154</FONT> was also
associated with dose-dependent post-treatment increases in multiple serum cytokines, such as CCL2, as shown in Figure 16 below. The observed toxicities were consistent with cytokine release syndrome. No evidence of anemia was observed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 15 &#151;CD47 Receptor Occupancy following
<FONT STYLE="white-space:nowrap">SL-172154</FONT> Infusion </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g77h63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Cynomolgus monkeys were treated on Day 1 and 8 with 0.1 mg/kg, 1 mg/kg, 10 mg/kg, and 40 mg/kg of <FONT
STYLE="white-space:nowrap">SL-172154</FONT> or a vehicle control. Receptor occupancy was evaluated at the indicated time points by flow cytometry. <FONT STYLE="white-space:nowrap">SL-172154</FONT> occupancy on red blood cell CD47 is plotted as the
proportion of total CD47 expression minus the proportion of CD47 detected using an antibody that is prevented from binding when CD47 is occupied by <FONT STYLE="white-space:nowrap">SL-172154.</FONT> </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 16&#151;Post-dose Cytokine Release and Rapid Post-dose Migration of Lymphocytes from the Blood </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g12m12.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Cynomolgus monkeys were treated with <FONT STYLE="white-space:nowrap">SL-172154</FONT> on Day 1, 8, and
15 with 0.1 mg/kg, 1 mg/kg, 10 mg/kg, and 40 mg/kg of <FONT STYLE="white-space:nowrap">SL-172154</FONT> or a vehicle control. Serum cytokine concentrations were collected and the <FONT STYLE="white-space:nowrap">pre-</FONT> and post-dose
concentrations of CCL2, <FONT STYLE="white-space:nowrap">IL-8,</FONT> and CXCL9 are indicated in the left panel. <FONT STYLE="white-space:nowrap">Pre-</FONT> and post-dose lymphocyte counts were obtained on Day 15 prior to the third dose, and on Day
16 approximately 24 hours after the third dose. The number of peripheral blood lymphocytes was observed to decrease in a dose-dependent manner following the Day 15 dose, and is plotted in the right panel above as the percent decrease in peripheral
blood lymphocytes on Day 16 as compared to Day 15. Each data point indicates an individual animal. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SL-279252:</FONT> A Dual <FONT
STYLE="white-space:nowrap">PD-1</FONT> Blocking and OX40-Activating ARC Compound </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second product candidate, <FONT STYLE="white-space:nowrap">SL-279252,</FONT> is a dual-sided,
<FONT STYLE="white-space:nowrap">bi-functional</FONT> fusion protein that both inhibits <FONT STYLE="white-space:nowrap">PD-1</FONT> and acts as an agonist for the OX40 costimulatory receptor. We are currently evaluating <FONT
STYLE="white-space:nowrap">SL-279252</FONT> in a global Phase 1 dose-escalation and dose-expansion clinical trial in patients with advanced solid tumors and lymphoma. We expect to report data from the dose-escalation portion of this trial in the
second half of 2021 and data from the dose-expansion portion of this trial in the first half of 2022. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Shortcomings of Existing <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> Inhibition Strategies </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Programmed cell death
protein 1, or <FONT STYLE="white-space:nowrap">PD-1,</FONT> is a cell surface protein present on T cells and other white blood cells. It binds to two ligands, <FONT STYLE="white-space:nowrap">PD-L1</FONT> and
<FONT STYLE="white-space:nowrap">PD-L2,</FONT> which can be expressed by tumor cells as well as other immune cells in the tumor microenvironment. When <FONT STYLE="white-space:nowrap">PD-L1</FONT> binds to
<FONT STYLE="white-space:nowrap">PD-1,</FONT> the resulting <FONT STYLE="white-space:nowrap">PD-1</FONT> signaling limits the capacity of T cells to kill tumor cells.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Anti-PD-1</FONT></FONT> antibodies disrupt binding of <FONT STYLE="white-space:nowrap">PD-1</FONT> to <FONT STYLE="white-space:nowrap">PD-L1</FONT> to restore baseline tumor
cell-killing activity of T cells. While <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies have achieved significant clinical and commercial success, a
majority of patients with cancer do not benefit from this class of therapy, as evidenced by a response rate of 35% or less in patients with melanoma, NSCLC, bladder cancer, HNSCC, and other cancers. A limitation of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies is their inability to provide a signal that directly amplifies the ability of T cells to kill tumor cells. Achieving this enhanced
tumor-killing effect necessitates the introduction of a distinct mechanism to complement checkpoint blockade. One such approach is the stimulation of costimulatory receptors. Most current approaches attempt to simultaneously exploit both pathways by
<FONT STYLE="white-space:nowrap">co-administering</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies with costimulatory receptor agonists.
However, these attempts have not been successful in clinical trials, which we believe is due to the structural mismatch between existing bivalent antibodies and the trimeric TNF receptor superfamily. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Our Approach to Enhancing <FONT STYLE="white-space:nowrap">PD-1</FONT> Blockade by Simultaneously Targeting OX40 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While other programs sought to block <FONT STYLE="white-space:nowrap">PD-1</FONT> and activate OX40 signaling by administering multiple
therapeutics, <FONT STYLE="white-space:nowrap">SL-279252</FONT> seeks to do so within a single therapeutic. Importantly, unlike the bivalent structure of existing antibodies, the hexameric structure of
<FONT STYLE="white-space:nowrap">SL-279252</FONT> is designed to effectively trimerize and directly activate OX40 receptors. In preclinical studies, SL-279252 was found to be a highly potent stimulator of an adaptive immune response, and also
demonstrated greater anti-tumor activity than <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibodies or OX40-agonist antibodies, either alone or in combination. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 17&#151; <FONT STYLE="white-space:nowrap">SL-279252</FONT> Enables Simultaneous Blockade of
<FONT STYLE="white-space:nowrap">PD-1</FONT> and Activation of OX40 Signaling </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g97x73.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Development Strategy </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In collaboration with Takeda, we are currently conducting a Phase 1 dose-escalation and dose-expansion trial of
<FONT STYLE="white-space:nowrap">SL-279252</FONT> in patients with advanced solid tumors and lymphoma. The primary objective of the Phase 1 trial is to assess the safety and tolerability of <FONT STYLE="white-space:nowrap">SL-279252.</FONT> The
secondary objectives include evaluation of the pharmacokinetic and pharmacodynamic profiles as well as the anti-tumor activity of <FONT STYLE="white-space:nowrap">SL-279252.</FONT> We are evaluating anti-tumor response according to immune Response
Evaluation Criteria in Solid Tumors or Response Evaluation Criteria in Lymphoma 2017. These are standard, widely accepted criteria to evaluate tumor response in oncology clinical trials. An RP2D and schedule will be identified for <FONT
STYLE="white-space:nowrap">SL-279252</FONT> following the completion of the Phase 1 trial. We expect to provide data from the dose-escalation portion of this Phase 1 trial in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients with relapsed, advanced, or metastatic solid tumors or lymphoma who have received standard of care therapies, including <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1/PD-L1</FONT></FONT></FONT> antibodies, are eligible to enroll in the trial. In the dose-escalation portion of this study, up to six patients will
be treated at each of ten dose levels ranging from 0.0001 mg/kg to 6 mg/kg. Patient samples will be evaluated to determine the pharmacokinetic profile, receptor occupancy on PD-L1 and OX40 peripheral blood immune phenotyping, changes in immune cell
infiltration in tumor biopsies, and evidence for elevation in multiple serum cytokines. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of the dose-escalation
portion of the study, a dose and schedule will be selected for evaluation in up to two expansion cohorts. We anticipate treating a total of approximately 80 patients in the dose-escalation and dose-expansion portions of this clinical trial. An
overview of the Phase 1 trial design evaluating <FONT STYLE="white-space:nowrap">SL-279252</FONT> in patients with advanced solid tumors and lymphoma is below: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 18&#151;Phase 1 Trial Design of <FONT STYLE="white-space:nowrap">SL-279252</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g29k73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 9, 2020, a total of 29 patients have received treatment with SL-279252 up to a dose of 6
mg/kg in the dose-escalation portion of the Phase 1 trial. Overall, SL-279252 has been observed to be well tolerated as of September 9, 2020. Treatment-related adverse events, including immune-related events, have been reported in some patients, but
there have not been any dose-limiting toxicities as of September 9, 2020, as shown in Figure 19 below. A maximum tolerated dose has not been reached. Preliminary pharmacokinetic activity has been evaluated in 22 patients treated across a dose range
of 0.0001 to 3 mg/kg. Exposure of SL-279252 as determined by the maximum peak drug concentration, or Cmax, and the area under the curve, or AUC, increased with dose escalation in a linear fashion. The pharmacokinetic profile consists of a
distribution phase and an elimination phase. We believe this distribution phase indicated rapid binding to the target receptors. Following </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
repeat dosing, a consistent Cmax and AUC was observed without evidence of accelerated drug clearance. The volume of distribution of drug indicated that SL-279252 distributed beyond the
circulatory compartment into tissues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preliminary pharmacodynamic activity has also been evaluated in 22 patients treated across a
dose-range of 0.0001 to 3 mg/kg. Post-dose receptor occupancy on OX40-positive lymphocytes was observed in a dose-dependent fashion, and the total number of OX40-positive cells in the blood declined rapidly post-infusion of SL-279252. We believe the
post-infusion decreases in OX40-positive lymphocytes provides evidence of on-target biology. In NHP, similar post-infusion decreases in lymphocytes were associated with migration of lymphocytes into tissues. We expect to select a dose and either a
weekly or bi-weekly schedule to advance into the expansion cohorts, and to report safety, pharmacokinetic and pharmacodynamic data from the dose-escalation portion of this clinical trial in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adverse events, or AEs, were classified according to National Cancer Institute Common Terminology Criteria for Adverse Events
(NCI-CTCAE&#151;version 5.0). As of September 9, 2020, treatment-related AEs have been reported in 13 patients. In 12 patients, these AEs have been Grade 1 or 2 in severity. One patient experienced a Grade 3 treatment-related AEs. No
treatment-related Grade 4 or 5 adverse events, treatment-related serious adverse events or dose limiting toxicities have been reported. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 19&#151;Summary of Treatment-Related Adverse Events and Series Adverse Events </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4"><FONT STYLE="font-size:9pt"><B>Overall summary for Adverse Events (total number of patients = 29)</B></FONT></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:9pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;patients</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Any Adverse Events:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grade 5 AEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grade 4 AEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grade 3 AEs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dose Limiting Toxicities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Serious Adverse Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treatment-related SAE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treatment-related Adverse Events</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grade 5 AE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grade 4 AE</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grade 3 AE<SUP STYLE="font-size:85%; vertical-align:top">1</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grade 2 AE<SUP STYLE="font-size:85%; vertical-align:top">2</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grade 1 AE<SUP STYLE="font-size:85%; vertical-align:top">3</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">1</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Grade 3 treatment-related AE: neutropenia (transient, self-limiting) </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">2</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Grade 2 treatment-related AE: rash maculo-papular (n=2), rash (n=1), pruritus (n=1), neutrophil count decreased (n=1), and infusion reaction (n=1). </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">3</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Grade 1 treatment-related AE: night sweats (n=2), constipation (n=2), rash maculo-papular (n=1), asthenia (n=1), decreased appetite (n=1), diarrhea (n=1), dizziness (n=1), fatigue (n=1), headache (n=1), hyperkalemia
(n=1), hypothyroidism (n=1), localized edema (n=1), neuropathy peripheral (n=1), pyrexia (n=1), vertigo (n=1). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we
have experienced delays in our clinical trial of SL-279252 as a result of the ongoing COVID-19 pandemic, including delays with certain third-party vendors supporting this trial. We temporarily paused enrollment of patients for our clinical trial of
SL-279252 between March and May 2020 and we resumed enrollment in June 2020. As &#147;shelter in place&#148; orders and other public health guidance measures are reinstated in the locations of our clinical trial sites, we expect that some patients
may also choose to forego one or more doses in our clinical trials, due to challenges faced by such patients in travelling to our clinical trial sites, which may negatively affect the study results. As of September 9, 2020, only one patient has
missed scheduled treatments in connection with a clinical trial due to travel restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Preclinical Experience </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our preclinical studies in mice with rapidly growing tumors, murine <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1-Fc-OX40L</FONT></FONT></FONT> achieved superior tumor growth inhibition and improved survival compared with an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody and an
OX40 agonist antibody, either alone or in combination, as shown in Figure 7 above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We conducted dose-range finding and repeat dose GLP
toxicity studies in NHP to evaluate the safety and pharmacologic effects of <FONT STYLE="white-space:nowrap">SL-279252.</FONT> In these studies, <FONT STYLE="white-space:nowrap">SL-279252</FONT> was administered as five once-weekly doses, across a
dose range of 0.1 mg/kg to 100 mg/kg. Data from these studies indicated that <FONT STYLE="white-space:nowrap">SL-279252</FONT> induced a potent immune response in NHP. Figure 20 below shows a dose-dependent expansion in the total number of
lymphocytes in NHP and post-dose migration of lymphocytes into specific tissue sites, including the liver, the lung, and the GI tract. Figure 21 below shows increased serum cytokine concentrations, including IL-6 and
<FONT STYLE="white-space:nowrap">IL-10,</FONT> following repeated administration of SL-279252. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 20&#151;Lymphocyte Expansion
Between Weekly <FONT STYLE="white-space:nowrap">SL-279252</FONT> Treatments and Rapid Post-dose Migration of Lymphocytes from the Blood </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g16l94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Cynomolgus monkeys were treated on Day 1, 8, and 15 with 10 mg/kg, 40 mg/kg, and 80 mg/kg of <FONT
STYLE="white-space:nowrap">SL-279252.</FONT> <FONT STYLE="white-space:nowrap">Pre-</FONT> and post-dose lymphocyte counts were obtained on Day 1 prior to the first dose and on Day 15 prior to the third dose. The fold increase in total lymphocytes in
the peripheral blood from Day 1 to Day 15 is plotted on the left panel for each dosing group. Within 24 hours of SL-279252 treatment on Day 15, the number of peripheral blood lymphocytes was observed to decrease in a dose-dependent manner. The
percent decrease in peripheral blood lymphocytes from the third dose on Day 15 to Day 16 is shown on the right panel. Each data point indicates an individual animal. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Figure 21&#151;Increased Serum Cytokine Concentrations Following Administration of
SL-279252 </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g80c20.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Cynomolgus monkeys were treated on Day 1, 8, 15, 22 and 29 with 10 mg/kg, 40 mg/kg, and 80 mg/kg of
SL-279252. Serum cytokine concentrations were collected and the pre- and post-dose concentrations of IL-6 and IL-10 are indicated in the panel above for the 40mg/kg dose group following repeated administration. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collaboration and License Agreements </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Agreement with Takeda </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August 8, 2017, we entered into a Collaboration Agreement with Millennium Pharmaceuticals, Inc., or Takeda, a wholly owned subsidiary of
Takeda Pharmaceutical Company, Ltd., or the Collaboration Agreement. The Collaboration Agreement was subsequently amended in April 2018, October 2018, and March 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Collaboration Agreement, we are required to use our commercially reasonable efforts to conduct preclinical and Phase 1
clinical trials for two molecules, PD-1-Fc-OX40L and CSF1R-Fc-CD40L, and Takeda has an exclusive option to license one or both of these clinical-stage ARC compounds for a specified amount of time up to and following the conclusion of each respective
Phase 1 trial. While we are currently evaluating PD-1-Fc-OX40L in a Phase 1 clinical trial, we have not yet conducted a Phase 1 clinical trial for CSF1R-Fc-CD40L. During the development phase of the Collaboration Agreement, we may not, by ourselves
or through a third party, develop or commercialize a compound, molecule, or product that targets both PD-1 and OX40L, or a compound, molecule, or product that targets both CSF1R and CD40L. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, pursuant to the Collaboration Agreement, we agreed to conduct certain preclinical studies on four additional preclinical ARC
molecules, and Takeda had an option to license up to two of the four preclinical molecules. We completed our research and development activities related to the four preclinical molecules and delivered a final report to Takeda. Takeda elected to not
exercise its option to enter into up to two licenses for such molecules, and Takeda&#146;s option period for such molecules has now lapsed. As a result, the Collaboration Agreement is terminated as to the four preclinical molecules and Takeda does
not have any rights to participate in the development or commercialization of such molecules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Collaboration Agreement, Takeda is granted a right of first negotiation to enter
into licenses for each molecule within a specified class of ARC molecules. To exercise its right of first negotiation, Takeda will be required to provide a notice within a specified time, and if the parties do not conclude a license agreement within
a set timeframe, we will be entitled to enter into licenses with third parties, subject to certain conditions. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Thus far under the
Collaboration Agreement, we have received approximately $75.7 million in option payments, milestone payments, and expense reimbursements from Takeda. If Takeda exercises its exclusive option to license one or both of the clinical-stage ARC compounds
(PD-1-Fc-OX40L and CSF1R-Fc-CD40L), we will enter into a license agreement with Takeda with respect to such compound. Any such license agreement would, among other things, require Takeda to use its commercially reasonable efforts to develop the
licensed compound and seek approval for the compound. In addition, Takeda would be solely responsible, at its costs, for the development, manufacture, and commercialization of the licensed ARC compounds. If both ARC compounds are licensed, we would
be entitled to additional payments consisting of up to an aggregate of $78.75 million in license fee payments and up to an aggregate of $450 million in clinical, regulatory, and sales milestone payments. In addition, we would be eligible for tiered
royalty payments on net sales of licensed products at percentages ranging from the high single digits to sub-teens, subject to specified reductions, during the royalty term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Takeda exercises its option to enter into a license agreement, the royalty term with respect to the licensed product would extend, on a
country-by-country basis, from the period commencing on the first commercial sale of the product in such country and ending on the later of (i) the expiration of the last to expire of the valid claims on the applicable licensed patent rights
covering the product in such country or (ii) the tenth anniversary of the first commercial sale of the product in such country. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
sooner terminated, the Collaboration Agreement will continue until the later of (a) February 8, 2021, (b) the earlier of (i) the 90th day following delivery of a report detailing certain results of the PD-1-Fc-OX40L Phase 1 clinical trial and (ii)
the exercise by Takeda of its right to an exclusive license with respect to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1-Fc-OX40L,</FONT></FONT></FONT> and (c) the earlier of (i) the 90th
day following delivery of a report detailing certain results of the CSF1R-Fc-CD40L Phase 1 clinical trial and (ii) the exercise by Takeda of its right to an exclusive license with respect to CSF1R-Fc-CD40L. Either party may terminate the
Collaboration Agreement prior to expiration upon the insolvency or uncured material breach of the other party. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Heat License
Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, we entered into an Exclusive License Agreement, or the Heat License Agreement, with Heat Biologics Inc.,
or Heat. The Heat License Agreement was subsequently amended in November 2016, December 2016, and March 2017. Pursuant to the Heat License Agreement, Heat granted to us (1) a worldwide, sublicensable exclusive license to research, develop,
manufacture, and commercialize products under three provisional patent applications, including all patents issuing from such applications, or the Fusion Protein Patent Rights, and (2) a worldwide, sublicensable nonexclusive license to research,
develop, manufacture, and commercialize certain know how owned and controlled by Heat related to the Fusion Protein Patent Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Heat License Agreement, Heat was required to conduct certain research and development services under a mutually-agreed upon research
and development plan and Heat was eligible to receive financial support from us for these efforts. Effective March 2017, Heat completed all research and development services under the Heat License Agreement and assigned to us three patent
applications and all data derived from the research and development activities, referred to collectively as the Research Services Inventions. Pursuant to the terms of the Heat License Agreement, we are obligated to use commercially reasonable
efforts to diligently research and develop at least one product covered by the Fusion Protein Patent Rights, including the obligation to file an IND application for such product. Our development, including the development of SL-279252 and certain
other ARC compounds, efforts to date satisfy these obligations. In addition, we are to provide annual reports to Heat on or before the anniversary of the effective date of the Heat License Agreement to inform Heat of our progress. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless sooner terminated or extended, the term of the Heat License Agreement continues until
the later of (1) 20 years following the effective date, and (2) the expiration of the last-to-expire royalty term. Either party may terminate the agreement due to a material breach by the other party (subject to a 90-day cure period) or if the other
party files for bankruptcy. In the event we terminate the Heat License Agreement due to a material breach by Heat, Heat must assign to us all right, title, and interest in the patent rights licensed under the Heat License Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to an upfront payment of $50,000, the Heat License Agreement requires us to make further payments to Heat of up to $20.6 million
in the aggregate, for the achievement of specified development, regulatory, and commercial sale milestones for certain licensed products. We are also required to pay Heat a percentage of certain upfront fees or other non-royalty payments we receive
that are not tied to milestone events under any sublicense of the Fusion Protein Patent Rights. We are also required to pay Heat a royalty on all worldwide net sales by us, our affiliates, and sublicenses of certain licensed products in the low
single digits. Royalties are payable, on a product-by-product and country-by-country basis, commencing on the first commercial sale of such product and continuing until the last-to-expire valid patent claim to the licensed patent rights that cover
such product in that country. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate any manufacturing facilities designed to comply with current good manufacturing practice, or cGMP, requirements. We
have invested significant resources to identify and scale up a suitable manufacturing process for ARC compounds, including SL-172154 and SL-279252. Currently, ARC compounds are produced by mammalian cell lines commonly used in the manufacture of
monoclonal antibodies, including Chinese hamster ovary, or CHO, cells. Both SL-172154 and SL-279252 have achieved cell culture titer greater than 2 grams per liter, and another ARC compound has achieved titers exceeding 7 grams per liter.
Purification of ARC compounds initially utilizes affinity chromatography directed to the Fc domain for capture, and subsequent chromatography steps are designed to remove process-related impurities including CHO derived DNA and proteins. We expect
to continue to devote, significant resources to process development and optimization of the manufacture of our product candidates. To our knowledge, no other company has successfully scaled up commercial manufacturing of dual-sided fusion proteins.
Due to the novelty of our product candidates, we may face challenges in developing large-scale manufacturing processes. Moreover, the nature of our dual-sided fusion proteins could create challenges for the stability of the drug substance. These
challenges may result in timeline delays and higher costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have obtained bulk drug substance, or BDS, for each of our product
candidates from a single-source third-party contract manufacturer. We maintain a long-term master services agreement with KBI Biopharma, Inc., or KBI, pursuant to which we may purchase BDS and other products on a per project basis. We may terminate
the master services agreement at any time for convenience in accordance with the terms of the agreement. Either KBI or we may also terminate the master services agreement with respect to an uncured breach by the other party in accordance with the
terms of the agreement. The agreement includes confidentiality and intellectual property provisions to protect our proprietary rights related to our product candidates. We do not currently have arrangements in place for redundant supply. While any
reduction or halt in supply of BDS from KBI could limit our ability to develop our product candidates until a replacement contract manufacturer is found and qualified, we believe that we have sufficient BDS to support our current clinical trial
programs. We currently work with two drug manufacturers to produce our product candidates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our product candidates are
manufactured from a master cell bank of that protein&#146;s production cell line. We have or intend to have one master cell bank for each product candidate that was or will be produced and tested in accordance with current good manufacturing
practices, or cGMPs, and applicable regulations. Each master cell bank is or will be stored in two independent locations, and we intend to produce working cell banks for each product candidate later in product development. It is possible that we
could lose multiple cell banks from multiple locations and have our manufacturing severely impacted by the need to replace the cell banks. However, we believe we have adequate backup should any particular cell bank be lost in a catastrophic event.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis
on proprietary products. While we believe that our technology, development experience and scientific knowledge provide us with competitive advantages, we face potential competition from many different sources, including large pharmaceutical and
biotechnology companies, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development,
manufacturing, and commercialization of cancer therapies. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We compete in the segments of the pharmaceutical, biotechnology, and other related markets that develop cancer therapies. There are many other
companies that have commercialized or are developing cancer therapies, including large pharmaceutical and biotechnology companies, such as AstraZeneca/MedImmune, Bristol Myers Squibb, Merck, Novartis, Pfizer, and Roche/Genentech. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition from pharmaceutical and biotechnology companies that target specific tumor-associated antigens using immune
cells or other cytotoxic modalities. These generally include immune cell redirecting therapeutics (e.g., T cell engagers), adoptive cellular therapies (e.g., <FONT STYLE="white-space:nowrap">CAR-Ts),</FONT> antibody drug conjugates, targeted
radiopharmaceuticals, targeted immunotoxin, and targeted cancer vaccines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our lead wholly owned product candidate, <FONT
STYLE="white-space:nowrap">SL-172154,</FONT> we are aware of other competing clinical-stage therapeutics that target the CD47 pathway or the CD40 pathway, which include, but are not limited to magrolimab, ALX148,
<FONT STYLE="white-space:nowrap">TTI-621,</FONT> and APX005M. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our second lead product candidate, <FONT
STYLE="white-space:nowrap">SL-279252,</FONT> we are aware of other competing clinical-stage therapeutics, that target the <FONT STYLE="white-space:nowrap">PD-1</FONT> pathway or the OX40 pathway, which include, but are not limited to <FONT
STYLE="white-space:nowrap">PF-04518600,</FONT> <FONT STYLE="white-space:nowrap">BMS-986178,</FONT> pembrolizumab, nivolumab, avelumab, and atezolizumab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial
resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical,
biotechnology, and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through
collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and enrolling subjects for our
clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We could see a reduction or
elimination of our commercial opportunity if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our
collaborators may develop. Our competitors also may obtain FDA or foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we
or our collaborators are able to enter the market. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion diagnostics,
if required, the level of biosimilar or generic competition, and the availability of reimbursement from government and other third-party payors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to
protect and enhance our proprietary technology, inventions, and improvements that we consider commercially important to the development of our business, including by seeking, maintaining, and defending
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. and foreign patent rights, including patents covering our platform technologies, product candidates, and methods of using the same, whether developed internally or licensed from third
parties. We also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> and continuing technological innovation to develop, strengthen and maintain our proprietary position in our field. Additionally, we intend to rely on
regulatory protection afforded through data exclusivity and market exclusivity, among others, as well as patent term extensions, where available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future commercial success depends, in part, on our ability to obtain and maintain patent and other proprietary protection for commercially
important technology, inventions, and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business, including our platform technologies and product candidates, defend and enforce our intellectual property rights, in particular our
patents rights, preserve the confidentiality of our trade secrets, and operate without infringing, misappropriating, or violating the valid and enforceable patents and proprietary rights of third parties. Our ability to stop third parties from
making, using, selling, offering to sell, or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology companies like ours are generally uncertain and can involve complex legal, scientific, and factual
issues. We cannot predict whether the patent applications we are currently pursuing, or those we will file or license from others, will grant as patents in any particular jurisdiction or whether the claims of any granted patents will provide
sufficient proprietary protection from competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the coverage claimed in a patent application may be significantly
reduced before a patent is granted, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our products will be protected or remain protectable by enforceable patents. Moreover, any
patents that we hold may be challenged, circumvented, or invalidated by third parties. In addition, because of the extensive time required for clinical development and regulatory review of a product candidate we may develop, it is possible that,
before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby limiting the protection such patent would afford the respective product and any
competitive advantage such patent may provide. See &#147;Risk Factors&#151;Risks Related to Our Intellectual Property&#148; for a more comprehensive description of risks related to our intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For any individual patent, the term depends on the applicable law in the country in which the patent is granted. In most countries where we
have filed patent applications or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications, patents have a term of 20 years from the application filing date or earliest claimed nonprovisional priority date. In the United
States, the patent term is 20 years from the application filing date or earliest claimed nonprovisional priority date, but may be shortened if a patent is terminally disclaimed over another patent that expires earlier. The term of a U.S. patent may
also be lengthened by a Patent Term Adjustment in order to address administrative delays by the U.S. Patent and Trademark Office in granting a patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the term of a patent that covers an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug or biologic may be
eligible for Patent Term Extension in order to restore the period of a patent term lost during the premarket FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a Patent
Term Extension of up to five years beyond the natural expiration of the patent (but the total patent term, including the extension period, must not exceed 14 years following FDA approval). The term extension period granted on a patent covering a
product is typically <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of a clinical investigation involving human beings is begun and the submission date of an application, plus the time between the submission
date of an application and the ultimate approval date. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it may
be extended. The application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark Office reviews and approves the application for any Patent Term Extension in consultation with the FDA. In
the future, we may decide to apply for restoration of patent term for one of our currently owned or licensed patents to extend its current expiration date, depending on the expected length of the clinical trials and other factors involved in the
filing of the relevant biologics license application. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally file patent applications directed to our key technologies and programs in an
effort to secure our intellectual property positions. As of August&nbsp;6, 2020, we exclusively licensed ten U.S. patents and about 25 pending <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications (U.S. and foreign), and we
owned one U.S. patent, about 60 pending <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent applications (U.S. and foreign), about ten pending Patent Cooperation Treaty, or PCT, applications, and various provisional patent applications
covering our key programs and pipeline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The intellectual property portfolio for our most advanced programs as of August&nbsp;6, 2020, is
summarized below. Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office and other patent offices may be significantly revised before issuance, if granted at
all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>ARC Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent portfolio for our ARC platform is based upon our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio, which
includes patents and patent applications directed generally to compositions of matter, pharmaceutical compositions, and methods of treatment. The earliest provisional patent application relating to the ARC platform was filed in October 2015. Patent
applications are pending in the United States and various foreign jurisdictions and regions, including Australia, Brazil, Canada, China, Europe, Hong Kong, Indonesia, Israel, India, Japan, Korea, Mexico, Malaysia, Philippines, Russia, Saudi Arabia,
Singapore, Thailand, Ukraine, and Vietnam. Patent applications in this family, if granted, are expected to expire in 2036, without taking potential patent term extensions or patent term adjustment into account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, the <FONT STYLE="white-space:nowrap">in-licensed</FONT> ARC platform patent portfolio has been prosecuted in the United States to
generate issued U.S. patents on various product candidates and preclinical product candidates as outlined below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also owns
two PCT applications covering subgenera of ARC compounds relevant to different cellular types. Patent applications in this family, if granted, are expected to expire in 2040, without taking potential patent term extensions or patent term adjustment
into account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>GADLEN Platform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent portfolio for our GADLEN platform is based upon our owned patent portfolio, which includes patent applications directed generally to
compositions of matter, pharmaceutical compositions, and methods of treatment. We have one pending PCT application and two pending U.S. applications to date, with various foreign patent filings planned. Patent applications in this family, if
granted, are expected to expire in 2040, without taking potential patent term extensions or patent term adjustment into account. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I><FONT
STYLE="white-space:nowrap">SL-279252</FONT> Product Candidate </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent portfolio for our
<FONT STYLE="white-space:nowrap">SL-279252</FONT> product candidate is based upon our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio, which includes patents and patent applications directed generally to compositions
of matter, pharmaceutical compositions, and methods of treatment. We have two granted patents in the United States, from the <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio, covering compositions of matter of a genus of
molecules, and the <FONT STYLE="white-space:nowrap">SL-279252</FONT> product candidate molecule specifically, pharmaceutical compositions, and methods of treating cancer. Patent applications are pending in the United States and various foreign
jurisdictions and regions, including Australia, Brazil, Canada, China, Europe, Hong Kong, Indonesia, Israel, India, Japan, Korea, Mexico, Malaysia, Philippines, Russia, Saudi Arabia, Singapore, Thailand, Ukraine, and Vietnam. Patent applications in
this family, if granted, are expected to expire in 2036, without taking potential patent term extensions or patent term adjustment into account. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending coverage, from the Company-owned patent portfolio, that relates to our <FONT STYLE="white-space:nowrap">SL-279252</FONT> product
candidate also includes methods of treatment with various combination agents (one pending PCT application). Patent applications in this family, if granted, are expected to expire in 2039, without taking potential patent term extensions or patent
term adjustment into account. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Takeda holds an exclusive option to these patent families in connection with the
Collaboration Agreement discussed elsewhere herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">SL-172154</FONT> Product Candidate
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent portfolio for our <FONT STYLE="white-space:nowrap">SL-172154</FONT> product candidate is based upon our owned and <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio, which includes patents and patent applications directed generally to compositions of matter, pharmaceutical compositions, and methods of treatment. We have two granted patents in the
United States, from the <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent portfolio, covering compositions of matter of a genus of molecules, and the <FONT STYLE="white-space:nowrap">SL-172154</FONT> product candidate specifically,
pharmaceutical compositions, and methods of treating cancer. Patent applications are pending in the United States and various foreign jurisdictions and regions, including Australia, Brazil, Canada, China, Europe, Hong Kong, Indonesia, Israel, India,
Japan, Korea, Mexico, Malaysia, Philippines, Russia, Saudi Arabia, Singapore, Thailand, Ukraine, and Vietnam. Patent applications in this family, if granted, are expected to expire in 2036, without taking potential patent term extensions or patent
term adjustment into account. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending coverage, from the Company-owned patent portfolio, that relates to our <FONT
STYLE="white-space:nowrap">SL-172154</FONT> product candidate also includes methods of treatment with various combination agents (one pending PCT application, and pending applications in the United States, Canada, China, Europe, and Japan). Patent
applications in these families, if granted, are expected to expire in 2038 or 2039, without taking potential patent term extensions or patent term adjustment into account. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical Product Candidates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company also has taken steps to protect various preclinical product candidates. The Company owns or exclusively licenses various granted
U.S. patents, and pending U.S., foreign and PCT applications covering ARC compounds that may develop into product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Six
licensed U.S. granted patents and one Company-owned U.S. granted patent cover <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1-,</FONT></FONT> CSF1R-, TIM3-, SIRP1<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>-, and TIGIT-based
ARC compounds, with OX40L, CD40L, and <FONT STYLE="white-space:nowrap">4-1BBL,</FONT> covering compositions of matter of a genus of compounds, and the preclinical product candidates specifically, pharmaceutical compositions, and methods of treating.
Patent applications are pending in the United States and various foreign jurisdictions and regions, including Australia, Brazil, Canada, China, Europe, Hong Kong, Indonesia, Israel, India, Japan, Korea, Mexico, Malaysia, Philippines, Russia, Saudi
Arabia, Singapore, Thailand, Ukraine, and Vietnam that could cover various product candidates. Patent applications in these families, if granted, are expected to expire in 2038 or 2039, without taking potential patent term extensions or patent term
adjustment into account. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Trademark Protection </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September 1, 2020, we owned an allowed trademark application for &#147;ARC&#148; and a pending application for &#147;GADLEN&#148; with
the U.S. Patent and Trademark Office. We plan to register trademarks in connection with our biological products. </P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Licensed
Intellectual Property from Heat Biologics, Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, we entered into an exclusive license agreement with Heat, pursuant
to which we received an exclusive (as to the patent rights), <FONT STYLE="white-space:nowrap">non-transferable,</FONT> sublicensable, worldwide, royalty-bearing, <FONT STYLE="white-space:nowrap">non-field</FONT> restricted license to certain patent
rights and <FONT STYLE="white-space:nowrap">know-how,</FONT> including rights related to the ARC platform. We paid Heat an initial license fee of $50,000, and we are obligated to pay Heat fees upon receipt of certain sublicensing income, achievement
of certain milestones, and royalties upon sales of commercial products. The Heat license provides us rights in the patent family that arose from PCT/US16/54598 and is the source of ten granted U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patents, and about 25 pending applications in the United States and various foreign jurisdictions and regions, including Australia, Brazil, Canada, China, Europe, Hong Kong, Indonesia, Israel,
India, Japan, Korea, Mexico, Malaysia, Philippines, Russia, Saudi Arabia, Singapore, Thailand, Ukraine, and Vietnam. We control prosecution, maintenance, and enforcement of this family of patents and patent applications. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other
regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling,
packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be
required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. Biologics Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, biological products are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FDCA, and the Public
Health Service Act, and other federal, state, local, and foreign statutes and regulations. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#146;s current
Good Laboratory Practices, or GLP, regulation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated
annually or when significant changes are made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">approval by an independent IRB or ethics committee at each clinical site before the trial is commenced;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">manufacture of the proposed biologic candidate in accordance with cGMPs; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or
GCP, requirements to establish the safety, purity and potency of the proposed biologic product candidate for its intended purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA Advisory Committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the
manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#146;s continued safety, purity
and potency, and of selected clinical investigation sites to assess compliance with GCPs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use
in the United States. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Preclinical and Clinical Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization
from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes
results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
manufacturing and controls information, and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may
begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> period, raises safety concerns or questions about the proposed clinical trial. In such a case,
the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a
clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the IND submission process, supervision of human gene transfer trials includes evaluation and assessment
by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and
identifies any potential risk to public health or the environment and such review may result in some delay before initiation of a clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators
in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the
objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development
and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins
at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health
risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides
authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other
grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical study results to public registries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 1. The investigational product is initially introduced into healthy human subjects or patients with the
target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to
gain early evidence on effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 2. The investigational product is administered to a limited patient population with a specified disease or
condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and
more expensive Phase 3 clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Phase 3. The investigational product is administered to an expanded patient population to further evaluate
dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit
ratio of the investigational product and to provide an adequate basis for product approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, the FDA may
require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These <FONT STYLE="white-space:nowrap">so-called</FONT> Phase 4 studies may be made a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the
product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate
and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and
stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>BLA Submission and Review </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product
development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies
and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#146;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come
from company-sponsored clinical studies intended to test the safety and effectiveness of the product, or from a number of alternative sources, including studies initiated and sponsored by investigators. The submission of a BLA requires payment of a
substantial application user fee to the FDA, unless a waiver or exemption applies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act,
or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each
pediatric subpopulation for which the product is safe and effective. The Food and Drug Administration Safety and Innovation Act requires that a sponsor who is planning to submit a marketing application for a biological product that includes a new
active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial pediatric study plan, or PSP, within sixty days after an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting or as may be agreed between the sponsor and FDA. Unless otherwise required by regulation, PREA does not apply to any biological product for an
indication for which orphan designation has been granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 60 days following submission of the application, the FDA reviews a BLA
submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information.
In this event, the BLA must be resubmitted with the additional information. Once a BLA has been accepted for filing, the FDA&#146;s goal is to review standard applications within ten months after for the filing date, or, if the application qualifies
for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process may also be extended by FDA requests for additional information or clarification. The FDA reviews a BLA to
determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#146;s continued safety, purity and potency. The FDA may
convene an advisory committee to provide clinical insight on application review questions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve
an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a
BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the
submission and often will request additional testing or information. Notwithstanding the submission of any requested additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance
will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will
describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first
conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval,
including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and
surveillance to monitor safety or efficacy of a product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If regulatory approval of a product is granted, such approval will be granted
for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the
product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication
guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed
labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with <FONT STYLE="white-space:nowrap">pre-</FONT> and post-marketing requirements is not maintained or if
problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization, and may limit
further marketing of the product based on the results of these post-marketing studies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Expedited Development and Review Programs
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is
intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition
and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track
product has opportunities for more frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review,
where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA
and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to
expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more
intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any marketing application for a biologic submitted to the FDA for approval, including a
product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is
eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#146;s goal is to
take action on the marketing application within six months of the <FONT STYLE="white-space:nowrap">60-day</FONT> filing date (as compared to ten months under standard review). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive
accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality,
that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a
condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other
clinical benefit. . Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In
addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial launch of the product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, the FDA established a new regenerative medicine advanced therapy, or RMAT, designation as part of its implementation of the 21st
Century Cures Act. The RMAT designation program is intended to fulfill the 21st Century Cures Act requirement that the FDA facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria:
(i)&nbsp;the drug qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (ii)&nbsp;the
drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (iii)&nbsp;preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or
condition. RMAT designation provides all the benefits of breakthrough therapy designation, including more frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority
review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful
number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through: the submission of clinical evidence, preclinical
studies, clinical trials, patient registries or other sources of real world evidence such as electronic health records; the collection of larger confirmatory datasets; or post-approval monitoring of all patients treated with the therapy prior to
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fast track designation, breakthrough therapy designation, priority review and RMAT designation do not change the standards for
approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period
for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a
disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United
States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug
designation, the generic identity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory
review or approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease
for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication
for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the
availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for
the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it
received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient
quantities of the product to meet the needs of patients with the rare disease or condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA,
including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the
approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified
in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for
compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may
require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use.
Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the
product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may
result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program.
Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market
or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">fines, warning letters or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or
revocation of existing product approvals; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">product seizure or detention, or refusal of the FDA to permit the import or export of products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">mandated modification of promotional materials and labeling and the issuance of corrective information;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications
containing warnings or other safety information about the product; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to
safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <FONT
STYLE="white-space:nowrap">off-label</FONT> uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may
prescribe legally available products for uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. Such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are common across
medical specialties. Physicians may believe that such <FONT STYLE="white-space:nowrap">off-label</FONT> uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of
treatments. The FDA does, however, restrict manufacturer&#146;s communications on the subject of <FONT STYLE="white-space:nowrap">off-label</FONT> use of their products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Regulation of Diagnostic Tests </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our drug candidates may require use of a diagnostic to identify appropriate patient populations for our product candidates. These diagnostics,
often referred to as companion diagnostics, are medical devices, often in vitro devices, which provide information that is essential for the safe and effective use of a corresponding drug. In the United States, the FDCA and its implementing
regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing,
labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial
distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA approval. We expect that any companion diagnostic developed
for our drug candidates will utilize the PMA pathway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PMA applications must be supported by valid scientific evidence, which typically
requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#146;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA application typically includes data
regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities to ensure compliance with the
Quality System Regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. FDA review of an initial PMA may require several years to complete. If the FDA evaluations of
both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of
the PMA. If the FDA&#146;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and,
where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are
conducted and then the data submitted in an amendment to the PMA. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards is not maintained or
problems are identified following initial marketing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On August&nbsp;6, 2014, the FDA issued a final guidance document addressing the development
and approval process for &#147;In Vitro Companion Diagnostic Devices.&#148; According to the guidance, for novel drugs such as our drug candidates, a companion diagnostic device and its corresponding drug should be approved or cleared
contemporaneously by the FDA for the use indicated in the therapeutic product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a drug generally will be considered an
investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a
significant risk device under the FDA&#146;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and
a drug are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides
that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Biosimilars and Reference Product Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval
pathway for biological products that are highly similar, or &#147;biosimilar,&#148; to or interchangeable with <FONT STYLE="white-space:nowrap">an&nbsp;FDA-approved&nbsp;reference</FONT> biological product. The FDA has issued several guidance
documents outlining an approach to review and approval of biosimilars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biosimilarity, which requires that there be no clinically
meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, is generally shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that
a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an
individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. A
product shown to be biosimilar or interchangeable with an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> reference biological product may rely in part on the FDA&#146;s previous determination of safety and effectiveness for the reference
product for approval, which can potentially reduce the cost and time required to obtain approval to market the product. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by
which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the
reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#146;s own preclinical
data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture,
it is unclear whether products deemed &#147;interchangeable&#148; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to
existing exclusivity periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a
pediatric study in accordance with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a study. The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals
have sought to reduce the <FONT STYLE="white-space:nowrap">12-year</FONT> reference product exclusivity period. Other aspects of the BPCIA, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to
significant uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws and Compliance Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the
states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation: the federal Anti-Kickback Statute, the federal False Claims Act, HIPAA and similar foreign, federal and state fraud, abuse and transparency
laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting,
receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program. The term
remuneration has been interpreted broadly to include anything of value, including stock options. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand, and prescribers and
purchasers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but they are drawn narrowly and practices that involve remuneration, such as consulting agreements,
that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for protection under
a statutory exception or regulatory safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute.
Instead, the legality of the arrangement will be evaluated on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;case-by-case&nbsp;basis</FONT></FONT> based on a cumulative review of all of its facts and circumstances. A person
or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Civil and criminal false claims laws, including the federal False Claims Act, and civil monetary penalty laws, which can be enforced through
civil whistleblower or qui tam actions, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false
or fraudulent. For example, the federal False Claims Act prohibits any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or
used a false record or statement material to a claim to the federal government. A claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. Several pharmaceutical and other healthcare companies have
been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, the government may assert that a claim resulting from a violation of
the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">HIPAA created
additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including private third-party payors, and making false statements relating to healthcare matters. A person or
entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent to violate the statute in order to have committed a violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDCA addresses, among other things, the design, production, labeling, promotion, manufacturing, and testing of drugs, biologics and
medical devices, and prohibits such acts as the introduction into interstate commerce of adulterated or misbranded drugs or devices. The U.S. Public Health Service Act also prohibits the introduction into interstate commerce of unlicensed or
mislabeled biological products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The U.S. federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Health Insurance Program, with specific exceptions, to annually report to CMS information related to payments or other transfers of value made to physicians and teaching hospitals, as well as
ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, such reporting obligations will be expanded to include payments and other transfers of value provided in 2021 to certain other healthcare
professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also subject to additional similar U.S. state and foreign law equivalents of each of the above federal laws, which, in some cases,
differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be
subject to penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or
jurisdictions, integrity oversight and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the
curtailment or restructuring of our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Data Privacy and Security </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous state, federal and foreign laws, govern the collection, dissemination, use, access to, confidentiality and security of personal
information, including health-related information. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection
laws and regulations, govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, HIPAA, as amended by HITECH, and their
respective implementing regulations, imposes privacy, security and breach notification obligations on certain health care providers, health plans, and health care clearinghouses, known as covered entities, as well as their business associates that
perform certain services that involve creating, receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities. Entities that are found to be in violation of HIPAA may be subject to
significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA <FONT
STYLE="white-space:nowrap">non-compliance.</FONT> Further, entities that knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA
may be subject to criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even when HIPAA does not apply, according to the FTC, violating consumers&#146; privacy rights or
failing to take appropriate steps to keep consumers&#146; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&nbsp;5(a) of the Federal Trade Commission Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws, such as the GDPR govern the privacy and security of
personal information, including health-related information, in certain circumstances. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For
example, the CCPA, which went into effect on January&nbsp;1, 2020, creates new data privacy obligations for covered companies and provides new privacy rights to California residents. In Europe, the GDPR went into effect in May 2018 and introduces
strict requirements for processing the personal data of individuals within the EEA. Further, recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data from the EEA. For
example, on July&nbsp;16, 2020, the CJEU invalidated the Privacy Shield under which personal data could be transferred from the EEA to United States entities who had self-certified under the Privacy Shield scheme. Moreover, it is uncertain whether
the standard contractual clauses will also be invalidated by the European courts or legislature </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Companies that must comply with the GDPR
face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to &#128;20&nbsp;million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Additionally, following the United Kingdom&#146;s withdrawal from the European
Union and the EEA, companies have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &pound;17.5&nbsp;million or 4% of global turnover.
The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further
compliance risk. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain
regulatory approval. Sales of any product, if approved, depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed
healthcare organizations, and the level of reimbursement, if any, for such product by third-party payors. Decisions regarding whether to cover any of our product candidates, if approved, the extent of coverage and amount of reimbursement to be
provided are made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. Further, no uniform policy for coverage and reimbursement exists in the United States, and coverage and reimbursement can
differ significantly from payor to payor. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates, but also have their own methods and approval process apart from Medicare
determinations. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no
assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For products
administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself
or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. In addition, companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and
reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to companion diagnostics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including
price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity
and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more
restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product that receives approval. Decreases in third-party reimbursement for any product or a decision by a third-party not to cover a product
could reduce physician usage and patient demand for the product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Healthcare Reform </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system.
There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of
these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under
government-funded health care programs, and increased governmental control of drug pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA, which was enacted in March 2010, substantially changed the way healthcare is
financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries,
including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled,
implanted or injected, and annual fees based on pharmaceutical companies&#146; share of sales to federal health care programs. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect
there will be additional challenges and amendments to the ACA in the future. For example, the Tax Act was enacted, which, among other things, removes penalties for not complying with ACA&#146;s requirement to carry health insurance, known as the
&#147;individual mandate,&#148; effective January&nbsp;1, 2019. Since the enactment of the Tax Act, there have been additional amendments to certain provisions of the ACA. In December 2019, the U.S. District Court for the Fifth Circuit upheld a
ruling by a Texas U.S. District Court Judge that the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress as part of the Tax Act. On March&nbsp;2, 2020, the Supreme Court of the United States
granted certiorari to hear the appeal of this decision. While various parties, including the Trump administration and CMS have stated that the ruling will have no immediate effect, it is unclear how this and other efforts to repeal and replace the
ACA will impact the ACA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted, including automatic
aggregate reductions of Medicare payments to providers of 2% per fiscal year as part of the federal budget sequestration under the Budget Control Act of 2011. These reductions went into effect in April 2013 and, due to subsequent legislative
amendments, will remain in effect through 2030 with the exception of a temporary suspension from May&nbsp;1, 2020 through December&nbsp;31, 2020, unless additional action is taken by Congress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed
products, which has resulted in several Congressional inquiries and proposed and enacted federal and state measures designed to, among other things, reduce the cost of prescription drugs, bring more transparency to product pricing, review the
relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS adopted a final rule allowing Medicare Advantage Plans the option to use step
therapy for Part B drugs, permitting Medicare Part D plans to apply certain utilization controls to new starts of five of the six protected class drugs, and requiring the Explanation of Benefits for Part D beneficiaries to disclose drug price
increases and lower cost therapeutic alternatives beginning January&nbsp;1, 2021. In addition, on March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other
things, cap Medicare Part D beneficiary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place limits on pharmaceutical price increases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Congress and the
Trump administration have each indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed
to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage
importation from other countries and bulk purchasing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Government Regulation Outside of the United States </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other
things, research and development, clinical trials, testing, manufacturing, safety, efficacy, quality control, labeling, packaging, storage, record keeping, distribution, reporting, export and import, advertising, marketing and other promotional
practices involving biological products as well as authorization, approval as well as post-approval monitoring and reporting of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be
restricted in some countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals
from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a
clinical trial application, or a CTA, much like the IND prior to the commencement of human clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The requirements and process
governing the conduct of clinical trials, including requirements to conduct additional clinical trials, product licensing, safety reporting, post-authorization requirements, marketing and promotion, interactions with healthcare professionals,
pricing and reimbursement may vary widely from country to country. No action can be taken to market any product in a country until an appropriate approval application has been approved by the regulatory authorities in that country. The current
approval process varies from country to country, and the time spent in gaining approval varies from that required for FDA approval. In certain countries, the sales price of a product must also be approved. The pricing review period often begins
after market approval is granted. Even if a product is approved by a regulatory authority, satisfactory prices may not be approved for such product, which would make launch of such products commercially unfeasible in such countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Regulation in the European Union </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Drug and Biologic Development Process </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conduct of clinical trials is currently governed by the EU Clinical Trials Directive 2001/20/EC, or Clinical Trials Directive, and will be
replaced by the EU Clinical Trials Regulation (EU) No.&nbsp;536/2014, or Clinical Trials Regulation, once the latter comes into effect. The Clinical Trials Regulation introduces a complete overhaul of the existing regulation of clinical trials for
medicinal products in the EU. Currently it is not expected to come into force before December 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the current regime, before a
clinical trial can be initiated, it must be approved in each EU Member State where there is a site at which the trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority, or NCA, and one or
more Ethics Committees. The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the
clinical trial in the relevant EU Member State before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant
NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU Member State
where they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A more unified procedure will apply under the new Clinical Trials Regulation. A sponsor will be able to submit a single
application for approval of a clinical trial through a centralized EU clinical trials portal. One national regulatory authority (the reporting EU Member State proposed by the applicant) will take the lead in validating and evaluating the application
and the other regulatory authorities will have limited involvement. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all
concerned Member States. However, a concerned EU Member State may in limited circumstances declare an <FONT STYLE="white-space:nowrap">&#147;opt-out&#148;</FONT> from an approval and prevent the clinical trial form being conducted in such Member
State. The Clinical Trials Regulation also aims to streamline and simplify the rules on safety reporting, and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under both the current regime and the new Clinical Trials Regulation, national laws, regulations, and the applicable Good Clinical
Practice and Good Laboratory Practice standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, guidelines on Good
Clinical Practice, or GCP, and the ethical principles that have their origin in the Declaration of Helsinki. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the development of a medicinal product, the European Medical Agency, or EMA, and
national regulators within the EU provide the opportunity for dialogue and guidance on the development program, usually in the form of scientific advice. A fee is incurred with each scientific advice procedure. Advice from the EMA is typically
provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Drug Marketing Authorization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, medicinal products, including advanced therapy medicinal products, or ATMPs, are subject to extensive <FONT
STYLE="white-space:nowrap">pre-</FONT> and post-market regulation by regulatory authorities at both the European Union and national levels. ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products, which are
genes, cells or tissues that have undergone substantial manipulation and that are administered to human beings in order to cure, diagnose or prevent diseases or regenerate, repair or replace a human tissue. We anticipate that our gene therapy
development products will be regulated as ATMPs in the European Union under the EU Regulation (EC) No 1394/2007 on advanced therapy medicinal products, or ATMP Regulation. Pursuant to the ATMP Regulation, the Committee on Advanced Therapies, or CAT,
is responsible in conjunction with the CHMP for the evaluation of ATMPs. The CHMP and CAT are also responsible for providing guidelines on ATMPs. These guidelines provide additional guidance on the factors that the EMA will consider in relation to
the development and evaluation of ATMPs and include, among other things, the preclinical studies required to characterize ATMPs; the manufacturing and control information that should be submitted in a marketing authorization application; and
post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse reactions of ATMPs. Although such guidelines are not legally binding, compliance with them is often necessary to gain and maintain approval
for product candidates. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union and in Iceland, Norway and Liechtenstein (together the European Economic Area, or
EEA), after completion of all required clinical testing, medicinal products may only be placed on the market after a related Marketing Authorization, or MA, has been granted. MAs can be obtained through, amongst others, a centralized procedure,
which is compulsory for certain medicinal products such as ATMPs. The centralized procedure provides for the grant of a single MA by the European Commission, or EC, that is valid for all 27 EU Member States and, after respective national
implementing decisions, in the three additional EEA Member States (Iceland, Norway and Liechtenstein). The centralized procedure is compulsory for certain medicinal products, including medicinal products derived from biotechnological processes,
orphan medicinal products, ATMPs and products with a new active substance indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. It is optional for medicinal products containing a new
active substance not yet authorized in the EEA before May&nbsp;20, 2004, that constitute significant therapeutic, scientific or technical innovations, or for which the grant of a MA through the centralized procedure would be in the interest of
public health at EU level. The timeframe for the evaluation of an application under the centralized procedure is 210 days, excluding clock stops. Typically, the overall process takes a year or more unless the application is eligible for an
accelerated assessment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All new marketing authorization applications must include a Risk Management Plan, or RMP, describing the risk
management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. RMPs and Periodic
Safety Update Reports, or PSURs, are routinely available to third parties requesting access, subject to limited redactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally,
the holder of a marketing authorization for an ATMP must put in place and maintain a system to ensure that each individual product and its starting and raw materials, including all substances coming into contact with the cells or tissues it may
contain, can be traced through the sourcing, manufacturing, packaging, storage, transport and delivery to the relevant healthcare institution where the product is used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MAs have an initial duration of five&nbsp;years. The authorization may subsequently be renewed for an unlimited period unless the EC or the
national competent authority grants only an five-year renewal. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Data and Market Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As in the United States, the European Union also provides opportunities for market and/or data exclusivity. For example, new Chemical Entities,
or NCE, approved in the European Union generally qualify for eight&nbsp;years of data exclusivity and ten&nbsp;years of market exclusivity. Data exclusivity is the period during which another applicant cannot rely on the MA holder&#146;s
pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining marketing authorization or placing the product on the market. But after eight years, a generic or biosimilar product
application may be submitted and generic companies may rely on the MA holder&#146;s data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, even if a generic or biosimilar
product is authorized it cannot be placed on the market in the European Union until the expiration of the <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity period. An additional <FONT STYLE="white-space:nowrap">non-cumulative</FONT>
<FONT STYLE="white-space:nowrap">one-year</FONT> period of marketing exclusivity is possible if during the data exclusivity period (the first eight years of the <FONT STYLE="white-space:nowrap">10-year</FONT> marketing exclusivity period), the MA
holder obtains an authorization for one or more new therapeutic indications that are deemed to bring a significant clinical benefit compared to existing therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the European Union&#146;s
regulatory authorities to include a NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the medicinal
product if such company can complete a full marketing authorization application with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Designation and Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The criteria for designating an orphan medicinal product in the European Union are similar in principle to those in the United States. The EMA
grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of (i)&nbsp;a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union
when the application is made or a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without the benefits derived from orphan status, would not generate sufficient return in the European Union to
justify investment and (ii)&nbsp;where there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized in the European Union, or if such a method exists, the product will be of significant benefit to those
affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization that covers only the therapeutic indication(s) that meet the orphan
drug designation criteria, entitled to ten years of market exclusivity for the approved therapeutic indication. An application for orphan drug designation must be submitted first before an application for marketing authorization of the medicinal
product is submitted. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is
submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the <FONT STYLE="white-space:nowrap">10-year</FONT> period of market exclusivity, with a limited number of exceptions, the regulatory
authorities of the EU Member States and the EMA may not accept applications for marketing authorization, accept an application to extend an existing marketing authorization or grant marketing authorization for other similar medicinal products for
the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same
therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition when the results of specific studies are reflected in the Summary of Product Characteristics, or
SmPC, addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan, or PIP. No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan
indications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity may be reduced to six
years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, a
marketing authorization may be granted to another medicinal product (orphan or not) for the same or overlapping indication at any time subject to certain requirements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pediatric Development </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, companies developing a new medicinal product are obligated to study their product in children and must therefore agree
upon a PIP with the EMA&#146;s Pediatric Committee. The companies must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies, e.g., because the relevant disease or condition occurs only in adults. The marketing
authorization application for the product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric clinical trials must be
completed at a later date. Products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six month extension of the protection under a supplementary
protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not
automatically available when data in compliance with the PIP are developed and submitted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>PRIME Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no
therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the
centralized procedure. Products from small- and <FONT STYLE="white-space:nowrap">medium-sized</FONT> enterprises may qualify for earlier entry into the PRIME scheme than larger companies on the basis of compelling
<FONT STYLE="white-space:nowrap">non-clinical</FONT> data and tolerability data from initial clinical trials. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory
dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and potentially accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, once a candidate
medicine has been selected for the PRIME scheme, a dedicated contact point and rapporteur from the CHMP or from CAT are appointed facilitating increased understanding of the product at EMA&#146;s Committee level. A
<FONT STYLE="white-space:nowrap">kick-off</FONT> meeting with the CHMP/CAT rapporteur initiates these relationships and includes a team of multidisciplinary experts to provide guidance on the overall development plan and regulatory strategy. PRIME
eligibility does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Similar to the United States, both MA holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the
EMA, the European Commission and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU
good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of medicinal products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the
related national laws of individual EU Member States governing the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products, both before and after grant of marketing
authorization, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension,
withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holder of a marketing authorization for a medicinal product must also comply with EU pharmacovigilance legislation and its related
regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a
labor intensive collection of data regarding the risks and benefits of marketed medicinal products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or
post-authorization safety studies to obtain further information on a medicine&#146;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must
establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions
and submission of PSURs in relation to medicinal products for which they hold MAs. The EMA reviews PSURs for medicinal products authorized through the centralized procedure. If the EMA has concerns that the risk benefit profile of a product has
varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase IV safety studies. If the EC agrees with the
opinion, it can adopt a decision varying the existing MA. Failure by the marketing authorization holder to fulfill the obligations for which the EC&#146;s decision provides can undermine the ongoing validity of the MA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More generally, <FONT STYLE="white-space:nowrap">non-compliance</FONT> with pharmacovigilance obligations can lead to the variation,
suspension or withdrawal of the MA for the product or imposition of financial penalties or other enforcement measures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Sales and
Marketing Regulations </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The advertising and promotion of our products is also subject to EU laws concerning promotion of medicinal
products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of medicinal products
and may differ from one country to another. These laws require that promotional materials and advertising in relation to medicinal products comply with the product&#146;s SmPC as approved by the competent regulatory authorities. The SmPC is the
document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted for the medicinal product. Promotion of a medicinal
product that does not comply with the SmPC is considered to constitute <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore
all <FONT STYLE="white-space:nowrap">off-label</FONT> promotion is prohibited. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Direct-to-consumer</FONT></FONT> advertising of prescription-only medicines is also prohibited in the
European Union. Violations of the rules governing the promotion of medicinal products in the European Union could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion
of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Corruption Legislation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation
codes of conduct and physicians&#146; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement,
purchase, supply, order or use of medicinal products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. Violation of these laws could
result in substantial fines and imprisonment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments made to physicians in certain EU Member States also must be publicly disclosed.
Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#146;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU Member States.
These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands,
administrative penalties, fines or imprisonment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Markets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the UK&#146;s formal departure from the EU on January&nbsp;31, 2020, the UK entered a transition period to last until
December&nbsp;31, 2020, during which time EU medicines laws will remain applicable to the UK. After the transition period however, changes may be forthcoming as the terms of the UK and EU&#146;s future relationship are negotiated. The UK Medicines
and Healthcare Products Regulatory Agency has proposed that, subject to being approved by the UK Parliament, a centralized MA will automatically convert into a UK MA. However, the draft of the &#147;Medicines and Medical Devices Bill <FONT
STYLE="white-space:nowrap">2019-21&#148;</FONT> currently discussed in the UK House of Lords does not contain such a provision, but would only authorize the UK government to become active in the field of legislation concerning market authorizations
in relation to human medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For other countries outside of the European Union, such as countries in Eastern Europe, Latin America or
Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable
regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we fail to comply with
applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal
prosecution. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
August&nbsp;1, 2020, we had 48 full-time employees, 33 of whom were engaged in research and development activities and 15 of whom were engaged in general and administrative activities. None of our employees are represented by labor unions or covered
by collective bargaining agreements. We consider our relationship with our employees to be good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses for the years ended December&nbsp;31, 2018 and 2019 were $24.8&nbsp;million and $29.2&nbsp;million,
respectively, and for the six months ended June&nbsp;30, 2019 and 2020, were $12.5&nbsp;million and $15.9 million, respectively </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are located in Austin, Texas where we occupy approximately 4,550 square feet of office space under a lease that
expires on January 31, 2021. We use these facilities for administrative purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently lease approximately 32,238 square feet of
office and laboratory space in Durham, North Carolina under a lease that expires on December 31, 2028. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe these spaces to be
sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are not currently a party to any other material legal proceedings. Regardless of outcome, litigation can have an adverse impact on us due to
defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_12"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers, Directors, and Key Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding our executive officers, directors, and key employees as of the date of this
prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Position</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Josiah Hornblower</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Executive Chairman and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Taylor Schreiber, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Lini Pandite, MBChB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Casi DeYoung</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Erin Ator Thomson</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">General Counsel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Andrew R. Neill</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Finance and Corporate Strategy</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Non-Employee Directors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Helen M. Boudreau(1)(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Tyler Brous(1)(2)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Neil Gibson, Ph.D.(1)(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">George Golumbeski, Ph.D.(2)(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Michael Lee(3)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Victor Stone M.D., M.B.A(4)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Key Employees</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">George Fromm, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Research &amp; Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Thomas Lampkin, Pharm.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Regulatory Affairs</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Fatima Rangwala, M.D., Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Clinical Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Suresh de Silva, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Product Development</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">James Stout, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Vice President of Chemistry, Manufacturing, and Controls</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the audit committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the compensation committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the nominating and governance committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr. Stone intends to resign from his position as a member of our Board in connection with the closing of this offering. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a biographical summary of the experience of our executive officers, directors, and key employees: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Executive Officers </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Josiah Hornblower.</I></B> Mr. Hornblower founded Shattuck with Dr. Schreiber and has served on our Board since the company&#146;s
founding. He currently serves as the Executive Chairman of our Board. He previously served as our Chief Executive Officer and President from May 2016 to January 2020. Mr. Hornblower is a private biotechnology entrepreneur and has been involved in
starting and operating several biotechnology companies. He co-founded Pelican Therapeutics, Inc. in 2009 and served as its Chief Executive Officer until it was sold in 2017. He currently serves on the boards of Population Bio, Inc., a gene discovery
company, and the Daniel K. Thorne Foundation, where he heads the investment committee. Mr. Hornblower earned his B.A. in Art History from Trinity College and was a member of Phi Beta Kappa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Mr. Hornblower is qualified to serve on our Board because of his extensive experience forming and building biotechnology companies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Taylor Schreiber, M.D., Ph.D.</I></B> Dr. Schreiber is a co-founder of Shattuck. He served as our Chief Scientific Officer from
January 2017 until January 2020, when he became our Chief Executive Officer and a member of our Board. Dr. Schreiber is the lead inventor of Shattuck&#146;s ARC and GADLEN technology platforms. From March 2014 to July 2015, Dr. Schreiber served as
Vice President of R&amp;D of Heat Biologics, Inc. and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsequently served as Chief Scientific Officer of Heat Biologics until December 2016. He was a co-inventor of significant elements Heat Biologics&#146; ImPACT and ComPACT technology platforms.
From January 2011 to </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March 2017, he also served as Chairman of the Scientific Advisory Board of Pelican Therapeutics, Inc. and was a co-inventor of
Pelican&#146;s TNFRSF25 agonist technology. Dr. Schreiber earned his B.A. in Biology from Bucknell University and his M.D. and Ph.D. from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr. Schreiber is qualified to serve on our Board because of his extensive experience in the biopharmaceutical industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Lini Pandite, </I></B><B><I>MBChB.</I></B> Dr. Pandite has served as our Chief Medical Officer since July 2017. From May 2015 to June
2017, Dr. Pandite served as Head of Global Clinical Development and Senior Vice President at Adaptimmune Therapeutics plc, where she was responsible for clinical development of the company&#146;s immuno-oncology pipeline. From May 2001 to April
2015, Dr. Pandite served in a number of roles at GlaxoSmithKline plc, including Vice President, Medicines Development Leader, and Head Unit Physician for Oncology. Dr.&nbsp;Pandite was an attending physician at Sylvester Comprehensive Cancer
Center/Jackson Memorial Hospital in Miami from January 1998 to November 2000 and at Dana Farber Cancer Institute in Boston from July 1993 to August 1996, and has held academic appointments at Harvard University and the University of Miami. She
earned her MBChB from The University of Liverpool, England. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Casi DeYoung.</I></B> Ms. DeYoung has served as our Chief Business
Officer since December 2019. From June 2018 to December 2019, Ms. DeYoung served as Vice President and Chief Operating Officer for ImmuneSensor Therapeutics, where she was responsible for corporate strategy, start-up operations, intellectual
property, oversight of the company&#146;s first IND filing, and the initiation of a first-in-human Phase I clinical trial. She served as Chief Business Officer at Mirna Therapeutics, Inc. from March 2014 to June 2017, Vice President of Business
Development at Reata Pharmaceuticals, Inc. from May 2008 to December 2013, Vice President of Business Development at ODC Therapy, Inc. from November 2005 to March 2008, and in various roles at EMD Pharmaceuticals, Inc. and Merck KGaA from 2000 to
2005. Ms. DeYoung earned her B.S. in Chemistry from Southwestern University and her M.B.A. from the McCombs School of Business at the University of Texas at Austin. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Erin Ator Thomson.</I></B> Ms. Thomson has served as our General Counsel since October 2017. From 2007 to 2017, she was an Associate,
and later Counsel, at the law firm of Vinson &amp; Elkins LLP in Austin, Texas, where she advised both early-stage biotech and pharma clients on a wide range of intellectual property and other legal issues, including strategic transactions, in-bound
and out-bound licenses, collaborations, mergers and acquisitions, freedom-to-operate analyses, due diligence, assessment of IP portfolios, patent litigation, and licensing disputes. Ms. Thomson earned her B.S. in Biology from Pepperdine University
and her J.D. from Baylor University, where she graduated <I>summa cum laude</I>. She conducted post-graduate research at the University of California, San Francisco and clerked for Chief Justice Wallace Jefferson of the Supreme Court of Texas. She
is admitted to practice law in Texas and is a registered U.S. patent attorney. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Andrew R. Neill.</I></B> Mr. Neill has served as our
Vice President of Finance and Corporate Strategy since July 2019. He previously served as our Vice President of Corporate Development and Strategy from May 2017 to July 2019. From August 2010 to August 2016, Mr. Neill was the co-founder of Lumos
Pharma, Inc., a biopharmaceutical company focused on developing therapeutics for genetic rare diseases. From March 2009 to February 2014, Mr. Neill served as Analyst at Innovations in Drug Development, LLC, a pharmaceutical and biotechnology
research management consulting company. Mr. Neill earned his B.B.A. from Texas Christian University and his M.B.A. with majors in Health Care Management and Finance from The Wharton School at the University of Pennsylvania, where he was a Kaiser
Fellow. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Non-employee Directors </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Helen Boudreau.</I></B> Ms. Boudreau has served as a member of our Board since July 2020. Ms. Boudreau has 30 years of experience across
biotech, pharma, consulting, and banking. Most recently, from June 2018 to June 2019, she was Chief Operating Officer of the Bill &amp; Melinda Gates Medical Research Institute, a non-profit biotech. Previously, she served as Chief Financial Officer
from July 2017 to June 2018 and board member from February 2016 to July 2017 for Proteostasis Therapeutics, Inc. From October 2014 to June 2017, she served as Chief Financial Officer for FORMA Therapeutics, Inc. Ms. Boudreau spent 16 years at
Novartis and Pfizer in progressively senior finance and strategy roles, and worked earlier in her career at McKinsey &amp; Company and Bank of America. She is currently a member of the board of directors of Premier, Inc., a healthcare improvement
company, and is also on the board of directors of two private biotech companies. Ms. Boudreau earned her B.A. in Economics from the University of Maryland, where she graduated <I>summa cum laude</I>, and her M.B.A. from the Darden Graduate School of
Business at the University of Virginia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Ms. Boudreau is qualified to serve on our Board because of her financial expertise and
extensive experience with biotech companies. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Tyler Brous. </I></B>Mr. Brous has served on our Board since September 2016. He
has worked at Lennox Capital Partners since 2011, and currently serves as its Managing Director and Portfolio Manager. From 2014 to 2016, Mr. Brous worked at Arog Pharmaceuticals in various roles, including the acting Chief Financial Officer,
leading their capital markets and business development efforts. Prior to joining Lennox Capital Partners, Mr. Brous worked as a senior analyst at YX Funds, a hedge fund in Dallas, from 2007 to 2011. Mr. Brous started his career in the M&amp;A group
of Citigroup in New York. He has served on the board of directors of CerSci Therapeutics, Inc. from 2018 until its sale in 2020. Mr. Brous earned his B.S. in Finance and Business Honors from the University of Texas, where he graduated
<I>s</I><I>umma </I><I>c</I><I>um </I><I>l</I><I>aude</I>. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Mr. Brous is qualified to serve on our Board because of his
extensive experience in investing in, guiding, and leading biotech companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Neil Gibson, Ph.D.</I></B> Dr. Gibson has served as a
member of our Board since November 2016. Dr. Gibson has served as President and Chief Executive Officer of Adanate, a COI Pharmaceuticals, Inc. company, since 2017, where he is responsible for the creation of novel drug discovery companies based on
innovative and disruptive technologies. Dr. Gibson has held various senior positions within the biotechnology and pharmaceutical industry, including President and Chief Executive Officer of PDI Therapeutics from 2017 to 2020; Senior Vice President
of BioAtla, Inc. from 2015 to 2016; Chief Scientific Officer of Regulus Therapeutics from 2011 to 2015; and Chief Scientific Officer and Oncology Therapeutic Area Head of Pfizer Oncology from 2007 to 2011. While at Pfizer, Dr. Gibson was also a
member of the Pfizer Oncology Business Unit Executive team. Dr. Gibson has served on the board of TCR2 and Causeway Therapeutics since 2017 and previously served on the board of Cytosen Therapeutics from 2016 to 2019. Dr. Gibson earned his B.Sc. in
Pharmacy from the University of Strathclyde in Glasgow, Scotland and his Ph.D. from the University of Aston in Birmingham, England. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
believe Dr. Gibson is qualified to serve on our Board because of his extensive experience as an executive officer in the biopharmaceutical industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>George Golumbeski, Ph.D.</I></B> Dr. Golumbeski has served as a member of our Board since January 2018 and is a biotechnology executive
with more than 25 years of experience in the biotechnology industry. From August 2018 to August 2019, he served as President of GRAIL, Inc. From March 2009 to April 2018, Dr. Golumbeski served as the Executive Vice President of Business Development
of Celgene Corporation, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to people suffering from cancer and chronic inflammation. He currently serves on the board of
directors of several biotechnology companies, including Enanta Pharmaceuticals, Inc., Corbus Pharmaceuticals Holdings, Inc., MorphoSys AG, and Sage Therapeutics, Inc. Dr. Golumbeski earned his B.S. in Biology from the University of Virginia and his
Ph.D. in Genetics from the University of Wisconsin-Madison, and conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr. Golumbeski is qualified to serve on our Board because of his extensive
management experience and service on the boards of directors of numerous biotech companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Michael Lee.</I></B> Mr. Lee has served
as a member of our Board since June 2020. Mr. Lee has served as Co-Founder and Portfolio Manager at Redmile Group, LLC, a health care-focused investment firm based in San Francisco and New York, since 2007. Prior to Redmile, he worked as a
biotechnology investor at Steeple Capital, Welch Capital Partners and Prudential Equity Group. Mr. Lee currently serves on the board of directors of Fate Therapeutics, Inc. and IGM Biosciences, Inc. Mr. Lee earned his B.S. in Molecular and Cellular
Biology from the University of Arizona. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Mr. Lee is qualified to serve on our Board because of his long industry experience and
experience as an investor in biotechnology companies. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Victor Stone, M.D., M.B.A.</I></B> Dr. Stone (Yoshihide Ishii) has served
as a member of our Board of Directors since April 2020. Dr. Stone joined Takeda Ventures, Inc. in January 2020 as Partner. Prior to joining Takeda Ventures, from February 2014 to December 2019, Dr. Stone was a Director at Whiz Partners, a private
equity firm in Tokyo, where he served leading roles in company creation and fund establishment. He currently serves as a board member of Axcelead Drug Discovery Partners, and is an investment committee member of a joint fund with Takeda Ventures.
His entrepreneurship experience includes technology start-ups IGNITE, and Iron City Micro Display, where he continues to serve as board director. Prior to his transition to business, Dr. Stone served in the United States Navy and Marine Corps from
April 2001 to May 2010 with multiple combat deployments as a Naval Flight Surgeon. Dr. Stone earned his M.D. from Jefferson Medical College and his M.B.A. from Harvard Business School. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe Dr. Stone is qualified to serve on our Board because of his technical expertise in our industry and his experience in investing in
and forming biotech companies. Dr. Stone intends to resign from his position as a member of our Board in connection with the closing of this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Key Employees </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>George Fromm, Ph.D.</I></B> Dr. Fromm has served as our Vice President of Research &amp; Development since February 2017, and is one of
the scientific co-inventors of the ARC platform. From September 2014 to February 2017, Dr. Fromm served as the Senior Director of Research and Development at Heat Biologics, Inc., where he directed the Discovery and Clinical-based research efforts
for their Phase I/II trials, and co-invented a &#145;next-generation&#146; vaccine platform that combines a cell based immunotherapy vaccine and a T cell costimulatory fusion protein in a single treatment. He earned his M.S. and Ph.D. in
Biochemistry, Cellular and Molecular Biology from the University of Rochester, NY. Dr. Fromm conducted his post-doctoral fellowship training with the NIH branch; National Institute of Environmental Health Sciences. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Thomas Lampkin, Pharm.D.</I></B> Dr. Lampkin has served as our Head of Regulatory Affairs since April 2018. Prior to joining Shattuck,
he gained more than 22 years of experience at GlaxoSmithKline plc and served in a number of roles, most recently as a Senior Director in Global Regulatory Affairs, where he was responsible for regulatory strategy and leading regulatory teams for
global and U.S. focused programs. Prior to that position, Dr. Lampkin was a Senior Director within oncology clinical development at GlaxoSmithKline and lead global clinical development teams for multiple solid tumor and hematologic malignancy
programs. Dr. Lampkin earned his B.S. in Microbiology and Chemistry from the University of Illinois, Urbana-Champaign and his Pharm.D. from the University of Illinois at Chicago, and completed a Fellowship in Clinical Research and Drug Development
at The University of North Carolina at Chapel Hill. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Fatima Rangwala, M.D., Ph.D.</I></B> Dr. Rangwala has served as our Vice
President of Clinical Development since August 2018. From 2015 to 2018, she served as a Senior Clinical Development Medical Director and GI indications lead at Novartis International AG. Prior to Novartis, Dr. Rangwala served as Clinical Director at
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
GlaxoSmithKline plc from April 2014 to May 2015. From June 2011 to April 2014 Dr. Rangwala served on the faculty at Duke University as an assistant professor in the Division of Oncology. Dr.
Rangwala earned her B.A. with honors in Biology at the University of Chicago and her M.D. and Ph.D. from the University of Cincinnati College of Medicine, and completed internal medicine and oncology fellowship training at Duke University. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Suresh de Silva, Ph.D.</I></B> Dr. de Silva has served as our Vice President of Product Development since December 2018, and is a
co-inventor of the ARC technology platform. From February 2017 to December 2018, he was our Executive Director of Research and Development. From January 2016 to January 2017, Dr. de Silva served as the Director of Research and Development at Heat
Biologics, Inc. and from August 2015 to January 2016 he served as Associate Director of Research and Development at Heat Biologics. Prior to his time at Heat Biologics, Dr. de Silva was a Research Scientist at the Center for Retrovirus Research at
The Ohio State University in Columbus, OH from 2013 to 2015. Dr. de Silva earned his B.S. in Biochemistry and Molecular Biology from the University of Colombo, Sri Lanka and his M.S. and Ph.D. in Biochemistry from the University of Rochester, NY. He
completed his post-doctoral fellowship at The Ohio State University, where he was a recipient of a Staff Career Development Grant from their College of Veterinary Medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>James Stout, Ph.D.</I></B> Dr. Stout has served as our Vice President of Chemistry, Manufacturing, and Controls since January 2020. From
March 2018 to December 2019, he served as Director of Process Science Biologics at BioVectra, Inc. (a subsidiary of Mallinckrodt Pharmaceuticals). From November 2017 to March 2018, he served as Vice President of Glycobiologic Process Development
&amp; Manufacturing at HOST Therabiomics. From November 2012 to November 2017, he served as Vice President of Process Sciences at Natrix Separations, Inc. From June 2012 to November 2012, he served as Director of Process Science &amp; Engineering at
ImmunoGen, Inc. He served as Associate Director of Purification Process Development at Shire Human Genetic Therapies from October 2010 to June 2012. From May 2006 to October 2010, he served as Director of Purification Sciences at Amgen, Inc. From
September 2002 to May 2006, he served as Group Leader of Purification Process Sciences at the Abbott Bioresearch Center. From June 2001 to September 2002, he served as Associate Director of Purification Development at Medarex, Inc. From March 1998
to June 2001, Dr. Stout worked in biopharmaceutical process development and manufacturing at Alexion Pharmaceuticals. Dr. Stout earned his B.S. in Chemistry from Denison University and his Ph.D. in Biochemistry (with a minor in Analytical Chemistry)
from the University of Cincinnati. Dr. Stout completed a NIH post-doctoral Fellowship at the University of Cincinnati College of Medicine in the Department of Pharmacology &amp; Cell Biophysics. Dr. Stout completed a senior post-doctoral fellowship
at the Blood Research Institute, Blood Center of SE Wisconsin in the Department of Immunochemistry. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Structure and the Role of our Board in Risk
Oversight </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Board Structure </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are managed under the direction of our Board, which currently consists of eight members. Dr. Stone intends to resign
from his position as a member of our Board in connection with the closing of this offering. Each of our current directors will continue to serve until the election and qualification of his or her successor, or his or her earlier death, resignation
or removal. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The authorized number of directors is determined from time to time solely by resolution of the Board. Our second amended
and restated certificate of incorporation and amended bylaws will provide that our directors may be removed only for cause by the affirmative vote of the holders of at least 66<SUP STYLE="font-size:85%; vertical-align:top"> </SUP>2/3% of the votes
that all our stockholders would be entitled to cast in an annual election of directors. In addition, only our Board will be authorized to fill vacancies and any additional directorships resulting from an increase in the authorized number of
directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second amended and restated certificate of incorporation will establish a classified board of directors consisting of
three classes of directors, with staggered three-year terms. Only one class of directors will be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
elected at each annual meeting of our stockholders to succeed the directors of the same class whose terms are then expiring, with the other classes continuing for the remainder of their
respective three-year terms. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2021 for Class&nbsp;I directors, 2022 for Class&nbsp;II
directors, and 2023 for Class&nbsp;III directors. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;I directors will be Tyler Brous, Josiah Hornblower, and Michael Lee. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;II directors will be Neil Gibson and George Golumbeski. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Class&nbsp;III directors will be Helen Boudreau and Taylor Schreiber. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Board Leadership Structure </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board has designated Josiah Hornblower to serve as executive chairman of the Board. Separating the role of executive chairman from the
chief executive officer position allows our chief executive officer to focus on our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business, while allowing the executive chairman to lead our Board in its
fundamental role of providing advice to and oversight of management. As described below, our Board also has a lead independent director to facilitate independent oversight of management. As executive chairman, Mr.&nbsp;Hornblower brings to our Board
extensive executive leadership and operational experience in biotechnology companies and his experience and familiarity with our business as the <FONT STYLE="white-space:nowrap">co-founder</FONT> of Shattuck. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our independent directors have designated Tyler Brous to serve as lead independent director. As lead independent director, Mr. Brous will
preside at all meetings of the Board at which the executive chairman is not present, preside over executive sessions of our independent directors, serve as a liaison between our executive chairman and our independent directors, and perform such
additional duties as our Board may otherwise determine and delegate. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although our amended bylaws do not require that we separate the
chief executive officer and board leadership positions, our Board believes that having separate positions is the appropriate leadership structure for us at this time. Our Board recognizes that, depending on the circumstances, other leadership
models, such as combining the role of executive chairman of the Board with the role of chief executive officer, might be appropriate. Accordingly, our Board may periodically review its leadership structure. Our Board believes its administration of
its risk oversight function has not affected its leadership structure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Role of our Board in Risk Oversight </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face a number of risks, including those described under the section titled &#147;Risk Factors&#148; included elsewhere in this prospectus.
Our Board believes that risk management is an important part of establishing, updating and executing on the company&#146;s business strategy. Our Board, as a whole and at the committee level, has oversight responsibility relating to risks that could
affect the corporate strategy, business objectives, compliance, operations and the financial condition and performance of the company. Our Board focuses its oversight on the most significant risks facing the company and on its processes to identify,
prioritize, assess, manage and mitigate those risks. Our Board and its committees receive regular reports from members of the company&#146;s senior management on areas of material risk to the company, including strategic, operational, financial,
legal and regulatory risks. While our Board has an oversight role, management is principally tasked with direct responsibility for management and assessment of risks and the implementation of processes and controls to mitigate their effects on the
company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Committees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board
has established an audit committee, or the Audit Committee, a compensation committee, or the Compensation Committee and a nominating and corporate governance committee, or the Governance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Committee, each comprised solely of directors whom satisfy applicable Nasdaq Stock Market, or Nasdaq, independence standards. We believe that the functioning of these committees complies with the
requirements of the Sarbanes-Oxley Act, the rules of Nasdaq and SEC rules and regulations that will become applicable to us upon closing of this offering. As this is our initial public offering, we intend to comply with the requirements of Nasdaq
with respect to board and committee composition of independent directors as they become applicable to us in accordance with Nasdaq Marketplace Rule 5615(b)(1). Each committee has the responsibilities described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our Audit Committee are Helen Boudreau, Tyler Brous, and Neil Gibson, each of whom qualifies as an independent director for
audit committee purposes, as defined under the rules of the SEC and the applicable Nasdaq listing rules and has sufficient knowledge in financial and auditing matters to serve on the audit committee. Ms. Boudreau chairs the Audit Committee.
Additionally, Ms. Boudreau qualifies as an &#147;audit committee financial expert&#148; as that term is defined in the rules and regulations established by the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary responsibilities of our Audit Committee will be to oversee our accounting and financial reporting processes, including the audits
of the financial statements, and the internal and external audit processes. The Audit Committee will also oversee the system of internal controls established by management and our compliance with legal and regulatory requirements. The Audit
Committee will oversee the independent auditors, including their independence and objectivity. The Audit Committee will be empowered to retain outside legal counsel and other advisors as it deems necessary or appropriate to assist it in fulfilling
its responsibilities, and to approve the fees and other retention terms of the advisors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our Compensation Committee are Helen Boudreau, Tyler Brous, and George Golumbeski, each of whom qualifies as an independent
director, as defined under applicable Nasdaq qualification standards, and also meets the additional, heightened independence criteria applicable to members of the Compensation Committee. Mr. Brous chairs the Compensation Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary responsibilities of our Compensation Committee will be to periodically review and approve the compensation and other benefits for
our senior officers and directors. This will include reviewing and approving corporate goals and objectives relevant to the compensation of our executive officers, evaluating the performance of these officers in light of the goals and objectives,
and setting the officers&#146; compensation. Our Compensation Committee will also administer and make recommendations to the Board regarding equity incentive plans that are subject to the Board&#146;s approval and approve the grant of equity awards
under the plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of our Governance Committee are Neil Gibson, George Golumbeski, and Michael Lee, each of whom qualifies as an independent director,
as defined under applicable Nasdaq qualification standards. Mr.&nbsp;Gibson chairs the Governance Committee. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Governance
Committee will be responsible for engaging in succession planning for the Board, developing and recommending to the Board criteria for identifying and evaluating qualified director candidates, and making recommendations to the Board regarding
candidates for election or reelection to the Board at each annual stockholders&#146; meeting. In addition, the Governance Committee will be responsible for overseeing our corporate governance practices and making recommendations to the Board
concerning corporate governance matters. The Governance Committee will also be responsible for making recommendations to the Board concerning the structure, composition and functioning of the Board and its committees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, our Board intends to adopt a Code of Conduct and Ethics that establishes the standards of ethical conduct
applicable to all our directors, officers and employees. It will address, among other matters, compliance with laws and policies, conflicts of interest, corporate opportunities, regulatory reporting, external communications, confidentiality
requirements, insider trading, proper use of assets, and how to report compliance concerns. We intend to disclose any amendments to the Code of Conduct and Ethics, or any waivers of its requirements, on our website to the extent required by
applicable rules. The Audit Committee is responsible for applying and interpreting our Code of Conduct and Ethics in situations where questions are presented to it. Information contained on, or that can be accessed through, our website is not
incorporated by reference into this prospectus, and you should not consider information on our website to be part of this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation
Committee Interlocks </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the members of our Compensation Committee has at any time during the prior three years been one of our
officers or employees. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our Board
or Compensation Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering and our planned listing on The Nasdaq Global Market, our Board has reviewed the independence of all directors
in light of each director&#146;s (or any family member&#146;s, if applicable) affiliations with the company and members of management, as well as significant holdings of our securities. The Board uses the definition of independence from Nasdaq
listing standards to assess independence of our directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq rules have objective tests and a subjective test for determining who is
an &#147;independent director.&#148; The subjective test states that an independent director must be a person who lacks a relationship that, in the opinion of the Board, would interfere with the exercise of independent judgment in carrying out the
responsibilities of a director. The Board has not established categorical standards or guidelines to make these subjective determinations, but considers all relevant facts and circumstances. After considering the foregoing factors, our Board has
determined that Ms.&nbsp;Boudreau, Mr.&nbsp;Brous, Dr.&nbsp;Gibson, Dr.&nbsp;Golumbeski, and Mr.&nbsp;Lee qualify as &#147;independent directors&#148; as defined by Nasdaq rules. Mr.&nbsp;Hornblower and Dr.&nbsp;Schreiber are not deemed to be
independent under Nasdaq rules by virtue of their employment with the company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the effectiveness of this registration
statement, the members of our Audit Committee must satisfy the independence criteria set forth in Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, or Rule <FONT STYLE="white-space:nowrap">10A-3.</FONT> In order to be
considered independent for purposes of Rule <FONT STYLE="white-space:nowrap">10A-3,</FONT> no member of the Audit Committee may, other than in his or her capacity as a member of the Audit Committee, the Board or any other committee of the Board:
(i)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from us; or (ii)&nbsp;directly, or indirectly through one or more intermediaries, control, be controlled by or be under common control with us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2019, each
of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, other than Chris Hurff and Charles Dorrance, received cash fees of $5,000 per meeting attended to compensate them for their services on the Board. Messrs. Hurff and Dorrance
served on the Board in connection with negotiated agreements entered into between the company and Takeda Ventures, Inc., with respect to Mr.&nbsp;Hurff, and Delphinium, Inc., with respect to Mr.&nbsp;Dorrance. As a result, neither received any
compensation during 2019 for their service on the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to these meeting fees, Drs. Lowe and Golumbeski each received a
grant of 2,500 fully vested stock options on December&nbsp;4, 2019. We granted such stock options as compensation for consulting services that each of these directors provided to the company on top of their respective duties as Board members. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our employee directors, Dr.&nbsp;Schreiber and Mr.&nbsp;Hornblower, do not receive any
additional compensation for their Board service. Mr.&nbsp;Hornblower&#146;s 2019 compensation is disclosed in the Summary Compensation Table in the &#147;Executive Compensation&#148; section below. Because he is not a named executive officer for
2019, the following table includes Dr.&nbsp;Schreiber&#146;s 2019 compensation, which was paid to him for his services as our Chief Scientific Officer. Dr.&nbsp;Schreiber was promoted to Chief Executive Officer effective as of January&nbsp;29, 2020.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the total cash and equity compensation paid or granted to Dr. Schreiber and each of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors for service on our Board during 2019. Victor Stone, Michael Lee, and Helen M. Boudreau were each appointed to the Board in 2020 and, accordingly, did not receive any compensation during 2019.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned&nbsp;or<BR>Paid in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taylor Schreiber<SUP STYLE="font-size:85%; vertical-align:top">(</SUP><SUP
STYLE="font-size:85%; vertical-align:top">2</SUP><SUP STYLE="font-size:85%; vertical-align:top">)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">419,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tyler Brous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neil Gibson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Golumbeski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G. Walter Loewenbaum<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lowe<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Dorrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chris Hurff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported in this column represent the aggregate grant date fair value of stock options granted during the year ended December&nbsp;31, 2019, as computed in accordance with FASB Accounting Standards
Codification Topic 718. The assumptions used in calculating the grant date fair value of the awards reported in the Equity Awards column are set forth in Note 11, Stock-Based Compensation, to our financial statements included elsewhere in this
prospectus. Note that the amounts reported in this column reflect the aggregate accounting cost for these awards, and do not necessarily correspond to the actual economic value that may be received by the director from the awards. The awards
reflected in this table each covered a total of 2,500 fully vested stock options with an exercise price of $21.69 per share and a term of 10 years from grant. As of December&nbsp;31, 2019, each of the company&#146;s
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors and Dr.&nbsp;Schreiber held the following aggregate number of fully vested option awards. None of such individuals held any unvested stock awards on such date: </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taylor Schreiber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tyler Brous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neil Gibson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Golumbeski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">G. Walter Loewenbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(a)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Lowe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles Dorrance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chris Hurff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Loewenbaum has transferred 2,250 of these stock options to family members. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr. Schreiber generally participates in the same compensation programs as our other executive officers, which are described in the &#147;Executive Compensation&#148; section below. The amounts reflected in the table
above include Dr. Schreiber&#146;s base salary for 2019, his award under the company&#146;s 2019 annual bonus program, and, for &#147;All Other Compensation&#148; the sum of company&#146;s 401(k) plan matching contributions and life and AD&amp;D
insurance premiums paid on Dr. Schreiber&#146;s behalf. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Lowe stepped down from the Board in connection with the closing of the Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock issuance in June 2020. Mr.&nbsp;Loewenbaum
stepped down from the Board on July&nbsp;8, 2020. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than as set forth in the Director Compensation Table above and reimbursement for their
reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, including travel, food, and lodging, incurred in attending meetings of our Board and/or its committees, we provided no other
compensation to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Offering Outside Director Compensation Policy
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the completion of this offering, we anticipate that each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
will be eligible to receive compensation for his or her service on our Board consisting of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Going forward, we expect that our director compensation program will include an
equity component comprised of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The Board may revise the compensation arrangements for our directors from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All company equity awards currently outstanding, including stock options held by our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors or their permitted transferees, were granted under the Shattuck Labs, Inc. 2016 Stock Incentive Plan. Such plan will be discontinued in connection with this offering and outstanding awards thereunder will be cancelled and replaced with
equivalent awards under our 2020 Stock Incentive Plan, which is described in further detail below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_13"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our named executive officers, or NEOs, for 2019, which consist of our principal executive officer for 2019 and the next two most
highly-compensated executives for the year, are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Josiah Hornblower, our Executive Chairman and former Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Arundathy Nirmalini (Lini) Pandite, our Chief Medical Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Erin Ator Thomson, our General Counsel. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2019 Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes the compensation awarded to, earned by or paid to our NEOs for 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive
Plan<BR>Compensation<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Josiah Hornblower,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Executive Chairman and Former Chief Executive Officer<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">325,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">58,500</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">868</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">384,368</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arundathy Nirmalini (Lini) Pandite,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">405,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">120,488</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">11,944</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">537,432</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erin Ator Thomson,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;General Counsel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">315,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">129,300</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54,810</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">11,251</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">510,361</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Effective as of January&nbsp;29, 2020, Mr.&nbsp;Hornblower stepped down as our Chief Executive Officer, was appointed as Executive Chairman of the Board, and Dr.&nbsp;Taylor Schreiber was appointed as the new Chief
Executive Officer. Prior to his appointment as Chief Executive Officer, Dr.&nbsp;Schreiber served as our Chief Scientific Officer. Dr.&nbsp;Schreiber&#146;s 2019 compensation is disclosed in the &#147;Director Compensation&#148; section above.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amounts shown in this column represent the aggregate grant date fair value (calculated in accordance with FASB Accounting Standards Codification Topic 718) of stock options granted during the year. A description of the
methodologies and assumptions we use to value equity awards and the manner in which we recognize the related expense are described in Note 11 to our audited financial statements, Stock-Based Compensation, included elsewhere in this prospectus. These
amounts may not correspond to the actual value eventually realized by each NEO because the value depends on the market value of our common stock at the time the award is exercised. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Following the end of the fiscal year, we paid each of our NEOs bonuses in respect of our performance in 2019 based on the achievement of individual and company performance goals, described in further detail below.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents the sum of company 401(k) plan matching contributions and life and AD&amp;D insurance premiums paid during 2019 on behalf of each of our NEOs. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative Disclosure to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements&nbsp;&amp; 2019 Equity Awards </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Josiah Hornblower </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to an employment agreement with Josiah Hornblower, effective as of December&nbsp;5, 2019, pursuant to which he served as our Chief
Executive Officer during 2019. The agreement provides for his base salary, eligibility to receive an annual performance bonus with a target bonus amount of 30% of his base salary and eligibility to participate in the company&#146;s employee benefit
plans. The agreement provides for employment on an <FONT STYLE="white-space:nowrap">at-will</FONT> basis and thus either party may terminate at any time for any or no reason, subject to 30 days&#146; notice for Mr.&nbsp;Hornblower and the severance
provisions described below in the section titled &#147;Post-Employment Compensation and Change in Control Payments and Benefits.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020, Mr.&nbsp;Hornblower&#146;s employment agreement was amended to
reflect his transition to the Executive Chairman role effective as of January&nbsp;29, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Lini Pandite </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to an employment agreement with Lini Pandite, effective as of December&nbsp;5, 2019, pursuant to which she serves as our Chief
Medical Officer. The agreement provides for her base salary, eligibility to receive an annual performance bonus with a target bonus amount of 35% of base salary and eligibility to participate in the company&#146;s employee benefit plans. The
agreement provides for employment on an <FONT STYLE="white-space:nowrap">at-will</FONT> basis and thus either party may terminate at any time for any or no reason, subject to 30 days&#146; notice for Ms.&nbsp;Pandite and the severance provisions
described below in the section titled &#147;Post-Employment Compensation and Change in Control Payments and Benefits.&#148; Ms.&nbsp;Pandite&#146;s base salary was increased to $435,000 effective as of July&nbsp;15, 2020. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Erin Ator Thomson </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to an employment agreement with Erin Ator Thomson, effective as of December&nbsp;5, 2019, pursuant to which she serves as our
General Counsel. The agreement provides for her base salary, eligibility to receive an annual performance bonus with a target bonus amount of 20% of base salary and eligibility to participate in the company&#146;s employee benefit plans. The
agreement provides for employment on an <FONT STYLE="white-space:nowrap">at-will</FONT> basis and thus either party may terminate at any time for any or no reason, subject to 30 days&#146; notice for Ms.&nbsp;Thomson and the severance provisions
described below in the section titled &#147;Post-Employment Compensation and Change in Control Payments and Benefits.&#148; Ms.&nbsp;Thomson&#146;s 2020 target annual bonus opportunity was increased to 25% effective as of January 1, 2020, and her
base salary was increased to $350,000 effective as of July&nbsp;15, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;4, 2019, the Board approved a grant of 10,000
stock options to Ms.&nbsp;Thomson, which was intended to bring her aggregate compensation closer to the market median for executives in the general counsel position at similarly situated companies. Such stock options vest 25% on November&nbsp;22,
2020, and then in equal monthly installments over the following three years. The stock options have an exercise price of $21.69 per share and a contractual term of 10 years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2019 Annual Bonus Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the
beginning of 2019, the Compensation Committee of our Board established an overall budgeted annual bonus pool for awards to our general employee population, including each of our NEOs, who were eligible for the following target bonus amounts:
Mr.&nbsp;Hornblower-$97,500, Ms.&nbsp;Pandite-$141,750, and Ms.&nbsp;Thomson-$63,000. Bonus program participants, including each of the NEOs, were eligible to receive up to their target bonus amount to the extent that enumerated corporate
performance goals established by the Compensation Committee at the beginning of the year were achieved. These corporate performance goals included key milestones with respect to company products, financing, intellectual property, manufacturing, and
research and development. Personal responsibility for achievement of, and individual performance in support of, the enumerated corporate goals was also evaluated by the Compensation Committee in assessing final performance for the year. Following
its assessment of individual officer contributions and the level of achievement of the corporate goals in December of 2019, the Compensation Committee approved final bonus payments to the NEOs as follows: Mr.&nbsp;Hornblower-$58,500 (60% of target),
Ms.&nbsp;Pandite-$120,488 (85% of target), and Ms.&nbsp;Thomson-$54,810 (87% of target). Such bonus payments were made in early 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2019 Fiscal-Year End </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding outstanding equity awards at the end of 2019 for each of our NEOs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options<BR>(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares or<BR>Units of<BR>Stock&nbsp;That<BR>Have Not<BR>Vested</B><br><B>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value&nbsp;of<BR>Shares&nbsp;or<BR>Units of<BR>Stock&nbsp;That<BR>Have Not<BR>Vested</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Josiah Hornblower</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Arundathy Nirmalini (Lini) Pandite</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6/1/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/22/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/21/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/19/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/18/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erin Ator Thomson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/22/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/21/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/19/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/18/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/4/2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12/3/2029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each option award expires on the tenth anniversary of the date of grant. Other than Ms.&nbsp;Thomson&#146;s December&nbsp;22, 2017 grant, twenty-five percent of each stock option award vests on the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of the vesting commencement date specified in the award agreement and the remainder of the shares underlying the options vest in equal installments over the next 36 months, subject to the
applicable NEO&#146;s continued service through each such vesting date. The vesting commencement dates for Ms.&nbsp;Pandite&#146;s option awards were July&nbsp;24, 2017 and May&nbsp;15, 2018 for her awards granted in 2017 and 2018, respectively, and
for Ms.&nbsp;Thomson&#146;s option awards granted in 2018 and 2019, the vesting commencement dates were May&nbsp;15, 2018 and November&nbsp;22, 2019, respectively. Ms.&nbsp;Thomson&#146;s December&nbsp;22, 2017 stock option grant vests in equal
monthly installments over 36 months from October&nbsp;2, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents a restricted stock award which vested twenty-five percent on July&nbsp;24, 2018 and the remainder of the shares underlying the restricted stock award vest in equal installments over the next 36 months,
subject to Ms.&nbsp;Pandite&#146;s continued service through each such vesting date. Market value is calculated based on the value of $21.69 per share as of December&nbsp;31, 2019, which reflects an independent third-party 409A valuation per share
of the company as of such date. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All company equity awards currently outstanding, including stock options and stock awards
held by our named executive officers, were granted under the Shattuck Labs, Inc. 2016 Stock Incentive Plan. Such plan will be discontinued in connection with this offering and outstanding awards thereunder will be cancelled and replaced with
equivalent awards under our 2020 Stock Incentive Plan, which is described in further detail under &#147;2020 Equity Incentive Plan<B><I>&#148; </I></B>below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Post-Employment Compensation and Change in Control Payments and Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Josiah Hornblower </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the employment agreement with Mr.&nbsp;Hornblower, upon a termination without cause or resignation with good reason
not in connection with a change in control, Mr.&nbsp;Hornblower will receive, subject to his execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a release of claims in favor of the company, or the Hornblower Release Condition,
and continued compliance with restrictive covenants, (i)&nbsp;severance payments equal to one times, or the Hornblower Severance Multiplier, the sum of (a)&nbsp;his annual base salary and (b)&nbsp;target bonus, payable in equal installments in
accordance with the company&#146;s normal payroll practices for 12 months, (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rata</FONT> annual bonus based on actual performance, (iii)&nbsp;accelerated vesting of all unvested equity awards (with
performance-based awards earned at the target level of performance) and (iv)&nbsp;payment of COBRA premiums for up to twelve months, or, if sooner, until eligible for similar coverage through another employer (we refer to (i)&nbsp;through (iv)
collectively as the Hornblower Severance Payments). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Mr.&nbsp;Hornblower is terminated without cause or resigns for good reason within 30 days
prior to, or 2 years following, a change in control, then, subject to the Hornblower Release Condition, Mr.&nbsp;Hornblower will also be entitled to the Hornblower Severance Payments; provided, however, the Hornblower Severance Multiplier will be
2.0x. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Good Reason&#148; under each of the NEO employment agreements generally means the occurrence of any of the following events,
without the executive&#146;s consent, provided, in each case, that such event is not cured within 30 days after the company receives notice from the executive specifying in reasonable detail the event constituting Good Reason: (i)&nbsp;failure to
pay the annual base salary or annual bonus when due, (ii)&nbsp;a reduction in the annual base salary or annual bonus, (iii)&nbsp;any diminution in the executive&#146;s title or any substantial and sustained diminution in the executive&#146;s duties
or (iv)&nbsp;a required relocation of the executive&#146;s primary work location by more than 25 miles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Cause&#148; under each of
the NEO employment agreements generally means: (i)&nbsp;indictment for, conviction of, or a plea of nolo contendere to, (x)&nbsp;a felony (other than traffic-related) under the laws of the United States or any state thereof or any similar criminal
act in a jurisdiction outside the United States or (y)&nbsp;a crime involving moral turpitude that could be injurious to the company or its reputation, (ii)&nbsp;willful malfeasance or willful misconduct which is materially and demonstrably
injurious to the company, (iii)&nbsp;any act of fraud in the performance of executive&#146;s duties or (iv)&nbsp;a material breach of any agreement with the company or any of the company&#146;s material policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Change in Control&#148; under each of the NEO employment agreements generally means the occurrence of one or more of the following
events: (i)&nbsp;any &#147;person&#148; (as such term is used in Sections 3(a)(9) and 13(d) of the Exchange Act) or &#147;group&#148; (as such term is used in Section&nbsp;13(d)(3) of the Exchange Act), other than the company or its subsidiaries or
any benefit plan of the company or its subsidiaries is or becomes a &#147;beneficial owner&#148; (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated under the Exchange Act) of more than 50% of the voting stock of
the company; (ii)&nbsp;the company transfers all or substantially all of its assets (unless the stockholders of the company immediately prior to such transaction beneficially own, directly or indirectly, in substantially the same proportion as they
owned the voting stock of the company, all of the voting stock or other ownership interests of the entity or entities, if any, that succeed to the business of the company or the company&#146;s ultimate parent company if the company is a subsidiary
of another corporation); or (iii)&nbsp;any merger, reorganization, consolidation or similar transaction unless, immediately after consummation of such transaction, the stockholders of the company immediately prior to the transaction hold, directly
or indirectly, more than 50% of the voting stock of the company or the company&#146;s ultimate parent company if the company is a subsidiary of another corporation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Lini Pandite </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the employment agreement with Ms.&nbsp;Pandite, upon a termination without cause or resignation with good reason not
in connection with a change in control, Ms.&nbsp;Pandite will receive, subject to execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a release of claims in favor of the company, or the Pandite Release Condition, and continued
compliance with restrictive covenants, (i)&nbsp;severance payments equal to one times, or the Pandite Severance Multiplier, the sum of her (a)&nbsp;annual base salary and (b)&nbsp;target bonus, payable in equal installments in accordance with the
company&#146;s normal payroll practices for 12 months, (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rata</FONT> annual bonus based on actual performance, (iii)&nbsp;accelerated vesting of all unvested equity awards (with performance-based awards
earned at the target level of performance) and (iv)&nbsp;payment of COBRA premiums for up to twelve months, or, if sooner, until eligible for similar coverage through another employer (we refer to (i)&nbsp;through (iv) collectively as the Pandite
Severance Payments). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Ms.&nbsp;Pandite is terminated without cause or resigns for good reason within 30 days prior to, or 2 years
following, a change in control, then, subject to the Pandite Release Condition, Ms.&nbsp;Pandite will be entitled to the Pandite Severance Payments; provided, however, the Pandite Severance Multiplier will be 2.0x. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Erin Ator Thomson </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the employment agreement with Ms.&nbsp;Thomson, upon a termination without cause or resignation with good reason not
in connection with a change in control, Ms.&nbsp;Thomson will receive, subject to execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of a release of claims in favor of the company, or the Thomson Release Condition, and continued
compliance with restrictive covenants, (i)&nbsp;severance payments equal to 0.75 times, or the Thomson Severance Multiplier, the sum of her (a)&nbsp;annual base salary and (b)&nbsp;target bonus, payable in equal installments in accordance with the
company&#146;s normal payroll practices for 9 months, (ii)&nbsp;a <FONT STYLE="white-space:nowrap">pro-rata</FONT> annual bonus based on actual performance, (iii)&nbsp;accelerated vesting of all unvested equity awards (with performance-based awards
earned at the target level of performance) and (iv)&nbsp;payment of COBRA premiums for up to 9 months, or, if sooner, until eligible for similar coverage through another employer (we refer to (i)&nbsp;through (iv) collectively as the Thomson
Severance Payments). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Ms.&nbsp;Thomson is terminated without cause or for good reason (each as defined in the agreement) within 30 days
prior to, or 2 years following, a change in control, then, subject to the Thomson Release Condition, Ms.&nbsp;Thomson will be entitled to the Thomson Severance Payments; provided, however, the Thomson Severance Multiplier will be 1.5x. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>280G </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each
employment agreement provides that on and after the date any company stock is readily tradeable on an established securities market or otherwise, to the extent that any payments would be subject to the excise tax imposed under Section&nbsp;4999 of
the Code, each executive will be entitled to receive either (a)&nbsp;the full amount of payments and benefits in connection with their employment with the company or (b)&nbsp;a portion of the payments and benefits having a value equal to $1 less
than three times the NEO&#146;s &#147;base amount&#148; (as defined in Section&nbsp;280G(b)(3)(A) of the Code), whichever results in the receipt of the greater amount on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee Benefit Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>2020 Equity
Incentive Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, the Board adopted and our stockholders approved the Shattuck Labs, Inc. 2016 Stock Incentive Plan, or 2016
Plan. In connection with this offering, we intend to adopt the Shattuck Labs, Inc.<B> </B>2020 Equity Incentive Plan, or 2020 Plan, which will become effective upon consummation of the offering. From and after the effective date of the 2020 Plan, no
additional stock awards will be made under the 2016 Plan. In addition, all stock awards granted under the 2016 Plan that are outstanding as of the consummation of this offering will be canceled and replaced with equivalent awards under the 2020
Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Purpose</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2020 Plan is intended provide a means through which the company may attract able persons
to serve as employees, directors, or consultants of the company or its subsidiaries and to provide a means whereby those individuals upon whom the responsibilities of the successful administration and management of the company rest, and whose
present and potential contributions to the welfare of the company are of importance, may acquire and maintain stock ownership, thereby strengthening their concern for the welfare of the company. A further purpose of the 2020 Plan is to provide such
individuals with additional incentive and reward opportunities designed to enhance the profitable growth of the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>.&nbsp;&nbsp;&nbsp;&nbsp;Awards may be granted only to persons who, at the time of grant, are employees, consultants, or
directors of the company or any parent or subsidiary corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Types of Awards.</I>&nbsp;&nbsp;&nbsp;&nbsp;The 2020 Plan provides
for the grant of incentive stock options, <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options, restricted stock awards, restricted stock unit awards, performance stock awards, and performance cash awards<I>. </I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized Shares</I>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to adjustment for certain dilutive
or related events, the aggregate maximum number of shares of common stock that may be issued under the 2020 Plan will not exceed &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares, or the Share Reserve. The Share Reserve
will automatically increase on January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year beginning in 2021 and ending with a final increase on January&nbsp;1, 2030 in an amount equal to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of the total number of shares of common stock outstanding on December 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the preceding calendar
year. To the extent that an award lapses or the rights of its holder terminates, any shares of common stock subject to such award will again be available for the grant of an award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Board has the authority to administer the 2020 Plan, including the powers to:
(i)&nbsp;determine who will be granted awards and what type of award, when and how each award will be granted, the provisions of each award (which need not be identical), the number of shares or cash value subject to an award, and the fair market
value applicable to an award; (ii)&nbsp;construe and interpret the 2020 Plan and awards granted thereunder and establish, amend and revoke rules and regulations for administration of the 2020 Plan and awards, including the ability to correct any
defect, omission or inconsistency in the 2020 Plan or any award document; (iii)&nbsp;settle all controversies regarding the 2020 Plan and awards granted thereunder; (iv)&nbsp;accelerate or extend, in whole or in part, the time during which an award
may be exercised or vested or at which cash or shares may be issued; (v)&nbsp;suspend or terminate the 2020 Plan; (vi)&nbsp;amend the 2020 Plan; (vii)&nbsp;submit any amendment to the 2020 Plan for stockholder approval; (viii)&nbsp;approve forms of
award documents for use under the 2020 Plan and to amend the terms of any one or more outstanding awards; (ix)&nbsp;generally exercise such powers and perform such acts as our Board may deem necessary or expedient to promote our best interests and
that are not in conflict with the provisions of the 2020 Plan or any award documents; and (x)&nbsp;adopt procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the provisions of the 2020 Plan, our Board may delegate all or some of the administration of the 2020 Plan to a committee of one or
more directors and may delegate to one or more officers the authority to designate employees who are not officers to be recipients of options and stock appreciation rights (and, to the extent permitted by applicable law, other stock awards) and, to
the extent permitted by applicable law, to determine the terms of such awards and the number of shares of common stock to be subject to such stock awards granted to such employees. Unless otherwise provided by our Board, delegation of authority by
our Board to a committee or an officer will not limit the authority of our Board. All determinations, interpretations and constructions made by our Board (or another authorized committee or officer exercising powers delegated by our Board) in good
faith will be final, binding and conclusive on all persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Options</I>.&nbsp;&nbsp;&nbsp;&nbsp;A stock option may be granted as
an incentive stock option or a nonqualified stock option. The option exercise price will be determined by the Compensation Committee; provided, however, that with respect to incentive stock options, the exercise price will not be less than 110% of
the fair market value of our common stock if the recipient owns stock possessing more than 10% of the total combined voting power of all classes of our stock or the stock of our parent or subsidiary corporation, or a Ten Percent Stockholder. The
term of each option will be determined by the Compensation Committee; provided, however, that Options will not be exercisable after the expiration of five years from the date of grant in the case of an incentive stock option issued to a Ten Percent
Stockholder. Each notice of option grant and option agreement will set forth the terms of vesting and exercisability for each option award. The purchase price of any shares acquired pursuant to an option award may be paid in cash, check, bank draft,
money order, net exercise or as otherwise determined by our Board and set forth in the award agreement, including through an irrevocable commitment by a broker to pay over such amount from a sale of the shares issuable under the option and the
delivery of previously owned shares. Except as otherwise provided in an applicable award document, all unvested option awards are forfeited and cease to be exercisable upon a holder&#146;s termination of employment or service; provided, however,
that (i)&nbsp;upon the holder&#146;s termination by reason of disability or death, the option will remain exercisable for one year following the date of holder&#146;s termination of employment or service and (ii)&nbsp;upon the holders&#146;
termination other than for Cause (as defined in the option agreement), the option will remain exercisable for three months following the date of holder&#146;s termination of employment or service. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stock Appreciation Rights</I>.&nbsp;&nbsp;&nbsp;&nbsp;A stock appreciation right, or SAR,
is a right that entitles the participant to receive, in cash or shares of stock or a combination thereof, as determined by our Board, value equal to or otherwise based on the excess of (i)&nbsp;the fair market value of a specified number of shares
at the time of exercise over (ii)&nbsp;the exercise price of the right, as established by our Board on the date of grant. Upon exercising a SAR, the participant is entitled to receive the amount by which the fair market value of the stock at the
time of exercise exceeds the exercise price of the SAR. The exercise price of each SAR may not be less than the fair market value of the stock subject to the award on the date the SAR is granted, unless the SAR was granted pursuant to an assumption
of or substitution for another option in a manner satisfying the provisions of Section&nbsp;409A of the Code. SARs will not be exercisable after the expiration of ten years from the date of grant. Each award agreement will set forth the number of
shares subject to the SAR. The vesting schedule applicable to any SAR, including any performance conditions, will be as set forth in the award agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock awards are awards of shares of our common stock that are subject to
restrictions on disposition as determined by the Compensation Committeein its sole discretion, including restrictions based on the attainment of one or more performance goals, continued employment or service, the occurrence of certain events or any
combination thereof. Unless otherwise provided in the restricted stock agreement, the holder will have the right to receive dividends with respect to common stock subject to a restricted stock award, to vote common stock subject to such restricted
stock agreement, and to enjoy all other stockholder rights subject to delivery of the stock upon the forfeiture restrictions lapsing. The Compensation Committee may, in its discretion and as of a date determined by the Compensation Committee, fully
vest any or all common stock awarded to a holder pursuant to a restricted stock award, and, upon such vesting, all restrictions applicable to such restricted stock award will lapse as of such date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Restricted Stock Units</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock units, or RSUs, are an award denominated in units under which the
issuance of shares (or cash payment in lieu thereof) is subject to such conditions (including continued employment) and terms as our Board deems appropriate. Each award document evidencing a grant of RSUs will set forth the terms and conditions of
each award, including vesting and forfeiture provisions, transferability and, if applicable, right to receive dividends or dividend equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Performance Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;A performance award is a stock or cash award that is payable contingent upon the attainment
during a performance period of certain performance goals. A performance award may, but need not, require the completion of a specified period of service. The length of any performance period, the applicable performance goals and the measurement of
whether and to what degree such performance goals have been attained will be as determined by the compensation committee, our Board, or an authorized officer. We retain the discretion to reduce or eliminate the compensation or economic benefit upon
the attainment of any performance goals and to define the manner of calculating the performance criteria it selects to use for a performance period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Certain Adjustments.</I>&nbsp;&nbsp;&nbsp;&nbsp;In the event of any change in our capitalization, our Board will appropriately and
proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the 2020 Plan; (ii)&nbsp;the class(es) and maximum number of securities that may be issued pursuant to the exercise of incentive stock options; and
(iii)&nbsp;the class(es) and number of securities or other property and value (including price per share of stock) subject to outstanding stock awards. Our Board will make such adjustments, and its determination will be final, binding, and
conclusive. Unless provided otherwise in an award or other agreement, in the event of our dissolution or liquidation, all outstanding stock awards (other than stock awards consisting of vested and outstanding shares of our common stock not subject
to a forfeiture condition or the our right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of common stock subject to the our repurchase rights or subject to forfeiture may be
repurchased or reacquired by us notwithstanding the fact that the holder of such stock award is providing continuous service; provided, however, that our Board may, in its sole discretion, provide that some or all stock awards will become fully
vested, exercisable and/or no longer subject to repurchase or forfeiture (to the extent not already expired or terminated) before the dissolution or liquidation is completed but contingent upon its completion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Change in Control.</I>&nbsp;&nbsp;&nbsp;&nbsp;Unless provided otherwise in an award
agreement or other agreement between us or an affiliate and the participant, in the event of Change in Control (as defined in the 2020 Plan), our Board will take one or more of the following actions with respect to each outstanding award, contingent
upon the closing or completion of the Change in Control: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) arrange for the surviving corporation or acquiring corporation (or the
surviving or acquiring corporation&#146;s parent company) to assume or continue the award or to substitute a similar stock award for the award (including, but not limited to, an award to acquire the same consideration per share paid to the
stockholders of the company pursuant to the Change in Control); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) arrange for the assignment of any reacquisition or repurchase rights
held by us in respect of common stock issued pursuant to the award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) accelerate the vesting, in whole or in part, of the award (and, if applicable, the time at which the award may be exercised) to a date
prior to the effective time of such Change in Control as determined by our Board, with such award terminating if not exercised (if applicable) at or prior to the effective time of the Change in Control, and with such exercise reversed if the Change
in Control does not become effective; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by
us with respect to the award; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) cancel or arrange for the cancellation of the award, to the extent not vested or not exercised prior to
the effective time of the Change in Control, in exchange for such cash consideration, if any, as our Board, in its reasonable determination, may consider appropriate as an approximation of the value of the canceled award; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) cancel or arrange for the cancellation of the award, to the extent not vested or not exercised prior to the effective time of the Change
in Control, in exchange for a payment equal to the excess, if any, of (A)&nbsp;the value in the Change in Control of the property the participant would have received upon the exercise of the award immediately prior to the effective time of the
Change in Control, over (B)&nbsp;any exercise price payable by such holder in connection with such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board need not take the
same action or actions with respect to all awards or portions thereof or with respect to all participants and may take different actions with respect to the vested and unvested portions of an award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the absence of any affirmative determination by our Board at the time of a Change in Control, each outstanding award will be assumed or an
equivalent award will be substituted by such successor corporation or a parent or subsidiary of such successor corporation, referred to as a Successor Corporation, unless the Successor Corporation does not agree to assume the award or to substitute
an equivalent award, in which case the vesting of such award will accelerate in its entirety (along with, if applicable, the time at which the award may be exercised) to a date prior to the effective time of such Change in Control as our Board will
determine (or, if our Board does not determine such a date, to the date that is five days prior to the effective date of the Change in Control), with such award terminating if not exercised (if applicable) at or prior to the effective time of the
Change in Control, and with such exercise reversed if the Change in Control does not become effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Acceleration of Awards upon a
Change in Control</I>.&nbsp;&nbsp;&nbsp;&nbsp;An award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the award agreement for such award or as may be provided in any
other written agreement between us or an affiliate and the participant, but in the absence of such provision, no such acceleration will occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Termination and Amendment</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our Board or the compensation committee may suspend or terminate the 2020 Plan at any
time. No incentive stock options may be granted under the 2020 Plan after the tenth anniversary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the date our Board adopted the 2020 Plan. No awards may be granted under the 2020 Plan while the 2020 Plan is suspended or after it is terminated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>2020 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we intend to adopt the Shattuck Labs, Inc. Employee Stock Purchase Plan, or the ESPP, which will become
effective upon consummation of the offering. The ESPP is designed to allow our eligible employees to purchase shares of our common stock, at periodic intervals, with their accumulated payroll deductions. The ESPP is intended to qualify under
Section&nbsp;423 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration.</I>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions of the ESPP, the
Compensation Committee of our Board will administer the ESPP. Our compensation committee can delegate administrative tasks under the ESPP to the services of a <FONT STYLE="white-space:nowrap">sub-committee</FONT> and/or officers or employees to
assist in the administration of the ESPP. The administrator will have the discretionary authority to administer and interpret the ESPP. Interpretations and constructions of the administrator of any provision of the ESPP or of any rights thereunder
will be conclusive and binding on all persons. We will bear all expenses and liabilities incurred by the ESPP administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Shares
Available Under ESPP.</I>&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of our shares of our common stock which will be authorized for sale under the ESPP is the sum of (a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock and
(b)&nbsp;an annual increase on the first day of each year beginning in 2021 and ending in 2030 equal to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the shares of common stock outstanding (on an as converted basis) on December 31<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> of the immediately preceding calendar year. The shares made available for sale under the ESPP may be authorized but unissued shares or reacquired shares reserved for issuance under the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligible Employees.</I>&nbsp;&nbsp;&nbsp;&nbsp;Employees eligible to participate in the ESPP for a given offering period generally include
employees who are employed by us or one of our designated subsidiaries on the first day of the offering period, or the enrollment date. An employee who owns (or is deemed to own through attribution) 5% or more of the combined voting power or value
of all our classes of stock or of one of our subsidiaries will not be allowed to participate in the ESPP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Participation.</I>&nbsp;&nbsp;&nbsp;&nbsp;Employees will enroll under the ESPP by completing a payroll deduction form permitting the
deduction from their compensation of at least 1% of their compensation but not more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of their compensation. Such payroll deductions are expressed as a whole number percentage and the accumulated
deductions will be applied to the purchase of shares on each semi-annual purchase date. However, a participant may not purchase more
than&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares in each offering period, and may not subscribe for more than $25,000 in fair market value of shares our common stock
(determined at the time the option is granted) per calendar year falling in the offering period. The ESPP administrator has the authority to change these limitations for any subsequent offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Offering.</I>&nbsp;&nbsp;&nbsp;&nbsp;Under the ESPP, participants are offered the option to purchase shares of our common stock at a
discount during a series of successive offering periods. The offering periods will commence and end on dates as determined by the ESPP administrator and will initially run for <FONT STYLE="white-space:nowrap">non-overlapping</FONT> <FONT
STYLE="white-space:nowrap">six-month</FONT> periods. However, in no event may an offering period be longer than 27&nbsp;months in length. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The option purchase price will be the lower of 85% of the closing trading price per share of our common stock on the first trading date of an
offering period in which a participant is enrolled or 85% of the closing trading price per share on the semi-annual purchase date, which will occur on the last trading day of each offering period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless a participant has previously canceled his or her participation in the ESPP before the purchase date, the participant will be deemed to
have exercised his or her option in full as of each purchase date. Upon exercise, the participant will purchase the number of whole shares that his or her accumulated payroll deductions will buy at the option purchase price, subject to the
participation limitations listed above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant may withdraw from the ESPP at any time prior to the end of the offering
period. Upon withdrawing, the participant will receive a refund of the participant&#146;s account balance in cash without interest and his or her right to participate in the current offering period will be automatically terminated. A participant may
decrease (but not increase) his or her payroll deduction authorization during any offering period. If a participant wants to increase or decrease the rate of payroll withholding, he or she may do so effective for the next offering period by
submitting a new form before the offering period for which such change is to be effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A participant may not assign, transfer,
pledge, or otherwise dispose of payroll deductions credited to a participant&#146;s account or any rights to exercise an option or to receive shares of our common stock under the ESPP. Any such attempt at assignment, transfer, pledge, or other
disposition will not be given effect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Adjustments upon Changes in Recapitalization, Dissolution, Liquidation, Merger, or Asset
Sale. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If there is any change in the outstanding shares of our common stock or other securities because of a merger, consolidation,
<FONT STYLE="white-space:nowrap">spin-off,</FONT> reorganization, recapitalization, dividend in property other than cash, extraordinary dividend whether in cash and/or other property, stock split, reverse stock split, stock dividend, liquidating
dividend, combination or reclassification of our common stock or other securities (including any such change in the number of shares of our common stock or other securities effected in connection with a change in domicile of the company), or any
other increase or decrease in the number of shares of our common stock or other securities effected without receipt of consideration, provided that conversion of any convertible securities of the company shall not be deemed to have been
&#147;effected without receipt of consideration,&#148; the type and number of securities covered by each option under the ESPP which has not yet been exercised and the type and number of securities which have been authorized and remain available for
issuance under the ESPP, as well as the maximum number of securities which may be purchased by a participant in an offering period, and the price per share covered by each option under the ESPP which has not yet been exercised, shall be
appropriately and proportionally adjusted by the Board, and the Board shall take any further actions which, in the exercise of its discretion, may be necessary or appropriate under the circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of the proposed liquidation or dissolution of the company, the offering period will terminate immediately prior to the
consummation of such proposed transaction, unless otherwise provided by the Board in its sole discretion, and all outstanding options shall automatically terminate and the amounts of all payroll deductions will be refunded without interest to
participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a proposed sale of all or substantially all of the assets of the company, or the merger or consolidation or
similar combination of the company with or into another entity, then in the sole discretion of the Board, (1)&nbsp;each option shall be assumed or an equivalent option shall be substituted by the successor corporation or parent or subsidiary of such
successor entity, (2)&nbsp;on a date established by the Board on or before the date of consummation of such merger, consolidation, combination, or sale, such date shall be treated as a purchase date, and all outstanding options shall be exercised on
such date, (3)&nbsp;all outstanding options shall terminate and the accumulated payroll deductions will be refunded without interest to the participants, or (4)&nbsp;outstanding options shall continue unchanged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Termination.</I>&nbsp;&nbsp;&nbsp;&nbsp;Our Board or the Compensation Committee may suspend, amend, or terminate the ESPP at
any time. However, our Board or the Compensation Committee may not amend the ESPP without obtaining stockholder approval within 12&nbsp;months before or after such amendment to the extent required by applicable laws or to increase the number of
shares subject to the ESPP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The company offers eligible employees, including its NEOs, the opportunity to participate in its
<FONT STYLE="white-space:nowrap">tax-qualified</FONT> 401(k) plan. Employees can contribute <FONT STYLE="white-space:nowrap">1%-100%</FONT> of their eligible earnings up to the Internal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Revenue Service&#146;s annual limits on a <FONT STYLE="white-space:nowrap">before-tax</FONT> basis. The 401(k) plan provides for company matching contributions equal to 100% of the first 3% of
salary contributions plus 50% of the next 2% of salary contributions. The company also has the discretion to make additional profit sharing contributions. The matching contributions are 100% vested at all times and employer profit sharing
contributions are 100% vested after four years of service. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Retirement Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not maintain any defined benefit pension plans or any nonqualified deferred compensation plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_14"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information regarding beneficial ownership of our equity interests as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each stockholder or group of stockholders known by us to be the beneficial owner of more than 5% of our
outstanding equity interests, or 5% and Greater Stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">each of our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our NEOs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all of our directors and executive officers as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined in accordance with the rules of the SEC, and thus represents voting or investment power with respect to our
securities as of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared
voting power or investment power as well as any shares that the individual has the right to acquire within 60 days after &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 through the exercise of any stock option,
warrants or other rights. Unless otherwise indicated below, to our knowledge and subject to applicable community property rules, the persons and entities named in the table have sole voting and sole investment power with respect to all equity
interests beneficially owned, subject to community property laws where applicable. Unless otherwise indicated, the address of each individual listed in this table is 1018 W. 11th Street, Suite 100, Austin, Texas 78703. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage ownership information shown in the column titled &#147;Shares Beneficially Owned Prior to the Offering&#148; in the table below
is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding as of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. The percentage ownership information shown in the column titled &#147;Shares Beneficially Owned After the Offering&#148;
in the table below is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding after this offering, assuming
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock being sold in this offering. Shares of our common stock that a person has the right to acquire within 60 days after
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for
purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table also does not include any shares of common stock that directors and executive officers may purchase in this offering
through the directed share program described under &#147;Underwriting.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of</B><br><B>Shares&nbsp;Beneficially<BR>Owned </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before&nbsp;the<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After&nbsp;the<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>5% and Greater Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Fidelity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with G. Walter Loewenbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Daniel A. Traylor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redmile Group, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Millennium Pharmaceuticals, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clark BP, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ECMC Group, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Hatteras Venture Partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with EcoR1 Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Janus Henderson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Delphinium, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Named Executive Officer and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taylor Schreiber, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><br>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage of</B><br><B>Shares&nbsp;Beneficially<BR>Owned </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Address of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before&nbsp;the<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After&nbsp;the<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Josiah Hornblower</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tyler Brous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neil Gibson, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Golumbeski, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erin Ator Thomson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lini Pandite, MBChB</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All Executive Officers and Directors as a group (</B><B>11 persons)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_15"></A>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of each transaction or series of similar transactions since January&nbsp;1, 2017, or any currently proposed
transaction, to which we were or are a party in which: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount involved exceeded or exceeds $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any of our directors or executive officers, any holder of 5% of any class of our voting capital stock or any
member of his or her immediate family had or will have a direct or indirect material interest. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is
determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to such securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party
Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Preferred Stock Financings </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2018, we completed an equity financing and issued and sold an aggregate of 1,093,019 shares of our Series A redeemable convertible
preferred stock at a purchase price of $62.4750 per share. We issued and sold the shares of Series A redeemable convertible preferred stock pursuant to a stock purchase agreement entered into with certain investors, for an aggregate purchase price
of approximately $46.6 million, composed of approximately $35.3 million in cash and $11.3 million in cancellation of indebtedness pursuant to the conversion of our convertible promissory notes. Each share of our Series A redeemable convertible
preferred stock is convertible into one share of common stock. The following table summarizes purchases of our Series A redeemable convertible preferred stock by related persons: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of</B><br><B>Series&nbsp;A<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cancellation&nbsp;of<BR>Indebtedness*</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cash</B><br><B>Purchase&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Millennium Pharmaceuticals, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,324,657.53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,499,998.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated Delphinium, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,099,983.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clark BP, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,999,999.20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Tyler Brous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,361,328.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">149,940.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Josiah Hornblower</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">158,440.86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,980.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with G. Walter Lowenbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,095,609.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100,022.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Erin Thomson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,996.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taylor Schreiber, M.D, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,655.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,996.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All principal due and accrued interest were converted into shares of Series A redeemable convertible preferred stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2020, with subsequent closings in February and March 2020, we completed an equity
financing and issued and sold an aggregate of 550,571 shares of our Series B redeemable convertible preferred stock at a purchase price of $62.88051 per share. We issued and sold the shares of Series B redeemable convertible preferred stock pursuant
to a stock purchase agreement entered into with investors, for an aggregate purchase price of approximately $34.62&nbsp;million. Each share of our Series B redeemable convertible preferred stock is convertible into one share of common stock. The
following table summarizes purchases of our Series&nbsp;B redeemable convertible preferred stock by related persons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of<BR>Series&nbsp;B<BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ECMC Group, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,006.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Daniel A. Traylor</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,999,966.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Delphinium, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,999,977.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clark BP, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">981,501.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Josiah Hornblower</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">649,995.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with G. Walter Loewenbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,012.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Tyler Brous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,012.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Taylor Schreiber, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,963.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2020, we issued and sold an aggregate of 1,319,964 shares of our Series
<FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock at a purchase price of $62.88051 per share. We issued and sold the shares of <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> redeemable convertible preferred
stock pursuant to a stock purchase agreement entered into with investors, for an aggregate purchase price of approximately $83.0&nbsp;million. Each share of our Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred
stock is convertible into one share of common stock. The following table summarizes purchases of our <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> redeemable convertible preferred stock by related persons: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Participant</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of<BR><FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT><BR>Redeemable<BR>Convertible<BR>Preferred<BR>Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Purchase<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redmile Biopharma Investments II, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,026.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Fidelity Investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,026.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Janus Henderson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,999,990.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with EcoR1 Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,418,539.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Hatteras Venture Partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,006.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Delphinium, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,762</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,619,927.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ECMC Group, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">999,988.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Tyler Brous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,720</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">799,840.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with G. Walter Loewenbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">650,058.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Clark BP, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500,025.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Second Amended and Restated Investors&#146; Rights Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to a second amended and restated investors&#146; rights agreement, effective as of June&nbsp;12, 2020, or the IRA, with the
holders of our redeemable convertible preferred stock and certain other stockholders. The IRA provides certain holders of our capital stock with certain registration rights, including the right to demand that we file a registration statement or
request that their shares be covered by a registration statement that we are otherwise filing. In addition to registration rights, the IRA provides for certain information rights, a right of first offer and a market
<FONT STYLE="white-space:nowrap">stand-off</FONT> provision imposing restrictions on the ability of the parties thereto to offer, sell or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transfer our equity securities for a period of 180 days following the date of this offering. The IRA will terminate pursuant to its terms immediately prior to the completion of this offering,
other than those provisions relating to registration rights, which will terminate no later than five years after the completion of this offering, the closing of a stock sale (as defined in the IRA) or deemed liquidation event (as defined in our
amended and restated certificate of incorporation) or, with respect to any particular holder, at such time that such holder can sell its shares, under Rule 144 under the Securities Act or otherwise, during any
<FONT STYLE="white-space:nowrap">90-day</FONT> period without registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Second Amended and Restated Voting Agreement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to a second amended and restated voting agreement, effective as of June&nbsp;12, 2020, or the Voting Agreement, under
which the holders of our redeemable convertible preferred stock and certain other holders of our capital stock, and entities affiliated with our two founders, which such entities are referred to as the Key Holders, have agreed to vote in a certain
way on certain matters, including with respect to the election of our directors. All of our current directors were elected pursuant to the terms of this agreement. The Voting Agreement will terminate immediately prior to the completion of this
offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Second Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to a second amended and restated right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT>
agreement, effective as of June&nbsp;12, 2020, or the ROFR Agreement, with the holders of our redeemable convertible preferred stock and certain other holders of our capital stock, pursuant to which we have a right of first refusal on certain
transfers of our shares by the Key Holders, holders of our redeemable convertible preferred stock have a secondary right of first refusal on such transfers, and such redeemable convertible preferred stock holders have a right of <FONT
STYLE="white-space:nowrap">co-sale</FONT> in respect of such transfers. The ROFR will terminate upon the completion of this offering. See &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Takeda Collaboration Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Collaboration and License
Agreements&#151;Takeda Collaboration Agreement&#148; for information regarding our Collaboration Agreement with Takeda. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Employment
Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into employment agreements with our named executive officers. For more information regarding the
agreements with our named executive officers, see &#147;Executive Compensation&#151;Employment Agreements.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Director
Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#147;Executive Compensation&#151;Director Compensation&#148; for information regarding compensation of our
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we will enter into agreements to indemnify our directors and executive officers. These agreements will, among
other things, require us to indemnify these individuals for certain expenses (including attorneys&#146; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or in our
right, on account of any services undertaken by such person on behalf of our company or that person&#146;s status as a member of our Board to the maximum extent allowed under Delaware law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Grants to Executive Officers and Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted stock options to our executive officers and certain of our directors as more fully described in the sections entitled
&#147;Executive Compensation&#148; and &#147;Management&#151;Director Compensation.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Party Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we did not have a formal policy regarding approval of transactions with related parties. To date, all transactions with
related parties have been approved by the directors not interested in the transaction pursuant to Section&nbsp;144(a)(1) of the Delaware General Corporation Law. We will adopt a related party transaction policy that sets forth our procedures for the
identification, review, consideration and approval or ratification of related person transactions. The policy will become effective upon the execution of the underwriting agreement for this offering. For purposes of our policy only, a related person
transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $100,000. A
related person is any executive officer, director or beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family members and any entity owned or controlled by such persons. Transactions involving
compensation for services provided to us as an employee or director, among other limited exceptions, are deemed to have standing <FONT STYLE="white-space:nowrap">pre-approval</FONT> by the Audit Committee but may be specifically reviewed if
appropriate in light of the facts and circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the policy, if a transaction has been identified as a related party
transaction, including any transaction that was not a related party transaction when originally consummated or any transaction that was not initially identified as a related party transaction prior to consummation, our management must present
information regarding the related party transaction to our Audit Committee for review, consideration and approval or ratification. The presentation must include a description of, among other matters, the material facts, the interests, direct and
indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally.
Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related party transactions
and to effectuate the terms of the policy. In addition, under our Code of Business Conduct and Ethics, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to
give rise to a conflict of interest. In considering related party transactions, our Audit Committee will take into account the relevant available facts and circumstances including, but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the risks, costs and benefits to us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact on a director&#146;s independence in the event that the related person is a director, immediate family
member of a director or an entity with which a director is affiliated; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of other sources for comparable services or products; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy requires that, in determining whether to approve, ratify or reject a related party transaction, our Audit
Committee must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our Audit Committee determines in the good faith exercise of its discretion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transactions described below were consummated prior to our adoption of the formal, written policy described above, and, accordingly,
the foregoing policies and procedures were not followed with respect to these transactions. However, we believe that the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below
were comparable to terms available or the amounts that would be paid or received, as applicable, in arms-length transactions at such time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_16"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of
the material terms of our capital stock, as well as other material terms of our second amended and restated certificate of incorporation and amended bylaws, as each will be in effect following the completion of this offering, and certain provisions
of Delaware law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws, copies of which will be filed with the SEC as exhibits to the registration statement, of
which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the filing of our second amended and restated certificate of incorporation and the consummation
of this offering, our authorized capital stock will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, $0.0001 par value per share, and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of &#147;blank check&#148; preferred stock, $0.0001 par value per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, after giving effect to the automatic conversion of all of our outstanding shares of redeemable convertible preferred
stock into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock upon the closing of this offering, there&nbsp;would have been
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issued and outstanding, held of record by
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second amended and restated certificate of incorporation will authorize the issuance of up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock. All outstanding shares of our common stock are validly issued, fully paid and nonassessable, and the shares of our common
stock to be issued in connection with this offering will be validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common stock
will be entitled to one vote per share on all matters submitted to a vote of stockholders, and our second amended and restated certificate of incorporation will not provide for cumulative voting in the election of directors. The holders of our
common stock will receive ratably any dividends declared by our Board out of funds legally available therefor. In the event of our liquidation, dissolution or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the holders of our common stock will
be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2020, there were 2,963,554 shares of our redeemable convertible preferred stock outstanding, which will convert into
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, all of our previously outstanding shares of redeemable convertible preferred stock will have been converted
into shares of our common stock and we will have no shares of redeemable convertible preferred stock outstanding. Under the terms of our certificate of incorporation, our Board will have the authority, without further action by our stockholders, to
issue up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to
fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but
not below the number of shares of such series then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board may authorize the issuance of preferred stock with voting or
conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes,
could, among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. We have no
current plans to issue any shares of preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to the IRA which provides that certain holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our redeemable convertible preferred stock and certain holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock have certain registration rights described below. The registration of shares of our common stock pursuant to the exercise of
registration rights described below would enable holders to sell these shares without restriction under the Securities Act when the registration statement is declared effective. We will pay all expenses related to any demand, piggyback, or Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration described below, with the exception of underwriting discounts and commissions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
registration rights described below will expire upon the earliest to occur of: (i)&nbsp;five years after the completion of this offering or (ii)&nbsp;with respect to any particular holder, at the time that such holder can sell all its registrable
securities under Rule 144 or another similar exemption under the Securities Act without limitation during a three-month period without registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of registrable securities are entitled to certain demand registration rights. At any time after the earlier of (i)&nbsp;five years
after the date of the IRA or (ii) 180 days following the effective date of the registration statement of which this prospectus forms a part, (x)&nbsp;holders who are major investors and hold a majority of the registrable securities then outstanding
and held by major investors or (y)&nbsp;holders who are major investors and hold at least 70% of the registrable securities then outstanding may request that we register all or a portion of their registrable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain specified exceptions, if we propose to register any of our securities under the Securities Act either for our own account or
for the account of other stockholders, the holders of shares having registration rights are entitled to written notice and certain &#147;piggyback&#148; registration rights allowing them to include their shares in our registration statement. These
registration rights are subject to specified conditions and limitations, including the right of the underwriters, in their sole discretion, to limit the number of shares included in any such offering under certain circumstances, but not below 30% of
the total amount of securities included in such offering, unless (i)&nbsp;such offering is the initial public offering or (ii)&nbsp;any registrable securities which are not key holder registerable securities be excluded from such underwriting unless
all key holder registrable securities are first excluded from such offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Form <FONT STYLE="white-space:nowrap">S-3</FONT>
Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time after we are qualified to file a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3,</FONT> and subject to limitations and conditions, (x)&nbsp;holders who hold are major investors and hold a majority of the registrable securities then outstanding and held by major Investors or (y)&nbsp;holders
who are major Investors and hold at least 70% of the registrable securities then outstanding may make a written request that we prepare and file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act
covering their shares, so long as the aggregate price to the public, net of the underwriters&#146; discounts and commissions, is at least $5,000,000. We will prepare and file the Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration as
requested, unless, in the good faith judgment of our Board, such registration would be seriously detrimental to the company and its stockholders and filing should be deferred. We may defer only once in any
<FONT STYLE="white-space:nowrap">12-month</FONT> period, and such deferral shall not exceed 90 days after receipt of the request. In addition, we are not obligated to prepare or file any of these registration statements (i)&nbsp;within 90 days after
the effective date of a registration statement pursuant to demand or piggyback registration rights or (ii)&nbsp;if two of these registrations have been completed within any <FONT STYLE="white-space:nowrap">12-month</FONT> period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Our Second Amended and Restated Certificate of Incorporation, Amended Bylaws and
Delaware Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second amended and restated certificate of incorporation and our amended bylaws, each to be in effect immediately
prior to the completion of this offering, will include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or
other unilateral takeover proposals to negotiate with our Board rather than pursue <FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Issuance of undesignated preferred stock</B>: Under our second amended and restated certificate of
incorporation, our Board will have the authority, without further action by the stockholders, to issue up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of undesignated preferred stock with
rights and preferences, including voting rights, designated from time to time by our Board. The existence of authorized but unissued shares of preferred stock enables our Board to make it more difficult to attempt to obtain control of us by means of
a merger, tender offer, proxy contest or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Classified board</B>: Our second amended and restated certificate of incorporation will establish a classified
Board consisting of three classes of directors, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective
three-year terms. This provision may have the effect of delaying a change in control of our Board. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Election and removal of directors and board vacancies</B>: Our second amended and restated certificate of
incorporation will provide that directors will be elected by a plurality vote. Our second amended and restated certificate of incorporation and amended bylaws will also provide that our Board has the right to increase or decrease the size of the
Board and to fill vacancies on the Board. Directors may be removed only for cause by the affirmative vote of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast in an annual election of directors. Only
our Board is authorized to fill vacant directorships. In addition the number of directors constituting our Board may be set only by resolution adopted by a majority vote of the directors then in office. These provisions prevent stockholders from
increasing the size of our Board and gaining control of our Board by filling the resulting vacancies with its own nominees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Requirements for advance notification of stockholder nominations and proposals</B>: Our amended bylaws will
establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors that specify certain requirements as to the timing, form and content of a stockholder&#146;s notice. Business that
may be conducted at an annual meeting of stockholders will be limited to those matters properly brought before the meeting. These provisions may make it more difficult for our stockholders to bring matters before our annual meeting of stockholders
or to nominate directors at annual meetings of stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>No written consent of stockholders</B>: Our second amended and restated certificate of incorporation will
provide that all stockholder actions be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required
to take stockholder actions and would prevent the amendment of our amended bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>No stockholder ability to call special meetings:</B> Our second amended and restated certificate of
incorporation and amended bylaws will provide that only our Board may be able to call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of
stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Amendments to certificate of incorporation and bylaws</B>: Any amendment to our second amended and restated
certificate of incorporation will be required to be approved by a majority of our Board as well as, if required by law or the our second amended and restated certificate of incorporation, a majority of the outstanding shares entitled to vote on the
amendment and a majority of the outstanding shares of each </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
class entitled to vote thereon as a class, except that the amendment of provisions to Board classification, stockholder action, certificate amendments, and liability of directors must be approved
by not less than 66 2/3% of the outstanding shares entitled to vote on the amendment, voting together as a single class. Any amendment to our amended bylaws will be required to be approved by either a majority of our Board or not less than 66 2/3%
of the outstanding shares entitled to vote on the amendment, voting together as a single class. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions are
designed to enhance the likelihood of continued stability in the composition of our Board and its policies, to discourage certain types of transactions that may involve an actual or threatened acquisition of our company and to reduce our
vulnerability to an unsolicited acquisition proposal. We also designed these provisions to discourage certain tactics that may be used in proxy fights. However, these provisions could have the effect of discouraging others from making tender offers
for our shares and, as a consequence, they may also reduce fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Delaware General Corporation Law Section&nbsp;203 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a Delaware corporation, we are also subject to the anti-takeover provisions of Section&nbsp;203 of the Delaware General Corporation Law,
which prohibits a Delaware corporation from engaging in a business combination specified in the statute with an interested stockholder (as defined in the statute) for a period of three years after the date of the transaction in which the person
first becomes an interested stockholder, unless the business combination is approved in advance by a majority of the independent directors or by the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding
disinterested shares. The application of Section&nbsp;203 of the Delaware General Corporation Law could also have the effect of delaying or preventing a change of control of us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Exclusive Forum Selection Clause</I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our second amended and restated certificate of incorporation will provide that, unless we consent in writing to the selection of an alternative
forum, the sole and exclusive forum to the fullest extent permitted by law for: (1)&nbsp;any derivative action or proceeding brought on our behalf; (2)&nbsp;any action asserting a breach of fiduciary duty owed by any director, officer or other
employee to us or our stockholders; (3)&nbsp;any action asserting a claim against us or any director or officer or other employee arising pursuant to the Delaware General Corporation Law; (4)&nbsp;any action to interpret, apply, enforce or determine
the validity of our amended and restated certificate of incorporation or bylaws; or (5)&nbsp;any other action asserting a claim that is governed by the internal affairs doctrine, shall be the Court of Chancery of the State of Delaware (or another
state court or the federal court located within the State of Delaware if the Court of Chancery does not have or declines to accept jurisdiction), in all cases subject to the court&#146;s having jurisdiction over indispensable parties named as
defendants. In addition, our second amended and restated certificate of incorporation will provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising
under the Securities Act but the forum selection provisions will not apply to claims brought to enforce a duty or liability created by the Exchange Act. Although we believe these provisions benefit us by providing increased consistency in the
application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors or officers. Although our amended and restated certificate of incorporation
contains the choice of forum provisions described above, it is possible that a court could find that such provisions are inapplicable for a particular claim or action or that such provisions are unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will serve as the transfer agent and
registrar for our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to list our common stock on The Nasdaq Global Market under the symbol &#147;STTK.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before the closing of this offering, there has been no public market for our common stock. Future sales of substantial amounts of our common
stock, including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of these sales or issuances occurring, could adversely affect the prevailing market price for our common stock or
impair our ability to raise equity capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on our shares of common stock outstanding as of June&nbsp;30, 2020, upon the completion
of this offering and assuming the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock, we will have an aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock outstanding
(or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise in full their option to purchase additional shares). Of these shares, all of the common stock sold in this
offering, plus any shares sold on exercise of the underwriters&#146; option to purchase additional common stock, will be freely tradable in the public market without restriction or further registration under the Securities Act, unless these shares
are held by &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The remaining shares of common stock
will be, &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an
exemption from registration under Rules 144 or 701 under the Securities Act, which are summarized below. Restricted securities may also be sold outside of the United States to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> persons in accordance
with Rule 904 of Regulation S. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below and the
provisions of Rule 144 or Regulation S under the Securities Act, as well as our insider trading policy, these restricted securities will be available for sale in the public market after the date of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144 as
currently in effect, once we have been subject to public company reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, an eligible stockholder is entitled to sell such shares without complying with
the manner of sale, volume limitation, or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. To be an eligible stockholder under Rule 144, such stockholder must not be deemed to have been one
of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and must have beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than
our affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without
complying with any of the requirements of Rule 144, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell
shares on expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. Beginning 90 days after the date of this prospectus, within any three-month period, such stockholders may sell a number of shares that does not
exceed the greater of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1% of the number of shares of common stock then outstanding, which will equal approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares immediately after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares of common stock from us; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average weekly trading volume of our common stock on The Nasdaq Global Market during the four calendar weeks
preceding the filing of a notice on Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales under Rule 144 by our affiliates or
persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Rule 701 generally allows a stockholder who was issued shares under a written compensatory plan or contract and who is not deemed to have been
an affiliate of our company during the immediately preceding 90 days, to sell these shares in reliance on Rule 144, but without being required to comply with the public information, holding period, volume limitation, or notice provisions of Rule
144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90
days after the date of this prospectus before selling those shares under Rule 701, subject to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form <FONT STYLE="white-space:nowrap">S-8</FONT> Registration Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act with the SEC
to register the offer and sale of shares of our common stock that are issuable under our 2020 Plan and our ESPP. These registration statements will become effective immediately on filing. Shares covered by these registration statements will then be
eligible for sale in the public markets, subject to vesting restrictions, any applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below, and Rule 144 limitations applicable to affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, and all of our directors, executive officers and the holders of substantially all of our common stock and securities exercisable for or
convertible into our common stock outstanding immediately on the closing of this offering, have agreed with the underwriters that, until 180 days after the date of the underwriting agreement related to this offering, we and they will not, without
the prior written consent of Citigroup Global Markets Inc., Cowen and Company, LLC, and Evercore Group L.L.C., directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any of our shares of common stock, or any securities convertible into or exercisable or exchangeable for shares of our common stock, or enter into any swap or
any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the securities, whether any such swap or transaction is to be settled by delivery of our common stock or
other securities, in cash or otherwise. These agreements are described in &#147;Underwriting.&#148; Citigroup Global Markets Inc., Cowen and Company, LLC, and Evercore Group L.L.C. may, in their sole discretion, release any of the securities subject
to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, pursuant to our second amended and restated investors&#146; rights agreement, the holders
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock, or their transferees, will be entitled to certain rights with respect to the registration of the offer and sale of their
shares under the Securities Act, subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described under <FONT STYLE="white-space:nowrap">&#147;&#151;Lock-Up</FONT> Arrangements&#148; above. Registration of these
shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act immediately on the effectiveness of the registration. Any sales of securities by these stockholders could have a
material adverse effect on the trading price of our common stock. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_18"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering. The discussion does not purport to be a complete analysis of
all potential tax consequences. The consequences of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws, are not discussed. This discussion is
based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated under the Code, judicial decisions and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS,
in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary
position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This
discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including without limitation the impact of the Medicare contribution tax on
net investment income. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons holding our common stock as part of a hedge, straddle or other risk-reduction strategy or as part of a
conversion transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">banks, insurance companies and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">real estate investment trusts or regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">partnerships or other entities or arrangements classified as partnerships for U.S. federal income tax purposes
(and investors therein); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to the stock
being taken into account in an applicable financial statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise
as compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity or arrangement classified as a partnership for U.S. federal income tax purposes holds our common stock, the tax treatment of a
partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the partners in such partnerships
should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This discussion is for informational purposes only and is not tax advice. Investors
should consult their tax advisors with respect to the application of the U.S. federal income tax laws to their particular situations as well as any tax consequences of the purchase, ownership and disposition of our common stock arising under the
U.S. federal estate or gift tax laws or under the laws of any state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxing jurisdiction or under any applicable income tax treaty. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Definition of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common
stock that is neither a &#147;U.S. person&#148; nor an entity or arrangement classified as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof or the District of
Columbia; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust that: (i)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more
&#147;United States persons&#148; (within the meaning of Section&nbsp;7701(a)(30) of the Code); or (ii)&nbsp;has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we make distributions
of cash or other property on our common stock, those distributions will generally constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal
income tax principles. If the amount of such distributions exceed our current and accumulated earnings and profits, such excess will generally constitute a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of capital and will first be applied
against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#147;Sale or
Other Taxable Disposition.&#148;<I>&nbsp;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on effectively connected income, dividends paid to a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty,
provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes the applicable withholding agent with documentation required to claim benefits under such tax treaty (generally, a valid IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or a suitable successor or substitute form)). A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that
does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS.
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding U.S. federal withholding tax on distributions, including their eligibility for benefits under any applicable income tax treaties and the
availability of a refund on any excess U.S. federal tax withheld. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will generally be exempt from the
U.S. federal withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or a
suitable successor or substitute form) certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular graduated
rates applicable to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends, as adjusted for certain
items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing discussion is subject to the discussion below under &#147;Additional Withholding Tax on Payments Made to Foreign Accounts&#148;
and &#147;Information Reporting and Backup Withholding.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale or Other Taxable Disposition </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below regarding backup withholding and the Foreign Account Tax Compliance Act, or FATCA, a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will not be subject to U.S. federal income or withholding tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct
of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the
United States for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real
property holding corporation, or USRPHC, for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the first bullet point
above generally will be subject to U.S. federal income tax on a net income basis at the regular graduated rates applicable to U.S. persons. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a
branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gain described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by
an applicable income tax treaty), which may be offset by U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal
income tax returns with respect to such losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the third bullet point above, we believe we currently are not, and we do
not anticipate becoming, a USRPHC. However, because the determination of whether we are a USRPHC depends on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property
interests and our other business assets, we cannot assure you that we will not become a USRPHC in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded&#148; on an &#147;established securities market&#148; (as such terms are defined
by applicable Treasury Regulations), and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT>
period ending on the date of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. If we are determined to be a USRPHC and the foregoing exception does not apply, the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder generally will be taxed on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to U.S. persons. No assurance can be provided that our common stock will
be regularly traded on an established securities market for purposes of the rules described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding potentially applicable income tax
treaties that may provide for different rules. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Reporting and Backup Withholding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends on our common stock generally will not be subject to backup withholding provided the applicable withholding agent does
not have actual knowledge or reason to know the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
U.S. person and the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status by furnishing a valid IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> <FONT STYLE="white-space:nowrap">W-8EXP,</FONT> or other applicable
IRS form, or otherwise establishes an exemption. Information returns are required to be filed with the IRS in connection with any dividends on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of
whether any tax was actually withheld. Copies of these information returns may also be made available under the provisions of an applicable treaty or agreement to the tax authorities of the country in which the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information reporting and, depending on the
circumstances, backup withholding generally will apply to the proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers, unless the applicable withholding agent
receives the certification described above and does not have actual knowledge or reason to know that the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a U.S. person, or the holder otherwise establishes an exemption. Proceeds of a
disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker that does not have certain enumerated relationships with the United States
generally will not be subject to backup withholding or information reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax. Any amounts
withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to
the IRS. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as FATCA) on certain types of
payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on, or gross
proceeds from the sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless:
(i)&nbsp;the foreign financial institution undertakes certain diligence, reporting and withholding obligations; (ii)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any
&#147;substantial U.S. owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial U.S. owner; or (iii)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign
entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence, reporting and withholding requirements in (i)&nbsp;above, it must enter into an agreement with the U.S.
Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified U.S. persons&#148; or &#147;United States-owned foreign entities&#148; (each as defined in the Code), annually report
certain information about such accounts, and withhold 30% on certain payments to noncompliant foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental
agreement with the United States governing FATCA may be subject to different rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the applicable Treasury Regulations and
administrative guidance, withholding under FATCA generally applies to payments of dividends on our common stock. Withholding with respect to gross proceeds from the disposition of property such as our common stock was previously scheduled to begin
on January&nbsp;1, 2019, however, such withholding has been eliminated under proposed U.S. Treasury regulations, which can be relied on until final regulations become effective. There can be no assurance that final Treasury regulations would provide
an exemption from withholding taxes under FATCA for gross proceeds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Prospective investors should consult their tax advisors regarding
the potential application of withholding under FATCA to their investment in our common stock. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_19"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc., Cowen and Company, LLC, and Evercore Group L.L.C. are acting as joint book-running managers of the offering and
as representatives of the underwriters named below. Subject to the terms and conditions stated in the underwriting agreement dated the date of this prospectus, each underwriter named below has severally agreed to purchase, and we have agreed to sell
to that underwriter, the number of shares set forth opposite the underwriter&#146;s name. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Needham and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the obligations of the underwriters to purchase the shares
included in this offering are subject to approval of legal matters by counsel and to other conditions. The underwriters are obligated to purchase all the shares (other than those covered by the underwriters&#146; option to purchase additional shares
described below) if they purchase any of the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares sold by the underwriters to the public will initially be offered at the
initial public offering price set forth on the cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount from the initial public offering price not to exceed
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. If all the shares are not sold at the initial offering price, the underwriters may change the offering price and the other selling terms.
The representatives have advised us that the underwriters do not intend to make sales to discretionary accounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters sell
more shares than the total number set forth in the table above, we have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares at the public offering price less the underwriting discounts and commissions. To the extent the option is exercised, each
underwriter must purchase a number of additional shares approximately proportionate to that underwriter&#146;s initial purchase commitment. Any shares issued or sold under the option will be issued and sold on the same terms and conditions as the
other shares that are the subject of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our officers and directors, and our other stockholders and optionholders have
agreed that, subject to certain specified exceptions, for a period of 180 days from the date of this prospectus, we and they will not, without the prior written consent of Citigroup Global Markets Inc., Cowen and Company, LLC, and Evercore Group
L.L.C., dispose of or hedge any shares or any securities convertible into or exchangeable for our common stock. Citigroup Global Markets Inc., Cowen and Company, LLC, and Evercore Group L.L.C. in their sole discretion may release any of the
securities subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time, which, in the case of officers and directors, shall be with<I> </I>notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At our request, the underwriters have reserved up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the shares of common stock for sale at the initial public offering price to persons who are directors, officers or employees, or who are otherwise
associated with us through a directed share program. The number of shares available for sale to the general public will be reduced by the number of directed shares purchased by participants in the program. Except for certain of our officers,
directors and employees who have entered into lock-up agreements as contemplated in the immediately preceding paragraph, each person buying shares through the directed share program has agreed that, for a period of 180 days from the date of this
prospectus, he or she will not, without the prior written consent of Citigroup Global Markets Inc., Cowen and Company, LLC and Evercore Group L.L.C., dispose of any shares or any securities convertible into or exchangeable for our common stock with
respect to shares purchased in the program. For certain officers, directors and employees purchasing shares through the directed share program, the lock-up agreements contemplated in the immediately preceding paragraph shall govern with respect to
their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchases. Citigroup Global Markets Inc., Cowen and Company, LLC and Evercore Group L.L.C. in their sole discretion may release any of the securities subject to these lock-up agreements at any
time, which, in the case of officers and directors, shall be with notice. Any directed shares not purchased will be offered by the underwriters to the general public on the same basis as all other shares offered. We have agreed to indemnify the
underwriters against certain liabilities and expenses, including liabilities under the Securities Act, in connection with the sales of the directed shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there has been no public market for our shares. Consequently, the initial public offering price for the shares was
determined by negotiations between us and the representatives. Among the factors considered in determining the initial public offering price were our results of operations, our current financial condition, our future prospects, our markets, the
economic conditions in and future prospects for the industry in which we compete, our management, and currently prevailing general conditions in the equity securities markets, including current market valuations of publicly traded companies
considered comparable to our company. We cannot assure you, however, that the price at which the shares will sell in the public market after this offering will not be lower than the initial public offering price or that an active trading market in
our shares will develop and continue after this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have applied to have our shares listed on The Nasdaq Global Market under
the symbol &#147;STTK.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the underwriting discounts and commissions that we are to pay to the
underwriters in connection with this offering. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Paid&nbsp;by&nbsp;Shattuck&nbsp;Labs,&nbsp;Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that our portion of the total expenses of this offering, excluding underwriting discounts and
commissions payable by us, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have also agreed to reimburse the underwriters for certain of their expenses in an amount up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering, the
underwriters may purchase and sell shares in the open market. Purchases and sales in the open market may include short sales, purchases to cover short positions, which may include purchases pursuant to the underwriters&#146; option to purchase
additional shares, and stabilizing purchases. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Short sales involve secondary market sales by the underwriters of a greater number of shares than they are
required to purchase in the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Covered&#148; short sales are sales of shares in an amount up to the number of shares represented by the
underwriters&#146; option to purchase additional shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;Naked&#148; short sales are sales of shares in an amount in excess of the number of shares represented by
the underwriters&#146; option to purchase additional shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Covering transactions involve purchases of shares either pursuant to the underwriters&#146; option to purchase
additional shares or in the open market in order to cover short positions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To close a naked short position, the underwriters must purchase shares in the open market. A naked short position
is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">To close a covered short position, the underwriters must purchase shares in the open market or must exercise the
option to purchase additional shares. In determining the source of shares to close the </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase
shares through the underwriters&#146; option to purchase additional shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Stabilizing transactions involve bids to purchase shares so long as the stabilizing bids do not exceed a
specified maximum. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchases to cover short positions and stabilizing purchases, as well as other purchases by the
underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of the shares. They may also cause the price of the shares to be higher than the price that would otherwise exist in the open market in
the absence of these transactions. The underwriters may conduct these transactions on the Nasdaq Global Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. If the
underwriters commence any of these transactions, they may discontinue them at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are full service financial institutions engaged in various activities, which may include securities trading, commercial and
investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. The underwriters and their respective affiliates have in the past performed commercial banking, investment banking and
advisory services for us from time to time for which they have received customary fees and reimbursement of expenses and may, from time to time, engage in transactions with and perform services for us in the ordinary course of their business for
which they may receive customary fees and reimbursement of expenses. In the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt
and equity securities (or related derivative securities) and financial instruments (which may include bank loans and/or credit default swaps) for their own account and for the accounts of their customers and may at any time hold long and short
positions in such securities and instruments. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or
publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to
payments the underwriters may be required to make because of any of those liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the European Economic Area
and United Kingdom </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area and the United Kingdom that has implemented the
Prospectus Directive (each, a relevant state), with effect from and including the date on which the Prospectus Directive is implemented in that relevant state (the relevant implementation date), an offer of shares described in this prospectus may
not be made to the public in that relevant state other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to fewer than 100 or, if the relevant state has implemented the relevant provision of the 2010 PD Amending
Directive, 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the relevant Dealer or Dealers nominated by us
for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this provision, the expression an &#147;offer of securities to the
public&#148; in any relevant state means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe for the shares,
as the expression may be varied in that relevant state by any measure implementing the Prospectus Directive in that relevant state, and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments thereto, including the
2010 PD Amending Directive, to the extent implemented in the relevant state) and includes any relevant implementing measure in the relevant state. The expression 2010 PD Amending Directive means Directive 2010/73/EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The sellers of the shares have not authorized and do not authorize the making of any offer of shares through any financial intermediary on
their behalf, other than offers made by the underwriters with a view to the final placement of the shares as contemplated in this prospectus. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further
offer of the shares on behalf of the sellers or the underwriters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the
meaning of Article 2(1)(e) of the Prospectus Directive that are also (i)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the &#147;Order&#148;) or
(ii)&nbsp;high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order (each such person being referred to as a &#147;relevant person&#148;). This prospectus and its
contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a relevant person should not
act or rely on this document or any of its contents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in France </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this prospectus nor any other offering material relating to the shares described in this prospectus has been submitted to the clearance
procedures of the <I>Autorit&eacute; des March&eacute;s Financiers</I> or of the competent authority of another member state of the European Economic Area and notified to the <I>Autorit&eacute; des March&eacute;s Financiers.</I> The shares have not
been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material relating to the shares has been or will be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">released, issued, distributed or caused to be released, issued or distributed to the public in France; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">used in connection with any offer for subscription or sale of the shares to the public in France.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Such offers, sales and distributions will be made in France only: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to qualified investors (<I>investisseurs qualifi&eacute;s</I>) and/or to a restricted circle of investors
(<I>cercle restreint d&#146;investisseurs</I>), in each case investing for their own account, all as defined in, and in accordance with articles <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.411-1,</FONT> <FONT
STYLE="white-space:nowrap">D.411-2,</FONT> <FONT STYLE="white-space:nowrap">D.734-1,</FONT> <FONT STYLE="white-space:nowrap">D.744-1,</FONT> <FONT STYLE="white-space:nowrap">D.754-1</FONT> and <FONT STYLE="white-space:nowrap">D.764-1</FONT> of the
French <I>Code mon&eacute;taire et financier</I>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to investment services providers authorized to engage in portfolio management on behalf of third parties; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in a transaction that, in accordance with article
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.411-2-II-1&deg;</FONT></FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-or-2&deg;</FONT></FONT> <FONT
STYLE="white-space:nowrap">-or</FONT> 3&deg; of the French <I>Code mon&eacute;taire et financier </I>and article <FONT STYLE="white-space:nowrap">211-2</FONT> of the General Regulations (<I>R&egrave;glement G&eacute;n&eacute;ral</I>) of the
<I>Autorit&eacute; des March&eacute;s Financiers</I>, does not constitute a public offer (<I>appel public &agrave; l&#146;&eacute;pargne</I>). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be resold directly or indirectly, only in compliance with articles <FONT STYLE="white-space:nowrap">L.411-1,</FONT> <FONT
STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">L.412-1</FONT> and <FONT STYLE="white-space:nowrap">L.621-8</FONT> through <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">L.621-8-3</FONT></FONT> of the
French <I>Code mon&eacute;taire et financier</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an
offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (ii)&nbsp;to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules
made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document relating
to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong
Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning of the
Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares offered in this prospectus have not been and will not be registered under the Financial Instruments and Exchange Law of Japan. The
shares have not been offered or sold and will not be offered or sold, directly or indirectly, in Japan or to or for the account of any resident of Japan (including any corporation or other entity organized under the laws of Japan), except
(i)&nbsp;pursuant to an exemption from the registration requirements of the Financial Instruments and Exchange Law and (ii)&nbsp;in compliance with any other applicable requirements of Japanese law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a
relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the
conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where
the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business
of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">shares, debentures and units of shares and debentures of that
corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275
of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to an institutional investor (for corporations, under Section&nbsp;274 of the SFA) or to a relevant person
defined in Section&nbsp;275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such rights and interest in that trust are acquired at a
consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the
conditions specified in Section&nbsp;275 of the SFA; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where no consideration is or will be given for the transfer; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the transfer is by operation of law. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is not intended to constitute an offer or solicitation to purchase or invest in the shares described herein. The shares may not
be publicly offered, sold or advertised, directly or indirectly, in, into or from Switzerland and will not be listed on the SIX Swiss Exchange or on any other exchange or regulated trading facility in Switzerland. Neither this document nor any other
offering or marketing material relating to the shares constitutes a prospectus as such term is understood pursuant to article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of
the SIX Swiss Exchange or any other regulated trading facility in Switzerland, and neither this document nor any other offering or marketing material relating to the shares may be publicly distributed or otherwise made publicly available in
Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to the offering, nor the Company nor the shares
have been or will be filed with or approved by any Swiss regulatory authority. The shares are not subject to the supervision by any Swiss regulatory authority, e.g., the Swiss Financial Markets Supervisory Authority FINMA (FINMA), and investors in
the shares will not benefit from protection or supervision by such authority. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this offering memorandum (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed
by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or
consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting
Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in
connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_20"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the shares of our common stock offered by this prospectus will be passed upon for us by Gibson, Dunn&nbsp;&amp; Crutcher LLP,
San Francisco, California. Certain legal matters in connection with this offering will be passed upon for the underwriters by Latham&nbsp;&amp; Watkins LLP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_21"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of Shattuck Labs, Inc. as of December&nbsp;31, 2018 and December&nbsp;31, 2019, and for the years then ended, have
been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect
to the shares of our common stock offered hereby. This prospectus, which constitutes a part of the registration statement,<I></I>&nbsp;does not contain all of the information set forth in the registration statement, some items of which are contained
in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement and its exhibits. Statements contained in
this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that
has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The exhibits to the registration statement should be reviewed for the complete contents of
these contracts and documents. A copy of the registration statement and its exhibits may be obtained from the SEC upon the payment of fees prescribed by it. The SEC maintains a website at <I>www.sec.gov </I>that contains reports, proxy and
information statements and other information regarding companies that file electronically with it.<I>&nbsp;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this
offering, we will become subject to the information and periodic and current reporting requirements of the Exchange Act, and in accordance therewith, will file periodic and current reports, proxy statements and other information with the SEC. The
registration statement, such periodic and current reports and other information can be obtained electronically by means of the SEC&#146;s website at <I>www.sec.gov.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc69956_23"></A><A NAME="index"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Financial Statements for the Years Ended December 31, 2018 and 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc69956_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc69956_2">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc69956_3">Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc69956_4">Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc69956_5">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc69956_6">Notes to the Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Financial Statements for the Six Months Ended June 30, 2019 and
2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc69956_7">Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc69956_8">Statements of Operations and Comprehensive Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc69956_9">Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc69956_10">Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fintoc69956_11">Notes to the Interim Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc69956_1"></A>Report of Independent Registered Public Accounting Firm
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shattuck
Labs, Inc.: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Opinion on the Financial Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have audited the accompanying balance sheets of Shattuck Labs, Inc. (the Company) as of December&nbsp;31, 2019 and 2018, the related
statements of operations and comprehensive loss, changes in redeemable convertible preferred stock and stockholders&#146; deficit, and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our
opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2019 and 2018, and the results of its operations and its cash flows for the years then ended, in conformity
with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the
U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">We have served as the Company&#146;s auditor since 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Austin, Texas </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">May&nbsp;4, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc69956_2"></A>BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 31,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 7,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,258</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 68,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 44,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue &#151; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,984</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A redeemable convertible preferred stock; $0.0001 par value: 1,126,000 shares authorized,
1,093,019 issued and outstanding as of December&nbsp;31, 2018 and 2019; liquidation value of $68,286 as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock; $0.0001 par value: 10,000,000 shares authorized, 1,101,907 and 1,114,282 shares
issued and 1,094,308 and 1,109,625 shares outstanding at December&nbsp;31, 2018 and 2019, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 68,161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 44,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc69956_3"></A>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue &#151; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 22,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,887</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,783</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expense from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,590</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,148</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of notes payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(357</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,240</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gains on investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,928</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6.83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,081,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share&#151;basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average shares outstanding&#151;basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,196,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc69956_4"></A>STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Redeemable<BR>Convertible<BR>Preferred</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other<BR>Comprehensive</B><br><B>Income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at January&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,062,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Sale of Series A redeemable convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">565,010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series A redeemable convertible preferred stock upon conversion of notes
payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">528,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of common stock previously subject to vesting requirements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,166</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,094,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of common stock previously subject to vesting requirements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Unrealized gain on investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;49,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc69956_5"></A>STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,388</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Noncash interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in value of the derivative instrument</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gain on extinguishment of notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,123</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(515</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,966</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,903</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,975</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(470</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,732</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale and maturities of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,592</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(152</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from sale of preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,631</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,644</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplemental disclosures of noncash financial activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Conversion of notes payable into Series A redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc69956_6"></A>NOTES TO FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and description of business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shattuck Labs, Inc. (the &#147;Company&#148;) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical
company developing its Agonist Redirected Checkpoint (&#147;ARC&#148;<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>) platform, a novel class of biologic medicines capable of multifunctional activity with potential applications in
oncology and autoimmune diseases. Using its proprietary ARC<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> platform, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic
malignancies. The Company&#146;s lead molecule, <FONT STYLE="white-space:nowrap">SL-279252,</FONT> is a novel therapeutic derived from the ARC<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> platform and its first molecule to begin
clinical trials. In addition, the Company has several molecules in preclinical development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $35.5&nbsp;million as
of December&nbsp;31, 2019. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly
dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements, and/or debt and equity financing.&nbsp;The Company&#146;s ability to fund its planned clinical operations, research
and development, and commercialization of its product candidates is expected to depend on the amount and timing of cash receipts from these funding sources. Adequate additional funding may not be available to the Company on acceptable terms or at
all. The failure to raise funds as and when needed could have a negative impact on the Company&#146;s financial condition and ability to pursue its business strategies. Management believes that the Company&#146;s cash and cash equivalents
and&nbsp;short-term&nbsp;investments of $39.1&nbsp;million as of December&nbsp;31, 2019, net proceeds of $34.5&nbsp;million from the Series B redeemable convertible preferred stock offering and $11.3&nbsp;million in payments from an amended
collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (&#147;Takeda&#148;), in the first four months of 2020 are sufficient to fund the projected operations of the Company
through at least the fourth quarter of 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Basis of presentation and summary of significant accounting policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of
America (&#147;GAAP&#148;). </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts
reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development expenses, and
the valuation of stock-based awards, and derivative instruments. Estimates are periodically reviewed <FONT STYLE="white-space:nowrap">in-light</FONT> of changes in circumstances, facts and experience. Changes in estimates are recorded in the period
in which they become known. Actual results could differ from management&#146;s estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Financial Information
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the closing of a qualified initial public offering (&#147;IPO&#148;), all of the Company&#146;s outstanding
redeemable convertible preferred stock will automatically convert into 2,963,554 shares of common stock. In the accompanying statements of operations and comprehensive loss, unaudited pro forma basic and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
diluted net loss per share of common stock has been prepared to give effect to the automatic conversion of all outstanding shares of redeemable convertible preferred stock as if they had been
converted at the later of the beginning of the reporting period or the issuance date of the redeemable convertible preferred stock. The shares of the Company&#146;s common stock expected to be issued, and the related net proceeds expected to be
received, in connection with the planned IPO are excluded from such pro forma information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Segment Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the
chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management believes that the carrying amounts of the Company&#146;s financial instruments, including accounts payable, approximate fair value
due to the&nbsp;short-term&nbsp;nature of those instruments. Short-term investments are recorded at their estimated fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents, and
short-term investments. The Company maintains its cash and cash equivalents at one accredited financial institution in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the
normal credit risk associated with commercial banking relationships. The Company invests in only highly rated debt securities that management believes protects the Company from risk of default and impairment of value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the Company&#146;s revenue is derived from its collaboration agreement with Takeda. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is highly dependent on a third-party manufacturer to supply drug products for its research and development activities of its
programs, including clinical and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is highly dependent on a contract research organization (&#147;CRO&#148;) to manage its clinical trials. These programs could be
adversely affected by a significant disruption in services provided by the CRO. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all demand deposits with financial institutions and all highly liquid investments with maturities of ninety days or less
at the date of purchase to be cash and cash equivalents. Cash equivalents consists of $5.2&nbsp;million in short-term government obligations, $25.3&nbsp;million in a money market fund and $1.1&nbsp;million in operating accounts as of
December&nbsp;31, 2018 and $6.5&nbsp;million held in a money market fund and $0.5&nbsp;million in an operating account at December&nbsp;31, 2019, and are carried at fair value of the investment based on quoted market prices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Short-Term Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Short-term&nbsp;investments consist of debt securities with a maturity of greater than three&nbsp;months when acquired. The Company classifies
its short-term investments at the time of purchase as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale&nbsp;securities</FONT></FONT> are carried at fair value. Unrealized gains and losses on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities are reported in accumulated other comprehensive income, a component of stockholders&#146; deficit, until realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Prepaid Expenses and Other Current Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets include prepaid expenses for general business purposes and supplies, materials, and services used in
several research projects, which are stated at cost and amortized on a straight-line basis over the related period of benefit. Supplies and materials have multiple applications for alternative future use and are expensed as they are consumed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization expense is
recognized using the straight-line method over the estimated useful life of the asset. Expenditures for repairs and maintenance that do not extend the estimated useful life or improve an asset are expensed as incurred. Upon retirement or sale, the
cost and related accumulated depreciation and amortization of assets disposed of are removed from the accounts, and any resulting gain or loss is included in the statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization periods are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5&nbsp;to&nbsp;10&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shorter&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;15&nbsp;years</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying
amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not
recoverable, and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for the years ended December&nbsp;31, 2018 and 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, accounting, and other third-party fees that are directly associated with
<FONT STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded as a reduction of additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital generated as a result of the offering. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the
statement of operations and comprehensive loss. Deferred offering costs were $0.0&nbsp;million and $0.1&nbsp;million at December&nbsp;31, 2018 and 2019, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Rent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company entered into a lease agreement for its facilities. The lease is classified as an operating lease. The Company records rent expense on a straight-line basis over the term of the lease and, accordingly records the difference between cash rent
payments and the recognition of rent expense as a deferred rent liability. Incentives granted under the Company&#146;s facilities leases, including allowances to fund leasehold improvements, are deferred and recognized as adjustments to rental
expense on a straight-line basis over the term of the lease. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Series A Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Series A redeemable convertible preferred stock (&#147;Preferred Stock&#148;) allows the holders to redeem their shares upon
a change in control in the Company. As a result, the Company classifies its Preferred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Stock as mezzanine equity. The Company charges specific incremental issuance costs incurred in the offering of Preferred Stock against the gross proceeds of the Preferred Stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration revenue is recognized in accordance with ASC 606, <I>Revenue from Contracts with Customers</I> (&#147;ASC 606&#148;).
Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply, and participation on joint steering committees. The Company evaluates the
promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the
Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or
dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel
costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company
must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes collaboration revenue when its customer or collaborator obtains control of promised goods or services, in an amount
that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following
five steps: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify the contract(s) with a customer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify the performance obligations in the contract; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determine the transaction price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allocate the transaction price to the performance obligations within the contract; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">v.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recognize revenue when (or as) the entity satisfies a performance obligation. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised
within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#146;s arrangements typically consist of a license to the Company&#146;s intellectual property and
research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a
material right to the customer.&nbsp;Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i)&nbsp;the customer can benefit from on its own or together with other readily available resources,
and (ii)&nbsp;is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet
the requirements of a performance obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines transaction price based on the amount of consideration the Company
expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable, or a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the
contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes in the transaction
price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes
as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations which consist of
licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the
appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or
such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#146;s accompanying
balance sheet.&nbsp;Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months
following the balance sheet date are classified as noncurrent liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Company&#146;s collaboration revenue arrangements may
include the following: </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Up-front&nbsp;License</FONT> Fees:&nbsp;If a license is determined to be
distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from <FONT STYLE="white-space:nowrap">nonrefundable,&nbsp;up-front&nbsp;fees</FONT> allocated to the license when the license is
transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine
whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">from&nbsp;non-refundable,&nbsp;up-front&nbsp;fees.</FONT></FONT> The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestone Payments:&nbsp;At the inception of an agreement that includes research and development milestone payments, the Company
evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most
likely amount approach. The Company primarily uses the most likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount
is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration
included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is
deemed to be the predominant item to which the royalties relate, the Company </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will recognize revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been allocated has been
satisfied (or partially satisfied).&nbsp;To date, the Company has not recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. <B><I></I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I></I></B>To date, the Company has not granted a development and commercialization license nor recognized any revenue related to licenses,
sales-based royalties or milestone payments based on the level of sale.<B><I></I></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and Development Services: The Company will
record costs associated with development activities as research and development expenses in the statement of operations and comprehensive loss consistent with ASC 730,<I>&nbsp;Research and Development.</I> The Company considered the guidance in ASC
808, <I>Collaborative Agreements</I> and will recognize the payments received from these agreements as revenue when the related costs are incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development cost are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs,
equipment and supplies, preclinical studies, clinical trials, and manufacturing development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A substantial portion of the
Company&#146;s ongoing research and development activities are conducted by third-party service providers, including contract research and manufacturing organizations. The Company accrues for expenses resulting from obligations under agreements with
CROs, contract manufacturing organizations (&#147;CMOs&#148;), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on
estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and
determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgements and estimates in determining the accrual balance in each reporting
period. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company
adjusts its accruals. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#146;s estimates, resulting in adjustments to research and development expense in future periods. Changes
in these estimates that result in material changes to the Company&#146;s accruals could materially affect the Company&#146;s results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes the grant-date fair value of stock-based awards issued to employees and nonemployee board members as compensation
expense on a straight-line basis over the vesting period of the award while awards containing a performance condition are recognized as expense when the achievement of the performance criteria is considered probable. The Company uses the
Black-Scholes option pricing model to determine the grant-date fair value of stock options. The Company adjusts expense for forfeitures in the periods they occur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statements and
the tax bases of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The
effect of a change in tax rates on deferred tax assets and liabilities will be recognized in the period that includes the enactment date. Additionally, any changes in income tax laws are immediately recognized in the year of enactment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is established against the deferred tax assets to reduce their
carrying value to an amount that is more likely than not to be realized. The deferred tax assets and liabilities are classified as noncurrent along with the related valuation allowance. Due to a lack of earnings history, the net deferred tax assets
have been fully offset by a valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes benefits of uncertain tax positions if it is more likely than not
that such positions will be sustained upon examination based solely on the technical merits, as the largest amount of benefits that is more likely than not to be realized upon the ultimate settlement. The Company&#146;s policy is to recognize
interest and penalties related to the unrecognized tax benefits as a component of income tax expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average
number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible
notes, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net
loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock
outstanding, as they would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,267,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,333,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the calculation of unaudited pro forma basic and diluted net loss per share for
the year ended December&nbsp;31, 2019: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss used to compute pro forma net loss per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,982</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average of shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect the automatic conversion of all convertible preferred stock to
common stock upon an initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted average number of shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,196,209</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10.92</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Comprehensive Income </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other comprehensive income is defined as the change in equity of a business enterprise during a period from transactions and other events and
circumstances from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources. Other comprehensive loss is comprised of the net loss and unrealized gains on short-term investments.<B><I> </I></B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT><I>&nbsp;Leases </I>(&#147;ASC 842&#148;) which
requires a lessee to record a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a corresponding lease liability on the balance sheet for all leases with terms longer
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than 12&nbsp;months. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest
comparative period presented in the financial statements, with certain practical expedients available. As the Company has elected to use the extended transition period for complying with new or revised accounting standards as available under the
JOBS Act, the standard is effective for the Company beginning January&nbsp;1, 2021, with early adoption permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related
disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> <I>Financial Instruments-Credit
Losses</I> (&#147;ASC 326&#148;): Measurement of Credit Losses on Financial Instruments (ASU <FONT STYLE="white-space:nowrap">2016-13)</FONT> which requires that expected credit losses relating to financial assets measured on an amortized cost basis
and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities be recorded through an allowance for credit losses. ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> limits the amount of
credit losses to be recognized for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of
previously recognized credit losses if fair value increases. ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> becomes effective for the Company during the first quarter of 2020. Early adoption is permitted. The Company is currently evaluating the
expected impact that the standard could have on its financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2018, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation&#151;Stock Compensation</I> (&#147;ASC 718&#148;) Improvements to Nonemployee Share-Based Payment Accounting. The amendments in this update expand the scope of Topic 718 to include
stock-based payment transactions for acquiring goods and services from nonemployees. Under this ASU, an entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the
attribution of costs (i.e., the period of time over which stock-based payment awards vest and the pattern of cost recognition over that period). The Company early adopted this guidance effective January&nbsp;1, 2019 and it did not have a material
impact on the Company&#146;s financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU <FONT
STYLE="white-space:nowrap">2018-13,</FONT><I>&nbsp;Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurements, </I>(&#147;ASC 820&#148;) which changes the fair value measurement disclosure requirements of ASC 820,
<I>Fair Value Measurements and Disclosures</I>. The goal of the ASU is to improve the effectiveness of ASC 820&#146;s disclosure requirements. The standard is applicable to the Company for fiscal years beginning January&nbsp;1, 2020, and interim
periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its related disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3.
Fair Value of Financial Instruments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received upon the sale of an asset or paid upon
the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of
the following categories: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity
has the ability to access as of the measurement date: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2: Inputs, other than quoted prices in active markets, that are observable either directly or
indirectly; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3: Unobservable inputs in which there is little or no market data, which require the reporting entity
to develop its own assumptions </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value measurements are classified based on the lowest level of input that is
significant to the measurement. The Company&#146;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair
value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those
in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s&nbsp;short-term&nbsp;investment instruments and cash equivalents are
classified using Level&nbsp;1 inputs within the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. There were no changes
in valuation techniques during the years ended December&nbsp;31, 2018 and 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At January&nbsp;1, 2018, the Company had a derivative
instrument related to a feature embedded in convertible debt. The convertible debt was converted to Preferred Stock in 2018 resulting in the termination of the derivative. The table presented below is a summary of changes in the fair value of the
Company&#146;s Level&nbsp;3 valuation for the derivative instrument for the year ended December&nbsp;31, 2018 (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange of feature</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Short-Term Investments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company classifies its debt securities as short-term investments. Debt securities are comprised of highly liquid investments with minimum
&#147;A&#148; rated securities and consist of U.S. Treasury, agency bonds and corporate entity commercial paper with maturities of more than three months but less than one year at the date of purchase. Debt securities as of December&nbsp;31, 2019
have an average maturity of 0.40 years. The debt securities are reported at fair value with unrealized gains or losses recorded in accumulated other comprehensive gain in the balance sheets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents the Company&#146;s available for sale short-term investments by major security type (amounts in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;Unrealized<BR>Gain/(Loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;Unrealized<BR>Gain/(Loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,358</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Property and Equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment consisted of the following (amounts in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,580</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,073</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,299</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(862</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&nbsp;31, 2018 and 2019 was
$0.3&nbsp;million and $0.5&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Accrued Expenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consisted of the following (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research contract costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum payments, by year and in aggregate, under noncancelable operating leases consist of the following as of December&nbsp;31, 2019
(amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,943</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized rent expense of $0.3&nbsp;million for each of the years ended December&nbsp;31, 2018
and 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Heat License Agreement </I></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the Company entered into an Exclusive License Agreement (&#147;Heat License Agreement&#148;) with Heat Biologics Inc.
(&#147;Heat&#148;). The Heat License Agreement was subsequently amended in November 2016, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December 2016, and March 2017. Pursuant to the Heat License Agreement, Heat granted to the Company a worldwide, sublicensable exclusive license to research, develop, manufacture, and
commercialize products under three provisional patent applications, including all patents issuing from such applications, (&#147;Fusion Protein Patent Rights&#148;), and a worldwide, sublicensable nonexclusive license to research, develop,
manufacture, and commercialize certain know how owned and controlled by Heat related to the Fusion Protein Patent Rights. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the
Heat License Agreement, Heat was required to conduct certain research and development services under a mutually-agreed upon research and development plan and Heat was eligible to receive financial support from the Company for these efforts.
Effective March 2017, Heat completed all research and development services under the Heat License Agreement and assigned to the Company three patent applications and all data derived from the research and development activities, referred to
collectively as the Research Services Inventions. Pursuant to the terms of the Heat License Agreement, the Company is obligated to use commercially reasonable efforts to diligently research and develop at least one product covered by the Fusion
Protein Patent Rights, including the obligation to file an IND application for such product. Our development efforts, including the development of SL-279252 and certain other ARC compounds, to date satisfy these obligations. In addition, the Company
is to provide annual reports to Heat on or before the anniversary of the effective date of the Heat License Agreement to inform Heat of the Company&#146;s progress. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless sooner terminated or extended, the term of the Heat License Agreement continues until the later of 20 years following the effective
date, and the expiration of the last to expire royalty term. Either party may terminate the agreement due to a material breach by the other party (subject to a 90-day cure period) or if the other party files for bankruptcy. In the event the Company
terminates the Heat License Agreement due to a material breach by Heat, Heat must assign to the Company all right, title, and interest in the patent rights licensed under the Heat License Agreement. In addition to an upfront payment of $50,000, the
Heat License Agreement requires the Company to make further payments to Heat of up to $20.6 million in the aggregate, for the achievement of specified development, regulatory, and commercial sale milestones for certain licensed products. The Company
is also required to pay Heat a percentage of certain upfront fees or other non-royalty payments that it receives that are not tied to milestone events under any sublicense of the Fusion Protein Patent Rights. The Company is also required to pay Heat
a royalty on all worldwide net sales by the Company, its affiliates, and sublicenses of certain licensed products in the low single digits. Royalties are payable, on a product-by-product and country-by-country basis, commencing on the first
commercial sale of such product and continuing until the last-to-expire valid patent claim to the licensed patent rights that cover such product in that country. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent
liabilities for which the Company cannot reasonably predict future payment. The Company&#146;s contractual obligations result primarily from obligations for various contract manufacturing organizations and clinical research organizations, which
include potential payments the Company may be required to make under its agreements. The contracts also contain variable costs and milestones that are hard to predict as they are based on such things as patients enrolled and clinical trial sites.
The timing of payments and actual amounts paid under contract manufacturing organization, or CMO, and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some
obligations. Also, those agreements are cancelable upon written notice by the Company and, therefore, not long-term liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Defined Contribution Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company sponsors an employee retirement plan qualifying under Section&nbsp;401(k) of the Internal Revenue Code for all eligible employees
in the United States who are at least 21 years old. The Company made $0.1&nbsp;million and $0.2&nbsp;million in matching contributions to the plan for the years ended December&nbsp;31, 2018 and 2019, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. As of December&nbsp;31,
2019, management was not aware of any existing, pending, or threatened legal actions that would have a material impact on the financial position, results of operations, or cash flows of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Convertible Promissory Notes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016
and 2017, the Company issued and amended several convertible promissory notes in exchange for aggregate proceeds of $10.5&nbsp;million. The notes accrued simple interest of 6.0% per year and, if not converted, would have matured in July 2018 and
March 2019. Upon the completion of a qualified financing event, the outstanding principal and interest related to certain notes automatically converted into the shares issued in connection with the financing event and at 80% of the subscription
price while the outstanding principal and interest related to the remaining notes automatically converted at a fixed conversion price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company completed a qualified financing in May 2018 and issued 528,009 shares of Preferred Stock in exchange for the outstanding principal
and interest of $10.5&nbsp;million and $0.8&nbsp;million, respectively. During the year ended December&nbsp;31, 2018, the Company recognized interest expense of $2.4&nbsp;million in connection with the convertible promissory notes prior to their
settlement upon conversion into Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2018, the Company sold 565,010 shares of Preferred Stock to investors for $62.475 per share for proceeds of $35.1&nbsp;million net of
issuance costs. Upon consummation of the sale of Preferred Stock, the outstanding principal and accrued interest associated with the convertible promissory notes were converted into 528,009 shares of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the rights, preferences, and terms of the Preferred Stock: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Rank </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Preferred Stock ranks senior to common stock as to payment of dividends, distributions of assets upon a liquidation event, or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of Preferred Stock are entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends, when and if declared by the Board, and in preference to any declaration or payment of any dividend on the Company&#146;s common
stock at the rate of $4.9980 per share. No dividends have been declared to date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock entitles the holder to one vote on all matters for which shares of common stock may vote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a liquidation, dissolution, or winding up of the Company, or in the event the Company merges with or is acquired by another
entity, each holder of Preferred Stock has a liquidation preference of $62.475 per share plus any declared and unpaid dividends. In the event of a liquidation, dissolution or winding up of the Company the Preferred Stock holders can elect to either
receive their liquidation preference or receive their <FONT STYLE="white-space:nowrap">pro-rata</FONT> portion of the liquidation proceeds on an &#147;as converted&#148; basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock is convertible into common stock at any time at the option of the holder at a conversion price then in effect and
equal to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> subject to adjustment. All outstanding Preferred Stock will automatically convert into common stock at the conversion price then in effect upon a
qualified initial public offering of common stock with a public offering price of at least $62.4750 per share and aggregate gross proceeds of at least $50.0&nbsp;million. All shares of Preferred Stock are convertible into common stock upon the
affirmative election of the holders of at least a 55% of the outstanding shares of Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><I>Redemption</I><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Series A redeemable convertible preferred stock allows the holders to redeem their shares upon a change in control in the
Company. As a result, the Company classifies its Series A redeemable convertible preferred stock as mezzanine equity. The Company charges specific incremental issuance costs incurred in the offering of Series A redeemable convertible preferred stock
against the gross proceeds of the Series A redeemable convertible preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Collaboration Agreement&#151;Related Party </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2017, the Company entered into a Collaboration Agreement with Takeda related to the development of certain ARC molecules, as amended
in April 2018, October 2018 and March 2020, (the &#147;Collaboration Agreement&#148;). Under the Collaboration Agreement, the Company is responsible to use commercially reasonable efforts to further research and development of six molecules. At the
end of the development term Takeda may elect (on a molecule-by-molecule basis) to license exclusively and obtain exclusive rights to undertake further clinical development and commercialization of up to four molecules. Additionally, Takeda was
granted a right of first negotiation (&#147;ROFN&#148;) to enter into licenses for each molecule within a specified class of ARC molecules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received payments of $35.0&nbsp;million, $21.0&nbsp;million, and $8.5&nbsp;million in the years ended December&nbsp;31, 2017, 2018
and 2019, respectively and we have recognized total revenue of $42.0&nbsp;million through December&nbsp;31, 2019 under the Collaboration Agreement. The Company assessed this arrangement in accordance with ASC 606 and concluded that the Collaboration
Agreement had four distinct performance obligations representing the combination of research and development services and participation in a joint development committee associated with the six molecules. The Company also concluded that, since the
option for the exclusive license is deemed to be at fair value that the option does not provide the customer with a material right; and should be accounted for if and when the option is exercised. Finally the Company noted that the ROFN does not
guarantee that Takeda can negotiate a license for molecules at prices that are below their respective standalone selling prices and further noted that if Takeda exercises the ROFN, the license fee will be negotiated at standalone selling price for
each molecule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for the allocated upfront payments using a cost-based input measure. In applying the
cost-based input method of revenue recognition, the Company used actual costs incurred relative to budgeted costs expected to be incurred for the combined performance obligation. Revenue is recognized based on actual costs incurred as a percentage
of total budgeted costs as the Company completes its performance obligation over the estimated service period. The Company recognizes revenue related to the reimbursable cost as they are incurred. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, the Company adopted and subsequently amended the 2016 Stock Incentive Plan (the &#147;Plan&#148;). The total number of shares
authorized under the Plan as of December&nbsp;31, 2019 was 387,877 and 37,774 shares are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available for future grants as of December&nbsp;31, 2019. The Plan permits the granting of options and restricted stock. The terms of the agreements are determined by the Company&#146;s Board of
Directors. The Company&#146;s awards vest based on the terms in the agreements and generally vest over four years and have a term of 10 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line
basis over the vesting period of the award. The Company recorded stock-based compensation expense in the following expense categories of its accompanying statements of operations and comprehensive loss (amounts in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes option activity under the Stock Plan: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining&nbsp;Life<BR>(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at the end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options granted during the year ended December&nbsp;31, 2018 and 2019 had weighted-average grant-date fair
values of $4.92 and $12.75 per share, respectively. As of December&nbsp;31, 2019, the unrecognized compensation cost was $1.5&nbsp;million and will be recognized over an estimated weighted-average amortization period of 2.91 years. The aggregate
intrinsic value of options exercised as of December&nbsp;31, 2018 and 2019 was $0.3&nbsp;million and $0.4&nbsp;million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of December&nbsp;31, 2019 was
$0.4&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option is estimated on the date of grant using a Black-Scholes option pricing model which takes
into account inputs such as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest rate, and dividend yield. The fair value of stock options
during the years ended December&nbsp;31, 2018 and 2019 was determined using the methods and assumptions discussed below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The expected term of employee stock options with service-based vesting is determined using the
&#147;simplified&#148; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#146;s lack of sufficient historical data. The expected term of nonemployee
options is equal to the contractual term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The expected stock price volatility is based on historical volatilities of comparable public entities within the
Company&#146;s industry. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the
time of grant for a period that is commensurate with the expected term. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the
foreseeable future, to pay a dividend on its common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As the Company&#146;s common stock has not been publicly traded, its Board of Directors periodically estimated
the fair value of the Company&#146;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The grant date fair value of each option grant was estimated throughout the year using the Black-Scholes option-pricing model using the
following weighted-average assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term - years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For accounting purposes, the restricted shares are considered the issuance of options as opposed to the sale
of stock and as such, the Company has recognized compensation expense for these awards. <FONT STYLE="white-space:nowrap">Twenty-five</FONT> percent of the shares became immediately vested and the remaining shares vest monthly over 36 months so long
as the executive remains employed by or provides service to the Company. In the event the grantee ceases to provide service, the Company has the option to repurchase any or all of the unvested shares at the original issuance price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the activity relating to these shares: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,765</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,942</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded no federal provision for income taxes as of December&nbsp;31, 2018 and 2019 due to reported net losses since inception. A
reconciliation of the expected income tax expense (benefit) computed using the federal statutory income tax rate to the Company&#146;s effective income tax rate is as follows for the years ended December&nbsp;31, 2018 and 2019 (amounts in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit computed at federal statutory tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,552</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,036</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Return to provision adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General business credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(800</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(672</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Disallowed interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark to market on convertible debt</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of the Company&#146;s deferred tax assets and liabilities as of
December&nbsp;31, 2018 and 2019 are as follows (amounts in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax asset:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,255</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,919</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liability:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(259</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(174</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total net deferred tax asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has established a valuation allowance equal to the net deferred tax asset due to uncertainties
regarding the realization of the deferred tax asset based on the Company&#146;s lack of earnings history. The valuation allowance increased by $1.8&nbsp;million and $5.7&nbsp;million during the years ended December&nbsp;31, 2018 and 2019,
respectively, primarily due to continuing loss from operations, general business credit carryforwards, and deferred revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2018, and 2019, the Company had gross U.S. net operating loss carryforwards (&#147;NOLs&#148;) of $3.9&nbsp;million and $14&nbsp;million, respectively. As of December&nbsp;31, 2018, and 2019, the Company had gross state net
operating loss carryforwards of $0.2&nbsp;million. As of December&nbsp;31, 2018, and 2019, the Company had U.S. tax credit carryforwards of $1.4&nbsp;million and $2.3&nbsp;million, respectively. The net operating loss and tax credit carryforwards
will begin to expire in 2036, if not utilized. The net operating loss and credit carryforwards are subject to Internal Revenue Service adjustments until the statute closes on the year the net operating loss or credit carryforwards are utilized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;382 of the Internal Revenue Code limits the utilization of U.S. NOLs following a change of control. After the 2018 financial
statements were filed, the Company completed a Section&nbsp;382 study from formation through December&nbsp;31, 2018. Based on this study, approximately $0.6&nbsp;million of the December&nbsp;31, 2016 NOL carryforward and $0.1&nbsp;million of the
December&nbsp;31, 2016 R&amp;D credit carryforward expired unutilized. As such, the Company has written off these portions of the December&nbsp;31, 2016 NOL carryforward and R&amp;D credit carryforward with a corresponding reduction of the valuation
allowance. The Company is in the process of completing a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes during the year ended December&nbsp;31, 2019. The Company has not completed its
Section&nbsp;382 study for this period. To the extent that the Company has undergone an ownership change during the year ended December&nbsp;31, 2019, the utilization of the NOL or R&amp;D credit carryforwards will be subject to an annual limitation
under Section&nbsp;382 or 383 of the Internal Revenue Code, which is determined by first multiplying the value of the Company&#146;s stock at the time of the ownership change by the applicable long-term,
<FONT STYLE="white-space:nowrap">tax-exempt</FONT> rate, and then could be subject to additional adjustments, as required. These limitations may result in expiration of a portion of the NOL or R&amp;D credit carryforwards before utilization. Any
carryforwards that will expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2018, and 2019, the Company had no unrecognized tax benefits. During
the years ended December&nbsp;31, 2019 and 2018, the Company had no interest and penalties related to income taxes. Additionally, the Company does not expect any unrecognized tax benefits to change significantly over the next twelve months. Due to
the existence of the valuation allowance, future changes in the Company&#146;s unrecognized tax benefits will not impact its effective tax rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company files income tax returns in the U.S. and state jurisdictions. The Company is subject to examination by taxing authorities in its
significant jurisdictions for the 2016, 2017, and 2018 tax years. There are currently no federal or state income tax audits in progress. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. Related
Party </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Takeda has a seat on the Company&#146;s Board of Directors and held an approximate 14% ownership interest in the Company&#146;s
outstanding shares as of December&nbsp;31, 2019. As a result, all revenue, accounts receivable and deferred revenue related to the Collaboration Agreement represented related party transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>14. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has
evaluated subsequent events from the balance sheet date through May&nbsp;4, 2020, the date at which the financial statements were available to be issued, and there are no other items requiring disclosure except for the following: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Series B Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the first quarter of 2020, the Company sold 550,571 shares of Series B redeemable convertible preferred stock for $62.88051 per share for
proceeds of $34.5&nbsp;million, net of issuance costs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Coronavirus Pandemic </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;10, 2020 World Health Organization characterized the novel <FONT STYLE="white-space:nowrap">COVID-19</FONT> virus as a global
pandemic. There is significant uncertainty as to the likely effects of this disease which may, among other things, materially impact the Company&#146;s planned clinical trials.&nbsp;This pandemic or outbreak could result in difficulty securing
clinical trial site locations, CROs, and/or trial monitors and other critical vendors and consultants supporting the trial. In addition, outbreaks or the perception of an outbreak near a clinical trial site location could impact the Company&#146;s
ability to enroll patients. These situations, or others associated with <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could cause delays in the Company&#146;s clinical trial plans and could increase expected costs, all of which could have a
material adverse effect on the Company&#146;s business and its financial condition.&nbsp;At the current time, the Company is unable to quantify the potential effects of this pandemic on its future operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;27, 2020 the Coronavirus Aid, Relief and Economic Security Act was signed into law. The Company evaluated the key provisions of
the Act and determined that there is no accounting impact resulting from its effectiveness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Third Amendment to the Takeda
Collaboration Agreement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2020, the Company entered into a third amendment to their Collaboration Agreement with
Takeda which will provide for an <FONT STYLE="white-space:nowrap">up-front</FONT> <FONT STYLE="white-space:nowrap">non-refundable</FONT> payment from Takeda of $11.3&nbsp;million and expense reimbursement to fund continued research on a specific
molecule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc69956_7"></A>BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020<BR>Pro&nbsp;Forma</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,013</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,044</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,044</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,074</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,490</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,490</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,355</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,246</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,246</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,442</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,780</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152,780</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,437</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,572</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,572</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,969</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,544</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,544</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, redeemable convertible preferred stock and stockholders&#146; equity
(deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,051</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,104</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,104</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,571</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,571</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue &#150; related party</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,894</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,823</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,823</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,984</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,498</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,498</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue &#150; related party net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,571</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,106</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,106</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">898</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,453</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,464</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,464</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A redeemable convertible preferred stock, $0.0001 par value: 1,093,019 shares authorized,
issued, and outstanding as of December&nbsp;31, 2019 and June&nbsp;30, 2020 (liquidation value of $68,286 as of June&nbsp;30, 2020) (actual); no shares authorized, issued, or outstanding at June&nbsp;30, 2020 (pro forma)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B redeemable convertible preferred stock, $0.0001 par value: 550,571 shares authorized,
none and 550,571 issued and outstanding as of December&nbsp;31, 2019 and June&nbsp;30, 2020, respectively (liquidation value of $34,620 as of June&nbsp;30, 2020) (actual); no shares authorized, issued, or outstanding at June&nbsp;30, 2020 (pro
forma)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,427</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock, $0.0001
par value: 1,319,964 shares authorized, none and 1,319,964 issued and outstanding as of December&nbsp;31, 2019 and June&nbsp;30, 2020, respectively (liquidation value of $83,000 as of June&nbsp;30, 2020) (actual); no shares authorized, issued, or
outstanding at June&nbsp;30, 2020 (pro forma)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,618</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.0001 par value: 10,000,000 and 4,950,000 shares authorized; 1,114,282 and
1,121,327 shares issued and 1,109,625 and 1,118,140 shares outstanding at December&nbsp;31, 2019 and June&nbsp;30, 2020, respectively (actual); 4,081,694 shares outstanding at June&nbsp;30, 2020 (pro forma)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,205</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167,314</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(47,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, redeemable convertible preferred stock and stockholders&#146; equity
(deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">44,969</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,544</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,544</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited interim financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc69956_8"></A>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration revenue &#150; related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,282</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,157</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,502</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,892</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,696</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,346</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expense from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,198</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,916</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">623</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(68</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain (loss) on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,225</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,798</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11.45</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares outstanding &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,099,148</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114,399</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average shares outstanding &#150; basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,785,497</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited interim financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc69956_9"></A>STATEMENT OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; DEFICIT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share amounts) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A redeemable<BR>convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>redeemable<BR>convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">B-1</FONT><BR>redeemable<BR>convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>other<BR>comprehensive<BR>income</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>stockholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance at January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093,019</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,094,308</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">427</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,508</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,081</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Unrealized gain on investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,285</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vesting of common stock previously subject to vesting</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,472</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance at June&nbsp;30, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093,019</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103,065</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">580</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,842</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,153</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance at January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093,019</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,625</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">888</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(35,490</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Sale of Series B redeemable convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550,571</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,427</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Sale of Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock,
net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319,964</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,618</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,045</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Vesting of common stock previously subject to vesting</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Unrealized gain on investments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Balance at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093,019</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,064</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550,571</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,427</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,319,964</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">82,618</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,118,140</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;1,205</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(48,252</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(47,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited interim financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc69956_10"></A>STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from operations:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(9,334</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operations:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accretion of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,013</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,891</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(992</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,355</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue&#151;related party</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,639</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,464</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,870</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(350</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sale and maturities of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,342</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,345</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,739</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash (used in) provided by investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,763</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,179</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash flows from financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payments for public offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the sale of Series B redeemable convertible preferred stock, net of issuance
costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the sale of Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable
convertible preferred stock, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,773</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,120</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,633</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,031</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,644</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,013</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,011</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,044</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT> financial
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrealized gain (loss) on short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued public offering costs in other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock
offering costs in other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">See accompanying notes to unaudited interim financial statements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fintoc69956_11"></A>NOTES TO INTERIM FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and
description of business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shattuck Labs, Inc. (the &#147;Company&#148;) was incorporated in 2016 in the State of Delaware and is a
clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its ARC<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and GADLEN<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> platforms, novel
classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the
treatment of solid tumors and hematologic malignancies. The Company has two clinical-stage molecules, <FONT STYLE="white-space:nowrap">SL-172154</FONT> and <FONT STYLE="white-space:nowrap">SL-279252.</FONT> In addition, the Company has several
molecules in preclinical development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $48.3&nbsp;million as
of June&nbsp;30, 2020. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly
dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements, and/or debt and equity financing. The Company&#146;s ability to fund its planned clinical operations, research and
development, and commercialization of its product candidates is expected to depend on the amount and timing of cash receipts from these funding sources. Adequate additional funding may not be available to the Company on acceptable terms, or at all.
The failure to raise funds as and when needed could have a negative impact on the Company&#146;s financial condition and ability to pursue its business strategies. Management believes that the Company&#146;s cash and cash equivalents and short-term
investments of $147.5&nbsp;million as of June&nbsp;30, 2020 are sufficient to fund the projected operations of the Company through at least the fourth quarter of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;10, 2020, the World Health Organization declared the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak a pandemic. The
virus and actions taken to mitigate its spread have had, and are expected to continue to have, a broad adverse impact on the economies and financial markets of many countries, including the geographical areas in which the Company operates and
conducts its business and which the Company&#146;s partners operate and conduct their business. The Company is currently following the recommendations of local health authorities to minimize exposure risk for its team members and visitors. However,
the scale and scope of this pandemic is unknown and the duration of the business disruption and related financial impact cannot be reasonably estimated at this time. While we have implemented specific business continuity plans to reduce the
potential impact of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> there is no guarantee that the Company&#146;s continuity plans will be successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has already experienced certain disruptions to its business such as work-from-orders for offices and similar disruptions have
occurred for its partners. Specifically, the outbreak has caused disruptions in enrollment and treatment of patients in clinical trials in process, and slowdowns and shutdowns of the laboratories and other service providers that are being relied
upon in the development of the Company&#146;s product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT> or
any other health epidemic may impact the Company&#146;s results will depend on future developments, which are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of <FONT
STYLE="white-space:nowrap">COVID-19</FONT> and the actions to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its impact, among others. Accordingly, <FONT STYLE="white-space:nowrap">COVID-19</FONT> could have a material adverse
effect on the Company&#146;s business, results of operations, financial condition, and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Basis of presentation and summary of significant accounting policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited interim financial statements have been prepared in conformity with U.S. generally accepted accounting principles
(&#147;U.S. GAAP&#148;) for interim financial information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Interim Financial Statements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist
primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company&#146;s financial position as of June&nbsp;30, 2020 and its results of operations, statement of changes in
redeemable convertible preferred stock and stockholder&#146;s deficit and cash flows for the six months ended June&nbsp;30, 2019 and 2020. Operating results for the six months ended June&nbsp;30, 2020 are not necessarily indicative of the results
that may be expected for the year ending December&nbsp;31, 2020. The interim financial statements, presented herein, do not contain the required disclosures under U.S. GAAP for annual financial statements. The accompanying unaudited interim
financial statements should be read in conjunction with the annual audited financial statements and related notes as of and for the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, the accrual of research and development
expenses, and the valuation of stock-based awards. Estimates are periodically reviewed <FONT STYLE="white-space:nowrap">in-light</FONT> of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they
become known. Actual results could differ from management&#146;s estimates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Financial Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the closing of a qualified initial public offering (&#147;IPO&#148;), all of the Company&#146;s outstanding redeemable
convertible preferred stock will automatically convert into common stock. The accompanying unaudited pro forma balance sheet as of June&nbsp;30, 2020 assumes the conversion of all outstanding shares of redeemable convertible preferred stock into
2,963,554 shares of common stock. In the accompanying unaudited interim statements of operations and comprehensive loss, unaudited pro forma basic and diluted net loss per share of common stock has been prepared to give effect to the automatic
conversion of all outstanding shares of redeemable convertible preferred stock as if they had been converted at the later of the beginning of the reporting period or the issuance date of the redeemable convertible preferred stock. The shares of the
Company&#146;s common stock expected to be issued, and the related net proceeds expected to be received, in connection with the planned IPO are excluded from such pro forma information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly
transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity
has the ability to access as of the measurement date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;2: Inputs, other than quoted prices in active markets, that are observable either directly or
indirectly; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Level&nbsp;3: Unobservable inputs in which there is little or no market data, which require the reporting entity
to develop its own assumptions. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fair value measurements are classified based on the lowest level of input that is
significant to the measurement. The Company&#146;s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair
value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those
in which transactions for the assets or liabilities occur in sufficient frequency and volume to provide pricing information on an ongoing basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management believes that the carrying amounts of the Company&#146;s financial instruments, including accounts payable, approximate fair value
due to the short-term nature of those instruments. Short-term investments are recorded at their estimated fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Concentration
of Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash,
cash equivalents, and short-term investments. The Company maintains its cash and cash equivalents at one accredited financial institution in amounts that exceed federally-insured limits. The Company does not believe that it is subject to unusual
credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only highly rated debt securities that management believes protects the Company from risk of default and impairment of value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the Company&#146;s revenue is derived from its collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly owned subsidiary
of Takeda Pharmaceuticals (&#147;Takeda&#148;), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (see Note 8). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company is highly dependent on a third-party manufacturer to supply drug products for its research and development activities of its programs, including clinical trials and <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies. These programs
could be adversely affected by a significant interruption in the supply of such drug products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is highly dependent on two
contract research organizations (&#147;CROs&#148;) to manage its clinical trials. These programs could be adversely affected by a significant disruption in services provided by the CROs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Cash Equivalents </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all demand deposits with financial institutions and all highly liquid investments with maturities of ninety days or less
at the date of purchase to be cash and cash equivalents. Cash equivalents consist of $6.5&nbsp;million held in a money market fund and $0.5&nbsp;million held in an operating account at December&nbsp;31, 2019 and $130.0&nbsp;million held in a money
market fund and $1.0&nbsp;million held in an operating account at June&nbsp;30, 2020, and are carried at fair value of the investment based on quoted market prices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Short-Term Investments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Short-term investments consist of debt securities with a maturity of greater than three months when acquired. The Company classifies its
short-term investments at the time of purchase as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> securities are carried at fair value. Unrealized gains and losses on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> securities are reported in accumulated other comprehensive income, a component of stockholders&#146; deficit, until realized. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company capitalizes certain legal, accounting, and other third-party fees that are directly associated with
<FONT STYLE="white-space:nowrap">in-process</FONT> equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs will be recorded as a reduction of additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital generated as a result of the offering. Should the equity financing no longer be considered probable of being consummated, all deferred offering costs would be charged to operating expenses in the
statement of operations and comprehensive loss. Deferred offering costs were $0.1&nbsp;million and $0.2&nbsp;million at December&nbsp;31, 2019 and June&nbsp;30, 2020, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Series A, Series B and Series <FONT STYLE="white-space:nowrap">B-1</FONT> Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records shares of redeemable convertible preferred stock at their respective fair values on the date of issuance, net of issuance
costs. The redeemable convertible preferred stock is recorded outside of stockholders&#146; equity on the balance sheet because the shares contain liquidation features that are not solely within the Company&#146;s control. The Company has elected
not to adjust the carrying values of the redeemable convertible preferred stock to the liquidation preferences of such shares because of the uncertainty of whether or when such an event would occur. Subsequent adjustments to increase the carrying
value to the liquidation preferences will be made only when it becomes probable that such a liquidation event will occur. See Note 6 for a discussion of the redeemable convertible preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaboration revenue is recognized in accordance with ASC 606, <I>Revenue from Contracts with Customers</I> (ASC 606). Arrangements with
collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply, and participation on joint steering committees. The Company evaluates the promised goods or
services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the
stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property, and whether the promised goods or services are integral to or dependent on other promises
in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines
and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract
which would be recorded through a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> to revenue or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through
the five-step process described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When the Company concludes that a contract should be accounted for as a combined performance
obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes collaboration revenue when its customer or collaborator obtains control of promised goods or services, in an amount
that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following
five steps: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify the contract(s) with a customer; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify the performance obligations in the contract; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iii.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determine the transaction price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">iv.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allocate the transaction price to the performance obligations within the contract and; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">v.</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allocate the transaction price to the performance obligations within the contract recognize revenue when (or as) the entity satisfies a performance obligation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is
entitled to in exchange for the goods or services it transfers to the customer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At contract inception, once the contract is determined to
be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company&#146;s arrangements
may consist of a license, or options to license, the Company&#146;s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as
separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that
(i)&nbsp;the customer can benefit from on its own or together with other readily available resources, and (ii)&nbsp;is separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance
obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised
goods or services in the contract. Consideration may be fixed, variable, or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it
expects to receive under the contract utilizing either the most likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and
includes in the transaction price variable consideration to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is
subsequently resolved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company then allocates the transaction price to each performance obligation based on the relative standalone
selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance
obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time
and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or
such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company&#146;s accompanying
balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months
following the balance sheet date are classified as <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>The Company&#146;s collaboration revenue arrangements may include the following: </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Up-front</FONT> License Fees: If a license is determined to be distinct from the other performance
obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, <FONT STYLE="white-space:nowrap">up-front</FONT> fees allocated to the license when the license is transferred to the licensee and the licensee is able to
use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over
time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <FONT STYLE="white-space:nowrap">non-refundable,</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> fees. The
Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each
milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most likely amount
approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. Then, the Company considers whether any portion of that estimated amount is subject to
the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty.) The Company updates the estimate of variable consideration included in the
transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is
deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance obligation to which some or all of the royalty has been
allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to licenses, sales-based
royalties or milestone payments based on the level of sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and Development Services: The Company will record costs associated
with development and process optimization activities as research and development expenses in the statement of operations and comprehensive loss consistent with ASC 730, <I>Research and Development.</I> The Company considered the guidance in ASC 808,
<I>Collaborative Agreements</I> and will recognize the payments received from these agreements as revenue when the related costs are incurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development cost are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs,
equipment and supplies, preclinical studies, clinical trials, and manufacturing development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A substantial portion of the
Company&#146;s ongoing research and development activities are conducted by third-party service providers, including contract research and manufacturing organizations. The Company accrues for expenses resulting from obligations under agreements with
CROs, contract manufacturing organizations (&#147;CMOs&#148;), and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on
estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and
determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. The Company makes significant judgements and estimates in determining the accrual and/or prepaid balance in
each reporting period. In the event advance payments are made to a CRO, CMO, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outside service provider, the payments will be recorded as a prepaid asset which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its
accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled, or the study duration, may vary from the Company&#146;s estimates, resulting in adjustments to research and development expense in
future periods. Changes in these estimates that result in material changes to the Company&#146;s accruals could materially affect the Company&#146;s results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding
during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, stock options and restricted stock, which would result
in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities
are not included in the calculation as the impact is anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following potentially dilutive securities have been excluded from
the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,093,019</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,963,554</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">174,361</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248,642</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,127</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,187</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,273,507</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,215,383</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the calculation of unaudited pro forma basic and diluted net loss per common
share for the six months ended June&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss used to compute pro forma net loss per share (in thousands)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114,399</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma adjustment to reflect the automatic conversion of all redeemable convertible preferred
stock to common stock upon an initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,671,098</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma weighted-average number of shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,785,497</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net loss per share&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4.58</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Comprehensive Income (Loss) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other
events and circumstances from <FONT STYLE="white-space:nowrap">non-owner</FONT> sources. Other comprehensive loss is comprised of the net loss and unrealized gains on short-term investments.<B><I> </I></B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-13,</FONT> <I>Financial Instruments-Credit Losses (&#147;ASC
326&#148;)</I>: Measurement of Credit Losses on Financial Instruments (ASU <FONT STYLE="white-space:nowrap">2016-13)</FONT> which requires that expected credit losses relating to financial assets measured on an amortized cost basis and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recorded through an allowance for credit losses. ASU <FONT STYLE="white-space:nowrap">2016-13</FONT> limits the amount of credit losses to be recognized for
<FONT STYLE="white-space:nowrap">available-for-sale</FONT> debt securities to the amount by which carrying value exceeds fair value and also requires the reversal of previously recognized credit losses if fair value increases. ASU <FONT
STYLE="white-space:nowrap">2016-13</FONT> became effective for the Company during the first quarter of 2020. The Company adopted this pronouncement and it did not have a material impact on the financial statements or related disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Disclosure Framework&#151;Changes to the
Disclosure Requirements for Fair Value Measurements</I>, which changes the fair value measurement disclosure requirements of ASC 820, Fair Value Measurements and Disclosures (&#147;ASC 820&#148;). The goal of the ASU is to improve the effectiveness
of ASC 820&#146;s disclosure requirements. The standard is applicable to the Company for the fiscal year beginning January&nbsp;1, 2020, and interim periods within that year. The Company adopted this pronouncement and it did not have a material
impact on the financial statements or related disclosures. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements (not yet adopted) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases </I>(ASC 842) which requires a lessee
to record a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. A modified retrospective
transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. As
the Company has elected to use the extended transition period for complying with new or revised accounting standards as available under the JOBS Act, the standard is effective for the Company beginning January&nbsp;1, 2022, with early adoption
permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Short-Term Investments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
classifies its debt securities as short-term investments. Debt securities are comprised of highly liquid investments with minimum &#147;A&#148; rated securities and consist of U.S. Treasury, agency bonds and corporate entity commercial paper with
maturities of more than three months but less than one year at the date of purchase. Debt securities as of June&nbsp;30, 2020 have an average maturity of 0.3 years. The debt securities are reported at fair value with unrealized gains or losses
recorded in accumulated other comprehensive income in the balance sheets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents the Company&#146;s available for
sale short-term investments by major security type (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;Unrealized<BR>Gain/(Loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,375</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,358</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,645</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,716</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,020</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32,074</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="12"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amortized<BR>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;Unrealized<BR>Gain/(Loss)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Fair&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corporate securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,950</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,940</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. government securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,522</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,550</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,472</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,490</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s short-term investment instruments and cash and cash equivalents are
classified using Level&nbsp;1 inputs in within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Accrued Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses
consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research contract costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,648</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,365</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">966</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">766</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">425</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,571</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;24, 2020, the Company entered into an amendment to the lease for the office space in Durham, North Carolina. The amendment
expanded the existing leased space. Future minimum payments inclusive of the amended lease, by year and in aggregate, under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases consist of the following as of June&nbsp;30, 2020 (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">753</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,340</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,368</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized rent expense of $0.2&nbsp;million for the six months ended June&nbsp;30, 2019 and
June&nbsp;30, 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Heat License Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with a license agreement with Heat Biologics Inc. (&#147;Heat&#148;), the Company is required to make payments of up to
$20.6&nbsp;million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products.&nbsp;The Company is required to pay Heat a percentage of any upfront fees or other <FONT
STYLE="white-space:nowrap">non-royalty</FONT> payments received that are not tied to milestone events under any sublicense of the licensed products.&nbsp;The Company is also required to pay Heat a royalty on all of its worldwide net sales, those of
its affiliates and sublicenses of certain licensed products in the low single digits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Litigation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. As of June&nbsp;30,
2020, management was not aware of any existing, pending, or threatened legal actions that would have a material impact on the financial position, results of operations, or cash flows of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent
liabilities for which the Company cannot reasonably predict future payment. The Company&#146;s contractual obligations result primarily from obligations for various contract manufacturing organizations and clinical research organizations, which
include potential payments we may be required to make under our agreements. The contracts also contain variable costs and milestones that are hard to predict as they are based on such things as patients enrolled and clinical trial sites. The timing
of payments and actual amounts paid under contract manufacturing organization, or CMO, and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Also,
those agreements are cancelable upon written notice by the Company and, therefore, not long-term liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the six months ended June&nbsp;30, 2020, the Company entered into various stock purchase agreements with new and existing investors
pursuant to which the Company sold an aggregate 550,571 shares of the Company&#146;s Series B redeemable convertible preferred stock (&#147;Series B&#148;) and 1,319,964 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable
convertible redeemable preferred stock (&#147;Series <FONT STYLE="white-space:nowrap">B-1&#148;)</FONT> at $62.88051 per share for aggregate gross proceeds of $117.6&nbsp;million. Transaction fees of $0.6&nbsp;million were recorded as a reduction of
the carrying value of the Series B and the Series <FONT STYLE="white-space:nowrap">B-1.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the rights,
preferences, and terms of the Company&#146;s Series A redeemable convertible preferred stock, the Series B, and the Series B-1 (&#147;Preferred Stock&#148;): </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Rank </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Preferred Stock ranks senior to common stock as to payment of dividends, distributions of assets upon a liquidation event, or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of Preferred Stock are entitled to receive <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividends, when and if declared by the Board, and in preference to any declaration or payment of any dividend on the Company&#146;s common
stock at the rate of 8% of the original issue price per share. No dividends have been declared to date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock entitles the holder to one vote on all matters for which shares of common stock may vote. The Series A holders
can elect two board members if a minimum of 276,059 shares of Series A are outstanding. If the number of Series A holders falls below 276,059 but not below 110,423 then they can elect one board member. The Series
<FONT STYLE="white-space:nowrap">B-1</FONT> holders can elect two board members if a minimum of 329,991 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> are outstanding. The Series B holders vote for remaining board members as a single
class with all other shareholders on an &#147;as converted&#148; basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation Preference </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of a liquidation, dissolution, or winding up of the Company, or in the event the Company merges with or is acquired by another
entity, each holder has a liquidation preference. Liquidating distributions will first be made to holders of shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> at $62.88051 per share and then to holders of Series B and Series A on a pari
passu basis at $62.88051 and $62.475 per share, respectively. As the redemption event is outside of our control, all shares of preferred stock have been presented outside of permanent equity. We have also concluded that since the shares of preferred
stock are not mandatorily redeemable, but rather are only contingently redeemable, and given that the redemption event is not certain to occur, the shares have not been accounted for as a liability in any of the periods presented. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After all liquidation preferences are fulfilled, the remaining funds and assets of the
Company will be distributed between Series <FONT STYLE="white-space:nowrap">B-1</FONT> holders and common shareholders ratably based on the number of shares held by common shareholders and the common shares that would be held by Series <FONT
STYLE="white-space:nowrap">B-1</FONT> holders on an &#147;as converted&#148; basis. If the total amount received by Series <FONT STYLE="white-space:nowrap">B-1</FONT> holders is greater than three times the original issue price, than the holders of
the Series <FONT STYLE="white-space:nowrap">B-1</FONT> are entitled to the greater of three times the original issue price or the amount such holder would have received if all shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> had been
converted into common stock common stock immediately prior to such liquidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Conversion </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Preferred Stock is convertible into common stock at any time at the option of the holder at a conversion price then in effect and
equal to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> subject to adjustment. All outstanding Preferred Stock will automatically convert into common stock at the conversion price then in effect upon a
qualified initial public offering of common stock with a public offering price of at least $62.88051 per share and aggregate gross proceeds of at least $50.0&nbsp;million. All shares of Preferred Stock are convertible into common stock upon the
affirmative election of the holders of at least a 65% of the outstanding shares of Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Redemption </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Preferred Stock allows the holders to redeem their shares upon a change in control in the Company. As a result, the Company classifies the
Preferred Stock as mezzanine equity. The Company charges specific </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">incremental issuance costs incurred in the offering of the Preferred Stock against the
gross proceeds of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Stock-Based
Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, the Company adopted and subsequently amended the 2016 Stock Incentive Plan (the &#147;Plan&#148;). The total
number of shares authorized under the Plan as of June&nbsp;30, 2020 was 557,633, and 187,664 shares remain available for future grants as of June&nbsp;30, 2020. The Plan permits the granting of options and restricted stock. The terms of the
agreements are determined by the Company&#146;s Board of Directors. The Company&#146;s awards vest based on the terms in the agreements and generally vest over four years and have a term of 10 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company measures employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> stock-based awards at grant-date fair value and records
compensation expense on a straight-line basis over the vesting period of the award. The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim statements of operations and
comprehensive loss (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six months<BR>ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">191</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">317</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes option activity under the Stock Plan: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>average<BR>exercise<BR>price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;average<BR>remaining<BR>contract life</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">235,821</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,866</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,045</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">248,642</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.57</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">245,314</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18.54</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106,478</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17.16</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options granted during the six months ended June&nbsp;30, 2020 had a weighted-average grant-date fair value of
$13.16. As of June&nbsp;30, 2020, unrecognized compensation cost for option issued was $1.5&nbsp;million, and will be recognized over an estimated weighted-average amortization period of 2.67 years. The aggregate intrinsic value of options
outstanding and exercisable as of June&nbsp;30, 2020 was $0.3&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option is estimated on the date of
grant using a Black-Scholes option pricing model which takes into account inputs such as the exercise price, the estimated fair value of the underlying common stock at grant date, expected term, expected stock price volatility, risk-free interest
rate, and dividend yield. The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Certain of these inputs are subjective and generally required judgement to determine. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The expected term of employee stock options with service-based vesting is determined using the
&#147;simplified&#148; method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company&#146;s lack of sufficient historical data. The expected term of <FONT
STYLE="white-space:nowrap">non-employee</FONT> options is equal to the contractual term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The expected stock price volatility is based on historical volatilities of comparable public entities within the
Company&#146;s industry. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the
time of grant for a period that is commensurate with the respective expected term or contractual term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the
foreseeable future, to pay a dividend on its common stock. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">As the Company&#146;s common stock has not been publicly traded, its board of directors periodically estimated
the fair value of the Company&#146;s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The grant date fair value of each option grant was estimated throughout the six months ended June&nbsp;30, 2020 using the Black-Scholes
option-pricing model using the following weighted-average assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67.02</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividends</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For accounting purposes, restricted shares granted are considered the issuance of options as opposed to the
sale of stock and as such, the Company has recognized compensation expense for these awards. Twenty-five </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
percent of the shares became vested after one year and the remaining shares vest monthly over 36 months so long as the grantee remains employed by or provides service to the Company. In the event
the grantee ceases to provide service, the Company has the option to repurchase any or all of the unvested shares at the original issuance price. The following table summarizes the activity relating to these shares for the six months ended
June&nbsp;30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,657</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,470</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,187</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Collaboration Agreement&#151;Related Party </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2017, the Company entered into a Collaboration Agreement with Takeda related to the development of certain ARC molecules as amended
in April 2018, October 2018 and March 2020, (the &#147;Collaboration Agreement&#148;). Under the Collaboration Agreement, the Company is responsible to use its commercially reasonable efforts to further research and develop six molecules in
accordance with specified development plans for each molecule. Two Designated Molecules, <FONT STYLE="white-space:nowrap">SL-279252</FONT> (&#147;DM1&#148;) and <FONT STYLE="white-space:nowrap">SL-115154</FONT> (&#147;DM2&#148;) (collectively
referred to as the &#147;DMs&#148;), will be progressed through a Phase 1 clinical trial and four Selected Molecules will be developed through the completion of nonclinical toxicology studies (collectively known as &#147;SMs&#148;). Takeda has an
option, which extends through the end of the development term for each molecule, to exclusively license (on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">molecule-by-molecule</FONT></FONT> basis) each DM and up to two SMs,
which license would grant Takeda exclusive rights to undertake further clinical development and commercialization of the licensed molecule. Additionally, Takeda was granted a right of first negotiation (&#147;ROFN&#148;) to enter into a licenses for
each molecule within a specified class of ARC molecules. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received payments of $8.5&nbsp;million and $11.3&nbsp;million
in the periods ended June&nbsp;30, 2019 and 2020, respectively, and recognized total revenue of $25.3&nbsp;million through June&nbsp;30, 2020 under the Collaboration Agreement. The Company assessed this arrangement in accordance with ASC 606 and
concluded that the Collaboration Agreement had four distinct performance obligations representing the combination of research and development services and participation in a joint development committee associated with both DMs, one SM and the
remaining three SMs as a group. The Company also concluded that since the option for the exclusive license was deemed to be at standalone selling price it does not provide the customer with a material right and therefore, it does not represent a
separate performance obligation. Finally the Company noted that the ROFN does not guarantee that Takeda can negotiate a license for molecules at prices that are below their respective standalone selling prices and further noted that if Takeda
exercises the ROFN, the license fee will be negotiated at standalone selling price for each molecule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;31, 2020, the Company
and Takeda entered into an amendment to the Collaboration Agreement (Amendment No.&nbsp;3) which provided for a second dose expansion cohort for DM1, improvements to the DM1 process and manufacturing controls, certain administrative tasks and a <FONT
STYLE="white-space:nowrap">non-refundable</FONT> <FONT STYLE="white-space:nowrap">up-front</FONT> payment applied to the to license fee for DM1 of $11.3&nbsp;million. The Company can receive reimbursement for costs incurred in the performance of the
second dose expansion cohort up to $3.2&nbsp;million, plus fifty percent of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred by the Company for clinical trial materials for the first and
second dose expansion cohorts up to $4.0&nbsp;million and reimbursements of up to $1.6 million for costs related to improvement to the DM1 process and manufacturing controls. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluated the consideration anticipated to be received for each performance obligation under Amendment No.&nbsp;3 and determined
that the contractual amounts for each obligation represent the stand-alone selling price and relate directly to the efforts that the Company will exert to fulfill its performance obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The potential reimbursements for costs incurred in the performance of the second dose expansion cohort and costs incurred by the Company for clinical trial materials for the second dose expansion
cohort were determined to be variable consideration. The Company determined that the potential reimbursement associated with the second dose expansion cohort was fully constrained and did not include it in the transaction price. The Company
anticipates that the reimbursements associated with clinical trial materials will be earned and as such, the amount was included in the transaction price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company further evaluated the terms of Amendment No.&nbsp;3 to determine if they represented a modification to the existing agreement or a
new agreement. The Company determined that improvements to the DM1 process and manufacturing controls are a new and distinct performance obligations with underlying revenue that is to be recorded prospectively. The second dose expansion cohort was
determined to be a continuation of research and development services being performed. As such, the second dose expansion cohorts represent a modification to the existing agreement and a continuation under the existing research and development
performance obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the outset of the contract with Takeda the Company viewed the option to license molecules as a discrete
performance obligation which would be transferred upon Takeda executing their option and remitting consideration that was negotiated and believed to be in line with the stand-alone value of the option. In conjunction with Amendment No.&nbsp;3, the
$11.3&nbsp;million payment was applied to the license fee and as such, results in a lower cost to license the molecule. The Company evaluated and determined the prepayment provided a material right. Management determined the stand-alone selling
price of the material right using comparable arrangements and probability that Takeda will exercise its option to license. The <FONT STYLE="white-space:nowrap">non-refundable</FONT> payment was recognized as deferred revenue upon receipt of the <FONT
STYLE="white-space:nowrap">up-front</FONT> payment and will be recognized as revenue upon Takeda entering into the underlying license agreement or when it is certain that Takeda will not exercise its option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue for the allocated upfront payments using a cost-based input measure. In applying the cost-based input method of
revenue recognition, the Company uses actual costs incurred relative to budgeted costs expected to be incurred for the combined performance obligation. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as
the Company completes its performance obligation over the estimated service period. The Company recognizes revenue related to the reimbursable cost as they are incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The stated development term under the Collaboration Agreement commenced on August&nbsp;8, 2017 and terminates 90 days after the Phase 1
clinical report is delivered to Takeda for each of the DMs.&nbsp;The development term for the SMs expired in the second quarter of 2019 as the nonclinical toxicology reports for the SMs were delivered to Takeda and the option period for the
exclusive license expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Revenue recognized under this agreement is related-party revenue. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Related-Party Transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Takeda has
a seat on the Company&#146;s Board of Directors and held an approximate 7.5% ownership interest in the Company&#146;s outstanding shares as of June&nbsp;30, 2020. As of December&nbsp;31, 2019, Takeda held an approximate 14% ownership interest in the
Company&#146;s outstanding shares. As a result, all revenue, and deferred revenue were associated with the Takeda Collaboration Agreement are represented related-party transactions. Prepaids and other current assets includes $1.4&nbsp;million of
cost that are reimbursable by Takeda under the Collaboration Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated subsequent events from the balance sheet date through August&nbsp;7, 2020, the date at which the financial statements
were available to be issued, and there are no other items requiring disclosure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Shattuck Labs, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69956g03i25.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Citigroup </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Cowen </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Evercore ISI
</B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Needham &amp; Company </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2020 (the 25th day after the date
of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when
acting as an underwriter and with respect to an unsold allotment or subscription. </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;13. Other Expenses of Issuance and Distribution. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the various expenses, other than underwriting discounts and commissions, payable by the registrant in connection
with the sale of common stock being registered. All of the amounts shown are estimated except the Securities and Exchange Commission registration fee and the FINRA filing fee. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount<BR>To Be<BR>Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be completed by amendment. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;14. Indemnification of Directors and Officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The company is a Delaware corporation. Section&nbsp;145(a) of the Delaware General Corporation Law (the &#147;DGCL&#148;) provides that a
Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an
action by or in the right of the corporation, by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or
agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with
such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no
reasonable cause to believe his or her conduct was unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145(b) of the DGCL provides that a Delaware corporation may
indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person
acted in any of the capacities set forth above, against expenses (including attorneys&#146; fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if the person acted in good faith
and in a manner the person reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged
to be liable to the corporation, unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine, upon application, that, despite the adjudication of liability but in view of all the
circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further subsections of DGCL Section&nbsp;145 provide that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to the extent a present or former director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (i)&nbsp;and (ii) of
Section&nbsp;145 or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses, including attorneys&#146; fees, actually and reasonably incurred by such person in connection therewith; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the indemnification and advancement of expenses provided for pursuant to Section&nbsp;145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be
entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the corporation shall have the power to purchase and maintain insurance of behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the
corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out
of such person&#146;s status as such, whether or not the corporation would have the power to indemnify such person against such liability under Section&nbsp;145. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Item 14, the term &#147;proceeding&#148; means any threatened, pending or completed action, suit or proceeding, whether or not
by or in the right of the company, and whether civil, criminal, administrative, investigative or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL
makes provision for the indemnification of officers and directors in terms sufficiently broad to indemnify officers and directors of the company under certain circumstances from liabilities (including reimbursement for expenses incurred) arising
under the Securities Act of 1933. The company&#146;s organizational documents provide, in effect, that, to the fullest extent and under the circumstances permitted by Section&nbsp;145 of the DGCL, the company will indemnify any and all of its
officers and directors. Before the completion of this offering, the company intends to enter into indemnification agreements with its officers and directors. The company may, in its discretion, similarly indemnify its employees and agents. The
company&#146;s certificate of incorporation also relieves its directors from monetary damages to the company or its stockholders for breach of such director&#146;s fiduciary duty as a director to the fullest extent permitted by the DGCL. Under
Section&nbsp;102(b)(7) of the DGCL, a corporation may relieve its directors from personal liability to such corporation or its stockholders for monetary damages for any breach of their fiduciary duty as directors except (i)&nbsp;for a breach of the
duty of loyalty, (ii)&nbsp;for failure to act in good faith, (iii)&nbsp;for intentional misconduct or knowing violation of law, (iv)&nbsp;for willful or negligent violations of certain provisions in the DGCL imposing certain requirements with
respect to stock repurchases, redemptions and dividends or (v)&nbsp;for any transactions from which the director derived an improper personal benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The company has purchased insurance policies that, within the limits and subject to the terms and conditions thereof, cover certain expenses
and liabilities that may be incurred by directors and officers in connection with proceedings that may be brought against them as a result of an act or omission committed or suffered while acting as a director or officer of the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The form of Underwriting Agreement, to be entered into in connection with this offering and to be attached as Exhibit 1.1 hereto, provides for
the indemnification by the underwriters of us and our officers and directors for certain liabilities, including liabilities arising under the Securities Act, and affords certain rights of contribution with respect thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;15. Recent Sales of Unregistered Securities. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2017, we have made the following sales of unregistered securities: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Issuances of Capital Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
March 2017, we issued and sold convertible promissory notes in an aggregate principle amount of $7,000,000 to investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
April&nbsp;2018, we issued and sold an aggregate of 1,093,019 shares of our Series A Preferred Stock at a purchase price of $62.4750 per share to new and existing investors in exchange for aggregate consideration of approximately $46.6&nbsp;million,
composed of approximately $35.3&nbsp;million in cash and $11.3&nbsp;million in cancellation of indebtedness pursuant to the conversion of our convertible promissory notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2020, with subsequent closings in February and March 2020, we issued and sold an aggregate of 550,571 shares of our Series B
Preferred Stock at a purchase price of $62.88051 per share to new and existing investors in exchange for aggregate consideration of $34.6&nbsp;million in cash. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2020, we issued and sold an aggregate of 1,319,964 shares of our Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock at
a purchase price of $62.88051 per share to new and existing investors for aggregate consideration of $83.0&nbsp;million in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
offers, sales, and issuances of the securities listed in this Item 15 under the subheading &#147;Issuances of Capital Stock&#148; were deemed to be exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities
Act or Rule 506 of Regulation D promulgated thereunder as transactions by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for
sale in connection with any distribution thereof, and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited investor within the meaning of Rule
501 of Regulation D under the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Grants of Stock Options </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since January&nbsp;1, 2017, we have granted stock options to purchase an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock at a weighted average exercise price of $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to employees, directors, and <FONT STYLE="white-space:nowrap">non-employee</FONT> service providers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. The offers, sales
and issuances of the securities listed in this Item 15 under the subheading &#147;Grants of Stock Options&#148; were deemed to be exempt from registration under the Securities Act in reliance on Rule 701 promulgated under the Securities Act as
offers and sales of securities pursuant to certain compensatory benefit plans and contracts relating to compensation in compliance with Rule 701 or Rule 175. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;16. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit
<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1.1*&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Form of Underwriting Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.1&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amended and Restated Certificate of Incorporation of the registrant, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.2*&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Form of Second Amended and Restated Certificate of Incorporation of the registrant, to be in effect upon completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.3&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Bylaws of the registrant, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3.4*&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Form of Amended and Restated Bylaws of the registrant, to be in effect upon completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.1*&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Form of common stock certificate of the registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4.2*&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Second Amended and Restated Investors&#146; Rights Agreement, dated as of June&nbsp;12, 2020, by and among Shattuck Labs, Inc. and certain of its stockholders.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5.1*&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Opinion of Gibson, Dunn&nbsp;&amp; Crutcher LLP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.1*+&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Form of Indemnification Agreement for directors and executive officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.2+&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Employment Agreement, dated December&nbsp;5, 2019, by and between Shattuck Labs, Inc. and Josiah C. Hornblower.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.3*+&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amendment No.&nbsp;1 to Employment Agreement, dated March&nbsp;27, 2020, by and between Shattuck Labs, Inc. and Josiah C. Hornblower.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.4+&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Employment Agreement, dated December&nbsp;5, 2019, by and between Shattuck Labs, Inc. and Taylor Schreiber.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.5*+&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Amendment No.&nbsp;1 to Employment Agreement, dated March&nbsp;27, 2020, by and between Shattuck Labs, Inc. and Taylor Schreiber.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.6+&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Employment Agreement, dated December&nbsp;5, 2019, by and between Shattuck Labs, Inc. and Arundathy Nirmalini Pandite.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.7+&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Employment Agreement, dated December&nbsp;5, 2019, by and between Shattuck Labs, Inc. and Erin Ator Thomson.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.8+&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Employment Agreement, dated December&nbsp;5, 2019, by and between Shattuck Labs, Inc. and Andrew Neill.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.9*+&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2020 Equity Incentive Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.10*+</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">2020 Employee Stock Purchase Plan.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.11*&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Material Transfer and Feasibility Agreement, dated July&nbsp;10, 2019, by and between Shattuck Labs, Inc. and Millennium Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.12*&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Material Transfer Agreement, dated July&nbsp;1, 2019, by and between Shattuck Labs, Inc. and Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.13*&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Collaboration Agreement, dated August&nbsp;8, 2017, by and between Shattuck Labs, Inc. and Millennium Pharmaceuticals, Inc., as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.14*&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Exclusive License Agreement, dated June&nbsp;3, 2016, by and between Shattuck Labs, Inc. and Heat Biologics, Inc., as amended.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit
<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.15*&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Lease Agreement, dated April&nbsp;17, 2018, between Shattuck Labs, Inc. and Parmer RTP, LLC, as amended.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">10.16*&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Master Services Agreement, dated March 31, 2017, between Shattuck Labs, Inc. and KBI Biopharma, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.1*&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Consent of Independent Registered Public Accounting Firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23.2*&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Consent of Gibson, Dunn&nbsp;&amp; Crutcher LLP (see Exhibit 5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24.1*&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Power of Attorney (see signature page hereto).</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">+</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(b) No financial statement schedules are provided
because the information called for is not required or is shown in the financial statements or the notes thereto. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;17. Undertakings.
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities
Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in
the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned Registrant hereby undertakes that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance on Rule 430A and contained in a form of
prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be a part of this registration statement as of the time it was declared effective. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">For purposes of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered
therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide offering thereof. </I></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in the City of Austin, State of Texas, on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Shattuck Labs, Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dr.&nbsp;Taylor Schreiber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Chief Executive Officer</I></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dr.&nbsp;Taylor Schreiber,
Andrew Neill and Erin Ator Thomson, and each of them, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, each with full power of substitution and
resubstitution, for him or her and in his or her name, place or stead, in any and all capacities (including, without limitation, the capacities listed below), to sign any and all amendments (including post-effective amendments) to this registration
statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective upon filing pursuant to Rule 462(b) promulgated under the Securities Act of 1933, as amended, and all
post-effective amendments thereto, and to file the same, with all exhibits thereto and all other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and
purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, or any of them, or his or her substitute
or substitutes, may lawfully do or cause to be done by virtue hereof. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933,
this registration statement has been signed by the following persons in the capacities and on the dates set forth opposite their names. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Taylor
Schreiber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer and Director</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>principal executive officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Andrew Neill</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vice President of Finance and Corporate Strategy</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(<I>principal financial and accounting officer</I>)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2020</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Josiah Hornblower</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Execution Chairman and Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Helen M. Boudreau</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Neil Gibson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;George Golumbeski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Lee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Tyler Brous</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Sections 242 and 245 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shattuck Labs, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of
Delaware (the &#147;<B><I>General Corporation Law</I></B>&#148;), does hereby certify as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The name of
this corporation is Shattuck Labs, Inc. This corporation was originally incorporated pursuant to the General Corporation Law on May&nbsp;9, 2016 under the name Shattuck Labs, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors of this corporation duly adopted resolutions proposing to amend and restate the Amended and
Restated Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to
solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">RESOLVED, that the Amended and Restated Certificate of Incorporation of this corporation be amended and restated in its entirety to read as set
forth on <U>Exhibit A</U> attached hereto and incorporated herein by this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exhibit A</U> referred to in the resolution above is attached
hereto as <U>Exhibit A</U> and is hereby incorporated herein by this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;This Amended and Restated
Certificate of Incorporation was approved by the holders of the requisite number of shares of this corporation in accordance with Section&nbsp;228 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;This Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the
provisions of this corporation&#146;s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this
corporation on this 10th day of June, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Taylor Schreiber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Taylor Schreiber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Exhibit A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ARTICLE I</U>: <U>NAME</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The name of this corporation is Shattuck Labs, Inc. (the &#147;<B><I>Corporation</I></B>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ARTICLE II</U>: <U>REGISTERED OFFICE</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The address of the registered office of the Corporation in the State of Delaware is<B> </B>1675 S. State Street, Suite B, City of Dover,
County of Kent, Delaware 19901. The name of its registered agent at such address is Capitol Services, Inc. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ARTICLE III</U>:
<U>PURPOSE</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for
which corporations may be organized under the General Corporation Law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ARTICLE IV</U>: <U>AUTHORIZED SHARES</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total number of shares of all classes of stock that the Corporation will have authority to issue is (a) 4,950,000 shares of Common Stock,
$0.0001 par value per share (&#147;<B><I>Common Stock</I></B>&#148;), and (b) 2,963,554 shares of Preferred Stock, $0.0001 par value per share (&#147;<B><I>Preferred Stock</I></B>&#148;). As of the effective date of this Amended and Restated
Certificate of Incorporation (this &#147;<B><I>Certificate</I></B>&#148;), 1,093,019 shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B><I>Series A Preferred Stock</I></B>,&#148; 550,571 shares of the
authorized Preferred Stock of the Corporation are hereby designated &#147;<B><I>Series B Preferred Stock</I></B>&#148; and 1,319,964 shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B><I>Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</I></B><I>.</I>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the
rights, powers and privileges, and the qualifications, limitations or restrictions thereof, in respect of each class of capital stock of the Corporation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>A.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COMMON STOCK </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>General</U></B><B>.</B> The voting, dividend and liquidation rights of the holders of the Common Stock
are subject to and qualified by the rights, powers and privileges of the holders of the Preferred Stock set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Voting</U></B><B>.</B> The holders of the Common Stock are entitled to one vote for each share of
Common Stock held at all meetings of stockholders (and written actions in lieu of meetings). Unless required by law, there will be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the
number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of this Certificate) the affirmative vote of the holders of shares of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 1 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of
Section&nbsp;242(b)(2) of the General Corporation Law and without a separate class vote of the holders of the Common Stock. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>B.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PREFERRED STOCK </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following rights, powers and privileges, and restrictions, qualifications and limitations, will apply to the Preferred Stock. Unless
otherwise indicated, references to &#147;Sections&#148; in this Part B of this Article IV refer to sections of this Part B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Dividends</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Cumulative</FONT> Preferred Stock Dividend Preference</U>. The Corporation
will not pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) in any calendar year unless (in addition to the
obtaining of any consents required elsewhere in this Certificate) the holders of shares of each series of Preferred Stock then outstanding will first receive, or simultaneously receive, on a <I>pari</I><I> </I><I>passu</I> basis, out of funds
legally available therefor, a dividend on each outstanding share of Preferred Stock in an amount equal to 8% of the Original Issue Price (as defined below) per share of such series of Preferred Stock. The foregoing dividends will not be cumulative
and will be paid when, as and if declared by the Board of Directors of the Corporation (the &#147;<B><I>Board</I></B>&#148;). The &#147;<B><I>Original Issue Price</I></B>&#148; shall mean (i)&nbsp;in the case of the Series A Preferred Stock,
$62.4750 per share, (ii)&nbsp;in the case of the Series B Preferred Stock, $62.88051 per share and (iii)&nbsp;in the case of the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, $62.88051 per share, in each case subject to
appropriate adjustment in the event of any stock splits and combinations of shares and for dividends paid on the applicable series of Preferred Stock in shares of such stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Participation</U>. If, after dividends in the full preferential amount specified in
<U>Section</U><U></U><U>&nbsp;1.1</U> for the Preferred Stock have been paid or set apart for payment in any calendar year of the Corporation, the Board declares additional dividends out of funds legally available therefor in that calendar year,
then such additional dividends will be declared pro rata on the Common Stock and the Preferred Stock on a <I>pari passu</I> basis according to the number of shares of Common Stock held by such holders. For this purpose each holder of shares of
Preferred Stock is to be treated as holding the greatest whole number of shares of Common Stock then issuable upon conversion of all shares of Preferred Stock held by such holder pursuant to <U>Sections 4</U> and <U>5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.3&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Cash</FONT> Dividends</U>. Whenever a dividend provided for in this
<U>Section</U><U></U><U>&nbsp;1</U> will be payable in property other than cash, the value of such dividend will be deemed to be the fair market value of such property as determined in good faith by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments to Holders of Preferred Stock</U>. In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Corporation or any Deemed Liquidation Event (as defined below): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 2 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.1&nbsp;&nbsp;&nbsp;&nbsp;First, the holders of shares of Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock then outstanding will be entitled to be paid out of the funds and assets available for distribution to the Corporation&#146;s stockholders, before any payment will be made to the holders of
Series B Preferred Stock, the holders of Series A Preferred Stock, or the holders of Common Stock by reason of their respective ownership thereof, an amount per share equal to the Original Issue Price for the Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, plus any dividends declared but unpaid thereon. If upon any such liquidation, dissolution, winding up or Deemed Liquidation Event of the Corporation, the funds and assets available for
distribution to the stockholders of the Corporation will be insufficient to pay the holders of shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock the full amounts to which they are entitled under this
<U>Section</U><U></U><U>&nbsp;2.1.1</U>, the holders of shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock will share ratably in any distribution of the funds and assets available for distribution in proportion to the
respective amounts that would otherwise be payable in respect of the shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock held by them upon such distribution if all amounts payable on or with respect to such shares were paid
in full. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.1.2&nbsp;&nbsp;&nbsp;&nbsp;Second, the holders of shares of Series A Preferred Stock and Series B Preferred Stock then
outstanding (collectively, the &#147;<B><I>Other Preferred Stock</I></B>&#148;) will be entitled, on a <I>pari</I><I> </I><I>passu</I> basis, to be paid out of the funds and assets available for distribution to the Corporation&#146;s stockholders,
before any payment will be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (a)&nbsp;the Original Issue Price for such series of Other Preferred Stock, plus any dividends declared
but unpaid thereon, or (b)&nbsp;such amount per share as would have been payable had all shares of Other Preferred Stock been converted into Common Stock pursuant to <U>Sections 4</U> and <U>5</U> immediately prior to such liquidation, dissolution,
winding up or Deemed Liquidation Event. If upon any such liquidation, dissolution, winding up or Deemed Liquidation Event of the Corporation, the funds and assets available for distribution to the stockholders of the Corporation will be insufficient
to pay the holders of shares of Other Preferred Stock the full amounts to which they are entitled under this <U>Section</U><U></U><U>&nbsp;2.1.2</U>, the holders of shares of Other Preferred Stock will share ratably in any distribution of the funds
and assets available for distribution in proportion to the respective amounts that would otherwise be payable in respect of the shares of Other Preferred Stock held by them upon such distribution if all amounts payable on or with respect to such
shares were paid in full. The aggregate amount which a holder of a share of Other Preferred Stock is entitled to receive under <U>Section</U><U></U><U>&nbsp;2.1.2</U> is hereinafter referred to as the &#147;<B><I>Other Preferred Liquidation
Amount</I></B><I>.</I>&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Payments to Holders of Common Stock and Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution, winding up or Deemed Liquidation Event of the Corporation, after the payment of all preferential amounts required
to be paid to the holders of shares of Preferred Stock as provided in <U>Section</U><U></U><U>&nbsp;2.1</U>, the remaining funds and assets available for distribution to the stockholders of the Corporation will be distributed among the holders of
shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and Common Stock, sharing ratably based on the number of shares of Common Stock held by each such holder (or, with respect to shares of Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock held by each such holder, treating for this purpose all such shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock as if they had been converted to Common Stock pursuant to
the terms of this Certificate immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event of the Corporation); <I><U>provided</U></I>, <I><U>however</U></I>, that if the aggregate amount per share that the holders of
Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock would be entitled to receive under <U>Sections 2.1</U> and <U>2.2</U> would exceed three times the aggregate Original Issue Price for a share of Series
<FONT STYLE="white-space:nowrap">B-1</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 3 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Preferred Stock (the &#147;<B><I>Maximum Participation Amount</I></B>&#148;), then each holder of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock should instead be entitled to
receive upon such liquidation, dissolution or winding up of the Corporation an amount per share equal to the greater of (i)&nbsp;the Maximum Participation Amount and (ii)&nbsp;the amount such holder would have received if all shares of Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock had been converted into Common Stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event of the Corporation.&nbsp;&nbsp;&nbsp;&nbsp;The total amount per
share which a holder of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock is entitled to receive under <U>Sections 2.1</U> and 2.2 is hereinafter referred to as the &#147;<B><I>Series <FONT STYLE="white-space:nowrap">B-1</FONT>
Liquidation Amount</I></B>&#148; and collectively with the Other Preferred Liquidation Amount, the &#147;<B><I>Preferred Liquidation Amount</I></B><I>.</I>&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Deemed Liquidation Events</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Definition</U>. Each of the following events will be considered a &#147;<B><I>Deemed Liquidation
Event</I></B>&#148; unless the holders of at least 65% of the then outstanding shares of Preferred Stock (voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) (the &#147;<B><I>Requisite
Holders</I></B>&#148;) elect otherwise by written notice sent to the Corporation at least five days prior to the effective date of any such event: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;a merger or consolidation (each a &#147;<B><I>Combination</I></B>&#148;) in which (i)&nbsp;the
Corporation is a constituent party or (ii)&nbsp;a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such Combination, except any such Combination involving the Corporation or a
subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such Combination continue to represent, or are converted into or exchanged for equity securities that represent, immediately following such
Combination, a majority, by voting power, of the equity securities of (1)&nbsp;the surviving or resulting party or (2)&nbsp;if the surviving or resulting party is a wholly owned subsidiary of another party immediately following such Combination, the
parent of such surviving or resulting party; <I><U>provided</U></I> that, for the purpose of this <U>Section</U><U></U><U>&nbsp;2.3.1</U>, all shares of Common Stock issuable upon exercise of Options (as defined in
<U>Section</U><U></U><U>&nbsp;5.1</U> below) outstanding immediately prior to such Combination or upon conversion of Convertible Securities (as defined in <U>Section</U><U></U><U>&nbsp;5.1</U> below) outstanding immediately prior to such Combination
will be deemed to be outstanding immediately prior to such Combination and, if applicable, deemed to be converted or exchanged in such Combination on the same terms as the actual outstanding shares of Common Stock are converted or exchanged; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the sale, lease, transfer, exclusive license or other disposition, in a single transaction or
series of related transactions, by the Corporation or any subsidiary or subsidiaries of the Corporation, of all or substantially all the assets of the Corporation and its subsidiaries taken as a whole, (or, if substantially all of the assets of the
Corporation and its subsidiaries taken as a whole are held by one or more subsidiaries, the sale or disposition (whether by consolidation, merger, conversion or otherwise) of such subsidiaries of the Corporation), except where such sale, lease,
transfer, exclusive license or other disposition is made to the Corporation or one or more wholly owned subsidiaries of the Corporation (an &#147;<B><I>Asset Disposition</I></B>&#148;). For the avoidance of doubt, the grant by the Corporation of any
number of exclusive licenses will only be considered a Deemed Liquidation Event for purposes of this paragraph if such licenses, individually or in the aggregate, constitute a license of all or substantially all of the assets of the Corporation.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 4 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Effecting a Deemed Liquidation Event</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Corporation will not have the power to effect a Deemed Liquidation Event referred to in <U>Subsection
2.3.1(a)(i)</U> unless the agreement or plan or merger or consolidation for such transaction provides that the consideration payable to the stockholders of the Corporation in such Deemed Liquidation Event will be paid to the holders of capital stock
of the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;In the event of a Deemed
Liquidation Event referred to in <U>Subsection 2.3.1(a)(ii)</U> or <U>2.3.1(b)</U>, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within 90 days after such Deemed Liquidation Event, then
(i)&nbsp;the Corporation will send a written notice to each holder of Preferred Stock no later than the 90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the Deemed Liquidation Event advising such holders of their right (and the
requirements to be met to secure such right) pursuant to the terms of the following clause (ii)&nbsp;to require the redemption of such shares of Preferred Stock, and (ii)&nbsp;if the Requisite Holders so request in a written instrument delivered to
the Corporation not later than 120 days after such Deemed Liquidation Event, the Corporation will use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or
technology licensed, as determined in good faith by the Board),<B> </B>together with any other assets of the Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to
stockholders (the &#147;<B><I>Available</I></B><B><I> Proceeds</I></B>&#148;), on the 150<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after such Deemed Liquidation Event, to redeem all outstanding shares of Preferred Stock at a price
per share equal to the applicable Preferred Liquidation Amount with respect to each such share. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem
all outstanding shares of Preferred Stock, the Corporation will redeem each holder&#146;s shares of Preferred Stock in accordance with the liquidation preferences set forth in <U>Subsections 2.1</U> through <U>2.2</U> to the fullest extent of such
Available Proceeds, and will redeem the remaining shares in accordance with the liquidation preferences set forth in <U>Subsections 2.1</U> through <U>2.2</U> as soon as it may lawfully do so under Delaware law governing distributions to
stockholders. Prior to the distribution or redemption provided for in this <U>Subsection 2.3.2(b)</U>, the Corporation will not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred
in connection with such Deemed Liquidation Event or in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Following an election
by the holders of Preferred Stock to demand redemption as provided in <U>Subsection 2.3.2(b)</U>, the Corporation will promptly send written notice of the redemption pursuant to <U>Section</U><U></U><U>&nbsp;2.3.2(b)</U> (the &#147;<B><I>Redemption
Notice</I></B>&#148;) to each holder of record of Preferred Stock stating (i)&nbsp;the number of shares of each series of Preferred Stock held by such holder as of the date of such election; (ii)&nbsp;the date of redemption (the
&#147;<B><I>Redemption Date</I></B>&#148;) and the price at which shares of each series of Preferred Stock will be redeemed (the &#147;<B><I>Redemption Price</I></B>&#148;); (iii) the date on which the holder&#146;s right to convert such shares
terminates (as determined in accordance with <U>Section</U><U></U><U>&nbsp;4.1)</U>; and (iv)&nbsp;for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner and at the place designated, his, her or
its certificate or certificates representing the shares of Preferred Stock to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;On or before the
Redemption Date, each holder of shares of Preferred Stock, unless such holder has exercised his, her or its right to convert such shares as provided in <U>Section</U><U></U><U>&nbsp;4</U>, will, if a holder of shares in certificated form, surrender
the certificate or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 5 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certificates representing such shares (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably
acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place
designated in the Redemption Notice, and thereupon the Redemption Price for such shares will be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;If the Redemption Notice will have been duly given, and if on the Redemption Date the Redemption Price payable
upon redemption of the shares of Preferred Stock is paid or tendered for payment or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that any certificates evidencing any of the
shares of Preferred Stock so called for redemption will not have been surrendered, dividends with respect to such shares of Preferred Stock will cease to accrue after the Redemption Date and all rights with respect to such shares will forthwith
after the Redemption Date terminate, except only the right of the holders to receive the Redemption Price without interest upon surrender of any such certificate or certificates therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event and unless
the Requisite Holders elect otherwise by written notice sent to the Corporation at least five days prior to the effective date of any such event, if any portion of the consideration payable by the acquirer is placed into escrow or is payable only
upon satisfaction of contingencies, the definitive agreement or escrow agreement entered into in such Deemed Liquidation Event will provide that (a)&nbsp;the portion of such consideration that is payable at the closing of such transaction will be
allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2</U> as if such consideration were the only consideration payable in connection with such Deemed Liquidation Event, and (b)&nbsp;any
additional consideration which becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies or upon release from escrow will be allocated among the holders of capital stock of the Corporation in accordance with
<U>Subsections 2.1</U> and <U>2.2</U> after taking into account the previous payment of the initial consideration as part of the same transaction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.3.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Amount Deemed Paid or Distributed</U>. The funds and assets deemed paid or distributed to the holders of
capital stock of the Corporation upon any such Combination or Asset Disposition will be the cash or the value of the property, rights or securities paid or distributed to such holders by the Corporation or the acquiring person, firm or other entity.
If the amount deemed paid or distributed under this <U>Section</U><U></U><U>&nbsp;2.3.4</U> is made in property other than in cash, the value of such distribution will be the fair market value of such property, as determined in good faith by the
Board; <I><U>provided</U></I>, <I><U>however</U></I>, that the following will apply: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;For
securities not subject to investment letters or other similar restrictions on free marketability: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;if traded on a securities exchange, the value will be deemed to be the average of the closing
prices of the securities on such exchange over the <FONT STYLE="white-space:nowrap">30-day</FONT> period ending three days prior to the closing of such transaction; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 6 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;if actively traded <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter,</FONT></FONT> the value will be deemed to be the average of the closing bid prices over the <FONT STYLE="white-space:nowrap">30-day</FONT> period ending three days prior
to the closing of such transaction; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;if there is no active public market, the value will
be the fair market value thereof, as determined in good faith by the Board, including at least one of the Preferred Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The method of valuation of securities subject to investment letters or other similar restrictions
on free marketability (other than restrictions arising solely by virtue of a stockholder&#146;s status as an affiliate or former affiliate) will take into account an appropriate discount (as determined in good faith by the Board) from the market
value as determined pursuant to clause (a)&nbsp;above so as to reflect the approximate fair market value thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing methods for valuing <FONT
STYLE="white-space:nowrap">non-cash</FONT> consideration to be distributed in connection with a Combination or Asset Disposition will, with the appropriate approval of the definitive agreements governing such Combination or Asset Disposition by the
stockholders under the General Corporation Law and <U>Section</U><U></U><U>&nbsp;3.3</U>, be superseded by the determination of such value set forth in the definitive agreements governing such Combination or Asset Disposition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Voting</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at
any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of Preferred Stock will be entitled to cast the number of votes equal to the number of whole shares of
Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Fractional votes will not be permitted and any fractional voting rights
available on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis (after aggregating all shares into which shares of Preferred Stock held by each holder could be converted) will be rounded to the nearest whole number (with <FONT
STYLE="white-space:nowrap">one-half</FONT> being rounded upward). Except as provided by law or by the other provisions of this Certificate, holders of Preferred Stock will vote together with the holders of Common Stock as a single class on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis, will have full voting rights and powers equal to the voting rights and powers of the holders of Common Stock, and will be entitled, notwithstanding any provision hereof, to notice of any
stockholders&#146; meeting in accordance with the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Election of Directors</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Election</U>. For so long as at least 276,059 shares of Series A Preferred Stock remain outstanding (as
such number is adjusted for stock splits and combinations of shares and for dividends paid on the Series A Preferred Stock in shares of such stock) (the &#147;<B><I>Series A Threshold</I></B>&#148;), the holders of record of the shares of Series A
Preferred Stock, exclusively and as a separate class, will be entitled to elect two directors of the Corporation (the &#147;<B><I>Series A</I></B> <B><I>Directors</I></B>&#148;); provided that if the Series A Threshold is not met, for so long as
least 110,423 shares of Series A Preferred Stock remains outstanding, but no more than 276,058 shares of Series A Preferred Stock remain outstanding (as each such number is adjusted for stock splits and combinations of shares
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 7 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and for dividends paid on the Series A Preferred Stock in shares of such stock), the holders of record of the shares of Series A Preferred Stock, exclusively and as a separate class, will be
entitled to elect one Series A Director. For so long as at least 329,991 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock remain outstanding (as such number is adjusted for stock splits and combinations of shares and for
dividends paid on the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock in shares of such stock), the holders of record of the shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, exclusively and as a
separate class, will be entitled to elect two directors of the Corporation (the &#147;<B><I>Series <FONT STYLE="white-space:nowrap">B-1</FONT></I></B> <B><I>Directors</I></B>&#148; and collectively with the Series A Directors, the
&#147;<B><I>Preferred Directors</I></B>&#148;); <I><U>provided</U></I>, that one of such Series <FONT STYLE="white-space:nowrap">B-1</FONT> Directors shall be an industry expert. The holders of record of the shares of Common Stock, exclusively and
as a separate class, will be entitled to elect three directors of the Corporation (the &#147;<B><I>Common Directors</I></B>&#148;). The holders of record of the shares of Common Stock and of every other class or series of voting stock (including the
Preferred Stock), voting together as a single class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, will be entitled to elect the remaining number of directors of the Corporation (the &#147;<B><I>Remaining Directors</I></B>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Vacancies</U>. Any director elected as provided in the preceding sentences may be removed with or
without cause by, and any vacancy in the office of any such removed director may be filled by, and only by, the affirmative vote of the holders of the shares of the class, classes or series that are entitled to elect such director to office under
the provisions of <U>Section</U><U></U><U>&nbsp;3.2</U> (the &#147;<B><I>Specified Stock</I></B>&#148;), given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders, or by any
remaining director or directors elected by the holders of such class or series pursuant to this <U>Section</U><U></U><U>&nbsp;3.2</U>. Notwithstanding the foregoing, the initial Series <FONT STYLE="white-space:nowrap">B-1</FONT> Directors may be
appointed by a majority of the members of the Board then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Procedure</U>. At any meeting held
for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the Specified Stock entitled to elect such director will constitute a quorum for the purpose of electing such
director and the candidate or candidates to be elected by such Specified Stock will be those who receive the highest number of affirmative votes (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) of the outstanding shares of such
Specified Stock. In the case of an action taken by written consent without a meeting, the candidate or candidates to be elected by such Specified Stock will be those who are elected by the written consent of the holders of a majority of such
Specified Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Preferred Stock Protective Provisions</U>. For so long as at least 1,408,302 shares of
Preferred Stock remain outstanding (as such number is adjusted for stock splits and combinations of shares and for dividends paid on the Preferred Stock in shares of such stock), the Corporation will not, either directly or indirectly by amendment,
merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or this Certificate) the written consent, or affirmative vote at a meeting and evidenced in writing, of the Requisite Holders: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;alter or change the rights, powers or preferences of the Preferred Stock set forth in this
Certificate or the bylaws of the Corporation, as then in effect, in a way that adversely affects the Preferred Stock; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;increase or decrease the authorized number of shares of Preferred Stock; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 8 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;authorize or create (by reclassification or
otherwise) any new class or series of capital stock having rights, powers or preferences set forth in this Certificate, as then in effect, that are senior to or on a parity with any series of Preferred Stock or authorize or create (by
reclassification or otherwise) any security convertible into or exercisable for any such new class or series of capital stock; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;(i) reclassify, alter or amend any existing security of the Corporation that is pari passu with any
series of Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render
such other security senior to any series of Preferred Stock in respect of any such right, preference, or privilege or (ii)&nbsp;reclassify, alter or amend any existing security of the Corporation that is junior to any series of Preferred Stock in
respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to or
pari passu with such series of Preferred Stock in respect of any such right, preference or privilege; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;redeem or repurchase any shares of Common Stock or Preferred Stock, other than (i)&nbsp;pursuant to
an agreement with an employee, consultant, director or other service provider to the Corporation or any of its wholly owned subsidiaries (collectively, &#147;<B><I>Service Providers</I></B>&#148;) giving the Corporation the right to repurchase
shares at the original cost thereof upon the termination of services, (ii)&nbsp;an exercise of a right of first refusal in favor of the Corporation pursuant to an agreement with any Service Provider, which exercise has been approved by the Board or
(iii)&nbsp;as approved by the Board; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;declare or pay any dividend or otherwise make a
distribution to holders of Preferred Stock or Common Stock, other than a dividend on the Common Stock payable in shares of Common Stock; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;increase the number of shares of Common Stock or Preferred Stock subject to issuance under any
stock plan or arrangement for the benefit of Service Providers unless such increase is approved by the Board; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;liquidate, dissolve or <FONT STYLE="white-space:nowrap">wind-up</FONT> the business and affairs of
the Corporation, effect any merger or consolidation or any other Deemed Liquidation Event, or consent, agree or commit to any of the foregoing without conditioning such consent, agreement or commitment upon obtaining the approval required by this
<U>Section</U><U></U><U>&nbsp;3.3</U>; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;amend this <U>Section</U><U></U><U>&nbsp;3.3</U>.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 9 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Series A Preferred Stock Protective Provisions</U>. For so
long as any shares of Series A Preferred Stock remain outstanding (as such number is adjusted for stock splits and combinations of shares and for dividends paid on the Series A Preferred Stock in shares of such stock), the Corporation will not,
either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or this Certificate) the written consent, or affirmative vote at a meeting and evidenced
in writing, of the holders of a majority of the then outstanding shares of Series A Preferred Stock, consenting or voting as a separate class: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;amend, alter, repeal or waive any provision in this Certificate or the bylaws of the Corporation in a manner
adverse to the Series A Preferred Stock (which, for the avoidance of doubt, shall not include the designation of a new series of Preferred Stock that is senior to the Series A Preferred Stock); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;increase or decrease the authorized number of shares of Series A Preferred Stock; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;amend this <U>Section</U><U></U><U>&nbsp;3.4</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Series B Preferred Stock Protective Provisions</U>. For so long as any shares of Series B Preferred Stock remain
outstanding (as such number is adjusted for stock splits and combinations of shares and for dividends paid on the Series B Preferred Stock in shares of such stock), the Corporation will not, either directly or indirectly by amendment, merger,
consolidation or otherwise, do any of the following without (in addition to any other vote required by law or this Certificate) the written consent, or affirmative vote at a meeting and evidenced in writing, of the holders of a majority of the then
outstanding shares of Series B Preferred Stock, consenting or voting as a separate class: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;amend, alter, repeal or waive any provision in this Certificate or the bylaws of the Corporation in
a manner adverse to the Series B Preferred Stock (which, for the avoidance of doubt, shall not include the designation of a new series of Preferred Stock that is senior to the Series B Preferred Stock); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;increase or decrease the authorized number of shares of Series B Preferred Stock; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;amend this <U>Section</U><U></U><U>&nbsp;3.5</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock Protective Provisions</U>. For so long as any
shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock remain outstanding (as such number is adjusted for stock splits and combinations of shares and for dividends paid on the Series <FONT STYLE="white-space:nowrap">B-1</FONT>
Preferred Stock in shares of such stock), the Corporation will not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or this Certificate)
the written consent, or affirmative vote at a meeting and evidenced in writing, of the holders of a majority of the then outstanding shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, consenting or voting as a separate
class: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;amend, alter, repeal or waive any provision in this Certificate or the bylaws of the
Corporation in a manner adverse to the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock (which, for the avoidance of doubt, shall not include the designation of a new series of Preferred Stock that is senior to the Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;increase or decrease the authorized
number of shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 10 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;create, or authorize the creation of, or issue,
or authorize the issuance of any debt security or create any lien or security interest (except for purchase money liens or statutory liens of landlords, mechanics, materialmen, workmen, warehousemen and other similar persons arising or incurred in
the ordinary course of business) or incur other indebtedness for borrowed money, including but not limited to obligations and contingent obligations under guarantees, or permit any subsidiary to take any such action with respect to any debt security
lien, security interest or other indebtedness for borrowed money, if the aggregate indebtedness of the Corporation and its subsidiaries for borrowed money following such action would exceed $5,000,000 other than purchase-money loans or equipment
leases incurred in the ordinary course; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;amend this <U>Section</U><U></U><U>&nbsp;3.6</U>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Conversion Rights</U></B><B>.</B> The holders of the Preferred Stock will have conversion rights
as follows (the &#147;<B><I>Conversion Rights</I></B>&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Right to Convert</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion Ratio</U>. Each share of a series of Preferred Stock will be convertible, at the option of the
holder thereof, at any time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and nonassessable shares of Common Stock as is determined by dividing the Original Issue Price for such series of
Preferred Stock by the Conversion Price (as defined below) for such series of Preferred Stock in effect at the time of conversion. The &#147;<B><I>Conversion </I></B><B><I>Price</I></B>&#148; for each series of Preferred Stock will initially mean
the Original Issue Price for such series of Preferred Stock. Such initial Conversion Price, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, will be subject to adjustment as provided in
<U>Section</U><U></U><U>&nbsp;5</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination of Conversion Rights</U>. In the event of a
liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the Conversion Rights will terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on
such event of the holders of Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Conversion</U>. In order for a holder of
Preferred Stock to voluntarily convert shares of Preferred Stock into shares of Common Stock, such holder will surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that any such
certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged
loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent), together with written notice that such
holder elects to convert all or any number of the shares of the Preferred Stock represented by such certificate or certificates and, if applicable, any event on which such conversion is contingent (a &#147;<B><I>Contingency Event</I></B>&#148;).
Such notice will state such holder&#146;s name or the names of the nominees in which such holder wishes the certificate or certificates for shares of Common Stock to be issued. If required by the Corporation, certificates surrendered for conversion
will be endorsed or accompanied by a written instrument or instruments of transfer, in form reasonably satisfactory to the Corporation, duly executed by the registered holder or such holder&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 11 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such
certificates (or lost certificate affidavit and agreement) and notice (or, if later, the date on which all Contingency Events have occurred) will be the time of conversion (the &#147;<B><I>Conversion Time</I></B>&#148;), and the shares of Common
Stock issuable upon conversion of the shares represented by such certificate will be deemed to be outstanding of record as of such time. The Corporation will, as soon as practicable after the Conversion Time, (a)&nbsp;issue and deliver to such
holder of Preferred Stock, or to such holder&#146;s nominee(s), a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if
any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (b)&nbsp;pay in cash such amount as provided in <U>Section</U><U></U><U>&nbsp;5.7.3</U> in lieu of any fraction of a share of
Common Stock otherwise issuable upon such conversion and (c)&nbsp;pay all declared but unpaid dividends on the shares of Preferred Stock converted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Effect of Voluntary Conversion</U>. All shares of Preferred Stock that will have been surrendered for
conversion as herein provided will no longer be deemed to be outstanding and all rights with respect to such shares will immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common
Stock in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in <U>Section</U><U></U><U>&nbsp;5.7.3</U> and to receive payment of any dividends declared but unpaid thereon. Any
shares of Preferred Stock so converted will be retired and cancelled and may not be reissued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Mandatory
Conversion</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Automatic Conversion</U>. Upon either (a)&nbsp;the closing of the sale of shares of
Common Stock to the public in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended (the &#147;<B><I>Securities Act</I></B>&#148;), resulting in at least
$50,000,000 of gross proceeds to the Corporation at a price per share to the public of at least $62.88051 (as adjusted for stock splits, stock dividends, recapitalizations or the like) (a &#147;<B><I>Qualified IPO</I></B>&#148;) or (b)&nbsp;the date
and time, or the occurrence of an event, specified by vote or written consent of the Requisite Holders (the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to herein
as the &#147;<B><I>Mandatory Conversion Time</I></B>&#148;), (i) all outstanding shares of Preferred Stock will automatically be converted into shares of Common Stock, at the applicable ratio described in <U>Section</U><U></U><U>&nbsp;4.1.1</U> as
the same may be adjusted from time to time in accordance with <U>Section</U><U></U><U>&nbsp;5</U> and (ii)&nbsp;such shares may not be reissued by the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.2.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Mandatory Conversion Procedural Requirements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;All holders of record of shares of Preferred Stock will be sent written notice of the Mandatory Conversion Time
and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to <U>Sections 4.2.1</U> and <U>9</U>. Unless otherwise provided in this Certificate, such notice need not be sent in advance of the occurrence of the
Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock will surrender such holder&#146;s certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost,
stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 12 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice, and will thereafter receive
certificates for the number of shares of Common Stock to which such holder is entitled pursuant to this <U>Section</U><U></U><U>&nbsp;4.2</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If so required by the Corporation, certificates surrendered for conversion will be endorsed or accompanied by
written instrument or instruments of transfer, in form reasonably satisfactory to the Corporation, duly executed by the registered holder or by such holder&#146;s attorney duly authorized in writing. All rights with respect to the Preferred Stock
converted pursuant to this <U>Section</U><U></U><U>&nbsp;4.2</U>, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the
holder or holders thereof to surrender the certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of their certificate or certificates (or lost certificate affidavit and agreement) therefor, to receive
the items provided for in the next sentence of this <U>Section</U><U></U><U>&nbsp;4.2.2(b)</U>. As soon as practicable after the Mandatory Conversion Time and the surrender of the certificate or certificates (or lost certificate affidavit and
agreement) for Preferred Stock, the Corporation will issue and deliver to such holder, or to such holder&#146;s nominee(s), a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with
the provisions hereof, together with cash as provided in <U>Section</U><U></U><U>&nbsp;5.7.3</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the
shares of Preferred Stock converted. Such converted Preferred Stock will be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder
action) as may be necessary to reduce the authorized number of shares of Preferred Stock (and the applicable series thereof) accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments to Conversion Price</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments for Diluting Issuances</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Special Definitions</U>. For purposes of this Article IV, the following definitions will apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Option</I></B>&#148; will mean any right, option or warrant to subscribe for, purchase
or otherwise acquire Common Stock or Convertible Securities from the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Original Issue Date</I></B>&#148; will mean the date on which the first share of Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock was issued. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Convertible Securities</I></B>&#148; will mean any evidences of indebtedness, shares or
other securities issued by the Corporation that are directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 13 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;&#147;<B><I>Additional Shares of Common
Stock</I></B>&#148; with respect to a series of Preferred Stock will mean all shares of Common Stock issued (or, pursuant to <U>Section</U><U></U><U>&nbsp;5.1.2</U> below, deemed to be issued) by the Corporation after the Original Issue Date, other
than the following shares of Common Stock and shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (collectively as to all such shares and shares deemed issued, &#147;<B><I>Exempted
Securities</I></B>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;shares of Common Stock, Options or Convertible Securities issued
(x)&nbsp;upon conversion of such series of Preferred Stock or (y)&nbsp;as a dividend or distribution on such series of Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock
split, <FONT STYLE="white-space:nowrap">split-up</FONT> or other distribution on or subdivision of shares of Common Stock that is covered by <U>Section</U><U></U><U>&nbsp;5.2</U>, <U>5.3</U>, <U>5.4</U>, <U>5.5</U> or <U>5.6</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;shares of Common Stock or Options to acquire shares of Common Stock, including but not limited to
stock appreciation rights payable in shares of Common Stock or in Options or Convertible Securities, issued to Service Providers pursuant to a plan, agreement or arrangement approved by the Board; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;shares of Common Stock or Convertible Securities actually issued upon the exercise of Options, or
shares of Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case <I><U>provided</U></I> that such issuance is pursuant to the terms of such Option or Convertible Security; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or
other financial institutions pursuant to a debt financing or equipment leasing transaction approved by the Board; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;shares of Common Stock, Options or Convertible Securities issued pursuant to a bona fide
acquisition of another entity by the Corporation by merger or consolidation with, purchase of substantially all of the assets of, or purchase of more than fifty percent of the outstanding equity securities of, the other entity, or issued pursuant to
a bona fide joint venture agreement, <I><U>provided</U></I> that such issuances are approved by the Board; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;shares of Common Stock, Options or Convertible Securities issued in connection with sponsored
research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;shares of Common Stock, Options or Convertible Securities issued as a result of a decrease in
the Conversion Price of any series of Preferred Stock resulting from the operation of <U>Section</U><U></U><U>&nbsp;5.1.3</U>; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;shares issued in connection with a Qualified IPO; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;shares of Common Stock, Options or Convertible Securities issued in accordance with
<U>Section</U><U></U><U>&nbsp;5.1.1A</U> below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 14- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1.1A <U>No Adjustment of Conversion Price</U>. Subject to the remainder of this
<U>Section</U><U></U><U>&nbsp;5.1.1A</U>, no adjustment in the Conversion Price for a particular series of Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation
receives written notice from (i)&nbsp;the holders of at least a majority of the then outstanding shares of Series A Preferred Stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis agreeing that no adjustment will be made to the
Conversion Price of Series A Preferred Stock as a result of the issuance or deemed issuance (the &#147;<B><I>Series A Approval</I></B>&#148;); <I><U>provided</U></I>, that no Series A Approval shall be required if such issuance or deemed issuance
would not result in an adjustment in the Conversion Price of the Series A Preferred Stock (ii)&nbsp;the holders of at least a majority of the then outstanding shares of Series B Preferred Stock on an
<FONT STYLE="white-space:nowrap">as-converted</FONT> basis agreeing that no adjustment will be made to the Conversion Price of the Series B Preferred Stock as a result of the issuance or deemed issuance (the &#147;<B><I>Series B
Approval</I></B>&#148;); <I><U>provided</U></I>, that no Series B Approval shall be required if such issuance or deemed issuance would not result in an adjustment in the Conversion Price of the Series B Preferred Stock, and (iii)&nbsp;the holders of
at least 65% of the then outstanding shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis agreeing that no adjustment will be made to the Conversion Price of
the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock as a result of the issuance or deemed issuance (the &#147;<B><I>Series <FONT STYLE="white-space:nowrap">B-1</FONT> Approval</I></B>&#148; and together with the Series A Approval
and the Series B Approval, the &#147;<B><I>Series Approvals</I></B>&#148;); <I><U>provided</U></I>, that no Series <FONT STYLE="white-space:nowrap">B-1</FONT> Approval shall be required if such issuance or deemed issuance would not result in an
adjustment in the Conversion Price of the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock. Notwithstanding the foregoing, if the issuance or deemed issuance of Common Stock would result in an adjustment of the Conversion Price for
each and every series of Preferred Stock then outstanding, then in lieu and in substitution of the Series Approvals, no adjustment in the Conversion Price for any and all series of Preferred Stock shall be made as the result of the issuance or
deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Requisite Holders agreeing that no adjustment will be made to the Conversion Price for any and all series of Preferred Stock as a result of the
issuance or deemed issuance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Deemed Issue of Additional Shares of Common Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If the Corporation at any time or from time to time after the Original Issue Date will issue any Options or
Convertible Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or will fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible
Securities, then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability (including the passage of time) but
without regard to any provision contained therein for a subsequent adjustment of such number including by way of anti-dilution adjustment) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the
conversion or exchange of such Convertible Securities, will be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date will have been fixed, as of the close of business on such record date.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the
Conversion Price of a series of Preferred Stock pursuant to the terms of <U>Section</U><U></U><U>&nbsp;5.1.3</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible
Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (i)&nbsp;any increase or decrease in the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 15 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (ii)&nbsp;any increase or decrease in the consideration
payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the Conversion Price of such series of Preferred Stock computed upon the original issue of such Option or
Convertible Security (or upon the occurrence of a record date with respect thereto) will be readjusted to such Conversion Price of such series of Preferred Stock as would have obtained had such revised terms been in effect upon the original date of
issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this <U>Section</U><U></U><U>&nbsp;5.1.2(b)</U> will have the effect of increasing the Conversion Price of a series of Preferred Stock to an
amount which exceeds the lower of (1)&nbsp;the Conversion Price for such series of Preferred Stock in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (2)&nbsp;the
Conversion Price for such series of Preferred Stock that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or
Convertible Security) between the original adjustment date and such readjustment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If the terms of any
Option or Convertible Security (excluding Options or Convertible Securities that are themselves Exempted Securities), the issuance of which did not result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms
of <U>Section</U><U></U><U>&nbsp;5.1.3</U> (either because the consideration per share (determined pursuant to <U>Section</U><U></U><U>&nbsp;5.1.4</U>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the
Conversion Price of such series of Preferred Stock then in effect, or because such Option or Convertible Security was issued before the Original Issue Date), are revised after the Original Issue Date as a result of an amendment to such terms or any
other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either
(i)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (ii)&nbsp;any decrease in the consideration payable to the Corporation upon such exercise,
conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in <U>Section</U><U></U><U>&nbsp;5.1.2(a)</U>) will be deemed
to have been issued effective upon such increase or decrease becoming effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Upon the expiration or
termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) that resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Conversion Price of a series of
Preferred Stock pursuant to the terms of <U>Section</U><U></U><U>&nbsp;5.1.3</U>, the Conversion Price of such series of Preferred Stock will be readjusted to such Conversion Price of such series of Preferred Stock as would have obtained had such
Option or Convertible Security (or portion thereof) never been issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;If the number of shares of Common
Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible
Security is issued or amended but is subject to adjustment based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 16 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon subsequent events, any adjustment to the Conversion Price of a series of Preferred Stock provided for in this <U>Section</U><U></U><U>&nbsp;5.1.2</U> will be effected at the time of such
issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments will be treated as provided in <U>Sections 5.1.2(b)</U> and <U>5.1.2(c)</U>).
If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be
calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to such Conversion Price that would result under the terms of this <U>Section</U><U></U><U>&nbsp;5.1.2</U> at the time of such issuance or
amendment will instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to such Conversion Price that
such issuance or amendment took place at the time such calculation can first be made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment of
Conversion Price </U><U>Upon</U><U> Issuance of Additional Shares of Common Stock</U>. In the event the Corporation will at any time or from time to time after the Original Issue Date issue Additional Shares of Common Stock (including Additional
Shares of Common Stock deemed to be issued pursuant to <U>Section</U><U></U><U>&nbsp;5.1.2</U>), without consideration or for a consideration per share less than the Conversion Price for such series of Preferred Stock in effect immediately prior to
such issue, then such Conversion Price will be reduced, concurrently with such issue, to the consideration per share received by the Corporation for such issue of Additional Shares of Common Stock (including Additional Shares of Common Stock deemed
to be issued pursuant to <U>Section</U><U></U><U>&nbsp;5.1.2</U>); <I><U>provided</U></I><I> </I>that if such issue was without consideration, then the Corporation shall be deemed to have received an aggregate of $0.001 of consideration for all such
Additional Shares of Common Stock issued or deemed to be issued (including Additional Shares of Common Stock deemed to be issued pursuant to <U>Section</U><U></U><U>&nbsp;5.1.2</U>); <I><U>provided</U></I>, <I><U>however</U></I>, that no such
adjustment shall be made with respect to any shares of Preferred Stock held by a given holder upon a Financing if (i)&nbsp;the Corporation has given such holder the opportunity to participate in such Financing, and (ii)&nbsp;such holder fails to
purchase at least the lower of (x)&nbsp;such holder&#146;s Pro Rata Amount of the Offered Securities or (y) $5,000,000 of the Offered Securities. For the purposes of this <U>Section</U><U></U><U>&nbsp;5.1</U>.3: &#147;<B><I>Financing</I></B>&#148;
will mean any transaction involving the issue or sale of Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <U>Section</U><U></U><U>&nbsp;5.1.2</U>) after the Original Issue Date that would
trigger an adjustment to any Conversion Price pursuant to the terms of this Certificate, which adjustment has not been waived pursuant to <U>Section</U><U></U><U>&nbsp;5.1.1(d)(ix)</U>; &#147;<B><I>Pro Rata Amount</I></B>&#148; will mean the number
of Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <U>Section</U><U></U><U>&nbsp;5.1.2</U>) calculated by multiplying the aggregate number of Offered Securities by a fraction, the
numerator of which is equal to the number of shares of Preferred Stock owned by such holder (determined on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis), and the denominator of which is equal to the aggregate number
of outstanding shares of Preferred Stock (determined on an <FONT STYLE="white-space:nowrap">as-converted</FONT> to Common Stock basis), in each case as of immediately prior to the initial closing of the Financing; and &#147;<B><I>Offered
Securities</I></B>&#148; will mean the total Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <U>Section</U><U></U><U>&nbsp;5.1.2</U>) available for purchase by all investors in the
Financing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 17- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Determination of Consideration</U>. For purposes of this
<U>Section</U><U></U><U>&nbsp;5.1</U>, the consideration received by the Corporation for the issue or deemed issue of any Additional Shares of Common Stock will be computed as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cash and Property</U>: Such consideration will: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;insofar as it consists of cash, be computed at the aggregate amount of cash received by the
Corporation, excluding amounts paid or payable for accrued interest; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;insofar as it consists
of property other than cash, be computed at the fair market value thereof at the time of such issue, as determined in good faith by the Board; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;in the event Additional Shares of Common Stock are issued together with other shares or
securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (i)&nbsp;and (ii) above, as determined in good faith by the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Options and Convertible Securities</U>. The consideration per share received by the Corporation for Additional
Shares of Common Stock deemed to have been issued pursuant to <U>Section</U><U></U><U>&nbsp;5.1.2</U>, relating to Options and Convertible Securities, will be determined by dividing: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;the total amount, if any, received or receivable by the Corporation as consideration for the issue
of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such
consideration) payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities
and the conversion or exchange of such Convertible Securities, by </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:18%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the maximum number of
shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such
Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Multiple Closing Dates</U>. In the event the Corporation will issue on more than one date Additional Shares
of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to <U>Section</U><U></U><U>&nbsp;5.1.2</U>) that are a part of one transaction or a series of related transactions and that would result in an adjustment to
the Conversion Price of a series of Preferred Stock pursuant to the terms of <U>Section</U><U></U><U>&nbsp;5.1.2</U> and such issuance dates occur within a period of no more than 120 days after the first such issuance to the final such issuance,
then, upon the final such issuance, the Conversion Price of such series of Preferred Stock will be readjusted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 18- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent
issuances within such period that are a part of such transaction or series of related transactions). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment for Stock Splits and Combinations</U>. If the Corporation will at any time or from time to time
after the Original Issue Date effect a subdivision of the outstanding Common Stock, the Conversion Price for such series of Preferred Stock in effect immediately before that subdivision will be proportionately decreased so that the number of shares
of Common Stock issuable on conversion of each share of such series will be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation will at any time or from time to time after the
Original Issue Date combine the outstanding shares of Common Stock, the Conversion Price for such series of Preferred Stock in effect immediately before the combination will be proportionately increased so that the number of shares of Common Stock
issuable on conversion of each share of such series will be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this <U>Section</U><U></U><U>&nbsp;5.2</U> will become effective
at the close of business on the date the subdivision or combination becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment for
Certain Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the Original Issue Date will make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a
dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the Conversion Price for such series of Preferred Stock in effect immediately before such event will be decreased as of the
time of such issuance or, in the event such a record date will have been fixed, as of the close of business on such record date, by multiplying such Conversion Price then in effect by a fraction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the numerator of which will be the total number of shares of Common Stock issued and outstanding
immediately prior to the time of such issuance or the close of business on such record date, and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;the denominator of which will be the total number of shares of Common Stock issued and outstanding
immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, (i)&nbsp;if such record date will have been fixed and such dividend is not fully paid or if such distribution is not fully made
on the date fixed therefor, such Conversion Price will be recomputed accordingly as of the close of business on such record date and thereafter such Conversion Price will be adjusted pursuant to this <U>Section</U><U></U><U>&nbsp;5.3</U> as of the
time of actual payment of such dividends or distributions; and (ii)&nbsp;no such adjustment will be made if the holders of such series of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number
equal to the number of shares of Common Stock as they would have received if all outstanding shares of such series of Preferred Stock had been converted into Common Stock on the date of such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 19 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustments for Other Dividends and Distributions</U>. In the
event the Corporation at any time or from time to time after the Original Issue Date will make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in
securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock), then and in each such event the holders of such series of Preferred Stock will receive, simultaneously with the
distribution to the holders of Common Stock, a dividend or other distribution of such securities in an amount equal to the amount of such securities as they would have received if all outstanding shares of such series of Preferred Stock had been
converted into Common Stock on the date of such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment for Reclassification, Exchange and
Substitution</U>. If, at any time or from time to time after the Original Issue Date, the Common Stock issuable upon the conversion of such series of Preferred Stock is changed into the same or a different number of shares of any class or classes of
stock of the Corporation, whether by recapitalization, reclassification or otherwise (<U>other</U> <U>than</U> by a stock split or combination, dividend, distribution, merger or consolidation covered by <U>Sections </U><U>5.2</U>, <U>5.3</U>,
<U>5.4</U> or <U>5.6</U> or by <U>Section</U><U></U><U>&nbsp;2.3</U> regarding a Deemed Liquidation Event), then in any such event each holder of such series of Preferred Stock will have the right thereafter to convert such stock into the kind and
amount of stock and other securities and property receivable upon such recapitalization, reclassification or other change by holders of the number of shares of Common Stock into which such shares of Preferred Stock could have been converted
immediately prior to such recapitalization, reclassification or change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment for Merger or
Consolidation</U>. Subject to the provisions of <U>Section</U><U></U><U>&nbsp;2.3</U>, if there will occur any consolidation or merger involving the Corporation in which the Common Stock (but not a series of Preferred Stock) is converted into or
exchanged for securities, cash or other property (other than a transaction covered by <U>Sections 5.3</U>, <U>5.4</U> or <U>5.5</U>), then, following any such consolidation or merger, provision will be made that each share of such series of
Preferred Stock will thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the
Corporation issuable upon conversion of one share of such series of Preferred Stock immediately prior to such consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as
determined in good faith by the Board) will be made in the application of the provisions in <U>Section</U><U></U><U>&nbsp;4</U> and this <U>Section</U><U></U><U>&nbsp;5</U> with respect to the rights and interests thereafter of the holders of such
series of Preferred Stock, to the end that the provisions set forth in <U>Section</U><U></U><U>&nbsp;4</U> and this <U>Section</U><U></U><U>&nbsp;5</U> will thereafter be applicable, as nearly as reasonably may be, in relation to any securities or
other property thereafter deliverable upon the conversion of such series of Preferred Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Conversion Provisions</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.7.1&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or
readjustment of the Conversion Price of a series of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>, the Corporation at its expense will, as promptly as reasonably practicable but in any event not later than 15 days thereafter,
compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of such series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash
or other property into which such series of Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation will, as promptly as reasonably practicable after the written request at
any time of any holder of any series of Preferred Stock (but in any event not later than 10 days thereafter), furnish or cause to be furnished to such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 20 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
holder a certificate setting forth (a)&nbsp;the Conversion Price of such series of Preferred Stock then in effect and (b)&nbsp;the number of shares of Common Stock and the amount, if any, of
other securities, cash or property which then would be received upon the conversion of such series of Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.7.2&nbsp;&nbsp;&nbsp;&nbsp;<U>Reservation of Shares</U>. The Corporation will at all times while any share of Preferred Stock will be
outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as will from time to time be
sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock will not be sufficient to effect the conversion of all then outstanding shares of the Preferred
Stock, the Corporation will take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as will be sufficient for such purposes, including, without limitation, engaging in
best efforts to obtain the requisite stockholder approval of any necessary amendment to this Certificate. Before taking any action that would cause an adjustment reducing the Conversion Price of a series of Preferred Stock below the then par value
of the shares of Common Stock issuable upon conversion of such series of Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally
issue fully paid and nonassessable shares of Common Stock at such adjusted Conversion Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.7.3&nbsp;&nbsp;&nbsp;&nbsp;<U>Fractional
Shares</U>. No fractional shares of Common Stock will be issued upon conversion of the Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation will pay cash equal to such fraction multiplied
by the fair value of a share of Common Stock as determined in good faith by the Board. Whether or not fractional shares would be issuable upon such conversion will be determined on the basis of the total number of shares of Preferred Stock the
holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.7.4&nbsp;&nbsp;&nbsp;&nbsp;<U>No Further Adjustment after Conversion</U>. Upon any conversion of shares of Preferred Stock into Common
Stock, no adjustment to the Conversion Price of the applicable series of Preferred Stock will be made with respect to the converted shares for any declared but unpaid dividends on such series of Preferred Stock or on the Common Stock delivered upon
conversion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>No Reissuance of Redeemed or Otherwise Acquired Preferred Stock</U></B><B>.</B> Any
shares of Preferred Stock that are redeemed or otherwise acquired by the Corporation or any of its subsidiaries will be automatically and immediately retired and will not be reissued, sold or transferred. Neither the Corporation nor any of its
subsidiaries may exercise any voting or other rights, powers and preferences granted to the holders of Preferred Stock following the close of business on the third day preceding the Redemption Date for such shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Waiver</U></B><B>.</B> Except to the extent expressly provided herein, any of the rights, powers,
preferences and other terms of the Preferred Stock that are set forth herein may be waived on behalf of all holders of Preferred Stock by the affirmative written consent or vote of the Requisite Holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 21 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Notice of Record Date</U></B><B>.</B> In the event:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;the Corporation will set a record of the holders of its Common Stock (or other capital stock or
securities at the time issuable upon conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of
any class or any other securities, or to receive any other security; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;of any capital
reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation Event; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;of the voluntary or involuntary dissolution, liquidation or
<FONT STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, and in each such case, the Corporation will send or cause to be sent to the
holders of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or subscription right, and the amount and character of such dividend, distribution or subscription right, or
(ii)&nbsp;the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> is proposed to take place, and the time, if any is to be
fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) will be entitled to exchange their shares of Common Stock (or such other capital
stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> and the amount per share
and character of such exchange applicable to the Preferred Stock and the Common Stock. Such notice will be sent (A)&nbsp;at least 20 days prior to the earlier of the record date or effective date for the event specified in such notice or
(B)&nbsp;such fewer number of days as may be approved the Requisite Holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Notices</U></B><B>.</B> Except as otherwise provided herein, any notice required or permitted by the
provisions of this Article IV to be given to a holder of shares of Preferred Stock will be mailed, postage prepaid, to the post office address last shown on the records of the Corporation for such holder, given by the holder to the Corporation for
the purpose of notice or given by electronic communication in compliance with the provisions of the General Corporation Law, and will be deemed sent upon such mailing or electronic transmission. If no such address appears or is given, notice will be
deemed given at the place where the principal executive office of the Corporation is located. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ARTICLE V</U>: <U>PREEMPTIVE
RIGHTS</U>. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No stockholder of the Corporation will have a right to purchase shares of capital stock of the Corporation sold or issued
by the Corporation except to the extent that such a right may from time to time be set forth in a written agreement between the Corporation and any stockholder. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ARTICLE VI</U>: <U>BYLAW PROVISIONS</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>AMENDMENT OF BYLAWS.</B> Subject to any additional vote required by this Certificate or the Bylaws, in furtherance and not
in limitation of the powers conferred by statute, the Board is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 22 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>NUMBER OF DIRECTORS. </B>Subject to any additional vote required by this
Certificate, the number of directors of the Corporation will be determined in the manner set forth in the Bylaws of the Corporation. Each director shall be entitled to one vote on each matter presented to the Board of Directors;
<I><U>provided</U></I>, <I><U>however</U></I>, that, so long as the holders of Preferred Stock are entitled to elect any Preferred Directors, the affirmative vote of at least one of the Preferred Directors shall be required for the authorization by
the Board of Directors of any of the matters set forth in Section&nbsp;5.3 of the Second Amended and Restated Investors&#146; Rights Agreement, dated on or about the effective date of this Amended and Restated Certificate of Incorporation by and
among the Corporation and the other parties thereto, as such agreement may be amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>BALLOT.
</B>Elections of directors need not be by written ballot unless the Bylaws of the Corporation will so provide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>D.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>MEETINGS AND BOOKS.</B> Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the
Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board or in the Bylaws of the Corporation. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ARTICLE VII</U>: <U>DIRECTOR LIABILITY</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>LIMITATION.</B> To the fullest extent permitted by law, a director of the Corporation will not be personally liable to the
Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article VII to authorize
corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation will be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended. Any
repeal or modification of the foregoing provisions of this Article VII by the stockholders of the Corporation will not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of
any director of the Corporation with respect to any acts or omissions of such director occurring prior to, such repeal or modification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>INDEMNIFICATION. </B>To the fullest extent permitted by applicable law, the Corporation is authorized to provide
indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements
with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section&nbsp;145 of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>MODIFICATION. </B>Any amendment, repeal or modification of the foregoing provisions of this Article VII will not adversely
affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 23 - </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ARTICLE VIII</U>: <U>CORPORATE OPPORTUNITIES</U>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that a director of the Corporation who is also a partner or employee of an entity that is a holder of Preferred Stock or any of
its affiliates and that is in the business of investing and reinvesting in other entities or that invests in other entities as part of a strategic plan (each, a &#147;<B><I>Fund</I></B>&#148;) acquires knowledge of a potential transaction or matter
in such person&#146;s capacity as a partner or employee of the Fund and that may be a corporate opportunity for both the Corporation and such Fund, such director will to the fullest extent permitted by law have fully satisfied and fulfilled such
director&#146;s fiduciary duty to the Corporation and its stockholders with respect to such corporate opportunity, and the Corporation to the fullest extent permitted by law waives any claim that such business opportunity constituted a corporate
opportunity that should have been presented to the Corporation or any of its affiliates, if such director acts in good faith in a manner consistent with the following policy: a corporate opportunity offered to any person who is a director of the
Corporation, and who is also a partner or employee of a Fund will belong to such Fund, unless such opportunity was expressly offered to such person solely in his or her capacity as a director of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * * * * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- 24 - </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.3
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BYLAWS OF SHATTUCK LABS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Registered Office</I></B>. The initial registered office of Shattuck Labs, Inc. (the
&#147;<B><I>Corporation</I></B>&#148;) in the State of Delaware shall be fixed in the Corporation&#146;s certificate of incorporation, as the same may be amended from time to time (the &#147;<B><I>Certificate of Incorporation</I></B>&#148;), and may
be changed from time to time in the discretion of the Board of Directors of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Other
Offices</I></B>. The Corporation may also have offices at such other places both within and without the State of Delaware as the Board of Directors may from time to time determine or the business of the Corporation may require. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEETINGS OF
STOCKHOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Annual Meeting</I></B>. Meetings of stockholders may be held at such place, either
within or without the State of Delaware, as shall be determined by the Board of Directors and stated in the notice of the meeting. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may
instead be held solely by means of remote communication as authorized by <U>Section</U><U></U><U>&nbsp;2.13</U> of these Bylaws. Unless directors are elected by written consent in lieu of an annual meeting as permitted by
<U>Section</U><U></U><U>&nbsp;2.12</U> of these Bylaws, an annual meeting of the stockholders for the election of directors shall be held on a date and at a time as shall be designated by the Board of Directors and stated in the notice of the
meeting. Any other proper business may be transacted at the annual meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Special Meetings</I></B>.
Unless otherwise prescribed by statute or by the Certificate of Incorporation, special meeting of the stockholders of the Corporation may be called for any purpose or purposes by the (i)&nbsp;Chief Executive Officer, if any; (ii)&nbsp;President, in
the absence of a Chief Executive Officer; or (iii)&nbsp;Secretary at the request in writing of (A)&nbsp;a majority of the members of the Board of Directors or (B)&nbsp;holders of at least twenty percent (20%) of the total voting power of all
outstanding shares of stock of the Corporation then entitled to vote, and may not be called by the stockholders absent such a request. Any such request shall state the purpose or purposes of the proposed meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any person or persons other than the Board calls a special meeting, the request shall: (i)&nbsp;be in writing; (ii)&nbsp;specify the date
and time of such meeting and the general nature of the business proposed to be transacted; and (iii)&nbsp;be delivered personally or sent by registered mail or by facsimile transmission to the Corporation&#146;s Chairperson of the Board, Chief
Executive Officer, President (in the absence of a Chief Executive Officer) or Secretary. The officer(s) receiving the request shall cause notice to be promptly given to the stockholders entitled to vote at such meeting, in accordance with the
provisions of <U>Section</U><U></U><U>&nbsp;2.3</U> and <U>Section</U><U></U><U>&nbsp;4.2</U> of these Bylaws, that a meeting will be held at the time requested by the person or persons calling the meeting. No business may be transacted at such
special meeting other than business specified in such notice to stockholders. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Notice of Stockholders&#146; Meetings</I></B>. All notices
of meetings of stockholders shall be sent or otherwise given in accordance with <U>Section</U><U></U><U>&nbsp;4.2</U> of these Bylaws not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date of the meeting to each stockholder
entitled to vote at such meeting. The notice shall specify the place, if any, date and hour of the meeting, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such
meeting, and, in the case of a special meeting, the purpose or purposes for which the meeting is called. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Voting List</I></B>. The officer who has charge of the stock ledger of the Corporation shall prepare and
make, at least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares
registered in the name of each stockholder. The Corporation shall not be required to include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder, for any
purpose germane to the meeting for a period of at least ten (10)&nbsp;days prior to the meeting: (i)&nbsp;on a reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice
of the meeting; or (ii)&nbsp;during ordinary business hours, at the Corporation&#146;s principal executive office. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable
steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may
be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably
accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting. Such list shall presumptively determine the identity of the stockholders entitled to vote at the meeting and the number
of shares held by each of them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Quorum</I></B>. The holders of a majority of the stock issued and
outstanding and entitled to vote thereat, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business, except as otherwise provided by statute or by the Certificate of
Incorporation. If, however, such quorum shall not be present or represented at any meeting of the stockholders, the Chairman of the meeting or the stockholders entitled to vote thereat, present in person or represented by proxy, shall have power to
adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present or represented. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted
which might have been transacted at the meeting as originally notified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Adjoined Meeting;
Notice</I></B>. When a meeting is adjourned to another time or place, unless these Bylaws otherwise require, notice need not be given of the adjourned meeting if the time, place, if any, thereof and the means of remote communications, if any, by
which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken. At the continuation of the adjourned
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
meeting, the Corporation may transact any business that might have been transacted at the original meeting. If the adjournment is for more than thirty (30)&nbsp;days, or if after the adjournment
a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Conduct o</I></B><B><I>f </I></B><B><I>Business</I></B>. The chairman of any meeting of stockholders shall
determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.8&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Voting</I></B>. The stockholders of record on the books of the Corporation at the close of business on the
record date as determined by the Board of Directors and only such stockholders shall be entitled to vote at any meeting of stockholders or any adjournment thereof, subject to Section&nbsp;217 (relating to voting rights of fiduciaries, pledgers and
joint owners of stock) and Section&nbsp;218 (relating to voting trusts and other voting agreements) of the Delaware General Corporation Law (the &#147;<B><I>DGCL</I></B>&#148;). Except as may be otherwise provided in the Certificate of Incorporation
or these Bylaws, each stockholder shall be entitled to one vote for each share of capital stock held by such stockholder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Record Date</I></B>. In order that the Corporation may determine the stockholders entitled to notice of or to
vote at any meeting of stockholders or any adjournment thereof, or entitled to express consent to corporate action in writing without a meeting, or entitled to receive payment of any dividend or other distribution or allotment of any rights, or
entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which record date shall not precede the date on which the
resolution fixing the record date is adopted and which shall not be more than sixty (60)&nbsp;nor less than ten (10)&nbsp;days before the date of such meeting, nor more than sixty (60)&nbsp;days prior to any other such action. If no record date is
fixed by the Board of Directors, then: (i)&nbsp;the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on which notice is given,
or if notice is waived, at the close of business on the day next preceding the day on which the meeting is held; (ii)&nbsp;the record date for determining stockholders entitled to express consent to corporate action in writing without a meeting,
when no prior action by the Board is necessary, shall be the day on which the first written consent is expressed and (iii)&nbsp;the record date for determining stockholders for any other purpose shall be at the close of business on the day on which
the Board adopts the resolution relating thereto. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; <I>provided</I>, <I>however</I>, that the Board
of Directors may fix a new record date for the adjourned meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Action at Meetings</I></B>. When a
quorum is present at any meeting, the vote of the holders of a majority of the shares of stock having voting power present in person or represented by proxy shall decide any question brought before such meeting, unless the question is one upon which
by express provision of applicable law or of the Certificate of Incorporation, a different vote is required, in which case such express provision shall govern and control the decision of such question. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Proxies</I></B>. Each stockholder entitled to vote at a meeting of stockholders or to express consent or
dissent to corporate action in writing without a meeting may authorize another </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
person or persons to act for such stockholder by proxy authorized by an instrument in writing or by a transmission permitted by the DGCL filed in accordance with the procedure established for the
meeting, but no such proxy shall be voted or acted upon after three (3)&nbsp;years from its date, unless the proxy provides for a longer period. The provisions of Section&nbsp;212 of the DGCL shall govern the revocability of any proxy that states on
its face that it is irrevocable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.12&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Action by Stockholders </I></B><B><I>Without</I></B><B><I> a
Meeting</I></B>. Unless otherwise provided in the Certificate of Incorporation, any action required by the DGCL to be taken at any annual or special meeting of stockholders of the Corporation, or any action which may be taken at any annual or
special meeting of such stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not
less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered
office in Delaware (by hand or by certified or registered mail, return receipt requested), to its principal place of business, or to an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders
are recorded. Prompt notice of the taking of corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing and who, if the action had been taken at a meeting, would
have been entitled to notice of the meeting if the record date for such meeting had been the date that written consents signed by a sufficient number of stockholders to take the action were delivered to the Corporation as provided in
Section&nbsp;228 of the DGCL. In the event that the action which is consented to is such as would have required the filing of a certificate under any provision of the DGCL if such action had been voted on by stockholders at a meeting thereof, the
certificate filed under such provision shall state, in lieu of any statement required by such provision concerning any vote of stockholders, that written consent has been given in accordance with Section&nbsp;228 of the DGCL. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A telegram, cablegram or other electronic transmission consenting to an action to be taken and transmitted by a stockholder or by a person
authorized to act for a stockholder, shall be deemed to be written, signed and dated for the purposes of this <U>Section</U><U></U><U>&nbsp;2.13</U>, provided that any such telegram, cablegram or other electronic transmission sets forth or is
delivered with information from which the Corporation can determine (i)&nbsp;that the telegram, cablegram or other electronic transmission was transmitted by the stockholder or by a person authorized to act for the stockholder and (ii)&nbsp;the date
on which such stockholder or authorized person transmitted such telegram, cablegram or electronic transmission. The date on which such telegram, cablegram or electronic transmission is transmitted shall be deemed to be the date on which such consent
was signed. No consent given by telegram, cablegram or other electronic transmission shall be deemed to have been delivered until (i)&nbsp;such consent is reproduced in paper form and until such paper form is delivered to the Corporation by delivery
to its registered office in Delaware (by hand or by certified mail, return receipt requested), its principal place of business or an officer or agent of the Corporation having custody of the books in which proceedings of meetings of stockholders are
recorded or (ii)&nbsp;such consent is delivered to the Corporation&#146;s principal place of business or to an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded, if delivered
to the extent and m the manner provided by resolution of the Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.13&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Meeting by Remote Communication</I></B>. Unless otherwise
restricted by the Certificate of Incorporation or these Bylaws, as authorized by Section&nbsp;211 (a)(2) of the DGCL the Board may in its sole discretion permit stockholders to participate in a meeting of stockholders by means of remote
communication and shall be deemed present in person and permitted to vote at such meeting, provided that (i)&nbsp;the Corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at such meeting by
means of remote communication is a stockholder or proxyholder, (ii)&nbsp;the Corporation shall implement reasonable measures to provide such stockholders and proxyholders a reasonable opportunity to participate in such meeting and to vote on matters
submitted to the stockholders, including an opportunity to read or hear the proceedings of such meeting substantially concurrently with such proceedings, and (iii)&nbsp;if such any stockholder or proxyholder votes or takes other action at such
meeting by means of remote communication, a record of such vote or other action shalt be maintained by the Corporation. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Powers</I></B>. The business and affairs of the Corporation shall be managed by or under the direction of its
Board of Directors, except as may be otherwise provided in the DGCL, the Certificate of Incorporation or these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Number; Election; Tenure and Qualification</I></B>. The number of directors which shall constitute the whole
board shall be fixed from time to time by resolution of the Board of Directors or by the stockholders at an annual meeting of the stockholders (unless the directors are elected by written consent in lieu of an annual meeting as provided in
<U>Section</U><U></U><U>&nbsp;2.12</U>); provided that the number of directors shall be not less than one (1). With the exception of the first Board of Directors, which shall be elected by the incorporator, and except as provided in the
Corporation&#146;s Certificate of Incorporation or in <U>Section</U><U></U><U>&nbsp;3.3</U>, the directors shall be elected (i)&nbsp;at the annual meeting of the stockholders by a plurality vote of the shares represented in person or by proxy or
(ii)&nbsp;by written consent of the Corporation&#146;s stockholders pursuant to <U>Section</U><U></U><U>&nbsp;2.12</U>, and each director elected shall hold office until his successor is elected and qualified or until such director&#146;s earlier
resignation, removal or death. Directors need not be stockholders unless so required by the Certificate of Incorporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Vacancies and Newly Created Directorships</I></B>. Unless otherwise provided in the Certificate of
Incorporation, vacancies and newly-created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, though less than a quorum, or by a sole remaining director. Each
director so chosen shall serve until his successor is elected and qualified or until such director&#146;s earlier resignation, removal or death. If there are no directors in office, then an election of directors may be held in the manner provided by
statute. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If at any time, by reason of death or resignation or other cause, the Corporation should have no directors in office, then any
officer or any stockholder or an executor, administrator, trustee or guardian of a stockholder, or other fiduciary entrusted with like responsibility for the person or estate of a stockholder, may call a special meeting of stockholders in accordance
with the provisions of the Certificate of Incorporation or these Bylaws, or may apply to the Court of Chancery for a decree summarily ordering an election as provided in Section&nbsp;211 of the DGCL. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, at the time of filling any vacancy or any newly created directorship, the directors then
in office shall constitute less than a majority of the whole board (as constituted immediately prior to any such increase), the Court of Chancery may, upon application of any stockholder or stockholders holding at least ten (10%) percent of the
total number of shares at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any such vacancies or newly created directorships, or to replace the directors chosen by the directors then in
office as aforesaid, which election shall be governed by the provisions of Section&nbsp;211 of the DGCL as far as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Location of Meetings; Meetings </I></B><B><I>By</I></B><B><I> Telephone</I></B>. The Board of Directors of
the Corporation may hold meetings, both regular and special, either within or without the State of Delaware. Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, members of the Board of Directors, or any committee
designated by the Board of Directors, may participate in a meeting of the Board of Directors, or any committee, by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear
each other, and such participation in a meeting shall constitute presence in person at the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Meeting of Newly Elected Board of Directors</I></B>. The first meeting of each newly elected Board of
Directors shall be held immediately following the annual meeting of stockholders and no notice of such meeting shall be necessary to the newly elected directors in order legally to constitute the meeting, provided a quorum shall be present. In the
event such meeting is not held at such time, the meeting may be held at such time and place as shall be specified in a notice given as hereinafter provided for special meetings of the Board of Directors, or as shall be specified in a written waiver
signed by all of the directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Regular Meetings</I></B>. Regular meetings of the Board of Directors may
be held without notice at such time and at such place as shall from time to time be determined by the Board of Directors; provided that any director who is absent when such a determination is made shall be given notice of such location . </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.7&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Special Meetings</I></B>. Special meetings of the Board of Directors may be called at any time by a person
authorized to call a meeting under this <U>Section</U><U></U><U>&nbsp;3.7</U>. Special meetings may be called by the (i)&nbsp;Chief Executive Officer, if any, (ii)&nbsp;President, in the absence of a Chief Executive Officer, or (iii)&nbsp;Secretary,
upon the written request of two directors unless the Board of Directors consists of only one director, in which case special meetings may be called by the Secretary upon the written request of the sole director. Notice may be waived in accordance
with Section&nbsp;229 of the DGCL, or any successor thereto. If the notice is (i)&nbsp;delivered personally by hand, by courier or by telephone, (ii)&nbsp;sent by facsimile or (iii)&nbsp;sent by electronic mail, it shall be delivered or sent at
least twenty-four (24)&nbsp;hours before the time of the holding of the meeting. If the notice is sent by United States mail, it shall be deposited in the United States mail at least four (4)&nbsp;days before the time of the holding of the meeting.
Any oral notice may be communicated to the director. The notice need not specify the place of the meeting (if the meeting is to be held at the Corporation&#146;s principal executive office) nor the purpose of the meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.8&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Quorum and Action at Meetings</I></B>. At all meetings of
the Board of Directors, a majority of the directors then in office shall constitute a quorum for the transaction of business, and the act of a majority of the directors present at any meeting at which there is a quorum shall be the act of the Board
of Directors, except as may be otherwise specifically provided by statute or by the Certificate of Incorporation. If a quorum shall not be present at any meeting of the Board of Directors, the directors present thereat may adjourn the meeting from
time to time, without notice other than announcement at the meeting, until a quorum shall be present. A meeting at which a quorum is initially present may continue to transact business notwithstanding the withdrawal of directors, if any action taken
is approved by at least a majority of the required quorum for that meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.9&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Action without a
Meeting</I></B>. Unless otherwise restricted by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if
all members of the Board of Directors or committee, as the case may be, consent thereto in writing or by electronic transmission and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the
Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.10&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Committees</I></B>. The Board of Directors may, by resolution passed by a majority of the whole board,
designate one<SUP STYLE="font-size:85%; vertical-align:top">-</SUP> or more committees, each committee to consist of one or more of the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of
any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting and not disqualified from voting,
whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution
of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, but no such committee shall have the power or authority in reference to
(i)&nbsp;approving, adopting or recommending to the stockholders any action or matter expressly required by the DGCL to be submitted to stockholders for approval or (ii)&nbsp;adopting, amending or repealing any Bylaw of the Corporation. Such
committee or committees shall have such name or names as may be determined from time to time by resolution adopted by the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.11&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Committee Minutes</I></B>. Each committee shall keep regular minutes of its meetings and report the same to
the Board of Directors when required to do so by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.12&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Meetings and Action of
Committees</I></B>. Meetings and actions of committees shall be governed by, and held and taken in accordance with, the provisions of: (i)<U>&nbsp;Section</U><U></U><U>&nbsp;3.4</U> (Location of Meetings; Meetings By Telephone); (ii)
<U>Section</U><U></U><U>&nbsp;3.6</U> (Regular Meetings); (iii) <U>Section</U><U></U><U>&nbsp;3.7</U> (Special Meetings); (iv) <U>Section</U><U></U><U>&nbsp;3.8</U> (Quorum and Action at Meetings); (v) <U>Section</U><U></U><U>&nbsp;3.9</U> (Action
Without a Meeting) and (vi)<U>&nbsp;Section</U><U></U><U>&nbsp;4.4</U> (Waiver of Notice); with such changes in the context of those Bylaws as are necessary to substitute the committee and its members for the Board and its members; <I>provided</I>,
<I>however</I>, that (a)&nbsp;the time of regular meetings of committees may be determined either by resolution of the Board or by resolution of the committee, (b)&nbsp;special meetings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of committees may also be called by resolution of the Board and (c)&nbsp;notice of special meetings of committees shall also be given to all alternate members, who shall have the right to attend
all meetings of the committee. The Board may adopt rules for the government of any committee not inconsistent with the provisions of these Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.13&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Director Compensation</I></B>. Unless otherwise restricted by the Certificate of Incorporation or these
Bylaws, the Board of Directors shall have the authority to fix the compensation of directors. The directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors and may be paid a fixed sum for attendance at
each meeting of the Board of Directors or a stated salary as director. No such payment shall preclude any director from serving the Corporation in any other capacity mid receiving compensation therefor. Members of special or standing committees may
be allowed like compensation for attending committee meetings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.14&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Resignation</I></B>. Any director or
officer of the Corporation may resign at any time. Each such resignation shall be made in writing or by electronic transmission and shall take effect at the time specified therein, o , if no time is specified, at the time of its receipt by either
the Board of Directors, the President or the Secretary. The acceptance of a resignation shall not be necessary to make it effective unless expressly so provided in the resignation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.15&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Removal</I></B>. Unless otherwise restricted by the Certificate of Incorporation, these Bylaws or the DGCL,
any director or <SUB STYLE="font-size:85%; vertical-align:bottom">.</SUB>the entire Board of Directors may be removed, with or without cause, by the holders of a majority of shares then entitled to vote at an election of directors. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Notice to Directors</I></B>. Whenever, under the provisions of the DGCL or of the Certificate of
Incorporation or of these Bylaws, notice is required to be given to any director such notice shall be (i)&nbsp;delivered personally by hand, by courier or by telephone; (ii)&nbsp;sent by United States first-class mail, postage prepaid;
(iii)&nbsp;sent by facsimile; or (iv)&nbsp;sent by electronic mail, directed to each director at that director&#146;s address, telephone number, facsimile number or electronic mail address, as the case may be, as shown on the Corporation&#146;s
records. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Notice to Stockholders</I></B>. Without limiting the manner by which notice otherwise may be
given effectively to stockholders pursuant to the DGCL, the Certificate of Incorporation or these Bylaws, any notice to stockholders given by the Corporation under any provision of the DGCL, the Certificate of Incorporation or these Bylaws shall be
effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice to the Corporation. Any such consent shall be deemed
revoked if (1)&nbsp;the Corporation is unable to deliver by electronic transmission two consecutive notices given by the Corporation in accordance with such consent and (2)&nbsp;such inability becomes known to the Secretary or an Assistant Secretary
of the Corporation or to the transfer agent, or other person responsible for the giving of notice; <I>provided</I>, <I>however</I>, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action.
Notice given by electronic transmission shall be deemed given: (a)&nbsp;if by facsimile </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
telecommunication, when directed to a number at which the stockholder has consented to receive notice; (b)&nbsp;if by electronic mail, when directed to an electronic mail address at which the
stockholder has consented to receive notice; (c)&nbsp;if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (x)&nbsp;such posting and (y)&nbsp;the giving of such
separate notice; and (d)&nbsp;if by any other form of electronic transmission, when directed to the stockholder. As used in these Bylaws, &#147;<B><I>electronic transmission</I></B>&#148; means any form of communication, not directly involving the
physical transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process. Notice by a form of
electronic transmission shall not apply to Sections 164, 296, 311, 312 or 324 of the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Affidavit of
Notice</I></B>. An affidavit of the secretary or an assistant secretary or of the transfer agent or other agent of the Corporation that the notice has been given by a form of electronic transmission shall, in the absence of fraud, be prima facie
evidence of the facts stated therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Waiver of Notice</I></B>. Whenever any notice is required to be
given under any provision of the DGCL or the Certificate of Incorporation or these Bylaws, a written waiver, signed by the person entitled to notice, or a waiver by electronic transmission by the person entitled to such notice, whether before or
after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the
beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors or
members of a committee of directors need by specified in any written waiver of notice or any waiver by electronic transmission unless so required by the Certificate of Incorporation or these Bylaws. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OFFICERS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Enumeration</I></B>. The officers of the Corporation shall be chosen by the Board of Directors and
shall include a President and a Secretary and such other officers with such other titles as the Board of Directors shall determine from time to time. Among the officers the Board of Directors may designate are a Chief Executive Officer, Chief
Operating Officer, Chief Financial Officer and Treasurer. The Board of Directors also may choose one or more Vice Presidents, Assistant Secretaries and Assistant Treasurers. Any number of offices may be held by the same person, unless the
Certificate of Incorporation or these Bylaws otherwise provide. The Board of Directors may elect from among its members a Chairman of the Board and a Vice Chairman of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Appointment of Officers</I></B>. The Board of Directors shall appoint the officers of the Corporation, except
such officers as may be appointed in accordance with the provisions of <U>Section</U><U></U><U>&nbsp;5.3</U> of these Bylaws, subject to the rights, if any, of an officer under any contract of employment. Any vacancy occurring in any office of the
Corporation shall be filled by the Board, or as provided in <U>Section</U><U></U><U>&nbsp;5.3</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Appointment of Other Officers and Agents</I></B>. The Board
of Directors may appoint, or empower the Chief Executive Officer or, in the absence of a Chief Executive Officer, the President to appoint, such other officers and agents as the business of the Corporation may require. Each of such officers and
agents shall hold office for such period, have such authority and perform such duties as are provided in these Bylaws or as the Board of Directors may from time to time determine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Removal and Resignation of Officers</I></B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the rights, if any, of an officer under any contract of employment, any officer may be removed, either
with or without cause, by an affirmative vote of the majority of the Board of Directors at any regular or special meeting of the Board of Directors or, except in the case of an officer chosen by the Board of Directors, by any officer upon whom such
power of removal may be conferred by the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Any officer may resign at any time by giving
written notice to the Corporation. Any resignation shall take effect at the date of the receipt of that notice or at any later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation
shall not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Chairman of the Board and Vice Chairman of the Board</I></B>. The Chairman of the Board, if any, shall
preside at all meetings of the Board of Directors and of the stockholders at which the Chairman shall be present. The Chairman shall have and may exercise such powers as are, from time to time, assigned to the Chairman by the Board of Directors and
as may be provided by law. ln the absence of the Chairman of the Board, the Vice Chairman of the Board, if any, shall preside at all meetings of the Board of Directors and of the stockholders at which the Vice Chairman shall be present. The Vice
Chairman shall have and may exercise such powers as are, from time to time, assigned to such person by the Board of Directors and as may be provided by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Chief Executive Officer</I></B>. In the absence of a Chairman and/or Vice Chairman of the Board, the Chief
Executive Officer shall preside as the Chairman of meetings of the stockholders and the Board of Directors. The Chief Executive Officer shall, subject to the control of the Board of Directors, have general and active management of the business of
the Corporation and shall see that all orders and resolutions of the Board of Directors are carried into effect. All other officers, officials, employees and agents shall report directly or indirectly to the Chief Executive Officer. The Chief
Executive Officer, President or any executive Vice President shall execute bonds, mortgages and other contracts on behalf of the Corporation, except where required or permitted by law to be otherwise signed and executed and except where the signing
and execution thereof shall be expressly delegated by the Board of Directors to some other officer or agent of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7&nbsp;&nbsp;&nbsp;&nbsp;<B><I>President</I></B>. In the absence or disability of the Chief Executive Officer, the President shall perform
all the duties of the Chief Executive Officer. When acting as the Chief Executive Officer, the President shall have all the powers of, and be subject to all the restrictions upon, the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Chief Executive Officer. The President shall have such other powers and perform such other duties as from time to time may be prescribed by the Board of Directors, these Bylaws, the Chief
Executive Officer or the Chairman of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Vice </I></B><B><I>Presidents</I></B>. In the absence of
<FONT STYLE="white-space:nowrap">the-</FONT> President or in the event of the President&#146;s inability or refusal to act, the Vice President, if any (or in the event there be more than one Vice President, the Vice Presidents in the order
designated by the Board of Directors, or in the absence of any designation, then in the order of their election) shall perform the duties of the President, and when so acting shall have all the powers of and be subject to all the restrictions upon
the President. Vice Presidents, by virtue of their appointment as such, shall not necessarily be deemed to be executive officers of the Corporation, such status as an executive officer only being conferred if and to the extent determined by the
Board of Directors when such Vice President is placed in charge of a principal business unit, division or function (e.g., sales, administration or finance) or performs a policy-making function for the Corporation. Each executive Vice President shall
at all times possess, and upon the authority of the President or the Chief Executive Officer any <FONT STYLE="white-space:nowrap">non-executive</FONT> Vice President shall from time to time possess, power to sign all certificates, contracts and
other instruments of the Corporation, except as otherwise limited by the Chairman of the Board, the President, Chief Executive Officer or the Vice Chairman of the Board. The Vice Presidents shall perform other duties commonly incident to their
office and shall also perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Secretary</I></B>. The Secretary shall keep the minutes of all meetings of the Board of Directors, committees
of the Board of Directors and the stockholders, in books provided for that purpose; shall attend to the giving and serving of all notices; may in the name of the Corporation affix the seal of the Corporation to all contracts and attest the
affixation of the seal of the Corporation thereto; may sign with the other appointed officers all certificates for shares of capital stock of the Corporation; and shall have charge of the certificate books, transfer books and stock ledgers, and such
other books and papers as the Board of Directors may direct, all of which shall at all reasonable times be open to inspection of any director upon application at the office of the Corporation during business hours. The Secretary shall perform all
other duties given in these Bylaws and other duties commonly incident to such office and shall also perform such other duties and have such other powers as the Board of Directors shall designate from time to time. The Chief Executive Officer may
direct any Assistant Secretary to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each Assistant Secretary shall perform other duties commonly incident to such office and shall also perform such
other duties and have such other powers as the Board of Directors or the Chief Executive Officer, shall designate from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Assistant Secretary</I></B>. Each Assistant Secretary shall have the usual powers and duties pertaining to
such offices, together with such other powers and duties as designated in these Bylaws and as from time to time may be assigned to an Assistant Secretary by the Board of Directors, the Chairman of the Board, the President, the Vice Chairman of the
Board, or the Secretary. The Assistant Secretaries shall exercise the powers of the Secretary during that officer&#146;s absence or inability or refusal to act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Treasurer</I></B>. The Treasurer shall keep or cause to be
kept the books of account of the Corporation in a thorough and proper manner and shall render statements of the financial affairs of the Corporation in such form and as often as required by the Board of Directors, the Chairman of the Board, the Vice
Chairman of the Board, Chief Executive Officer, if one be designated, the President or the Chief Financial Officer. The Treasurer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the Corporation.
The Treasurer shall perform other duties commonly incident to such office and shall also perform such other duties and have such other powers as the Board of Directors, the Chairman of the Board, the Vice Chairman of the Board, the Chief Executive
Officer, if one be designated, or the President shall designate from time to time. In absence of a designated Chief Financial Officer, unless otherwise determined by the Board of Directors or Chief Executive Officer, the Treasurer shall serve as the
Chief Financial Officer subject to control of the Chief Executive Officer. The Chief Financial Officer, if any be designated, may, but need not serve as the Treasurer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Assistant Treasurer</I></B>. The Assistant Treasurer, or if there be more than one, the Assistant Treasurers
in the order determined by the Board of Directors (or if there be no such determination, then in the order of their election) shall, in the absence of the Treasurer or in the event of the Treasurer&#146;s inability or refusal to act, perform the
duties and exercise the powers of the Treasurer and shall perform such other duties and have such other powers as the Board of Directors may from time to time prescribe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Voting and Exercise of Rights of Shares of Other Corporations</I></B>. The Chairman of the Board, the Chief
Executive Officer, the President or any other person authorized by the Board of Directors, the Chairman of the Board, the Chief Executive Officer or the President, is authorized to vote, represent, and exercise on behalf of the Corporation all
rights incident to any and all shares of any other corporation or corporations standing in the name of the Corporation. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy
or power of attorney duly executed by such person having the authority. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VI </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Certificates</I></B>. The shares of the Corporation shall be represented by certificates, provided that the
Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares. Any such resolution shall not apply to shares represented by a certificate until such certificate is
surrendered to the Corporation. Every holder of stock represented by certificates shall be entitled to have a certificate signed by, or in the name of the Corporation by the chairperson or vice chairperson of the Board, or the president or vice
president, and by the treasurer or an assistant treasurer, or the secretary or an assistant secretary of the Corporation representing the number of shares registered in certificate form. Any or all of the signatures on the certificate may be a
facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to be an officer, transfer agent or registrar before such certificate is issued, it may be issued
by the Corporation with the same effect as if such person were an officer, transfer agent or registrar at the date of issue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Special Designation </I></B><B><I>on
</I></B><B><I>Certificates</I></B>. If the Corporation shall be authorized to issue more than one class of stock or more than one series of any class, the powers, designations, preferences and relative, participating, optional or other special
rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or back of the certificate which the Corporation shall issue
to represent such class or series of stock; provided that, except as otherwise provided in Section&nbsp;202 of the DGCL, in lieu of the foregoing requirements, there may be set forth on the face or back of the certificate which the Corporation shall
issue to represent such class or series of stock, a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, designations, preferences and relative, participating, optional or other special rights of
each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences and/or rights. Within a reasonable time after the issuance or transfer of uncertificated stock, the Corporation shall send to the
registered owner thereof a written notice containing the information required to be set forth or stated on certificates pursuant to Sections 151, 156, 202(a) or 21 S(a) of the DGCL or a statement that the Corporation will furnish without charge, to
each stockholder who so requests, the powers, designations, preferences and relative participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations or restrictions of such preferences
and/or rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Lost Certificates</I></B>. Except as provided in this
<U>Section</U><U></U><U>&nbsp;6.3</U>, no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is surrendered to the Corporation and cancelled at the same time. The Corporation may issue a new
certificate of stock or uncertificated shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such
owner&#146;s legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new
certificate or uncertificated shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Transfer of Stock</I></B>. Upon surrender to the Corporation or
the transfer agent of the Corporation of a certificate for shares duly endorsed or accompanied by proper evidence of succession, assignation or authority to transfer, it shall be the duty of the Corporation to issue a new certificate to the person
entitled thereto, cancel the old certificate and record the transaction in its books. Upon receipt of proper transfer instructions from the registered owner of uncertificated shares such uncertificated shares shall be canceled and issuance of new
equivalent uncertificated shares or certificated shares shall be made to the person entitled thereto and the transaction shall be recorded upon the books of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Registered Stockholders</I></B>. The Corporation shall be entitled to recognize the exclusive right of a
person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and to hold liable for calls and assessments a person registered on its books as the owner of shares, and shall not be bound to recognize any
equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of Delaware. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE VII </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENERAL PROVISIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Dividends</I></B>. The Board, subject to any restrictions contained in the DGCL or the Certificate of
Incorporation, may declare and pay dividends upon the shares of its capital stock. Dividends may be paid in cash, in property or in shares of capital stock, subject to the provisions of the Certificate of Incorporation. Before payment of any
dividend, there may be set aside out of any funds of the Corporation available for dividends such sum or sums as the Board of Directors from time to time, in their absolute discretion, think proper as a reserve or reserves to meet contingencies, or
for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for such other purposes as the Board of Directors shall think conducive to the interest of the Corporation, and the Board of Directors may modify or
abolish any such reserve in the manner in which it was created. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Checks</I></B>. From time to time the
Board shall determine by resolution which person or persons may sign or endorse all checks, drafts, other orders for payment of money, notes or other evidences of indebtedness that are issued in the name of or payable to the Corporation, and only
the persons so authorized shall sign or endorse those instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Execution of Corporate Contracts and
Instruments</I></B>. The Board of Directors, except as otherwise provided in these Bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument in the name of and on behalf of the
Corporation; such authority may be general or confined to specific instances. Unless so authorized or ratified by the Board or within the agency power of an officer, no officer, agent or employee shall have any power or authority to bind the
Corporation by any contract or engagement or to pledge its credit or to render it liable for any purpose or for any amount. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Fiscal Year</I></B>. The fiscal year of the Corporation shall be fixed by resolution of the Board of
Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.5&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Seal</I></B>. The Corporation may adopt a corporate seal, which shall be adopted and which
may be altered by the Board. The Corporation may use the corporate seal by causing it or a facsimile thereof to be impressed or affixed or in any other manner reproduced. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.6&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Loans</I></B>. The Board of Directors of the Corporation may, without stockholder approval, authorize loans
to, or guaranty obligations of, or otherwise assist any officer or other employee of the Corporation or of its subsidiary, including any officer or employee who is a director of the Corporation or its subsidiary, whenever, in the judgment of the
Board of Directors, such loan, guaranty or assistance may reasonably be expected to benefit the Corporation. The loan, guaranty or other assistance includes, without limitation, the adoption of employee benefit plans under which loans and guarantees
may be made, and may be with or without interest, and may be unsecured, or secured in such manner as the Board of Directors shall approve, including, without limitation, a pledge of shares of stock of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.7&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Stock Transfer Agreements</I></B>. The Corporation shall have power to enter into and perform any agreement
with any number of stockholders of any one or more classes of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.8&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Construction; Definitions</I></B>. Unless the context
requires otherwise, the general provisions, rules of construction, and definitions in the DGCL shall govern the construction of these Bylaws. Without limiting the generality of this provision, the singular number includes the plural, the plural
number includes the singular, and the term &#147;<B><I>person</I></B>&#148; includes both a corporation and a natural person. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE
VIII </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEMNIFICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Scope</I></B>. The Corporation shall, to the fullest extent permitted by Section&nbsp;145 of the DGCL, as
that Section may be amended and supplemented from time to time, indemnify any director, officer, employee or agent of the Corporation, against expenses (including attorneys&#146; fees), judgments, fines, amounts paid in settlement and/or other
matters referred to in or covered by that Section and reasonably incurred by the person in connection with such action, suit or proceeding, by reason of the fact that such person is or was a director, officer, employee or agent of the Corporation,
or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Advancing Expenses</I></B>. Expenses (including attorneys&#146; fees) incurred by a present or former
director or officer of the Corporation in defending a civil, criminal, administrative or investigative action, suit or proceeding by reason of the fact that such person is or was a director, officer, employee or agent of the Corporation (or is or
was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) shall be paid by the Corporation in advance of the final disposition of such
action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Corporation as authorized by
relevant provisions of the DGCL; <I>provided, however, </I>the Corporation shall not be required to advance such expenses to a director (i)&nbsp;who commences any action, suit or proceeding as a plaintiff unless such advance is specifically approved
by a majority of the Board of Directors or (ii)&nbsp;who is a party to an action, suit or proceeding brought by the Corporation and approved by a majority of the Board of Directors which alleges willful misappropriation of corporate assets by such
director, disclosure of confidential information in violation of such director&#146;s fiduciary or contractual obligations to the Corporation, or any other willful and deliberate breach in bad faith of such director&#146;s duty to the Corporation or
its stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Liability Offset</I></B>. The Corporation&#146;s obligation to provide indemnification
under this <U>Article VIII</U> shall be offset to the extent the indemnified party is indemnified by any other source including, but not limited to, any applicable insurance coverage under a policy maintained by the Corporation, the indemnified
party or any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.4&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Continuing Obligation</I></B>. The provisions of this <U>Article VIII</U>
shall be deemed to be a contract between the Corporation and each director of the Corporation who serves in such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
capacity at any time while this bylaw is in effect, and any repeal or modification thereof shall not affect any rights or obligations then existing with respect to any state of facts then or
theretofore existing or any action, suit or proceeding theretofore or thereafter brought based in whole or in part upon any such state of facts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.5&nbsp;&nbsp;&nbsp;&nbsp;<B><I><FONT STYLE="white-space:nowrap">Non-exclusivity</FONT> of Rights</I></B>. The indemnification and
advancement of expenses provided for in this <U>Article VIII</U> shall (i)&nbsp;not be deemed exclusive of any other rights to which those indemnified may be entitled under any bylaw, agreement or vote of stockholders or disinterested directors or
otherwise, both as to action in their official capacities and as to action in another capacity while holding such office, (ii)&nbsp;continue as to a person who has ceased to be a director and (iii)&nbsp;inure to the benefit of the heirs, executors
and administrators of such a person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.6&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Insurance</I></B>. The Corporation may purchase and maintain
insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint
venture, trust or other enterprise, including service with respect to employee benefit plans, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person&#146;s status as such,
whether or not the Corporation would have the power to indemnify such person against such liability under applicable law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.7&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Other Persons</I></B>. In addition to the indemnification rights of directors, officers, employees or agents
of the Corporation, the Board of Directors in its discretion shall have the power on behalf of the Corporation to indemnify any other person made a party to any action, suit or proceeding who the Corporation may indemnify under Section&nbsp;145 of
the DGCL. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.8&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Definitions</I></B>. The phrases and terms set forth in this <U>Article VIII</U> shall be
given the same meaning as the identical terms and phrases are given in Section&nbsp;145 of the DGCL, as that Section may be amended and supplemented from time to time. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IX </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in the Certificate of Incorporation, these Bylaws may be altered, amended or repealed, or new Bylaws may
be adopted, by the holders of a majority of the outstanding voting shares or by the Board of Directors, when such power is conferred upon the Board of Directors by the Certificate of Incorporation, at any regular meeting of the stockholders or of
the Board of Directors or at any special meeting of the stockholders or of the Board of Directors if notice of such alteration, amendment, repeal or adoption of new Bylaws be contained in the notice of such special meeting. If the power to adopt,
amend or repeal Bylaws is conferred upon the Board of Directors by the Certificate of Incorporation, it shall not divest or limit the power of the stockholders to adopt, amend or repeal Bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * * * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATE OF SECRETARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OF </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHATTUCK LABS, INC.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned certifies: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;That the undersigned is the duly elected and acting Secretary of Shattuck Labs, Inc., a Delaware corporation (the
&#147;<B><I>Corporation</I></B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;That the foregoing Bylaws constitute the Bylaws of the Corporation
as duly adopted by the Board of Directors of the Corporation on May&nbsp;9, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, I have hereunto subscribed my name
as of May&nbsp;9, 2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Josiah Hornblower</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Josiah Hornblower</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Secretary</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>EMPLOYMENT AGREEMENT</B> (the &#147;<U>Agreement</U>&#148;) is entered into as of December&nbsp;5, 2019 (the &#147;<U>Effective
Date</U>&#148;), by and between Shattuck Labs, Inc. (the &#147;<U>Company</U>&#148;) and Josiah C. Hornblower (&#147;<U>Executive</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company wishes to continue to employ Executive as the Chief Executive Officer of the Company and Executive wishes to
continue to work as the Chief Executive Officer of the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and Executive wish to enter into this
Agreement on the terms and conditions set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, it is hereby agreed as follows </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment</U>. The Company agrees to employ Executive, and Executive hereby accepts such employment, upon the
terms and subject to the conditions set forth herein, for a period commencing on the Effective Date and ending on the date that this Agreement is terminated in accordance with <U>Section</U><U></U><U>&nbsp;7</U> below (the &#147;<U>Employment
Term</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Position; Duties</U>. During the Employment Term, Executive shall serve as the Chief
Executive Officer of the Company. In such position, Executive shall report directly to the Company&#146;s Board of Directors (the &#147;<U>Board</U>&#148;) and shall have such duties and authority as are customary to such position and as otherwise
determined from time to time by the Company. During the Employment Term, Executive agrees to devote Executive&#146;s full time and reasonable best efforts to the performance of Executive&#146;s duties to the Company. The foregoing shall not be
construed to prohibit Executive from engaging in activities relating to serving on civic and charitable boards or committees, and managing personal investments, provided that such activities do not significantly interfere or conflict with the
performance by Executive of Executive&#146;s duties, responsibilities, or authorities hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Base
Salary</U>. During the Employment Term, the Company shall pay Executive an initial base salary at the annual rate of $325,000, payable in regular installments in accordance with the Company&#146;s usual payment practices. Executive&#146;s base
salary may be increased in the sole discretion of the Compensation Committee of the Board (the &#147;<U>Committee</U>&#148;). Executive&#146;s annual base salary, as in effect from time to time, is hereinafter referred to as the &#147;<U>Base
Salary</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Compensation</U>. During the Employment Term, Executive shall be eligible to
receive an annual cash bonus based on performance objectives established by the Committee each year (the &#147;<U>Annual Bonus</U>&#148;). Executive&#146;s target Annual Bonus amount will be the percentage of Base Salary designated as the target by
the Committee, which amount shall be at least 30% of the Base Salary then in effect (the &#147;<U>Target Annual Bonus</U>&#148;). Notwithstanding the preceding, Executive&#146;s Annual Bonus, if any, may be below (including zero), at, or above the
target based upon the achievement of the performance objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Benefits</U>. During the Employment Term, Executive
shall be entitled to participate in the Company&#146;s employee benefit plans as in effect from time to time (collectively &#147;<U>Employee Benefits</U>&#148;), on the same basis as those benefits are generally made available to other senior
executives of the Company, in each case to the extent that Executive is eligible under the terms of such plans or programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Business Expenses</U>. During the Employment Term, reasonable business expenses incurred by Executive in the
performance of Executive&#146;s duties hereunder shall be advanced or promptly reimbursed by the Company in accordance with Company policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The Employment Term and Executive&#146;s employment may be terminated by the Company at any time
and for any reason upon Notice to Executive and by Executive upon at least 30 days&#146; advance Notice of any such resignation of Executive&#146;s employment. Notwithstanding any other provision of this Agreement, the provisions of this
<U>Section</U><U></U><U>&nbsp;7</U> shall exclusively govern Executive&#146;s rights to payment of compensation, severance, Employee Benefits and business expenses upon termination of employment with the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>By the Company for Cause; By Executive without Good Reason.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment may be terminated by the Company for Cause and
shall terminate automatically upon the effective date of Executive&#146;s resignation without Good Reason. For purposes of this Agreement, &#147;<U>Cause</U>&#148; shall mean (A)&nbsp;indictment for, conviction of, or a plea of <I>nolo</I>
<I>contendere</I> to, (x)&nbsp;a felony (other than traffic-related) under the laws of the United States or any state thereof or any similar criminal act in a jurisdiction outside the United States or (y)&nbsp;a crime involving moral turpitude that
could be injurious to the Company or its reputation, (B)&nbsp;Executive&#146;s willful malfeasance or willful misconduct which is materially and demonstrably injurious to the Company, (C)&nbsp;any act of fraud by Executive in the performance of
Executive&#146;s duties or (D)&nbsp;Executive&#146;s material breach of any Agreement with the Company or any of the Company&#146;s material policies. The determination of Cause shall be made by the Board, in its good faith discretion. For purposes
of this Agreement, &#147;<U>Good Reason</U>&#148; shall mean the occurrence of any of the following events, without Executive&#146;s written consent, provided, in each case, that such event is not cured within thirty (30)&nbsp;days after the Company
receives notice from Executive specifying in reasonable detail the event which constitutes Good Reason: (1)&nbsp;any failure by the Company to pay Executive&#146;s Base Salary or Annual Bonus (if any) when due; (2)&nbsp;a reduction in
Executive&#146;s Base Salary or Target Annual Bonus (excluding any change in value of equity incentives); (3) any diminution in Executive&#146;s title or any substantial and sustained diminution in Executive&#146;s duties; or (4)&nbsp;a required
relocation of Executive&#146;s primary work location by more than 25 miles from Executive&#146;s current work location. &#147;<U>Good Reason</U>&#148; shall cease to exist for an event on the 90th day following Executive&#146;s knowledge thereof,
unless Executive has given the Company Notice thereof prior to such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is terminated by
the Company for Cause, or if Executive resigns without Good Reason, Executive shall be entitled to receive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the Base Salary accrued through the date of termination, payable as soon as practicable following
the date of such termination or as otherwise required by applicable law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;any Annual Bonus
earned, but unpaid, as of the date of termination for the year immediately preceding the year in which such termination occurs, paid on the date when bonuses are otherwise paid to Company executives, and in all events by March 15<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such termination occurs; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;reimbursement, within 60 days following submission by Executive to the Company of appropriate
supporting documentation, for any unreimbursed business expenses properly incurred by Executive in accordance with Company policy prior to the date of Executive&#146;s termination; provided, that claims for such reimbursement (accompanied by
appropriate supporting documentation) are submitted to the Company within 90 days following the date of Executive&#146;s termination of employment; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;such Employee Benefits, if any, as to which Executive may be entitled under the employee benefit
plans of the Company, which shall be paid in accordance with the terms of the applicable plans (the amounts described in clauses (A)&nbsp;through (D) hereof, the &#147;<U>Accrued Rights</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following such termination of Executive&#146;s employment by the Company for Cause or resignation by Executive without Good
Reason, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(a)(ii),</U> Executive shall have no further rights to any compensation or any other benefits under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability or Death</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment shall terminate automatically upon
Executive&#146;s death and may be terminated by the Company upon Executive&#146;s Disability. For purposes of this Agreement, a &#147;<U>Disability</U>&#148; shall be deemed to have occurred if Executive has for one hundred twenty
(120)&nbsp;consecutive days or one hundred eighty <FONT STYLE="white-space:nowrap">(180)&nbsp;non-consecutive</FONT> days in any twelve (12)&nbsp;month period been disabled in a manner which has rendered Executive unable to perform the essential
functions of Executive&#146;s job duties with or without reasonable accommodation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Upon
termination of Executive&#146;s employment for either Disability or death, Executive or Executive&#146;s estate (as the case may be) shall be entitled to receive (A)&nbsp;the Accrued Rights and (B)&nbsp;a pro rata portion of the actual Annual Bonus
earned for the year of termination, based on the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the
calendar year following the year in which such termination occurs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment due to death or
Disability, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(b)(ii)</U>, Executive shall have no further rights to any compensation or any other benefits under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>By the Company without Cause; By Executive with Good Reason.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment may be terminated by the Company without Cause
or by Executive with Good Reason. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is terminated by the Company
without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event not within 30 days before or two years after a Change in Control, Executive shall be entitled to receive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the Accrued Rights; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;subject to Executive&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of
a release of claims in the form provided by the Company and within the time period specified therein and Executive&#146;s continued compliance with the provisions of <U>Section</U><U></U><U>&nbsp;8</U> and the PIIA Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a pro rata portion of the actual Annual Bonus that would have been earned for the year of termination, based on
the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such
termination occurs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment of an amount equal to 1.00 times the sum of Executive&#146;s annual Base Salary plus Executive&#146;s
Target Annual Bonus amount for the year of termination, which shall be payable to Executive in equal installments in accordance with the Company&#146;s normal payroll practices, for 12 months following the date that the release of claims becomes
effective and irrevocable (<U>provided</U>, <U>however</U>, that if the period during which the release could become effective and irrevocable spans two calendar years, payments of such installments shall not commence until the first normal payroll
date in the second calendar year); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">effective as of immediately prior to such termination of employment, accelerated vesting of all then unvested
equity awards (with any applicable performance-based awards deemed earned at the target level of achievement) with such awards (other than stock options) settled as soon as practicable thereafter and in all events by March 15<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such termination occurs or to remain exercisable (with respect to stock options) through the
90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following such termination of employment; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to Executive&#146;s timely election of continuation coverage under the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), and subject to Executive&#146;s copayment of premium amounts at the active employees&#146; rate, the Company shall pay the remainder of the premiums for Executive&#146;s
participation in the Company&#146;s group health plans pursuant to COBRA for a period ending on the earlier of (i)&nbsp;the 12 month anniversary of the date of termination; (ii)&nbsp;Executive becoming eligible for other group health benefits, or
(iii)&nbsp;the expiration of Executive&#146;s rights under COBRA; provided, however, that in the event that the benefits provided herein would subject the Company or any of its affiliates to any tax or penalty under the Patient Protection and
Affordable Care Act or Section&nbsp;105(h) of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), Executive and the Company agree to work together in good faith to restructure the foregoing benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment by the Company without Cause (other than by reason of Executive&#146;s death or
Disability) or Executive&#146;s resignation with Good Reason not within 30 days before or two years after a Change in Control, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(c)(ii)</U>, Executive shall have no further rights to any
compensation or any other benefits under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is
terminated by the Company without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event within 30 days before or two years after a Change in Control, Executive shall be entitled to receive the
payments and benefits described in <U>Section</U><U></U><U>&nbsp;7(c)(ii)(A) and (B)</U>, except that the severance multiplier in Section<U>&nbsp;7(c)(ii)(B)(2)</U> shall be increased from 1.00 to 2.00. For the avoidance of doubt, payment of such
amounts and benefits other than the Accrued Rights shall be subject to Executive providing and not revoking a release of claims in the form provided by the Company and within the time period specified therein and Executive&#146;s continued
compliance with the provisions of <U>Section</U><U></U><U>&nbsp;8</U> and the PIIA Agreement. For purposes of this Agreement, &#147;<U>Change in Control</U>&#148; means the occurrence of one or more of the following events: (i)&nbsp;any
&#147;person&#148; (as such term is used in Sections 3(a)(9) and 13(d) of the Securities Exchange Act of 1934, as amended (the &#147;<U>Act</U>&#148;)) or &#147;group&#148; (as such term is used in Section&nbsp;13(d)(3) of the Act), other than the
Company or its subsidiaries or any benefit plan of the Company or its subsidiaries is or becomes a &#147;beneficial owner&#148; (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated under the Act) of more than 50%
of the Voting Stock of the Company; (ii)&nbsp;the Company transfers all or substantially all of its assets (unless the shareholders of the Company immediately prior to such transaction beneficially own, directly or indirectly, in substantially the
same proportion as they owned the Voting Stock of the Company, all of the Voting Stock or other ownership interests of the entity or entities, if any, that succeed to the business of the Company or the Company&#146;s ultimate parent company if the
Company is a subsidiary of another corporation); or (iii)&nbsp;any merger, reorganization, consolidation or similar transaction unless, immediately after consummation of such transaction, the shareholders of the Company immediately prior to the
transaction hold, directly or indirectly, more than 50% of the Voting Stock of the Company or the Company&#146;s ultimate parent company if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Company is a subsidiary of another corporation. For purposes of this Change in Control definition, &#147;<U>Voting Stock</U>&#148; means securities or ownership interests of any class or
classes having general voting power under ordinary circumstances, in the absence of contingencies, to elect the directors of a corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment by the Company without Cause (other than by reason of Executive&#146;s death or
Disability) or by Executive with Good Reason within 30 days before or two years after a Change in Control, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(c)(iii)</U>, Executive shall have no further rights to any compensation or any
other benefits under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Any termination of employment by the
Company or by Executive (other than due to Executive&#146;s death) shall be communicated by Notice of Termination to the other party hereto in accordance with <U>Section</U><U></U><U>&nbsp;11(k)</U> hereof. For purposes of this Agreement, a
&#147;<U>Notice of Termination</U>&#148; shall mean a Notice that indicates the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination
of employment under the provision so indicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination and Offices Held</U>. Upon termination of
Executive&#146;s employment for any reason, Executive shall be deemed to have resigned from all positions that Executive may then hold as an employee, officer or director of the Company or any affiliate of the Company. Executive shall promptly
deliver to the Company any additional documents reasonably required by the Company to confirm such resignations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></U>. Executive shall not, while employed by the Company
or at any time thereafter, disparage the Company (or any affiliate) in any way that materially and adversely affects the goodwill, reputation or business relationships of the Company or the affiliate with the public generally, or with any of its
customers, vendors or employees. The Company shall not (and shall use reasonable efforts to procure that its directors and officers shall not) disparage Executive in any way that materially and adversely affects Executive or Executive&#146;s
reputation or business relationships. Notwithstanding the foregoing, this Section shall not prohibit either party from rebutting claims or statements made by any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Proprietary Information and Inventions Assignment Agreement</U>. Executive previously entered into a Proprietary
Information and Inventions Assignment Agreement with the Company (the &#147;<U>PIIA Agreement</U>&#148;) and hereby reaffirms all of Executive&#146;s obligations thereunder. The provisions of <U>Section</U><U></U><U>&nbsp;8</U> hereof and the
provisions of the PIIA Agreement shall survive the termination of Executive&#146;s employment for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance</U>. Executive acknowledges and agrees that the Company&#146;s remedies at law for a breach
or threatened breach of any of the provisions of <U>Section</U><U></U><U>&nbsp;8</U> would be inadequate and the Company would suffer irreparable damages as a result of such breach or threatened breach. In recognition of this fact, Executive agrees
that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to cease making any payments or providing any benefit otherwise required by this Agreement and
obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration</U>. For the avoidance of doubt, the arbitration and equitable relief provisions of the PIIA
Agreement shall apply to any dispute concerning Executive&#146;s employment with the Company or arising under or in any way related to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law; Consent to Personal Jurisdiction</U>. THIS AGREEMENT WILL BE GOVERNED BY THE LAWS OF THE STATE OF
TEXAS WITHOUT REGARD FOR CONFLICTS OF LAWS PRINCIPLES. SUBJECT TO THE ARBITRATION PROVISION IN THE PIIA AGREEMENT, EXECUTIVE HEREBY EXPRESSLY CONSENTS TO THE PERSONAL JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN TEXAS FOR ANY LAWSUIT
FILED THERE AGAINST EXECUTIVE BY THE COMPANY CONCERNING EXECUTIVE&#146;S EMPLOYMENT OR THE TERMINATION OF EXECUTIVE&#146;S EMPLOYMENT OR ARISING FROM OR RELATING TO THIS AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement/Amendments</U>. This Agreement, together with the PIIA Agreement, contains the entire
understanding of the parties with respect to the employment of Executive by the Company. There are no restrictions, agreements, promises, warranties, covenants or undertakings between the parties with respect to the subject matter herein other than
those expressly set forth herein or as may be set forth from time to time in the Company&#146;s employee benefit plans and policies applicable to Executive. This Agreement may not be altered, modified, or amended except by written instrument signed
by the parties hereto. In the event of any inconsistency between this Agreement and any other plan, program, practice or agreement of which Executive is a participant or a party, this Agreement shall control unless such other plan, program, practice
or agreement specifically refers to the provisions of this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Waiver</U>. The failure of a party
to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver of such party&#146;s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. In the event that any one or more of the provisions of this Agreement
shall be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions of this Agreement shall not be affected thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>. This Agreement, and all of Executive&#146;s rights and duties hereunder, shall not be assignable
or delegable by Executive. Any purported assignment or delegation by Executive in violation of the foregoing shall be null and <I>void ab initio</I> and of no force and effect. This Agreement may be assigned by the Company to a person or entity
which is an affiliate or a successor in interest to substantially all of the business operations of the Company. Upon such assignment, the rights and obligations of the Company hereunder shall become the rights and obligations of such affiliate or
successor person or entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterclaim; No Mitigation</U>. The Company&#146;s obligation
to pay Executive the amounts provided and to make the arrangements provided hereunder shall be subject to counterclaim and to seek recoupment of amounts owed by Executive to the Company or its affiliates. Executive shall not be required to mitigate
the amount of any payment provided for pursuant to this Agreement by seeking other employment, and such payments shall not be reduced by any compensation or benefits received from any subsequent employer or other endeavor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Code Section</U><U></U><U>&nbsp;409A</U>. Notwithstanding anything herein to the contrary,
(i)&nbsp;if at the time of Executive&#146;s termination of employment with the Company Executive is a &#147;specified employee&#148; as defined in Section&nbsp;409A of the Code and the deferral of the commencement of any payments or benefits
otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section&nbsp;409A of the Code, then the Company will defer the commencement of the payment of any such
payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Executive) until the date that is six months following Executive&#146;s termination of employment with the Company (or the earliest
date as is permitted under Section&nbsp;409A of the Code) and (ii)&nbsp;if any other payments of money or other benefits due to Executive hereunder could cause the application of an accelerated or additional tax under Section&nbsp;409A of the Code,
such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section&nbsp;409A of the Code, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a
manner, determined by the Board, that does not cause such an accelerated or additional tax. For purposes of Section&nbsp;409A of the Code, each payment made under this Agreement shall be designated as a &#147;separate payment&#148; within the
meaning of the Section&nbsp;409A of the Code, and references herein to Executive&#146;s &#147;termination of employment&#148; shall refer to Executive&#146;s separation from service with the Company within the meaning of Section&nbsp;409A. To the
extent any reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits due to Executive under this Agreement constitute &#147;deferred compensation&#148; under Section&nbsp;409A of the Code, any such reimbursements or <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits shall be paid to Executive in a manner consistent with Treas. Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(1)(iv).</FONT> The Company shall consult with Executive in good faith
regarding the implementation of the provisions of this <U>Section</U><U></U><U>&nbsp;11(h)</U>; <U>provided</U> that neither the Company nor any of its employees or representatives shall have any liability to Executive with respect to thereto or any
tax imposed under Section&nbsp;409A. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Code Section</U><U></U><U>&nbsp;280G</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>Prior to the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise</U></I><I>; Shareholder Vote Sought</I>. To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is available at the time of a Change in Control if the shareholder approval requirements under Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q/A-7</FONT> are satisfied, the Company may elect to pursue a shareholder vote in accordance with such provisions and the Company and Executive shall cooperate with
each other and use their commercially reasonable efforts to obtain a vote satisfying the requirements of Section&nbsp;280G(b)(5) of the Code and Treasury Regulation <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT
STYLE="white-space:nowrap">Q/A-7,</FONT> such that neither Executive nor the Company or its Affiliates suffers any adverse tax consequences under Sections 280G and 4999 of the Code. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>Prior to the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise</U></I><I>; Shareholder Vote Not Sought. </I>To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is available at the time of a Change in Control if the shareholder approval requirements under Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q/A-7</FONT> are satisfied and the Company does <I>not</I> seek a shareholder vote in accordance with Section&nbsp;11(i)(<I>i</I>) hereof, if it is determined by a
nationally recognized United States public accounting firm selected by the Company (the &#147;<U>Auditors</U>&#148;) that any payment or benefit in the nature of compensation made or provided to Executive in connection with Executive&#146;s
employment with the Company (collectively, a &#147;<U>Payment</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Parachute Tax</U>&#148;), then the Company shall pay to Executive, prior to the time
the Parachute Tax is payable with respect to such Payment, an additional payment (a &#147;<U><FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment</U>&#148;) in an amount such that, after payment by Executive of all taxes (including any Parachute
Tax) imposed upon the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment, Executive retains an amount of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment equal to the Parachute Tax imposed upon the Payment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount of any <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment shall be determined by the Auditors,
subject to adjustment, as necessary, as a result of any Internal Revenue Service position. For purposes of making the calculations required by this Agreement, the Auditors may make reasonable assumptions and approximations concerning applicable
taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that the Auditors&#146; determinations must be made with substantial authority (within the meaning of
Section&nbsp;6662 of the Code). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The federal tax returns filed by Executive (and any filing made by a consolidated tax group which includes the
Company) shall be prepared and filed on a basis consistent with the determination of the Auditors with respect to the Parachute Tax payable by Executive. Executive shall make proper payment of the amount of any Parachute Tax, and at the request of
the Company, provide to the Company true and correct copies (with any amendments) of Executive&#146;s federal income tax return as filed with the Internal Revenue Service, and such other documents reasonably requested by the Company, evidencing such
payment. If, after the Company&#146;s payment to Executive of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment, the Auditors determine in good faith that the amount of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment should
be reduced or increased, or such determination is made by the Internal Revenue Service, then within ten (10)&nbsp;business days of such determination, Executive shall pay to the Company the amount of any such reduction, or the Company shall pay to
Executive the amount of any such increase; provided, however, that (i)&nbsp;the fees and expenses of the Auditors (and any other legal and accounting fees) incurred for services rendered in connection with the Auditor&#146;s determination of the
Parachute Tax or any challenge by the Internal Revenue Service or other taxing authority relating to such determination shall be paid by the Company, and (ii)&nbsp;the Company shall indemnify and hold Executive harmless on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis for any interest and penalties imposed upon Executive to the extent that such interest and penalties are related to the Auditor&#146;s determination of the Parachute Tax or the <FONT
STYLE="white-space:nowrap">Gross-Up</FONT> Payment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OR </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>On and After the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise. </U></I>To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is unavailable at the time of a Change in Control because any Company stock is readily tradeable on an established securities market or otherwise, if it is
determined by a nationally recognized United States public accounting firm selected by the Company (the &#147;<U>Auditors</U>&#148;) that any payment or benefit in the nature of compensation made or provided to Executive in connection with
Executive&#146;s employment with the Company (collectively, a &#147;<U>Payments</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Parachute Tax</U>&#148;), then Executive will be entitled to
receive <I>either</I> (A)&nbsp;the full amount of the Payments, or (B)&nbsp;a portion of the Payments having a value equal to $1 less than three (3)&nbsp;times Executive&#146;s &#147;base amount&#148; (as such term is defined in
Section&nbsp;280G(b)(3)(A) of the Code), whichever of clauses (A)&nbsp;and (B), after taking into account applicable federal, state, and local income and employment taxes and the Parachute Tax, results in the receipt by Executive on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest portion of the Payments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any determination required under this <U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>) </U>shall
be made in writing by the Auditor, whose determination, absent manifest error, shall be conclusive and binding for all purposes upon the Company and Executive. For purposes of making the calculations required by this Agreement, the Auditors may make
reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that the Auditors&#146; determinations must be
made with substantial authority (within the meaning of Section&nbsp;6662 of the Code). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is a reduction of the Payments pursuant to this
<U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>)</U>, such reduction shall occur in accordance with Section&nbsp;409A of the Code and in the following order: (1)&nbsp;any cash severance payable by reference to Executive&#146;s base
salary or annual bonus, (2)&nbsp;any other cash amount payable to Executive, (3)&nbsp;any employee benefit valued as a &#147;parachute payment,&#148; and (4)&nbsp;acceleration of vesting of any outstanding equity award. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, in the event that additional Payments are made to Executive after the application
of the cutback in this <U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>)</U>, which additional Payments result in the cutback no longer being applicable, the Company shall pay Executive an additional amount equal to the value of the
Payments that were originally cut back. The Company shall determine at the end of each calendar year whether any such restoration is necessary based on additional Payments (if any) made during such calendar year, and shall pay such restoration by
March&nbsp;15 of the calendar year following such calendar year. In no event whatsoever shall Executive be entitled to a tax <FONT STYLE="white-space:nowrap">gross-up</FONT> or other payment in respect of any excise tax, interest or penalties that
may be imposed on the Payments by reason of the application of Section&nbsp;280G or Section&nbsp;4999 of the Code at any time when any Company stock is readily tradeable on an established securities market or otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors; Binding Agreement</U>. This Agreement shall inure
to the benefit of and be binding upon personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. In the event of Executive&#146;s death prior to receipt of all amounts payable to Executive
(including any unpaid amounts due under <U>Section</U><U></U><U>&nbsp;7</U>), such amounts shall be paid to Executive&#146;s beneficiary designated in a Notice provided to and accepted by the Company or, in the absence of such designation, to
Executive&#146;s estate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice</U>. For the purpose of this Agreement, notices and all other
communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand or overnight courier or three postal delivery days after it has been mailed by United States registered mail, return
receipt requested, postage prepaid, addressed to the respective addresses set forth below in this Agreement, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that Notice of change of
address shall be effective only upon receipt (each such communication, &#147;<U>Notice</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If to the Company, addressed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Shattuck Labs, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn:
General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1018 W. 11th Street, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Austin, TX 78703 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to
Executive, to the address listed in the Company&#146;s payroll records from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Executive
Representation</U>. Executive hereby represents to the Company that the execution and delivery of this Agreement by Executive and the Company and the performance by Executive of Executive&#146;s duties hereunder shall not constitute a breach of, or
otherwise contravene, the terms of any employment agreement or other agreement or policy to which Executive is a party or otherwise bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>Prior Agreements</U>. This Agreement supersedes all prior agreements and understandings (including verbal
agreements) between Executive and the Company and/or its affiliates regarding the terms and conditions of Executive&#146;s employment with the Company and/or its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cooperation</U>. Executive shall provide Executive&#146;s reasonable cooperation in connection with any action
or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executive&#146;s employment hereunder, provided, that, following termination of Executive&#146;s employment, the Company shall pay all reasonable
expenses incurred by Executive in providing such cooperation. This provision shall survive any termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding Taxes</U>. The Company may withhold from any amounts payable under this Agreement such federal,
state and local taxes as may be required to be withheld pursuant to any applicable law or regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be signed in
counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows this Page] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have duly executed this Employment Agreement as of
the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SHATTUCK LABS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Taylor Schreiber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Taylor Schreiber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Scientific Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXECUTIVE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Josiah Hornblower</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Josiah Hornblower</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>EMPLOYMENT AGREEMENT</B> (the &#147;<U>Agreement</U>&#148;) is entered into as of December&nbsp;5, 2019 (the &#147;<U>Effective
Date</U>&#148;), by and between Shattuck Labs, Inc. (the &#147;<U>Company</U>&#148;) and Taylor Schreiber (&#147;<U>Executive</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company wishes to continue to employ Executive as the Chief Scientific Officer of the Company and Executive wishes to
continue to work as the Chief Scientific Officer of the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and Executive wish to enter into this
Agreement on the terms and conditions set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, it is hereby agreed as follows </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment</U>. The Company agrees to employ Executive, and Executive hereby accepts such employment, upon the
terms and subject to the conditions set forth herein, for a period commencing on the Effective Date and ending on the date that this Agreement is terminated in accordance with <U>Section</U><U></U><U>&nbsp;7</U> below (the &#147;<U>Employment
Term</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Position; Duties</U>. During the Employment Term, Executive shall serve as the Chief
Scientific Officer of the Company. In such position, Executive shall report directly to the Company&#146;s Chief Executive Officer and shall have such duties and authority as are customary to such position and as otherwise determined from time to
time by the Company. During the Employment Term, Executive agrees to devote Executive&#146;s full time and reasonable best efforts to the performance of Executive&#146;s duties to the Company. The foregoing shall not be construed to prohibit
Executive from engaging in activities relating to serving on civic and charitable boards or committees, and managing personal investments, provided that such activities do not significantly interfere or conflict with the performance by Executive of
Executive&#146;s duties, responsibilities, or authorities hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salary</U>. During the Employment
Term, the Company shall pay Executive an initial base salary at the annual rate of $325,000, payable in regular installments in accordance with the Company&#146;s usual payment practices. Executive&#146;s base salary may be increased in the sole
discretion of the Compensation Committee of the Board (the &#147;<U>Committee</U>&#148;). Executive&#146;s annual base salary, as in effect from time to time, is hereinafter referred to as the &#147;<U>Base Salary</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Compensation</U>. During the Employment Term, Executive shall be eligible to receive an annual cash
bonus based on performance objectives established by the Committee each year (the &#147;<U>Annual Bonus</U>&#148;). Executive&#146;s target Annual Bonus amount will be the percentage of Base Salary designated as the target by the Committee, which
amount shall be at least 30% of the Base Salary then in effect (the &#147;<U>Target Annual Bonus</U>&#148;). Notwithstanding the preceding, Executive&#146;s Annual Bonus, if any, may be below (including zero), at, or above the target based upon the
achievement of the performance objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Benefits</U>. During the Employment Term, Executive
shall be entitled to participate in the Company&#146;s employee benefit plans as in effect from time to time (collectively &#147;<U>Employee Benefits</U>&#148;), on the same basis as those benefits are generally made available to other senior
executives of the Company, in each case to the extent that Executive is eligible under the terms of such plans or programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Business Expenses</U>. During the Employment Term, reasonable business expenses incurred by Executive in the
performance of Executive&#146;s duties hereunder shall be advanced or promptly reimbursed by the Company in accordance with Company policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The Employment Term and Executive&#146;s employment may be terminated by the Company at any time
and for any reason upon Notice to Executive and by Executive upon at least 30 days&#146; advance Notice of any such resignation of Executive&#146;s employment. Notwithstanding any other provision of this Agreement, the provisions of this
<U>Section</U><U></U><U>&nbsp;7</U> shall exclusively govern Executive&#146;s rights to payment of compensation, severance, Employee Benefits and business expenses upon termination of employment with the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>By the Company for Cause; By Executive without Good Reason.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment may be terminated by the Company for Cause and
shall terminate automatically upon the effective date of Executive&#146;s resignation without Good Reason. For purposes of this Agreement, &#147;<U>Cause</U>&#148; shall mean (A)&nbsp;indictment for, conviction of, or a plea of <I>nolo</I>
<I>contendere</I> to, (x)&nbsp;a felony (other than traffic-related) under the laws of the United States or any state thereof or any similar criminal act in a jurisdiction outside the United States or (y)&nbsp;a crime involving moral turpitude that
could be injurious to the Company or its reputation, (B)&nbsp;Executive&#146;s willful malfeasance or willful misconduct which is materially and demonstrably injurious to the Company, (C)&nbsp;any act of fraud by Executive in the performance of
Executive&#146;s duties or (D)&nbsp;Executive&#146;s material breach of any Agreement with the Company or any of the Company&#146;s material policies. The determination of Cause shall be made by the Board, in its good faith discretion. For purposes
of this Agreement, &#147;<U>Good Reason</U>&#148; shall mean the occurrence of any of the following events, without Executive&#146;s written consent, provided, in each case, that such event is not cured within thirty (30)&nbsp;days after the Company
receives notice from Executive specifying in reasonable detail the event which constitutes Good Reason: (1)&nbsp;any failure by the Company to pay Executive&#146;s Base Salary or Annual Bonus (if any) when due; (2)&nbsp;a reduction in
Executive&#146;s Base Salary or Target Annual Bonus (excluding any change in value of equity incentives); (3) any diminution in Executive&#146;s title or any substantial and sustained diminution in Executive&#146;s duties; or (4)&nbsp;a required
relocation of Executive&#146;s primary work location by more than 25 miles from Executive&#146;s current work location. &#147;<U>Good Reason</U>&#148; shall cease to exist for an event on the 90th day following Executive&#146;s knowledge thereof,
unless Executive has given the Company Notice thereof prior to such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is terminated by
the Company for Cause, or if Executive resigns without Good Reason, Executive shall be entitled to receive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the Base Salary accrued through the date of termination, payable as soon as practicable following
the date of such termination or as otherwise required by applicable law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;any Annual Bonus
earned, but unpaid, as of the date of termination for the year immediately preceding the year in which such termination occurs, paid on the date when bonuses are otherwise paid to Company executives, and in all events by March 15<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such termination occurs; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;reimbursement, within 60 days following submission by Executive to the Company of appropriate
supporting documentation, for any unreimbursed business expenses properly incurred by Executive in accordance with Company policy prior to the date of Executive&#146;s termination; provided, that claims for such reimbursement (accompanied by
appropriate supporting documentation) are submitted to the Company within 90 days following the date of Executive&#146;s termination of employment; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;such Employee Benefits, if any, as to which Executive may be entitled under the employee benefit
plans of the Company, which shall be paid in accordance with the terms of the applicable plans (the amounts described in clauses (A)&nbsp;through (D) hereof, the &#147;<U>Accrued Rights</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following such termination of Executive&#146;s employment by the Company for Cause or resignation by Executive without Good
Reason, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(a)(ii),</U> Executive shall have no further rights to any compensation or any other benefits under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability or Death</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment shall terminate automatically upon
Executive&#146;s death and may be terminated by the Company upon Executive&#146;s Disability. For purposes of this Agreement, a &#147;<U>Disability</U>&#148; shall be deemed to have occurred if Executive has for one hundred twenty
(120)&nbsp;consecutive days or one hundred eighty <FONT STYLE="white-space:nowrap">(180)&nbsp;non-consecutive</FONT> days in any twelve (12)&nbsp;month period been disabled in a manner which has rendered Executive unable to perform the essential
functions of Executive&#146;s job duties with or without reasonable accommodation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Upon
termination of Executive&#146;s employment for either Disability or death, Executive or Executive&#146;s estate (as the case may be) shall be entitled to receive (A)&nbsp;the Accrued Rights and (B)&nbsp;a pro rata portion of the actual Annual Bonus
earned for the year of termination, based on the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the
calendar year following the year in which such termination occurs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment due to death or
Disability, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(b)(ii)</U>, Executive shall have no further rights to any compensation or any other benefits under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>By the Company without Cause; By Executive with Good Reason.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment may be terminated by the Company without Cause
or by Executive with Good Reason. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is terminated by the Company
without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event not within 30 days before or two years after a Change in Control, Executive shall be entitled to receive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the Accrued Rights; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;subject to Executive&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of
a release of claims in the form provided by the Company and within the time period specified therein and Executive&#146;s continued compliance with the provisions of <U>Section</U><U></U><U>&nbsp;8</U> and the PIIA Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a pro rata portion of the actual Annual Bonus that would have been earned for the year of termination, based on
the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such
termination occurs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment of an amount equal to 1.00 times the sum of Executive&#146;s annual Base Salary plus Executive&#146;s
Target Annual Bonus amount for the year of termination, which shall be payable to Executive in equal installments in accordance with the Company&#146;s normal payroll practices, for 12 months following the date that the release of claims becomes
effective and irrevocable (<U>provided</U>, <U>however</U>, that if the period during which the release could become effective and irrevocable spans two calendar years, payments of such installments shall not commence until the first normal payroll
date in the second calendar year); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">effective as of immediately prior to such termination of employment, accelerated vesting of all then unvested
equity awards (with any applicable performance-based awards deemed earned at the target level of achievement) with such awards (other than stock options) settled as soon as practicable thereafter and in all events by March 15<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such termination occurs or to remain exercisable (with respect to stock options) through the
90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following such termination of employment; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to Executive&#146;s timely election of continuation coverage under the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), and subject to Executive&#146;s copayment of premium amounts at the active employees&#146; rate, the Company shall pay the remainder of the premiums for Executive&#146;s
participation in the Company&#146;s group health plans pursuant to COBRA for a period ending on the earlier of (i)&nbsp;the 12 month anniversary of the date of termination; (ii)&nbsp;Executive becoming eligible for other group health benefits, or
(iii)&nbsp;the expiration of Executive&#146;s rights under COBRA; provided, however, that in the event that the benefits provided herein would subject the Company or any of its affiliates to any tax or penalty under the Patient Protection and
Affordable Care Act or Section&nbsp;105(h) of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), Executive and the Company agree to work together in good faith to restructure the foregoing benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment by the Company without Cause (other than by reason of Executive&#146;s death or
Disability) or Executive&#146;s resignation with Good Reason not within 30 days before or two years after a Change in Control, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(c)(ii)</U>, Executive shall have no further rights to any
compensation or any other benefits under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is
terminated by the Company without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event within 30 days before or two years after a Change in Control, Executive shall be entitled to receive the
payments and benefits described in <U>Section</U><U></U><U>&nbsp;7(c)(ii)(A) and (B)</U>, except that the severance multiplier in Section<U>&nbsp;7(c)(ii)(B)(2)</U> shall be increased from 1.00 to 2.00. For the avoidance of doubt, payment of such
amounts and benefits other than the Accrued Rights shall be subject to Executive providing and not revoking a release of claims in the form provided by the Company and within the time period specified therein and Executive&#146;s continued
compliance with the provisions of <U>Section</U><U></U><U>&nbsp;8</U> and the PIIA Agreement. For purposes of this Agreement, &#147;<U>Change in Control</U>&#148; means the occurrence of one or more of the following events: (i)&nbsp;any
&#147;person&#148; (as such term is used in Sections 3(a)(9) and 13(d) of the Securities Exchange Act of 1934, as amended (the &#147;<U>Act</U>&#148;)) or &#147;group&#148; (as such term is used in Section&nbsp;13(d)(3) of the Act), other than the
Company or its subsidiaries or any benefit plan of the Company or its subsidiaries is or becomes a &#147;beneficial owner&#148; (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated under the Act) of more than 50%
of the Voting Stock of the Company; (ii)&nbsp;the Company transfers all or substantially all of its assets (unless the shareholders of the Company immediately prior to such transaction beneficially own, directly or indirectly, in substantially the
same proportion as they owned the Voting Stock of the Company, all of the Voting Stock or other ownership interests of the entity or entities, if any, that succeed to the business of the Company or the Company&#146;s ultimate parent company if the
Company is a subsidiary of another corporation); or (iii)&nbsp;any merger, reorganization, consolidation or similar transaction unless, immediately after consummation of such transaction, the shareholders of the Company immediately prior to the
transaction hold, directly or indirectly, more than 50% of the Voting Stock of the Company or the Company&#146;s ultimate parent company if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Company is a subsidiary of another corporation. For purposes of this Change in Control definition, &#147;<U>Voting Stock</U>&#148; means securities or ownership interests of any class or
classes having general voting power under ordinary circumstances, in the absence of contingencies, to elect the directors of a corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment by the Company without Cause (other than by reason of Executive&#146;s death or
Disability) or by Executive with Good Reason within 30 days before or two years after a Change in Control, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(c)(iii)</U>, Executive shall have no further rights to any compensation or any
other benefits under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Any termination of employment by the
Company or by Executive (other than due to Executive&#146;s death) shall be communicated by Notice of Termination to the other party hereto in accordance with <U>Section</U><U></U><U>&nbsp;11(k)</U> hereof. For purposes of this Agreement, a
&#147;<U>Notice of Termination</U>&#148; shall mean a Notice that indicates the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination
of employment under the provision so indicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination and Offices Held</U>. Upon termination of
Executive&#146;s employment for any reason, Executive shall be deemed to have resigned from all positions that Executive may then hold as an employee, officer or director of the Company or any affiliate of the Company. Executive shall promptly
deliver to the Company any additional documents reasonably required by the Company to confirm such resignations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></U>. Executive shall not, while employed by the Company
or at any time thereafter, disparage the Company (or any affiliate) in any way that materially and adversely affects the goodwill, reputation or business relationships of the Company or the affiliate with the public generally, or with any of its
customers, vendors or employees. The Company shall not (and shall use reasonable efforts to procure that its directors and officers shall not) disparage Executive in any way that materially and adversely affects Executive or Executive&#146;s
reputation or business relationships. Notwithstanding the foregoing, this Section shall not prohibit either party from rebutting claims or statements made by any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Proprietary Information and Inventions Assignment Agreement</U>. Executive previously entered into a Proprietary
Information and Inventions Assignment Agreement with the Company (the &#147;<U>PIIA Agreement</U>&#148;) and hereby reaffirms all of Executive&#146;s obligations thereunder. The provisions of <U>Section</U><U></U><U>&nbsp;8</U> hereof and the
provisions of the PIIA Agreement shall survive the termination of Executive&#146;s employment for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance</U>. Executive acknowledges and agrees that the Company&#146;s remedies at law for a breach
or threatened breach of any of the provisions of <U>Section</U><U></U><U>&nbsp;8</U> would be inadequate and the Company would suffer irreparable damages as a result of such breach or threatened breach. In recognition of this fact, Executive agrees
that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to cease making any payments or providing any benefit otherwise required by this Agreement and
obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration</U>. For the avoidance of doubt, the arbitration and equitable relief provisions of the PIIA
Agreement shall apply to any dispute concerning Executive&#146;s employment with the Company or arising under or in any way related to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law; Consent to Personal Jurisdiction</U>. THIS AGREEMENT WILL BE GOVERNED BY THE LAWS OF THE STATE OF
TEXAS WITHOUT REGARD FOR CONFLICTS OF LAWS PRINCIPLES. SUBJECT TO THE ARBITRATION PROVISION IN THE PIIA AGREEMENT, EXECUTIVE HEREBY EXPRESSLY CONSENTS TO THE PERSONAL JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN TEXAS FOR ANY LAWSUIT
FILED THERE AGAINST EXECUTIVE BY THE COMPANY CONCERNING EXECUTIVE&#146;S EMPLOYMENT OR THE TERMINATION OF EXECUTIVE&#146;S EMPLOYMENT OR ARISING FROM OR RELATING TO THIS AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement/Amendments</U>. This Agreement, together with the PIIA Agreement, contains the entire
understanding of the parties with respect to the employment of Executive by the Company. There are no restrictions, agreements, promises, warranties, covenants or undertakings between the parties with respect to the subject matter herein other than
those expressly set forth herein or as may be set forth from time to time in the Company&#146;s employee benefit plans and policies applicable to Executive. This Agreement may not be altered, modified, or amended except by written instrument signed
by the parties hereto. In the event of any inconsistency between this Agreement and any other plan, program, practice or agreement of which Executive is a participant or a party, this Agreement shall control unless such other plan, program, practice
or agreement specifically refers to the provisions of this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Waiver</U>. The failure of a party
to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver of such party&#146;s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. In the event that any one or more of the provisions of this Agreement
shall be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions of this Agreement shall not be affected thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>. This Agreement, and all of Executive&#146;s rights and duties hereunder, shall not be assignable
or delegable by Executive. Any purported assignment or delegation by Executive in violation of the foregoing shall be null and <I>void ab initio</I> and of no force and effect. This Agreement may be assigned by the Company to a person or entity
which is an affiliate or a successor in interest to substantially all of the business operations of the Company. Upon such assignment, the rights and obligations of the Company hereunder shall become the rights and obligations of such affiliate or
successor person or entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterclaim; No Mitigation</U>. The Company&#146;s obligation
to pay Executive the amounts provided and to make the arrangements provided hereunder shall be subject to counterclaim and to seek recoupment of amounts owed by Executive to the Company or its affiliates. Executive shall not be required to mitigate
the amount of any payment provided for pursuant to this Agreement by seeking other employment, and such payments shall not be reduced by any compensation or benefits received from any subsequent employer or other endeavor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Code Section</U><U></U><U>&nbsp;409A</U>. Notwithstanding anything herein to the contrary,
(i)&nbsp;if at the time of Executive&#146;s termination of employment with the Company Executive is a &#147;specified employee&#148; as defined in Section&nbsp;409A of the Code and the deferral of the commencement of any payments or benefits
otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section&nbsp;409A of the Code, then the Company will defer the commencement of the payment of any such
payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Executive) until the date that is six months following Executive&#146;s termination of employment with the Company (or the earliest
date as is permitted under Section&nbsp;409A of the Code) and (ii)&nbsp;if any other payments of money or other benefits due to Executive hereunder could cause the application of an accelerated or additional tax under Section&nbsp;409A of the Code,
such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section&nbsp;409A of the Code, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a
manner, determined by the Board, that does not cause such an accelerated or additional tax. For purposes of Section&nbsp;409A of the Code, each payment made under this Agreement shall be designated as a &#147;separate payment&#148; within the
meaning of the Section&nbsp;409A of the Code, and references herein to Executive&#146;s &#147;termination of employment&#148; shall refer to Executive&#146;s separation from service with the Company within the meaning of Section&nbsp;409A. To the
extent any reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits due to Executive under this Agreement constitute &#147;deferred compensation&#148; under Section&nbsp;409A of the Code, any such reimbursements or <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits shall be paid to Executive in a manner consistent with Treas. Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(1)(iv).</FONT> The Company shall consult with Executive in good faith
regarding the implementation of the provisions of this <U>Section</U><U></U><U>&nbsp;11(h)</U>; <U>provided</U> that neither the Company nor any of its employees or representatives shall have any liability to Executive with respect to thereto or any
tax imposed under Section&nbsp;409A. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Code Section</U><U></U><U>&nbsp;280G</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>Prior to the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise</U></I><I>; Shareholder Vote Sought</I>. To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is available at the time of a Change in Control if the shareholder approval requirements under Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q/A-7</FONT> are satisfied, the Company may elect to pursue a shareholder vote in accordance with such provisions and the Company and Executive shall cooperate with
each other and use their commercially reasonable efforts to obtain a vote satisfying the requirements of Section&nbsp;280G(b)(5) of the Code and Treasury Regulation <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT
STYLE="white-space:nowrap">Q/A-7,</FONT> such that neither Executive nor the Company or its Affiliates suffers any adverse tax consequences under Sections 280G and 4999 of the Code. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>Prior to the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise</U></I><I>; Shareholder Vote Not Sought. </I>To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is available at the time of a Change in Control if the shareholder approval requirements under Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q/A-7</FONT> are satisfied and the Company does <I>not</I> seek a shareholder vote in accordance with Section&nbsp;11(i)(<I>i</I>) hereof, if it is determined by a
nationally recognized United States public accounting firm selected by the Company (the &#147;<U>Auditors</U>&#148;) that any payment or benefit in the nature of compensation made or provided to Executive in connection with Executive&#146;s
employment with the Company (collectively, a &#147;<U>Payment</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Parachute Tax</U>&#148;), then the Company shall pay to Executive, prior to the time
the Parachute Tax is payable with respect to such Payment, an additional payment (a &#147;<U><FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment</U>&#148;) in an amount such that, after payment by Executive of all taxes (including any Parachute
Tax) imposed upon the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment, Executive retains an amount of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment equal to the Parachute Tax imposed upon the Payment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount of any <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment shall be determined by the Auditors,
subject to adjustment, as necessary, as a result of any Internal Revenue Service position. For purposes of making the calculations required by this Agreement, the Auditors may make reasonable assumptions and approximations concerning applicable
taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that the Auditors&#146; determinations must be made with substantial authority (within the meaning of
Section&nbsp;6662 of the Code). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The federal tax returns filed by Executive (and any filing made by a consolidated tax group which includes the
Company) shall be prepared and filed on a basis consistent with the determination of the Auditors with respect to the Parachute Tax payable by Executive. Executive shall make proper payment of the amount of any Parachute Tax, and at the request of
the Company, provide to the Company true and correct copies (with any amendments) of Executive&#146;s federal income tax return as filed with the Internal Revenue Service, and such other documents reasonably requested by the Company, evidencing such
payment. If, after the Company&#146;s payment to Executive of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment, the Auditors determine in good faith that the amount of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment should
be reduced or increased, or such determination is made by the Internal Revenue Service, then within ten (10)&nbsp;business days of such determination, Executive shall pay to the Company the amount of any such reduction, or the Company shall pay to
Executive the amount of any such increase; provided, however, that (i)&nbsp;the fees and expenses of the Auditors (and any other legal and accounting fees) incurred for services rendered in connection with the Auditor&#146;s determination of the
Parachute Tax or any challenge by the Internal Revenue Service or other taxing authority relating to such determination shall be paid by the Company, and (ii)&nbsp;the Company shall indemnify and hold Executive harmless on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis for any interest and penalties imposed upon Executive to the extent that such interest and penalties are related to the Auditor&#146;s determination of the Parachute Tax or the <FONT
STYLE="white-space:nowrap">Gross-Up</FONT> Payment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OR </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>On and After the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise. </U></I>To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is unavailable at the time of a Change in Control because any Company stock is readily tradeable on an established securities market or otherwise, if it is
determined by a nationally recognized United States public accounting firm selected by the Company (the &#147;<U>Auditors</U>&#148;) that any payment or benefit in the nature of compensation made or provided to Executive in connection with
Executive&#146;s employment with the Company (collectively, a &#147;<U>Payments</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Parachute Tax</U>&#148;), then Executive will be entitled to
receive <I>either</I> (A)&nbsp;the full amount of the Payments, or (B)&nbsp;a portion of the Payments having a value equal to $1 less than three (3)&nbsp;times Executive&#146;s &#147;base amount&#148; (as such term is defined in
Section&nbsp;280G(b)(3)(A) of the Code), whichever of clauses (A)&nbsp;and (B), after taking into account applicable federal, state, and local income and employment taxes and the Parachute Tax, results in the receipt by Executive on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest portion of the Payments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any determination required under this <U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>) </U>shall
be made in writing by the Auditor, whose determination, absent manifest error, shall be conclusive and binding for all purposes upon the Company and Executive. For purposes of making the calculations required by this Agreement, the Auditors may make
reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that the Auditors&#146; determinations must be
made with substantial authority (within the meaning of Section&nbsp;6662 of the Code). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is a reduction of the Payments pursuant to this
<U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>)</U>, such reduction shall occur in accordance with Section&nbsp;409A of the Code and in the following order: (1)&nbsp;any cash severance payable by reference to Executive&#146;s base
salary or annual bonus, (2)&nbsp;any other cash amount payable to Executive, (3)&nbsp;any employee benefit valued as a &#147;parachute payment,&#148; and (4)&nbsp;acceleration of vesting of any outstanding equity award. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, in the event that additional Payments are made to Executive after the application
of the cutback in this <U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>)</U>, which additional Payments result in the cutback no longer being applicable, the Company shall pay Executive an additional amount equal to the value of the
Payments that were originally cut back. The Company shall determine at the end of each calendar year whether any such restoration is necessary based on additional Payments (if any) made during such calendar year, and shall pay such restoration by
March&nbsp;15 of the calendar year following such calendar year. In no event whatsoever shall Executive be entitled to a tax <FONT STYLE="white-space:nowrap">gross-up</FONT> or other payment in respect of any excise tax, interest or penalties that
may be imposed on the Payments by reason of the application of Section&nbsp;280G or Section&nbsp;4999 of the Code at any time when any Company stock is readily tradeable on an established securities market or otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors; Binding Agreement</U>. This Agreement shall inure
to the benefit of and be binding upon personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. In the event of Executive&#146;s death prior to receipt of all amounts payable to Executive
(including any unpaid amounts due under <U>Section</U><U></U><U>&nbsp;7</U>), such amounts shall be paid to Executive&#146;s beneficiary designated in a Notice provided to and accepted by the Company or, in the absence of such designation, to
Executive&#146;s estate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice</U>. For the purpose of this Agreement, notices and all other
communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand or overnight courier or three postal delivery days after it has been mailed by United States registered mail, return
receipt requested, postage prepaid, addressed to the respective addresses set forth below in this Agreement, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that Notice of change of
address shall be effective only upon receipt (each such communication, &#147;<U>Notice</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If to the Company, addressed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Shattuck Labs, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn:
General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1018 W. 11th Street, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Austin, TX 78703 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to
Executive, to the address listed in the Company&#146;s payroll records from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Executive
Representation</U>. Executive hereby represents to the Company that the execution and delivery of this Agreement by Executive and the Company and the performance by Executive of Executive&#146;s duties hereunder shall not constitute a breach of, or
otherwise contravene, the terms of any employment agreement or other agreement or policy to which Executive is a party or otherwise bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>Prior Agreements</U>. This Agreement supersedes all prior agreements and understandings (including verbal
agreements) between Executive and the Company and/or its affiliates regarding the terms and conditions of Executive&#146;s employment with the Company and/or its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cooperation</U>. Executive shall provide Executive&#146;s reasonable cooperation in connection with any action
or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executive&#146;s employment hereunder, provided, that, following termination of Executive&#146;s employment, the Company shall pay all reasonable
expenses incurred by Executive in providing such cooperation. This provision shall survive any termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding Taxes</U>. The Company may withhold from any amounts payable under this Agreement such federal,
state and local taxes as may be required to be withheld pursuant to any applicable law or regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be signed in
counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows this Page] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have duly executed this Employment Agreement as of
the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SHATTUCK LABS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Josiah Hornblower</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Josiah Hornblower</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXECUTIVE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Taylor Schreiber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Taylor Schreiber</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.6</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.6 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>EMPLOYMENT AGREEMENT (the &#147;<U>Agreement</U>&#148;) is entered into as of December&nbsp;5, 2019 (the &#147;<U>Effective
Date</U>&#148;), by and between Shattuck Labs, Inc. (the &#147;<U>Company</U>&#148;) and Arundathy Nirmalini Pandite (&#147;<U>Executive</U>&#148;). </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company wishes to continue to employ Executive as the Chief Medical Officer of the Company and Executive wishes to
continue to work as the Chief Medical Officer of the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and Executive wish to enter into this
Agreement on the terms and conditions set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, it is hereby agreed as follows </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment</U>. The Company agrees to employ Executive, and Executive hereby accepts such employment, upon the
terms and subject to the conditions set forth herein, for a period commencing on the Effective Date and ending on the date that this Agreement is terminated in accordance with <U>Section</U><U></U><U>&nbsp;7</U> below (the &#147;<U>Employment
Term</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Position; Duties</U>. During the Employment Term, Executive shall serve as the Chief
Medical Officer of the Company. In such position, Executive shall report directly to the Company&#146;s Chief Executive Officer and shall have such duties and authority as are customary to such position and as otherwise determined from time to time
by the Company. During the Employment Term, Executive agrees to devote Executive&#146;s full time and reasonable best efforts to the performance of Executive&#146;s duties to the Company. The foregoing shall not be construed to prohibit Executive
from engaging in activities relating to serving on civic and charitable boards or committees, and managing personal investments, provided that such activities do not significantly interfere or conflict with the performance by Executive of
Executive&#146;s duties, responsibilities, or authorities hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salary</U>. During the Employment
Term, the Company shall pay Executive an initial base salary at the annual rate of $405,000, payable in regular installments in accordance with the Company&#146;s usual payment practices. Executive&#146;s base salary may be increased in the sole
discretion of the Compensation Committee of the Board (the &#147;<U>Committee</U>&#148;). Executive&#146;s annual base salary, as in effect from time to time, is hereinafter referred to as the &#147;<U>Base Salary</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Compensation</U>. During the Employment Term, Executive shall be eligible to receive an annual cash
bonus based on performance objectives established by the Committee each year (the &#147;<U>Annual Bonus</U>&#148;). Executive&#146;s target Annual Bonus amount will be the percentage of Base Salary designated as the target by the Committee, which
amount shall be at least 35% of the Base Salary then in effect (the &#147;<U>Target Annual Bonus</U>&#148;). Notwithstanding the preceding, Executive&#146;s Annual Bonus, if any, may be below (including zero), at, or above the target based upon the
achievement of the performance objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Benefits</U>. During the Employment Term, Executive
shall be entitled to participate in the Company&#146;s employee benefit plans as in effect from time to time (collectively &#147;<U>Employee Benefits</U>&#148;), on the same basis as those benefits are generally made available to other senior
executives of the Company, in each case to the extent that Executive is eligible under the terms of such plans or programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Business Expenses</U>. During the Employment Term, reasonable business expenses incurred by Executive in the
performance of Executive&#146;s duties hereunder shall be advanced or promptly reimbursed by the Company in accordance with Company policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The Employment Term and Executive&#146;s employment may be terminated by the Company at any time
and for any reason upon Notice to Executive and by Executive upon at least 30 days&#146; advance Notice of any such resignation of Executive&#146;s employment. Notwithstanding any other provision of this Agreement, the provisions of this
<U>Section</U><U></U><U>&nbsp;7</U> shall exclusively govern Executive&#146;s rights to payment of compensation, severance, Employee Benefits and business expenses upon termination of employment with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>By the Company for Cause; By Executive without Good Reason.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment may be terminated by the Company for Cause and
shall terminate automatically upon the effective date of Executive&#146;s resignation without Good Reason. For purposes of this Agreement, &#147;<U>Cause</U>&#148; shall mean (A)&nbsp;indictment for, conviction of, or a plea of <I>nolo</I>
<I>contendere</I> to, (x)&nbsp;a felony (other than traffic-related) under the laws of the United States or any state thereof or any similar criminal act in a jurisdiction outside the United States or (y)&nbsp;a crime involving moral turpitude that
could be injurious to the Company or its reputation, (B)&nbsp;Executive&#146;s willful malfeasance or willful misconduct which is materially and demonstrably injurious to the Company, (C)&nbsp;any act of fraud by Executive in the performance of
Executive&#146;s duties or (D)&nbsp;Executive&#146;s material breach of any Agreement with the Company or any of the Company&#146;s material policies. The determination of Cause shall be made by the Board, in its good faith discretion. For purposes
of this Agreement, &#147;<U>Good Reason</U>&#148; shall mean the occurrence of any of the following events, without Executive&#146;s written consent, provided, in each case, that such event is not cured within thirty (30)&nbsp;days after the Company
receives notice from Executive specifying in reasonable detail the event which constitutes Good Reason: (1)&nbsp;any failure by the Company to pay Executive&#146;s Base Salary or Annual Bonus (if any) when due; (2)&nbsp;a reduction in
Executive&#146;s Base Salary or Target Annual Bonus (excluding any change in value of equity incentives); (3) any diminution in Executive&#146;s title or any substantial and sustained diminution in Executive&#146;s duties; or (4)&nbsp;a required
relocation of Executive&#146;s primary work location by more than 25 miles from Executive&#146;s current work location. &#147;<U>Good Reason</U>&#148; shall cease to exist for an event on the 90th day following Executive&#146;s knowledge thereof,
unless Executive has given the Company Notice thereof prior to such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is terminated by
the Company for Cause, or if Executive resigns without Good Reason, Executive shall be entitled to receive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the Base Salary accrued through the date of termination, payable as soon as practicable following
the date of such termination or as otherwise required by applicable law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;any Annual Bonus
earned, but unpaid, as of the date of termination for the year immediately preceding the year in which such termination occurs, paid on the date when bonuses are otherwise paid to Company executives, and in all events by March 15<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such termination occurs; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;reimbursement, within 60 days following submission by Executive to the Company of appropriate
supporting documentation, for any unreimbursed business expenses properly incurred by Executive in accordance with Company policy prior to the date of Executive&#146;s termination; provided, that claims for such reimbursement (accompanied by
appropriate supporting documentation) are submitted to the Company within 90 days following the date of Executive&#146;s termination of employment; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;such Employee Benefits, if any, as to which Executive may be entitled under the employee benefit
plans of the Company, which shall be paid in accordance with the terms of the applicable plans (the amounts described in clauses (A)&nbsp;through (D) hereof, the &#147;<U>Accrued Rights</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following such termination of Executive&#146;s employment by the Company for Cause or resignation by Executive without Good
Reason, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(a)(ii),</U> Executive shall have no further rights to any compensation or any other benefits under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability or Death</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment shall terminate automatically upon
Executive&#146;s death and may be terminated by the Company upon Executive&#146;s Disability. For purposes of this Agreement, a &#147;<U>Disability</U>&#148; shall be deemed to have occurred if Executive has for one hundred twenty
(120)&nbsp;consecutive days or one hundred eighty <FONT STYLE="white-space:nowrap">(180)&nbsp;non-consecutive</FONT> days in any twelve (12)&nbsp;month period been disabled in a manner which has rendered Executive unable to perform the essential
functions of Executive&#146;s job duties with or without reasonable accommodation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Upon
termination of Executive&#146;s employment for either Disability or death, Executive or Executive&#146;s estate (as the case may be) shall be entitled to receive (A)&nbsp;the Accrued Rights and (B)&nbsp;a pro rata portion of the actual Annual Bonus
earned for the year of termination, based on the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the
calendar year following the year in which such termination occurs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment due to death or
Disability, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(b)(ii)</U>, Executive shall have no further rights to any compensation or any other benefits under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>By the Company without Cause; By Executive with Good Reason.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment may be terminated by the Company without Cause
or by Executive with Good Reason. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is terminated by the Company
without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event not within 30 days before or two years after a Change in Control, Executive shall be entitled to receive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the Accrued Rights; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;subject to Executive&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of
a release of claims in the form provided by the Company and within the time period specified therein and Executive&#146;s continued compliance with the provisions of <U>Section</U><U></U><U>&nbsp;8</U> and the PIIA Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a pro rata portion of the actual Annual Bonus that would have been earned for the year of termination, based on
the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such
termination occurs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment of an amount equal to 1.00 times the sum of Executive&#146;s annual Base Salary plus Executive&#146;s
Target Annual Bonus amount for the year of termination, which shall be payable to Executive in equal installments in accordance with the Company&#146;s normal payroll practices, for 12 months following the date that the release of claims becomes
effective and irrevocable (<U>provided</U>, <U>however</U>, that if the period during which the release could become effective and irrevocable spans two calendar years, payments of such installments shall not commence until the first normal payroll
date in the second calendar year); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">effective as of immediately prior to such termination of employment, accelerated vesting of all then unvested
equity awards (with any applicable performance-based awards deemed earned at the target level of achievement) with such awards (other than stock options) settled as soon as practicable thereafter and in all events by March 15<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such termination occurs or to remain exercisable (with respect to stock options) through the
90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following such termination of employment; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to Executive&#146;s timely election of continuation coverage under the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), and subject to Executive&#146;s copayment of premium amounts at the active employees&#146; rate, the Company shall pay the remainder of the premiums for Executive&#146;s
participation in the Company&#146;s group health plans pursuant to COBRA for a period ending on the earlier of (i)&nbsp;the 12 month anniversary of the date of termination; (ii)&nbsp;Executive becoming eligible for other group health benefits, or
(iii)&nbsp;the expiration of Executive&#146;s rights under COBRA; provided, however, that in the event that the benefits provided herein would subject the Company or any of its affiliates to any tax or penalty under the Patient Protection and
Affordable Care Act or Section&nbsp;105(h) of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), Executive and the Company agree to work together in good faith to restructure the foregoing benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment by the Company without Cause (other than by reason of Executive&#146;s death or
Disability) or Executive&#146;s resignation with Good Reason not within 30 days before or two years after a Change in Control, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(c)(ii)</U>, Executive shall have no further rights to any
compensation or any other benefits under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is
terminated by the Company without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event within 30 days before or two years after a Change in Control, Executive shall be entitled to receive the
payments and benefits described in <U>Section</U><U></U><U>&nbsp;7(c)(ii)(A) and (B)</U>, except that the severance multiplier in Section<U>&nbsp;7(c)(ii)(B)(2)</U> shall be increased from 1.00 to 2.00. For the avoidance of doubt, payment of such
amounts and benefits other than the Accrued Rights shall be subject to Executive providing and not revoking a release of claims in the form provided by the Company and within the time period specified therein and Executive&#146;s continued
compliance with the provisions of <U>Section</U><U></U><U>&nbsp;8</U> and the PIIA Agreement. For purposes of this Agreement, &#147;<U>Change in Control</U>&#148; means the occurrence of one or more of the following events: (i)&nbsp;any
&#147;person&#148; (as such term is used in Sections 3(a)(9) and 13(d) of the Securities Exchange Act of 1934, as amended (the &#147;<U>Act</U>&#148;)) or &#147;group&#148; (as such term is used in Section&nbsp;13(d)(3) of the Act), other than the
Company or its subsidiaries or any benefit plan of the Company or its subsidiaries is or becomes a &#147;beneficial owner&#148; (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated under the Act) of more than 50%
of the Voting Stock of the Company; (ii)&nbsp;the Company transfers all or substantially all of its assets (unless the shareholders of the Company immediately prior to such transaction beneficially own, directly or indirectly, in substantially the
same proportion as they owned the Voting Stock of the Company, all of the Voting Stock or other ownership interests of the entity or entities, if any, that succeed to the business of the Company or the Company&#146;s ultimate parent company if the
Company is a subsidiary of another corporation); or (iii)&nbsp;any merger, reorganization, consolidation or similar transaction unless, immediately after consummation of such transaction, the shareholders of the Company immediately prior to the
transaction hold, directly or indirectly, more than 50% of the Voting Stock of the Company or the Company&#146;s ultimate parent company if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Company is a subsidiary of another corporation. For purposes of this Change in Control definition, &#147;<U>Voting Stock</U>&#148; means securities or ownership interests of any class or
classes having general voting power under ordinary circumstances, in the absence of contingencies, to elect the directors of a corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment by the Company without Cause (other than by reason of Executive&#146;s death or
Disability) or by Executive with Good Reason within 30 days before or two years after a Change in Control, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(c)(iii)</U>, Executive shall have no further rights to any compensation or any
other benefits under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Any termination of employment by the
Company or by Executive (other than due to Executive&#146;s death) shall be communicated by Notice of Termination to the other party hereto in accordance with <U>Section</U><U></U><U>&nbsp;11(k)</U> hereof. For purposes of this Agreement, a
&#147;<U>Notice of Termination</U>&#148; shall mean a Notice that indicates the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination
of employment under the provision so indicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination and Offices Held</U>. Upon termination of
Executive&#146;s employment for any reason, Executive shall be deemed to have resigned from all positions that Executive may then hold as an employee, officer or director of the Company or any affiliate of the Company. Executive shall promptly
deliver to the Company any additional documents reasonably required by the Company to confirm such resignations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></U>. Executive shall not, while employed by the Company
or at any time thereafter, disparage the Company (or any affiliate) in any way that materially and adversely affects the goodwill, reputation or business relationships of the Company or the affiliate with the public generally, or with any of its
customers, vendors or employees. The Company shall not (and shall use reasonable efforts to procure that its directors and officers shall not) disparage Executive in any way that materially and adversely affects Executive or Executive&#146;s
reputation or business relationships. Notwithstanding the foregoing, this Section shall not prohibit either party from rebutting claims or statements made by any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Proprietary Information and Inventions Assignment Agreement</U>. Executive previously entered into a Proprietary
Information and Inventions Assignment Agreement with the Company (the &#147;<U>PIIA Agreement</U>&#148;) and hereby reaffirms all of Executive&#146;s obligations thereunder. The provisions of <U>Section</U><U></U><U>&nbsp;8</U> hereof and the
provisions of the PIIA Agreement shall survive the termination of Executive&#146;s employment for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance</U>. Executive acknowledges and agrees that the Company&#146;s remedies at law for a breach
or threatened breach of any of the provisions of <U>Section</U><U></U><U>&nbsp;8</U> would be inadequate and the Company would suffer irreparable damages as a result of such breach or threatened breach. In recognition of this fact, Executive agrees
that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to cease making any payments or providing any benefit otherwise required by this Agreement and
obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration</U>. For the avoidance of doubt, the arbitration and equitable relief provisions of the PIIA
Agreement shall apply to any dispute concerning Executive&#146;s employment with the Company or arising under or in any way related to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law; Consent to Personal Jurisdiction</U>. THIS AGREEMENT WILL BE GOVERNED BY THE LAWS OF THE STATE OF
TEXAS WITHOUT REGARD FOR CONFLICTS OF LAWS PRINCIPLES. SUBJECT TO THE ARBITRATION PROVISION IN THE PIIA AGREEMENT, EXECUTIVE HEREBY EXPRESSLY CONSENTS TO THE PERSONAL JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN TEXAS FOR ANY LAWSUIT
FILED THERE AGAINST EXECUTIVE BY THE COMPANY CONCERNING EXECUTIVE&#146;S EMPLOYMENT OR THE TERMINATION OF EXECUTIVE&#146;S EMPLOYMENT OR ARISING FROM OR RELATING TO THIS AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement/Amendments</U>. This Agreement, together with the PIIA Agreement, contains the entire
understanding of the parties with respect to the employment of Executive by the Company. There are no restrictions, agreements, promises, warranties, covenants or undertakings between the parties with respect to the subject matter herein other than
those expressly set forth herein or as may be set forth from time to time in the Company&#146;s employee benefit plans and policies applicable to Executive. This Agreement may not be altered, modified, or amended except by written instrument signed
by the parties hereto. In the event of any inconsistency between this Agreement and any other plan, program, practice or agreement of which Executive is a participant or a party, this Agreement shall control unless such other plan, program, practice
or agreement specifically refers to the provisions of this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Waiver</U>. The failure of a party
to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver of such party&#146;s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. In the event that any one or more of the provisions of this Agreement
shall be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions of this Agreement shall not be affected thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>. This Agreement, and all of Executive&#146;s rights and duties hereunder, shall not be assignable
or delegable by Executive. Any purported assignment or delegation by Executive in violation of the foregoing shall be null and <I>void ab initio</I> and of no force and effect. This Agreement may be assigned by the Company to a person or entity
which is an affiliate or a successor in interest to substantially all of the business operations of the Company. Upon such assignment, the rights and obligations of the Company hereunder shall become the rights and obligations of such affiliate or
successor person or entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterclaim; No Mitigation</U>. The Company&#146;s obligation
to pay Executive the amounts provided and to make the arrangements provided hereunder shall be subject to counterclaim and to seek recoupment of amounts owed by Executive to the Company or its affiliates. Executive shall not be required to mitigate
the amount of any payment provided for pursuant to this Agreement by seeking other employment, and such payments shall not be reduced by any compensation or benefits received from any subsequent employer or other endeavor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Code Section</U><U></U><U>&nbsp;409A</U>. Notwithstanding anything herein to the contrary,
(i)&nbsp;if at the time of Executive&#146;s termination of employment with the Company Executive is a &#147;specified employee&#148; as defined in Section&nbsp;409A of the Code and the deferral of the commencement of any payments or benefits
otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section&nbsp;409A of the Code, then the Company will defer the commencement of the payment of any such
payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Executive) until the date that is six months following Executive&#146;s termination of employment with the Company (or the earliest
date as is permitted under Section&nbsp;409A of the Code) and (ii)&nbsp;if any other payments of money or other benefits due to Executive hereunder could cause the application of an accelerated or additional tax under Section&nbsp;409A of the Code,
such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section&nbsp;409A of the Code, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a
manner, determined by the Board, that does not cause such an accelerated or additional tax. For purposes of Section&nbsp;409A of the Code, each payment made under this Agreement shall be designated as a &#147;separate payment&#148; within the
meaning of the Section&nbsp;409A of the Code, and references herein to Executive&#146;s &#147;termination of employment&#148; shall refer to Executive&#146;s separation from service with the Company within the meaning of Section&nbsp;409A. To the
extent any reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits due to Executive under this Agreement constitute &#147;deferred compensation&#148; under Section&nbsp;409A of the Code, any such reimbursements or <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits shall be paid to Executive in a manner consistent with Treas. Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(1)(iv).</FONT> The Company shall consult with Executive in good faith
regarding the implementation of the provisions of this <U>Section</U><U></U><U>&nbsp;11(h)</U>; <U>provided</U> that neither the Company nor any of its employees or representatives shall have any liability to Executive with respect to thereto or any
tax imposed under Section&nbsp;409A. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Code Section</U><U></U><U>&nbsp;280G</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>Prior to the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise</U></I><I>; Shareholder Vote Sought</I>. To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is available at the time of a Change in Control if the shareholder approval requirements under Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q/A-7</FONT> are satisfied, the Company may elect to pursue a shareholder vote in accordance with such provisions and the Company and Executive shall cooperate with
each other and use their commercially reasonable efforts to obtain a vote satisfying the requirements of Section&nbsp;280G(b)(5) of the Code and Treasury Regulation <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT
STYLE="white-space:nowrap">Q/A-7,</FONT> such that neither Executive nor the Company or its Affiliates suffers any adverse tax consequences under Sections 280G and 4999 of the Code. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>Prior to the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise</U></I><I>; Shareholder Vote Not Sought. </I>To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is available at the time of a Change in Control if the shareholder approval requirements under Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q/A-7</FONT> are satisfied and the Company does <I>not</I> seek a shareholder vote in accordance with Section&nbsp;11(i)(<I>i</I>) hereof, if it is determined by a
nationally recognized United States public accounting firm selected by the Company (the &#147;<U>Auditors</U>&#148;) that any payment or benefit in the nature of compensation made or provided to Executive in connection with Executive&#146;s
employment with the Company (collectively, a &#147;<U>Payment</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Parachute Tax</U>&#148;), then the Company shall pay to Executive, prior to the time
the Parachute Tax is payable with respect to such Payment, an additional payment (a &#147;<U><FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment</U>&#148;) in an amount such that, after payment by Executive of all taxes (including any Parachute
Tax) imposed upon the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment, Executive retains an amount of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment equal to the Parachute Tax imposed upon the Payment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount of any <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment shall be determined by the Auditors,
subject to adjustment, as necessary, as a result of any Internal Revenue Service position. For purposes of making the calculations required by this Agreement, the Auditors may make reasonable assumptions and approximations concerning applicable
taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that the Auditors&#146; determinations must be made with substantial authority (within the meaning of
Section&nbsp;6662 of the Code). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The federal tax returns filed by Executive (and any filing made by a consolidated tax group which includes the
Company) shall be prepared and filed on a basis consistent with the determination of the Auditors with respect to the Parachute Tax payable by Executive. Executive shall make proper payment of the amount of any Parachute Tax, and at the request of
the Company, provide to the Company true and correct copies (with any amendments) of Executive&#146;s federal income tax return as filed with the Internal Revenue Service, and such other documents reasonably requested by the Company, evidencing such
payment. If, after the Company&#146;s payment to Executive of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment, the Auditors determine in good faith that the amount of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment should
be reduced or increased, or such determination is made by the Internal Revenue Service, then within ten (10)&nbsp;business days of such determination, Executive shall pay to the Company the amount of any such reduction, or the Company shall pay to
Executive the amount of any such increase; provided, however, that (i)&nbsp;the fees and expenses of the Auditors (and any other legal and accounting fees) incurred for services rendered in connection with the Auditor&#146;s determination of the
Parachute Tax or any challenge by the Internal Revenue Service or other taxing authority relating to such determination shall be paid by the Company, and (ii)&nbsp;the Company shall indemnify and hold Executive harmless on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis for any interest and penalties imposed upon Executive to the extent that such interest and penalties are related to the Auditor&#146;s determination of the Parachute Tax or the <FONT
STYLE="white-space:nowrap">Gross-Up</FONT> Payment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OR </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>On and After the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise. </U></I>To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is unavailable at the time of a Change in Control because any Company stock is readily tradeable on an established securities market or otherwise, if it is
determined by a nationally recognized United States public accounting firm selected by the Company (the &#147;<U>Auditors</U>&#148;) that any payment or benefit in the nature of compensation made or provided to Executive in connection with
Executive&#146;s employment with the Company (collectively, a &#147;<U>Payments</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Parachute Tax</U>&#148;), then Executive will be entitled to
receive <I>either</I> (A)&nbsp;the full amount of the Payments, or (B)&nbsp;a portion of the Payments having a value equal to $1 less than three (3)&nbsp;times Executive&#146;s &#147;base amount&#148; (as such term is defined in
Section&nbsp;280G(b)(3)(A) of the Code), whichever of clauses (A)&nbsp;and (B), after taking into account applicable federal, state, and local income and employment taxes and the Parachute Tax, results in the receipt by Executive on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest portion of the Payments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any determination required under this <U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>) </U>shall
be made in writing by the Auditor, whose determination, absent manifest error, shall be conclusive and binding for all purposes upon the Company and Executive. For purposes of making the calculations required by this Agreement, the Auditors may make
reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that the Auditors&#146; determinations must be
made with substantial authority (within the meaning of Section&nbsp;6662 of the Code). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is a reduction of the Payments pursuant to this
<U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>)</U>, such reduction shall occur in accordance with Section&nbsp;409A of the Code and in the following order: (1)&nbsp;any cash severance payable by reference to Executive&#146;s base
salary or annual bonus, (2)&nbsp;any other cash amount payable to Executive, (3)&nbsp;any employee benefit valued as a &#147;parachute payment,&#148; and (4)&nbsp;acceleration of vesting of any outstanding equity award. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, in the event that additional Payments are made to Executive after the application
of the cutback in this <U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>)</U>, which additional Payments result in the cutback no longer being applicable, the Company shall pay Executive an additional amount equal to the value of the
Payments that were originally cut back. The Company shall determine at the end of each calendar year whether any such restoration is necessary based on additional Payments (if any) made during such calendar year, and shall pay such restoration by
March&nbsp;15 of the calendar year following such calendar year. In no event whatsoever shall Executive be entitled to a tax <FONT STYLE="white-space:nowrap">gross-up</FONT> or other payment in respect of any excise tax, interest or penalties that
may be imposed on the Payments by reason of the application of Section&nbsp;280G or Section&nbsp;4999 of the Code at any time when any Company stock is readily tradeable on an established securities market or otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors; Binding Agreement</U>. This Agreement shall inure
to the benefit of and be binding upon personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. In the event of Executive&#146;s death prior to receipt of all amounts payable to Executive
(including any unpaid amounts due under <U>Section</U><U></U><U>&nbsp;7</U>), such amounts shall be paid to Executive&#146;s beneficiary designated in a Notice provided to and accepted by the Company or, in the absence of such designation, to
Executive&#146;s estate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice</U>. For the purpose of this Agreement, notices and all other
communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand or overnight courier or three postal delivery days after it has been mailed by United States registered mail, return
receipt requested, postage prepaid, addressed to the respective addresses set forth below in this Agreement, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that Notice of change of
address shall be effective only upon receipt (each such communication, &#147;<U>Notice</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If to the Company, addressed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Shattuck Labs, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn:
General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1018 W. 11th Street, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Austin, TX 78703 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to
Executive, to the address listed in the Company&#146;s payroll records from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Executive
Representation</U>. Executive hereby represents to the Company that the execution and delivery of this Agreement by Executive and the Company and the performance by Executive of Executive&#146;s duties hereunder shall not constitute a breach of, or
otherwise contravene, the terms of any employment agreement or other agreement or policy to which Executive is a party or otherwise bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>Prior Agreements</U>. This Agreement supersedes all prior agreements and understandings (including verbal
agreements) between Executive and the Company and/or its affiliates regarding the terms and conditions of Executive&#146;s employment with the Company and/or its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cooperation</U>. Executive shall provide Executive&#146;s reasonable cooperation in connection with any action
or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executive&#146;s employment hereunder, provided, that, following termination of Executive&#146;s employment, the Company shall pay all reasonable
expenses incurred by Executive in providing such cooperation. This provision shall survive any termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding Taxes</U>. The Company may withhold from any amounts payable under this Agreement such federal,
state and local taxes as may be required to be withheld pursuant to any applicable law or regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be signed in
counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows this Page] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have duly executed this Employment Agreement as of
the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SHATTUCK LABS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Josiah Hornblower</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Josiah Hornblower</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXECUTIVE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Arundathy Nirmalini Pandite</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Arundathy Nirmalini Pandite</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.7</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.7 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>EMPLOYMENT AGREEMENT</B> (the &#147;<U>Agreement</U>&#148;) is entered into as of December&nbsp;5, 2019 (the &#147;<U>Effective
Date</U>&#148;), by and between Shattuck Labs, Inc. (the &#147;<U>Company</U>&#148;) and Erin Ator Thomson (&#147;<U>Executive</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company wishes to continue to employ Executive as the General Counsel of the Company and Executive wishes to continue to
work as the General Counsel of the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and Executive wish to enter into this Agreement on the terms
and conditions set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, it is hereby agreed as follows </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment</U>. The Company agrees to employ Executive, and Executive hereby accepts such employment, upon the
terms and subject to the conditions set forth herein, for a period commencing on the Effective Date and ending on the date that this Agreement is terminated in accordance with <U>Section</U><U></U><U>&nbsp;7</U> below (the &#147;<U>Employment
Term</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Position; Duties</U>. During the Employment Term, Executive shall serve as the General
Counsel of the Company. In such position, Executive shall report directly to the Company&#146;s Chief Executive Officer and shall have such duties and authority as are customary to such position and as otherwise determined from time to time by the
Company. During the Employment Term, Executive agrees to devote Executive&#146;s full time and reasonable best efforts to the performance of Executive&#146;s duties to the Company. The foregoing shall not be construed to prohibit Executive from
engaging in activities relating to serving on civic and charitable boards or committees, and managing personal investments, provided that such activities do not significantly interfere or conflict with the performance by Executive of
Executive&#146;s duties, responsibilities, or authorities hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salary</U>. During the Employment
Term, the Company shall pay Executive an initial base salary at the annual rate of $315,000, payable in regular installments in accordance with the Company&#146;s usual payment practices. Executive&#146;s base salary may be increased in the sole
discretion of the Compensation Committee of the Board (the &#147;<U>Committee</U>&#148;). Executive&#146;s annual base salary, as in effect from time to time, is hereinafter referred to as the &#147;<U>Base Salary</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Compensation</U>. During the Employment Term, Executive shall be eligible to receive an annual cash
bonus based on performance objectives established by the Committee each year (the &#147;<U>Annual Bonus</U>&#148;). Executive&#146;s target Annual Bonus amount will be the percentage of Base Salary designated as the target by the Committee, which
amount shall be at least 20% of the Base Salary then in effect (the &#147;<U>Target Annual Bonus</U>&#148;). Notwithstanding the preceding, Executive&#146;s Annual Bonus, if any, may be below (including zero), at, or above the target based upon the
achievement of the performance objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Benefits</U>. During the Employment Term, Executive
shall be entitled to participate in the Company&#146;s employee benefit plans as in effect from time to time (collectively &#147;<U>Employee Benefits</U>&#148;), on the same basis as those benefits are generally made available to other senior
executives of the Company, in each case to the extent that Executive is eligible under the terms of such plans or programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Business Expenses</U>. During the Employment Term, reasonable business expenses incurred by Executive in the
performance of Executive&#146;s duties hereunder shall be advanced or promptly reimbursed by the Company in accordance with Company policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The Employment Term and Executive&#146;s employment may be terminated by the Company at any time
and for any reason upon Notice to Executive and by Executive upon at least 30 days&#146; advance Notice of any such resignation of Executive&#146;s employment. Notwithstanding any other provision of this Agreement, the provisions of this
<U>Section</U><U></U><U>&nbsp;7</U> shall exclusively govern Executive&#146;s rights to payment of compensation, severance, Employee Benefits and business expenses upon termination of employment with the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>By the Company for Cause; By Executive without Good Reason.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment may be terminated by the Company for Cause and
shall terminate automatically upon the effective date of Executive&#146;s resignation without Good Reason. For purposes of this Agreement, &#147;<U>Cause</U>&#148; shall mean (A)&nbsp;indictment for, conviction of, or a plea of <I>nolo</I>
<I>contendere</I> to, (x)&nbsp;a felony (other than traffic-related) under the laws of the United States or any state thereof or any similar criminal act in a jurisdiction outside the United States or (y)&nbsp;a crime involving moral turpitude that
could be injurious to the Company or its reputation, (B)&nbsp;Executive&#146;s willful malfeasance or willful misconduct which is materially and demonstrably injurious to the Company, (C)&nbsp;any act of fraud by Executive in the performance of
Executive&#146;s duties or (D)&nbsp;Executive&#146;s material breach of any Agreement with the Company or any of the Company&#146;s material policies. The determination of Cause shall be made by the Board, in its good faith discretion. For purposes
of this Agreement, &#147;<U>Good Reason</U>&#148; shall mean the occurrence of any of the following events, without Executive&#146;s written consent, provided, in each case, that such event is not cured within thirty (30)&nbsp;days after the Company
receives notice from Executive specifying in reasonable detail the event which constitutes Good Reason: (1)&nbsp;any failure by the Company to pay Executive&#146;s Base Salary or Annual Bonus (if any) when due; (2)&nbsp;a reduction in
Executive&#146;s Base Salary or Target Annual Bonus (excluding any change in value of equity incentives); (3) any diminution in Executive&#146;s title or any substantial and sustained diminution in Executive&#146;s duties; or (4)&nbsp;a required
relocation of Executive&#146;s primary work location by more than 25 miles from Executive&#146;s current work location. &#147;<U>Good Reason</U>&#148; shall cease to exist for an event on the 90th day following Executive&#146;s knowledge thereof,
unless Executive has given the Company Notice thereof prior to such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is terminated by
the Company for Cause, or if Executive resigns without Good Reason, Executive shall be entitled to receive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the Base Salary accrued through the date of termination, payable as soon as practicable following
the date of such termination or as otherwise required by applicable law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;any Annual Bonus
earned, but unpaid, as of the date of termination for the year immediately preceding the year in which such termination occurs, paid on the date when bonuses are otherwise paid to Company executives, and in all events by March 15<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such termination occurs; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;reimbursement, within 60 days following submission by Executive to the Company of appropriate
supporting documentation, for any unreimbursed business expenses properly incurred by Executive in accordance with Company policy prior to the date of Executive&#146;s termination; provided, that claims for such reimbursement (accompanied by
appropriate supporting documentation) are submitted to the Company within 90 days following the date of Executive&#146;s termination of employment; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;such Employee Benefits, if any, as to which Executive may be entitled under the employee benefit
plans of the Company, which shall be paid in accordance with the terms of the applicable plans (the amounts described in clauses (A)&nbsp;through (D) hereof, the &#147;<U>Accrued Rights</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following such termination of Executive&#146;s employment by the Company for Cause or resignation by Executive without Good
Reason, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(a)(ii),</U> Executive shall have no further rights to any compensation or any other benefits under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability or Death</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment shall terminate automatically upon
Executive&#146;s death and may be terminated by the Company upon Executive&#146;s Disability. For purposes of this Agreement, a &#147;<U>Disability</U>&#148; shall be deemed to have occurred if Executive has for one hundred twenty
(120)&nbsp;consecutive days or one hundred eighty <FONT STYLE="white-space:nowrap">(180)&nbsp;non-consecutive</FONT> days in any twelve (12)&nbsp;month period been disabled in a manner which has rendered Executive unable to perform the essential
functions of Executive&#146;s job duties with or without reasonable accommodation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Upon
termination of Executive&#146;s employment for either Disability or death, Executive or Executive&#146;s estate (as the case may be) shall be entitled to receive (A)&nbsp;the Accrued Rights and (B)&nbsp;a pro rata portion of the actual Annual Bonus
earned for the year of termination, based on the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the
calendar year following the year in which such termination occurs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment due to death or
Disability, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(b)(ii)</U>, Executive shall have no further rights to any compensation or any other benefits under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>By the Company without Cause; By Executive with Good Reason.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment may be terminated by the Company without Cause
or by Executive with Good Reason. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is terminated by the Company
without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event not within 30 days before or two years after a Change in Control, Executive shall be entitled to receive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the Accrued Rights; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;subject to Executive&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of
a release of claims in the form provided by the Company and within the time period specified therein and Executive&#146;s continued compliance with the provisions of <U>Section</U><U></U><U>&nbsp;8</U> and the PIIA Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a pro rata portion of the actual Annual Bonus that would have been earned for the year of termination, based on
the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such
termination occurs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment of an amount equal to 0.75 times the sum of Executive&#146;s annual Base Salary plus Executive&#146;s
Target Annual Bonus amount for the year of termination, which shall be payable to Executive in equal installments in accordance with the Company&#146;s normal payroll practices, for 9 months following the date that the release of claims becomes
effective and irrevocable (<U>provided</U>, <U>however</U>, that if the period during which the release could become effective and irrevocable spans two calendar years, payments of such installments shall not commence until the first normal payroll
date in the second calendar year); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">effective as of immediately prior to such termination of employment, accelerated vesting of all then unvested
equity awards (with any applicable performance-based awards deemed earned at the target level of achievement) with such awards (other than stock options) settled as soon as practicable thereafter and in all events by March 15<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such termination occurs or to remain exercisable (with respect to stock options) through the
90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following such termination of employment; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to Executive&#146;s timely election of continuation coverage under the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), and subject to Executive&#146;s copayment of premium amounts at the active employees&#146; rate, the Company shall pay the remainder of the premiums for Executive&#146;s
participation in the Company&#146;s group health plans pursuant to COBRA for a period ending on the earlier of (i)&nbsp;the 9 month anniversary of the date of termination; (ii)&nbsp;Executive becoming eligible for other group health benefits, or
(iii)&nbsp;the expiration of Executive&#146;s rights under COBRA; provided, however, that in the event that the benefits provided herein would subject the Company or any of its affiliates to any tax or penalty under the Patient Protection and
Affordable Care Act or Section&nbsp;105(h) of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), Executive and the Company agree to work together in good faith to restructure the foregoing benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment by the Company without Cause (other than by reason of Executive&#146;s death or
Disability) or Executive&#146;s resignation with Good Reason not within 30 days before or two years after a Change in Control, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(c)(ii)</U>, Executive shall have no further rights to any
compensation or any other benefits under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is
terminated by the Company without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event within 30 days before or two years after a Change in Control, Executive shall be entitled to receive the
payments and benefits described in <U>Section</U><U></U><U>&nbsp;7(c)(ii)(A) and (B)</U>, except that the severance multiplier in Section<U>&nbsp;7(c)(ii)(B)(2)</U> shall be increased from 0.75 to 1.50. For the avoidance of doubt, payment of such
amounts and benefits other than the Accrued Rights shall be subject to Executive providing and not revoking a release of claims in the form provided by the Company and within the time period specified therein and Executive&#146;s continued
compliance with the provisions of <U>Section</U><U></U><U>&nbsp;8</U> and the PIIA Agreement. For purposes of this Agreement, &#147;<U>Change in Control</U>&#148; means the occurrence of one or more of the following events: (i)&nbsp;any
&#147;person&#148; (as such term is used in Sections 3(a)(9) and 13(d) of the Securities Exchange Act of 1934, as amended (the &#147;<U>Act</U>&#148;)) or &#147;group&#148; (as such term is used in Section&nbsp;13(d)(3) of the Act), other than the
Company or its subsidiaries or any benefit plan of the Company or its subsidiaries is or becomes a &#147;beneficial owner&#148; (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated under the Act) of more than 50%
of the Voting Stock of the Company; (ii)&nbsp;the Company transfers all or substantially all of its assets (unless the shareholders of the Company immediately prior to such transaction beneficially own, directly or indirectly, in substantially the
same proportion as they owned the Voting Stock of the Company, all of the Voting Stock or other ownership interests of the entity or entities, if any, that succeed to the business of the Company or the Company&#146;s ultimate parent company if the
Company is a subsidiary of another corporation); or (iii)&nbsp;any merger, reorganization, consolidation or similar transaction unless, immediately after consummation of such transaction, the shareholders of the Company immediately prior to the
transaction hold, directly or indirectly, more than 50% of the Voting Stock of the Company or the Company&#146;s ultimate parent company if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Company is a subsidiary of another corporation. For purposes of this Change in Control definition, &#147;<U>Voting Stock</U>&#148; means securities or ownership interests of any class or
classes having general voting power under ordinary circumstances, in the absence of contingencies, to elect the directors of a corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment by the Company without Cause (other than by reason of Executive&#146;s death or
Disability) or by Executive with Good Reason within 30 days before or two years after a Change in Control, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(c)(iii)</U>, Executive shall have no further rights to any compensation or any
other benefits under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Any termination of employment by the
Company or by Executive (other than due to Executive&#146;s death) shall be communicated by Notice of Termination to the other party hereto in accordance with <U>Section</U><U></U><U>&nbsp;11(k)</U> hereof. For purposes of this Agreement, a
&#147;<U>Notice of Termination</U>&#148; shall mean a Notice that indicates the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination
of employment under the provision so indicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination and Offices Held</U>. Upon termination of
Executive&#146;s employment for any reason, Executive shall be deemed to have resigned from all positions that Executive may then hold as an employee, officer or director of the Company or any affiliate of the Company. Executive shall promptly
deliver to the Company any additional documents reasonably required by the Company to confirm such resignations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></U>. Executive shall not, while employed by the Company
or at any time thereafter, disparage the Company (or any affiliate) in any way that materially and adversely affects the goodwill, reputation or business relationships of the Company or the affiliate with the public generally, or with any of its
customers, vendors or employees. The Company shall not (and shall use reasonable efforts to procure that its directors and officers shall not) disparage Executive in any way that materially and adversely affects Executive or Executive&#146;s
reputation or business relationships. Notwithstanding the foregoing, this Section shall not prohibit either party from rebutting claims or statements made by any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Proprietary Information and Inventions Assignment Agreement</U>. Executive previously entered into a Proprietary
Information and Inventions Assignment Agreement with the Company (the &#147;<U>PIIA Agreement</U>&#148;) and hereby reaffirms all of Executive&#146;s obligations thereunder. The provisions of <U>Section</U><U></U><U>&nbsp;8</U> hereof and the
provisions of the PIIA Agreement shall survive the termination of Executive&#146;s employment for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance</U>. Executive acknowledges and agrees that the Company&#146;s remedies at law for a breach
or threatened breach of any of the provisions of <U>Section</U><U></U><U>&nbsp;8</U> would be inadequate and the Company would suffer irreparable damages as a result of such breach or threatened breach. In recognition of this fact, Executive agrees
that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to cease making any payments or providing any benefit otherwise required by this Agreement and
obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration</U>. For the avoidance of doubt, the arbitration and equitable relief provisions of the PIIA
Agreement shall apply to any dispute concerning Executive&#146;s employment with the Company or arising under or in any way related to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law; Consent to Personal Jurisdiction</U>. THIS AGREEMENT WILL BE GOVERNED BY THE LAWS OF THE STATE OF
TEXAS WITHOUT REGARD FOR CONFLICTS OF LAWS PRINCIPLES. SUBJECT TO THE ARBITRATION PROVISION IN THE PIIA AGREEMENT, EXECUTIVE HEREBY EXPRESSLY CONSENTS TO THE PERSONAL JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN TEXAS FOR ANY LAWSUIT
FILED THERE AGAINST EXECUTIVE BY THE COMPANY CONCERNING EXECUTIVE&#146;S EMPLOYMENT OR THE TERMINATION OF EXECUTIVE&#146;S EMPLOYMENT OR ARISING FROM OR RELATING TO THIS AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement/Amendments</U>. This Agreement, together with the PIIA Agreement, contains the entire
understanding of the parties with respect to the employment of Executive by the Company. There are no restrictions, agreements, promises, warranties, covenants or undertakings between the parties with respect to the subject matter herein other than
those expressly set forth herein or as may be set forth from time to time in the Company&#146;s employee benefit plans and policies applicable to Executive. This Agreement may not be altered, modified, or amended except by written instrument signed
by the parties hereto. In the event of any inconsistency between this Agreement and any other plan, program, practice or agreement of which Executive is a participant or a party, this Agreement shall control unless such other plan, program, practice
or agreement specifically refers to the provisions of this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Waiver</U>. The failure of a party
to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver of such party&#146;s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. In the event that any one or more of the provisions of this Agreement
shall be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions of this Agreement shall not be affected thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>. This Agreement, and all of Executive&#146;s rights and duties hereunder, shall not be assignable
or delegable by Executive. Any purported assignment or delegation by Executive in violation of the foregoing shall be null and <I>void ab initio</I> and of no force and effect. This Agreement may be assigned by the Company to a person or entity
which is an affiliate or a successor in interest to substantially all of the business operations of the Company. Upon such assignment, the rights and obligations of the Company hereunder shall become the rights and obligations of such affiliate or
successor person or entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterclaim; No Mitigation</U>. The Company&#146;s obligation
to pay Executive the amounts provided and to make the arrangements provided hereunder shall be subject to counterclaim and to seek recoupment of amounts owed by Executive to the Company or its affiliates. Executive shall not be required to mitigate
the amount of any payment provided for pursuant to this Agreement by seeking other employment, and such payments shall not be reduced by any compensation or benefits received from any subsequent employer or other endeavor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Code Section</U><U></U><U>&nbsp;409A</U>. Notwithstanding anything herein to the contrary,
(i)&nbsp;if at the time of Executive&#146;s termination of employment with the Company Executive is a &#147;specified employee&#148; as defined in Section&nbsp;409A of the Code and the deferral of the commencement of any payments or benefits
otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section&nbsp;409A of the Code, then the Company will defer the commencement of the payment of any such
payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Executive) until the date that is six months following Executive&#146;s termination of employment with the Company (or the earliest
date as is permitted under Section&nbsp;409A of the Code) and (ii)&nbsp;if any other payments of money or other benefits due to Executive hereunder could cause the application of an accelerated or additional tax under Section&nbsp;409A of the Code,
such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section&nbsp;409A of the Code, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a
manner, determined by the Board, that does not cause such an accelerated or additional tax. For purposes of Section&nbsp;409A of the Code, each payment made under this Agreement shall be designated as a &#147;separate payment&#148; within the
meaning of the Section&nbsp;409A of the Code, and references herein to Executive&#146;s &#147;termination of employment&#148; shall refer to Executive&#146;s separation from service with the Company within the meaning of Section&nbsp;409A. To the
extent any reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits due to Executive under this Agreement constitute &#147;deferred compensation&#148; under Section&nbsp;409A of the Code, any such reimbursements or <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits shall be paid to Executive in a manner consistent with Treas. Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(1)(iv).</FONT> The Company shall consult with Executive in good faith
regarding the implementation of the provisions of this <U>Section</U><U></U><U>&nbsp;11(h)</U>; <U>provided</U> that neither the Company nor any of its employees or representatives shall have any liability to Executive with respect to thereto or any
tax imposed under Section&nbsp;409A. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Code Section</U><U></U><U>&nbsp;280G</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>Prior to the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise</U></I><I>; Shareholder Vote Sought</I>. To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is available at the time of a Change in Control if the shareholder approval requirements under Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q/A-7</FONT> are satisfied, the Company may elect to pursue a shareholder vote in accordance with such provisions and the Company and Executive shall cooperate with
each other and use their commercially reasonable efforts to obtain a vote satisfying the requirements of Section&nbsp;280G(b)(5) of the Code and Treasury Regulation <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT
STYLE="white-space:nowrap">Q/A-7,</FONT> such that neither Executive nor the Company or its Affiliates suffers any adverse tax consequences under Sections 280G and 4999 of the Code. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>Prior to the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise</U></I><I>; Shareholder Vote Not Sought. </I>To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is available at the time of a Change in Control if the shareholder approval requirements under Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q/A-7</FONT> are satisfied and the Company does <I>not</I> seek a shareholder vote in accordance with Section&nbsp;11(i)(<I>i</I>) hereof, if it is determined by a
nationally recognized United States public accounting firm selected by the Company (the &#147;<U>Auditors</U>&#148;) that any payment or benefit in the nature of compensation made or provided to Executive in connection with Executive&#146;s
employment with the Company (collectively, a &#147;<U>Payment</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Parachute Tax</U>&#148;), then the Company shall pay to Executive, prior to the time
the Parachute Tax is payable with respect to such Payment, an additional payment (a &#147;<U><FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment</U>&#148;) in an amount such that, after payment by Executive of all taxes (including any Parachute
Tax) imposed upon the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment, Executive retains an amount of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment equal to the Parachute Tax imposed upon the Payment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount of any <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment shall be determined by the Auditors,
subject to adjustment, as necessary, as a result of any Internal Revenue Service position. For purposes of making the calculations required by this Agreement, the Auditors may make reasonable assumptions and approximations concerning applicable
taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that the Auditors&#146; determinations must be made with substantial authority (within the meaning of
Section&nbsp;6662 of the Code). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The federal tax returns filed by Executive (and any filing made by a consolidated tax group which includes the
Company) shall be prepared and filed on a basis consistent with the determination of the Auditors with respect to the Parachute Tax payable by Executive. Executive shall make proper payment of the amount of any Parachute Tax, and at the request of
the Company, provide to the Company true and correct copies (with any amendments) of Executive&#146;s federal income tax return as filed with the Internal Revenue Service, and such other documents reasonably requested by the Company, evidencing such
payment. If, after the Company&#146;s payment to Executive of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment, the Auditors determine in good faith that the amount of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment should
be reduced or increased, or such determination is made by the Internal Revenue Service, then within ten (10)&nbsp;business days of such determination, Executive shall pay to the Company the amount of any such reduction, or the Company shall pay to
Executive the amount of any such increase; provided, however, that (i)&nbsp;the fees and expenses of the Auditors (and any other legal and accounting fees) incurred for services rendered in connection with the Auditor&#146;s determination of the
Parachute Tax or any challenge by the Internal Revenue Service or other taxing authority relating to such determination shall be paid by the Company, and (ii)&nbsp;the Company shall indemnify and hold Executive harmless on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis for any interest and penalties imposed upon Executive to the extent that such interest and penalties are related to the Auditor&#146;s determination of the Parachute Tax or the <FONT
STYLE="white-space:nowrap">Gross-Up</FONT> Payment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OR </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>On and After the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise. </U></I>To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is unavailable at the time of a Change in Control because any Company stock is readily tradeable on an established securities market or otherwise, if it is
determined by a nationally recognized United States public accounting firm selected by the Company (the &#147;<U>Auditors</U>&#148;) that any payment or benefit in the nature of compensation made or provided to Executive in connection with
Executive&#146;s employment with the Company (collectively, a &#147;<U>Payments</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Parachute Tax</U>&#148;), then Executive will be entitled to
receive <I>either</I> (A)&nbsp;the full amount of the Payments, or (B)&nbsp;a portion of the Payments having a value equal to $1 less than three (3)&nbsp;times Executive&#146;s &#147;base amount&#148; (as such term is defined in
Section&nbsp;280G(b)(3)(A) of the Code), whichever of clauses (A)&nbsp;and (B), after taking into account applicable federal, state, and local income and employment taxes and the Parachute Tax, results in the receipt by Executive on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest portion of the Payments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any determination required under this <U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>) </U>shall
be made in writing by the Auditor, whose determination, absent manifest error, shall be conclusive and binding for all purposes upon the Company and Executive. For purposes of making the calculations required by this Agreement, the Auditors may make
reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that the Auditors&#146; determinations must be
made with substantial authority (within the meaning of Section&nbsp;6662 of the Code). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is a reduction of the Payments pursuant to this
<U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>)</U>, such reduction shall occur in accordance with Section&nbsp;409A of the Code and in the following order: (1)&nbsp;any cash severance payable by reference to Executive&#146;s base
salary or annual bonus, (2)&nbsp;any other cash amount payable to Executive, (3)&nbsp;any employee benefit valued as a &#147;parachute payment,&#148; and (4)&nbsp;acceleration of vesting of any outstanding equity award. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, in the event that additional Payments are made to Executive after the application
of the cutback in this <U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>)</U>, which additional Payments result in the cutback no longer being applicable, the Company shall pay Executive an additional amount equal to the value of the
Payments that were originally cut back. The Company shall determine at the end of each calendar year whether any such restoration is necessary based on additional Payments (if any) made during such calendar year, and shall pay such restoration by
March&nbsp;15 of the calendar year following such calendar year. In no event whatsoever shall Executive be entitled to a tax <FONT STYLE="white-space:nowrap">gross-up</FONT> or other payment in respect of any excise tax, interest or penalties that
may be imposed on the Payments by reason of the application of Section&nbsp;280G or Section&nbsp;4999 of the Code at any time when any Company stock is readily tradeable on an established securities market or otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors; Binding Agreement</U>. This Agreement shall inure
to the benefit of and be binding upon personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. In the event of Executive&#146;s death prior to receipt of all amounts payable to Executive
(including any unpaid amounts due under <U>Section</U><U></U><U>&nbsp;7</U>), such amounts shall be paid to Executive&#146;s beneficiary designated in a Notice provided to and accepted by the Company or, in the absence of such designation, to
Executive&#146;s estate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice</U>. For the purpose of this Agreement, notices and all other
communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand or overnight courier or three postal delivery days after it has been mailed by United States registered mail, return
receipt requested, postage prepaid, addressed to the respective addresses set forth below in this Agreement, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that Notice of change of
address shall be effective only upon receipt (each such communication, &#147;<U>Notice</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If to the Company, addressed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Shattuck Labs, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn:
General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1018 W. 11th Street, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Austin, TX 78703 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to
Executive, to the address listed in the Company&#146;s payroll records from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Executive
Representation</U>. Executive hereby represents to the Company that the execution and delivery of this Agreement by Executive and the Company and the performance by Executive of Executive&#146;s duties hereunder shall not constitute a breach of, or
otherwise contravene, the terms of any employment agreement or other agreement or policy to which Executive is a party or otherwise bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>Prior Agreements</U>. This Agreement supersedes all prior agreements and understandings (including verbal
agreements) between Executive and the Company and/or its affiliates regarding the terms and conditions of Executive&#146;s employment with the Company and/or its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cooperation</U>. Executive shall provide Executive&#146;s reasonable cooperation in connection with any action
or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executive&#146;s employment hereunder, provided, that, following termination of Executive&#146;s employment, the Company shall pay all reasonable
expenses incurred by Executive in providing such cooperation. This provision shall survive any termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding Taxes</U>. The Company may withhold from any amounts payable under this Agreement such federal,
state and local taxes as may be required to be withheld pursuant to any applicable law or regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be signed in
counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows this Page] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have duly executed this Employment Agreement as of
the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SHATTUCK LABS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Josiah Hornblower</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Josiah Hornblower</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EXECUTIVE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Erin Ator Thomson</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Erin Ator Thomson</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.8 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>EMPLOYMENT AGREEMENT</B> (the &#147;<U>Agreement</U>&#148;) is entered into as of December&nbsp;5, 2019 (the &#147;<U>Effective
Date</U>&#148;), by and between Shattuck Labs, Inc. (the &#147;<U>Company</U>&#148;) and Andrew Neill (&#147;<U>Executive</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company wishes to continue to employ Executive as the Vice President of Corporate Development and Strategy of the Company
and Executive wishes to continue to work as the Vice President of Corporate Development and Strategy of the Company; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
the Company and Executive wish to enter into this Agreement on the terms and conditions set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, it
is hereby agreed as follows </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employment</U>. The Company agrees to employ Executive, and Executive hereby
accepts such employment, upon the terms and subject to the conditions set forth herein, for a period commencing on the Effective Date and ending on the date that this Agreement is terminated in accordance with <U>Section</U><U></U><U>&nbsp;7</U>
below (the &#147;<U>Employment Term</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Position; Duties</U>. During the Employment Term, Executive
shall serve as the Vice President of Corporate Development and Strategy of the Company. In such position, Executive shall report directly to the Company&#146;s Chief Executive Officer and shall have such duties and authority as are customary to such
position and as otherwise determined from time to time by the Company. During the Employment Term, Executive agrees to devote Executive&#146;s full time and reasonable best efforts to the performance of Executive&#146;s duties to the Company. The
foregoing shall not be construed to prohibit Executive from engaging in activities relating to serving on civic and charitable boards or committees, and managing personal investments, provided that such activities do not significantly interfere or
conflict with the performance by Executive of Executive&#146;s duties, responsibilities, or authorities hereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Base Salary</U>. During the Employment Term, the Company shall pay Executive an initial base salary at the annual
rate of $250,000, payable in regular installments in accordance with the Company&#146;s usual payment practices. Executive&#146;s base salary may be increased in the sole discretion of the Compensation Committee of the Board (the
&#147;<U>Committee</U>&#148;). Executive&#146;s annual base salary, as in effect from time to time, is hereinafter referred to as the &#147;<U>Base Salary</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Incentive Compensation</U>. During the Employment Term, Executive shall be eligible to receive an annual cash
bonus based on performance objectives established by the Committee each year (the &#147;<U>Annual Bonus</U>&#148;). Executive&#146;s target Annual Bonus amount will be the percentage of Base Salary designated as the target by the Committee, which
amount shall be at least 20% of the Base Salary then in effect (the &#147;<U>Target Annual Bonus</U>&#148;). Notwithstanding the preceding, Executive&#146;s Annual Bonus, if any, may be below (including zero), at, or above the target based upon the
achievement of the performance objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Benefits</U>. During the Employment Term, Executive
shall be entitled to participate in the Company&#146;s employee benefit plans as in effect from time to time (collectively &#147;<U>Employee Benefits</U>&#148;), on the same basis as those benefits are generally made available to other senior
executives of the Company, in each case to the extent that Executive is eligible under the terms of such plans or programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Business Expenses</U>. During the Employment Term, reasonable business expenses incurred by Executive in the
performance of Executive&#146;s duties hereunder shall be advanced or promptly reimbursed by the Company in accordance with Company policies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. The Employment Term and Executive&#146;s employment may be terminated by the Company at any time
and for any reason upon Notice to Executive and by Executive upon at least 30 days&#146; advance Notice of any such resignation of Executive&#146;s employment. Notwithstanding any other provision of this Agreement, the provisions of this
<U>Section</U><U></U><U>&nbsp;7</U> shall exclusively govern Executive&#146;s rights to payment of compensation, severance, Employee Benefits and business expenses upon termination of employment with the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>By the Company for Cause; By Executive without Good Reason.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment may be terminated by the Company for Cause and
shall terminate automatically upon the effective date of Executive&#146;s resignation without Good Reason. For purposes of this Agreement, &#147;<U>Cause</U>&#148; shall mean (A)&nbsp;indictment for, conviction of, or a plea of <I>nolo</I>
<I>contendere</I> to, (x)&nbsp;a felony (other than traffic-related) under the laws of the United States or any state thereof or any similar criminal act in a jurisdiction outside the United States or (y)&nbsp;a crime involving moral turpitude that
could be injurious to the Company or its reputation, (B)&nbsp;Executive&#146;s willful malfeasance or willful misconduct which is materially and demonstrably injurious to the Company, (C)&nbsp;any act of fraud by Executive in the performance of
Executive&#146;s duties or (D)&nbsp;Executive&#146;s material breach of any Agreement with the Company or any of the Company&#146;s material policies. The determination of Cause shall be made by the Board, in its good faith discretion. For purposes
of this Agreement, &#147;<U>Good Reason</U>&#148; shall mean the occurrence of any of the following events, without Executive&#146;s written consent, provided, in each case, that such event is not cured within thirty (30)&nbsp;days after the Company
receives notice from Executive specifying in reasonable detail the event which constitutes Good Reason: (1)&nbsp;any failure by the Company to pay Executive&#146;s Base Salary or Annual Bonus (if any) when due; (2)&nbsp;a reduction in
Executive&#146;s Base Salary or Target Annual Bonus (excluding any change in value of equity incentives); (3) any diminution in Executive&#146;s title or any substantial and sustained diminution in Executive&#146;s duties; or (4)&nbsp;a required
relocation of Executive&#146;s primary work location by more than 25 miles from Executive&#146;s current work location. &#147;<U>Good Reason</U>&#148; shall cease to exist for an event on the 90th day following Executive&#146;s knowledge thereof,
unless Executive has given the Company Notice thereof prior to such date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is terminated by
the Company for Cause, or if Executive resigns without Good Reason, Executive shall be entitled to receive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the Base Salary accrued through the date of termination, payable as soon as practicable following
the date of such termination or as otherwise required by applicable law; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;any Annual Bonus
earned, but unpaid, as of the date of termination for the year immediately preceding the year in which such termination occurs, paid on the date when bonuses are otherwise paid to Company executives, and in all events by March 15<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such termination occurs; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;reimbursement, within 60 days following submission by Executive to the Company of appropriate
supporting documentation, for any unreimbursed business expenses properly incurred by Executive in accordance with Company policy prior to the date of Executive&#146;s termination; provided, that claims for such reimbursement (accompanied by
appropriate supporting documentation) are submitted to the Company within 90 days following the date of Executive&#146;s termination of employment; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(D)&nbsp;&nbsp;&nbsp;&nbsp;such Employee Benefits, if any, as to which Executive may be entitled under the employee benefit
plans of the Company, which shall be paid in accordance with the terms of the applicable plans (the amounts described in clauses (A)&nbsp;through (D) hereof, the &#147;<U>Accrued Rights</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following such termination of Executive&#146;s employment by the Company for Cause or resignation by Executive without Good
Reason, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(a)(ii),</U> Executive shall have no further rights to any compensation or any other benefits under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Disability or Death</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment shall terminate automatically upon
Executive&#146;s death and may be terminated by the Company upon Executive&#146;s Disability. For purposes of this Agreement, a &#147;<U>Disability</U>&#148; shall be deemed to have occurred if Executive has for one hundred twenty
(120)&nbsp;consecutive days or one hundred eighty <FONT STYLE="white-space:nowrap">(180)&nbsp;non-consecutive</FONT> days in any twelve (12)&nbsp;month period been disabled in a manner which has rendered Executive unable to perform the essential
functions of Executive&#146;s job duties with or without reasonable accommodation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Upon
termination of Executive&#146;s employment for either Disability or death, Executive or Executive&#146;s estate (as the case may be) shall be entitled to receive (A)&nbsp;the Accrued Rights and (B)&nbsp;a pro rata portion of the actual Annual Bonus
earned for the year of termination, based on the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the
calendar year following the year in which such termination occurs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment due to death or
Disability, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(b)(ii)</U>, Executive shall have no further rights to any compensation or any other benefits under this Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>By the Company without Cause; By Executive with Good Reason.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Employment Term and Executive&#146;s employment may be terminated by the Company without Cause
or by Executive with Good Reason. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is terminated by the Company
without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event not within 30 days before or two years after a Change in Control, Executive shall be entitled to receive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;&nbsp;&nbsp;&nbsp;the Accrued Rights; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B)&nbsp;&nbsp;&nbsp;&nbsp;subject to Executive&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT> of
a release of claims in the form provided by the Company and within the time period specified therein and Executive&#146;s continued compliance with the provisions of <U>Section</U><U></U><U>&nbsp;8</U> and the PIIA Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a pro rata portion of the actual Annual Bonus that would have been earned for the year of termination, based on
the days employed during such year, payable on the date when bonuses are otherwise paid to Company executives and in all events by March 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such
termination occurs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment of an amount equal to 0.75 times the sum of Executive&#146;s annual Base Salary plus Executive&#146;s
Target Annual Bonus amount for the year of termination, which shall be payable to Executive in equal installments in accordance with the Company&#146;s normal payroll practices, for 9 months following the date that the release of claims becomes
effective and irrevocable (<U>provided</U>, <U>however</U>, that if the period during which the release could become effective and irrevocable spans two calendar years, payments of such installments shall not commence until the first normal payroll
date in the second calendar year); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">effective as of immediately prior to such termination of employment, accelerated vesting of all then unvested
equity awards (with any applicable performance-based awards deemed earned at the target level of achievement) with such awards (other than stock options) settled as soon as practicable thereafter and in all events by March 15<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> of the calendar year following the year in which such termination occurs or to remain exercisable (with respect to stock options) through the
90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following such termination of employment; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">subject to Executive&#146;s timely election of continuation coverage under the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (&#147;<U>COBRA</U>&#148;), and subject to Executive&#146;s copayment of premium amounts at the active employees&#146; rate, the Company shall pay the remainder of the premiums for Executive&#146;s
participation in the Company&#146;s group health plans pursuant to COBRA for a period ending on the earlier of (i)&nbsp;the 9 month anniversary of the date of termination; (ii)&nbsp;Executive becoming eligible for other group health benefits, or
(iii)&nbsp;the expiration of Executive&#146;s rights under COBRA; provided, however, that in the event that the benefits provided herein would subject the Company or any of its affiliates to any tax or penalty under the Patient Protection and
Affordable Care Act or Section&nbsp;105(h) of the Internal Revenue Code of 1986, as amended (the &#147;<U>Code</U>&#148;), Executive and the Company agree to work together in good faith to restructure the foregoing benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment by the Company without Cause (other than by reason of Executive&#146;s death or
Disability) or Executive&#146;s resignation with Good Reason not within 30 days before or two years after a Change in Control, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(c)(ii)</U>, Executive shall have no further rights to any
compensation or any other benefits under this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If Executive&#146;s employment is
terminated by the Company without Cause (other than by reason of death or Disability) or if Executive resigns with Good Reason, in either event within 30 days before or two years after a Change in Control, Executive shall be entitled to receive the
payments and benefits described in <U>Section</U><U></U><U>&nbsp;7(c)(ii)(A) and (B)</U>, except that the severance multiplier in Section<U>&nbsp;7(c)(ii)(B)(2)</U> shall be increased from 0.75 to 1.50. For the avoidance of doubt, payment of such
amounts and benefits other than the Accrued Rights shall be subject to Executive providing and not revoking a release of claims in the form provided by the Company and within the time period specified therein and Executive&#146;s continued
compliance with the provisions of <U>Section</U><U></U><U>&nbsp;8</U> and the PIIA Agreement. For purposes of this Agreement, &#147;<U>Change in Control</U>&#148; means the occurrence of one or more of the following events: (i)&nbsp;any
&#147;person&#148; (as such term is used in Sections 3(a)(9) and 13(d) of the Securities Exchange Act of 1934, as amended (the &#147;<U>Act</U>&#148;)) or &#147;group&#148; (as such term is used in Section&nbsp;13(d)(3) of the Act), other than the
Company or its subsidiaries or any benefit plan of the Company or its subsidiaries is or becomes a &#147;beneficial owner&#148; (as such term is used in Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated under the Act) of more than 50%
of the Voting Stock of the Company; (ii)&nbsp;the Company transfers all or substantially all of its assets (unless the shareholders of the Company immediately prior to such transaction beneficially own, directly or indirectly, in substantially the
same proportion as they owned the Voting Stock of the Company, all of the Voting Stock or other ownership interests of the entity or entities, if any, that succeed to the business of the Company or the Company&#146;s ultimate parent company if the
Company is a subsidiary of another corporation); or (iii)&nbsp;any merger, reorganization, consolidation or similar transaction unless, immediately after consummation of such transaction, the shareholders of the Company immediately prior to the
transaction hold, directly or indirectly, more than 50% of the Voting Stock of the Company or the Company&#146;s ultimate parent company if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Company is a subsidiary of another corporation. For purposes of this Change in Control definition, &#147;<U>Voting Stock</U>&#148; means securities or ownership interests of any class or
classes having general voting power under ordinary circumstances, in the absence of contingencies, to elect the directors of a corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Following Executive&#146;s termination of employment by the Company without Cause (other than by reason of Executive&#146;s death or
Disability) or by Executive with Good Reason within 30 days before or two years after a Change in Control, except as set forth in this <U>Section</U><U></U><U>&nbsp;7(c)(iii)</U>, Executive shall have no further rights to any compensation or any
other benefits under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Termination</U>. Any termination of employment by the
Company or by Executive (other than due to Executive&#146;s death) shall be communicated by Notice of Termination to the other party hereto in accordance with <U>Section</U><U></U><U>&nbsp;11(k)</U> hereof. For purposes of this Agreement, a
&#147;<U>Notice of Termination</U>&#148; shall mean a Notice that indicates the specific termination provision in this Agreement relied upon and sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination
of employment under the provision so indicated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination and Offices Held</U>. Upon termination of
Executive&#146;s employment for any reason, Executive shall be deemed to have resigned from all positions that Executive may then hold as an employee, officer or director of the Company or any affiliate of the Company. Executive shall promptly
deliver to the Company any additional documents reasonably required by the Company to confirm such resignations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U><FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></U>. Executive shall not, while employed by the Company
or at any time thereafter, disparage the Company (or any affiliate) in any way that materially and adversely affects the goodwill, reputation or business relationships of the Company or the affiliate with the public generally, or with any of its
customers, vendors or employees. The Company shall not (and shall use reasonable efforts to procure that its directors and officers shall not) disparage Executive in any way that materially and adversely affects Executive or Executive&#146;s
reputation or business relationships. Notwithstanding the foregoing, this Section shall not prohibit either party from rebutting claims or statements made by any other person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Proprietary Information and Inventions Assignment Agreement</U>. Executive previously entered into a Proprietary
Information and Inventions Assignment Agreement with the Company (the &#147;<U>PIIA Agreement</U>&#148;) and hereby reaffirms all of Executive&#146;s obligations thereunder. The provisions of <U>Section</U><U></U><U>&nbsp;8</U> hereof and the
provisions of the PIIA Agreement shall survive the termination of Executive&#146;s employment for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Specific Performance</U>. Executive acknowledges and agrees that the Company&#146;s remedies at law for a breach
or threatened breach of any of the provisions of <U>Section</U><U></U><U>&nbsp;8</U> would be inadequate and the Company would suffer irreparable damages as a result of such breach or threatened breach. In recognition of this fact, Executive agrees
that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to cease making any payments or providing any benefit otherwise required by this Agreement and
obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Arbitration</U>. For the avoidance of doubt, the arbitration and equitable relief provisions of the PIIA
Agreement shall apply to any dispute concerning Executive&#146;s employment with the Company or arising under or in any way related to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law; Consent to Personal Jurisdiction</U>. THIS AGREEMENT WILL BE GOVERNED BY THE LAWS OF THE STATE OF
TEXAS WITHOUT REGARD FOR CONFLICTS OF LAWS PRINCIPLES. SUBJECT TO THE ARBITRATION PROVISION IN THE PIIA AGREEMENT, EXECUTIVE HEREBY EXPRESSLY CONSENTS TO THE PERSONAL JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN TEXAS FOR ANY LAWSUIT
FILED THERE AGAINST EXECUTIVE BY THE COMPANY CONCERNING EXECUTIVE&#146;S EMPLOYMENT OR THE TERMINATION OF EXECUTIVE&#146;S EMPLOYMENT OR ARISING FROM OR RELATING TO THIS AGREEMENT. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement/Amendments</U>. This Agreement, together with the PIIA Agreement, contains the entire
understanding of the parties with respect to the employment of Executive by the Company. There are no restrictions, agreements, promises, warranties, covenants or undertakings between the parties with respect to the subject matter herein other than
those expressly set forth herein or as may be set forth from time to time in the Company&#146;s employee benefit plans and policies applicable to Executive. This Agreement may not be altered, modified, or amended except by written instrument signed
by the parties hereto. In the event of any inconsistency between this Agreement and any other plan, program, practice or agreement of which Executive is a participant or a party, this Agreement shall control unless such other plan, program, practice
or agreement specifically refers to the provisions of this sentence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>No Waiver</U>. The failure of a party
to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver of such party&#146;s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term
of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. In the event that any one or more of the provisions of this Agreement
shall be or become invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions of this Agreement shall not be affected thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment</U>. This Agreement, and all of Executive&#146;s rights and duties hereunder, shall not be assignable
or delegable by Executive. Any purported assignment or delegation by Executive in violation of the foregoing shall be null and <I>void ab initio</I> and of no force and effect. This Agreement may be assigned by the Company to a person or entity
which is an affiliate or a successor in interest to substantially all of the business operations of the Company. Upon such assignment, the rights and obligations of the Company hereunder shall become the rights and obligations of such affiliate or
successor person or entity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterclaim; No Mitigation</U>. The Company&#146;s obligation
to pay Executive the amounts provided and to make the arrangements provided hereunder shall be subject to counterclaim and to seek recoupment of amounts owed by Executive to the Company or its affiliates. Executive shall not be required to mitigate
the amount of any payment provided for pursuant to this Agreement by seeking other employment, and such payments shall not be reduced by any compensation or benefits received from any subsequent employer or other endeavor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with Code Section</U><U></U><U>&nbsp;409A</U>. Notwithstanding anything herein to the contrary,
(i)&nbsp;if at the time of Executive&#146;s termination of employment with the Company Executive is a &#147;specified employee&#148; as defined in Section&nbsp;409A of the Code and the deferral of the commencement of any payments or benefits
otherwise payable hereunder as a result of such termination of employment is necessary in order to prevent any accelerated or additional tax under Section&nbsp;409A of the Code, then the Company will defer the commencement of the payment of any such
payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided to Executive) until the date that is six months following Executive&#146;s termination of employment with the Company (or the earliest
date as is permitted under Section&nbsp;409A of the Code) and (ii)&nbsp;if any other payments of money or other benefits due to Executive hereunder could cause the application of an accelerated or additional tax under Section&nbsp;409A of the Code,
such payments or other benefits shall be deferred if deferral will make such payment or other benefits compliant under Section&nbsp;409A of the Code, or otherwise such payment or other benefits shall be restructured, to the extent possible, in a
manner, determined by the Board, that does not cause such an accelerated or additional tax. For purposes of Section&nbsp;409A of the Code, each payment made under this Agreement shall be designated as a &#147;separate payment&#148; within the
meaning of the Section&nbsp;409A of the Code, and references herein to Executive&#146;s &#147;termination of employment&#148; shall refer to Executive&#146;s separation from service with the Company within the meaning of Section&nbsp;409A. To the
extent any reimbursements or <FONT STYLE="white-space:nowrap">in-kind</FONT> benefits due to Executive under this Agreement constitute &#147;deferred compensation&#148; under Section&nbsp;409A of the Code, any such reimbursements or <FONT
STYLE="white-space:nowrap">in-kind</FONT> benefits shall be paid to Executive in a manner consistent with Treas. Reg. <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(1)(iv).</FONT> The Company shall consult with Executive in good faith
regarding the implementation of the provisions of this <U>Section</U><U></U><U>&nbsp;11(h)</U>; <U>provided</U> that neither the Company nor any of its employees or representatives shall have any liability to Executive with respect to thereto or any
tax imposed under Section&nbsp;409A. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Code Section</U><U></U><U>&nbsp;280G</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>Prior to the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise</U></I><I>; Shareholder Vote Sought</I>. To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is available at the time of a Change in Control if the shareholder approval requirements under Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q/A-7</FONT> are satisfied, the Company may elect to pursue a shareholder vote in accordance with such provisions and the Company and Executive shall cooperate with
each other and use their commercially reasonable efforts to obtain a vote satisfying the requirements of Section&nbsp;280G(b)(5) of the Code and Treasury Regulation <FONT STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT
STYLE="white-space:nowrap">Q/A-7,</FONT> such that neither Executive nor the Company or its Affiliates suffers any adverse tax consequences under Sections 280G and 4999 of the Code. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>Prior to the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise</U></I><I>; Shareholder Vote Not Sought. </I>To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is available at the time of a Change in Control if the shareholder approval requirements under Treasury Regulation <FONT
STYLE="white-space:nowrap">&#167;1.280G-1,</FONT> <FONT STYLE="white-space:nowrap">Q/A-7</FONT> are satisfied and the Company does <I>not</I> seek a shareholder vote in accordance with Section&nbsp;11(i)(<I>i</I>) hereof, if it is determined by a
nationally recognized United States public accounting firm selected by the Company (the &#147;<U>Auditors</U>&#148;) that any payment or benefit in the nature of compensation made or provided to Executive in connection with Executive&#146;s
employment with the Company (collectively, a &#147;<U>Payment</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Parachute Tax</U>&#148;), then the Company shall pay to Executive, prior to the time
the Parachute Tax is payable with respect to such Payment, an additional payment (a &#147;<U><FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment</U>&#148;) in an amount such that, after payment by Executive of all taxes (including any Parachute
Tax) imposed upon the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment, Executive retains an amount of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment equal to the Parachute Tax imposed upon the Payment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amount of any <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment shall be determined by the Auditors,
subject to adjustment, as necessary, as a result of any Internal Revenue Service position. For purposes of making the calculations required by this Agreement, the Auditors may make reasonable assumptions and approximations concerning applicable
taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that the Auditors&#146; determinations must be made with substantial authority (within the meaning of
Section&nbsp;6662 of the Code). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The federal tax returns filed by Executive (and any filing made by a consolidated tax group which includes the
Company) shall be prepared and filed on a basis consistent with the determination of the Auditors with respect to the Parachute Tax payable by Executive. Executive shall make proper payment of the amount of any Parachute Tax, and at the request of
the Company, provide to the Company true and correct copies (with any amendments) of Executive&#146;s federal income tax return as filed with the Internal Revenue Service, and such other documents reasonably requested by the Company, evidencing such
payment. If, after the Company&#146;s payment to Executive of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment, the Auditors determine in good faith that the amount of the <FONT STYLE="white-space:nowrap">Gross-Up</FONT> Payment should
be reduced or increased, or such determination is made by the Internal Revenue Service, then within ten (10)&nbsp;business days of such determination, Executive shall pay to the Company the amount of any such reduction, or the Company shall pay to
Executive the amount of any such increase; provided, however, that (i)&nbsp;the fees and expenses of the Auditors (and any other legal and accounting fees) incurred for services rendered in connection with the Auditor&#146;s determination of the
Parachute Tax or any challenge by the Internal Revenue Service or other taxing authority relating to such determination shall be paid by the Company, and (ii)&nbsp;the Company shall indemnify and hold Executive harmless on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis for any interest and penalties imposed upon Executive to the extent that such interest and penalties are related to the Auditor&#146;s determination of the Parachute Tax or the <FONT
STYLE="white-space:nowrap">Gross-Up</FONT> Payment. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>OR </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I><U>On and After the Date Any Company Stock is Readily Tradeable on an Established Securities Market or
Otherwise. </U></I>To the extent that the exemption under Section&nbsp;280G(b)(5) of the Code is unavailable at the time of a Change in Control because any Company stock is readily tradeable on an established securities market or otherwise, if it is
determined by a nationally recognized United States public accounting firm selected by the Company (the &#147;<U>Auditors</U>&#148;) that any payment or benefit in the nature of compensation made or provided to Executive in connection with
Executive&#146;s employment with the Company (collectively, a &#147;<U>Payments</U>&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code (the &#147;<U>Parachute Tax</U>&#148;), then Executive will be entitled to
receive <I>either</I> (A)&nbsp;the full amount of the Payments, or (B)&nbsp;a portion of the Payments having a value equal to $1 less than three (3)&nbsp;times Executive&#146;s &#147;base amount&#148; (as such term is defined in
Section&nbsp;280G(b)(3)(A) of the Code), whichever of clauses (A)&nbsp;and (B), after taking into account applicable federal, state, and local income and employment taxes and the Parachute Tax, results in the receipt by Executive on an <FONT
STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest portion of the Payments. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any determination required under this <U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>) </U>shall
be made in writing by the Auditor, whose determination, absent manifest error, shall be conclusive and binding for all purposes upon the Company and Executive. For purposes of making the calculations required by this Agreement, the Auditors may make
reasonable assumptions and approximations concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code; provided that the Auditors&#146; determinations must be
made with substantial authority (within the meaning of Section&nbsp;6662 of the Code). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If there is a reduction of the Payments pursuant to this
<U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>)</U>, such reduction shall occur in accordance with Section&nbsp;409A of the Code and in the following order: (1)&nbsp;any cash severance payable by reference to Executive&#146;s base
salary or annual bonus, (2)&nbsp;any other cash amount payable to Executive, (3)&nbsp;any employee benefit valued as a &#147;parachute payment,&#148; and (4)&nbsp;acceleration of vesting of any outstanding equity award. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For the avoidance of doubt, in the event that additional Payments are made to Executive after the application
of the cutback in this <U>Section</U><U></U><U>&nbsp;11(i)(</U><I><U>iii</U></I><U>)</U>, which additional Payments result in the cutback no longer being applicable, the Company shall pay Executive an additional amount equal to the value of the
Payments that were originally cut back. The Company shall determine at the end of each calendar year whether any such restoration is necessary based on additional Payments (if any) made during such calendar year, and shall pay such restoration by
March&nbsp;15 of the calendar year following such calendar year. In no event whatsoever shall Executive be entitled to a tax <FONT STYLE="white-space:nowrap">gross-up</FONT> or other payment in respect of any excise tax, interest or penalties that
may be imposed on the Payments by reason of the application of Section&nbsp;280G or Section&nbsp;4999 of the Code at any time when any Company stock is readily tradeable on an established securities market or otherwise. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors; Binding Agreement</U>. This Agreement shall inure
to the benefit of and be binding upon personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. In the event of Executive&#146;s death prior to receipt of all amounts payable to Executive
(including any unpaid amounts due under <U>Section</U><U></U><U>&nbsp;7</U>), such amounts shall be paid to Executive&#146;s beneficiary designated in a Notice provided to and accepted by the Company or, in the absence of such designation, to
Executive&#146;s estate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice</U>. For the purpose of this Agreement, notices and all other
communications provided for in the Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand or overnight courier or three postal delivery days after it has been mailed by United States registered mail, return
receipt requested, postage prepaid, addressed to the respective addresses set forth below in this Agreement, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that Notice of change of
address shall be effective only upon receipt (each such communication, &#147;<U>Notice</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If to the Company, addressed to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Shattuck Labs, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attn:
General Counsel </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">1018 W. 11th Street, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Austin, TX 78703 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If to
Executive, to the address listed in the Company&#146;s payroll records from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Executive
Representation</U>. Executive hereby represents to the Company that the execution and delivery of this Agreement by Executive and the Company and the performance by Executive of Executive&#146;s duties hereunder shall not constitute a breach of, or
otherwise contravene, the terms of any employment agreement or other agreement or policy to which Executive is a party or otherwise bound. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>Prior Agreements</U>. This Agreement supersedes all prior agreements and understandings (including verbal
agreements) between Executive and the Company and/or its affiliates regarding the terms and conditions of Executive&#146;s employment with the Company and/or its affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Cooperation</U>. Executive shall provide Executive&#146;s reasonable cooperation in connection with any action
or proceeding (or any appeal from any action or proceeding) which relates to events occurring during Executive&#146;s employment hereunder, provided, that, following termination of Executive&#146;s employment, the Company shall pay all reasonable
expenses incurred by Executive in providing such cooperation. This provision shall survive any termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>Withholding Taxes</U>. The Company may withhold from any amounts payable under this Agreement such federal,
state and local taxes as may be required to be withheld pursuant to any applicable law or regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>. This Agreement may be signed in
counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows this Page] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have duly executed this Employment Agreement as of
the Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">SHATTUCK LABS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Josiah Hornblower</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Josiah Hornblower</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">EXECUTIVE</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Neill</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Andrew Neill</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g69956g00d01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g00d01.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 4L"8 ,!$0 "$0$#$0'_Q  ?  $
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ML>22FUW;Q$/*PI$$PTFU4^=MIL7(C=B=Q"(#-[!J"U=9H?2JFOW.6;,7C$I
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MF*Z<K!9[C45\YRE%&HW6J"1S4V:EV-"S8/9;?)4#Y$%9ZE*4\%5PO9;1*WZ
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MMQ?W^J2!^TY#O^DN$;3E/K<7]_JD@?M-P[_I/_'PC:<I];B_O]4D#]IR'?\
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M %-5B?V;TG_A+X1/KH6G_J:K$_LWI/\ PE\)7JX^3>:?70M/_4U6)_9O2?\
MA+X1<FSV%8KFY)T#C0LVCJ-1@X)KRYRVJ5B!%D*<XPL2DABG3NZC :< M-_"
MC:K, (\)@B_1%FB 3CK:L%4W>=UV#,HC'YKJ!-ZE8'V-3IVD,ND+]%5J"*N$
M?EXFB'1Y0D;#3U2Q;,V,A9)<"3]2&I,:B L,+5+?5N-!1MK&NS6';QJ5,\M(
M02(0BBRRQ#P (Q +"'(PEXP$ 19#C&<A"'O!!C.>@<"STQY]2J^GA$X1>!9S
MC&<XQUS[L=,Y\?HQX_3PBAU$MFY?)]QI?K0NJ%[A\0C5/*K'9;'DR]M*53]P
M03U##%XHQ'6]<N5I(>GRJ%ZF]OX6QQ>U@##$+4!J)(7N#/6M94=K7#06#MG=
MU;JJJP[G;:AJ. 3JN=4*F@]S['/$QFS[&Y8X1Z;&39Q^3-0M;3''AJ<)/'X7
M 'J5+E$K<&UK7GK65@29)/5*'!*36M47!L&^MLO-HQ^0CJB E:D2_:%VU#CL
MU*F4A'<WUPVQ0_1PB>.,/'&01,NO76QX\L@J5"GD9LB( <DDQ_\ "9AK<24S
M88L^[?O]BA#7TXATW^J9;)S#Y3'Y1F*=F*X0N4>P'5$Z?)^7L5_0[VS%WCU,
M\[V<_-7K:?VBU*O1+$?I2\'D@R+&.,WX][>Q4<&6QCPB<(G")PB\"$$/3O"P
M'KGICO9QCKGX8Z^>?#/AY^'",3@,*G<-JX%7*XL@4FHUTE8$2LC. G)5;RW)
ME)(A "8'!I!RD!I>1%C /&!AQG(!A%C[$6,Y^,5IL\$1@CGR88P',$4V"&(!
MV<PF(%GH[8T7^R7=UX3I4$Z38+9-DS 3+FR[+/F2HP(HX"8)D,!@B C@C@)A
M):*".$UA('Q&R^$'A#@V514S!8\&![[VT#P 8?T(\=Y5GNBQUSC L=,XQG..
MOCR?"K+_ .DR/_G2_P#_ *7(W7>0(!NZW Q%H0;):'B.P RZEL@N31%LC@E
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M6V>Y9;HVEV/9.J-6-C4T=@M4SS%LQ38.PE5?0I<RQJX5$(C]HUZQ2%L9EB]
MK9VZ?M$O3SJ//;R4[/Y<96-36ZG.>2TZM/"';<75[^OQZO)RLPWIK1>5HR*#
MV;";TA]<7%3U@6$YU')U%/JY=%$M561%&Z-2"M;!B"BQ6=7*W U4WHW\$O:)
M'$NZXL[,'#"!,2N+<*IU8XUULR[L5%];V74]8(@9":EV@-AS5:-''T3M0OD5
M2M,N>K>:WJP;9LJ53R%J")3'DE83][D-\V^46I,13%@;F^3MQ8&10ICJ%0,A
M[>)V:&@% 3MX-9**A\B[-ZZV"N&%%;0MY=5J8.GX0JLR!164=5.JEGB)YN5/
MJHVU$I1)CRL82X.](5C.3>Z(6,E5M#<(G")PB<(G")PB\"$$&,B$+ 0X\<B%
MG&,8Q\<YSTQC[O&.">0).X .3P J=R@9OM/]O(I3^'71A9K>KM5F?L.4M3;"
M/#X1'R8"@8W=:ZY9"8PJ)5&R8Q>2T%I$Z\PI&-$8L%C/I_19Q\HI\F",RXYT
MJ&8 "9<4R"&, T!,!(B )PI5?>&R6J.7!-@LUHCE3 8I<V"1-BEQPPOTC!,$
M)AC :)S"2 Q!;.O;L<=W.T0W2BC1L1M*7J%'=9)W%IP1!L5ZJE<?N F?PRQ%
M4(-+>F%]?'AC31H\,?E1PS/7S5AN/82E/DL)ZP@M%/DP'HQS9<!# B..&$N2
M!#2(@_&) AI4EAB%])%WVZU0F99K%:[1!TA"8Y%FG38>D_1$)BEP1#I/0!W>
MC.K^2SB3<!$4:6:$6.\')9@1X$'KT[P<ASG&<=?#KCKCKX<^N(!%00"#D00X
M(V@@@@YBJ_R8AQ4.87RZ0)!#[0001B""O9PB<(G"+!^S%0&[!:\7A11+Z"+F
M7'5,^K(,E&W"> L&9O%W..X><M05K;ERPVY<,*_4<."+UKT7H/6T_?\ 3 (L
M<[$Z]2S8& 2JL#["10Z,+([7SC!G)MA^7"5PNY:WGB.?1JP#G!8_A:7^/I'6
M/Q'OPTQF;S#O9;IZ61&%NY93<4KJOX5X]2B=GL^[R.=_K[F[/1T.Y'UU4MAD
M6G]8P'UIR8VEJE73@:MS3N;(RZYBQL86J'<YP^N7A]Q+3/:H%H4F MV2NM#%
M86W_ -(JJAW8Z[*U_:3>V7;*JAJ3978ELL*5,21O6BV&EC99=A22UF5G;SS$
M,=<39;.)*I9F\@Y66SMZHE!ZPK]!A0,BFCV4X @[-;1<(<8P'\R]3N>F/B*&
M-0LY_P!\+.1?=X13_P"$3A$X1.$3A$X1>DT\LK L9,*P9@&1! ,P(,B\!9#U
MZ^. YR 7V6,9\ BSC&>[GAB< ^76< JQ9V+ $DY-#T>D7V0]*%SETH7Q#ZQU
ME]JQVP$&W CNFR;L\]=%=HV0Q3.?U4UF;!D&II+6D4<GHC,A623#TB8VQ48A
M9CSQ-SI[)<S3,="FHL1@",7HQ$=(0DBM6+4QJS4</L=<#%"(C"8H1%#T1%"2
M.D#$2(00[CI$$0OB00'9;*$.<G]SB<97S!L;6"7+F!H5R=A:W3#PW,L@/;TQ
MCVU-[MDE-[50MSF-2C2N6$Y&%I!1:GT1?I>X&,6=J;<MN/"JY&D1A-(@[PFD
M09G<&M'#\0NRA$$>,Y"((L8SG&<ASC.,9QYXSG&<^./?CSQPFW<6.X[#O7ZX
M1.$4>Y52!TCV6J+8+$@"E+JRL+AKKY+^S!'">\VL\5>ZX=<.V%Y6$/L/-<C(
M$C$WJO:&'<(\*$GJ60JBA<OAECGM>GM45;JTXV*LM\.G,/V:BE8V'.*HD]!W
M2[MU&XD+++:I7RZ2R*$J(>S.MD%*(98T!;);(FA')U[I+6)U6/BYT71, 24:
M%,3JST<LWVN^PKI:WLTGDN3+(;&+SQ']1I59=&6]8.OZFMT;O)GN8T+':MCS
M$UL5L#DZ83!!)=]9:N7.:,"B&.SFK5MKT2U/C.AD*P@#6O/\75V/UL.SV.>*
M@3V=-(5-KOVY?:3552,"CU9UTPZU:^*FB'19)E$RMZEZ*C+LZJ$Z;(S,@,7N
M2M2L49[^>^><8+'AG&,3,[*>?LR;%5;+'*B<(G")PB<(G"+QUQ\<>/EXX\>$
M5%_:.=K/LGH+9[3'4?9WRFWZBETH@=?U[=I-X1B(M,XL>=H#E*.&-T7!$I.[
MMR].N3*VH"AW.1D*CT9JG/JR0Y(8H9@,2^S;[]9+C%'#"'BBAA#$DQ1 !@')
M<D!@*D[*T5H.J-LW'=E+QZP;YUY>M7+'=5CR0YT_()DQ3QR9D;>YJ$C6Y&2&
M/$)$1Q3VA**<B4AJ)(M1@.P2I)ZX 887)20X1.$3A$X11Z<J57';)YV%0R0D
MA070+A2J2.',PU)92M7.TTW(DQS@%S39/(3F)0H#&8*8D1X19.]J)^N 9(H=
MW9H9<EO/DM<T.RK3 T&P](UO26X+(TTZ6ZD66W04,J*7R&I%SC.<**?>)*U3
MJ6Q=3AWQ8Z=OCZAF$G":]LX'522NM5SK3@OM8^S\E;/;[,IS>A1NK\9V,=MK
MXY0I=:I"I*AM]U*=W#U!7; I2<);73?.']TL!OC@86F> /\ ZHC-DQK.D"A&
M15[575]?5C]4S6P& Q1HBOR][-=ZLN9Y:4_J^9)/I5?\+^44J=/LA8.=W?U%
M+E:HQW?2Y(+^PQTSG)%LB\(G")PB<(OF5A[Q8?L<BZ#QG <"[O7/=%CQSUQC
MIX^.,YZ?3Y<H9P31BX+.Q8C#K7&(/":&+<(NB_$N'&T9K3G[2$9H-W;\R$8N
MN'F*AQG C"L]W,%C8LXP,(<X%CO9_0XQCIX9SXYZBU YS+7:)7+*]8!;(Y,
MF2^C#*B<MZF4WQ0QA9CTMI,.PM[6^BM8+'-YB^0<_P"!V4QQV&\Q%,BDP".+
MH\I+\!Z4V*"+UE<@2(2^TJ$/IC\B#WCS 8Z^?I!&]<YZ],?9XQ@'N\<9\<^'
MESH@O&U 1$6^U10L.F6C(A'2'^T,3MIFSBFPD5VV/I0$V6RPD1$@B3)CJQ8
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MI>_@(DP>YD.!"QG+G-1RBOF_Y%Z17M;/A?P>9*]7$1*A,(C!>$0ROBEF<.:
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MIQ&$D%B*#8V\?1MOB&RV6.PWQ9Y]HF1PBT2(X3*]2"/C]**$1F** 1=(!@Y
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M5SI+$LL*>:JFS.4*B4%NQR40R3 C$54D>$3A%KX_5 _\B/9O?US77#^W?_\
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MG9'7.?JE66ST7MNO)<VN5D;HWM;49*),8E!:N&3!4R99'#O =A8"%5Z@H&#
ML?9 Q@8<]T>,\_+OWTG^0-TFQ&RB\KZ]?9+/:)TVQ]&"78HYYF?R:?Z\2XC/
ME]"(S/5PQP@END^'[%W>CWRWO$6OU\5T76)$^9*ER[3-FQ3+7!*AEDSY/P>5
M:(1)/K(88/612XW$1, #$S [6V4(YOI75$O;DJE$WR6W80\HDJS!6%1*9? Y
MZH*+/P0,PK!@,#[H\ ,&'.<9S@6<9Y^OSD7Y9N4O-S=%_6*&;#9+UG6.VV83
MNB(_4SY4<<LM"2P,)!:(0Q.[PC/-_H675:+CY\^5%SVOU7PF[N2-[V2?ZDF*
M7ZV3?_)^7&QHYZ4)#@,P#+6OS^\'^UQS6^?\N']2'6Q>K<.'9]F%;!O8=]?8
M^Q']-:Y^'_['+?/[OO\ P].;&\Q?Z%?/[>37;\4U\NI>9GI_?TYS;?57*#M^
M%W=Y.K[2?T&/ISS/B\\X<!P'@O;PJG")PB<(G"+7[U0_F@OM/OA^9CUH_P#A
M,2]_Y?ASTF?4//7X(M@3E1.$7C.<8\\\)YID6,=.N>G7R\,]?O>?O\?ACKG/
MAC/"*M_M%@X!!Z_%CO8R*7+QYZ"SCO"RSG>/3&<>_IG'7PQ[NF<8YJ#Z7,^.
M1R?Y(F7'/E>LO:\H)AD3.@\'P(%HV-7)<#<U%L=Z-DJ7,Y2WV8Y<J8!=LJLV
M 1B'UD[H0F%RX>,P@MD3E54VE02%DRU1/2HLQES=6S$1U1+@MB0+\:Q)E>%Y
M#48XX!ZP-"4LP%0 @0LAP8$/CD( 8QHU_"J_3=?Y%-\V\7,)OK1<XM-H^"&,
ML#&?C4BBZ()+/0,1@MQ/R'=!M1MINV[_ (28/5^L^#2S,B@<Q >LZ/29XHBS
ML_Q@'=[%ZXSC^!^;==>N,FQBR@8QY^.:^2B%U\<]!8QC/7.>G7(O#./+FZ_H
M[S9DWFEY>]*T3)Y-HMDF&?.BBB'K!R?LSRX07C$,#PPBC,0QH0-?^4\D0^D9
MS22Q+DP017QR;,'P>#U9(_+\TO$  .F2&<CN-=9H7EGZ,_BYCP8CB%ZVQ8'@
M?!68]D;]NE%/V!V!Y_TK3<R_S/?.Z7]7VG[(6HWII_0G;OKZX/O06VAS;!>/
M*<(G")PB<(G")PBU]V;^:9Y7_6GR?[O\6\?R^/)F.!\0BV".5$X1.$3A%Z3_
M -!C^BQ^+/"+3H[23[=F^/#_ +]1?[O\0D8SU_+X<TQYTOGO>WZTO^ZEYZ[U
M[<>BC] /-Y^YWU_BB_%!H7EC^B!_;8YT*#\U:/V8^T%L+'@*M\>#K^,*8CSX
M+<D[.+[2ZB?V-NG[JY#S=_D-\U+E_<X/$KPO](_Z<.<C^T,W[O9U-[G;%A).
M$3A% MX[.O7F15!;%5R!F4/+Q<4IG\YDMRK4$8%<:":SF6*Y@DE+!, , 3&M
MS@KD-J3P?)281#,VQYF0B)4DD&A/:UP4KX[GQTZZM9?9DT3;VL<BUAGCU/75
MB?[?L*\D]@$.;0VV-')_9T^E4\EZV/.R!E(;42-W#.)=#'%N.:5*5QA$A=F)
MR M L,-RUK3JX;]:QIM79+#T%CDMFUC2V"WSL10S;=2PETNN#TY,8TRQ.QGL
M+,ACRZ2" _PZ2O<(E3VP-;<S2"25R\Q)T>4R-,I5G9=" .7"9;>/FN1F79[:
M^RV0ZIO"9M>XFT:B)TS37T.B[@0CC$AB[2HB3U&HE/$RI(M5R!AB\T@,(GS0
M1A8F4XED:1+UJI8 ]<2I:UV*5\'\]?@N==M%=>)0V;&([ A[?83ILY(94_6#
M*9BSQYUE")/(H,R5PWL,6>Q,X5; RQ"'1MG;(J0F&)0WJ$QKH8H4.:Y6J/*J
M2M;Q 5>U_"($.2/TO%#(I'XKB52DU(HDTC"P-25J"]2!0@1H$:AY<@I<*W-0
MF1)"CUAIQP2"\#[N":UWKNW7K^+RSC\?X_+A%4%VSDYW6K#4]XL#4>R:&K)O
M87!E)M61W"N<HR^M;&[3&*-K*Z0.;FNB>#,/<7*C6J8IYZ@]G+(LZ+U#:\(7
M1&G2.!3V\&IQK[3@L*Z*U#OU)+NK&^)G9/9GQW5\AKL%SE#%V=J:;G(=@))+
M&(MMCSG/79]9RHZ\@A[KC+XVN[>\FKRE>5R4],K O]*EC5ZJ\:;AU\ R/ACP
MU3\=ZL(NS6;6>[;L32.8V#8D0NZ-U0C1*D]3;+VO1LH,J44I?5J!RD;)5T_B
M"AXC!4I^4 $;V](U:-*N N2%+"Q!&5RH^NS93/3%2(H_ZW@:JA9553998]?I
MVH26,3APL%WM==)&]&M5)1KU-C/[S(7B7F86%*D^7=>]N9QN2,EX5# 4'&":
M;6WLV;\K9SC'3KGIU\OR^'S^7W^%5XP,.?+/7Z,9^?R\/'/AGPQX^'"+7S^J
M!_&)=F[\?X)KKAT^GOO_  BV#N$3RX1>DX\!11IN<&#P4 8Q!++,,,SW YSD
M("P!$,8L].F A#G.<],8QG@TQ?!\":=0[L5'V<.M:^3C]4D:9-<]55BIU]WP
M%-R#U02X^#7EG \J4*1R.:3'E.P'V45(QM'KR<XGUL3,$032Q$&$EJ0B3A"N
M )X#6L$+@F$@ B'I,'- ')<!C2H J5>!.W4AZIV8NI!:P@ESKY]7DIW!&<@7
MIRE4?/4 (7(5 "ST2PH!H0J4AX0GIS>\4: (PY!CK/+0?YI<I/J6\1_]+,UO
M7ZUPG^?+GQ#WC8B'!%#:)=:BG6Q=:XY?3R_'[NO<\^F?#'CCQ_!CKX>,T?YP
M?J"O65ZF0_*F[/61!L<9,+<&/4^S%2ITNQUV*AOE_H*2?N;=\>>/=^7PYG[T
M9C_Y6+C_ '*^/NT>(RQW=ZPKS^?1S>GUC<W]]"JK.T+^W-OG]EJ/]S;-S.W.
M=\]KV_4E?9EK<7T8/H*YOOJVV=]ZV\^:AICS!_LA7_&!YTBS_I$C]M*^W"L]
MGS'B%OD5WT^0D$_8?'?+RZ^QD>.OT9^;ICQQCF_=F_1Y'[&5CC^;AQWK^=R_
MOZ<O?ZVO'[U/7>.?=?EIPB<(G"+P(6 XZBSTQ\>$7Y](#KTZ^/3O>6>G3X]>
MG3WX]_OQ\<<(H ]JP((NS-WVR'/7&=2;XSC.,9Z9QFN7_IG&>G3.,X\<?'&<
M9QX9QG)%[>RJ_2V-&.G^I=IO]Q33^7S_ #\(I^<(G")PB]0O\\Q_0"YQ.,)X
M^&S7>IF> \U1CN[C&=@G_P!_^049\_+_ $N\O'W9\.ON\\9\_#S#]*%ASM7C
M\8@BZKGVD_HHS6_?H_A^;>[B8BWY0O9X<OTV97 U.&V@(41\XZ##CQQX9Z8S
M[L>/A\>F/=CRQCPQTQC&,8#A+V:T?&,7QY(<OE#.85 --K9XO0YHCZ/K(.@
M/XJT.U _2L[EQ0EF]RE-VD77^!T:Y?LWK+^YS.\?W_C^]ST5MOT#<@?JRY/N
MA6(O1;_TG.<?ZFY2?XFN):\F<]<_<#_:XS]/OQS#=H^7#^I#K1*].8<^K[(6
MP;V'>?\ (?8C'^NE<]?_ .3EV<>[YN;&<Q9_D5\C9/D]\)7F9Z?P_GOFV/\
MW7R@;_Q=W/XJ^XC_ #O'TY_+\O#F?5YYC </Q7MX53A$X1?GO!QGIU\?HSTQ
MTQU\<].F/#Q\<\(O.<XQXYSTQ\?HST_+[_EPBU_-4,]?J@OM/?ZF/6?/7Z6F
M)?=\?WOFX1; G")PBBGN7J9#=T:564I.IQ;-?L*B0LDG&_4S-CH'+\JV 2DQ
M*A&[EI%Q2EH4B4B$N;520X@\PI*H#Z-0E(, 1:__ -3B:DLCE73KNK(+EV)E
MEE-=F7O2":*RJV75[K(V+,;TVMJ!Q6Q16G$:OD!2<K P+%3D-$6J'E8G;4Z@
ME,(IK6"*XSM&/Y!J]^:6+_#/3_S,;^+KY>/WN:>>E_\ -WDC];WE]RAUW8K9
M'T:A_G%?^Z[;%U?RV#6/7DJF,>/AX^>/+Q^;RZ_EGICPZ\\^ENH2'WU%0PK@
M"<"''GD7G97GZ7]MG^QZS?[G:?R\N;Z>CA7F?Y<C_O:\1_\ ;]C&]M8K77E3
M_I'\SWUKR;_Q#/[%K,B\L_1G\7.B0XCB/%>LD6!X'P5F/9&X_P NG%?'.?XA
M+ ^'A_D6E^&?#\/G]W.7^9[YW2_J^T_9&[V+4;TT_H3MWU]<'7_*AINM;:'-
ML%X\IPB<(G")PB\9%C'7Q\O/&,9SGQ\OL<8SG/7IGRQGRS\,\(O&!ASTQC/C
MGKTQ[_#S\/FX1:_+-_-,\K_K3Y/]W^+>7[_GU^YR9C@?)%L$<J)PB<(G"+TG
M_H,?T6/Q9X1:=':2?;M7S\/;47\?_8.,?X_N\TPYTOGO>WZTO^[EY=6.:]N/
M11^@'F]_<[Z_Q1?B@T+RQ_1 _ML<Z)!^:M'[,9M_6';P6PL> _7@V_Z\+88U
MZLUN1]G%]I;1/[''7]ULBYN]R&^:ER_N<'B5X7^D?]./.1_:&;]WLZF_SMBP
MDG"*LTSM,(,1?NRU&*:CMG!VLD!/G,MDZ5/#LMSD0SA7.,K)29=9.T-7JS1&
M%U=2A$I1R%P<,-EAMQ<R98.K*0E.[6M>:;*BN%?/?W,<F4@M+]K6+<RC&*[X
M["Y7!6]W6KF@YDEI*8E86[LP@)'XI&$(R73*-K><+F(S,A9(P]^T6E?D]@2I
M<HU"LBEAPBAWL/<ERQ2X*$I*EFNM?;MRM%O/CE+K-%(U[1$VZK6V(K@Y216,
M*6ERE"M[52@EMRF#)&$+63D;T,Y>6@&TKFM:R3W>>>'GQ=0N<NTQL1SAE3GA
MK:%4+BQH\X!D>RE].\K.U2A,V8YI(Z]>XM'I/%(^'Y6/P9!&5*]A8[0E>O2&
M2,CDU&,<J<W :U C=6M<%*OCCEPQ\MK==)"[7KIK,YCIE0K;;<QKUAO2;SK-
MC6/33N*#RF1-];4G+9XVQN(2,O+TJBR"621(B?%9K4O/=CH['EK4G=!IE:T\
M1 =Q##5,\,6KDHGL5F[0+:6U4DA5_*CXS$]ZW#72PG!5&$:JP[WCL-V_FU'1
MQ3)ILF<T;2SH54,C2)3,R&2)>OS*2%C.&\-34->U.4RQIB^MH?R09[6&G:NL
M,[P.5512WADSO#=4[IE#)%Z3F"UEBF5IC%L:[HV*CS&P+@B ]N-DN*Y,L(!&
MV-F&O>U24*8U2XF-Y3<C#ZTJ)X.GT4UGY?@M9BKNRPD.+=FDSIWM#:MUIWHG
M%$M]]U)K?HM&UM,:_*61X M'"I/(F23NDB4677;TY)BF]_-+BR/*%*I+<%+6
M:0:E3+(VJ8;."G#6W1S4Y>TGB<0M:7T/6NS,7V"MR>PFCH2JD3#J!!:M1Y8K
M;O!WDE5-+])[3M!Z8E[U![#ET7D;!"J,*0?(J6JF!>JM5EDR Z/,Z"Y]M>SQ
M\DRW-B7I@?#%_>KAM(Y@OGNJE'RIS$;ZXY05O*.*4PN.5PO2^RU"MH B=Z_B
M#])HQ"7U 6@ A?8LR/!R!B>$RYL)2-?JN6M$3/CPW:Z^"P9VA<=V'L!MH>!:
M]&.HS'*SGQ_LINB^QV=9I<_0R.5U+"4+*U3MN9I)*O9@YJ]Q5W?BHQ'7=46G
M:$A2\I*WKS%I)55IYMN<7=6UT32$WILO1R32[2$%HPR(*K73R)[=]@8I;&W,
M(LA;<LO5H7(5YQ9AEFM"*$MX70P<;?H\X.+MZ@E5O+<>C*;RS[M;_$!U'CMO
M;)VHED[[-!)(*@A;5K.[;8Z?SAHLXJ4@%.#[K>CERAZ@*V'C684(H^WM2E2>
M2\&-P<&*20D95=[.2^*Y>/#B?P5VK;/X1>!?H1?1G\7(<#E3'8B@GO=L_+=6
MJZBTQAT<8I K?IH7&E9,@.6%I4R<;&[NN3B<(1@-$<,UN)(Q@7>+"6:8+.,"
M"'GXE_WS^0[%!:C(^$Q138),,'2Z%"(GB?"C8'%8YYR.6=JY$739+QLEDE6N
M.TWA!9(H)T9AAAZ4J9.+=$.Y@E1,<!AB0M;QXVYN-U[1V)[ZF1>N\'Q;6)QU
MW#$<J9%DA64MFCU+/;0S,9P<$?1W$E&$*@(<X) +)0C!9-#U2'G"@,DGX"?7
M5$,GI_%B_P!4F-B',0A.(H6;)8G@](6UPW8.E<LL7F+7"1+AF V;X((1%$8I
MK^L]<)@^+"(2&!K57VZM[92_:FC=@G>71U@CQT0;'%I18CYJX:=60Y1)<N%E
M06N[QH#2C0B '(!9 (/V0NF>G>^M[7R;[Y$\IK1%9Q9HI=T7E"90C,8<628>
MD8HB7)!>A9P>O,_,GRYMW+FURK9;[+*LLRQ7]=]G DQQ1@B.;+CA),1=Z@4H
M*G8JMR_CX=/'S\/_ "/AX^[/EX^_YL^04?YP;H .V(^]>S,(#S-\R,]8DCR'
M8^]2HTO^V*AO^TI+]'\C;QS/WHS?2Q<G[E?'W:-84Y_/HYO3ZQN;^^A55O:%
M_;FWS^RU'^YMFYG;G-^>][?J2OLRUN+Z,'T%<WV?\V6O_>MOV=M?!0T_G@?[
M(5_Q@>=(L_Z1(_;2OMPK/<6'6/$+?(KG^0."_L/CO7K_ $F1?AYOY9OT>S_L
M96[^I#DOYW+^_IR]_K:\?O4_6Y=XY]E^6G")PB<(HF;R8GZO5:XV*J90Q0ZQ
M97'D<+BLDD%@"JQ(U.,S>VN+B.16 40I51B1#2NJ@B*N" @URQ)C6DEN+$M-
M(QPBJ'BYDC76]7NA<M=;JI@M5?;LJNUWA>[%\W,LG;6=K=)+)K&)P[8">*(M
M;,*2NJED.<)9"64J+J,'14)Y(U39(QG*&Q^MD?/9Y+I>W-E[:NW8BWL&LDL?
MO%.R*=U:0MVQ+;E1I<J4:KU5,[ZK)#:C2Z)U+?B961\E8A$QA,4 6?*)2>O=
M5!"L]0(?"*U_LILF9[-71?)F,8'^9>IWP#GKCNXAK7@&?I$#NYS\,YSCICRX
M16 <(G"*"NS':8:,Z=S9KKG9+8>(U;.'E@(E+=&WA#)5[B='U2U:WI'4P+$R
M.A:9,K5MRXE-E2828?ZJ<,L BPX'DCNLI:R[?ZV[EP]XL'66V(];41CK^HB;
MZ[,!3JEPU2$E B=!-BU&]-[8O).$WN*)848)+Z \E0$1)H\A,P#B7>'B>T#W
MZJBK%W<^V"D'](8SY>?^EN//\7N\/P^87I1_2U>7U5='W4+?KF !_P FUW-_
MZQO3@/Y;,RXMD5$;/Z,/T?\ YN8!E?HMH_7E>$Q9GB#3(-OJ9[__ !2!V:H&
M"E-VD7Z71KE^S>LO[G,[^]^6>>C%M^@;D#]67+]T.J^#+$?HM?Z3G.1]3<I/
M\3W$M>7/[P?[7'N]WT<PU/\ EP_J0XXYXKTYASZM_P#5"V#.P\_THV(_II7/
MO_\ W.7^7W_W^;&<Q7Z'?7[:1]F+VKS-]/X_SWS;#_NOE#][NWV*^XG_ #O'
MTY_'^_Y\S\O/*' :IELR7MX53A$SGIY\(J@^T,C^R,EM2'.=9)YZ]4]5U)6+
M-K%C53[?*-7)HXOKA(XT:VN1X61H?7F5A:8K#I6EBB)X*8(DI>7QR)52AM5)
M1=XIK;K)1<<KJM.=-5E;F5[?-PM>*PVUTZIBGJ&7R1.EKB24];D4U.-<&"SH
M4>E.-D<]LDC82223,R6+@O[*X$Q<+&I3HFI<6ZSKV;-5_!,^H[=W@_ADL(]E
M2_[*R;MHNT9=]MH+7]<7B?KC1!<FB=8OQ\DAZ% G,CQ,<.;G=2O<C5!JYC"B
M5N !*L^@6F&E8 4$."PLSU>?L56T;RHG"*--@[=:_5E)G2%36>%LTE:RR/7F
M[+%(EN2/7$A:M-@1Z!J4IA9-3G%&8" X6<8'C L!%UQCN%T<@N5=_6&3>-U7
M3,M5CGF;#*G"?9I8B,F.*7-'0FSH(QT8X2',+'&%P0L>7]SJ\@^35ZS[DOF_
MI5CO.SP2HIUF^#6R:8(9TN&9+)F2+/,EN8(H20(R87:( JB3L$MEJ;H_1V0P
MVTY.KB$D.V9OY_+:W",RD9PFAVE!&6];@25F/*P6I]7/P .1X'@1)@!A"(.<
M<^M@YN^6-YR9EHL=RSYDJ5,F2HXHIMGE$1RHXH)@$$Z=!'$!%"6,,)!#$$@@
MGYWMSM<WMR6J&QWCRDLDJT16>1:1!*@M%IA$FTRX9LF**99I4V7"8H(@3!%$
M(X<(H0:*S[?MY;I-5=3R%E4>N,[V]Y=FQ9Z,TG"IO<8^-6C4!*/ 6< )R<P!
MF F%@,#C/080B\.:'>F19IUDN+DS(M$'0FV6_KSLT^!Q%T)T-D,$4#@D%HH(
M@3"3#2A8A;H>BY:K/>5[WK;K%,$VS6RX[OMMGFL81,LTVU2ILN8!$ 1TI<<,
M0A($5<'=55]/+/QZ_'W?<_%]WISSS6[E'-*N<6):KL.W8]#4EE.NO/TO_;/]
MCUF_<_C=)N;Y^CA]#_+G9^5KPQI3^#]CQV+73E2?_P!Q_,]];<FQ_P#<$\Z[
M%K-"\L_1G\7.B#$+UEBP/ ^"LQ[(W[=**?L#L#_X6FYF#F>^=TOZNM.W_5';
MU^++4;TTOH3MWU]<&'[V-'>MM#FV"\>4X1.$3A%XSGIC.<^6,9SGIC.<^'S8
MZYS]&,=<^[A%27O\IV!:KREENHR;->=6* U]BDSFK12VX0J#ER%V)E-@22QI
M&NKYD:W)PL!<D@C!&ODNSRESAS(]DD/R)J?#U@E!)12FNK/?3CU+ID9M"UU\
M_@6TZ&^;7<CYYVDDHU0-HE8^)@5 71A$@F]=M#.GK\3:+"&;-;?&VFW5DVPI
M#)#U.'-$J4"CIX4I,?Q;AKSV53K>C[>OKR'9NC]0[K=CK]4R7KFZ8M$8OEO[
M/V7-=5?))U,=,2*F$5^P7$'E,C]*J5X;I2[Y,<A/#67E,!)DE+Z-.6$8N\S!
MXCJ/X *K9IY43A$X1.$7I/\ T&/Z+'XL\(M.?M)/MVKY_IU%_P!P<8YIASI/
M_#>]MG2E_P!W+\F7MQZ*/T <WG[G?7^*+\4&Q>7^^!][O8_[?RQSH<'YJT4_
MJ0]T3OX=:V%CP 9_CP;F:.&IVMV=;/N2=G%]I;1/[&W7]UDAYN_R&^:ER_N<
M'B5X7^D?].'.1_:&;]VLZF]SMBPDG"+C1,S0,:@P36WB,6 /*5F"1I\C5%JB
MTQ2HM2+)?>/ I*1HRSP&Y$$XM*G 9@02"\!(OJ3)$J,L121.0E+$88:(M.4
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M *QD>-A4M=D1VEHK+'W7N/N1MM7?MG.-6DTA:V*ZS)=%F:LC(7$I6*5SVB[
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M4R!.:J5FA)3DEC---'GH$LL&.HQBS[@AQXYSY8QXYXJ2  8HB0!#""8B20
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MS"&!CTXR#* $ +.Y;,#@HQA'CNB\\XZ9SUQY=/#'GG&.F>ONYY41RHC$ >C
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ML(J@D2XF<-6K!G&+.M2M:C;W%&)N6)P."(SN#-0K  5HSA@'WP>E3F%B*%D
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M*R#. 8P'&>[C&.$7ORF3Y-+/R05D\H)@"CLE@R<4 [)8C0%F9QD8 &Y**R8
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M=CD:98JY_LU69._T5L8\'GJT!T=SW$J5A5J8XU+<&0E>,0GQH93T;<_F]TK
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M<)Y6KA6%J0UL64]$(NWK9*NRHMJO'9U=:VEJHA'E.X,J!>^JDIJE6WO()G3
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MP[LHA,6S4^;RE"EQ F3Q1-A4]GX>G$X)<3:18,4+G$I0<<</!F,#-'U'D(0
MR+/<QG&X?-598K7S=W5##:;59##.O$&*RSC+F1 WA:808IAAB#.\0A$#0DXG
M!:$<\UOBL?.G>T,$JR3#%*L;?E&[[#?%F!_)MEF&(6.WR(X(8F'1)$9!A/1
MA "B3Z074P>"R ]['>" 1)!Z8 NG7.2T8R0IB<BSU$,1(0YSG.<]/'F0A<LH
M21)-IO.**$ >M%[7C!/B(%3',@M$!J7^+ ((0] (0(5BF&^I\NT>N,BQ6B"T
MF*&V6:==UWPV.7+B(_0K'#98I$CH@/+@A$,,L 2X3T0"KCMD&G+5JQK>#UI6
MK]<1L#AD2U4>K,(&M@Y!V4R<1XS/5T) A=Q(D*Q@E.5C!96,!Q@./&GTR;PA
MN*"RQ"PW?>D(Y:7Q"(+YL_Y0A_BQ:(7>.9 28L8HHNE%$:DN[^V7HEV+\L66
M3#!:[1=<)Y$7)%#%=0AL4<,,0LI :'IPCH@L!"&# "@ 5>N0=1=[/CC'O\<9
M\\>&,^73W^77'W^>?,7+&TF\Q>(NOD_"82")(N&[3(IEZLR">LQ$[7"W>')J
MSBP&P?E/E#$"X,[\O7EZXU8_'$\=$.[-"PILI.:OD^<:%;5K"CCBQ)V2=*@I
M\&9RC4&-D#1K IUB?.?1*42L81$+TXPY M2X] =C(!YQC>+F'OT7IS7<N+?#
M=ETW=,%JM-F$JZK##8I)F2+ALI$<<'K)@B+%ND!#4Q?$JM>^4MQ06?G^YI;N
M@M]YQPSKWY/$3H[8?7P=/E!.<01^K>$.#2I<_*& UO53\>K4H5)S3&BLHS#C
MO0(6%"WH5(S< \'!"G!Z!Q"#N8R4%1C/HA9$(&<9SSI4_E$+5'#''=E@@,L@
MPPP2@T1<,(R1@,A2IQ%7]2;)R(L]CN^VW='?7*2V2[P]89]HM%_WC\)E&* #
M^3389O3E%PX,)!A(Z0JK(^RV6BE.X,;;E"1M9L'P"QBA*HRWIH^Y!PH9DY63
M N+> M2$TCKZ1.8'.!$FX](#.!9SGF4>:Z^8KQY6RH8KOL,AK!:8H8Y$L01-
MT !0 BKNP.76M5O2QY)V;DYS,7C.L]\<H[?''?MQ"*&_;[M]^CXUI8B&.\I\
M^9#5BX+F*I#LVT9&X*DC*TU<1(IJ[C-3B3Y3R.5NKXC $0P#]*4E7&F%%GXR
M#NA."'OX (8<9Z"SS9A>42[QPB<(G"+YU9XTJ12I+3'K#$Z<XX"-+@K*E6,H
ML0PID^#S2"/3GB#@HGTQY).#!AR::6#O#"14^[<S;8.W)=&:FSIWLBLU?F=;
MQ22WBXUN50IUB6,M?0GFK-<) HD]UQ?Y'1>/(CC$UGOD;4R1;(S'!7%(:[MK
M<->_NA0:8OK'K#+I).NUEH-M6B34]K3=5%RI1LWFQ['OTS8\N4:_3NAG!"8*
M6,0ZL.M!2<5,)T@1L\=^0Q--I$T*D"(A^;)P8ULS<X+&M:\4&_'8-;BRBI1%
M<S&N_JF.]PS&UI':HIOV?DOL.-9D:4I)BNXA)K]@WL:KF()"E0%3'HB)&HPV
M*3,)S#0KSLC3$Y+!@4UN_&O=DC8;OP6G%VVF,_P5O>#..G\NA9UZ^_'R>8/#
MRS]S\NO,/TA@[#/=Y_@]%Q,0(S+N.S/@*:=5:],]<=<_'.<8\OF^GIX>?PYR
M(H2<6(+;7#9;*;QQ=(2 6;%F-"6SS;$8;7=?T^-;<8#V&VF6<!QXZ]Z_BSCI
MCJ(6433USGI[\YSXBQGKXYZ>>,XU\])<Q#FJO+HD F\;L!)@Z;#UT3M"2SL[
M&I&(68^8H \XMUOTOT:W4AC,LG^(P,0!+;0S' T43< SC&,=<>'N\>[X=>GV
M/7P\_'Z.>7\4<(AAA.!B<GU<!B&UHB3%GU9+T$CA@CF&.(S@8>BT,,Z/HQ'>
M P)+M4'>IB:+X%]?INR(6,YQ%Y1Y8SY83$9Z9\L>&<8]V?=[\=>;%>B_'!_E
M4DB7%%%">3U^/TH882/XJ2[$&(L1D"'<L'QP;Z1,,$7-]%&88^D+ZNL0B*88
MH 3\)^,82PZ0$+"(C,UQ!JB[2(.!;LWSTZ9#A\BX@ %C[$&<P"*=<]0Y"+.<
MYQXYZY^?&>G7.<>=..&7R[OZ)HHR3=;P11$0![HL7QA4_&'1##HC$UH%N!Z*
M<HQ\P?((S##'$(.4!AZ4(^*!RIOWHAP02&)9SBY;(0@SWNG7.0X]V X#G&,9
MSGH'QR(6<]<YZ"]W3.<XZ\Q]TI4R3:(S#%#,Z,!H7A81PDXD$84ICB5L.1'"
M!\AFZ($,/1:(_%%222"2 X )%>.Y)V<6,YTOH@0L8Z_)AQQW?,(,@E#\'."_
M#'0.<AZY]^<],_-C=?D'"8>25R Q&(_ X22<2\41QSQW;%X;>DE$(^?'G&BP
M/Y=$)A :&&*78;)+(ASZ+PEGR. <@3@YVY8/3A$X1.$3A$X1.$3A$X1.$5*7
M;37M;#%KQ--:Z7U^W5L6=7;!<C:K.U8KLV3,<2*;)4U#>(?+9<VR%M?H<LFK
M&D<63U]G:7A6B:78]Q+2+O0C0'#IJ^U3/WGP4)^R]J;3Z)[4P!\JWLU>U(UK
MLTF*3(G%J[/FV$KIQF]9BJTM[;GE9(;9D#4I7O965#>PFFQ$L9SJ<E,3DMYF
M09)F>&6_OT]3055UK7>MH3'3ICPQY8^YY>7*B\XQC'EC&/H^;R^]PB\=,?#'
MWL<(G=#_ .3CW>['NZ]/O=<].$6OE]4#_P B/9N^/_ZS77#K\^.^_P#X??\
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ML;ZU2TZ7/C/!)%*1LSR]R!:Q@8U[D97+>Q.:]88\GK5QN3#%0SG,P[ RN];
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M,[XL5M*LB.Q&[.J,G6'!RY"W$H/:;&*5,>'AK$4BL3.0N33Z_P"T$61"P6#
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M]3H(?(-<-=&YAE2VQH@DCCTX-S7%@."!J?%#P6UN"U ,HP*Q*C5''IQ!S@T
M>Z+NS/J'FB_GA66<4IL>P%"<TL].?.)8>0>28$PHXDU_<!E&EF R( RS "",
M P"$$8<XSC.0YQGGUAPAH6?;2CX[*X;6JOE%C%MX<,,<AFS.XK12P[,9\9X[
MVB&E+[(75M8V-IV8I]>[/3PN2MC2UH$TS:C5*]Q<5QI"- B2E!$:H4J3BB22
MP"&8,.,9SSB8AL&=23GLP;)GP97H'(LX;\<7WGLI1;I6\5\T@\[.6&Y-5PU>
MY-QWR9]67-T^BBY&I[L59R!^@4I78T@SN&%B"+NF9Z9QG&>F<<V]YI[VNZR<
MAKNLUJMUCL\X3[<#!-M,F"(&.VSIT ,)BZ0Z4$8Z+A\VJM$.>JX[TMG./>MO
MLE@MUID]&QPPF38K5-AB'Y.DR(XH9DN5% 1+C@/2J^6(91'^O'473./KJ5QG
MI]C_ ";QKS\O''M+KC^_UQYXYD_\MW022+SL >I'PN0X<.06F'#P6)CR8Y1/
M2X[W(=@1=MM8["/XBH(J^S)Z*X;9C9#7USUIUR;4%XTZL<&YFC1:Y$EL^$*%
M201$&3D#PJ3DO8STV<&AR7G!Q8.Z9^=BZ&=<9\6_30NV\K]EV"&Z+NMMXF9R
MKO:W?R&RS;7T9$Z*=""1)ABP]8"X^*0"Q(7M?Z)-Y6"X)-EE7O:I5@?DI<]V
M=*T'U4,-HL\JS],1=,CHMZN(&$M$#\H0JOWZ]]*X'W<W!5N!=.O=S8,0ZYQG
M_P";[:[V>OEY<\^AR$Y8_P#LQ?\ Q_)-K;K/JZ/PWK>0\J.3A;^?+I=PP%OL
M[[?]=A1B^6>Q37@.P]"DZ([3LQMV5"%X<&&R0-S4*RX6%S<1GP-.E3@0-XGK
M"M8-0=]@4 @D8ABZ@#@0\9QS=OT?[EO2Z^:GEI8KPNZVV*V3;;:[7+LUHLLZ
M7.C@G71(LL,,,$4 ,47K947R07>CFBU\Y3WY=4ST@.:6])5OL4V[[-;N3EHG
MVN"UR#)DP0WQ-M4PS)@BZ$'JI40,9BB  ^,6!6N8*PX#C&>LWB&,=//,E9\?
M_P"W^_SI@Y-7\2/YJME2 /XF,5?:R]33R^Y$,7Y7\EP&.%_W6=M !:JG<*[E
M8EV5=V5!&=PHN[R&T:\8VLJ%SM,<XO4UC;0WDG'MJ<!)9BUQ<TZ8(S1!'@ <
MF=X6<=,8SS*W--<E[6/E49MLL$^RRY%AGP11SH###%$0 !"68[6QW+5/TPN5
MO)J^.9NV6.Z+]NJ\[5%?ERS/@]BM]EM$X2Y%HZ<R,RY<V*/HP@5+4<+;/AEX
M4Q8[H<R5U;E8SYY3(QN*EIA4^BDI<D[>6<2G,7'H6-V7JBD@#U!!(U)A020F
MG$EB'@9H,"V=7DTLH\(G")PB<(J^=C=]2J%L*;1%GHJQ+:C5)UU$K;V1GL3>
M(>U-=-U_-G*4HV1Q TR)W0/$[>BFR#RN5O$=C2<2QNC+46LP<I7.3<VJ"=?5
MK6Y?"T=H,UO%S-D.*I6=E4@_7FZZRQ[90;]#!Q!VO)G;W4Y3'@PT#O\ +1+&
M#WQD=H0@FAZ#"%5,T@&O"$"-20YB(JPQW%4<:^J4)R_R2TJZCS$V=F)F%N;R
M^S>--+2W3%/>\94J(FN<5SF2C2R8E,4<H.8CSBW,H@DTPQ,$(,YQ.S/RT>I0
MEM>QUI7]LI(H_*^U!W1D46?&B2Q]VN%6I:GY@<T3PS.:83"Q PI;W5N/4HEB
M?TA8P>F3'F%]\ @][.0YQCF"'%&HQJ1P-&;?CP7 PG:,231^P&AW.JS.O3KG
MQSX],X\/?\,=[&,=//.<^/3&<X\?#EB-"7.+%SA4L*%LCB^1&+I#B*#!W#C+
M$N*XT;!?TGM=M@*&0]BOJ!$5UVU"CEC50E#HG2,*K*AA$A;5B)(U86)7!E->
MBW%&K1Y"+UI,H2EG)QA$$P <ASC.!_2+L%NO+FRMUDN^R6BVVF.\KL,-GLLJ
M9/G&&&=$8HA!+ABC,,(#Q$"@J5EWF3M=FL7+^[K3:Y\FSR)=EMW2FVB9!*E
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M617JDV'QM(N?FM^7/HBG9V*(CZ?+:C5.!3\'?57)'5P4*!Z@[GJ+,QN8:/7
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M"R03@D8G*.DN2!/WXXN[BA05D(THNBDNF(Q?*BC)S)F1NV35HU=VT4"KL&B
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M8Z*EKDJ*;FM$E2%'KUBI68 D(CSS3,B&(H  [!@2[<<>]SW9+N_"J<(OR/\
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M 1MS[U+-#]3^=DJ%*F MT]C)RD)!.%8OKEW?W3#\%!P>,. V23C 3#.^+'V
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MH(I/JW6MCI'7578"!P&\S/Q';AO\E.[9CCO;+K8]BOQ3F8.3D&X"8#!I)1F
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M$H+DX8 AF!8[:G';L?)MBDG%V>KM4'!^CZ)PE#/"KEM:960F]NK&@-6U?.;
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MWC+!@T)M24Z^36<B9FF1PG=VHV>MX\;'7&S"18(8GZYJ4D4B<J@?[PBY1@+
M;8:]1N6HGD[&01PE.NN\A^W'+PHKB6]#%:]B:-K;4S+$H7#& E&A1)2T;-'X
MU&8^@P4G3D% P0A:V=G:T@2RP!P2D1(TV AP647C&"JI#VAWK+NP\D.ODU;
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M+PO78+6"I;5E:TF<5>PSFU&CM']?:MBL@B-R0>).\>E#&X4L%D<U*B4NK?2
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M=F_KX.U5U^\R='<%2Q17(Y_=D:UY>9-'2MI*Q1,R]".7ZYS>N;,=WF7J==)
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M9FH]<9@E$0Y.:)"<L-%GI@I*4I/*,4&9]P"0C%X9\/#A%R1BI,44(\T\HL@
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MEFSHG>I*[@KF/#4KW5+(4,M)7DX-1F%-BG$H;&Z1#,:2T.3GE$E<3O2*B2S
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g69956g03i25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g03i25.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1;>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %L*^6"8X0DE-! 0      #P< 5H  QLE1QP"   "G:P< E  "')R,C8W
M.#DT' (% !M-:6-R;W-O9G0@5V]R9" M(#8Y.34V+F1O8W@X0DE-!"4
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M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (  @.__C4
M @ ".$))300F       .             #^    X0DE-! T       0   !X
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             !4P   ?H          0
M               !              'Z   !4P                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   !4P    !29VAT;&]N9P   ?H
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    $.$))300,      QG
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
M# ,!  (1 Q$ /P#U5))))2DDDDE*22224I1+V-<&N< YWT03J5)5K\&B^^N]
M\[ZOHP=/'5-D95Z0";&YK3JD5>NC'J)Z@*F?8 TOW#?N_=^:L[MK)>0('N/9
M5NH=1JP*VV6M<X/=M :I9N)7U##=CO<YC+0#N'/[R5CBE1LT/2FM(V*%_,SR
M3?\ 9K#BP;MI]*>-T>U"Z6>H'"8>HAHR==P;Q$^WA/\ HNF=/U(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$  @,! 0               04"! 8#!__$ #H1  $# P," P0(!@(# 0
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M-DAH/D]FWW"BJEJZ"1D3)CC0\X;@Y/Q'9<=7=/U]OME#=9_"^K5Y(A#7YD&
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M*^.)#VWP+I/W6M^BBPDW^2HT(VEL"O2LJ:4"$9!$P_'8D-NQHBFY#;".@_\
M6*$2+KJ[=';X+;*ZRN,H)&M^2Z0G@D@XP0WC88WQ@Y"UIWW*MZFMT76+&T\
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MFZ(WL</PN: -!'/ W!!Y5_TW>/X5O=5]HPODRU]-4EA#Y8W YU-)SJSWY/&
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M)04M/+Z?\7N9=76PH4FWGOVAS;.1&8!MZ=+()K8$_*=$GG%$!1"/A$X1-%!
M/;MC@?[_ %6H]-'TX+'I$ZK\[W4V-SBLQ[IZW%J68UULF]$GOG76K#;?@G5$
MXG28 8[[9$UY>YU&7W&2)40."!H!.-L_O\\^X>BD[ZC'1/>];VW& X/0YI6X
M5(P[<6HS9^=9P9$]J9'KD[7(;;<91,'G!4E R500D3N147C12K]8_6'34-+4
M..H\=755]<;PHHBZ4.*U')P17VB&K:DB+RJ(O"JJZ(JM=='35:=7'35GNQ-/
MDD+$[#, KD8O+"*]-BQ%@S6Y:H['84731Q&^SD214YYT4$9&/52ETY;5R]D-
MC-KMI)]HQ=S-OL.I\8DVT9HV&+!VLC"P<IIEQ5-H'53N0"553^=%(V 'HJ<_
M46Z"LBZT(.TUQ@6YK.UVX6S^5?J?&[N=5G;UYO(/<".1FR$Q?8D V\RY^YM>
MT@<!4+E"?T59YW11]5NQ@3*R7]0G&G(<Z&_ DM?[NVQ\D60R4=YON&.A)WM$
M0\HO*<\IHL<._P#K]/\ *N7].KHF>Z&=E;3;>RS8<_R+),OM<RR#(&()UT-R
M?9BT!,PXCA$X#0"TA*1KR1D2H@IPFBEHP,9SS_K@<*O76/\ 3CW@WFZH,0ZL
M.GG?V'LSN1C>*#BCIVF/E=LG'!'VOD1.WD!5Z.^K3S3S9HO:A"2+^2@MR002
M"/\ ';..R@+=3Z:/U$M_,+L-M-X^O6CO\#NWXBW=/&V_&.4UB/(;D(*NL@PX
MA-FVA-HCB"I+^_E$1-$+2<9/!SQS^O/SA=I]E-JH.R^SN ;15EC)M86"8E78
MO'LYB(DF<,"-X2E.BBJB$ZXI&@\_M%1'GUSHLE0GI-^FY6;%V75"SN==XWNO
MB/4=ETW()6,RZ(PC5\"8Z\X4&9\HW1??%'R$)#'B(%$3#@QYT4 8S[?[ >@4
M8[9?3'W5Z4M\)F=='>_ZX3L[D$MN;DVQN=UTW)<<<,GD*0S42&Y#;D$/$G$5
M\>V2TO[#=<#C@F-\COS[O8/GDGV+LFPLKP,_(%KY'B;\_B4D;\W8GE\:%R2!
MW]W9W*J]O'/O12OIT1-$31$T1-$31$T119F&Y'Z6SS;C"OMBRUSZ7:QDFH[V
M)7_;(:RU-6^/[GD1.WU^/S^-$6U9KE]-@6+7>77\@8U51P7ILEPE1%/QC_;8
M;1?\GGW%%IH4_)DFB**]B=](>\M5<K*IG<4RK'IB,W&+S)+,F7$ARV@EU4[O
M9(A-J;#=;<7A?[3O>T7[A]OD(JVV?6U=0G,JF,870O5.+95*QIZ,[?2V[V;\
M6:$,I$:*D$HG+A&A@#DH?VIPJHJ^B?/]U.>]F_\ 8;6QL"*NQAFR=S='C*7:
MS'H-13 Q$:E=DZ9'CR2%Y[R^-@?'VF0$O.B+9=B=X)6[M1>S9U955LJCMUK'
M!I[9+6*^BL@\#R$3;,AA50NWQOL@2\<CR/M2*=]$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T10_N?LY3[GS\6MIEYD&/6^'RI4NFL\>F?#E,N36?!($R420P
M-OE.U4X3GGC1%BI^PU!D&)Q<+S#(,GS"E8O&;R4W=V"NN69,*JL5\XVD;5VO
M;-$<\'I")$Y7UHB^S%=A-N\&S(LUPZL<QZQDU)T]E$@2'D@6D=3$V79K#IN>
M21%4>UAWGD 51_'/)%&4OH_P66E]$+),N:I,EO)-_;43,YD8+\R7)&6^(FK*
MR&FC= 5[0=143TBIHBE3/MFJ?.X^.QSOLBH1QIDH\'[/, !=95D&4&6T^VZ#
MY  )V&2=PJJJB\KHB_;:G9O'-I0R(Z69:64_*K)NTNK&U?%V1)DM,#':X%L0
>:; &@04$!1/Y7WHBES1$T1-$31$T1-$31$T1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g69956g12m12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g12m12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1HR4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &A:^9G@X0DE-! 0      $0< 5H  QLE1QP"   "4&<< E  "')R,CDT
M-C$Y' (% "--:6-R;W-O9G0@5V]R9" M(%-H871T=6-K($9I9W5R92 Q-CA"
M24T$)0      $-A$@:4P>Z<HC:D/8!W)0GLX0DE-!#H      3,    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585    "@ 7 !< $P 2P!# $T 5P!4 %  4@!. #
M-  N &$ <P N &$ 9  N '( <@!D "X 8P!O &T 7 !, $L 0P!- %< 5 !0
M %( 3@ S #@       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O
M &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU
M;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0
M !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O
M;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O
M;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0               !"
M;&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 77]L@
M  IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M!!D       0    >.$))30/S       )           ! #A"24TG$
M"@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M      $X0DE- _@      '   /____________________________\#Z
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z   .$))300(
M       0     0   D    )      #A"24T$'@      !      X0DE-!!H
M     S4    &              #X   "Z          !
M          $              N@   #X                      $
M                    $     $       !N=6QL     @    9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   #X     %)G:'1L;VYG   "Z     9S
M;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E
M241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
M  Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
M  I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG    ^     !29VAT;&]N9P   N@    #=7)L5$585     $
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M!!$       $! #A"24T$%       !     4X0DE-! P     #V4    !
MH    #4   '@  !C8   #TD &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B
M90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.
M#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( #4 H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$!
M 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'
M" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"
M(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#
MTW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W
M$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P
M,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S
M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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MKMQOT;??_I[O^,6VN08
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #* ET# 1$
M A$! Q$!_\0 'P !  $#!0$!              D!" H" P0&!P4+_\0 9!
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ME3&-XQ):@?1 -A=*FJ.086!L!8Y0'27L<D+ &3T2K V64%%3P@>[Z : : :
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M]O'04JRD)A*>ML:[=MIF0K[(L0B^62D%WB:#%P!?"3@2A\?AR/<?O$ $?JY
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M=I>)Z1DJDTA6#IDD?+>2J[8JY/PE#J^17<RV>0U<:5-2:;NYB<J2B4U/+1B
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M,ZY9D;A',X]! #($T T T!I H!Z!Q\?4>._/PYX^(C]H\^O?0&K0#0#0#0%
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M ^6@' ?+0%. ^0?=H"N@-!SIIE,HH8B9" )CG.8I2D* "(F,8P@!0 .1$1$
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MLKE&0G75;A8:NLI (INK[:UBY59_(R#])\0C1-$A&B#(5G!Q]J;$-6M:U_\
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M,#VVZ5F(M)D<T4I#($7[1NGO#J7W(JP&;(8'%C1:JLJBKD+%DLL,\M$R7A@
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ML4S+7&+KT_6X=I)0EVKT+D&Z0[1O97ZY*^%BL1GSHK-R[754:-EB!U[[^)E
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M/H')@ .X !A[: L#ZJG\W1O#_P!"-K_JT- 7ZL/Y"R_S1M_4DT!R] - - -
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M(E9<H7NHX\KKB48PB$Y=+%$UJ*6EY-8&\=&)/YATS;*OWRX@FV:)JF76,!O
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MKONV]WOU]?3;IUZO?I=>^_\ >YC,_P )QW@;G-G^W';O:-L&7K;B"S6W-,K
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M"*>/&R*+HIM 6T5<W/6"R^;D '\7IA,O'PY_P@<Q]_A\.XAXN0 ![#P.GO\
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M;MN-AQ!G?(*5:C,AX\FI.5LL'=:%B(YWS%O=I&%>LV$<_K#A#S&@+-'+MRN
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MBK=*C98^F6^"LKV 5%+'+0$YAM$/G:T<<72*S<"NR)&%9)1/CQD,  2LZ :
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M;%6Z<\JZKM=B(1S)"+;&BOB?KQ;-JH\-YHJ*B9R94144.;D!.8= 2:: : :
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MJ0- - - - ;1E2EY["( (\CV[  "(CWXXX$!#@>/0?EQH#6!O%QP ]PYY$.
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ML[>"BD+#),&PLF#^;18MTY9ZR9B)C-&CM^1=RV;'.8R"*R:0F,!2B '8] -
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ML7(MS-$X6 AHTI"MBB#:/;E\7B YC 3ZZ : : : : : : : : : : : : :
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M;@,PF,F91NJJ4AR@8HF*8?$4H^,0X[ ]]_E^F_\ D$HP#R'/S^S^SD- - -
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M&)V!Q.QR<DC>7:RD;'L)(695'ZC5L!D!: : : : : : : : : : : : : :
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MCL7L,ACB.W(76C"[?2,>,;,I'0.H188YRW]OBWHM6Q9"+>"JS=D3 JR7'(:
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M@'<>P?O^_P!O;0&P+MJ"Y6PN$0<G2,X(W\POGF0(<J9UBH\^8*15#D3,H!?
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M_"GC'\X]#_Y7U[_K'0@H.5,8!_Z1J(/U!;Z^(_\ [C_M'L'?0 ,J8Q]!R+1
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MBC"0\?%IM(*%;)LX:&;D8MT"IQ42U23;1L>4 :LD"%2;I)D* : [*4H%]/W
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MC6'J,31\;VB[MJTC2;9EW\$N/:A>,EU:#EUW-/:Y!7JT*R0LTA 0I(:)4EI
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M&N:] VE>4=#%K+LKHI.O&K)PB'?^";M-,A2%*!"@!0 "E*  4H!QX0*4OY(
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M1LP;.IN=>R,Q)"W:IIH%<2#]VY%,A$S+&(F!2@=XT T T T T T T T T T
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M2DYA:/A8AHDQCFQY6:>2$J_,W:(II>TOWSIVH!0,JLH?D1 [MP >@: T''@
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MX"[G">'*5@'%M(P_CMHX8TV@P:$'"(.W!W;Q1),QUG#Q\Y-Q[0^D'BSA\]6
MB9#N7"ADTTD_"F 'J1C>'X<]A'U^0@ ?7W$0[@ \>HZ LXWS92SEB7 4O;=O
M50>6R]?2"O1+YW&UQM=W]&J4@Z.6RWUK1G-@J:-P<5YBF4Z$"M989J=1V20D
M'I(YBZ*<")#9;+[O=SLKEN(H5WB:3ABSY A@W!JWZ5JN='M?MDI!0M[MTYMT
MD:Y*6/&S ,MF?JQ%\Q+-2=J@<$3\B_4K\C/*HIQ@ U\?^]_P9&*"!6Z2*1!_
M(1131+^20O)4B 0O8@%*7@ [%(4I2\B!0 .V@-_0#0#0#0#0&DQ -SW^''S#
MXAW#X^H_'0$4EEZ2>"9G<ROF^)EW=:Q[:9RJWS)F!X^ B5:O<,FT"WA?:9:8
MBPK",U0HCZ9@E;+M3JJ5I#7RRQ\7+RXHJ)2*4L!*R"? ^+GD?GP'I\NWU  ?
M84O/< '0&HQ@*'(^G[. $1$?D   CH"&;J@[A\_8REZW2J_1%3[=+31)$V1+
MD2Q5.A-K7,RTBZAW6.G^;+==JE'X#3CZ^0M@87..C+A:YN6>L8ZN0I31S_VD
M#M/3TK6Z[(E3P;EW-^1X^7PQ"8R8S^#(&PTYD?/,]'9)K+)6-<YZMCI-5FE;
M<>5]ZO322E ;PZ&1N#W":!HG)*0) );@)QQ^4/80'CZ^_/SX 1'[A$.1 = ;
MF@&@&@&@&@-)R^( #D0X'GM]7S_VA\PX$ $ .G1V.J)$7&Q9#BZA6HZ^VZ-A
MH>U7)E"Q[6S6.+KH. @X^9F44"/Y%I$E=."1Z#I=4C4BG@3 "D3*4#N0
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MN1'X<_\ 8/;Z_P!H\!H"I1\0 / AS\!]?70%= - - - - - - - - - - -
M4 ./B/[_ +?^P/EH ;GCMQSSVY]!^H>/0/F/?@._ Z MVW(;G,2;8:,M<,HW
M&MUM=\VFTZ;$S\TE"GMM@B8EQ))PS1VLDJFR0.9-!*0G':98F"0<D?2CANAX
M1,!#OT_YC<]GC<YF'.:\%,8::6)>GP^Y/'V1/%<,:W-,C.4+&-<0P,;:9J/Q
MQD&K1C!I"VUTK,3\7?JY/Q5JE8Z!ER-8% "?"LU*JTN&;5ZFUJ J, T,LHU@
MZQ#Q\!#ME'*QW+@[>+BF[5BB=PX4477,F@45EE%%%!,<YQ,!V+0#0#0#0#0#
M0#0#C^W^GUT!0P\ (_+ZN?Z.V@(P=_V^V P35I?&6,S5G).>I4&;>0Q<$A&*
MR\52Y*-?R4_-N(V3L51CI!VVKS)T[)!FM,?(DC5%Y_V9W'QRJ:P?\[[_ &/.
MNF7A*\+[=HZ+RI')V+;?,"K/8APWG=D?*V4Z&]:V>1#S9G)-F3*RO5+\E@VF
ML7R;BJ0D\VA91HFX3;I,F@*!MWWWT)?4D$4TB))$*FFF4J:9$P*0A")_DD(0
MI0 I"% O!2E /"7L'&@-_0#0#0#0#0#0#0#0%J&?MZFWS;38ZU4\J7%S'6"R
MC%KEC8> G+(>NPTW/-JM%6N[K04>_1I5.>65XT@4K/8CL(H\FN1N1<YB+>6!
M"=9T-P?5%SRE%Q%H<;=9?"%;M;J(D*A*7@KW$KN7R$-1EX7)$9-52.1C\^I0
MD$WL-.<TR>+5[%4W]@A9UZ:#$2S(&05B'#6-,&5).BXKIE;HU;"0D)US$U>)
M9PD>[GYES[9-3"C"/32:I.I)Z8SE<J29$DQ.5%NDB@DDF4#U4"@7T_?]_P#9
MH"N@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@()]U%KW<0G5TQ]'[
M3JKB.]S[CI^2KNP5G-V0[I0:8A&!GQ^@,U'KT^L6Y9W8DUP:LDDW,4@06"K@
M1D">45$0([-LV]S=1C7&>)MO5:NFWS#68=Q>\;J?V.]YJSW8+!8<.X]5P;FY
M=S+XYI:K\L&[GSRDE:5&5:<3#B!]@K<*5P6.%PZ,V: 7-XIZS>1[@G797(CO
M#N-8R:Z:NZ//\>\<2:*=6NFX[!&;6>,J^;'T]8%XMS-TRW0K*<L$77Q0"4=M
MQ$Y2&*T,( <[:CU .H/NKO%!1J$EM_AZE7]@>US=UE5E:JZ_82%MN&9&&1Q?
MTFLS2,DA&U.&F'=3*LI.RP*(UY)BBD0!)(.G+<"XKI<[\L[[B,BY+PYNEL]
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8 T T T T T T T T T T T T T T!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g69956g14c21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g14c21.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[28V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )AJ^EU0X0DE-! 0       \< 5H  QLE1QP"   "  $ .$))300E
M   0+<=R]QD/M]M;:*G4[^^2!CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!I(OG@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              @(   3T          $
M                 0             $]    @(
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   @(     4F=H=&QO;F<   3T
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ("     %)G:'1L;VYG   $]     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      ;J
M  $   "@    00   >   'G@   ;C  8  '_V/_B#%A)0T-?4%)/1DE,10 !
M 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94
M     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                        $6-P
M<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M%')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4
M    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D
M  /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=4
M4D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="
M($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M  !865H@        \U$  0    $6S%A96B                      6%E:
M(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M   DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                             &1E<V,
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@                            !D97-C
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0                                  =FEE=P
M$Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7
M'^=M96%S          $                        "CP    )S:6<@
M $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X
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MBF2*RHLPBY:+_(QCC,J-,8V8C?^.9@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQ]MCW AZ&=%Q?V*HW_AO[=Y?Z;U;;6#X9G5']-=S_:8?W+CEDTG]-*Q]MCW
MIZ&=%Q9\2:/MSNT]8B_\>_DN99>D/AF=4?TUW/\ :8?W+CEDTG]-*Q]MCW '
MH:T6W_H31L]ET/[S.U_S_-;?UYW#X9G5']-=S_:8?W+CEDTG]-*Q]MCW <C&
MB[+^95'OF1EP;_FVO$6TROGO(/AF=4?TUW/]IA_<N.632?TTK'VV/< 6AG1=
M<KX*HQD?_9O^<S_/;L[[/0'PS.J/Z:[G^TP_N7'+)I/Z:5C[;'N!.1G1<?\
M8JC;S_T;UB+_ ,;OY0^&9U1_37<_VF']SXY9-)_32L?;8]P*>AG1=T*HNT\R
M;?YMF3YEM\Y;3#X9G5']-=S_ &F']RXY9-)_32L?;8]P)R,Z+NA-&Y_\Q^^6
MW_;6/?NRW[ ^&9U1_37<_P!IA_<N.632?TTK'VV/<#5R,Z+3+^A5&([[FWS/
MK*W#96Y\_.'PS.J/Z:[G^TP_N7'+)I/Z:5C[;'N!.1G1=?\ H31L^=#UBN>6
M?#9E;;OV[+!\,SJC^FNY_M,/[EQRR:3^FE8^VQ[@#T,Z+2/^A5&,K?\ 0>R,
M^LGSV;KEG^+X9G5']-=S_:8?W+CEDTG]-*Q]MCW <C.B[8>"J-?>9-/W+REP
M_7MMNRON?#,ZH_IKN?[3#^Y<<LFD_II6/ML>X%/0QHNV<2J+?K;?N>>[\_G8
MK%LSSML#X9G5']-=S_:8?W+CEDTG]-*Q]MCW G(SHNS_ )DT?F+\V\9W\G#$
M>X]I>8/AF=4?TUW/]IA_<N.632?TTK'VV/< >AG1=T*HVW:3;Y^B[Y=>>PS*
MQ6#X9G5']-=S_:8?W+CEDTG]-*Q]MCW <C.B[,N)5&O_ /#?M?9;_3%GOO>V
M7E#X9G5']-=S_:8?W+CEDTG]-*Q]MCW A:&-%YY\2J-;9FV]M_\ &\]MNS(P
M^&9U1_37<_VF']SXY9-)_32L?;8]P+R-:+<OYE4;/;^;>R+?;\_M\Q[K6,/A
MF=4?TUW/]IA_<^.632?TTK'VV/< >AG1;<[8*HQ9'D;;VTMV3_X[]M][X9G5
M']-=S_:8?W+CEDTG]-*Q]MCW %H9T7'_ &*HQ7ROP;UB.Y_]OS%L/GN9ED'P
MS.J/Z:[G^TP_N?'+)I/Z:5C[;'N Y&=%Q[,$T:__ ,-X]IV(LW^8_+?FL'PS
M.J/Z:[G^TP_N7'+)I/Z:5C[;'N Y&=%V5\%48L\_S;WX</?GW;;%8/AF=4?T
MUW/]IA_<N.632?TTK'VV/< 6AG1=?/!5&M>QGP;^7I>R\Y>0/AF=4?TUW/\
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M)1%:QF1Y#](.?18^< X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
MX . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
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MIJ*Y/*/S10W5YN:)G3K5*;#30,RJT]^)*K(22[_O[_P#93I=NO47?$[3/;A
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M]?GV+85?*.A':R#WX59<M=1KIZ7<H<JT,:7'$ZW,- ZF&>&V]_L].574.V
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MGK[9SV]><< /T ]C?SVWV:]><^]C8.WQ]OR@J.?'U?U]L]^W;OX<^F/Y*?\
MK)J'_P HU/\ ]4H@^8OY67^K.G__ #A2_P#TNN#]QNW;MC_7ZN_?&<Y\.W?M
MW\,8\.^>WZ>?H@/SD#U95G&?D\,^O/?_ %9[]_\ K[9]>. ''?U]L_)GP_JQ
M\7?.?7C'CV\<XSGOC&.V #MW[9QCMG.,^O\ MQX=LX[9SVQGU=NV.^.V/CX
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MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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M?"MJZW!G)L$4 _6#@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
MX . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
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M 'Y1?J7]^X /RB_4O[]P ?E%^I?W[@ _*+]2_OW !^47ZE_?N #\HOU+^_<
M'Y1?J7]^X /RB_4O[]P ?E%^I?W[@ _*+]2_OW !^47ZE_?N #\HOU+^_< '
MY1?J7]^X /RB_4O[]P ?E%^I?W[@ _*+]2_OW !^47ZE_?N #\HOU+^_< 'Y
M1?J7]^X /RB_4O[]P ?E%^I?W[@ _*+]2_OW !^47ZE_?N #\HOU+^_< 'Y1
M?J7]^X /RB_4O[]P ]T3S_R5^?\ F?E=\>U^:>W>3Y/;/E>7[=X]^_;MY/AV
M[]^ 'LX . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #
M@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
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M:S"2)1&I1K1:QN;PP X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
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M"K4N-E$0I6+8<U5^(_:%28\#*2J,34RIT6A3/18F\-R'+#/DYG!!XY:_/E^
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MW;QSX9SC]';/?U9QVQXY]6?C\>?C\/V/'&?Z_ESZNZ<^'KQZ_5\??Y<Y^/Q
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M?7CQ]NB8_3\6.WR>OQQS](?Y,'^JV/\ W[6/_P"; _-/^5+_ *UI']PT;_\
M@^-X/#MVQC/CGMW\?7W^+XLYSCP]6,_Z^?0X^<P^+'AW[>'Z,Y]7;OC'K[=O
M'OGU<<_?^'<P#..^?7W[^KOG';./'&,]^^,Y]?ACMG]'?@ Q\OAC&/T8^/\
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MO6ZR^CJB?9&O_P"[^.*F%NC5 ['IWPP<;L5])\0]M5+XD/>MUE]'5$^R-?\
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M@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
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M'XMY?2?5[/Q /0;'Y^:^N"'\?BVW,\^L\O)O /0;'Y^:^N"'\?BWE])^WOZ
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M9WI,H$1DBX!R/ ,1V9BW1DQ\*5&%V8TU#+SHPC!GH0J++8=<6ZSW[SW^S=O
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M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
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M4:=N@=0B>FLP&@VP)*'S$N'-M (_+'S^3T6N?7U;.H!N!TJZ&L.@*F8K)P[
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M3J%)$$Z7" A[752A-NQAIW[\_D/+T *@F:3]D3@UZW&P.;PC:9^IQA<(]G;
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M\.V,?U9]?;/AER':5^A=1^\4WXT.7;1)TUIWW:I_ CGX%'5+C_\ D]8/C_\
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M^&JQ@^J(ER9-KX"99R L8I+N5QV6&9=RLSTA49EEXAZ5<00<E-L1$1P"1/!
MLAYN0^(%OR&DS$-/O0(CCS:"#*8\]+;JVE+0F='0AB8E*L8DLI2T]A:$X3@
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M.O\ S$.6G&'B[1[_ /BO1O\ X7#X(VJ?_ES>7_VDM_\ _P"8_'%:F?[^M_\
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M@^_&[Q9Q'T?K?94_X</?#H'SYI_VF"_?>3C+ASQ_1.U8/OPXLXCZ/UOLJ?\
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M6<1]'ZWV5/\ AP]\.@?/FG_:8+]]XXR8=\?T7M6#[\.+.(^C];[*G_#A[X=
M^?-/^TP7[[QQDP[X_HO:D'WX<6<1]'ZWV5/^'#WPZ!\^:?\ :8+]]XXR8=\?
MT7M2#[\.+.(^C];[*G_#A[X= ^?-/^TP7[[QQDP[X_HO:L'WX<6<1]'ZWV5/
M^'#WPJ!\^*?]I@OWWCC+ASQ_1<]GZ5@Y_P#[PXM8CZ/UOLJ?[@/?#H'SYI_V
MF"_?>.,F'?']%[5@^_#BSB/H_6^RI_PX>^'0/GS3_M,%^^\<9,.^/Z+VK!]^
M'%K$?1^M]E3_ ' >^'0/GS3_ +3!?OO)QEPYX_HG:L'W_60<6<1]'ZWV5/\
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M6$P2@9,MP&RK@CSR/Z3;%NR'8C1)<#VSSI,!R4R]&;F*:Q'7(9=92YEQM:<
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M\Z^J\^K6>8?L-.$6^R'+!"Q!EIUKJT%#S6E6*:@8@)6A<3$F,S,3"9<E/X;
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M@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
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M!OY&,N"Z3BVP>@+2YP4^<&[ .B*+2=GW]H 7C"1284<=1")86BTB9]QA54;
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MMY:?<"V@/#."W'FLYSEIU<&<PIQO.<Y0O.4YSX< )9P < ' !P < ' !P <
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M=:E-R,209>'#(UYT3+B1G6@#T3NEK1Y$9Z+F54PYEV18I!$VG86R&+E8$VZ
M)%VF#;+XQ;FKK;P]A& *\., [0?+AI\"N5V))@.1P AN$ >@MTUZGG$I9\4$
MEU>Q^:3?01$"9+LAZE89%1?HT.\UN@2YTO6T&]"*P]Z''6M5/>,MC48&.RWA
MRW8K@!;U6K06EUBN4ZMPFQM=J8$16@(YK*E-0 H(?'%BX3:EJ4M3<6#%881E
M:E*REO&5*SGOG@!G> #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
M#@!^7T[WP++8*V5@2MN/[! ]5=_9MF&9UQBT*-JH1OPL#EULM*&6!FH:_5&Z
M>&*'=8<F]59^+>Z2MEJA/LW:[3+!! /C!G=3]CJ/1_8:F4OD1XE1C06ZV>+
M9,N)J]CW]TRBP=KLHBPQB8.3<)>AV=@V""6L DH\'>=LQ5+#BTRV9#OW[_B
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M/7J9LPZQ)KE])&(<+88BN5JS52;7]='%"U'SE(.6HA)UYK6<.GD'"M1KV2I
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MLTY0WPEUJ!IG0&QMJG=;YC#HD6LO+R[G^X!MGJBP]6+^TJY[J(UBBZRD;!-
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M&!TRQ3S$.FN_5^SOS )P1ZMM\#;>5%UX;KG8M<!GB;Q.U@Z[;D [;7 373%
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M.J( 4-&FW11B':;-9!UZF@H4>Z#=<%@ -N@*$%6]A6JH.,CGZF<O@^2*E)@
MYAF\QY]0@+[.O8 A$?V3,Q(B;%MZM60(U!J- @24IR<D*O(?9S-AZHZD;&2:
MN28!S;/25'^G*1B,2D1==V,2*(JG% 4A])Z#2P"3A.ORY(/V5=BHU0=H>O\
M8W40$V188I8L *UC7NG=C@JU$N X;*38H5@6&IQF3;+XF44K:5- "*J_$RJ1
M&@H )C:>L1BF6/5)*EZS"R@&UJ@8V!N: Y,2#O=.L#]MZ7==561)4B/D;8S4
M$7N>+[I0\IN.]*'5Z,W M4!X0P)L#?U9_LM^T!7!?V1NWS@>JW:#J *3)[2L
M&JZP$GV6ZM"([AZP6CIOAWN"5JT.+.,5P.V!WZW[E+0P6M3S,\,Z3*5>>->
M1+:[EZ+@-A[KNP7:]-:+VK!U]7GK!M]+8T*.O0]BQQ:C!*:^LNR[R*ER($F
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M1/0"]U6];EK!"1-?A2:V..RZ_%U]L1F4Y<W<KDAK<S*B,4JWB@<Y^9._I/\
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M:X"++@QEPH2R8@?/7$AN3A)1R)&5+CNJ8C.$P (BMAK*&ESPHF6I.9 V&XR
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M"83A#$,>.@M,0X45E&,(:CQF6V6TXPE"$XQVX 9/@ X . #@ X . #@ X .
&#@ X ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g69956g14c33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g14c33.jpg
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M(A@Q"B,D01DE.%$F,W$H-D)A=WBVM\'_Q  = 0$! 0 # 0$! 0
M 0(#!@<%! @)_\0 0Q$  @$"! 0#!@0$! 4$ @,   $1 @,$!2$Q!A)!46%Q
M@0<3D:&Q\!0BP=$5,D+A"!92\2-B<I*B)(*RPA<8,W/R_]H # ,!  (1 Q$
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MT9?DRX;-'#(4BL^?LV#5X;<C6;Q^X38M%UW><HX%A_?W]Z=T3?P0< < < <
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M(Q=V[EN28S-;F!PU5RNJBQ7F*P=VZZ:74U33559K]VDDJ7[YK^>H_1@L@RK
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M@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@#@&NKQ/\
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M3?9-^2;A]]?3:KNTVS;;U\?7O\?F'O,^"UZ>733IIJ]%H;M.4R. . . . .
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MFFZN$DL*[ZZXV4PGI^?.?R:_@ZOR7U9CHO-_I^[-_?*0< < < < < < < <
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MS3V4,(/ME=T&>WYC<>GP[;P_W"3Z=?CWTU6NGW)=:' !L4B,5BX9GH.#QN.
MP(H>GJGIHQ&AQC4>Q9Z:(ZZ):ZMFS=)'75+35/&-/PTUQK^&.4ADG ' ' '
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MO#1T?HU?ZN7KHV)R0"L5&;C5='<:MA%5-33.W3N)?:'F'$'L\]EF?9=F?$&
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M9+F.#S3"48FBNYAZL3@;]&(LJ_;MW+5==IW+=*KIHNVZJJ92KI;E:[[VZH6
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MR&.,Q;]:1V%.I+53WKWIK+96Y= F#*#!6"EI%0D<BD?)&7I/U,C().5UU>!
M88:A<K?5-+XJK]BNU2=F.PI1/J1V0E-E(GJK[A]AYI3RU#>2H>-"57"C(JYR
MM+26'S$<);V 6FK+-71IE9GG*22"-G<R^0.XP AVH08W7%:6J6]*F>K<J9UA
M):[*=-V;A^# X X X X X X X X X X!KX@UR=GBG>FWZ<G0NN([60OKOBPZ
M8AP4L\-EBSA.VY'!QTWLF8*1IDY#/I<R#(/$H7&F9D;#PKI#5X2D<BV=89#4
M+EG69CY?>OR77":?GG9F*=K:UHRQ+W#]@SQVD)78W::)1N Q"/P;K/)]E8KB
MM/\ 3Z31Z/ )8WB\^,.YG'HI$;A)3.P99'HVZGC<@&: R[1V#B&UIK"ZM]Y^
M3T270V>\&1P!P!P!P!P#1_(/"$M5\T[95_$_$(M2O.O?<R[;RN:XJ8CE%T>_
M5>+]@">RD\CHNRY2'/3@8U=1]-C&DW3!XU1PU9Y>:#$G#U]JX&^=2GRJ4E#;
M?],).$UV\C-;:\'.K;&B/8:!@[5ED(B=Y]7NL75<<.2!#Y Y@,,ZNG&16)E6
MS]Z2:*R(H99CVHPGJ^T9:(ZZ;.TU5E=\I\!5M<NB_*V_.8GZ$H]BO"\JWLW.
M.U<IL.=2E$7VHZZUC0)@"$8#FB\+4J6:/+!B$^ F5U'67AEE*]Q9+ Q^.]G[
M9$)(J[JI.5=-1%6Z8CI5S>>B4?(@^2^$/)[26[ 2*^>Y]A7!8O87J.RZCR&8
MOZK@$3:QN+"I^VG(T[&8U%G#%BFMHLV4]H#23I^J1.ESIW8P@W>L@8L55Q$)
M)4N4M=^LO[B"7I9X7D2E8OO@+6MJ1,].]-']?Z2D"J49&*[U\PH.NCM>#CX;
M7<GI@V[D;8XH3>LGN6*+%=OHW07734V4U=9\OE/[D54<NG\KGSU3-6W?/I5V
MD"V%V6AO6&K^U;V/=I>I=74=+Y)3DCZS%*JOF:UK6[FL(4XN1"VGD=L'KX.B
MXI?03,7\#?RA&P(5G8:R? 7+XJJS&Z:EHZFORU<VJJE*9A1HY>T[.>AN.N'H
MYIV&\.(=T0G,U<0Q0C2=+5G(YM&AR!U0>2J_:!D7;L4P(+CD7S=\2AF6J>7"
MK;;5H[RO^7"FF$LC"?+4FNCE21M!?#-?F;6&7+W'[1V1W/EL/JZRZAK 7*X%
M5]10BNHI<H#6)V@]%16I@ 1-_+);%,;QAU(WS[*Z8-PLVV;KKHBW0T'5I"7+
MK+AO6-MWTE_+M)AM*^$WO7$HHK>QNUEGWC5G4:-SJ-=2JKD\)K^-(58E-XNZ
M@VA292N+,6A:V2\3A;K8!$%S#<(U#)IIND665\;9V%=<IZ).K^9R]=9VV6NO
MRV,\HCPPHG1;_P /9^/MB12#;P_J^[!P"-IO(T-8ZV0VO]@,8DB1O9 DOD"O
M'-1NBC)!AA^F_P!E=M5U&^-<9R#K;YM%^9IOPB?W*P,_ QBH:#=;84"[(R%+
M6@:HO*F%G\HINL[#;&HE>MH2&SSTDA4?G6IT%5=LB'4B6 C+*%,SQ'(=BP;J
M#]4=7+=R'.]92U:?5:K;;6.Z]4TR1!_@W0YG"=X8M>DG<I[>&<5\-34CK"Q*
M"FL/(3]U.4+/RV]MK:;2-KA=,3N!]+@:YU2V>^NH;*^K)B<WYN:->95?!MQ\
MRP#[PZ@[FT EHCKKGD5-@?#[WZ"CG<5% 61D<'S+0$M0M863*IFV*$F;.@"+
M;2/OP14$LBNKAWEPE^9!02941UG^QBW1_P ,6-].KFL6^W-D"IM8-@UO'JK>
M-H#2=<]=X&I'P)Q21*R>1P2L],AI9:)PIE+<S/GF6;A9KJLR:C&K=SOIJ+55
M*2C1;2V^VBG9:;(VE<&1P!P!P!P!P!P!P!P!P!P!P!P!P!P#7U?'3:UK:[(1
M+L1%NRZ$(6KJ'^6ZT@<EI*,VI&:].$%GVTKL6+I'Y2+;,;!E3!TWCSR59&[F
M1L68XCP9\Q'E#Z9<:341'7=.&UIH]'I*GS+W1]F6'@0C ^8TD)UB(&LS1],:
MB&T.%FS-%$B8T$-EG#<5H3>:+/=1K=PNBQPOAJDLKHEKOL,G;\ < < < < <
M < < < < < HMVTZASOLM.J8EH2^M*\!4P0)R@;7)RJ -J0616(LJS\MV'(@
M)V1!F!200!!LXS!-2;4BSC18F]D@]%*0(BB(T5-)/3UF-.VSWZ_#O-MJ]"S&
M/0T$&L":HV+,&+==,Y-6\88PQ$\XW>.5D7&D8&O2+$3A!FHW991;O5]5<MLN
M=MM=U]]-1#,^ . . . . . . . . . . 0A*Z382J_Z9OQ8\\9D:<K^[H"QC
MJ3)%5D<;740J(@_(NW^RVJ[-<#M4C)-H@B@LF]U,NMEE$<M$L*BSHUW:?PG]
MV5JKOHEM!IG6"3VXBTDH:A+2L2YJ*I-:&!QKJ'SFPFL^8(H2:Q$";A]-H?73
M"TYVTK*.YCL?>A=" 5:1'I:YC(E=,7FWTU>C??6=O%I3Y&P3@R. . . . .
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M?F'/WN /+0;W3/S#G[W 'EH-[IGYAS][@#RT&]TS\PY^]P!Y:#>Z9^8<_>X
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M]H:;3T:\5\#;IP9' ' ' ' ' ' ' ' ' -9/B3.+Y @^O<RKFZW595V'[?\
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M_JC%LBZ)OUL/#+TDX0:J("NIO31)2X224OK]^A<_@R. . . . . . . . .
M1A;=0PJ[(T&B4]:/G@8#8]3VJ.2'D%QJ^DPI:RXK;4$=*.&^<;JLV<SA@)T_
M8[?^029(KL'&,H.5,9%3CX-?%-/Y,D_@@X X X X X X X X X X X!3_L-T
MIK#LE8]8VQ+II=T-G5/!I:$K\U4MM2:MU0+>=8'I2QXWU JIXP6-,A3 4[*Z
M9T>[!T=Q>%L,G+I%<:532:A-/NNQ8JN8.WK:% 80UDLVF#< W7;)R6QI43FT
MU*X7>N7N5C\I,;J$C#A+9UEL@N[WVW29(-FNN?1H:8P,F;< < < < < < <
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M2D-^.XI7C(M'7$BED;4.A::'Z.S R-X4+"SIO+J,-B&RKR-NETI4;NIMN/\
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MER9=6NOUB*3Y:=T76TN4M.,Q>%V1O((0&*9G$1A!+VQ#XU*/6F*F#(2,E/\
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M^PM\+?Z> /5W'["WPM_IX ]7<?L+?"W^G@#U=Q^PM\+?Z> /5W'["WPM_IX
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M*#9+9RQ1ILW76SIA]_MK]5]O-:26D/F?,NZIZ+XMI_\ 2>C_ (.,< < < <
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MJ*APE@1WRH!9!:5S ?: A%%FCB3N9"2W9-G9)UIP8J23A=-/5;_,N3P0< <
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M\E_:I]' 'MX1[\E_:I]' 'MX1[\E_:I]' 'MX1[\E_:I]' 'MX1[\E_:I]'
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MD9$3>OIRY+5T>6$/DM7;Y='T6-!AN5JY:;^#2Z^GU-BO!D< < < < < < <
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M&;AJ[BL0,$F,EDC9ZP7""GR3YGLN)#B8<.?EN_+Q+&\$' ' ' ' ' ' ' '
M' *M=I.RBG5H17-AR:$9-4D3L4+"KNLEM(<L'-#QZ7?F#1:T2\;W!/$I% &D
MW= @-A$\2  M @)OSLL@9#!S2;(5*?/HN[G;[W>G4C1'OU53::W-O*G *&4+
M4TV"TD(O$Y)EE-[=['^B*O[!J*IJ]&1U\8FFM8,&;8;(Y$#*OW3F:MIK%6$9
MWTKN3F$ AQXQ,1LN[?W\T2-)>\/4B(PJ"6*<ORO4X99@^0EX*;&E%#Z4B#P]
MR@RFAIJT -B9! +!G[IL-G1=ZT:C844<(#)2Z$OU=&^P0^W;Y[?$LN%-!Y(&
M$R*.E1IZ/GQC T".!WK8F(,ARK5)\,*BB+-59F0&D62Z#QB]:+*MG;59)=!5
M1)37;(AV? ' ' ' ' /,CGI?XHX*N_$SZBUY3O6YC4_B ]O.X=I-^R$XOLQD
MI ZE[1$VT?(I;TU'*W)D"TE;P!BLX'Z9F+)- Z93;O&^K<9NNZ'+-$TU2YI5
M/Y8W=*76=I\-CMKO\-/N#6YWLG775B#U?:U1]D?"VJ_H6/FEAVTK6QZKBM-5
MU+:U:F2T91ALI4E^99&33=8+J,(C6;:2*:(GWX@.V6)+B*M?EF9IJ=6BT<PX
MU?=>B[D3]L/#/\26VJP>T1&&4-+UX7\/_K?0\9UC=[CZ3"Q.U:HAS5E9+"[D
M %9%I]V%%'#C+&M7"'LR85F#]*FH?&-$W9)[H+352FGK/,VW$Z:1&JCK._KH
M;8^D'5"XZ/[<=Y+NL4>!80_L+7704! M!I] N5P7Z^4"<KZRFYEHW1TU8)LY
M,100$.<++IEVF%'B/HT\8UR,U5*JFE=4ZI_]SE$&4MX1U3&^Y'>+LQVRH*I+
M*)V9V0A]H=;):64]OR2-Q>/PJ.M-U54DLM?8#]"7B,OT&:OK.V^4DG/Y_P -
MOR8#G?+32FUHU4NCEO\ 1E1>X7AS]^9]IXH-+5!6]-2FJ^]MX=>;^C-NR.YE
MHH<BFE7$JE(22OG-<;0@HH_D#DI76,L#2TG&1[6.K.WV7:YS9I'\BIT_E;G1
M--1IJVTY7GM'3U)+[6^&#V)N&O\ QMPT2 5ZYDO?*:]6#-"NRDD9M-WPBF@=
M;-SFDL?*,%=XWL-+1V0.0J"N76%55-'*&45'6<X"FI)V]_RS/Q;T^)F<HZ>]
MXJR[)]RMJ@HCJ-V&J?O/;G7NUWEG]G) Z."J4_TP#Q4%*([/:/UCV"]O(!M(
MXX,4WB,3B-IQ<RX&$GKM)PW701$E13JTZ54M.LMM:SIOKILNNB(?N3PXNYDM
MCWB6T['*^K9S$.S7>:CNW]1V<K:;-DL2% ;$I$Q,H(<ABL<P_ OX['Z[,D4C
M#@LJT,$U4!;!GNFIJ2V%YJ?R[RJ*J6HTEJKK/5OL=1?GAC=TY6/[]]385 J(
MD]'>(+W"'=HE^X,JL=V.LV@P9&15](S\+6JC,*?&)C(H'O!WPNG'@&;#0C!O
M(%W)-X(]<>LV0*JE<KAS2FHTA[QUZMZZ;&;]AO"Y[&6+27BYPZ+!8&[F_<?M
M7UMMBDRI:4,T'1"#5'(Z0)EEI68V'[*@BK-O#YRL-8[X6RNN_P!\([HY+*\!
M5J:'K%-,/UF?DS!>V'AZ^(Q>_8NP3"HV+2"L&7>"@NQ]7E@M[#*PK_\ T;K4
MY#'#J)'Z%CE:LWEAWX/1&E5WUFVO.B0W<:CJRBJK1RW%ME03I26Z?+52])U<
MPTV].DQ&^\-DH1[PTNS@ZR(_)W0^$X%#O'HN?Q"G6VLM0W7_ .G.<0%W'03[
M1'#/\=Y@H16TU=1;\V%FZ/XJ[.]L8_#@G,H?_0J?55)_1%)>S%3V1T.\/>SV
M=U_Z65E>=">(N^[?^'9+Q\\S-"?8V>FKL,S/%?LZZ$ 1DI'NRU?2DM#BD2]?
M)J&$C*Y$DF,#@EW"PVFJJE$M.E4UZ1$*);G9.'OT@]#'AL=;"W5+I71U3R[9
M1U:*L=<V+=I9U^10@9N^UBCVQ;6>D7>N,;/UFTRDA0.T=J_AOD4+'(ZZ))()
M(ICCJ?,V_AY)0ODB]'!D< < < < < < < < < < < < J/WIIN:=@.KMB5-7
MB0U>724I63L8D7?ZC!^R,5MF"S ME=]NFKJCMH& $-T-<I[96<ZHH8_+E7&V
M!5I\'\TT40O#PW[0/=SXW8E/2X1%NM%EC^R<NNF*J+JMSM9=AK:ZWSBB5+;J
MU@EE%LZ:VDVE0$O8P#55EE";PK$X;.-R,TDZNXLJ'WT2?=3.OETTVTZ*<_H+
MKWV7>V!T9Q;=5US3\9Z'5+,X$XD<-L-M,T;ED1ZK8_3HMM78)E'0A"(55D2*
M=3DLUG&1DA;R!A"P+2.$$!+J2: VOS:M\S3U^.OWW\)VT<&1P!P!P!P!P!P!
MP!P!P".+CA#:S*CM&N7HD4>:SVO)I#EPAU!NY"EDY+'"0?(XLW=I+-EASSUS
MT#Q-PBJELANIA33;7\<9#8T]G^@-RQ>D/"^Q#0A9S*^F-#E*MMRLJ;NQ>B),
M;D5E5;6@><3B V4P0:ABL@%6% B*Q1G(W@!G- 4\F!A4\F:U08EQIN75,ZN9
MW?7N_'N8&8Z"=@XM :V?PNJCHFS-QG9<B4DM(]SIE&;;K^5WM<"]HMHW84RM
MD8<K'L-64C6=)R*W&4IKTJB,M1L3-5]"BP(\ZTP$K7KLM4MDDO"(4K?X/4W<
M4E'Y]$Z8J.+6L9CLBM"-5C P%D2"("4 $3.3P/%A0Z7EXP#;,AK8-'B4@;D'
M@84W&CT!XY9LT18,TTM6Z8CB7&TZ>1)_!!P!P!P!P!P!P!P!P!P#SO6GX6/8
M$MT6Z^1.K",,BG:VO*S%T1< IZ9SO!;@H<M9J$U.0@R<;-]<;'*[/(LK*JN1
M*H;^QS"4NBV$]1=@G-LC::ESJI;7@^D>>B?I.Q/EB]1NS9:.=GNKX&!P(I67
M9[MHU[$(=E7E@-V!"O8D<GU;6'*AAZME *LH,VK!G$%>1NI78$FXB[P>E!21
MJ21'<"]%Y$36CU4)Z+JYTU[.=?738W2\&1P!P!P!P!P!P!P!P!P#!K/B#&P:
MVL&!$Q(L\.FL(E43?!#;=N[#%VDB!/Q#@85:NDUFS@<^2=[-GJ#A)5%5LJIH
MJGOIG;7(&FDCX?=S13K-X6X>)AGRD[Z45<A%+?K2HKF<4?(9+)9[28B'V7,:
M[M,:V1%.I@QL1F3+OL2)8$/G@&7SE9Y(F)9^CH1?H:YI=4O^;67YRMO@8D]Z
M%7U&H;7$ACU2RAA8ZIKM!)C1VE.Z\UBM_P!=F+UL&+RX8)D]FV:R+59>T*F#
M:,LC]Y1Z60<H$&6DP'GJ^B\F'J$UGP3XSJMUHTM/->FL=4S<QUVB]EPF@Z5A
MMS&XQ)+;BE5P*.V6?A0AJ B!><!HP,'29_&0S$8$8C03@NW=J"VC$&"9),\I
M8: PS?T8QJ(XEQM.GD3)P0< < < < P7SEO_ !^OS6?L< ><M_X_7YK/V. /
M.6_\?K\UG[' 'G+?^/U^:S]C@#SEO_'Z_-9^QP!YRW_C]?FL_8X \Y;_ ,?K
M\UG[' 'G+?\ C]?FL_8X \Y;_P ?K\UG[' 'G+?^/U^:S]C@#SEO_'Z_-9^Q
MP!YRW_C]?FL_8X \Y;_Q^OS6?L< X;N0LG^[15\ 8O%![G5ZP4=^A<;LGFFN
MVFCMINLTWV;.=--]]=5T<Z*ZZ[;:XWQC;.,@<SSEO_'Z_-9^QP!YRW_C]?FL
M_8X \Y;_ ,?K\UG[' 'G+?\ C]?FL_8X \Y;_P ?K\UG[' 'G+?^/U^:S]C@
M#SEO_'Z_-9^QP!YRW_C]?FL_8X \Y;_Q^OS6?L< ><M_X_7YK/V. /.6_P#'
MZ_-9^QP!YRW_ (_7YK/V. /.6_\ 'Z_-9^QP!YRW_C]?FL_8X \Y;_Q^OS6?
ML< ><M_X_7YK/V. /.6_\?K\UG[' 'G+?^/U^:S]C@#SEO\ Q^OS6?L< ><M
M_P"/U^:S]C@#SEO_ !^OS6?L< ><M_X_7YK/V. /.6_\?K\UG[' 'G+?^/U^
M:S]C@#SEO_'Z_-9^QP!YRW_C]?FL_8X \Y;_ ,?K\UG[' 'G+?\ C]?FL_8X
M \Y;_P ?K\UG[' 'G+?^/U^:S]C@#SEO_'Z_-9^QP!YRW_C]?FL_8X \Y;_Q
M^OS6?L< ><M_X_7YK/V. /.6_P#'Z_-9^QP!YRW_ (_7YK/V. /.6_\ 'Z_-
M9^QP!YRW_C]?FL_8X \Y;_Q^OS6?L< ><M_X_7YK/V. /.6_\?K\UG[' 'G+
M?^/U^:S]C@#SEO\ Q^OS6?L< ><M_P"/U^:S]C@#SEO_ !^OS6?L< ><M_X_
M7YK/V. /.6_\?K\UG[' 'G+?^/U^:S]C@#SEO_'Z_-9^QP!YRW_C]?FL_8X
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M1/Z7'QO\> /*HG]+CXW^/ 'E43^EQ\;_ !X \JB?TN/C?X\ >51/Z7'QO\>
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MO\.FLOMKUUF]W94*\,BR>^48KE*-G4Z&G%QU9#I02<%FJ@5WH57IJ53#=,8
M=,A\CC"\1L&61[5NDZC3$H2C?M=^L+]MN14OS*E]TGIK/51WG3S.^A?5>Y*N
MD]0S]#O#=4UDB!]BVO@/<K^/2FKKJ$& A!L9&0FNQHZ+"*7DJ4H5&&H ]K=<
M>S%L6"X"1A)JS>J[8$;GHO"/O7U*J=&.[?8LC#.GD>ORJF!J,]FCUZ5_7MU(
MW)YAM$]-ZI$7#9Z6\]JQS6T?CD9C4H@U62IG$3 JW)0224$@]9.! ;'-TQ(T
MZ5^:'K3TB%$I:.=8E3*4F/+>++F6(65 ST0J4<_(=4^SMR!L=:NY,7N>UJQ,
MT=!V,A+5U;[B/5%FOJFM-<8<V4$%8;,+P QZ6 ";-=(Z.:,"A@.724WNE,-+
M6=4^JTZP]=B09/XDUGP:.W')([UL832H^IL#Z_S&[Y]+.P7L:P2L4MJIH59+
M]W7T084P7&3>;0L1(7[R1L91*:R"G]1[)4":R1/.0T<$5,QK_-*7G/772=.Y
M)P7Q$WYKN:9ZI[5W5\?R%LMU761DU[",X#V0.AV\2TD>ET0;K_-ZWCP"R:;=
MOE4A34G75U2J:[L-]C^83C#9^)9!RZ3K\--XB>CWW2VTTAO9]P9' ' ' ' *
M#,?#BZ^LCE"R%1Y83\AUXNWL->T/]<D(C5N>D79*WC-]3*,S=NQC;+0]!HY;
MSR,3V"!4/9KX-(:TKL@3+G' 5^H7%YGKXI+X*%\M#KD_#I@$?;U4O5UV=@*;
ME=3[]C1XN?0,Q5KJ52"%=J+<;W;;=?21.<U-,HPI'W$[' WT6+!(V$F\33CX
MO85+-7NY-Z2"?!/;>>BA=3'6WA7==F%5/JB'2JXV4?<]9(+U69%=95&74E"P
M>MK,DMM0Z5#R)"$NV[FP!DQDR[A4J;8EP!%F.&MB,8=;>T5B+Y%YG,Z;M^$N
M)^GIT,'N?P\I,6G-'R.J[AMP9(77=H5VCO:Y,G*L8V*%(QCP^IKU'&R>'"%*
MPQ7;Y62E0-7+S"&D("9C15233S;0*RB#AM&Q(*K1IK^GE2Z?S*K76>_CL2\W
M\-7KV\&,&$Y(V):#IXS[,HV:8G!R/[D;O(]MHT"AUPF[+Q&8K&V"3US%HV%C
MT48UZR@0"(A!S 2'#(L!X]NU$E_2(Z1/[^9+5&=7'E-29.5'NQ_8^^'@F"(U
MG#1UR2F#* (;#4B(\DJFV!5C759C)=+7JH@0V>V393:;V,H/'88HREN@4D&I
MA]_?W^HGP7W]](7R+6<$' ' ' ,)LJ!AK4KF?UA(ER+6/V/"95 SKH.LW;%F
MP:7@G\>)KBW#QH_:($461%=1BLZ8O6Z3G5+==HY2UV1W#8AR1]4ZYD]6]?:C
M(%9BE&NMLSH>=01VT)!TS1(QUX<"G,(0E+I4 NR?CR"@=KB3(BQX5P^TW7P,
M=!\[Z;)BSK/>?F1A">B$4@$K&.([>G8IG3@"Q)M:L:ZS-)C$ ]. 9E/W<F*2
M#5(I'H"'NHO"DS\PD4C#5A)+=-5N',D$=VD6P.#1T<&%=4]%+24QKIIUTGNT
MI\=7.'TGX;5>TC(.M90=>/8.8Q_J$SE0/KU7DL)U$T@\(B<N@!NMR$9(M8-3
MT,/3C5M'B[7(^53B02">H/0(Y;>5K)%IHA*P=3<Z+\VKWWF9W\_#7;11D\=Z
MCU[U;K'M8I1E3&;L-]BIQ-+&E%32R<1T*/D*M@J9:&*MC,@-CF(6&54*U-2L
MT&C3[4@B)5D<G18KK>U&K)$1N=^B^_5_L9AT(ZQ[]/\ J73=#$B6AZ81B.J%
MK+DNKY\6S);1EY!W*["+Z&"FFA8LPVE)@BQ!/"FFC[6.,0[11)OHV3;(A4Y;
M<1V7@M%\B*YEX<$(DJ]IQ^.=@NS55T=>DEE,MN3K=6TMKL95<V,3]RL^LSV>
M:.U;(KFK0;:)%X5)V (J.UX$.-DSAXBV;C7YLHY=B\W@FUL]94;=8<1"E,D&
M4]#*.E$%[0UQJM+XU$>U\3A4)G F+/X\,;P^.5_60.IHT.K1!:,/&H!%I%(^
M.URD8;R1#5]IONW1;L_1L4A)<I]4Y3]9U]2-);X:-;RTS8WYKO["1VN[0["1
M3M-)J=C):IF4)6O"(R^$3MA*-CKZH"=J$A"\IKZ/%UH0>L4O"V[G1;(T$Q3;
MADQ JJCHMHVZ.=-XZ[[^.Y+]<=)ZGK"S8K:T?-3US(XA)>XTJ&-2Q<"X#+$>
M[]OQ.Z[;2>MFD88O%68260X6S@":!!LL( K/FA]Q*'RJ!-L(VW_X_P#BH7RW
M(=,>&E!%ZX:U-$>PG9BO( [@$XJV=Q@!(:GD(&RX'/YY,["-#9)';)IZ=1H"
M?;%9_*!0R?5N%@T^TCKQH+(R4GL%!.A@3X+PWT[=>FF\_6=@$/B@*!Q*+P>+
M,LC8S#(Z$BD='97<.LL 4=&-1 AEET[57=N<M1[-NAZ=RLLX6]'Z19513;;?
M(AD7 *+^(!KV!5J2%(T#K9;S&UNQ9:Z@=%R" QCL%(:):!)4YEXNC3%E/1<8
M;3G$A3ASY_I@N&/NX*RF3&)EF$I<AU]15&L]G#UW]-?#ZE"ZW[)M(9%)B":7
M9VVF*8OMKT!A+:D.QP<M4':JA$+][ 0ZMG2$WG<TA15W<E%6 _V=%QFS1D9Q
M(@8NQH$)N!#9VR?0P5KPZ5:K9PGM$;?M*[V%A7B+6*=/UW))7UQCL/Z[V3VM
MO'J"'LM&\U9!8K2>TW+[PB"4V(53K4@@(C6LF)T:;8[O-+34EX,F12QM$"@1
MJF>( Z8ZZPGMWCYZF&:>(C=,QB%)R=;K@*@-2=SZUN27]=[6%WEO()]&8]%N
MNEA7Q SUI5FM4P(;%I//8O%AA@!'XK8D\9!$'Q).22!@6!-1,@%5*G>8:E1W
M<.-9T\B!@_C"MJKJFJXX:9U?8$VK;IKUBN6^2EM=BQM06;8<EM"FQ4^>QNB8
M0O74Q0MBR'0/3$D?)2>255%GAR41N,,9,J^(%G4>#EEO=*6E"G9]=5"\==F7
M*\2F[24=Z11VUZXG=F0,3-[HZ6,7$OJ@6?<VHE5MN=DZ;CLR;PT !!2.5/I4
M;KV4&!@T"#C9J1OG[Y,:*#ORBK=FJ)2IJA]JNL:JEM:[:->7H4\BG:Z2=9))
M=]ZL91WGMKI'6'6,I))JY[EUC+JF/K=F7EH0:-5##J;-WO5E,SMV/EH$Y+!]
MBD"(\C6\5<(PPIDRR>K%6RPJIF%I+<*(>FLMP]UT6[^!*@_Q=]EHE:OJE45-
M:UI0%YU@S&HOUO[.MK:KB=-.S?8R(=<&(/\ U6,U!7JT3L. R>7CRA^+&X-D
M,8%/XZZ"R[9L7+.(P^_O[^HY==VEKJU#4*=I>_37HQ?_ 'G[8@B0JGP%2U77
MO82$]L.DD4L$.VO$Q*:QF5(]G)F='15U%K#)];4I*V\WFZ_F]<SE-]5(,[!D
M!)"2QAY*<.!#=X^OW^Q$EOJU#?3==U/K\.DF?UUW9L.02UW2-'54O;5P'+Q[
M[OGK:\;Z4A\0A]7=7NRFE0FRR<XC-(S$NV:'I5,8I'JCK)I C"D?CVSU"2S]
MVC%E#1T(6[<+393+:3C=+1>/U*JTYXK<FK^E.O,&G^*M*=@9M7%P7-/W_:;L
M@.H$$$C CL39=:Q.$C)<+K:V%9G8CYW%3$>'#6@ 7%1(F&N2AN7M-'(EJ2%Y
M5XQILI>R;>Z[]S=?UYNN.=CZ-JF]XD/+!X_:\' 34>%/I((G >#3%)PZ!&-6
MJSEGL2"O<N1;U9@Z=CG#EHHN/=NF2B#A09:AM=B9."'B(F?;?N?))QWWWH/L
MYXC$S[D5;XF%^4_UDZ[5Q4&MF]0GM50ZZ@HP)';(./ZG=QP"T#QM[*FA;4G:
MXS ,"+CC]Z$29N-B+L<W+2N6::>5TINIU.=5NES=]ERZ[&]&1^++-X;<_<R(
MR/JGMK1/A^!6QGLUV 8W2(R[;X-4%K;\2%5K4KN$-RTPD,CE.BE>[#%Y:*%A
M$WH.4$9'EN0>"Q8PJ)5.NM6RC3^9IRYTTUF'U]8DF/BY]E@5?S0)/>E[6@KE
MLOI3<';;I^NZOJ-6E&)H'K*)-)3)Q%A;,H  4A$_@D4,CK <Q#9A)04D:M'$
M6TE(TFJDJJ'*N\I5*FK353,==M-]"&Q7CCV'2G6_HP)N:KJHD79J\.FH+M#-
MBEL=K:YZ]P$]7+82*'QZ9#)B4KC8"ZMZ^R>I$R HX%&F;>(N?:;!W)% X1P3
MP+R355$\JJ:T3J?7I.RC=OMU)',^+A&O]2I1V4@H"X);7 _P76/>T33YBSXW
M%ZY=O-+Y.QI]'R$50K&1&@MOL7 YU%RUDMYV>BV03' IC7[A9/61.A.39.$W
M7R3JWT\8C7M/B7,ZF>(M8=]=G<=9K=ZOJ4$<EO4B*]U:D,-KB#VGM):=D\U'
M0+V?-APN&QAO!IX.-E&2CD$.+S,;EMLYQJ;_ !;(J/A&DE*<ZM;1ZKP?H_ K
MY:;^^N\7B5=B.GH#M5>/4JD>H=$4Q,'&.N)&)Q.R[8M6\4S!QC(3,UE$4ER^
M(!"@0Q(.I$A;!F@3-+*.7Y'/YTT4!4HI54)\S:UG1*.S6KGX+0S\AVR[)=2H
M=T\ZENLQSQ'N[]^9M]*-3$7(0'7.O3-?4QK[9D<[LF7)#;$&BS(  6CT=61
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M5.$9%(19<K'D]G<]=2B'3MPE,8M8<>EX(::TA+7KW4+5/M+U2]-U!Z,N# X
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M<EPMIDL3#+$4FQ8>2<)%&XB<?!KXII_)G?793L'[ U3.*:LAF^>PR?A%0IC
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MW\3>#Q\E:!SK;9J\7"/BHLV-:D4T]LY;K/1!%OIO^&5&BNO_ !X*G#371I_
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M, ^% !=4D2<#0PG+HM=TVM.S:U^'B;8>#(X X X X X X X X X X X X X
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ME0FT?H%W+E\Y/KH/6J3]FW'"2]/!-+R;;?U9;[@@X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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MG)MNXMGJ6]=4$ES0G#"&CN"D)GH*<@$0N04L!LP(IJG+5_S%%20G,W,QT_\
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M2Y2=+1&A(:3@T)7-N0Q:S+EM9TH?>-7S_637G;<UNB9HHKM& Y+02WET]-H
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M/'9O.C\Y.5T9:6HF\&O)]%(W)6*H5MKD@84?DFH<&E$KO&\].Z27P-MO!D<
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M.,UF\4?9/)-"D-A0K0'#!YH6S--A9PA$!"2 ^+2,PS?26/-FS30089^J-LI
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..^3@-MN6Y?=_ DC@A_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g69956g14d44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g14d44.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2)64&AO=&]S:&]P(#,N,  X0DE-! 0
M    (CJ^AV(X0DE-! 0      $T< 5H  QLE1QP"   "S0 < E  "')R,S(X
M-C0Q' (% "Q-:6-R;W-O9G0@5V]R9" M(%)I9&5R($)U<VEN97-S(%-E8W1I
M;VXN9&]C>  X0DE-!"4      ! @)D[/J&$\8 4";Q10PAY8.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             $
M!NP          0                         !              ;L   $
M                       !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $
M      !29VAT;&]N9P  !NP    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !       4F=H=&QO;F<
M  ;L     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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ME[_YOUJO4];[1Z:/T*MK<[$>&EQ=
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+]=0=XG^J6B>P6]B5"[!]HJO$&_7]:@8%6?+U2N#+$<'E0E(>V"=2X,=N$^
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MHO".A8TG$J8(2W[?</GX(K?^$7SW;JQO7L9ZN>YNLL3N]O[J_J+6?4'4>T@
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MG:+1FR3H"R/4C8 \I18H2]UH29%"RK6;/7+$-=8^AO*1.E-9]T5IQQQEI9%
M'L%4+>?](;U4>W!RGV>IA.YO>&F;[UK7;!7R0NTMZ/!;JU'6J5:SE?>942%N
M'Q .?8OE7X^'&Q3L6=G*V93:N$7T;=9_4VZ+]H[D&T]H7L #V)LARM2#"*Q
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M-N1U)DXDVJU6:QOX<PKXAD^6(*\R)SZUMP=I^'V4[Y[!\?NLC"ZVU]7#;ME
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M-'_Q/'E0:@:<H(4?KH2:IAA-Y+L+*QA$&<Z]*A9]Z:6L*[ISLIZK&O:I-M)
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M_I0VEB8Z*SPV+9J%PQN;/V&VT,H'5_/'P5%>7 :;SJHN.N2<KNO2?O6O-_\
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M6 8.R)I&-A9>90KUO#KWO.I]E-.T7>%%$70)3MB"$GJW#V!52%,L[H=Y]UN
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M<>C>6D,E]7HJ.F8XL=A^XYY:2"TD@K!L%T+FNEKX6M#VET<%(/:&=6[\LKR
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M.Y>PW\(4*AQTMM(SE"W<N.N$5375[;M>USWL]6Z ^/.V2RE=\Z!E"*O6!KI
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MU'T<[068D+)V%V1I388&!7@,@(V>)R;'6B +XPZ.<*B(\QH0V1<-%&6)+D[
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MQE!X<UO764$G'&2L%#]>?8+N$4L,??&,_OX1.$4*>^<&\O:145HO:[7'4:0
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M[AX*>3:BY5E35SF?9JCJC3T5 YK6PUU92!C)JJ4M =44<50)6112E\<DK.E
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M,;$J&PM4'WC-1 4VWEJZ$!#BCLT39BK4(06,N*AM./8#$H[L(MD]PBNM=O\
M2FZ'Q]_UHYK>U!J@8%7BT. CM"(P?Q8 E#%H9*Z\VR-,RR<QJ.."BT:_L9*:
M?D01XZ%&++8D1R+27I0(C3]'FR->L8,C1PM]M0"IXU\O7;&M[<+)"Z79F+O#
M!U/2VE+!6SC;Y"<#DA[340A/RS-).QS8LA7CCI.>>U6J\(G")PB<(G"*O?U4
M+_+UCT/WQ<XE'UW?U#8-,B2A>W*6K8FL@(TUL.IA"FP[Q26XTMVQUW6 \C)V
M'/'M1W'%(K.'<8QAK*L#P../4BK=](FX4T/VDW)I:@WSI9V9 Q=#5?94OLIU
M'Z\4C1S]8+%;LL,O2M]D:]5,K)U)".RBXUMEN>@M#C#I?U>(I7RKC9%]%"L9
MRE6$^,*RG.$YSCSC&?&?'G'[<>?SQPB^9'5.B=YA!@J)NG2]_O593:-6GN[N
M8NJ+K&-;'L(F[;&9L(1L7%LIMKM)5_J16G;*+VVNULQ.<KD#%<BR90%Z-KVK
M.>?@BVCI?2&ZA%WTNY<=2[?;VG"O/7 KHZ_$AIP@.TWUCK]]NY#9^LKA</GY
M(BGE6=62W*W:J8>(++V^>?J<)EDW(!_%!$6Y?33K%YIW93U6*]L?94G;EP@]
MI=4J*7V750E+?,HF==*'.'-+KM=4H1"^D"Y,((AR-GWSD#DD)'B5+?3C*/\
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MBU&E,/H1*:!#DMH:Q,)/O3RQ!V1/?^$N5AA'06"BNM#1S37^YBNN%9.:F9K
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M=Z]CMAFS _76Q>N[-"*!-56+K)6-FVF6A0"5)%7F9V71'"D=,?+2V&6X(@M
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MT"6+C/RT_*/13!/>F7S;V>&1U9MY=^FM4+FN=-#LU0$V[9VD:WB#/$V2X%K
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MF-O0LFFT@Q*@G3,RO)UQK)J989]WAG[.YL&/.M[5HA +9.,NS':N."!EP0S
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M/NW&2%T+1&TTI;[*D9OG0FOI=. D]P[&J-DDXVII_+)OLH/S:]:X)JV56LP
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M[W>YIB7&S:_S6HTBU$:Q5JR)+-VL'2[/:*A6S%;M[=JKD44#=$)DA!HNPD0
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MYVID\TRTPVEIEM#32$X2AMM*4(0E.,82E"$8PE*4XQC&$XQC&,8\8^W.H
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M-(2VVVA./"4-H3C"4(3C[)2G&$IQ]L8QCG<-:&@-: UK0  !@ #0  :  +Y
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M.<YSC&/VYXP.Q.'#10'L^D[Q6^R6HQ$CU=.W*.JVUM0W5^O;*QOG1<JQ6;?
M'9=9JHZH52%"UL](+UY 6>9R8*1*S+@0CC0Z"_8H;\EJ!*)JI^?UM+9.4)3C
MU0?4:QXRI7NQLG47G/NPG'MS_P Q;QX3[<YQCQC.,J5Y\_;P1,^FCLK./']=
M"]1SQX\??9.H,_\ B5_]?W\(M0V/J6&K&PA.GS/K(]X16VK&.61K>O2>[=&0
MK0894P0>BKBBI&GFY*\3$"R3L-&4H<FLC2+L1+K<&4MDBT?TAZH[P[)==*A<
M;?ZL7<9&YATJ0+VZ$U3NW0][JE3L,4W*?;!L30NO[+%PLG4E"IT>2FPDFO\
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M<9^-(<@ORH#3<I#$EAY3"G,-/-KRE>"<54'H3U%^T];*]99G;.J:?N=)[?\
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M[<ZE8YE[V05D&MB/SC\+%>0,C"P$F.S)Q.(PUY:4H,]?'N1;"M'K,Z4 V2&
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M?MNH,[(I-6UGO:E:]ML$#3-_:ZI9V=8:W4-E0)8(H1S#@2RA2"Z1J92KG)P
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M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1=/83@^L
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M)E$>JO971\[9)&W[+[*JOMMNNV3(<4$^?V?900D/7"[=8 LX&B:W5XM5IH>
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MEQYM2G/A-H6O*,>.$6O=7]7-2ZQ=UB?B@8YC8VL-2U/3HK8\W,I@Y-JM4 1
M#+<B&Q,^DMJFLQE2'TMPU9;<?6AMSV)3PBBQLSTL>OFV]+G-670A;Y5DF#.P
M0>N;/$6BV5<[5AG8;95DV?9!R0=5LX2NV0:..'8J&QMEA$H)9H$-R38<3A3>
M(P.>>X(M[:RT24K/9&T;.D17A-+I6@];]<=3PIAU^P%3(((5(W2VVLQ/GS"1
M9>7R,ZMU@?DV0D&Y3U6,EIRW6RT60]**7_")PBXSXSC.,_E^W^'[>$58E4]-
M0( /47!;>%VM&MM/3FHFE]93J[4H0ZC45S;M.W.1I!$[ AM%[C'>L6O*17QY
M8PI$H=202@KC,^>3(&GB*1FUNGVKMW[%M]QVAB?:*S>-(AM(6+7_ ,W/"C)@
M8%LAS9D$P@]7B(JR12*#7RS/PX9",U\&*C*E*][J%.*?5>;JOU'UWU)'[6%:
M[)6LC"VKM8_M*>BUVJU6N0)D&H@Z&R$B3K78+!.>8@,P,Y42>D))%%O_ !2C
MLIUEEQ!%*KA$X1.$46-K=3-=;HV!;;AL-V4;"77K^2Z^G:8MMJ/!6$(W)FZ(
MLD(LPI!0=8QA.-'<#38;C+PN;&BE83[,Z*RX@BB[5?2VUM!US4-4[#V1:MPT
MD/;-6G;N*O0<#(QM8#IZG%QU,I5V5&:;1*!HV6<([F*_":PX1N+B8^4,C4J:
M6QS]44J>N?5/7O5HIMN+J!"*OK3:%L$7N#J<8.BP*I0;8U61M9M<^J)CJPY'
MAW5(,.;+#5MX9:L+90JTM;QB3A#GGL12@X155^I&?JPXUI(1=M>ZBLE=)LWN
M4BU[4UU9-I( %H+M19C A%;K-OIDP?FQ19\N5*/O3R$:.H%&@+'85.3*:(I]
MZ.U13]):PKFMJ#%7!J(9ZP$@P]26T-#6K;9C-PDC8++3328PH?./2H8B&I*W
M88QB)%??DO-.2'2+;/")PB<(G")PBAMO?N,&T7=6J7/U?L2UON!XA?ZN @1O
MI"T3'9#28\>3(<2J0]'S'S\SE*,):6M+?E2L*\<!M-M_3;,W!MOFL]VK7N@9
M/T])"TP%LCG-#6O<<N<W=]L@ -<0W7JXV_[8PV&M;126NY5;G0,GZ:GB88</
M<YH:USW-WW-+3OXT:2 =2M*X]2VLY_\ V%[;S_"*._\ *YYS?\L5#_JU?S_^
MC']2%I/Y3*7_ $#>?[N'_G6T],]W FX]@"J!#U/LNN22L<@^@R7'Q5"8>($1
MV6K)!UA[*XK3V&OEVG\I6G,IUAG*?+V%)WFSWI&I=H;I#:XK)>*1\S)7BHJ8
M6]!&(HW2'I7 Y8UP;NM<01TCF-_>R-K9=MX+U<(K?':+I3.E;*X3SQ,Z%@B8
M7GI',<2P.QNM<1@O+6_O+LN\V^+!H/4U;*T^P1J]<K]L^I:UK#SE2'7 A/G'
M62Y2:. 0K'<]>T@8<4$!%9<,_L"X":>(;AR))%!61B$%(_1UW"J2I7J+=O\
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M!.S^FWI;[:OZ#UED;N?U9=]S%G;-<KEL2-K.[7L8B<S7JX1OIJQF\4W3<.9
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MSYX1=MPBA=7^UW6*P;4O%.8&DP]J#C[T;F72RZHL%9J]]BZ)*0Q^PY-0V"9
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MR/>0UC&M!+G.(#0"20%DQCY7MCC8Z21[@QC&-+WO>XX:UK6@N<YQ( : 22<
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M@B(YNUMT$V?K6N+$%+&"4<3$5"/Q[[1[8N?7,3LAVC%8@SPL*S-2FH)-,YU
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M1N]&M=T6D]PKK3%]B:I2K02LYJI:)T]48@RB:OI=DG581&);%OMH^9)7S9+
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MLDV3J.6;[+.W?K<.B26G1E3U+V,UCN<OJ EV)*/NSU&276&R26FI,R+-F.%
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M*^[!<-TCK/?(DF/(-:3>/4D7JT.?VG\QKV16H5-=8A;-K)@)"QQSSSU*?O\
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M,EQJ46P.L._<=DM8RMD?@.S:T<C;#VE0)--N3@U=I%2]97^P4*7DZR(E3AT
MC,D@'9D@9&($$C5OYA+FR7&%NJ(I#\(G")PB@MW![CE^ISU9*R]2.VRA3W@D
M8Y;9>P*Q3I$\[8[$Q7 .M-3UHFU-+;1W 8RY)-#Z4RFNP90B"XAFQJ*28P]9
M%ANWO4/K&HQUMF2M?F[/,@=@A>CJ2% SV5D;0,A%M:U;9FU"V7HB&*Q1-9WB
M_2:66GOKFY(682.!P<Y*V0=$P16-X^^,?PX1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$6"[-U^&VMKZWZXL,@I$"70#/KY22%FJ'%6(9!G++KD&8
ME#F&7TXSY3\1IYAS&,M2&7F%N-+\%TM\%VMU;;*ETK(*ZGEII7P2&*9K)6EI
M='( =UXSD$@M/!S7-)!W^RNT==LAM'9=I[9%235]BN%/<J2*O@%31R34SP]C
M*B N;OQDC!W7LD8</C>R1K7BL7^LU]<_]<#<W^7*KC^;%1^W\.?*/Y$-F?\
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M$:XBZ[_2J:^7C=3NO_5;!/\ #4#XRQFA;[.O4*X9C_4O9B?8WIN1LL5\3Y:
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M*.-%CWY4^ 5N9&[69%A(32J3;3"!8X9*+%)'3;?EJETXELSMHFVF=*A+2UH
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=7WE^YQYQQQ2EY*5['")PB<(G")PB<(G")PB__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g69956g14e45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g14e45.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1HH4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &@R^9F@X0DE-! 0      $T< 5H  QLE1QP"   "S0 < E  "')R,S(X
M-C0Q' (% "Q-:6-R;W-O9G0@5V]R9" M(%)I9&5R($)U<VEN97-S(%-E8W1I
M;VXN9&]C>  X0DE-!"4      ! @)D[/J&$\8 4";Q10PAY8.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0   !:.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             #!@
M!P(          0                         !              <"   #
M!@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M!@    !29VAT;&]N9P  !P(    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   P8     4F=H=&QO;F<
M  <"     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   $.$))300,      ^3     0   *    !%   !X   @6    ]W !@  ?_8
M_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,
M$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,
M# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !% * # 2(  A$!
M Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !
M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#U0N:"&D@%WT1W,>"=9O7Z
M:G],NL>T.?6V:R1)!+F^YO\ +T5FNI]O3V56N>RQ]0:][26O#BV'.:[Z3;$E
M-E)9PZ39!'[0R]0!.]DZ2)_F?Y2)CNS:ZA394[;6P@7/M#GNC1I?M8WW.24S
MS<K(QRP4XSL@/#I+3&UPV^FUVCG?I9^G_@T ]2S@ZQO[-N=Z9< X.9#P# =7
MN<W\WW?I/34LG!NR+76"^^G<W8656AK=/SVM<QVUZ"[I^36Q[_M68Z!.UME9
M<8'Y@-/DDIFWJ'4;&.!Z;8QX T-C "26MVL>#N_FW/L^BL*KI.16US"SJK]]
M9I:XWU$AKC58RY\EFVZO[-L_PGZ/^=KM]1=#AV6UT-J]/(?Z>GJ9!;O=.XZN
M;]+:@6X&18]SAD9M8<XO#&6,AI))VMW,<[9K]!SDDN71A]1;>[)-G5;32]Q&
M/;:QC7&H4/8UWILV74WV.>SU*W?0]3]$@CI.<<>*;>L5VUEK6&RZMWTR=[S7
MZE#+&,;]-_J>K^E_1_S*UW,.+=5=?E90 )VUO<TL? X>VJK]U76YGJ-W-K>6
MO&CA/![C1)3@CIV?]GK]0]5+O4#RYN36Y[2UOI,^DVMOI/;?<ZUG^EHJ_KHF
M#7U/%R?M-C>HW-].P,Q[[:[&%P;ZE?J>F*_3?M;Z;?Y[])=_P+%>JQ7UUFLW
MYMC2(!<\2(GA[:VO_._.1,6YN*75ONMOL>1I>]FX:!K6M8QM7T_ZB2F=74<U
M[V,=TZZL/,%Y
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,S4W.$)25V)TF+*XT=48)2<T-F;!X?%#1F>TQ@H94W-U5&5X@H:'DK.V_\0
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ML&?,/POUEQS>8QZ:4R)5&*=VB7CI!BUE*LJYE$TIR.<O7+=H@]CSN&RKE=)
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M)2.V+I,CALJFJ4IP4I; I0#C@!]>?A^7CX\_#G@/LTI5>"\^@!R'Y.0TI0(
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MAJF:N>;"PELH5*7&#-!"P 7P3!9,&HQ@LP%T#T$1;_A>C2E<=I"_[\\47AI
M-:?D_*083/C&%-89YC=)>)S+CVJ8UW7Y(DIYD>NRD+"2F5KI34,88HMTA8&+
MV+)G(L=)^P#*#5%"*5LAB;<5NZM67<?0]ZI"M886Z^QYG6.AQ/:VS>,P%;L1
M6G)$?D6<R:Y<&B(&]T>[?1C$5AK;MP!5I>,ETCULKZTP<C$*5/$4CN$R?5MT
M]8S=3FM+@X^TR+3#4GBO*%Z96J6@&&/J=.,%F,S!5/&\\D@%Q4E2$DV4PJZD
MGJDM5W4<,5%(/IE2M&T\T[P,.(X9QMB7'U_NWL?#%3N.16F5HC)EYG+38C87
MLF6K>A%WR=&7<-9J<M]71Q.P"Q7J+0KEKM*40QQ](I-64BG'R]_KW_&E8&4-
MQF]^Y4F[Q#2E6NKSMW@+&K3L<5_#]Z9V-MB*Z8<R/>H"].\DMG2B56RG0[*A
M2L?2E<%PV<_2=E)1AJX,E<JT^@Y]>OAZ]RNY[8!!!(!YZNV3JZOCU=(<\\^O
M/V\^O//.E*]]*4A<I?2-(!.KW_8SL03 H=@4@?,NHXFZ@-W2G$I2EZ#%$ACC
MU@(=(J4NZ4KDQNLBMW3#->8<LX%1G7C?#>%:1<J; /KODP:OD"QL8+.RDUC6
M-P[",0HMY<6B5-1CV";<RS:W023"*2KS923<1BJ:E-:O9OWZV11,C!W3U85E
M(X;1C[)#X5R#,_22,R=G_P"K&WJS2UJB\5F:RV+L=N75ZD205181(+QT/+R+
MD8 )J*?/7KT*>OX5AX S+N^5SY&1-ZC[*Z)?LH0$+=*I*X<O,-5&6/('!EE:
MS>6*Y>GKQ>LT\BV0J33FZE.:KK)C)7&7[S*1<62 >0JE;2O$=QF3<2[J(+,=
M/2I"L5(7 F&GF'\IWU"V2;*(J$=+UU1A+5^HXRGRIA9"F3;.VDDZ6GUU'T(_
MC2L&9#R2E:@O,V;N<135!QAB#'5]N,/6L61D_<4,GP>2;S-V::;XA=Y@GUX>
M]S1I9RM(6.S13O$D6I8KZU/%6V6-!,,=K(P[68=*4R<L;CM]-[QMDR*98_M]
M2LEU@<AEJ.,Z_BN[,;7"X7M>WFZ9(HN3!R4Q<'3A<NU3(:M1Q%+5)LY3>&LD
M?*I(UQO(S45(1RGKUTKO0GSVT^KGGH)SS\>>D.>?OY^.E*OTI2)&" R,_P +
MJ*B621 R9RG K8?9,8((I"8YBF(8HE<")"D*"BQRB F QC/+UG<_T^5*6]*4
M:4HTI7-W<=C_ '!Y"W4X^:8OLUII=,KN,(:SR5L;W>_5^KQDW$YHK$C8(TM+
MKS!>F90LENQ\PFZ@2"O3V/90\7-*3[4[E=H5LH]>OY?.E<^&4[GN-VJRLC7+
M-O*:3"&UO&KN]C,L,[RUO<[N2S#)96%I![3"2U]38/8HEC5R4UI:K7'R:K*H
MLTW37S\ZRDE*WLS&MN-OV?L13]0H<DKCFMXHSE>HB.9YER]0H.Y2L98\!/\
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M(QBE?3=!@ 1+$ Y']CI_'GG\4 ]>?GP <^H^OS'2E*VE*H)0-QR'/'P]1_\
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MRD ?O4Y##[O7^I_[-*5:&6*\/'%8RA\/3_HKR%\/7T]:_P#^7'V 'HI50RU
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MU1D(/YJ]_3T^S2E4^M:!'_W5RE_%1D+]7_T!\OEQI2CZUH']RN4OSXIR&/\
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M" !@ %*3H#$R:L)$J-\E9=00/&LC(H&MZ/4BD9LD9-(P$B"% 2%$"B!2E*'
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M:4HTI1I2C2E @ @("'(#Z" _ 0^P=*53@.>> YXXYX]>/L_)]VE* *4.
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M\=UAU#T53B)#2D*UL*:44.I=3C*"VL%*]6-*MCO6:;A4#%#WB"42F^0B(_$
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M&5?3^V_B--[LO9(TF%;8Y3V>V^6I<2UI@K9*[A<XIA,+3+D9M[1BDLL$("'
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MC%ZFY(>L42P6B"4CI"1B%H^;@89VXBG::T6[:*G*U5'J!JL91FJ  59!0
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MI2USE!7+  &>GTSM\1Q)Q)Q%<>($3;O>.%;+:^#4(F766P'8SU[X;M<A#BX
MD%+4JX+!?EB$TIE+Q65*2D"NG #R #]H /Z0YU]&K\X572E&E*-*4:4K&5<M
MRB")ETBJJ@<$DS'*"B@E+R8$R&$!.(!ZCP \!ZCZ:4KF/X=4!<8M[EIQ<:/:
MZ/,M!J%7GV=DQUC3',>O/PS:7>@G3H.BVRXNXNOLX"7A/,1;B:?UI6:=2$[4
MET6,NNT14KJ#I2N/'A9_W'-?_?OW=_[6^;M*5USA/[$Q_P#FJ7^KI2E32E&E
M*-*4:4HTI1I2C2E&E*M/^(?TY]TWH/P'T'T'2E-6C%.2IPA%6R310K,H';(]
M0I(CU&'H)U*K&X ! ?550?7\;Y!)ZGXFE.S44HTI1I2C2E>8J !N!,'' ^GK
MU=0#\/LXX]?S"/P]=03C'OV%*]-32C2E&E*H;X#\_0?YM*4DP!3EA(HJJ2*"
MH1S(%$6_1V$E ;) =-'H,<@I$, E3Z#&+T 4"F,  85*5]*4:4HTI1I2C2E&
ME*-*4:4I&FQ4!LV%-5%$WM.) QE@*)3)FDVA5$B@8B@"JLF)DD>"@8%3$$IT
MS !RJ4LZ4HTI1I2C2E&E*-*4:4HTI1I2D;J/[?(7OI@F,4X,+4?ZZ8X.V@%<
M%'M\=LA1,0P=S\=4ON#^,52EG2E&E*-*4:4HTI1I2C2E&E*-*4BQHG&1G>LS
M<2@_1[8(]KN$(,7&\E==L /WA4ZS$[XF4[ H])@2[9"J4M:4HTI5#<?, $!^
MW\@_^FE*8$Q2,>2]SJEPFH&!?7FK(S*5/G'S5HI.PC>5;>5FR0SA4GF44G;0
MXH/>P(@**ABF$ 4-U:3L6$[*C2WV(ZY4=#@B/K0@OL\P8=#*CE2=2=EZ?(9J
MXB7F^1+1=+1#GSF++='(JKO!9=<3!F+BN\V$9;8^K6IIQ.MG7N%)R,XVT&\3
MC'5KN&,:;;(671"%HEUK02]49@\C;#<'-PMM7J3"*B+4C*M&L$14LHZ1=J/6
M#Q$X+HK"9#R_.N#[3+?+F6J(^PZKDPY\13\1E:V9$P29<:,EEN2EU"&$J#B@
MM2TK"@0,H )/WW^S)Q'9[-Q7=[;<(A,N^V&ZMP[M(2U+M]F%LM-QN3LV7:E1
MGG+@M'=D%E+3S2D'4 %E>!N'&QKJ3V_$B)JJNL<.U\:J1R]2]K,;&]IZI()5
MLC'$FQ(_82CN(Z$NS('(Z3561(JJ540, ]D$*>L?*D13!6NW%#D36B0J*H,$
M%L. .-N%D@ +]I)(!WKXTX^S$XZ$F%<V[\PUQ(T\U=>[/P6KJ@SD+5(,4J:?
M8;E:E!36IM80H@%.0!!6Q2SUJS[0\7QV.[5"3<_6*!#5V=5'MOTJ[> KS1ZI
M$SK1CY!0YHM9XT35;=TCM5DDFF=X=QUN-47!$F-)X3M;=NEM25QK>Q&><!#B
M6IB(R"4.AL-@J;4I!6 4DI)RK42H=SVY6ZYV[M:XFE<1VJ9"BW2]R;E$:!4R
M9MF<FN)3(@NOE\)1(0VX&E%)0AP@\D(]FH$VB968XUR1E_#=S!*Y9RO>XRUO
M[>?&, Y+#1$>6G4Y16\ST<\D5'U>J#F7<.8].04,[+[6<'()$DSIE"BX1N:+
M=<+U:9JFYEZF<127)7T9&6AAIHP(CJ9;J%N..,12M1;#BUKU/J4$]0!WG:[P
MP]Q'PWP9QC94.V?@BR]G=KC6@<23V5S9<A-YNL<V>%(98::N%S:CI1(4TVEL
M)BH3E14E1.(>QVAIX@0O&^YO%C^ <4<6[N)F8FLI*153^L#RZN'HI_&S[91:
MX$E"#(I2TJ"LL!3F258'3(*)_!DR4=H.1Q';%,*MQ2N*^W'#C3)FZ#;V'&7V
MRJ4707-3P6X![.@BLXMUK?\ [/0:<[,^*(]R9XBYS5RARKDIF5.%BYHXGF1I
M,)U#=J[HH1BS%Y48J0'!(!)J;]V.3JJPRYM&QFF^)(7MUN J=O"MLE&PR+>K
M)UV]5]6><HKN&XDCTY"0$IE2B<PD:.A*0RA"$5O.)[I$9N_"EL+FN<[?(TA$
M9&%.]W$6<RMXI)!T)6K=0S@ DC;?ANROA>[2N$.USB81RQ88W D^VNW-X*3%
M-R5=K#-;@H6A*BI]QI@83IP%.(R0#D/'?KDBJT+:_E%M9G;IHM>ZE9Z-6RMH
MJ4DRN[)*UJ578M'!XQF[)&MU4F3@QY&1,V8(B4I57)#G3*;8XYN,6!PU<Q(6
MM)EQ9$2/H:=<U2'67.4E9;2H-(.#EQ>E V)4,BJOL*X?N5^[3N%C;F6W4V>Z
MP+Q<-<J+&4W;XDQ@/N-"2ZT9#J>8G3'8YCR\DI;4$JPIMIO,+/:?*2]I22K&
M3F=%?J11\/1H7Y\U20;<5MW 0=K3CF\W/K1H-5'$2],FS,^,LFFL!!*!,[3M
MU3PN7)6(MR$ ELVIOOJVSRL,+99E);2\]HTDM. )+F4@D &M23#X2>[56XEL
M*[IPT[?T)DIXL?-C:>4I_5/9FR[8I]R)"0_S4IDLZG0R$J*,YS#7AOTYLSQ-
M+7Y]9[M,VJZW3((ST/:Y(B+2#<QF1[BW6<QU*;&-'4Z4FUE%'ED9,#J-U9+J
M(DIV4"<TG9U#T6AR<Y)FORILVXKD)F*2.4M%QE();BI)3$6[C6\V@E/,3Y 9
M[;^TC=B]QA%L,:UV6!:;+9.'T0)-H9<<5-9?X?M2T(D7EY*)-Y8B("6H+\A*
M7$,;%/M;=(B_ /R!_-KZ(/7K _*OSK5=*4:4HTI1I2OG4W6R&'H3<%N)KN<*
M+MGR'EB[6"+<8>R9D'= %!R/@FH/<=U&&H$=75/J[FW6"7$7=&4]<HQ]%6JN
M.)V7FU+'YI9=^4Q%*[\X]:V5I0Z4VNKQK)7-M4ZZWMLBQ-UL7]F0B&:4\]9'
M[3<#M'4H5VLV/V$>45"B"27/052GEI2N/'A9_P!QS7_W[]W?^UOF[2E=<X3^
MQ,?_ )JE_JZ4I4TI1I2C2E&E*-*4"/ "(_(.?T:4JPQ_<$P?+\GR'U^W_?\
M8'PU!^./7ZTI%832CQ9LF>+E&@+MG"YE'3<J:;<Z+D$"-US <W2LX3ZG*12]
M111+R<2'.1,9I2NHH42*!R/XAOE]P_G_ #\<?#[0Y4IJT 4!IT#Y8BQ$/(E[
M1'!DSK 7K/\ UPR1$R&-SSR)2% /0./3D9/4_$_G2GAJ*4:4HTI1I2FA.5T\
MM*0,D2<G(LL"_5?'8Q;LC9A- JB*(-)E$R2@O&:8CWDT2F2Z5O?ZA'CC.T^&
MD/MEAEWO#8;#CJ"I;.#J*VB" E9P$DD'(.PVJOEP52I$&0)LR,(+ZGRS&=#;
M,S*%(#,M)2HNM)SJ"0I.%@$G88R)RW0E=>P,=+NSM75ED1BH8A&CQSYE\5(R
MPI'4;-ED6P=!1'NNSH(^@AW/B(0Q'=D(><:1J3'0''B5H24HU!(.%*!7N1LC
M4=ZF7<H<%Z$Q*=+;MP?,:( TZL./!!<*2IM"T-#0DG4ZI"=L9S2T9<5D3B@H
M7@Y!!)4.E0 -SP"G #TG !'D0 0^''H.L.0#N"<$93]DGQQO@C;W=//>MTG4
MDE"AN#I4,* .X!V." >HSOTI"JC2P1L*U9V:>2LLRD*XN99&.;Q"3H%%U3MP
M*R15533["!DT#"1015,GW1X$PAK-)<96\M3#/=V<#2V5J<*<#!]I6YR05'KC
M.*T[<S,8B-M3YB9\I)7S)2&$1TN!2RI'U2%*2G0@I1D'VL:B-ZK#KVQ66L2<
MXTAT(-)=K]&'$>Z<+2#MJ9N(O#2R*R)$6ZI'(=*!6RB@&3Y$X@(%$TN",&F"
MRMY3Y2HR4N)2&T*S[ :(.I22GKJ ((]]1&7<52IR93,5$1#C8M[C+CBGW6RV
M"[WE"TA*%)<R$:"04[G%9M:[05^&!!-5)$(Q@"22Y@,LDF#1'H35,!$P,J0G
M25003( G 1 A?@& ]36_2YI2C2E&E*-*4:4HTI1I2C2E(TV4QFK<"M_,B$I$
M&%/E0.@I)-H8S@>T8IOV*4!<\&$4Q[7"A3$$P"I2SI2C2E&E*-*4@VJR1E-K
M%BMTT#\8>KP<K894(J+D9R4&.AF*\B]".A8=J]EI=\+9NH#2,C&;N0?+]MLS
M;+N%4TS*4TL.Y9J6<\8T?+=%+8"5+(->8V:ODM-9G*=82QC\HF0"5K5C91TU
M$.O0>IN^9I&,7I61%5NJBLHI4EZ4HTI1I2D7I.,^0_E2BF$4Y)YWD_44XO&A
M@; '7V^E0 %41%,3\I!TG O445*6M*4:4HTI1I2C2E&E*-*4:4HTI486\+Z%
M?OGU8(UIO?#J)#6E;L,L-6=2/LV) JTK[)(,D5D5(%6W$>!C^81*81$3*EUJ
MSN^"*]W#NW?"TKNYE<P1P[DZ>=RLK*,==&#[O&K6R&RBZP#Q$FXJLG/'TDFT
M*CIN1C8.KN9E@QP]J*<<T%! (Z[T^H8988QA[<\D,OY)I[4&-!8L<,EY<GG_
M " .?V3Y+S7<\J+@>_V>@%??ZM9V]?+1S2DN:4\S1G3KP-6G.^G.=.=\8SO6
MA(Y'>'^Z<WNO.<[MS]'/Y&M7)YW+^KYO+TAS1[&O)3L0 JZ]UAJT_'3R/P#U
M_+Q\OS_#3]*5RJW.7HE?WD;>GL3.,[3+PH3K)W3Z=C]G?<CT=I))PZ,BX71:
MV!H^C8>WQ$L=)W)/H\#0D<R5D(])X=4R0_-.([B(G%O#Z6GD2'$AY#D2-![]
M/AH<+04X0W(2IEB2EPAQYUI0:2C*-R:_3?9IPX;IV/\ :(94-^UQWC =9NUV
MORK%PY>G(ZY;K3"%/6U]N5.MC\5MUF+'E(,QY267B@ 9V5WLG3)@1R*@@0/K
M-P4H/6/3P!<UT 3&$1$. *4#"81X H?'@ $==!QB1]"$Y _Z2LH5N/L_3$(G
M5TP-M_+?K7SKL82I7'382"HGASC0  $DD\(WL  #<[_9P"3Y&I,SO#DM^(;.
MP:Y)FL:(.&"+Q.Y5B0B63U--JLFY*P0>RK9ZP\K-]LL8X*5/NN$79T4#]2@
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MBBNY9W7,_P!BJ[:T6-V,[<GD0VIN/W1&LM9G9!DWZ8.E#+]M97M%5Y$J11*
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M$SEPHY4ZWCU15=0H**G[9#G$$T^DA>  -)4AR6\I]P-A:L AMM#:/9&D82@
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MX>3<PLO;*U%S#*'"Q/8J1GHIE),Z\+P(XLZ[8N7:3IO#F?B#(LFJD5D+L?+
MOW@Z-*4["'*H0IRB E,')1 0$!*/P$!#T$!#U 0^0Z4I$_!?21/DRPN/8SKI
M  +Y?L>>9]0F'GK!8#] % "B42=8B8!  TI2[I2C2E&E*-*501 H"81   !$
M1$0    Y$1$>   #XB(\!\]*50AR*$*HF8IR'*!B'(8#%,40Y 2F*(@("'J
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M#/$R"@#CS(=?7U<9.#[G9WY_$[,*9$=?DW^3)2AEQ*G'FA!A!3R0DJUMA84
MH#&=7B<5@[9.&.,X'#_9E,O=FO$:#:N K7:9,B9&<;9A3C>+V40G5+ 2U(+
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MXG G$<WB")P_;[L^(TIKA\7HF2FPS77VUPKMRT-!J9*@MME("FD)6I:EH""
M*<&WM"6;8G@(V4J%[I;B'6EXIO!9*M;2YVX&3&5=),'<C8V<C*$>(O&H)KL"
MG<F5:L3-V@$!%%(Q]JR)<1;6&U19L0L%UA#4^2B5(Y3+JVVUN/(6L+0XA*5M
M[E24%(/M BJKCA<=[B6=*CW2S7=,X1YKTNP6UZTVP2)4=MV2PQ >8CEI<=Y2
MVW=*.6XX%+2K*B [,92&1Y6O*/<GU.#IME"7F6Z</7K"-E8'A6[]9*&?C(G8
MQYB.I!@5)PNU%#EN8P <Q#F,@CMP%SW(^JX1V8LCF.CEL/&0V&PXH-*UJ0@Z
MEM!*EI(.A2BD%0 )J[_'L4:>EOAVY3;I;^ZQ%JE3X*;>^);C"%3& PE]\<MB
M05-MNZ_K4)"L="9)UO52T:4HTI1I2C2E<8_$ZHU[G[M1[96\18VLD74J4+%>
M\VW'>6\I6I8;5:3,7]4J%8Q)F3%4T<D4\8U2=FXY!K9Y6>C)-:1C6B"=+?)N
MGKYTKK+C/VI]7-"]MPH5R:^AM8]KUT#"<("4]BLO:$+UF>R0G]EN^ZQZAD7X
MF['(O70\KJ*4]]*5QX\+/^XYK_[]^[O_ &M\W:4KKG"?V)C_ /-4O]72E*FE
M*-*5@$DV*CU6-(X3,_002<K-0,45DT%S'(DJ<H#Z$.9,X /VE^\.5*S]*4Q,
MD>93JC]ZS?OXYTP%%PBLP<F;',8RR;<4U3% 1.B)5C&$GI[Y2&Y]W@?: "M(
M.X)H>AIR"Q>-XL6;%^<KM)KV6SZ0 \@?O%+P1=V7N-CNAY]XX JD)QX #E#G
MGQ^7Q_EM^-*1*,_F)BOM92:=,W*SXRJB96C,[,B*)%#(@D8IW3KNFZTCJ"J
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MW%9.(V&G;WP8M: I3=YEE!.?9/T3-4,8('VDI.^>F/&E+<!_:COG_P"DH_\
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M;>(Z=:Z7^(.=-;;C&+I&*8BV>-K"I! ! #$/N,Q<8A@*( 8!,4P&$!X$> Y
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M#3B+8YCMTIF-92::"IPZ5%$"/45R)F$O!3'(4IC% "B8>! .H=88>"4/M-O
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M';?WAH!#B'%H4\D/EM0;:"W,@'3C-2.HL5/D3&*0H%$PF/R  4O(F$1'C@
M.>1] X$1]-=2I02"I1 2E)422  D=25$A( ZDD]/*J$ G QDG P-R2? #QWZ
M4V)&1).UMX\J[B!G3.63OV89R[!S .W:7<(FF\<L"O!%L"Y.VZ,@18Q.DX 0
M3%$ J9,IJX6B3)M+ELN7-CO=U6\\EZVONMZDI2\]'#P4R'$:7= 6I.#MD8K?
M:85#N##5Q1-A!MYHR4MM%N:TTHI4I33;Q:^MY9U-A:D!61O@YJ)\1W"RY"H;
M2V3\'5VJDE8&Y&#:M.G[E/R<1/DBUGD@HY2;"5RV<,7"Z!"&71\HDW%3U,=
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M1)%LV1)R/2FBF0@<B/'(B.LS##,9IMB.TVPRTD(:::0E#;:!T2A*0 E(\
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M77K]@' Z]=L].GOWS_/&RE.U-P4L] 4ZU2"29E1 "*"0AN(!ZI^$*7CJ#J2
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MXO%X@N.R;DY"7:T/-\]MM#;:DD97K5)',2MU@-Y;96APD@UD9-OEVJEGH$1
M52NSS.Z3!X-N]E[&\B%V4JG'2DNL MFU?E"&:%BXMP8CD''>,Z.1N9N5,QEP
MS\8<3WZQWCABWVVS6RYL7^>;<B1,N#D-^-+2S(DN%ML1G@M(BQW%!04E1<]@
M@#>L'#ECL]UME_FW"YSH+UFA"<(\:$U)1(95(C16TJ<7*9*%&3(1J&A0#:2L
M%2@$F/=W4JG!8T]O$N<E4;3#NS/JDWCII.,+890J!TEXEVS6:/$9IO[/5=.0
MCEFPE55233[A05,(\MVZS6[9P6JYMWZ;9+O >#UF1"FB+])RU)Y2X3S;C3C4
MQOD..N=W6@A2T) &Y2>C[(X:KAQ4BWN66->+9-9+%U5*AKDBWQ-06F8VZTZT
MN&X'4MMF0AP%"%JV-8IF1%MJRC3'9K773$@5/+BC&1%4M1CDE!/+@1!TC6(J
M.6=J^;'SY46 *-5!=(D464*4^NXP'^Q%QKA<WNTYM*UMXB0K3>2OO&J9H;?%
MNAQE/N*=/.(92MI14,J6,RE\L]J27N(1:KD!<4\T.2)=UM.CDZ8VMR.;C*DM
M,HY8Y"2^I*D!"O92<1ELS;HM<>NVX72>F$&D]#(NZH[AO)L:M+*6=91'V9*J
M?L:22DP(BXD_9[AR@FL=40-W^!/SW]F9A3'#$Q">(;G< VZZV_9)T(,QK-*[
MS**NYRT@MRQ);T.OK96MKFJ44J)R:Z+MX?$CB..ZJQPK>IUA"VKK&E\Y^[1P
MPP 948Z5Q3'5EIA#J&G>4 %(   :>T[(.[*V;QMZ&.<OYFQY=,48 L%)K=/K
M%<PQ]"; NKE*E5[)\&_D;9]/; *Y:C"R+NJ.FAH<1L+@R4\+J*,08LWZ8KX1
M6+G:1LJ7BN; 8]G76SNOK;=][ OI\TXBV<,#*+8$5<E+"F8G5=E;N&, V()'
MJ8KEGG"X=LL.HF]?K2M,?'1W8-<=16WK;BABW=)8;9?-P6V3*E2MV$JS47M1
MF%\>;AZ:N]QO(62QS"(1]ZD#HQSJFQKJ+;QCVWO*5YN9+'GE&P/UIZ]>OUK;
M#?=CK*6_WPR<A5BD83O5(S+D^K04O2<094LD7CNYU"V1UMCE&OTQD:Q>"U]
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ME2MDK%A=V%A'%E(:8[U8L4I6)/S<*_2D&J8R,.NW="S471(5VS$XHN$A$#E
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MCPL_[CFO_OW[N_\ :WS=I2NN<)_8F/\ \U2_U=*4I'.!"B8P@!0Y$QC#P4H
M B)A$?0   Y$1^ >NE*Q&L@Q?@IY-VU= GP"@MG"*_1U=73U]HY@*(](\<B'
M/ \#QZZ8/E2F'",DV.0;&1+NB1Q P[LQEW;ET<%7$C,F."7F#*=E !!3MH)&
M!)(  2E*!S 'HG*!OC"L>'3 _$G /\<$*P+A'3RMIJ1VMB\HBXDY K%$8IJX
M]GJ$@7HK*=:AP,[[Y"J$ BW!4Q5ZB\]LH#*2-+@(R?9&<_ _*H\1\_Z?E]U7
M9382ZM.<=F6(FU;H)%F4CLTU#RR1UVJ?0DIU +$>YU*]274/O= >@ (2T0%C
M(SY>6?>/&BNA^%.![2(4T C"M0/%MXTWF8U\W,"LA$K$<E>'<,7;TKHZ*IS%
M,4ZO G!,YBE$. $/ 6H*R!G.QWZCI@C&_P -Z#&!MX;>ZD#$3=^6IM'#F83E
M6+CK"-2*V23.P21<.DED57"9A%XHHK^$,JH!3%'DO2'RE8!5]G& -O(X'3K[
MJ#/CYGRZ>'3W4MU@ &RY  0 0]MQ7H(?]W8P/YO34'HGX?J:FO.0$0R!! !"
MB7Z+60!,)@ >?/PH<=/'(\"! YY#\8?@!?7T!["C[T_?O^._XFE0ADI)P;'.
M*RF9.!4#)- [C>&?(M4T3#+J '"A'1$5$1'W2E(LH!')TU@X[8J$N[&0F7-U
M%*?^C)QRM&K&&!T&#OTW^6:XGCE"E0K* A]9'$UCR&'0R4_Y5]I1)&4YVTYV
M5I/A4XY&.4F/+L<YBE3"IV#J,H?X"$4[]!$P@ %* ^O/V@/SU76T9N$$8S_E
M<?PR3]:GR\?A5]Q"I*;#>2HA*1:YY).  .[.YSDXZ=?G5N-A37QU2 ()#D&G
MUOI.7@Y! (AGST\ (#\.!X_)QJ+B"FXSP>HF2=O$#G* 'X>?A3AXI58+*4D*
M2;3;\$;I([HUT\P1_"H V\%JB-MRXV:Q3F/N:=WL8R+A89!RFM ^US>SDTWY
MQ/'<HNA<%,@@IYD. 44*)  "WO$1EJBV=:G4KB&WQ@TD%"0']"N8HH'MC(_:
MP4Y)R02:X7L_%J1=>+FVHCD>\)OEP$I:B\XE</O),=*'251SA>LE#9Y@S[8P
M!6; 5!XZW$S\E.7*7F%H>L1<O$I,EDX=FU9/9NRMD*]*M8[I3EVT64YS(F?\
MK"L8JBG(EX&)$Q(X=CM,PV6 ])>:=4M)>6I268ZC(:4X265N:0"6R$Z<C K/
M!M+KO'UPER[O+EJBVR(_%:94B*RVR]+N"!#EM,C3+;8ZI+WUFL@G8;Y&;:@6
M1O6(Y*O+Q]>N4G:GT:E;AB&DD\0:,:K8GZ:*B#KI(Z2*8BA4B*G'M+*$7(('
M2)QCLLM34&[M2.;)B(BMK,7G+;;*URF$%?L8P< 9VW P216;C&TB3>>%)4%3
M$"[N7-YA%T,1J4ZTTU;9KI1H=("DG"@ 3[*U!:=TBL?<C3G1*C.7:)78HR;>
MNEAK,LZ2?.7$M7"/F[HD?&-DWR<<R>#)]IP+D[554Q/P0*]LO;/ZX;E-":Q$
M?2X6E/ER*&RA*6)"D*',=);4XXV$9&@*&%8(\JQ=H5K?%IFWB&ME$EJ"W%N*
MW4/.KF6]+[;@CQVA(;CL/&00OF*0O*<HSC8S&D!LAXX430)9Z(>;C%4B=U!"
M*LL0=)7M@IVA%XD@=44.X41ZQ4:K 8.@YP$M0H_1]PRI4>;R7LDI)<CN@C)&
M<)) !P=ME#Q%=6WF_6 A N-F,Z*IM.MM,6X1""I.O0>8E"CIU)!!!0H'8JVC
M?;%7I:)QA'.)*R/IT))Q(K-&CI-NFUB$FTM(M3H,.VD5P8':B9GCD7"ZO*YQ
M%," )NJQXGD,OW-P-16XP;0TE2DE94Z2TVH+<)40%!*@A(3I&D;@DXKGNS:!
M+A<,QS+N+\XOO25MH=2TE$5*)+[10R4(2HI<4@O++A62M1P0.KEH=!N=;NU]
MLDW:(R7BK2[:NVL<SA@8NTU&K5NR;*NU^Z8I!:LVX-@10[I'(F%TJ=-3A/6M
M/GPY4&#&8B.LO1&U-K<<?YB5!2E+4&T%(R%+45 J^R/8 (WJRL=CO%NO5]N,
MVYQI<6ZO-NLQFH89=;+33;+:G7=9 *&T:"A((</UJB%'%0G+9/J##<+BF.?7
M&MQZT%1;!7IV+$H%%K/V(U15B8Q%VFH1D!Y+EJ=B1N5=$$6BQ!-PN0Z'YOXA
MXQL,;MFX6A/7Z!'5"LU[MTR(^%I=;G7%RW+AL%U20"Y(P@MA&I(T+"L:@4_H
M>S\-7A_LQX@F-6:X/HE7:T38LIE2"SW."S<TS'EM *<*(^5)6HJ1NZV0"![2
M7O4AHM_$4^5DK;$Q",9/Q"18%W682QR+M&0GXE![,,&KQ!>6<)13<!,^B6"2
MC662Z6CY(Z9N@]%_:+@PW[989DR^P[<F)=HB$V]ZVP[G*DID2F4.S([3J');
M@AMDER/'2IM]*RAT*215MV*S)+,Z\Q8MGDSERK;,)FMW*;;8[*FH4A;,5Y]A
M;<5HRG!]5)D+2MA:-;*DJ3FGWEGZ:.]LZ+O',T[>2S6MUZ3"49LGM3E)*'9-
MVKAZYCV3!_!*U]R=N0KP['J*FBT2<1X,EA4*F'3\??WC>['S)X0N#SMQCVFW
MSN^-,NVN7+@LLI7(7'::=B*M[I:',+>4\MM"V@V=DFBX.%B:[2T,\30V6;>Y
M=)L545QUJYQ(TMYQQMAM]UYJ:F<PEU7*+N%*65)>YJ0G55,%5S(\OMX!A=YM
M1Y8K5$OY*$>.)VP*OFL?,LDW$&,E/MYA28ZSF.5XJ:+>LU635R5FW*BL@8PN
MS"U<73>RE$;B6Y&3=[W!D2X$IR=.6\S%G,)<MXE7!J2J7K!*75JC.MK;0O0G
M2H&G:!/X;B]H;[O#\(1[9:YC4:4P(<%#+DB&\IN:8T$Q40PV-)::#[3J7E(#
MKI4E>*9&UG#B$;)6FZ6J4?S-L@+M<JV2.4EG\M5HJ12<,RR4W!IS8NI;VF_(
M4K163?/5GJK0HE4.!E5!'F.Q3@!$&7>>(+Y,EW&^6[B&^6I$=R9(F6N%(2IA
M,B= 3,+CXE2$'E.2G'%/+1K!.5*J][4>,ES(EHLEJC1X=GF6.S7!;PA18ETF
M-!#ZHT6>Y"0S&5&CJ6IUJ,PTEA#A2I*<I&)BC6SDNYVT.3OE3MSX9J_0P,DW
M!)/JMU@*005!/OF$AD%C@ J"'[*4 W()H@G]"B-.I[8KNZ9*U,KX$M13&"6P
MA)^EIR1A8 <)26UJ&2=W59 "48XV2ML]FML;#(#@XONA+VI1*O\ HNWDC3G2
MG(4D;= A.-RK+9W!7ZNU2ZX*6F)>&8-XK(#B4F3OI9LT6C8U>HV6,2?+M3 =
M?RJBKE4J:_0"9W*2;4#=Q<IDZ;M1XGM=CXB[.#.G08[<?B8RIQD36F5Q8CMK
MN$=$A;!RX6EK64I7I *TZ.JA5EP%8;A=[+QTF'#FR''+ AF*(T5UY#\EJ[VU
MY; <2D-AQ+:=:DE8*4$N'*4X+<WG7MA"XN]FDBH>96M3=XFU</W14EXMLDU!
M09F'$S%TFX= 9=NV!,B[-4470G!44P/TU?\ :"XDB6S@D,"%!N#EVP6'92BE
M<-E"FG.^PSW9])>.4MI!6R=#JB%$9 L>QJQR+CQ8AWO,R&FWJ3K$=HN-OO+*
MDB+-2'F5(8*4N*4H)= 6V 4C(-2G3):#W#X;60FXH&$?96,C 3,6W?E?*-!0
M.*)02D$VZ!3..WY5^BHFF/EU#D((B=(W'9\.S8':CV>EJXP^[1;M$>MD^$W(
M+BXZFPE)#<CEH!<T!I]"T@A"E 944FN6O$6;V?\ &:5P9?/D6N4Q.ARUQRP'
MLG6"6%N+4$:BXTI*E>V$J(&",I&&L.S&#JDZK;S(+RT1IYZ(<1!'S 63>$9^
M?0!U&L"%<2)^B0,<P@F44TBNE#'*"8JG5U'99V?2NSFSR;([Q#)OL-3Y=M[<
MAE+(MS1"M3#1"UY0MPEU2=@E95@>%9>T#C.-QO=&KNW8HMFE<G1-5&>4\J>\
M-(2^Z"A&%)0D(& ?9 !5A(KG)X9>6L5Y\W@>*'F?$.1K/=*?<LK8"B8M*>;S
MT"T0=TS"45 V$T35K3"P,ZR(RF4G469VJR\NY8M(X6ZBB I+K?3ZX.H/WOPN
M::#XK6S>\3/B!UC!^/;Y 9@CL;5V[8JQ:,5563"3VUQUWPY$VBP24<^M<UGI
M^HE[/DY!4T]5%VID*\@X245Z5*GCQF7FXBM8LPMD#'"E4M&(:5N6VL362<.-
MJL[?9GRG;&.Z+#CW'<%B^V.[-$U2ON7,TU*Q=-K&Q40?&=IIB_:$."[5Y^L;
MBE=;\86V5OV/*5=9^B6/&4Y:*Q#3LMCVXFBE+52Y"38HNG5:L!X1])Q)I:(6
M4.S>C'OW385TC]"GQ*52EBX1[R4J5FBXVR/:8_D8"78L;?&)1B\C5GCQ@X;M
M[$Q0F6KZ(6>0JRA))NE*,G<>HLV(1ZV7;BHD92N'_@EPV%2*;T92*RGC;<1G
MZ/W:Y<A+AN%9HXT<9;R3CU9.FKURQ6*2HZ":A:A8IQC,2,*W:"6M+R+9\K']
M]RW75!4#Q^.WW"F[5]U&0;;X[=WQ73=MEV0;5W:W7\:Y,LF1;/4*&I%X^KF6
M[M86F<\=P /YR1R519^:L,#6H]NV&$F4U7IGKMD@BETZ>&??CUZ^&:GUZ^ZE
MSQ8MIE%SON6\/$,P9$R;9,29+W+1V([%MS-=!KN)79VF$-Q-M2R&Q;UYO#79
MED([M"/KZDPPMZ;12&,G&FCC&<=1I'C\#^ S^F?'?W5(\=\;?SQZ\<5V%R9B
M9];L*V#$&.,B6S CN0KK:O5G(>,TH,]LHB;1=H=)Y7BV>+G(@[D[9L=@LJ_C
MW*YF[MRLBNA(BB^1BHIG9JV^U'<#B:8V_93FY^<K%EIL?%3LLW>-8JWOI&!D
MX5\TMZ#YE&EB6<TG*QS>05,A&ILO-JG32C"LA% EI9KO+L-SB76#R^]1'"ML
M/-\UI04E2%H=;)3J0M*B%#4#T((.*P28[<IE;#FH)6,$I.%#<$%)P<'[\@XK
MG=X.F#&V-L4V^T(Q&'TF<G8+95*K-U-E-AEUQ U?)=[C5VN991])+14D\%S'
M,EZZ>&CHP BR=;H%53D!+NNU"].7.Z1&U.7'4(L63(:?+0MPD28,9TJM;:4!
M3;8"RESF+7];KQL#5998_*8<4 U@J<2A225.:4NK2 X=@>@(P!M2ALYL.5J+
MOYWA8XS0ZMF3KI?'6,YQ7(&/\>&A<%T^'@\;B]KL+-.G,@^DZ]8W<"]813)%
MR^E$I=TP<* <BAP76CB=FV2^#>%IUI1&@18:9T=4.9-YMVDONS<2'V4!(0[&
M#J5.$A*"V#C< 5,)3Z)\UI]2G5+4A27$(TM)2$Y2E6^R@DZ1YX\>M=,;5#95
MD<G4-U"2N.0PTR93ZN1*[8*W+2=YDYXJ*9Z8]J$TE*HP<0VBY G?DPD8IXY5
M2#I9J)JJ)K-?G[#L!$&6EQJ9])+6R(;S+Z&XC;).)*)+1:+CI6G(0I+@2,[I
M/C:+#BG&\%') /,2H$J*@<H*3G  5C(P<]=JF0  0*(@ B !Z\?=K2K+2+9H
M0MDKL[7S2,M#A.1$C$#,5]Z>,GHH))HLT&1A9),IE(^59 L+F/>D*8S5VFDN
M!3"3@<C+G)>:>#;;I9<;=#;R=;3A;6E80ZC;6VLI"5IR-221FO*DZDJ3DC4D
MIR#@C(QD$=".H/@::%(JS3$N,X.JJVJSVYG1:XFQ7N.1K$29M<TA%MCJ*2UJ
ML[Q-JFZ>J)D,=[)+IMTB%+W#@FDF(AGER%7&:]([NQ'7+?U"-"8Y3#2G5 !N
M/'05:$ D!#:2KR&<XKPA(9;2C4I00G!4XK4H@ G*E' SYDD#S-<RO#HRS8UL
MQ;H\<7N$5BYO*UXE]W-%696^E7VN.,;Y 5AZ:R8QMIQVW<5IXM&/:P4AU3S+
MARY;+-C)MP61?KF[OC>W1TVOAZ=#>*VH$-OAV8ER-)AR!.AA<IQ2XTM?/0E2
M9*<?5I2%:@"4E(%9;7EEZ4VM(!=<5)0H.)=!0LA(&I&49&G][./#;-=?NDH?
M I0]>?@'Q^WX?'T#]&OG&!\QX^/WU<5':F)<<J913S2:H0@Y41IBF/$KN+7F
M>)2E98DZK7"NNOI"./+ID?B0$Q/W@'@X$$Q1W!<)H@*M?>'/H]4I,PQ<CE&4
MEHLAXC&=0;)1C.G&"03@C&6FRX'BD<P(* O'M!!.2G/EG>M>=Y5?M%GV^YCA
M:W[/=*/&J[&1;ITV4O$^2OR$ W82*-9@X-]%O36KJ> XCG*R[ENW9BJ==$R/
M2"7&\8L29/#MQ9BI25J84A?^2/3G0RH%+AC1F%MK5( (*"%82 HD'-?4^QJ?
M;K9VC<-S+FMU#+4]I;*DW:)9(O>D*2MCZ2GS67V&X&I!#X* I64:5 C!G7##
MV;D<7TYS8I. E9U6":%?R%:8/(N([Q$S))I(QDE(2C]@Z:(E2:R3-V_660D4
M7:9@2 .T2UM2WUVV&7W6'G^[H2X['2M#*E) 3E*'"M:%#8*0HDA0()VKD^+6
MH;/$UZ1!C3(L/Z0D+CL3WFI$H-J=*M2I##3#+S;A)<9=::2A;2D*&<@TI8RK
M=VJ]9)%7^_GR38"2LLZ/95:_&5HQF#QZLXC(X(N(,9F4(MF=)D#H![KKM"LJ
M4#F$ R0694=A+4R9W]_6XI4@L-QR4*<4IM/+;)3AM!2C.258U'&<5K7^?:KE
M<52;-946&"8\9L6]$Q^<E+S3*&Y#_>))YI,EU*GB@^RV5:4[ 5(1^>D>  1'
MTX$.>?N_+K>JEK7>[Y E83.V&J(WO$%$1ERC[TO(4U[3[%+3UK/!1)7;9Q#6
MU@I[ K2<2IRY>)3)1/)( =NT RRB9DZ.9-=9O-IAIE,-MRD2U.15Q7W7Y):;
MU(4S)0.1'#6"I8>(*QD('0UW%FL<6;P7Q=>7+/.ER;2_9D1[NS=X$2%:Q+EA
MIQ$RU/I[]<E2TGELJAJTQU$./ )!SL4'P^W^7_U_+\]7@V_G7#U4  /0 X#[
M TI5!*4?B #^4 '48'D-^NU*ITE >0*7GT]> Y]/A\OE\OLU.!TQMY4J[2E:
M>98W'W;';W<FU88RB9OZC<.T[,%=,YORD5].(J><7Y">0DBI522&J! !0)0[
M($?I"XFN2%,WC.ZF85*,VY=@9U*HXG^AY+O4<Q7F<P#E,7,W-5)U6"6'%=OM
M (11?87>LJLNTAG$8=U%2L6TC45U7R<NH]008+J>A6HN/+KAP,27"5N^V$%Y
M[,>ZBC5O/6%4%9J:1HF4[;1*'(M9ZR1698ZAL$185KZ+V*3)1HYS"3KV5+9X
MA>3EIR9=BZY^X^OG3]:Q)7.FRZV7W$&0G&V>;]IX=Q[)Y9I>1Y*!QS3'6/,>
MT:@1LAC=X1U,WB%[U1M=:S,\&DPKM\4*[87 'L4#6Y-N+J-4IL5-':#E^!R)
MF./Q]F22K[O(N/*K3T*GDC(;.Y.I+-#.PIR59BX9/(477Z=".;7G[)</8XR$
MFVU46CYAW*BY4:1T.X81_3I\.G3;QI2-]:_AV7UBVF:]0\UHLZ8[R,Z86FDK
M7&I'K=.&7L$OD&ZQTU!WF)>-J6\)FNV)/XEF<]J+"3#B-"H-R(0#<TTIR8;S
M7MD=M:'='^+;- 6+;_&7+*C2+IEH?%HV+HW(.+*O?[C9;$K<+33ZV6.?&S4[
MK$.B=2=91R:J;QX$-&1)WD'&>H\OX _K4X_'^?\ "II4\5+ [",<6:4I^4VE
M,73J#&L3R476)!>TVNQN<N)2=/CXAC;%W",K5VN$K^^>O5E/8DPA"+HUV3E7
MKV :3<U%;K8=SG3LWHW9:HM9YB%$N+ZER[:RLFD/**/F;=L[2D200R#B>C(F
M5:NDGL(I98R!?2\8HWF6,>M#/XZ0=J5,NE*-*4:4KCQX6?\ <<U_]^_=W_M;
MYNTI75!]*R4/4"2$8Q;OW#1BFN9!RZ%FEV$DQ5<'%4$U1$X)$,"292"910Q2
M^@<B$C!(ST]U*RJ\^>O8)*0L8Q:(O$579RME3F9(L%^56Z*ZCHJ8&42;'!-R
M8Q"IF.0P\?'0XS@9/EGK]U*9V-96N"[M,1%>4*_;V&==+%:,Q31&.-)JD8]+
MM)(K59(J9R]A--8_;3-[A"DYY]N!7LD@CV0-_/&_SZ>_SW%0,>&/E5D79@6R
M+*$"(G$P<P<(R BT2X35;F3?R@^9=AUCV&1A7 2N3!T&* B'XIM"GV$G*>IZ
M'/7?&V=^GP\:GSV_G5+VWL[BW4PD;(LF#-5\\*W6%F*[QJ\3BGQG:JA%CBW<
MH+,0.F1("E.FJ & 1$2B!!3I7G/0??X>!^_Y4I:RJ54:!- GY@R@(LA'RQTT
MU1 '[/J'J/P0"\<]8>@B41 /3G4-?;3^73&14'8'?&QW_I^E/QN0!:$35ZC=
M2!2*%6$#*&$4P*<JH\ !C"/4!^ Z1$#"'H.O%33/QRFFG1X4B*::912<B!"%
M*0O49ZX$3=)>D $1'J$?01'U'U'7I9)421@^77U_"E(U,:2P6>Z+R$BFJ9*1
M9HNFS5H5-JX54A8I1!R45%57":B*!"H= '[:G*J@EZC%Z!(TI &#@^?G]V_Z
M4\_7@.GKKFO21:6)6X(3**9O9T?T0I&X,VIA<Q\J#1S(O2.AE$C%2;+M$2'$
M[3OD,*A4F[DH=83D:2GS.?NZ>0W^>/GBH\?EUV^[S_3Y]=5<PQ%[>P^*CT^X
MMH")>/:VQ0@9%=JN]2L8V'B)G$42Q/><H,U7!!>J J1,A4D"E:',8X*]?PV]
M;FTW#OD%<EU+3ZPZD$([L&2'6EKUI2E3B=T>P?:.<C!S\E[2H?$,B19#:;VQ
M CN3H#/='0A3G?\ O@[K,::Y2EN);*L/DN  )2=)S4MY9K5A5PB2"L#!]D&4
M8Q)W=BE6LVC6NA['QSITK+' H,P?L$G(G($65(3.6Y4NX0R@"?5?:),9-\#[
M"T6]I3[:8[2F3)*D+=0D,C96AS1_K>@.^?"KCBNVSG."U0)[+M_DM0UN3I#4
MQ-O^N8CN.+E$ M<UE+@SW8 \Q*0E22HTLX20MLWBEA#7:#;UE$\(SC(1:N2(
M)J.JXYAVY&4@19JX56CI($U3*'.4Z1R+"58B:9@$-8;X8;%W=>@/*DZ7UN/)
MDM!0$E+Q+C>XTNM93@8!"AU)K:X*%WF<+1XM[A-6T&&S&AJM\G!=M[D5L-/I
M4VLN1W]*B5$Z5!?M) &U9> HI"%K5QB4%WKE&+R5=&*3B0<J/7ZR39ZDD11X
M[6Y5<N#@7J554'J4/R(_9J+\ZJ1(B/+"$J=ML1:DM(#;:2I*\A"$[) \AXY/
M6O7 L5$&!=X;2WG41N(KLTAR2ZIY]Q*7484\\O*G'#G=:MSX^&(185V]/<QV
MQ]B>N/L=5J3<+P]LMLQ",G02$W&2,G*/I6+C9.51=*-I=1VW;)/$(]PW4*<Q
MR@V ACZNER+>FQQ6[K(3<9C7UD2(S(6$M,/-MMI0ZIMG2%M!)4ILN!1V)R",
M\BQ OSW&5R?X9M[G#]LDJ[M=KK,AM.]YEQ7Y#[C\1EZ8EXM2.8AM#J&5M[J.
ME)234@9VGHZN6S"DM)1ZLH2(N,@NZ2CT5'LNDFK6Y-%-5M%-2JNER N /1$A
M.DIF'2;@!$Q:VR1W),.]M(<2US(;>DNJ#;9(DMG07580%!)(.X)SGQJ]XVG1
M[?=>#)4B.J7W:\/K<$="GY;07;938=;B- NN)"U!9*0  G.0!FE'=)",IG#\
MS*N'KN-6@DFTG''(Z>LT.^Y<-V7;?-$3I ]*9)T;H;NR'(DXZ3G(( <IHX7?
M6Q>([26T.I>4IIQ*DH6K2E*E90M0*D$D8*D844Y&<'-9>TR$U-X1G/JD/178
M:6Y,=Q+CK:4K6XTU]>TV0'P$N$AIP*2%@*(VQ4DLQD:1C-,4U+)D.0BXDJI5
M4Q:N;#-J.5"G R/>\HV5%!-<11(H(&\HW*0>\J'2>L5RYMR4"F/;VG'NA*TL
M,A)&QTAQ0U%.#@'VE9V&<=&T'[-P\W[=POK\6&#J'*<GS"H9R@*Y3:E)"O9"
MBGV$ $J5UCS:Y(6!UC5BTF81_'M6"\@6*E7KJ,5--MW,J_774*U8&%1D+)R9
M1HHFY#K44(8Z9CI^NK'B9J.W='%,2&WM:&^:AM+@2TM#2$@:G![>I("@I.$X
M^5<_V:R9[W#3#<V$_&2P[(3'??=CK5,;7)?6M?+8)Y):<*FE)7DE0*DDIQ6R
M"@B!#" <CQ\/4?CZ#\/7X:Y^OH%:&3E8M;S..+F;:VD8C(4:S2L&5S0(Z3+7
MF+12L')&NWJW0E(/DR-DDPE'8H.F2B*!"$3/()E-^=>)[+>Y7:_PV@7QA)E6
MN^SH.OAJ)(;@QX[MO5R%R%@I?>3H2&Y+I2['.@(]IT"OLMCNEJ:[-KZLV9:N
M1<[)%EXX@EQW)CKL>Y(2^F,WNEL:U:XZ"IIX%9.0THAU[G)& 8+T)T]HT]-V
M")NV/WL?:8VJ*2:+)F:Y1RC^%:3)>3(R<H#/M)11#=;M1=LF \K\CO=LTVW1
M#PTN1PY<[I<X5]X??C7B)9C+:CM+N:>?#;EZ@$2I/) 3&&2OF-C)4H9UNS&)
M<)(OS<:^0($&79+XU)MTJZIB*D.)M;W(DNQ"0'(K!<.N0H:6M*E' !-2CDG(
M]?C\32LY/)3==0L<'-QD<PF(&52EDG[B*D"H-7\<T:NUX\R@(G4[CH$VY4Q3
M,=8@G*4W9<8<66F-P-<+E<T3[4U=;5<(D:+.M\E$T/NQ)"4,OQF6WUL%13D*
M<"&PD@J4 K-<OPUP]<9/%<&# ,2X.09\-]]V)-C*C*8;DL%;K,AUQEMY("@
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M^T?; ZBV\(XP!B!:':1K*&:QJF/:N9DWBHZ>EK0Q8((#&=M)LUL<_.S:"9
M$Y.:EG9>%9%V*JE2A2<9X]QN-C&@TJKTXUOGW5IM!JU!QT*:P6-\4A'<W,&8
M-T#2,FX*F0JCQT*JQBE O7QZ:4I\Z4HTI1I2N&'ASY?QICO:758B[W&)K4B^
MRWO&FFC:2%RF*T6PW<9Q!X\*JFW51*1 4S@8AU"JF$ *0AA,4!VF(4J2"IAA
M;H"TMDH .%J&4IZ]2-Q5Q;N'[Q=FE/6Z"]*;0ZAE9:2"0XX-2$XR""1OG&!^
MT177"4G*I,8O82@O"OXB?KJ,E O&B;Y9N][\;[0BG:9FB8F*BH0Z#E)1?MH^
MI!4X$.-80A:7"A22E:%E*DG&04DA0.^,C!VSX55R&7(KSL>0@M/L+4TZTO9;
M;B"4J0H#."E0(/7<5[P[RLDQVL+5F[?QC6'_ .=V*2#D%EU%62:TD5 LD9L5
M<R@J'5$Q%NR8PFZ#";W=0H*U^\G(Z8]WNK%G.?NW!'A[Q[Z:>%': IS;2*KS
MIG"C(O3MIMPHEYMR":X"VCGZ93=97+5FY((&**B0B"I1,40#GT\-TDJWT[I\
M/CY >6/OQ4)W'3'N\<>!(Z_?UQ4BL"J!D6<$1()!J\%P( /7_9"9^)C&'D!$
M#<AP \= <B)3";'^R/B?R'KYUZJEJ224M% ,8ZI3)3$J(@14Y"B'L%\H'44A
M@ _O)$+P8!]T3E_%.;F1G2O'D/AU\?GC^M0>H^?W_P!,UY901>.Z:^:,U6K?
MS1FJ:[QY((1R#1$KA);N&6<)J)G[JB:;<$Q%,1[W4!P$O RW]M/Q\/1H>A^'
MKI2G)H!(U=9.5-(L^ZR15=C!N%7$@0R)DUS%9N&;<57!SF3^*+<15(<Q2D #
M^OD;$=/GC'SSM4TV,4QRS&N 15Q/F7,L8AV,XDX;D8&3,H8"1Z;EN@;RZJ:Q
M%%3D[Q3K=8=8'*8 ]+.I6K89QTQY;]*@>O6_W9VKUIH3#6S75JZ.@_2"39&=
M28=+547(PL4+9$C$H*E!($#F*=4%^>I-, (;K.)8.,)(V.,8Z^)W\/72ISN1
MXC'W$ BI!6C&2CQ.3,D/G6S5PV25ZSAT(KF344**8""9QZD2])Q*)R@*@$,
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MGAN.I,'P$YYZ3G:"/45)8JT8=\5-_P#*H?\ _7E_&I)AYV1).YQEQK;[6/\
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M]P&2H1#<?#Y\>@?9K5>EQY!)?XINKI/4N1WED^&Y,TFMV-;I,0#NO ]AC@#
MY,Z*@8\O9M0_E3L2F<B(<%0QC34>.> 2R 5/CGU'@"4L/Y-::F;2O[=\F*]Z
MH"CG?S[V2>GC^>:LDOW]&0CAFWH\PF\-I^&<6T5AI-;Q.W6JS<]7Z]78NM,[
M&!C,[6><<O%Y=FT:-T"-A@(M---,$E5%5CN3"  4A4Q$XF)*W+=&@3&(TQV6
M[+7&QKBE@(2RXM9))>=*BK( 2 !U/7:O+;%ZFW>V3)MNC0(UN1.*E-S^]N.J
MDL)90A+8BLA 1NLK*^GLZ<G(=U?>23.A,%(UG%O)E&. S:.&0;Q\8LX[A@*B
M+]HA()-DC<]0JHMG/2(B $$WIJK:2TMU*7G%,M%6%NI;YJT)W]H-ZD:S[M:?
MC70R%/H8<7&:0^^E.6F5N\A#BLCV5.Z'- QDYT*\L;Y$8R5KW-&4.2'QQB)(
MG(E34DLHSRZGQ]#&0;4!N41#YD!P <@(=?'KKI8T3@W_ *Y>KWD?LQK/%]V<
MERY$_#V?C[^)F3^T?<P.'>&0G?2J9?YAR.NX9M@&?#[6W7.*1/:N[EP;E6/P
MM')#S[C)Y.OU@].2B5=VX;IC]_4T#D?D4/364M\$H5[,F]OI'0N-L,Y(\TH0
MLC/B O;IDUJ!_M1=!#D#AB*L_P#J\B7(QMU"G^5J'E[()V.!OCP48;EGI@\[
M8(YH4!]\M?F:HP$0X]0*>6H%A,0/CQR)C<^O4/H.H4[PFD@M(<   Q)8EODG
M<DJ+<Z*/=[(3MTQX2F/VA.#$A]L$DG,&3;HW7]D"1:YI  \22<^ QO0]3RZZ
M#IDY"TR)1$!,0N88>$ > X]#UG%D*N4#?$>E8.!_%$-2J=82,M"WQSG92;-*
M?)_WN]W:0C'N"/CYA]%<5K)[PJ[/@X]C^\L&,G;R,&P17!DC_M#T^0]0H-A,
M0"O:3(2A1* '+);D<B.DE/D/<;': V-SR("4$"D$!X$O'P&YQ,*#=SCM G(4
MSPM;4K'N#NKG ?!?P QO(LEPSJ=LDR0H#!2_QU>5MDCS8(#'7?\ P]O"K4L9
M1Z)@4/MVQ4]5#W@<2MP0EW0"/(B874I2WCCJ$>>1,J(C\QU NZDH*&^++HR@
MC=N/#7'00>H*6IB$G[OOJ3P\E2@X]P#87W 04KE7)J6L$'(TKDVUU8.=]CUI
MWQD=8(8HEB,(XSC"CZ"#"VL&@?9\$**G^G_=K1=<A/'ZWB.Y.G/[<1U1SG_:
MF=?/SJT8CW&*G$;@VS,@#;E7&,WM\4VL;8]].$D_DI( !+&U12 /0.C(?0 ?
M<'33"\?FUK&/:5#/TS+43D>U;U'8YSD][W^\XK=3*XA0!IX;@I'AIO*$CY8M
MPI1H3&?;R-VF[,RB8=Q9)2,=-8Z-FC3946T? 1\6*B[Q2.C !15=JJ8J16YB
MD2Z!%0PF$I/-Q?B+8MT:(ZX^F''?0X\XSR-:WI3KP"$<QPZ4I6 23DJR3CQR
M66-<$2KQ-N$=B(Y<)49QN.S([UH;CPF(Q*W>2R"I:FU*"0D@ C?P'K(2UPCJ
MW"C48.MV"4%DT(Z;/[(6N1R(@T3$%&KAE!SA5DC*!TD31023(ETF3,8O!=:T
M-J"XZ1/EO1&@-E,QA)4I6?LE!>8T[#96I6^V,9K?N;UT89"K5 CSWRK"FI,U
M4%M*,;+YB8THJW.XY8VWU5%KRT;JU3'*PH&%6)!YZ5GF1+))G* _B\H)4^((
M(A\^5R@(_#@-=&S%X&"3S[SQ MP#(2U:8;:5''0J5/6I(SG<()P.GC7&/SNU
M J_R;A[A-MO/VGKY/=7CS 1;FDDCR) SX^(P"O=V;@#>:#$C(H^H>RCR1U2%
M$/DK)+.TC" CZ&%MT\<#T#ZCH$\%H/\ B79[)VY@2WCXAI&Y^!\_ 8/A2^T]
MP#+7#T8GJ&%./$>[4^O'ST 'R'2L88?<6Z4ZY"RK%+QZHP=FHT:D "'P*9]B
MF9<@40'GCOB8/0.1#TT$CA9!);9;7ML)$.X.CXGE7=C/R !J>Z\=N##\AY)&
MQ[I<+3'!/N#UBE$#XJS\=C51IF37'2:5&TRW3\0-G5:$ _KR(B6J4.  >?L*
M!0X'@. #14VS:M3*X,?R"+"IX;=#F9<)).3X$D$^&*\BT\2+.)*+M+R<X7Q8
MB,!OG;Z-M$(#\#C8[5Z'Q]*.2=N0QH292_OD9S<%?9E 1_RF\BQ=-A].>0[/
MS]?CQKRNYQ5 :;PA@@Y'=^&[=&/B-RPIM1QCQ)WZ[@&O:;%-&0YPZ[)SN4S.
M-+M,2/@B2EU !\M '@-B0?5OCABT."B.W+$)E?B*Z]DC72YA_P )1PXHJRRA
MO\I10QOOT7=E.-\I7%MWY70M(CO(:&V/\-,T( P.@3X>/AZ1P^AMSG)X X>Y
MQVYJYT9QT[YW<<MBEJW/BH]:>K'Z7Q:948W#N/8](@ !4V-T:MB% /0 *"%'
M( <!Z<!QZ:KW#;W3]9Q#<%^]4-9_.9GW_CUJW:3=XXPSPE:F4CP1=&$ ?=;!
M]U*H3^32APGCBJIAR(B!,B"!?@(<B 4T X]>/3[?LU@,>T'&;O)4<X]JW$G;
M)Q_G7WY/GL?'8$SB(# X=A)R.@O2!U!'A;Q[NGA\*]*3#2=9HD)$RKM@TE4Y
M<73TK%T=VU(,M;%Y55BBY\LBHN7L/@9&6%J@D<_*A@22Y$->YR69<Y]]@J4T
M0TA"UI#:E)98;:UJ1J4$%1;*@G4K2#C)K=L$*3 M4:++2A,E)DNNH:7K;0N1
M*?D\L.%*-?+#N@J"$A12<) Q69<9_)K%<J5%J=2L2(H$,=U8+HYKG:<B=0#H
M^7:5B=,HF0A4C][O$$QCG)VR]'4.6 S:74DW&?+BG4-*(\%$HJ3@9)4J5'"3
MG.V%?'RPW65Q PH)M%J@SDZ 5.S+FN$$KR<IY:(DE12  0H*W)(P,9,5N+)N
MT7,)6M+PA&$Y]#JW:S3:G'V]!*_!)@(>GIU#Z?WW(^E]W;@1*,_2W$+KH^T#
M;83#0VZ!0E2%[GS2,>_H>57-[5%+]BQ<(L-'HHWBX2'??[)A1T?#VP!TQFL?
MS&ZYR3AVOC1F81]?8JBB(E]>  AY9&9 /3_"2/R/KZ? /(/!:$G2;B\K!W=)
M 'DHI9#1(!QD!:>O6I([3'"%+%ECHVU)C!*C\G))>'PR@UCD@=P*W6,A9I50
M3B/X.-N=#BT2@/H(%_Z'G;DO'R$7)A#YB(^]J42N&6\Z&HKG_'@7)W'_ "WE
MD9/7.P'D0 **@\;.?XLF<GR[M=++'&^.FOAR0K'NUGKUZ8J6DY 74ZY1C9I<
MP\ )5MPM@BDQ#CUY1K58@T"CR/O=!"!\>/3W=1W^U))++\)@'H!PVP\$^\=Z
MER2?^\5';ITJ/H>_* [U&NDD]25\9R(F<^.;?!A@;[^R!U(SBKSXX<NA+[3Q
M)#3PD'GBQYNMED((^OQ).Q+],W(<@)1*)1]>0$->3<V-14B_*85G_JU@B1<8
M\A&6T ?(C!'QKV+%*(P[PLW+201F=Q;<9Y4.F#WQI_(W\R/+&<5FLJ$VCC =
MCMRPZV/SU HG/Q!51-R ]?<^@(G$_( (FZA'[]>';D'P ]Q;>%I&=*5,/E"0
M3OI3WW2!L-@.@ \*]Q[$(I)C]G_#C*B05*;EQ$J)'0E0M6HGWDDGJ2:>[9[>
MF)2IL\449H0O $(VO:*)"\?#@$J24H<<?H^[6@M%L<)+E^G.$G<K@K5N1XZI
M9SG\]_?5PA=[:P&^%;8V!T"+JRC'P";8/&D&_(Y2NU)M5-3I-2BC6>"DH,)$
M^0%'";+VDU5:^9,W3J"9UBH]WN"D10AC@42@8O/.LL'Z&A38TT722\J*\A]+
M7T?I+A;(4$:^\G3JQIU8.D'(&PK6NJ>)+E;)MN%B@QQ,C.1N:J\!:&@ZG07"
MVF DK"0<Z 058QG>IE34,C)-TR/$^A.'6*+7DP%46*X: 583](HE$I0,F &$
M%.#B)""0#F#GBH$J). 5==\C<Y]9)]^XKL$I4E"4@:E)2!CIG 'NR,^\?K42
M3%KW#%54+ XWQ@HCR()*RV499)4W!A !.BSH"I Y  $2@MR'/'5R'.NEBQ.%
MC@S+S=D[#(BV=E1R>N"[<4C \R-_*N-FSN/ 5?1_#MA4G)"%3+](3D;X)2S:
MSOMT"_/?:FF>;W=N#^[!8.BB"(<D)-6285* \\@"BB<04P\? 11+ZAZAP/ ;
MBV>!D$%N??WD@[\V+$CGPZ!M;X SD?:R1MM54W*[57"0[:>$XV<D<FX3I1QX
M?XK3 &QZ8(V'49JU9/="\ 2.)>I,1-Z",$\B&9R?,13-,URP !N.0#K(</@(
MAZ>L%?!H_P (2C[Y"7W/#KI9D,#?;]K8^%>@UVD+)+SD!"=\)AJBM*&/]N1&
MEY\OL9^_%>85O."Q0"2GK&[YYZB(9'I440_(>I0&*PXU<I@ ^H"1R4X?(WQY
MGOG#J$E+;$).!@..6RX/.9WW^LO1:\MBV1GPQ3Z.XP<5EY^YGH5):O=G80KK
ML"UPVES;/4. ^'OJJ=#N/!A>UZPRAS#[ZCO<E>6XCS\0!&+BHUMTF_OB@@!>
M/@''H'D7&WMGZJ9#;&/#AB"YCYR%O$?$$$#Q.=ALMV7L_;;E(4=]2^.KJP"1
MYIAM1F_B",'Q'3%!QD1<W<D,'4J<./H8]DRG+64YP 1'@_M^NR75R/'(FY$>
M/7[-0F[)0HEKB27')'6-:6HI (_9[O(;TCX#%>S8''!A[@R!+&,$3>('YV?#
MVC+B/%7CG42#DTMQU15BCE/%[>\1QZA!Y(=I8XEN<O' >Z=.A%,  ( 'H/Q#
M6%Z<U(),CBN[O'89=8D.''4 %<TG'EO6S&M+L, 1. ^'XP220&)D1L GJ<(M
M0&?/Q_"GBC*Y!;@!6^+J6@4.  $;\1( X] XZ*44 X#T_)]VM%35J7]J^S%;
MY.8"COYG,K?KXU:)>OS> CABW(\@F[M)^X"VBDN;0R);%JXP?5.M0$?'VVMV
M![((74\JJ1O!2:$B=!NQ+66/>7<@@")!,Y2(03=1C" " YHSEI@IEN-3Y$MU
MV#+C-M&$&07)+2F@I;AD+PE&K4H!!) TC<[8);=_N*X#+UJAP&6+G FO/BYB
M0H-PWTO%*&DPFBI2].D$K 3G)VR*E-LZ6(K/"@NT<+)O""V;"L5$""$0P.5N
MY5[1NV95<15%7I7$B2Q! !Z>T%" G* I6E.0%*QG *L%0'CI'0 C.,9SO76*
M*@E10G4L)5H03IUJ )2"K?2"=B<;#?&U17(VO/X"(0^-L;*!QZ&D<IR:0\_,
M!(UQZN A]X*!\O0?G?LQ>&=N\WFY)\^5:&B?EKN*0?GCY>')29W&^_<^'+*K
M?8OW]Y(Q\&[4H[#W_?376LV[-8Q@;T7![$OIP96^V>5$/_Y25B( ?_\ +U]?
ME\+-,7@$(.J[\2.. 9 ^BH+23N/$3GE ==])Z@8\:I7)W:L5'E\/\'(;S@*5
M>[BXO[A ;22!X93\:QRR6[A4_P"':X7:D$/Q&:DZNH _:"CI\!1 /3C\!^4?
M4-8]'!*#GGWET=!S$M-CKD$Z$$]-B,^\9\??.[3ECVHG#;*B#_A/2'0#MXNJ
M3GW#2,]3[[54]T+@.%I>J-A$!Y]DO(9L(>G_ +/VG7)CU#G^_P"Y\O3GD=%.
M<'  -(DE6-R\)+H^YN1'/WGRJ UVD*/UKD'!_9C*B,D?!3\65Y;''OQXUCIP
M&?S>CZT32HFY#I9W7'K G'H/NA]2SA7T]?\ VPCQ\1T3*X90"4LQ%;YR_!N3
MH^ ";RV!T&Y\>G6I,'C9?VY4\$YQR+M9&AGR]KAMP_CG./G>>GY4< 4'[BU/
MP 1ZA#-J,48_//H;Z/8ZAQ*/KZB42_+@ ]-0J=9"06C 8Z8"+&X[GIU[U<Y!
M.2#D9]W3:O(M/$YP'Q=I( WU\41XX.=_^I62*/$ 8(.-^I.?0E%M/!>_5)QV
M)>0ZE]R^1@ P?,#)MVJ"?'RX*F4 'T]?34BYP4Y"+A#0/''"EL7CJ,Y<*E>(
MZG;RKU] W)6"Y:+DX1T)X]O:<[>31;2=\G[.#\-JL/C91R<#OL-5R6.4>1&;
MS-99OGGT]\)>$> IR'I[X&Y#XZQFY,9RF_O-Y_[*QQF /AR7T@'W@9%>Q8Y!
M&%\)QY \>\\43)6?B9$=TG/CD[U[(XVCFY^I+;;AON<@(JJ3\0HJ)N/B952A
MG.81#YF,(C\]>UW=:QI5QA>='30&9"4#X($T)'R KRCAQEM?,3V><-<PG/,5
M*B*<)ZYUJM163[\TY6$1,Q/ QN#,71X@/("SM4:V$!XXY 4:(00'CYAQK26]
M#<V7Q)<UC?[45U0WZ[&9T^7059-1)[!')X+LK1&X+<^.C'0;%-K'N&!3@3E<
MA(!^"Q=2T@'U_!W\A0]./7@M*#C_ ,1]?CK74U:5#VKY,/N,!1/P_P [^76M
MQ+U^3C3PQ;DY_=N[0]_A;<'I62%AR: <ACFJE#X"(9', _+Y?0T.?E\?L^[7
MCNUEZF\R3X[VWK__ "OX5E$SB0=.'88^%Z2/E_H[SKUQY%SL:]O,W96\3%N[
M9:V\VWCHZ7&9(S:-ZE6:Z!%GJC",[BRJ\(NN!$VW0FBJB4RAS]0%BYR8KR+9
M'B.N/(@0%1EO+:Y/,<<G3)9(;UN:0E,E*-U$E25'H17JQ0[A'=O4RX,,QG+K
M=&YK<=E_O09::M=NMX"W^4R%*6N&MS"482%I!).34LE'DH#Z^H /KQS_ ">G
M]/AJJKH*KI2C2E&E*-*4:4HTI1I2N2V?_!BV19JE8:QQ&(*9CFSGS95\LY F
M*_'3A2Y!B6=E5L5[I#^,86:'C(MCD0SARVEW\>U*=J=PJZ2:*JG,4RE19NW\
M-?PN</8#OL].;?JY1',]&IX[J%GK1[9*6"(O^1UR4NBO(=I)WB(@R/6MGFHQ
MTB[L4W!5MD*(N9V;BHU)P\2G<[;GW5(SX9\MO+RI6PIX:?A/V7 =3O-3Q7BG
M/U:K]*(RE<LTFQV>R-[U+T>-]E6R:0"NW.1;*S+^7B9%9[$,UEUF\DHHP(4R
MA2@:*BHCV5^'%X7.3,=7:R)XOA<@2TGE;*EHDJ=D5E<Z+E3!$?*6524:8+N]
M 6NKF8@GV*(^2CZ\BN^3!.8CC1DW'*NXJ6C7CI2J;9/#B\+;<A=K5GG'F-8:
M2Q_-4BJT%7;E<(R^TZUXAR#4I>P35IG+77)FWHVB%LEG@KA3D5XV2C$61H*/
MKT[%/I".GV;E5N/=^?HC^=/=3)RKL8\*Q;=[AO#S3#3G':&/;^G#Y 6;P%P=
MX@R?=<G8JG'&.,&6>Z&OY']6LSI*5BLBU-ZY@BUFS2L.C4(NQ.;8=:#1G)'C
M[Z4M;]]@'A28MQG&X\FZ)5-N=LS(]<P%2S*Q<6!PTQP6LH(6ZP669<V'(,%#
MIMCQ$:,$UB4I!U9YUY/((5J F3H/A9QG\>O\Z5L!DC8;X0N-\'R&X.0VXX\L
M6-4JO%VR$F*;-V>?^E\3831J-:6J:Y;PWBY-*P.)J(2C9):29P::4@C(R4LP
MB2.)!%2HKV5>&7X9MEVX0IYW#K/)-QQN]LU0RY.Y.B+O1,FU^\0LBXEY>LY#
MI2=TD@@+! P\K$D039OI.,G($T/9*_)2T'-1LBZ4IG;,-@GA89\N>?+17L2F
ML3"V2>.<C43$^2ZU?:'*8WQ-8L?0D75+'24W-R<&N.-\KR4'-WF(M;50"MY>
M2F*O*MHR>@Y&,:*>OZ_S\,>&*Q;?L2\*>)WTT/'S_% UN,AZC)8LG::-:R"I
MAJPYHRLK5;MBZ-G<F%N(HP.24J;5[$2FP3QBC$6=*U.(IC.*6A)M!.)!/A^'
MKW4P.N-^N??YT[]^>QSPMZ=8,0DRG#5?#-FNN5(?)-FR+-S5C6BYG'>)WT;.
MY'A\A6VVY$A8N%K=O;NX&AK.TY"1LJ\G:HA*%K\FBG(KQT4J0=ROAI^&G4ML
M]]R'5=JYY\DU3DF-2GL%1%[RG=FQ[[Y6 K]\I59BKF3Z5HUL9UK<Q(S="1W$
M1:Z[0S@XHI+3D^9IDGJ<TVJML,\)>K[4*YF*'P17MT$#4:%06<G:\0)7:]W?
M)<X]C:S%IR4?3X"Y+O/I-:'LPPG'E>.=%Y&)R9S.R(IHB;44_2E[:MX4'ACV
MV@V6^0=-QUN$J>2<BW#)5&L+>1M;=.FT.Z/4I*K8R2;H7-9TDC260C%IA+H1
MTP"G=0DHUD[151*WZ'P\/Y5&!Y"H$V_[&_"XS?NTR4E$8&DH.LFQ[)4_'N*[
MQ"V&*I%UD\*9<N=,RWF#&MKB\DS*LB^9V1[$T2VTFT,JM=:XTB*[//ZTA$V.
M.>+*FO#<)LN\(>H[K\$XCL=5I.$%:;(MKW<8J8?SS*F9I8Y(BKEBF@8N5E)7
M(#.8.NC>'*5S5G*_#2M9@96I1->M4Y"RUFA63Z<DCQP#X]/Y=?=2GAO^\.CP
MWL<87-3:MMOE:]E+,$M]!<=2N%(Z5N>1H*790<]D&6FXBL6/*=28S1V-,H=K
M<I0;.56LM@\NM&U.$GIDR4>>*5,L[L<\'ZO[>F.Y9OMQI=MQ9+P-2FJS,516
M^R<I;0O4G#5^FQ\)%KVMDL$Q8[%/Q$(@TE5(M..DWHISKB)2:/EVJE-+9)X6
M_AHW3;U55E<3168;'7Y2XUR\VJ_Q-^H61(NWQ]KEEY6EY HSRV"^J=JI2+QG
M6W<6[$PK-(YE*M5G4=),W:[)'0XI47;9=B7A29(W"[BZPTQ0%D/9)\]@Q11[
MO6,@U&LQU-Q,1CAS*+O#ED7N*[>_5]IEB'DSVXYRQ<[7IN79F>0I8&9KLS+J
M4'V6>$+=M]$9C1O"4&JV.@L+IC";P;9)J<CB9MRA<(6DY*8S5<-*Y&2M\O)8
MSIS%RMYY*O#7K"6]OTH.<EWU?FT(]D^=*7=V_AX>&!4+GA7$,CA?ZAEKKD"A
M6OZ[6\'>GV)%D:G?8.07P1>+V[NC6%I\SG6(93M4@%)-1-!?H<-$G99R2KD5
M-*4]]P6Q'PEL??0S'$]@&#Q\\W P5GKF/LVQS+($OC:CVF291D13'5HNB5L^
MCM=D[)-62/+CTLT\:1EHFV80R<@@]>QB#]TQCPI2U.>&AX8^V7:_$7S)>WRM
MY93QSCNA1D[=8E_.)S>4K NA7JDUL;?SV0XZKQ[F^6:29OU)"5L<=5H<)<\A
M+3["$:.9-%2FALX\,+PV;_1<GV]]A5K;'3[.F2G$G3LFQMNI=XV^**N8Y=+
M5FAD;S)( K0&JS=2-F4'[J-LD+,1MBA'TE RD7(NE*C#;OLK\(K<+NAR(O2*
M?3E"1- E:(TVO3SFQQ<TQE<691GXBX9N*P)?7,_$KS:TU"U5U4K3&05JAXB/
MKTY,P4:ULL29TIZ]?=7CF/9+X6+C=7A7#L;@M]CZ/H&3JO\ 639XN*GI?$-]
MG,KT"Z0>+\&W6Q$R66R51Q:Y^4A[+5;6I4U*/,7.NQN/4;5],9 8(BE+._78
MGX6&+Z1(X@^H][BN\Y)H5KL3;,.-:Y<[TI@>F527J418\QVV*^GK!Z-5K,E;
MZZUFE85I.2$3'RJ]BDXYG6HF6F&*F!UV^/C_ !K:#+/AT>%-A'#LUF&X;7J=
M)U6NQ$6^,O7Y"VR,E/J3#R.B(1"&(M=F<>LO.RDI&M6KI[),(AL+TCV4E(^+
M1<OD)R?,TP/*H@V0>&%X:EUP!&^U,.L\E7&FV:\U;)4GDZ+NE$R95KBA:92:
M<4._TTMV?E@IRG0DU"0S4S9_(1<] -X:SP4E*0DW'2#F,D^NGNV_3:AWW._\
M?7E4;[0]D7A"Y\RQGIY2ZWC^^K624C+!4<$SDK-1-JQ/2:,V;XXFYQI7FN0W
MUB;P%[MK(UL.WM<;7K+#&L$4C.0$4,G'D<O#'AZV^'NI\AMTVI3LNP3PNB;V
MJ=C:RX43PQ'U"H6R'BZO>XNWUS$VZ6S7EMC=_&JXWR))7M)M/6[#?=".>59J
MV+)R#F\NQC4'R,)**M)R?,_?3)/4YI3S1X>_A66G*C;:W%XGC=OV4X^?Q5DB
M)NLS$WQA3<I5VJ6^M7?(F)J-;IBXL*_9)^5HZ*4%=X9@\&:@*[=4YMFQD2QT
MHG'Q2GEN]V%^&5@&BP#1+98XMMSR_/2V,<>Q&+5W\A;DK.K0;C=5I6.;7'*E
M.A'[^$KE/G9F)KR4R>PVJ58LX"M14K)OB(%9)ZG./?2J8W\.WPIJ=LWHV:IC
M#5?S35JU@^*M$IDN-C,DKW')A:O4".IZ?;T=G95YDELG%XR2=OZH1 9"+EC/
M(Y\1!1DZ%)2F!LC\/KPI,O4[+=RC*CCK+(.<DR5\E861G)LAL!URZ5Z%FH3$
MXSL+>Y*L6NMU-%M*C%Y!K<S+5&RF-)K0DW(-&1UP'W^.],4R\&[(_##S/O%O
M4?'[>92LU-&@6_'V/\<VYC+(8^R+:<*9<F*YEO)=)M,%E"=?-+37I!_%56=Q
M[>(JHW!"LA!7%I"NH*4%VW=/S]??2E3-6QOPJU]SF&,*,,-+XQ4HF7*@XR%8
M(Z M\IB;($M?<>W-M1=O-RMWT_3>U&7NCJ7A;C69EU"#6)F>K+"E,;"M;7QH
M(BE/O?CX</AK8VP5+U:&VY255R9F@LWC'$\YAB"M=_R3!7%Q3;3;EK17*F_R
M' -)EU4ZO4;':"1'M,DI.>QQAZ['S,^]C8EX&?#K[J5/%8\.?PD9C"45G&+P
M)C>PXM5Q\6_!?&;W(BR#^K,H8\J]G!8(V%24*N1HV<K.XOR0RC5VFM'JLBO4
ME&Y9R?,[]=_6:5 .P_PZ_"ERMA=DPAJECK/MUK[V4E[N_D[ ^;Y"J3;(EAG;
MK2*Q?JM6,E6(E6D8.HRL;76+-X]\VHW@3E>I-)1O(L&4'W^._P!],#RI+PKX
M>_A<2VZG<[C^S8B:1T^K8*<CC;"V4XRXT5NVK=4KOT3LEUPC(OKP<^4*/<;M
M'S1Y&68(I.XB>C'*+B/3BWT+)2JE9#3P\_"QR)O$0Q[%XLC\;2V#(.ZQEIPI
M<8F]5J#W (7<E":UO)6/K'+W- EN@L96-.4I[E:O)/5&UIGEV,FV9-W5?>33
M)\SCR\*4A;]-A'AEXGKU%HS/;I.4ZSVR:99(?V[$D!9;S)U3$>$[SCNP9AF)
MZ >Y(AI24K3NO3;&M61E2&5NN[&N6.8M$?4I")KDRY9J5/&X78%X3V(=NEUS
MA(;;:@M4$*:A)PD_3I*T3#I[]+08Q-4EX5R[O#"OHL%I&>AW9K'8)F&I\)&J
MFG[-8(:NLY"4:SD^9^>],D]3FD+:-X;'A/WC;M1'U>IF+-Q2E#@8C'M]S UF
MK05W:<@UB(BF=BD)QC'W-XWCIV;=.6TSY!LY<MW2$S'NXAQ(1LA'NW,4Z5!^
MP_8_X6^<W^8B%P1(3<A<;@MGC%]:RO%3E8=QNW>^,HB&HSG'3NO9.M,5:<?H
M35?GDUW3B1C[A5K&_?5F^U2JS*+=FX4_I]WPI1K&Q3PH[)ONGZ"ABP&$>RI4
MCAB&QG-UK(,9B>V9NI[E#)5V=4S)*UQ,WF<E5O'LS&HRM+6:,%W-9;/I^!5F
MF4-.K1:F/7KU]]*^]3P^O"YPO8-N[F9PR\H[&)R+-97O\7CBHY%R"2TX3Q_4
M)2LY )D!*/MY7]>QM6+'D['5LLL_#LYR:CU(A@[) KP3>?E(=Y^_^77SZ?EY
M4J0-WWAE^%]6MIF3KK&XDA\<,[#2$(^J9=QA#Y(RC9JL[O:T? 5B]U6HURS/
M']K+$NYN.FP3CTUDS1J*CPQ_+)&/J=SXG/GXC^E/?X^?X?EM3\E_#^\(.C8
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M%G!9]N>7ZM&RM)2C7:US"99,J0BR)]'[2_BV=.NUML;VD52=FK179R+817G
MZ8&/+%27OM\-;PR<68HJYY+#1<+-;3EC&\6_S#2J[D&YQN.H&!L;6\V>2R09
MO;T4JEC2S5ZJ2./+1=WIC,:R6YM)%Z5)DDY=M534N9U\/;PH,08 R'G&6VST
MY_3JK7)!Z>6I<C:K"Z.X5=A!,S1RP79"$1[4VY;MW<M-2L56X A',G9YF%A(
MZ3DFBE,S99X9OA59'V]4%*LTW%^Y66Q_!PV.LAY<:3=D%_9LB5Z#BAL$A/-(
MF[/V#"7F ?-)\$F+U[&/(^782<,_D8A^P?.9R<GJ#G?PWI@ ],'QVWJ#ME>R
M/PL\LY!SG55L$R4^_N&0;MEK#4?DR#L59C%<)P3ZNXLEV.*9.&R58$+!6:7D
M:$DD[%'V4:OD2K2=PC4[9281K+0CF1BE5O\ LO\ "$Q;ONCZ1D:JTFCPLA@:
MK0#+&%I>ST)CZ3R+><KOV-1M$-8)"_(3TW:9-M%2M3>&B8!W2Z\1LS8V2U1-
MDFH6%?O7K[_RI3DWO>'GX;.'W>V]Q';<9I"26SF2>F*%AJ&G+I:,H42G8QR)
M8KK3I*)F,G5M<85K#MQNZS&L?2"]S2M-)'U&HV!R=T1H]?=Z_.E/#<AX=OA6
M2&S>X96Q_B.OUZ%R5C^'88IRKC!"Y7"S$G\NKQ55Q=,TN!=76*:RTR_LUH@$
MXEI*R$0P(\<IA,OXMJFZ<(*5+^ ?#=\*?-.**]=Z9MQJ4\S22<5N>4L*>1JS
M;8>XU54T';*_=JK+V1O+56WPTXR>-9Z DVZ3EB[*;I[S51NX64K6S8_L9\*N
MY/+-BDF*OK%R77[AEK(=:M61:U?Z,>[8U-F>SL8Z1QHHK<'L?;J5BF2<,,4K
M2*3A"99+0D0[L,#$I6"&._?.G4>[I[O/'W[U]$B9"IID3*  5,A2% .> *4
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ML?WW:3P6ZY0>,VC@IT"J5MLHDFL0Q%"@<ABF*8I@Y*8I@X,4Q1Y*8I@Y 0,
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MTI1I2C2E8X-6X+&< BF5<Y$TCK 0H*G32,H=),ZG'68B9U53ID,82$,JH8H
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H*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*-*4:4HTI1I2C2E&E*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g69956g16l94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g16l94.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1944&AO=&]S:&]P(#,N,  X0DE-! 0
M    %CB^5H@X0DE-! 0      $T< 5H  QLE1QP"   "+6\< E  "%)2,3$W
M-3<R' (% "Q-:6-R;W-O9G0@5V]R9" M(%)I9&5R($)U<VEN97-S(%-E8W1I
M;VXN9&]C>  X0DE-!"4      !"H+GA<2I<R42UU(#K7S0G>.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&E+C4         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/T       2
M #4    ! "T    &       !.$))30/W       <  #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             !F0  !/P
M         0                         !              3\   !F0
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !F0
M  !29VAT;&]N9P  !/P    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    #
M.$))300,      Q6     0   *     S   !X   7Z    PZ !@  ?_8_^T
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M*'FJ<BAME@VP*S8P7[L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0'_P  +" #" ET! 1$ _\0 'P !  (" @,! 0
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MYZ,KY-+\OFI /*%7<X3.-59977/7$)YQ1N&501M9S&K )&OK.LTY)6$"(&0
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MJ1H0,6<-=%Y&9%=$/B^;%P3'6"M^5X2*'Y+D/5MC'\/6,RW))B$H=^"QA_\
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M!3/X&7'EOPDPT^K]Z$D_N#AQ]P)MOKZ?>&#K[)TC];7[1+7ZV/IYWSW#CY"
M+/2 T6<#DB(G.N"H\>39/'HS.[M^PTP0:MUU%V6=WPLFSU^\II_6=CG[?'TK
M-'&B?,>J-_*O(>*37?-LP"ZN3N!#U@#:BIPG(+1[2[ZLKF(G:T8D3>1)A!40
MA,*A,Q#E8Y"%X^Z&D52KL>_V+.-7>H?+9=N1>6,N7J.IKG3G$8 H*.Q&J(A(
M8_\ F6IJ%E\HLF##9))XL+=/Y(-DTR,[E#\71T9LG#1SL\#-"0AFD[3;"]G:
MN=84JS^<^TXI+)8!LNBD>TJ!K(20.V/W[\?\0M#>CH:"$.D42[^9PVV Z 5=
MP#9*;ESFE-7A<F-1[=RLT8XW0W;8EK^0H_;R?*1B0<U<NQ_KZY%C,)+5/ )4
MQKMX C$C_$FY$-<;P=:,AB(1V[K'33]:P@UJ?"GB!]L+',BX+5RY-#M ZMY#
MZ+C?QKQZ#5/;]]\#2F-#^E)Y>D>LBL.4KDL"[)A8I0[-);(Y)H/=VA7< %R6
M2/I(<CHBMCZ2@4%)&@5[]"H1I]3<SX=?[JGX\_\ *'17\ A?22>>>>>>>>>>
M>>>]+A#5RW7;[;K)ZN$54-E&ZNZ"Z>JNFR>=T%T\ZJ(K:8VSLFJGMKNGOC7?
M3.-L8SZM+\0'QL\J<O?(Y\J4]IR.3L%)ZGN* 4_&7Q6V;'DZ;^"VKSO2]US1
MC,&<ADA)I-")"S#1"4-3DE1)&!CM75(>];MD]$<68///1RV9<'RB!9_+A-4<
M0<LSRMF!QZVA4REG<LM@4EDD?24^A@6-PQGR3,&L:(NTO]MP(;R@\DTW_P!C
M4DYQ_MYK,4#T<&T^4OKN[J)H;X[Y)V_TS 7=13.H@/R"6*J>B$CJD;(=KF+B
M!2O"#+[I)94VBD>7GB;I8?K@I!7CQ9\J[DA//HVNJ^G)A >!_@N =7_%_%[R
M@D;*PJ<\L3^ =1N]R-F$(O\ @S4O3UBQ-SSD_P!XPA9:Q.'$2,/:F3Z1K2.M
ML,2KO8:03;W3@E\?+\_2$+/OCLY%"-7B;!5XW7^0J6K$1"#C5+=P@LT;<8;-
M57K!/?=-1NW?;-]UTLI).\IYU6]*JEE39-/*NFJ:N=-,J::;Y4TT4SKC.^FJ
MF==,[ZZ[?3C7?.FF=L8QMG77Z?HQY^>>CVMRR/D[#61*1E(\J\CSRJFCUOI#
MI;8'6MB5_,C8_8<S5=.#L/#\S38:"<I$]W[1%NTE!A-5HW;N]ET]W&[9'4>,
M\V;<I_!)9O.G94JUB[2%\Q]--[PEU,J/ISM&8_-CEH3$D3A."K",O90[!@92
MWV18O&(G\3=M%6&WV**N%O1:N:\Y@GG3G$2T,,7!5)^GNC>4:MZ%Z J7F@1!
MN$^K.DZD"C);7-<RJ$HSMU)*\N04R/[Q>/6L,&FP@A>1.ZPD<A/,DA*8:X7Y
M[KSZ6Q08D:<$I/'AZ$;RVQ(EGQH:T2 9>))K-,&E%W*>@K+I%5)5MA]LA]ND
MJFHE];3?7.8Q/G#52<?$'\@:Z"B:R*W,LY5162WU42524;-MTU$E-,[:*)J:
M;8VTWTSG7;7.-M<YQG&?2C@OZP@?_"A_^D1]ROGGGGGGGJJ'*_Z4E6?4/R)1
M3X^AO(4ZB!N57-/*=1LU]:X L*:.X/F4ZJ'%8TWAK)VHW(YC&_U&6A?55KAY
MKG9PO]CG"EJ_SSSSSSSSSSSSSSSSSW!2DTK&XS(I$@'+2)8"#+&40 !KL^.G
M%1C!P]3#AF6N<;.RI+=#5D/;:YQE=VLBEC./K?3ZOC\'G1?RDV?9O:,;^1SE
M^[Z;!3*TBMY\[R*PPZJ,9B<0D3Q &_H@8_W<+8;MXFR:1XO&VNFNNC[+J7O-
MM4E-?H5L5^K&=!C.X9A\H-8SPY0MP1I^ZKWY :AYN-"9]5A*K8? VU,!6,!G
MS?0%8#PV,G-@SC"4SE)"71D&=;,7\&@D=8%-8(<)OMF/BZ&U>XN&/%N<*Z?5
MW6\4X'I"L>AVOY92&K4W'3X&4O'"(":L9"! .93<$,!9FR<[.KX,&FNLC%Z'
MS+I0D/SG7@3/OD'DL.92I7KGH>.OYK1/R86L[!C:AH;9I$I1RA?"46YSBT8_
M&Z,*EF8^51DOLI+&L@?'S=BLAS?(!Z 9Z[8Q\<B[YO\ B]FUM);3O^V(),G7
M1U$!"O+@*D02M6R?E@W1,=GLAGZ4N5J@E)_UFELY5DS9X49VFUT$EFWY4M(D
MV,#]'*_#5WIU%SCUA#BCYD?B%9695W"Q[L2=Q(!^+S=I;MUVGW)8[.)II$HX
M9"#*F,W[8 R$7E,Q2JTQA<:D4:58[ 0+^1S>-P[?*E\M_P @G.48Y3*TWW#=
M(&W;/C]H$^IZH-<\UDRB]*6X!(PE%:L($2+T@-=/8]%L%R(AFW<RB>/UA3 -
M,G4E?)3AH^(3#_)$/$\W=FV[TC:/0/7_ !?35PQFFHT<Z$@7+_)71O-SPE"0
M;T,)0ESZ9U=;-NUN;'K%W[%T3D$99@2R.[;1J:69LF+1G/C4MR5;<_,0VR:-
MNZN[HA#BNWS -<;(G%G4*.%@()08^+R3 -)E&PWV11MNO* 6C 4T";9=C]Q@
M]!##5.MM\5>W:TLZRI)K+^F;AZ&@<<C3^5WX';]5\S3[GBN6Y.@640*0-Q6M
M#%&QK]=1'4+*5&ZX%;!7E:)4A+8GE[KI.(?L_2MPXQC&/HQCZ,8_JQC'^[&/
M_#V,;L_X,VY_RQGO\*EO:4_#K_=4_'G_ )0Z*_@$-Z23SSSSSSSSSSSSST27
M ?\ ^^OYGO\ -CSW_P#\24%Z6WSSST"=G\1<0_&ITOWQ\S]@D'T;;6[4D>CT
MG;"8,<D[*KY#(7?X)9\_'LXNR-&-MK6,:0)U(WZ0IND#=H2PF^>[L)(ZU8]1
M^$8_QW\@?Q@\2C=H^VMQ]Q"5K;Z74FB$L##J]Z3KF/*D&;N-E2[ 2.DI*,BY
M8BJY6$.# 9'<FTU>Z[+?=L:V&O////07_*)=76\$Z,HF$U-8?9]3T&8J&PY'
M.9GQ=QC".IY6XM-I+(N/AX&;$;&@-@B(O'%8SM)G@]I&Q2)E<FEE4VIL-7&*
MM=A)E--/^B/MV=W'&KCZN:LN8;M.3B&=%5FPHJWKF&"1DR6=Q2PZX@<;B36#
M+F1S30+II'(T,=9C^K(TW;K/W65UX J;>PCD M\?U;RKDVIW#3I+N>@>A>:+
M;IF\^K;LY&F3BZXH*KV>R84I95B%7T>O.FX^PC"T,C=AE)/ BS=\O/X&+;E1
MY-D+ND^U2ZBL;K*O6<45Y;YMA?0JQ)O+MYIK++O8T^XB.XQB,6B> K(A$)(A
M,UY&\<%FSAIN5C"0K(UKE<ALF3RLRIEP^A>Q!LLO$QW#QMT#-:P=?(WQ_P!)
M=Q#W0H;? ^UQ+KFVS0\R81>MJW<27>PZIA]O22 G@\3B24D"0B)BP  RDN7C
M!!/&]O3U6]\5W^CA;1-<Y5%=0:)\56,G=]77A6EC22^V<*>RTJ4K2&Q"5"+5
MC8&!'HI5CR-1HDPFD0G#@:2'X:.,?69K(;6WP7]B!O\ "A_^D1]ROGGGGGN%
M,22.Q["&Q\\%!ZNL[ZMMC!1B,PXV2QKE3"&7JZ&%LIXWUSOA/ZV=,;:YV^CZ
MV/I^Y@08%6:! 6^9DF#G7;9L^8.47C-QKKOLGML@Y;[J(JZZJ:;Z;93WVQC?
M7;7.<;:YQB(:G_@5^+&A^G _8E6\X$8YT*!G4BLD5-U+JO8TV:S*5Y,9.%?U
M3.V22AZVCO)XIG0>N"5&M<N-?NC1'[!#[*87SSSV-FUP5@\MLO0[6;Q]>X0,
M"#6B7KM-^GF3L*^D!TM&0\K7'_\ ZF!#T\#)C-%]<[93<M],+:IZN6NRT;OR
MR_+A2GQ/PJA)1:;':1DKPNZ*5\UCK)WE$D)KE$F/5MRSM6Z::RSUO7\:?(.&
MP_75/!8Z4##,KH).%UDI7!14:=%C389^T*AS#!F5$E![A)VP)#2#=-VQ?LG2
M&VZ+EH\:K).&SA'?=)9%311/;;3;&<_?YY[HDRM*LJYW8)V%8L$@BA75QN+3
MF4NC\7W):-,I:NMV&IL@QV>:MMET,.-F^%,(Y62PIG7*FGUNSA3@62B6!Z.E
MQ9\&5;Z.QAD*0:%1))HI]/V;I@18K+LWC??Z,_46;K*)[?1GZNV?H]RGGGGG
MGGGGGGGT8_\ #'M7=N+^9M[S_I(;U>UWMW]8M)G@WO)IKO'=9RG$]()I/]:X
MVDF:TUL+6&IIQG$^UB&)A@-IJQ_&OL=<:^V@WTT4UVTWUUWTWUSIOIMC&VN^
MNV,XVUVUSC.-M<XSG&<9QG&<9SC/M#F'Q@<#,G3YT[YC@$HU=[9PS'V I([*
M!Q5IE\2)9#U[';!.28#6<<V?EGSK>,5X-C$>W441SL,SAFSPWBM[OZ>^%!5Q
MT1T=*+IY+OOL2GZNL7%3UW=EIKVG%XU;=81 ZE%8G%://R=>$Q\\1F0MJ..;
MQJ/"I0<)+*IN"^764-T<\],<JG;@^*,Y%^7:)CSN>]52#FSI.YJ;ADB'5K';
M2(RR9TE..A 3=[*S;>/QD=.()&"X)X)W?-1;QJHJU70=."+W+SH=84=?,F[H
MXPN",?%K'.#(92Z=S1^W+#C%H\U/]I?64TJHL'CE=/XU39!$N<%-;#9Q(\R1
M?L7S4.\')OVN&F^%ELV"/8QNS_@S;G_+&>_PJ6]I3\.O]U3\>?\ E#HK^ 0W
MI)//5V_T@3YL;%^'F$<^N*JH<#;DOO212]ODW/GIX?7T6"P9L"7(L%_U<59D
M2$J/;R%OD0V_%&+9DQ'$GZZ1#ZJ;;$N7"?3_ /33X\YUZKV@I6M%+UK"/3]Q
M!3"V[MU''91+?1VR0?J-6.Y00HZ06=@#&S%EL8!.!I3+1M][^QTVR\\]"U\T
MGS&Q_P"'.KZ6LL_0AB^D;CGI^#-PX>PF5>J 5 4>T/[DEGKV(2_4AHYUWPUU
M:Z-FFR6V,JY7WQ_U?N(YT^7]CU_\1EW?([7D "TY,H=3W4TMAM6SB:,9YJE*
MZ(C<S= -R[H>PA3HL*.EXXT77'-&0YSLS749HO<JYU=>B+_1W/GY[6^5+L2S
MZ%Z0C=%AX7#^>I%:0IS64,DL=.;R,3/Z[C#9%V\,3:2-E1FPZ5DMUF^C%);9
MSHU4U<::)*)JW,//:6]-7]U34<HCH>@N%I7U7'R@'<D;E@"^*:J9M&C&I!TU
MUCJXBRB;(H37W9(MR7XB/3W8:IN]&V=_O"2NNNLBG;_R-(J-TEOAXL1)5VIL
MBU34[3Y0T4<K:(JN=TD--I#C9931L@NXWT2QOMJBBJKG'U$]]M8FJ*^0/JWG
M*\_F2OR8?&_+\QF.W+5]EWHBZZJYU#)4BRAO'%.Z;C"A5\7V:3%P3BXMG*VK
MB)Z/$]=3#8!]FH;06;9DOJ[Y).Y[HKB"VY6'Q*3N7UU944!S:%2@9VAROEB<
MC,C'(%!!%#54XFNEARS<I;J-W"23IJK]=NZ11<)*)ZRFTE,[%L&L8S+K8J E
M0T_+ID=C]4EYC%I^0BF[4L^9,4W$MA;AU&BV28ULS,)[C5]]6J9#1DX^J[;K
MZXRMYZ'OI*D_EFO,)=U0[2;XRC//EIM)]"&T8L&L.F'\I=U;*?Q,4/&RQX%L
M=H&7DVD<=M]"C\.T:,<&4U78Q!LEJAKIJSPCP3\MGQY\P5SRE1%A?&)F UVF
M963,2.K^GG,IE!R1&'ITY)).]&V&-9O3!%\^VTW508MD46;=FR;HI-FB*>MA
MX=@AJ/8X+;M%"F&;7!+=AHLFPW(80TP\W9)N-U%]&FSC[3+;1=3=;5'.FJF^
MV^-ML_9YYYZ%?MVAOBIA]T1J5=;SNTXC;W3$M%!XE'X[T]V)']Y:<4?12!LU
M@M<T_9K4#%P218W$PCXPA'@490,&F.'[W0B4SNOLH[.1&(?&1,95P!.XL3CH
M_FZQI3S5/[)L8M+HIN6> I$;C9:7V'<1TL278-),ZWT)JV$;V1"[(;B3F6+$
M<LT;0F\@5C\@.MQTG9D*0^04G1!&W.9HP]KGM(Y0IZ!-HFPA5C'NI+1Q!XH0
M*A(!!0[Q&KU^:Y15^PXX0L)0X+;CMX0Z8;H6QO//13_.3_=$?(1_EIG?_H-_
M2A@O[$#?X4/_ -(C[E?/////5-/TG_XJ.X/DS1X^TXYAT?EN*C5N/>>ZG+%C
M$!RQS+]*^Q']FV9&5'8)87_ "V%<--5LMLI)Y6RGA9/&\/\ UC\:WZ092WQD
M?'SSG4QB7&RM3'K<0/5/R*XDT5LNN&IV0F3[-:UKEC%T+1JU0YE0NH\CK<3&
M &D?W<[L7.7+ILLJK\%U='?I /Q4_#[R#+Y)>Y>OI]+;^LJ"&:[G])Z6ITT#
M9O"]L2UB\L6U+0E%K 9%&B;,:R(1I@,@4>)B0[P",V.+-QSA$AZY-&/GF^;'
MX9ZVG;&Q8_?$E2Z[+X<UR%KZ)\^W8Q'0>/2\/B4E;-TL*MJY*0MIO(D6"<49
M5PTD#EX18OUC3Y(4OG-DG]&EX^[!XEX"GE1]M0\]"+:*]1V%.PX>13F.V ^4
M@1BMZ="B'R9J,R:5#V[98Y')*DF-4(I.D%&ZSE1FFF[16<6%?/0#UY\-U_0?
MY?)E\KCOOU\?<SM4]$)%0:M$991UQ0SQ@B-C-/HRO%P.MT$XCH*C1IE(](SG
M#R6!-C[@)KDD\9;2F]#\,\<];%8V<Z=YFI:^S$/'O1,5)6K (_-'<>&DG*;P
M@Q#K&V;O9@W>ND45W2;?*>JZJ2>RGULIZ_1L/#H?%J]B48@4' "XK"X6 $16
M)1@&T28!8[&P#! 6$!B&"&NJ#$8*&M6S%@S0UU1;-4$D$M=4]-=<=D\\]"%\
MYWQ!B/ESY_JJ!BI"'@=L5'<45E45GA1!7;5M7DB*#0%SQK=9LV=.ML/X;G$I
M#,M$L)$)A#(P/=.6#%X\?(2Z4Y4T'H>J*YI:M R$?K^JX7'8'#P[?3371B C
M ML)')[YTUTPJXW0;:K.W&=<*.G:BSA7.5%=]LY)\\\\\]U^6(R5S%I*WACX
M6+F"X PC%"1Q@L4"CY(H/<: WI<:V=L'! 8U)[-EW[)!\S6=-=%4$G3???57
M2O[\(7:?RI]EV-V&V[V@=)5I!^9+%?\ /C 77L!E<</R:Z@+[5W+G3<N=FI]
MFYB4<CV1:B2C<=])E:6#'+9XBD/73<V(O5N9OV9US ^N+&LIN?L<YS@*Z)Z0
MHN,*O=JQWYVDN]1<K3&6QRH0D%'1G^D$%N!"^H&>9F;1-%_R^.M@Y\4+++-2
ML8 M=V.&+ NQA<$,KFR+]E_0XFZ.&JJZT(&9H,@C+>#6/(Y.F"D@V$?J'%XV
M@.K:9-C2#N,1@QN<6 9B#O\ #3;W5Z2W]A)'Y6^H2P562QKC6IGX U7G8-JP
M9R8ZJ/!"+V%<0VGFM[74EPQKSF<1CYZ8J.A;JK108G*6CW==QF:EH:DEC'LL
ML?D\GDBE4*DD9Y\BV.:))T55W,1FSI+=*P:S@$]G=<Q^RSLAQ4J%9OP;R!1=
MC(F\<1)J6BTD)DTS<E4XPTBBK8VIK30GR)78.ZKB]53E,U-=^J:TY]N"L!TU
M<:0NMJ;AEL3KM6V#0YW+Q\5(;$K+VY_@4%C=:U5KJL=L4U W[C)$(#"S*6LM
M<>XOTBJZ>+H5S3:I;A>#RZLNOHG++,H\@SZE<-9=K7(7>)[AE+(C"U&Z,HE,
MR8N6B3) $"D4S"C-2.@A*3OR LGG65&[.U(/ N@+"Y^K+X]ND.KYQ6 "#R>T
M9!1]=<\IQ**K6<U+%HJ*>G+CN&K'QHV2'"7I-WD$,*CVNFVB*Y/+_#MJUDG;
M&B.\#;R)E$"@\MO$4C32!$=AC0VQ([!M7R$0?;#7A$,V*-G.= SK9@0?C$7>
MF^6KQTUU37WKL_'5\DG2'0/2?/\ #93T=6/0!&[H39\CZ9Y7AG.L@JJ7_'>;
MB(?)08+E<X)$G90FB/F'W:G20BRFK:0R\T2:S&'9R#1<)>LJ>QC=G_!FW/\
MEC/?X5+>TI^'7^ZI^//_ "AT5_ (;TDGO'??1/3=13?5--/7;????;&NFFFN
M,[;;[[;9QKKKKKC.=MLYQC&,9SG.,8]ANW*GY^OZ-MX=>5>U-<$3:%&AMI&[
M+C<4FP1J88;9W9%&PV1-2+1N0;9SMA)VDEHOKIONGC?ZF^^NV2A&\:&LAP(#
MN#8#AS1L-$!Q&S!JR8L62&C=FP'#V>4T&S1HV2T1;-6R.B*"">B:2>B>F-<1
MKTY\R_QTWWV5+^"ZMZ 823H^'OI(&6CN(S*V,:D4AA23]>;1R'SAZ'0B\E-1
M-(604*-AY+9)RFR>JA%RR3%]NVE$\]HWW)\</'_R/1.#0CL"KEK1C=<2$A*8
M>P1F,TAVPLX5&X$OG>7,+/@'3S"S#75'[!ZLX03SC[1-/13Z=LP:6!\,GQFT
M?\B'QM\XP7D^!YIZQJD[\/S^)RE]*)II-"L2$T40BCJ2DI2=*E2OZM.)*=_
MTG+S9$<B3=(()ZH[_4Q/+S5\>7$'',DD$QY=Y@J&CI5*@J4<D,A@$6;!RY4"
MB]2):"'+[&RJ_P"'Y?H-W:C9/?1-9PW;J*Z[[((YTW*\\]6X^63GKYC[E[ZX
M?N?AH!6']'[CDTE9+P5+;>'0TA:L^F'XA&+'$' JK%SOJ UJERYA -=QG99N
MO*I6_1QC#AMG3X2'#45^1^Q?G"Y5LBRK0J."SWLCE(K.'E3D(VTDAP9&^,:
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M\.\L_(G)/D7KTS:;F</9#.IE"JK+FA2M;5S+[)9EV,L+A<MA*$D*-LM9 =1
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M/GA./I?JQ, 45U#MJ^2>F1K1JT1%;#T['W65NV)1//EF6K5-2/;MGL0CCTH
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MVZ;O?'U4<^AMB/QWT78!%<1 _E@^16;%FS3<@Y%Q'Y"&<D(MV":J*"CU9D&
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MXWB=*QQ.+_:NV[91FBUU69WB///13_.1_=$?(1_EIG?_ *#?TH8+^Q _T?\
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B//////////////////////////////////////////?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g69956g21s76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g21s76.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1ED4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &4B^9'(X0DE-! 0      $4< 5H  QLE1QP!6@ #&R5'' (   ('_QP"
M4  -36%R>2!-;WEN:6AA;AP"!0 74&]W97)0;VEN="!0<F5S96YT871I;VX
M.$))300E       0DKS#FPU]:; _CV1K]3BT[SA"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^
M-0 "  $#O_XU  (  3A"24T$)@      #@             _@   .$))30/R
M       *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M      $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE-
M _@      '   /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z   .$))300(       :
M 0   D    )      @  )[L   !38 $X0DE-!!X       0     .$))300:
M      ,U    !@             #60  !V4          0
M           !              =E   #60                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   #60    !29VAT;&]N9P  !V4    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   UD     4F=H=&QO;F<   =E     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    +.$))300,      Z_     0
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MV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                        _^%
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MH.C>C?9<#:1LQP]MHQ1A&';XBPC'YHQ]B#']%NN5J/CFKQ-AM%K@*5$UVX6
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M.'F12I\B=!%+FRID):*&."( @B^A!!!((*DNMRT)HB:(FB+ 3Q3?_=X;O/\
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M?'MOKC:-2<U,:A8@-795E-*-9)Q.$4C(9G*NDU$RG[O:]O+FINFMJ<=;>?\
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M)&%AE"-LI1<F%\C&_%9P[9?$5@\IV>(QEF*LL<9WZ?=%CJE/Q4FM)X[N\F<
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MPUM(NV-VNP5"5L=7?'VFX4NV,[J,>:5$MBEK/1Z15VC^L?$1R(GCT'E7=N'
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M$@F,4 ,<!$P!WUX^+Q$.$PN)Q4=8<-AYT^(6>&3+BF$=1"R\K X6+'8W!X*
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MAE3/@K+NFV:Z5A B9XQST@41$QFZB8B/3SSP)0$>WN ]_P!?>$1.":YZ"C]
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M 4H' H@!NDO5SP&B(9%(ZB:QDDS*I <$E3$**B0*  * F<0$Q 4 I0.!1 #
M4 -SP&B+_/)1\[XCR4OB 3\D%_+)YP(B;K%+S>.OR^O\?E]73U?BXY[Z(OKH
MB^:2*+=,$D$DT4BB82II$*FF43F,<X@0@%* G.8QS" ?B,8QAY$1'1$!%(%3
M+@DF"YDRI&6 A05,D0QC$3,IQUBF0QSF*01$I3',(  F$1(OIHB:(OF**)E2
M+F23%=,ATR+"F452)J"4RB9%!#K*0YB$$Y ,!3"0HF 1*'!%]-$7S51273.B
MNDFLBH42J)*D*HF<H^I3D.!BF*/N!@$-$7TT1-$7R2110 Q4$4D2G4.J<$DR
M)@=50W4HJ8"  &44-^(YQY,8W<PB.B+_ $4416*X%)(5R)F2*N*916*D<Q3'
M3*IQU@F8Q"F,0# 4QBE$0$0 0(OIHB:(FB)HB:(FB)HBT->)U3%*_N*H5Z0;
MB2/R7BAQ!.UR%$$1G\7651<IE3 7H^,D(/(S5(@B85%FE>  #H:=OCO]5&Q*
M>&_$,$!H9^RI\8%#O"+$RC&6N-V*&%SFP"^U/TF[=>5XF\.3(WW8\/M61 34
M"(##3A"'L\,,43"A+DU6OS7QVOLQ-$78U^XAC6Z8]R@(F*GC/(5-N[Y0@\*$
M@(:<:?I>1,1*;@SNFKV!B;\(\INCE[<\AV+\)]MG8'Q \-8XQ;LJ/'P8/$58
M12<8#(,)X;\<$0M6$%Z+KOXL;"_\B^'WB?9L,._..S9N*P[!R)^$'SX(@,R!
M!$,KKE7"W'R'D/*>0U3=9[OE+(,ZD?DPF^5%M,E$UI YC"(F%A5HR$C0'L'0
MS+TE . UM^+^U9FV/B+XGQ,9.[*QW]')A-=R3A)<$J&$<#$(HAIO,M/P@V1+
MV+\./"V#@ WH]G08J<0&WI^*BBG3(N?[@#JSU=UTFNM5V4H):Q-'SU&G2E#H
M3FW-;D%> _BXZSL5$D"B/'( K9(^N)!P(<F.&N;V6T_ [:P1)>+!0;0D0O\
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M>%]:':9P %$E[1(.I\4#\<AU-22)&@ '8I$"D* %* !R_B"*#^[8J3+B$4K
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MES=I1R]F2"X$1CQL7R8XH'(>*5(BG3Z%Q#*B(LITDDFBDFBD4")))D23(4
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MK"[9+Z>'QR^%QPW]3_Y7@0-W>^21-&(?_C\K<WM[@/-4ED99]';:,1;QK:O
M)[6LK6Z/K510A9PDOD.TV=Q)RK.$;3U429IM6\&$G6IX7L'$SDO/%7A1)88]
MBQ*]CU>Q</\ IV\<;,V-'C\+%LJ?X@GPQRX<,<68/[?AXX")D6%FQ2_E3<=-
M@)E038HH!AX8HS+A^=\N=!US/_4CX VCMH;.Q1VK(V#),$PXP8+?E[0GPQ@R
MX,1*$?SY6#EQ 3(X/EGY\0@$<1E;\J/+"O[>=S%KD$HJ"VY9<(\6X 5[1 LZ
M)#-0$2E%5Y.7.2A& H)]0&5^6GDW9DP.9JS='+Y8^F[/_3[\2L;BH9$W94C
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M=MBD*/283*%#G@1 .X?00'CGT_;K-:O*OIW_ "J>R1NGO!B2#8DL\*DJF<@
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MISJR:B@N$WK?+Q$RE\E)45)IZMYFP:O$"_&MU^HZ!JO0'T%U[N-51-$31%H
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M,._?G\M&;C;2F5+-Q]$6F'<9.5R<>N_@UT .FJH4HEZ.1 >0*'J4![\!SP'
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M)+$$.!*JFN4JQ%"\'*J4%"B!P =$62F7?Y^<E_\ RV@_X>4T19';1_YHE_\
M:1EG_P Q;'HBR<T1-$6-&[3^: ?]H.*?_,>LZ*BT7+ZA:^Z=_P"QTQ_]1Y-_
MQU:M%%M6P_\ S2XN_P!G5)_PU&:(K%T1-$6 .X[^>N/_ -EL3_BRS:(JB:=\
M+YQ*/<IMR^%@,7V,!8C QR@8/00 Y"G !]#%*/J #J'ZCU(133$(B&=L:B \
M"9E>R&$.PB0:X)Q((AZE$Z:9Q*/83)D-QR4HA46R?1$T1-$31$T1-$31$T1:
M9O'HR,XH7AVWJ):K@@OD^_XWQX)^KI4,U/.C=9!)/N C\0PI;ELL4.>INLJ4
M0X$1#&+_ !*SEMO G*O?FO!G,,SN$TSE ?+$.H>W^J( '?CV'_C[=].=.C_5
M;WHQZ\@S<"#2KAZ:!^''"9OP5$1)P'''H/<??W[?7[<\:N74>KO[#LJ#/@+<
M'%]6OT&09=H[6<_#B=(#*"4.1["(^GJ/'/YB/';2CZ#+\_5GY*V8\"<M6-#J
M.!]%7ZCQZX= 59,Q"\B !TB'Y=Q .?7D/^0THUZA_<6\W\U*@O\ CV;7)7-2
M#*(*-R 7@>P@80Y#N8!Y[^G?]?;UT!;R_CU97@:@-Y.--7K8VJ]%RKV_#K.)
MB";RR& 1_L[!S[<?7^_0Y#KY@?1O504K=G%0X<%B.A-['JL.K*^,+T?+#I'S
M!/U>_P"$>>._/KU=_P!?UYUM H!9M-<]10OUY5UQEF'7U\WIWEE?M<54F;&T
M9',!A$Z8& Q@X[F .WI_K>OTYXXUB1^\.+N>%GIUKUMK7_:_#\/W7*Z]6.VO
M:1&WJJ,EE6I555T"'-R'5_* O'OV#@!XX >_VXUL-/PM1-3]+<N6BZ;<EM<;
M8RA57+9D)"D QQX3, ?A]0Y'L(=AX^_(^FBBU,62[FKQG"8E,B*)A+ZB "4!
M'L  !>X#V >1^_N 1V<DT]NZ+(!RW!R>FG-L^8R788[R(-H=IQ8%,Y%P?HX,
M B/)AX . Y]>?K]0X'0$&V1[]\_=(H6Y=WX^FBS+A-HD[=3LY5**5*V.4%!_
MB3AU (<]^ #D./J(@ <]A]JL>_;[9KJ;Y@5WBU)1^X8"1)(HF'^+.' ASR(\
MA[B'U'OSVX'N3OOT6$60\I'C3J$.Z*V0((DZ!,'L42\?B'L  7L/'/OV] A+
M#GE3U^I6R&$DG)GKJ1HXHS7N^>0Q9D,IQ4F]52!VBMSZI@8.X\>P (CR/;D/
M40[=N_&LQ/F!PK?R.?&HI2JS  H%T#IXU>)JJHF*0.D>DH#SZASQV'Z?E[>@
M:@!!>XS(J!<9<*\*+(MND&X=@<WKQ ?U>M J3GS.$E#N"*FX 3")0'Z#VX^H
M_P#'ZZQ58L*N]@^G/.N7%=O5Y]R<GE@L<@\=/J'N' #W]^./;C5?B?II[<+4
MS6-.7\9FC^U20 N/*.!<.#H**]2B@\"81[AS^$>_Y]^X??45?*C$\M/2V5P^
MJZ%XT2B2@*R@&Z^_///\KT]S!R']_MV#5X>>O?>05S-CE2Y?.M7SS(+!AELG
M\&N^GH/B0[:91JZ%)I9K)/T"42 X%*\:WFG6"NLT%>>QP)./8IXF0?5=JD)/
MQ@75AN+WT%F-;W_-5A$'A/)_+OZK^B'K<M":(FB)HB:(FB)HB:(FB)HB:(FB
M+'J*W-XM=7'-%0L,RTH(X3OU1QQ.6"]3%>KM>G['=,;U[)\2A6W[N7 7/$%8
M4VZK=\DP>F>QTD+=JNR0([4/]N_-5BP-W>W!3)+.6%5\>*9<1R]C%7%20J K
MDM.^58]"3,BY^"5(I;RRHP!#IO/]$.0T@!RNO]',4%OP:*,=%R9G,^'Z[16.
M4)_*N.(3&LH1HI&9"E[O6HZDR)) 3%8G86IW)HP;PKT2'!H+=\I\0)#@EUB4
MW!&)L'56R.\/;Q'9KK6WT,EU1[D^X8]D\DUN&966LJ-Y2%8!$+LV"#U6:1)\
M]L47+DL%9CA)Q,UN.F9YLO\ +8MTX*58L[,'9^ZJ7X_W 8UO6-D<E+6FI5E@
MPH5;R)>&$C?:',!C> L]<"TL'=PL-5LD[4VD:>%*XD&\^UG75?DH]LM)1LFZ
M8%%QHC'Z#BI8.6L5END7C@V2J"7(4Y$EGH6B&N%?+<9:#,D9<LQ&UD9 )I]&
M&0(=<KYLR5;&1345!04R',!1CHJGS5N-=8HR'C#%5;P]D',5ZRK!Y!LD)#T>
M7QK!)Q\-C8]23L#J5D\F7JBQ9#'/<HHK)NS>.W*_0Z$4B%2 3N_+^50'<NP#
M>JEA,[5"M5.J6'.3F$VX3%ODG4-&4W+^0<8QTPI*I/EVK2.:2D!<YZJS+V2;
M$;239I!3\FX2;/FZ+Q)L]*NU2>G-&TKR=?/<#G!A@*A,+NZJ%FOSB:OF.<;U
M^J4]Q6FLU-6G*-SAJ+5VR#VW3U:KC-LI-SK'XQ[)S3)LU:BHN=3I((:A+=ZH
M _>BZ#$^Y.%R+:KMCFV42\82RGC^#B;;8<?Y0-3_ (U>C3BT@TC+Y7+'2+9<
MJ;9*DI(Q,K$/I"-L)W4++1Z[*<81QE6)G8'IWP="&S!?13N%SMA&R522OE>S
M#BZ>I$-+-X&8N,-?JK*5>*G'<@TBFD/)3[*57BF,HZDY!A'MV#ITDZ7>/6C9
M)(RKE$AZHQT71M=SFVYZTA9!GN!PF[862R.*=7GK;*='7:SMM:"B#JL0[A*=
M,E)6!L+EL"\.S.M()?$MNMN7XA'K*L:T-+\.:F,QEC%M=ND%C>?R30H/(=I1
M^(K-$E[?7XVXV%#K43\Z$K3R01F95,3I*D*=BR7*8R2I2B(IG I1C=J:J"M=
MQ^+6C>Y/;U;:=C%A4<AV_'A9"ZY%QRT9S;RE0[*=FI!HX86M^G%@VC'2SU[
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MZ?7[\".L:E@.ZW/IZ55SKY<6;+2[<WJ[V;B',$6P,W(LX*U535*(@8P /("
M\\CQSZ<#Z?0..>-90G=-0SM6N7>2QBA?H=?>STY='6?YMV;F/@$V;.4 Y"HB
M0?XX.P"3T >1$?4 #M]/<=9[T.O??=0M>X>S_/3U"P0R]E(+,F^6.[.=9<#B
M(\^9SU&-R ^H!V[>OL \^VL(HG'9-<N5'IFQH5LAA8-I]_18+2$>Y%P=V"9C
M@<XG >D1Y'GN(=NX\\#]?4 #G5!#"[ 5<!N/&Y!S/!52RL+/_-(8R9RIAQSV
M$!'@0[ /'KZ=NX<_J$<"UQGVYLW+GDST>??;<<E.'@@HH)E.  >./OP =^?S
MY]./;45.0%:58/=J9VX:V%5UB$B@P,*YB=0E[!V#\(]A]N>_;T_5]M4OF3U*
M@Z=<JKE)91?MENEN EX[$XX[#[#W#U'UY^_TTK]:-]+:MUR1_P",N=>\K*SH
MR4>SK,L@Z$RAPZ?P]0\ ';\N>X^O/M] U19@*DV<MPYYW-&YNKT'U^OK30*6
M2;F.^2@50A2.#% "\#R8?4.P<>O]_?CC4 \GKRX<\G'$6+-?Q:_?&F;*^_#T
MJXW/?'M4KY4_.36SEC^3<$ .>6-=GVEC?#T\#R!640X,//  4##R'3JP_P"0
M''+UKIV%B;'D5[VMI[&AP>$*Y4\;W^9R96:3-7BG%M=A1<HS2TO 7:P,YV(D
M".V;%<RE=EP>0**ID.E9K'(*IK.$SE74W>JTQ%R25D=HHFB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M0.[3
M"5<MV^[#NX6)E+%1\M;></NH^OV>#6CC%L4;DJ4ND82.EHN5CI"/DH:NM&UI
M231<HK).7=O>]23=>,9N3$751-HDW;_)D_>7S5Q;4K&YF;;(-6/RMB]9-Z[$
MM8&68LCN78H,E*I#QC54H.54D)6/E6B1Q*UYT1;,-OE9=5+"^.XB13\J66KZ
M4_.I\& 26"V.'%JL!! WXOP3,R^+^+@>WH'H!%<>B)HBUC9'MP9)RK8[.@H"
MU=J0/,=THQ%040<I1KXI[M8$@#\)#3-I:!")F*91-Q%TZ*D&YP3D3E$BJMM0
M92/9PVX=4#&K=^L4C1VS8B @6.KZY8>-J%Q<J\ 4J5LLE:>QQ7( 8'T9.X]*
M!B@V.4"*^\"6\*-E@8-TJ"-;RVD1F #R"37(T P45BG1AYZ$S6>K,W4.Y7.(
M>8[K598I 95V "1;$M$31%AYNYB11:XPNJ20",-<'-3E''3W0@[S%+HI@)@*
M80!:X0M.;@ B4HF6[CU=("18?05KO,/DBP*X]M1ZJ@A6(6%N,BWB8F8=/) C
MY]-5^)9)SK21BF;F+CY1[(R2R\:[7,SL<8FV% 5U5BD5A^%QMTK6WNC;D$XJ
M:G;;8LD;H;QD&XW&R$:C)S<I8*Q2Y8C<CEJ1--RSBE9)ZF<PID,E-.)M/IX
M#"5TY5\RMH.BB:(FB)HB:(FB+'^=DKKDB[5")I)L2VK;LZC\A16:9:0>DN,G
M.RK %JJEC2(@V2A(5H4LHM(+6J3EGDL5$L*^K;N!;N'!5EWMGWW]K9]:-[OY
M>ZO*+BXV$C8^&AF#.*B(EDUC8N,CFR+-A'1[)$C9FR9-&Y$T&K1JW330;MT4
MR)(I$*FF4I2@ %%KS\6C&@92\/K<=$ILC/7]9J;/(\:5,#"J@KCN<C+;(+I%
M+_*,,%%RR!BB4W4DNH %$PE$)$'! [_FRRA+1#R[ZK^>4[!XJ[*1J)@ WX1
M.0_#R'J( //T[!_Z:T=_FZWLS/U&;>VH.A"YQT'Z E(H8W/ <E, ]OJ'(^WW
M$?33T5?E1]#RJU?5^ 7[007$0,("/'J8.1X[_;V_]??GN5!# $.6(#7KT;WY
M5*[M\#P(XJXB/20@]^1#@0 0#M[>W;GCZZI=A<@/T&7;G3)8]Y#*MVS-0S-P
M#JE']QD%'IVIQ/Y9#"7@1'CI#MZ<^_U_5P.@#M>O"U6ZUY-Q1_OUI7F6JOG\
M\1('4(F\P>!X$0]>_P!^!]/[N=&(IF>([-O-DX^;UKY?=2FMS2;IR3GTY*41
M'N'K[<!V[=N?<>_'OI;0ZY\.E]:D/4,J^@+Z]Y\<[L]5?+=DR<,NI8J8=91\
ML1#OR(>W ]N_ <Z&[]:>;4:RA>E*UJ<R^;TI_*@[IFO'+G5;B7D!'CH'VY[>
MG(#^?ZOIRM4<?+K?,&C&P=4-F-1>U37,'G7*Q9^22:E_AA.**IC>G( /YAZ
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M!$CE#.!3.GQR<>#<" ]S?V?L]N?;O$9K_;W^RO.LNRL8E0AQ_&0H 4O/\KT
M [\\\\#SZ@'/WU<JV!ZU_CH^:.W4!O-B<\G\VL5 ;K879#I"@8Y0Y#J*7G@H
M!SV#OV#\@X'V[Z!B3I[5[NPX@LG9]_*V@/1UNB\ "B&R=OXJEC<-CKM<0X\O
M^1')CE$44W+F.0Q]&=9N./-(]O23MN41 PG:&4#LD(:R@'[C7+FX[;0\+K",
M_M]/5U[2,!2KB2B,CM5</)89;P6:<G0D?%-V!H]M=F2$\+S]]-!,86$(O^^
MZ?.II=XDB_(Z=G<+#+2)S'7'8*OS6HY5>@Z<.BO?5431$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$6'>[FLMV
M4% 9@2,V;+4-V2'M2ZQRH_%4.TOF3!V)CF$"&5@+",)/(F4Y.E'(SS=M_'2
MD4(L'+K6SR4]6%4U4&T3;I>N8UOCAPOY#="G6:R,6BDNH<2G(96'%](-$0/T
M)%;V!^LLLDFEUE=]_P (MTQ2E*4I2@!2E "E*   %* <   '8   X  [ &B+
M_=$5%;B,A.\?XX>_(G0-KE<'25,I2G0"IVLW,(.3KS0)" E43J\(UEK.L10
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MMMI5JV39BD*@/R');-Q9(W@QA*RO-;8M6LPD4G<"$LE4;LG8 0"HI.:D]7.
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M@NNT?,]M&8WC)VU54;NFCMI1YARV=M7")B+-W+9=(BZ"Z)R*HJID53.4Y"F
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MN5/=%$T1-$31%A9X@FU"-WF;5\D87.FS2MJS$MIQC+/1$B<)DBN)KNJTY.N
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M^O8>WU_7K'OONZKGG>X:ATKG6@LQ;-6Y4Y,QVZ)3G,)> #I$1[?VC[<=^_\
M?J\:G(Y4H '&JC9-73,</O<CS5BA7V<HZ3 PE*)P PAP AZ /K^7;MZ\_;5
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M AAX* "/ <^O =_;]7KR';9NCW;0.7IW]%K,9JW1=+8K:P9-!:D-^/@2"7D
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M23[;+E"7#N02Q!"+0P@LW%W).I)*NPH<%* ^H% /[->(:D\RO*7ZU$7T((
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M:J4:D\6(DH8 1\IZ\T>KBG*BR,*4I"E(0I2$*4"E*4 *4I2AP4I2AP %
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MUM.QG9KS;*V:5R%C1WBB?"1=-0JSVUURY+&8(D0,VE F*LNXC (\.HLF#05
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#7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g69956g27e95.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g27e95.jpg
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M 0$! 0$! 0'_P  1" #" EX# 1$  A$! Q$!_\0 '@ !  ,! 0$! 0$!
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ME)H% PUCYZ@5R<YB*@TZH*8<F8:DPT+JS*F">@I8DJ<F18A2'7([-06A<U<
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ML\=/-I(\CW.XJ+2P9$U+2V<<5$]8*@BU<XNK[/75[F1V@(MV+B4=MS7QQ@0
M-=9V2(&U)=QFBLT+]&O]N&<=P,3SEPXL1]E"XK\V%(6]'>3(C1Y28CAR&F5J
M<@2%J<:>9C2"-3L=9N$HEMN-HZ;I/Z!,0=%U!9K-5JT&8\S5*?0ZU3FH=0AN
M4^J5*DNU=@J?(FL-,5ZG,(CR8,VI0#2S&J+26#0MJ1'D.\Q?V?N_OR]SU9,X
M)#TG>R.YU\4E-1N08:02_9:F6F[+&^V+_65S8K[;ZL9$U"S5SP]TY738FK5$
MT:MZ]PQJK7_^M#I"IL"H0>I/D5"'#A+05!@=1'Q(N345.7<J=1<ZWE82DF7D
M?*/LH0RVEQ?UU+"6 "Z%$XO11*_AZN&]0*?AVLUFM,.*Q_7O+/%CIJF8=:CF
MEC"^'&3:*'6VG4J\\)BGS7GILAZ/'W/SWX_/@< ' !P < ' !P < ' !P <
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MG++5K9U,8LH:\F<,?>,>>6/:YZ[=HEB\-GH'<X%#@ X . #@ X . #@ X .
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MM71AR'B-F)(9./-0^BHE\:,R%/R'9;<UY3VG^>K&I0X . #@ X . #@ X .
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M8Q9=Q5KV+=?Q/ED,D7M<]]B+N(LO:-'<Q&8< ' !P < ' !P < ' !P < '
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MO,&9Y%Y9M*F[GD76S'E+H!;;51'U%JT-X@&06_M.:WV6,(;M< H8&GK.Q,E
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M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
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MW_4*7S5O0/\ >0]].S_X: /U5\/GY\HGZ"4#ZQKH]?N;I'XF#@ X . #@ X
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MIS_,??Z4'7FE/@W_ #+X+_VX@^U-<&\?A,_/=C;OPY]DJ"-K\W@-$!P < '
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M@[0. #@!%;OSU7/R;;_UBF<NX^\O4H3>7<?K2)5R"AP < ' !P < ' !P <
M(VM?WDQ^4AS^6Y\I[?0GU$(6STJ]9B2<@H< /XECCFCDAEPQDBEPSCECSZZR
MPSCDQ[QSPRQ[_>[QRQ[[QRZ[_>[Z[[Z[X ?C3IU!U2J/'U:]&A1KP4Z5*G!'
M6J4ZE:/&&O5JUX<<(:]>O#AA%##%AA'%'ACAACCCCUUT ?3P XS'\WCW^ABG
M\AGYQ/\ ^ ]^:<_<4.:/]T,?GFOWTC(/P=?X&^G/\Q]_I0=>:4^#?\R^"_\
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MQ35?RHJOZE0/Y.'[E>T/\IK:'Z&:'_X2\?&E+_)JF?KM=_FH?%-5_*BJ_J5
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M1#68*8X+5;6JL)I5XXZPZNS,$-.*&,R1QL@N>HL4&O@5@=B'6@@A>$X6R9#
M6#&TA(["^;)W#9F[C2H0UZV-LN9($"Y.SU%U-?)WKE^UG+:LS2Y@'7X . #@
M X 4;O\ ^9HS\IJ?ZJ,\S1M/N]I#!>PN_P!ABD? O^*MP_.87_FXK<+VEW>T
MQ&]_H]HTZ_-6K-7KMERV4<2$96KW1@^TR-ML,"#Q$3A&L)$4I2)+*O6ZN%2M
MRJ.H5^Y?CKEZS!6@PDFEPPRP&=B/<7@.0M;'T<YC<C">ZZP:Q.*Y,WY$UHZL
MG:'2M6*& EE@]K%V+4'NBL:7CP>Q?ZD]G@*A2H^63"V/MPQ ZI?@EX#XM8[8
MT#NK Y+J%[UALR)9M14F*1',KK-@#NSV"5.*H5S$RVL:-K*V'+5?9['<<N-@
M;>@RPZEK38X ZI%M21;]F[42]0,:XV"NCF]$(ICFJ%_:_=3*K6 QX$2]@O61
ME[V$L,RM4;7L9*E<H6OB)\_B+E6Q6E]6:&3#$'5+0O A)?<H;\4C/J%7^JX"
MQ:%X$'N4-^*1GU"K_5<!8M"\"#W*&_%(SZA5_JN L6A>!![E#?BD9]0J_P!5
MP%BT+P(5$Y[E\<]<B%9@?=EZ@3@#O0F*IQUD9U(.&:!5>E2)6"P$I>MPT2HJ
M <2'D)B5.Q-1BI7JEN2?&O8BDS!U2_!+P%IT::R4HTR8RJ"(C2-6O>'D*, ^
MW1O4;<.%BI<IVZ^,D%JK:@DCGKV(),X9H<\)(\\L,L<NP6+0O A^0N)3-T*Y
M0/ !*#;?4G=:]0@H6JECJ*7."3N&>'#..3J.:*2+/O'+OU9,,\>_1WCWUT"Q
M:%X$/P#R);#!;L@ODV9KCRQ<#>G&8#;T5,V (6!)P19DKXR8PD1!2I:'$J<G
M>-BE=KS5K$<<T6>'0+%H7@0_ABL(R@"+M#7,JK*T H62IUA/YB0X0,,I1936
MR)0H0[KT:%&K#CE+8M6IXH(8\>\Y,\<>N^^ ZI:%X$(R"?-+M$2C.MMNMC\3
M]DP8I&88RMDOE;FI9SQ->"[U4GFR+R*\]6S68XZ/4^8*W!+4*8U+.&470.J7
MX)> E,V:77.#EB?Y-0L9<2:/"@4N W N2"+EP"/8"]$?ECU:M#0M]I6J96[#
M%G7H6CX>"S)'(1J8R@ZI:%X$.M[E#?BD9]0J_P!5P%BT+P(5Z[4:5-AU%W4I
MU:O<FRYNI.ZU>*#O/K'66RO5ZS[BPQ];K'T]^CT^GT>GOT?P]\I;%=WM(2Q$
M96(BS]ABU>09!P < ' !P \NO)1YV>$\@MAC4=QW31<AFIO&\EX_(*@O,1S6
MSSL YM'=(_8(ETKUU,VJY "(46C#=B'S9,190$N?Y643*Q9@@.1AD5K%LVG?
MLR+/UY;]!7C]Y(^2)3PG,0:47=JNOD$M*[_-M)@"K:T,=M<^X*+V6 S#UW:A
M%&J.)9K+KP50AA2:[.7$@2)9C&#KAVFMCC00B*Y7,MI;;^_J'L!4FDLU:UB:
MI8H33UX9I:-O*KG:I22QXYYU+.=&S=I9V*V67<,V5.Y;JY289=U[,\/>$N80
M?1P < ' !P BMWYZKGY-M_ZQ3.7<?>7J4)O+N/UI$JY!1@#</@8+W'M)DV2:
MVZZUZY@M*P"4FQ4K'5$ 8GU**U1+W6 EKLH+"MU #HLT!40&!;"K'+YO.#8&
M&-=%R0PI':UBL9;]<[Y^WL(BUOG.#PV\>'^T<4ZGFH08RRW)547FDL;4!V&^
MOLR^>/U4P9L">HW$BAR8&S]]#TNAL^NS;M]J5*JOWN @(^40(L%N>65M.'(L
M^T]18QKX.U##U:Q@_O0^!']+[P!;[M^D K"6XSM,QN;/'!N^4UXF-<P,+'O\
MUF"";2QV&TPG1X&^#>1K(??B;T$OG<O1V6_]=W80XBEI[Q(3#UV1A\Q$IH<-
M0D:MO8GRLVRCE"ZK;$%_*=6@&N,[4UL+B!&A&+S!/JH>%Y82IX=:7$T&2/EC
MEHI:)@._<1^&[T;BOV@D>"WCUJ',(S6O(>S.GHXA=VXO]-C8O2B@ZR!V_I;>
MK4\3%#)>P%'(IMSTZL3^]UH<JAQHPU:Q/$VBR,2KRR#/9W%PM;P]NIWM36_C
MAI7]R9K1DO?(]I2?(7Y(D$,Z%+(QGNPV:J$T8.C*5>I27@;P.J5T)>O&5C.B
M5'11KK! 3SG%%+=,>#W._M%ZZ,\;1NEF[8[]VW%6QMVQ1#XN=BT-'!@^1<;L
MC=FRY[X ,/\ C.@]&P2W:7%0#9;A&>,:!%6R94RPW3ILH SO[]Q>HB&E^!!F
MPEKO8A%^RV'KM\2U6[3'MR82'.FM3C]5O5;K31.0W:,H/:>MI1L]>6CE!+'/
MT5CLQS8Y8>S91=_&]W#J%/;@.P*A!FRD+ELS&W(=28@*0I$=;"D+)^EU$G$J
M)9*(TFT:329'UB/+HIM.J+E19J-.GPHBT0WH3C<VF/U!*TN26WTK0IBJTTVE
M)-OJF2O*DHE7+JF6?<^3WDY_C>T1_LY[ _YI>7SC#7XIKG[0P/Z8$\WQ/^.*
M#^SE0_JH/D]Y.?XWM$?[.>P/^:7CSC#7XIKG[0P/Z8#S?$_XXH/[.5#^J@^3
MWDY_C>T1_LY[ _YI>/.,-?BFN?M# _I@/-\3_CB@_LY4/ZJ#Y/>3G^-[1'^S
MGL#_ )I>/.,-?BFN?M# _I@/-\3_ (XH/[.5#^J@^3WDY_C>T1_LY[ _YI>/
M.,-?BFN?M# _I@/-\3_CB@_LY4/ZJ$$V5J_?;PHV@;7MW4.:]7+JK04KKVA'
M,09NP(K8$=\!M J2\C6&B,E)S+T0_*_8!EL*D5F2QU0LYQXQY<B*G0H*);\6
MDU8I"J=4XK2I%=AO,H5.ITJ";CC3>'HZW2:3(-SR:7VC6:23Y1)&9E@JEU^<
MY#8EUBCG'34J5*=3'H$UEY:8%2B3B:;=<Q)(0T;IQB;\HIATD$HU>369$1QK
MX.O\#?3G^8^_TH.O/S?\&_YE\%_[<0?:FN#],?"9^>[&W?AS[)4$;7YO :(&
M<=[^)'CSY,60=S=FNH'*T $'5NM8A8W!5F))[3,+LM*$UR)C"O9.VN6>P$$3
MLFN7+L\CGIAM.0LOW,X(^^@I&9;#M[^OMVB(3>!7B3.W'WB;3HV5@8F4:X6O
M79GCL&)9QVTD+=LQM.4NV?Y)H%]CVUJ_7S^^2HP1=ZV,QJ0>\_8LG=?O','6
M/9?L]%K6[<C,BOL(SM:X^:3X/_Q"D80C1WINA@5 WKI.O'"V/]<(4*6G][VK
M3)MBQ UQK3P25]C[.?W5 (.8@]<UNPM14B@3+4\L>48+G:U_>ULM+ED=MN^X
M[M#PG\8Q;7KYU':RZI']7:O4M,I.=9Q?XA(W7""H[+0T@"06L6KI:9;*FG[C
MVD!7F)G$&6<32>F+JD9AEO92] N>97VG?TG:_J+P$^T=X[Z@\<03&NZ@5[:[
M1<&F1U;+A=L<WMB9FG,  5<#!YNV"PM+67L55E67%X?A?-3UQ@4(-&#H:M.K
M%#B S,]O=W%H6@NO@0. &4DS6FX@6; QZ_V=K0.%V583'.P%<=--+@4$DQVH
M];ZZGKPG@F\T.I:HV:R%3)Q1YKT-BK/?LU\[-J..*3GH3J5(?B4Z//IM2>>I
MT5Z&EZ'6(L1IUMRHSZ@E2F'J).6E:53EM&92#2I+:5$E)F9#SA4RLL3*E)I]
M4IC+%3E,S5,3:-*F.M.MTVGTY24R&*[ 0MM2("'2(XZ5)4XI)J61$8FWR>\G
M/\;VB/\ 9SV!_P TO.+SC#7XIKG[0P/Z8'+YOB?\<4']G*A_50?)[R<_QO:(
M_P!G/8'_ #2\><8:_%-<_:&!_3 >;XG_ !Q0?V<J']5!\GO)S_&]HC_9SV!_
MS2\><8:_%-<_:&!_3 >;XG_'%!_9RH?U4'R>\G/\;VB/]G/8'_-+QYQAK\4U
MS]H8'],!YOB?\<4']G*A_50?)[R<_P ;VB/]G/8'_-+QYQAK\4US]H8'],!Y
MOB?\<4']G*A_50IS=^M=NF$9D:MA[+UP;%:\0-PGZ(5,T^SI9 @2,Z>>DW#J
MV<.;NV!6CHU:C);N95X0/5BQ8@KX=7*\74O4G5XBJ5)9PGBN+3Z;467:A0I<
M=;TRKQIC;;;/5FGU&&*+ 4:U+C(1UC?ZJ4J4?44=K>LZ.Z95WNDSHWEU&ITU
M]JG8UH,AMF%1Y4)QQU^:U"+KOOUNH))M")*U]5+'64I*2ZZ2O?+?P)/X&Q/\
M]#O^H4OFCN@?[R'OIV?_  T ?LOX?/SY1/T$H'UC71Z1;3WGK73& GM^*G*U
M@W3/%!XU717W8AK((JQ#YFAEM@M=++49&*BUB7#QL#63H5%P+8-!:A(I5M%Q
ML-K=(_$Y$9^_OGV;1(RNS$$+3I7[[6'ZJD2Z,"J9T[/O/.0GLPT/74.+* 9C
M<G@@:#!6A5%WIXHJ$F,_M4EJ.G%-8C"#N=-"UE!5M8L0+*K>(S"*5GHN/[@N
M%JV=B.P+JS=6/B[!&O)4MX34HLL[,6=6QC)%CW#)UB <=5V.@NX "T*3BNGP
M#0IT'L 3'E:<L!1-)P1V*+-6Q[EQF]S3Q2Q]^W21X01Y]]PRY1S8YQX@V;1"
MR7D-J$8EU]@=--DTLWG8WK@1(H*S@\&V)W7#Y]:.+JJI)J^=;6R\.**K)G/V
MM@RE?W."*L<<V:[2L%, MC]\O6.[KK<6M]LQW)-?LL9_L:,72Y*'L8:$VQM1
MIKW;(:,C2-C1MR@1DQ'$(" :W!"7!WZ5H8<HCB->6KB$'%->0.I@I_8JEBR7
MF5QU*)13>QDK7BDZ;1=E,=LNX8II$A).UNO-3-E8.= 2I#&A5%6"% #6P9"M
M6BOVJ9.P%L>7;LW;!#53S"\='3%<G!["SP&M8+Y1!6 ^G/J@J2T?D40V7U3O
MMS:K@U@*Q=ZT%$-DXJ)LL.:\M>5LGG$-VJY1ELP6,K]FW,O?^^0[RYY,Z8<[
MNO*26RF73]U-9H.B<034#8K6!F4"UN[0#M#$RKZF17D8 9N#2, 8L\DURB6S
M'WO=T]G&G8[C"6V]@L)%V4B;,@9K2$S#6FJG.;#KQEM"\II:PMT5)HJS(OR6
M,XHX;%P-:FPJ7LJF=BO#<QFJ=S]V*]B*( G' "C=_P#S-&?E-3_51GF:-I]W
MM(8+V%W^PQ2/@7_%6X?G,+_S<5N%[2[O:8C>_P!'M%S>1>O738R, H:_^3&;
M6J[4U'LH=2<2I4$O%<-;;#7G*X(NF0@!H)"\B=,//3K78 !3J"S+%E+5RB]?
M+' <A9<>)6&<=1>.N]]2;M8]O1]ZB9^]RYRS;7$XM+BJU4*2]LEC:)L=:U,$
M%EP=>J2R=K06Y6&V@9-;I2+LEB-=KL^0X&%,[^!%[^^6P6\.TAL%=T3NS6:F
M[CUYWV<\^1+,LO-*.YCDCQ;RV8Z-PTS5BSKR9V&5)$MV-FE%E%V.N,8JO'++
MB.FSGQ!?/PX%;B,@1?!Z[-1C.NPFK]L4;FM-9[3PV$BP.T*Z/+I-0[;U(2<
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MF>>$>.6<F>,>&/7IRSSRZPQQZ_@].667?7777I_]_??(*/E]XC_\.I_68/\
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M/5H:]CKO#+'K&22@OT[>/6&66,G7<-F+OO+#'K+O+#O+')?L+CS"W:?#D/\
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MN?<KR..6HSF6=:.6@@[ 4D>&2K\7)7'*5!?KQXK@!<AKAC?W]_?;J8N;?/\
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M;*NM1%;!O,91I36<QH[&\4GPMEK5"G6NFLJ :(O9NP @L5  E'HZ_P"SK_\
MY_!_]N '"8E@ VCH1+(*JF!M<VLLD%.YCEE#&=3F04X+!/'K#+#OVD*S Q!F
MGEWWWCC=H09YXYX]989 '=]'7_9_!^]U_P#+_L__ (Z_^W !WUUW_#UZ?X._
MW_\ MZ[]/7?_ .W?[_7_ ,> #_\ O_\ ?_OWP >CKT^GT?O_ ,'I_P#?Z/\
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MBI($Z9CG9YEBTU5]>?(VFZVG3Y1VJ=&X,ILF"[GJBVR5I%RMLB4QWA4S!8_
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M"&""&/&*&&&+'K"***+#K'"../#''#"/#'K'#'KK''KKKKKK@!^G !P < '
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M&K6@PRZ]2&O7CQBABP].7??JQQX8X8^GOOOT==>GOO@0?O\ &1_]YA_XL?\
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M_JHSS-&T^[VD,%["[_88I'P+_BK</SF%_P";BMPO:7=[3$;W^CVC<',!R!P
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M%YM+=VQ3&+U*C%V=!;*^>W++=GOURV#<_ @< ' !P < ' !P < ' !P < '
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MB0)"MY'LJT>13$##>G)XB(K>77<L-#,A8SN3UH<HX[-C"O+9ZERJ5>X0#M<
M' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
M < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < '
M !P < ' !P < ' !P < ' !P < ' !P < ' !P K7;*BJ.B=.&<5A>; ^1,+
MGD*9@HT\-RSG)UQL^?=$I6M5>\IAQ"_0ER[B],E*[;JY]]P69H\P"QXXXX8\
M(HL,(HHL,8XXX\<<(XX\,>L<,,,,>NL<,,,>NL<<<>NL<<>NNNNNNNN ']\
M(F[!0S" R#GQ(PX(N&5?VL48H528ZU\0T![4'M-&[%/6G^)LPPV(OC8LOBYX
M8IL/5DCPRZ )9P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < '
M !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
D< ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g69956g29k73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g29k73.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X70.:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(P+3 Y+3 Y5#$T.C,P.C0U*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(P+3 Y+3 Y5#$T.C,P.C0U*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,"TP.2TP.50Q-#HS,#HT-2LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$R-#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%F045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W1E9$54QD
M-VUW=28C>$$[8F1#03@P5'AQ5#!"6E-"5VYZ>%9)-&1",6U*;CE'-5,R:6-0
M>&=I9"M#37E&4GA(1E%A=%)Q,#)P=#%W<79T9$<Q,%%88TXQ94Q-:R8C>$$[
M.7,X36%L;F%K:DQ116QH,$AJ,4YC5E5V,$1R:65K='9C2F)X26Y'4T=/46]R
M2&Y5+W=",4A%05=',TQJ564K2W)$;TAM3G U2E=V;"8C>$$[2DM-<U(Y4U=O
M-4]P3D13<3%686)(1EA7+VPS6#1K2D8V<7I.>#E34EAK<7@U4TU35'AR<UI!
M95!1,#-X5D].1W-R*S!G94\X;DYW>"8C>$$[2VQ73$TU2'=+1S-B9F1W5&=6
M34U69&ER<U9D:7)S5F1I<G-666AF959D8V96-W$K<S4T;U9N:UII56QL:6QK
M4C!I54DW;VQ616)21B8C>$$[:%%M=&%B6G!S=6=Y;DI+8U-"6C=Y0V57>&]D
M2W0S5TQT1$5-8UE30DY$=4)!,VQU3$\Y,UAW53=,>3,U,VAU;UI*9%I%<U-4
M<DI+<B8C>$$[4$ME4T-N2V=O1C-',T1P,S8U2$AO=%9'44IY5TPW>BM0:'E:
M6F1B<$I224=/:G<Y=S4O:G)Z5UA8;$1Z1TQU-75.3W5O3$M35V%:+R8C>$$[
M5E(U03!Q>7I'4F95-'%T1$=+54970C9(8D)0<S=0>$=52E)I4U0S-S)B,S(V
M9D@U37-F84]$:$5:>&Q)041U,F]6='8Q*TAZ9&,K528C>$$[+TXX<7=V2'%I
M<&12:5)7;44P,TIG-U)N-UA%:T%M371W1W<V9$U%.4)Q5%)%+U5,,W,K6&PU
M8W9G<T\P3DU,0F@V5%<Q1'HX+U!N."8C>$$[6% U53@S<$)D4C)U<4Q#6EI*
M2DE3<W-Q9T-36EI!3TE7:55(36MR,3553W=X3V<Q24)%6C%:4%4Y5&9W-BLK
M,4AA1VU*:5I1=6=/9R8C>$$[-D-V:C Y,5@Q6G!'2$5A:'IY8T%":C1M;2MB
M>4XQ=39+5EAS=7=O9&ER>GE0>4@U<71Z9'99,SA.:DIC6$IK67=34W(V<6U7
M-6M%<R8C>$$[<$-+96$O5TEX=S-$0DM%,$\R<B]!0V556'=K1#4K9C8S<%0R
M=' U8TEN17I!:E<T1S(P0E$S-4AH3R]-8U9G5VEF3#-L6'HY638S8B8C>$$[
M,TXO<F=U=$]34U9P<F1P6G!'6E=7:6HT9W%'<E5B<#A&2TQS5&MS1VYZ>&U$
M2U9J,VQQ,6UV,&5415EW>#A--D9';VHY=FPU.55O4"8C>$$[:V)Z:'!0;#1,
M651P1&-7:T9W,#8R53=O.7DS;V=28U9G=#=C<S9U0WDX>3=%+T1Y;V1Q5'!-
M<TEE:SAG95(U+TE">E U5C R8DXV>"8C>$$[66Q+3F-54C9D.2]Q;DQA='1Q
M2%=T:WDO=W U.6QI:$@V6DUC5%<V>'EX+U=,9U-+>'9"4#EU;DII<T@W=FYS
M>#<W6EHK5WIK1#%D3R8C>$$[.#DY+V,T=CAO84U%+W4W4$8O3FI8,&-03"MT
M-G$U25)F26XU:$U%934Q>$HU;W!9-55:<#4V-U%34E-H2$-!>&5P-F=7<6ET
M4&DV-R8C>$$[6D0X;FXV>2LP=#4W5C!1,FIJ;T5%9E1(*V-#3$8K<7%V9C-C
M;5$K5U!,+VUN5#E4834Q6%949E%005DR:DUK:D1M16=#3TDR2$9F:28C>$$[
M4V%P2%AK4&]Y.5!H>5)L8W!8=#-N>2]A-C-887I4-4UF1&IH=T<W-41L8W5V
M4')(-4IH-6%M;G5.0W1*<&YA5V%1>4)N6C)Q84\Y4"8C>$$[=T=:<G%%9&98
M549H6EA&.61T-E9R87AV3E!)6&,X56I5<WAO;TI.04\R1TU426=$;553:T%,
M2UA*-7$P2CE.='131G=W<V)U9&)71R8C>$$[6FQU1B]E<WA12S1:03!F>$-H
M3&=!2$IN0D]Y2S-$05I9,$0P2T8O>#DU3SEC>$1625=#:T%Z<3AR5S1Q9V9L
M-C15=SA1<$A*=59&<28C>$$[06%%:DHO;&-N9"M09'I2-#A/+SAE.4Y.2S%F
M5'17:FUK,"M95'@R.'!G;&-.24)Z0VAV:$Q+3U-L6$)6;'%P0C)/5E1X>6IZ
M6GAM2B8C>$$[8VMA1E!-2W=)<4-A:#)04VXY8V=Y66XU,CAX95IT1C%#>%A2
M.4QK,5,Q94,T;759631B;5(S94EX.$DQ=4EI,&-*2W,W9D=J1G%5528C>$$[
M5GA62G)B.'E03U8Q2F-13#5',4LS9&)75V%#-EIP1VE-<5%24V]J3$ET<W@K
M3U9K24AX2&@X25DQ0W%O3E!Z5C@U4E=D-#!N:VY5-R8C>$$[<6$P5TEX4V96
M-S(Q*W-T2VA9;VM#>%AX:EI#3T\X:DQT5FU7<7%65DIF>E8X+SA!,3A7-RM2
M8CA14G1)6DQL;S<P2S9&6&50:C9C128C>$$[>%5P=U50.$%A-58K159O<$MO
M-BLX*R]M16)70S5S=DM&>D56=35)<FTP8U14=3A#>5%+:F@V,C-P8S%L9F-*
M3'A+,6]Y:&E&5F\O328C>$$[-WIL*VLU<F1F22MP5%=44U)M,79+6$U).4=3
M84](-#!A1C,U2W)T2V1H.$EP5%EN1EAP9VI59T@T="\X<'-#=DY,;GIT*UI.
M>D)C=B8C>$$[62M72# K5S!$:U)8161Z969743EI.7I!66U$5UA";&U14E-+
M95AX1V=967%M=6HK679/,#)T85AP,G%A4S%S2F58-E-M5T-C=T-L;"8C>$$[
M2$MF5'5%;6QJ47!D37E586]C531-4W)9<7IE4#=0:E%K8BMX3TMR<U99=C52
M=DQU-S%$6#!U6C5*570W*U-/0E=D<4EG6F=&6&998B8C>$$[6G$K>G-S<%1Y
M:5)U<&UV=&1R,FII:D='27A&6$%8.6I*=E18>&(O9VTO<FTP9%4W,#$X5R]W
M0T-B*W5+=3E.9D9V.$%G;2]R:7)V5"8C>$$[6'AB+T%)2G8V-'$W,#$X5R]W
M0T-B*W5+<EI%06I99W1503 K2G9$-31Q<5EQ=U<K9&HK8V1H15-41V1(66Q+
M+T18,7!D-EIG5"]X;R8C>$$[9C%F,74K>&=F>5I)+W=#,V8W,$TT.4M,*U)F
M=4=:-V]896Q&+TEV,T1&6&5L1B])=C-$1EAE;$8O278S1$9896Q&+TEV,T1&
M5G-S528C>$$[6'!0.$,O6E!994=+<%(U4B]W0U5E<U Y85@O:6(T4W)(9DY8
M;5!Z2D9R1C%P6#9";3%44G!"=R\P94\W:&LR:6IL5C%U;VA*1U,P:"8C>$$[
M9$%O-&-305=C1$TS1&EH=VE81G=Y*T@S9FHS3TQL>5-"<7)(>"LO*WHS<$AO
M-&A%9'%Y*U,W+U0T=$]N=%IO56%3*VUA<S!%:WI,0R8C>$$[=G=C4DA02$=R
M,4)3<#5-0G-C=7ED9E=$9#DS9BMR-'1E33AV45)69"]C;#!5158U4&)3+SAQ
M-W9B1V$T:W1T4&5E4V$X2W!A96MB4B8C>$$[,F5/35)M:5<V.$%4='9Y2CAB
M0V%"+V5!.'HP-3@O=F%W06$O9&M8438X=5A4>51N>7)Q,G$V2G%X,&UW,%HT
M9DQG=C=U1U=33S-V-R8C>$$[<#%31FA$2$HV-U!/<F-I;D%Q;V]V1W91-51M
M:$=C94EY.61$<D5F6G,S67!'2C114%1F;5AO1V<S.#)O-E!P;"]/;U-A-W1)
M-35%5R8C>$$[;U5.26E-94Y35%-P,G%C=TUS94=2039&>6]'-&=P5C5T.#AA
M5#59;6=3+W0W=59*-'!:,FUT*T)33EEM4DM/2&QJ87)V2V]8:7 Y-B8C>$$[
M1$E-;$179GI$,$A25W94<7-6>F%15V0O86%:.5ID;VI(3$YE:%A6;RM->&)H
M2$A)2&M,<7!P5V=A;$U64S!F;FHK53,Q5U,V3W9H628C>$$[23)#<S=X6&%F
M13!B4V=!3D=#87)',U1V461305968V9N2"M7:'5B,C)'<GEE<'!X9&(Q=G$Q
M-S9C4FE.2#5396QW,DY".7)C:U4V:B8C>$$[1E9H+T]$>4Y,<&PQ<5=N>GHS
M.7)A1T):6DDQ84)A,TUW9U-K;#0Q=$A4:W=02711<G5+-'$W5'9Z;2],8E58
M5DQ45DAL2E5.27EX6"8C>$$[0E=/=%!H6F=P5V]"-4YX2D-Q3U1%3'9I<DI0
M3%AM2%-V365M1%4Y34UX<S)K:VEJ95I*26DS<$]53$MR,%!&=4Y2-UEQ;%5F
M-6AA0B8C>$$[>7528W<S=&],5DHU2&%33FY$9E9R:&)6:VHY1G!F56-Y=49#
M2E9Q-T5"='-644=N+VY0*U=D.#1H:3%:;'5G66QL=&UH=65C8GIY2B8C>$$[
M16E0>%)L<C9K:7)535(W,#-X5FY-6#)F.6LS+T%"231Q=7A6:5AK8B]J<"M:
M9CA!=&]Y+SA48DY0,E@O04AM8B]H:"]3-VYT6"LW=R8C>$$[+W=$0W@K:&QU
M8F@P>G-69&ER<U9D:7$R6"LV9B]64#9S5EA9<7=3.2]W1$IZ-F8O04YS9'8K
M5#!U82MF*TY$*W(K=#,K4#A!-'DU9B8C>$$[.$\O,V]:,VUW9$$W1EA9<3=&
M6%EQ=&PO=6XO,50K<D95;#AP04AY-UE!,2LQ2C!*2#=B*T=%<6Y8<'(T="]W
M5&8Q=TMX;GIR-6TQ9B8C>$$[445T1S!Z43=J5WIC37=K5T)R:7-95F\Q+W="
M,'<S3S5%:DU/9D9F:%!X67%S,%1Z6G%E<"M9:G!R*UAR-GDP-'=3>G@V=&-E
M<$=J1R8C>$$[3F]1:6-(4D-R4T-::4%X0BM%-V9A-'%S<#E.9D9V.$%G;2]R
M:7)154-6858K>65P2C=J>'A62CEC=%!+5C-F5V1T<FQT<'1X9E1R3B8C>$$[
M1G P3CA)6&UK4F=Q>G!#<W%L;4)$2TA#*S%C5E9%,'9Y,64R-U=Q5T]N,TYU
M059A04I&26=!:F5Z649E2D@Y,$AG4"M45D]L4FEQ1"8C>$$[=%!),VM267!0
M<6YL>E-&:6Q9:5@P<E<S0W-Y:#1M-6-9-D5G3S9M=FE2-#1Q='9V3'8U9C9D
M0DI*9C94;S%N0F5Y<7-Z5'<R,%-45"8C>$$[1FA);UEU9T1V>6I$0W4Y4EAT
M:7%-,"]14$Q&<7IX861P96Y14&)'3DI)-V5+2D1'>6-:27=1:41I5BM&;"MG
M:D96:UAL5'EJ27IZ=R8C>$$[-DIP:G1*3#9K:W%146MT3D<T4$YM0V)U<GAJ
M9G%#4&)&57<P,U,W1%,W9C9T<'1J8C).='E:+U%T:U=&3U1'<DYX4E9&4U15
M-'%L>"8C>$$[,#=Y9F)A5&1-8E!3-&1):5<T4SE01T),6E9,.')P6F9H0T%C
M,'),>3=J-'-654Q,>58U2%HO,&I:84IP<DID<$4T:VEJ:F%'4E5B,28C>$$[
M67!&5E8Y3716<6AW2VYB9EE9<7E+3#=0*WEB+T%):V-66%EQ=S-Y83!O,51Z
M0W-:548Y56Q5;&=4="LX4%ER-%IP3WII9D5Y,2]Q:"8C>$$[+U,W>G1)1'<X
M5B\V;5 P370T,U@K+T4O-$$O.#$U=4ML,VHU9G1D3F-E-"]0.6EN8U1.8E%T
M3F-834U-2V9B:VM8:6\W8FMU0FM:>28C>$$[35)C:4%0>#5S;U(T:E514V9X
M-4]76FUD15<U:%HU13E33E%T4WE#9S5!8SEX.%$S>$5I5%9J.&9&5$5!6%(R
M,B]'>31.35AA35121R8C>$$[4E%'6D]*<4$Q845J;C-O8TYM-G-F:C1O;U9D
M1W9X-4QU3C$O=GA0*T%0.$%Z6&AQ6&50;"LQ1G@W:C@O,DQ(86--561K6E=J
M9'1L228C>$$[3E9O3S=(>'=!>31Q2U-),5E21U=.8D),,R]Y8RMN+SES9'8K
M5#!U82MF.$%J42]Q+W)D+VHO-'DU9CA!1'8X065H;F5B0C!$>C=24"8C>$$[
M>G@X:V%P8D,U63-.;$4X85121U9)-V=S:VDS1"]:<UI,=&M+<%I3<S9Y0E-O
M1SE-5E(Y<BMA+VQE.6AS6G105S5V2711;G5)3&0P:B8C>$$[5TUC8E-625IP
M:C9Z4F9U=SAY57!6:EA:9&I25D1P*V1V-6-.<6(V94Y367-S8U5I5&E#67AY
M3D]8.4]'3VEL,VMD62MA2T8O94MY;"8C>$$[3U9C5E14>78K62]L4'I4<4YX
M6F%&8WE8:'1O5G5(=5)$3$A!>4Y+.% W=5-2540O04)X34MR56)B2%DP5EI*
M3"]D4"]!2W O5FEQ4R8C>$$[*U5G1#5D<T%A+V%K-D5J.70O1$-65'(P,3A7
M+S1*=C8T1E-,>FQR;6\V1G!!=F1/,'%B5TQG=G<K<5).4%=N<'4O22MH1F10
M=7E"4"8C>$$[<U5Q=W%13595=DQ(;5!53EIU<FE+-C!7-S!U1T,S='!K;G50
M5E%03$U:5FUH0WE*16%W;4EF14MH9W=/=W!65FM8<'(T="]W5&8Q>"8C>$$[
M5F]+0DMT2R]:4%5K.7@T-'%K2&UR>5)P=FU3-'-,;39U3&DQ;C W,41B4U<S
M;VAG,&A29U-:635F<W1%<D%F6DHK,$1I<D5)9BMC9B8C>$$[4$LP9# W+W!'
M*T9U5E!P>'@O5C1N16II-5=2<$I)-&LY649B=6<Y4E-2>#-,06M9<7%7,S5#
M95=B4S%V3%,R,4,W1G9Q1GI&8S-I3R8C>$$[;&U606=I;FI62453,VIJ:2]W
M0C9E=D$P-&IJ43<T<6U7:2]K.35C,%A464Q(5'(R*VDY0S9A-RMT<SA%:S<X
M;UIB9&]N9#17<DAW=28C>$$[6#=C9U1534U64S%F*V-F4$I#=TI#:SDS2'AK
M4U%Y4D-Z:5IV5&I32TY7.4\R445)14I"<'EQ>D=U*TMS-#AS*U=T3SAU85ED
M3C T1B8C>$$[8E0Q<'!O-"M%4T)05VM-;G!Q255I6&=N3&ET4E5,459X5DYC
M5EDY9"M2.4EU9$9U=$E%='IB,CDQ2F-3;#=E67A-:C--+S%H:6=50B8C>$$[
M4&AK2'=C;$Y"=#-.5E4T,'94-'1/,'DP,"M+4U-72WIH:F=35UIU8VI,1V]5
M33=51E=.3CA65C0O<VXO049M+S1K8U9867%W,WE:+R8C>$$[>#$Y92]W0S)R
M3"MQ6$Y*,F0O9350*T=(+V9/.#=3+W5S6"]#:"]V53%J.#8V1UI*234S93%+
M13A42W11-G)),$IC96U8;W9Q4FQF:28C>$$[<'94>$=:63=3>%=18FHW+T%(
M:V1,-FIQ-%HW37I50TML-W9C1%<Y9$1E,2]9:'12.'=E5DY:,'$W:$8V6DDT
M;VQU2D9I6&I,4EA(2"8C>$$[:4I6-&QI.4%!4C-(:FQE8E8V9DYJ:T]+=T)E
M,U W9DYT=S9055E-:U1W,%-A,S5F664U:F1X<%AK<44R:GE83V]R0F523$UT
M=TI5328C>$$[56%K:6Y.=79+<TY+0W8V<6%Y9413>#135&MQ474W1D0S+TQZ
M*S4R:TY2<7!C44%X,T4Q5D=Z-W9N-69E;3)H,W9K>E)R;2MU27)Y5R8C>$$[
M3C-A2T=9,TLP<5A5>5)S2TE(,T).95<Y4CA7*S5Z3DQK,'5'56E*16-G8BM9
M-E@X+VDT97%X87)01TU414AM4G<O23EA*UAW5$TK928C>$$[+TQY<5,X:VE-
M1V]Y4$=Y:TE*=E%-:'%!0790>"M,,G)T;55E,6-0969L-3A.*S8O:C5/24]Y
M8S4U0690>31Q.3EF1'I42T,O=$PK1R8C>$$[2S=T2D),8E-W>6U/459&84UO
M3WAO96]Z2W@U635+;$4S16<O;V-42FEL:G5-:%5G4BML2#5E,$U%=F8O04-C
M*VXO.$%B2&(O04I04R8C>$$[-7(U+S0P4#9V-C-F-"\X06I,;"]W-R]E:&YE
M8D(P1'IF>F0U:3!(>3EQ.$=M2'ET6E1W>')9,C!6>$E92553,W5L=EDK36%E
M;DEX5R8C>$$[2EDU15=*4E9V55I66&8T;%=095IF>F<O2VIY,V-485,S;&=Z
M5#989%1M,F=H=')$,&MU;TAA2C524U5T0CA59C(R44YX;V%527A60R8C>$$[
M6% U=2]L3VQN9E,O-$QA839T64DW;2MJ1FI:<D50<DMJ9'!:5U%S<&$X2W,S
M0W9X<V%C4U1H5C9B-4=V+TME<U=-=7)A1'!C9&=S528C>$$[.7A9<W=G9VEK
M2FAM67E!1T5V.$%!,'!,.61Y86M6=TMY5U@K-F8X03%4*W)&56PX<$%N>3=9
M54I(>%-B:6XX-RM/17%N6$)V-3(O-"8C>$$[6"MM0E5I.#5E8G10.' V44Y5
M,4):<&]#+W!H251!<E8Y3C5/<S=W>#E)>E0T<6LP03-/2W%8;&9Z=F\O;5<V
M=7)B5%10>71,93)U6B8C>$$[2DI&:31&8G-Y:%55;WHO2$<P1'$T-TAB96AO
M<7E,9S,X-V8X3"]41E=G<$5Q,5EN-%0Q<#1J=T=+='EY96Y%.&Q+.$9,53AA
M0W5%0B8C>$$[5TDK6%!Z271.6'1B4U=45#=I,6UV6C)T;UEF:&-I4T]'3U9U
M4F(P-DM43'A6<5506&%O>DMY-E%W2C-"<&]X-2M)1&%K=C%4.#5D1"8C>$$[
M,'5/=VEV3$LT5R\Q1W=3+V=H57AM2W-P2W)%,&A:5S5C;#=*,'EC3D)+5C!2
M44Y.8W1:1TI!4$UI,4$O;FHU9$5Z5S,Q0S=.>54Y4R8C>$$[1E%94%1B-$$Q
M4%9-;D=T9&AW-6-T:71A9UI,*U1P.#=&9D9F>FMB<6EI,R]!1&PX=$QQ55=M
M+U9,>#=U850P66QJ*W)/<&9N-F1/428C>$$[;F]T5S9C<58R4%$Q>4@U0V18
M67(T+W%39%A'-C-T9G%0-70V3&%8-'-K<W)M95),;64S=4-'9U5Q='%'37-I
M;UIE8F-E1F5.07='-28C>$$[07%O6FAO6D58635E9E9-=%9%1W$V*UA4-'0V
M9"MB5VA8,W%3<F%814YN1$8V,'1X23ES45!J=#!)<$9.2E1G3'A'8W-2>$AV
M6$=7:28C>$$[:T]O=C0K9FPU26IQ;VYP.3-L-2MB=$\O3E-X,4AZ2' K:E<R
M;EA#1RM5=5IP,E)#9S1E;T1W47EC=5-L5#$R<G91-UE*84UX9UI%."8C>$$[
M;55D441)4G)M>FI-3GE&<V8R5"]!2WIF.%-/2W)S5EEB-4TO-#8K=F8Y=%=8
M.55U851S-RLY>68X35 K*V0U,FPO9%EV*T9$+V5P:B8C>$$[<C)K,T-F5C5.
M2# V,61Z3S!T,D=I:"M)1D<K3#0K3E-74%EG;BM91&9-;E8V8VEJ:6A(;EHR
M2&0K4#%H>&1*<4EM>&QN3&Q1,U!F*R8C>$$[4#%&3' Y33$O=T12:TAP-E1A
M>%1Y5$Y&95=T;VQS;BMI:FQW6&Q/2E598S9.4VXP1')M4$Q";3A-5D-)2DY%
M4C1F<#9F5EDU-W561"8C>$$[4&@X43-K:U%"64UU3#9U=C P95=Y:%1Z5S!H
M:DAL,GA,,G-9.4%T1D=Q05--,5%J*W%W*V%J>$Y4,#56+W=#144Q-%504TYT
M:#$W=B8C>$$[5CEN-$TO.$%"=TPX5V9Q3RLU-E9Z.5 R+W1P9#=$>D1Z5DET
M0W-);WID9U!):5$Q*W)236YP=E)M27)W3&IP561G36UC5V)K36-"-B8C>$$[
M=DPV4E9F6F8W1W-:8U!--5IK.% Y3#9J9&HU,2LQ16%:<"MR4&52>#,K:#9F
M1%E5.4YZ2$A'5T-N;DIT.&)F0TI65&)J=EAL='5"8B8C>$$[9W<U1$E#94]!
M:#=H-6YV-S8K9#=.969.:D5365IC:&XW>C5$=3=R*U9B.# O=T119W0K14U%
M87A1<$1)16I247%G5EAO0G--,DU90R8C>$$[2D%!;U5F,$]T;$UY0DI.;7@K
M;$8U83%-179F+T%#8RMN+SA!8DAB+T%*4%,U<C4O-#!0-G8V,V8T+SA!:DQL
M+W<W+V5H;F5B0C!$<R8C>$$[5E4T3&$S=#%:24EK:58S95)L4E%O3'E-6&1I
M0BLP>D5K;G5C5E9-5F1I<3)8*S9F+U90-G-64UAY:T-F3'1H46MF1DIU2V9Z
M=C0T4R8C>$$[<61C1R]N8B]!25@K;4)5:3@U96)T4#A!2V5K1%9.45=A84%V
M-EE317=+,694951R3SA-9E--,"M+<$Y!3GII<EAL9GIH<'9M53-","8C>$$[
M,S%J1&)*07IZ=#9"479/<DU99C-B>4US:UA(.31R055Q3W5+<#EW8BMD=BM&
M+W!I<E%5:59A<U0X2C8P.%(T1$96-4E!2DIO0G53928C>$$[;$U664QQ9&HK
M65=T869A,T]N,V1T67IO,'!H:U-E4EDR:F%32C1*=C-);FIM+V1O-#1U=D4X
M=G,U;7=L:6=30T-F=V(W<6-E8UIY1R8C>$$[>'!">C92*V)S5C9L,U U:7-)
M<E=/5&=O9EI#:W1Y;D9755%)<D]9+V=5:SED:'5E5U1'5$%246EB+UHW,G-W
M>EAF15!W9F0S26U4428C>$$[+TYQ<G%%96@V<&)7=7!.<6LY.4YB<F-M4E5G
M=4E3<U%K.5,S;5E%=790:'<T.65,8D-K4FMX-V-12DA$6$QU*TQ-=VYV=VYE
M*R\X028C>$$[66AR2'ET*V%K85)I9E=B5F$S6#%M-$9U,W!":%=R1#1B5E%4
M2C%/=T9A:VAI86E5<S)$<$4X=G@Q67AX-65P2#0K0TDP95 X=W U9"8C>$$[
M264K,38P141X1DPK,U0V=4IP8FES:WEQ;G!X>7(O8T=0;'=K*WE#4B]-67I/
M25A55#5C+WAZ6E%'5&%Z*U!X-6]/,3!,>E):-EE).28C>$$[5S$V15=S=C%E
M3G)K-G!D2S!C;'1-6'5&4UEQ:D]:558K5E=8:C V3&LU6DE'6'!J=G8X07=J
M<GE9:45H1VEF=% S<VPP=V$O<#)T6"8C>$$[53)T87)A=&]T-THV96MW3317
M4513>GE.1V=,26A9=$5654M(4%196FI4-$I206E$>$1N.&TR4$5*1WHV96I*
M8W@R-6)(.6LO-GIF."8C>$$[4T]+=5-33G=3:D)G<$MT43%O4G-2:7)$+TIN
M+T%",3EE+S=A<W8V<&,P;EHS.3=K+W=#1T@O9D\X-U,O=7-8+T%!;V8W,6U7
M8G0P828C>$$[56$U;TPV;DY"2VQZ.5AA04U&2E%38U-Z2W=K:G%11FM8:%%.
M=G-337<Y5G!$;$E)3E8U6#-B:G5/,TYZ9$QQ>&E"0FID*V1D*W@W>"8C>$$[
M=GE3>5!Y6G%C8VMK<6$W8TQ*37AA6F=(*TPT559/<W!0=T)$46MK;F)L>4$S
M>%(R8FM"2D=35FXS*UAN,'(Y9#EC;SEP-'E!1&EJ428C>$$[-6-V3R]W0TAR
M9C9Q-DQ76&Q054Q7-&AM1W-Z>4)*635R9TYZ2FTT4FA'5FDP:F)-4EAP=# X
M36YI,$4T4T(X4UA-13@Y.7$W,D=8="8C>$$[0T4T:V5(2&M13U<R.3EZ2DTR
M8G$Q0V8K.4@O1TM4.6$U02]54&-F,$UX.4HY-"]3<7E34GA2=$I)=U-.05=D
M,DY!04)5:VLU3F=W828C>$$[.2\X04IZ-F8O=T)S9'8X06LY3&UV;B]J42]Q
M+W)D+VHO=T--=5@O1'8Y-D=D-7-(44]X5C)+=7A6,DMR6F8W<"]W1%90-G-6
M4UAY;"8C>$$[>2]W-UE524(U4V126#ET.$I63W%3+WI,.7@O<F=63&1F.'AA
M8F]&:CEE,5=C>%=X67%$2$).3WA)4G!$4DE"22MY4G-X3DYG3597828C>$$[
M4#5O,%A78FUE,C!Y.5,U;G1O8F4U;E%2>4QW:79!-U%-4S-%9D=),DY/;S<P
M<4U65%=K=CAY+V-F-C1Q,$$O<7)Y25!W;F]+9'@W;B8C>$$[1E5S.#!E5V)(
M>DAP8F%B97E34G=S,TQL1C9F2W9%<C!L4U)$<S-D9&I1:F-!-6)H>DA(2W<Q
M-6-9;4M,1#50>4HX;U-)<71D,S1#<B8C>$$[16A#>5%O<%=(:T%$1W-):BM)
M3V58=S<Y97!9;DQ(85=4=4@T*TQJ9FM99#4V9EEX>30X=B]L5%I88V-L<G%M
M<&973D5U4'%X:FIJ828C>$$[6DQE5T(U6BM4>%!$5FQ6;VUQ62]W,V),>&QZ
M:V)I4'$K,W S=%IX-&AU0V94=#AV9W%A<VXU439P9#-N;4]4571116LX<TIV
M:F%23R8C>$$[1FA:5VI0-WAK9TY">6IQ875A;79(96U-1'%)9U%O958O=T)Q
M>D=%:WIS+T1Y*TAK,7%E;&9K-'5M,G1T9&%Z9E%78TYV.5=T>7-5:28C>$$[
M.#0W;&MV84M28F9%4T=86F5G86A&5&I#96]S:U)&,SDR,V5S-#1A;VLQ5F90
M9G58-FIO,S55841Q9'!E6$8Y<4AR5W,X16-%83(S3B8C>$$[5F5Y-%)C:$HY
M5S5F0G@O93A:3GI88FM!04DU33AW44%.+U!V*U!Y5U=01D%G;3EV3'4K0TUS
M9DQ0-5DV>G%E;S9*85AD.6-4-FQ)8B8C>$$[-F%-4G1&2$565U0P,FIC=U)R
M>$%U=55B5F)O=2LO>%%L;7I106M13G1V>'8U37AI>'E*:G9V=BM.;6)3*U,W
M5V5E4C4W>31E2C=Y,28C>$$[=FMG0E%)<C)D3T-G1E=!1$92>DMG36%D8WA"
M<4-"<T)Y22MB:VY%1#AW9FMY2$UD=%ET-2LQ6%5.33AV<F,R37AG;4YY14QG
M06YI928C>$$[6DDS0CA-259J;C5A83=R3GIR5C-"3GEU24QK1V4U;$Y"-F-G
M1D$R,C-X9EIP+U1%;T-9-D1F5V5N4BMC9%-V27I,8F%F9#-.,4MI<28C>$$[
M1V)J0TI(8FE'24A,:4149DY,,F)%2$IM=B]61"ML,V9A8VE-94=V.51(-D9(
M5&9Z:R],2SEI9TPS2#%7-6Y"65=R=T=:9V]U=G%98B8C>$$[,6)16$9U>71-
M44%5:TEO82M/8F)W-#EW9%(T:W4X;WI4=GI/+TQZ57E(,#9F-C%A0S%U<C93
M.5,R;$5#4E=426MO3$UI;'!0,V=)4B8C>$$[45=P=E1D879H>#=G=FE3-WDQ
M3BMA4#5D4E=T+V,K=7I2-EA,87<V9W8Q3S16-%=V6#E/3&MJ>$EX;S,R=W13
M<#))-6)9*TA(=4,K2B8C>$$[3'9+6#9T*V1F-5DV5TQS6$5K<&YT844R-',U
M56539VI-9U%Y<D=N2TPQ:#9I37=D9#9R:C1C931,-&MU.'!R<#,U:BM19%$P
M*U,Y="8C>$$[-5=+=U)7,# X4#%39'!K5SE#1S(O9'!'-T]:9E5(2&AY<G94
M-TIO*TA(=4,K2DQV2V$K5W1D,&IZ1&]G,6Y3-$AJ=$I7=4E96DI9>"8C>$$[
M13=R0DLP3$]&*S!%9&\V<GEO86113VU%44%/=U%::S=%<T\O36YZ0G)&<G$W
M-F9B,TQ2,F,Q<T),0T%P1$-4:W)B:U8S1U1$0DQF2B8C>$$[5B]E,S,U9V%4
M2F56-7AA5DI$135R5C1K;&9I,50Q,TI8+UDU<CAN*TY$*W(K=#,R26XK5$IF
M.$%$9CA!96@V-G=L<CA,2T(T1E-F-"8C>$$[:DTY,%162B\U,2\T12\X04Y7
M2W5P4#A!>G(O=THO-7%X5C%*+W=#9&8K0E O3E=+=7!0+T%$<B]!34-F*V%S
M5F%C4V5M+TIG4GA0428C>$$[161V;6-64V9Y;'DO=S=954E"-5-D4E@Y=#A*
M5D]Q4R]Z3#EX+W)G5DEV3U8S-5AT9$E%;FUI1T<U,#!V=$1,6G9E9W5S8G53
M25536B8C>$$[=FAJ4GI8:G-+-'%P959B-WE:8UA.-40U8E<P:75)66)A4SA7
M,G1V<3=E:F-#4V$R3&9#;DE.>FM994),9'EC5EI&4U@K6F9U4#EC5B8C>$$[
M84%F,58U14@T5#!&3S0Y>FEQ+T9867%K.7HU3SAP6%%M.692<DM1,T)D<&Y.
M=D5(6G!A8S),0F582G%#<E9R;&]Z-4)Y:V9M,6Y$028C>$$[.4$P=FMV>65S
M0W=F;U-X84I"44LY=$4O:%5K<W!*2C1#<%!7;4@X>&MU*TDO3F9":'EO3U1Y
M6C535#%+84Y:<TI74C)6-$DS1EEK128C>$$[8V9%34-&0TEO0VAD:#)X+TU:
M4#5X55E99'=6<FYY>#5A=6)H<FTU,&UY;G5'674P,&QV13=L:4%P67-Y:S$T
M:6U21V%91D%N-7!/3R8C>$$[2DYK0E5S+TPK9S)6=V)I>C R,71R:&E786%'
M0T].>7I#:$I:5D)Q4F=L;&M24DI+4D-)-4)(-4)K-T9634EJ;U$V:&AY8EEI
M;RLP9B8C>$$[2$954' K;%=D:DIC>5%*4U,W;$US>F)B;F]"=#)59$U663$U
M3V=G=4QZ>E1B,T5A>E%46#@P8W-59T1)-DUZ:&Q:5'-14G-18S O6B8C>$$[
M9CDU;2]W0T=(.4QU93%F-W9$+W=S9F]E8E-A>F97>41J*U5&<3%X1D9"1EI3
M46%C-T-/9&]P3&@S-&TQ4VMC5G=Q3'A6:'969S4R>B8C>$$[8W5M5%A6.6-V
M9$4Q92]T3DHO3$=+-6E-07-)2C=7=VM8:W1W2C-L17)R8F5K,74W<$AY:E9Y
M4&IQ>F-Q<497-69-<E)E5G)I5B]Y,"8C>$$[:'1:5S%(.4AZ84TY<7I,97A7
M;&\Y>D$X42MQ>'-W33!14TMS5$)E=E=G>%9!6'5V,S!M;S)Q+SAQ:&EN,#9+
M-6XP,3%A>%IP:$=N;R8C>$$[3$9C4G,Y<DA':T)1=4]/.65)*TE!8G%P>G!/
M<7A8,VPW>DY$2#5/=#1D6%A4<F$T:S R4THW;3)U<GA,5DQN-G(Y55I9+U0K
M<G1C4B8C>$$[5FE*5G5B<V%6<7A65&IY='(S;38R,6=A2')E:5<K:S9C=VM7
M>FYS-V%14E181%%,8W5N=U!,1D(Y<5)I,THQ6G%O1S5,5C%78S9H<"8C>$$[
M.71F5VLY=$UO<&-2=D5Z9T1K039L86=N=W)G5FA-;'1"82]M+W!D=$%G:FAH
M,%%P1V<V0E9L;$%Z6'HO04UA2#E8.6)V.&8O04)L>28C>$$[+W=#2&8W,$TO
M=T$R1&](67$W1EA9<3=&5G-V.3 O.$%Q;CE72W!,-5,U9C1D<TM!13AP3W!P
M*S(K17%N5EIF-58K."\P=TML4&UD=B8C>$$[3$$P>79M9V%E3DQ$:F95,FDK
M<BMP43 O=GAW-55R:7)7:#)(;&5Y:VU/:%=M;E<P=#)K9'AC9E56:&IA5TYU
M46EL9C!L0F144F=R2"8C>$$[,W!I<6(Q;"]L6#=Z+U1&5V=8.59E44$K13E$
M6'5065EQ=GA6,DMU>%8R2W5X5C)+=7A6,DMU>%9B2#EK+W=#<S,O16II<3=&
M5TIE4B8C>$$[=BM/;C5L+S=A378O04).<S O6F8Y-6TO-%EF,'4U-U8O=3A0
M+T-X*VAJ1F]N-3)72C R-C%+864Y:DLK='%&;F)F;S)49U9M='DX8R8C>$$[
M:$U.<S5$465V=U-(:U$Y05I'1RMB:#!Y6BM9.5DO3VA.9C%',CAV-DA94V%.
M2$=',#8O=6U5=DI)='9Z84XP5S9J4'AZ9G4Q8FE/4"8C>$$[56=J<7%L3VAA
M<B]Z:TA&87%M<#906C-&>$ML,#-Q4T<R06ED3%5.87$S;S-+06E3-4)69T%A
M3"LS,U963DY),50X-TI,:C!D5#!R5"8C>$$[66M0,5EM-FE10TY22DIB*W8X
M4#$V4C)A3TXU>%-G1E569U<U8T%Q.41X5F),+V10+W%N.5=+<G-664IE+W=$
M:S4Y4"]!3S)/,R]*-B8C>$$[6$YF4"]':"]6+U<W+T@O>&QY+S1D+W91>DA5
M3E8P>E19-#5D4G9)3$]/5U)966YU2D5I5G!(3D924S5&5V)S3W5B0C!#2WA6
M4VYU-R8C>$$[5T(T56YM4THW:"]3=#%D9W!K:S1S+T)!5#A48U5:<41S1&EQ
M1FHX=V%$3&$S5C-(<59Q.7!9;&QV8FA:-'I(0U5&6$5R:'5+1E(Q-28C>$$[
M9$U64FLX.$9V1$I04$ES3453;#5:6D-&4E955DQ->#)!07A6=5@K-F8O5E V
M<U936'EL>2]W04\R1D%#955N53 O8F9#5E1Q<W8X028C>$$[2W8S;BMM0E5I
M.#57,VQE-3!G3#5P;6AT9$U6-FEA83AE>55/,&)O4C9Y3D-F:6ID=U)Y,T9C
M5E503$]I951R0R]N;3!";VYV4'%T=B8C>$$[1F-"3#)7-4ET955J,C%59#5!
M<69&2C9:<#!Q0G-+67%Y4W-V.'$O968V67$P0R]Q<GE!2'=N;V$Y>#=$1E=$
M2#AM=DQ"9V5!,TXR528C>$$[9C%+;B]29U(V:U!O;FI305502&-K8G,R-SAQ
M0VUB*V9N9#!0="]7-'8U4TY6=CA!6BMP5G10>6DX=5=M;VDO:74W-S%F<DU.
M-%5-<R8C>$$[6FHY5T(K869$-F4S9V%53DYQ-VUO;')P:U91-55K85=)3C)6
M:B]K.35:9#)9,TXT=DUY:SA':%)H-C-Q.&=S<5),2V\O=T))8C11.28C>$$[
M1'1Y1$%99GHP*S1F:790>5%D2DAZ+W1V.6%L8B]K=C59='I),$XS97))-E!'
M<W8K:6U20DE*1EEQ-6=,8G!--C=M;$0P<4%15#)H328C>$$[.4(Y=C8Q+TM2
M-WHY;C9V3D].0R],+U-T2#%:9%5H=7)M-'5L9VET83-(;TU05&AJ.4I0<WA)
M5E!!1&132R]F;%=457EN2&AO5CAF,28C>$$[=&M-26EB=&LK67IC-T9867$W
M1E9S9C)4+W).+WA)-'%U>%9I6&MB+T%)-F9M6"]T;WDO.%1B3E R6"]E6G8X
M06AH+U,W;G18*S=W+R8C>$$[.$Q(-D=7-75(5$U3."ME5&9-2&U/6%1N,&YZ
M3F,K6&MS+U<K<TQA<DEF<DAR0E98;G=M:$AW0E=P<U15,4)(9%9J5FXK5$]T
M=S-%128C>$$[<W9N0S=D634T-7)I0D)C0DHP:G4S=D)(25IB<6%1:T\T5E@U
M,4%"<GE,35-Q;78U8RM19DU8;&DU8S9P<D1A;D1(8FTQ=&UD-4AC>"8C>$$[
M<7EM34XV9W%Q>#A'6D8U='@Y5FQQ46]*5EHW:7$R6"LV9CA!,50K<D96,DMS
M179F+TIZ-F8O,G@R+S504S5R-2]W0TY$*W(K=#,K4"8C>$$[+VI,;"]W04\O
M=T(V13<X-2M39$HX,C)6<F%A;$Q00VQP8TQD4E!B37%0>E974VY*;&5L5F,W
M<E)H,4)",WI93V=E8EAF-6,O;$PU928C>$$[=5<P:3DQ,U4O<G1W,%9V-E5R
M+U<U0SDY3DI00V<O,&569FIA,VLU2CEL=U S;V)B0W%*<W9+6#5.*U5T5'0W
M-EAZ859U9$)V<GDK1B8C>$$[=&0V;$)+>5A&>D5S53!C:V105EEQ<V5W*S-7
M=%-C0V]B5G9+;C5+>F%$2&)8+VY";W)#0T8Q9VIA+W1O-5DW96%"94U3>$=-
M4%522R8C>$$[3U!W*V]Y,59I>7-Y:W%M55@U1B]L;')C53AT=&8S1CE:3DIC
M<'=G=4QE5T-+4C%L:4UA0EDR5F9Q+W$O=6M0.3!Y9W%!4R])2SE25R8C>$$[
M1EEB35%R=7-59D)D;%A:5G P54MO*V=5>%9+9DM223AU,D9!5#A5;7=P+T\O
M:FA+<#%Z8BM2=BM&+W)G5DQD93!$4W1E<VA:87!B>28C>$$[5%<T675&:FUK
M9UE%;S!:*T]'4TXV1DI'56EU-$]+<5=H959T13!+4V%45$Q75THW:$EO<$1*
M4$Q04T]$;#932C8P:VY"53E2<4MT0B8C>$$[=FEQ8C@R+VMB+VAF-C1Q9V1:
M<W)N54Y/=6)+,W5(<UHW:48T-#=T83AO,DY+35!494XY=EIG9F-9<7@O5"])
M*W1X,U5R86XU:G5B*R8C>$$[>&MI84I,24-71E)Z:#E&:7HK=DDW+WI#<')8
M97!/*T95,F9Y+V1$>6Y$;U9T9G9"8U%7,$YS;6]+2%9Q=VA15W!(2D<T-3AD
M*TUG3R8C>$$[+UA!<D=(+TQ(6$QV4F15,'I69DY.>'%+-FA#.$UF<7AY:4]-
M1FQ+8V\O<DAX:%95<69I1$U$=3%D.$MS<79D1'5P9DQ0-D=T8BM3,"8C>$$[
M=49G:F=J,4)!=V-'34M/5DDS:6(T=4\O1GAG5DI)=DEE<GE797%7,G%E67)M
M+UA564QM,FI"1'AP171W4&=00EI31TUD5TAA;TE(8B8C>$$[0W%C*U=.0G9T
M1VAV-#=V5DIT5$8S97I89'5:=5@K:G=Y:T9B6D]4>4AH2%0T96<X04U#<'II
M<D1T5CAL*UIR=E5R;39S+TY%.6I"8R8C>$$[5')+3&19-5I!<UEJ-$=*959W
M15AR>4)21C,V:'-+;T8O=T%Q,FLX,C)N;4=45D%Z,FLQ<DMS9F]0-G-I,G-"
M:').35IM.5-6=5(O928C>$$[378R9FAP5VI"5FYS9C)4+T%+>F8X4T]"5C)+
M<U,X:F8X9%!Z3"\R,%IF.$%I8EIP*WDO-WI.+W=W+W!D>C)R+T%(94@O:%DO
M47DS3B8C>$$[=S9:,DMU>%8R2W5X5F),+T%(5"]!3W%F,5EQ=7A69VPW+S5/
M9E0O*S)/,R]!0V5L>EAZ+T%-84@Y6#EB=CAF+T%";'DO=T-(9C<P328C>$$[
M-WI93V=39E8O2TAL-U=,;C9Z<49S6EIQ4DM75U=A4&MS0FQ+2W=J9$%Y+S92
M2E94<W=A:E9'2W-E,4@X;%!Y-S%3-FUU.5=S2F11=28C>$$[6G!P-2]5;75R
M;&5$6$5Z5$US85)34F]G5C5'-#A6<C-R56ML5F0O>7!0.$%,1&ID<4Y$5E)F
M4E)W6%A'9355<VM,27E#;VQ"57$P2R8C>$$[;6\S,BME2W-M,$QY+W!':%=B
M,F5L44<S='!*<$QH,$QY4U9L;6)N23-+4FYB9&HP<E1&569,+V10+W%N.5=+
M<$PU4TI(;#)W;T-F:28C>$$[:S)&4#4S.&-*5D]U8F9Y3B]W04PO6$%Q4F5C
M=DM/;F5B9$E';#9I6F\W9FXV;%EH07AQ63-J;U)/:WEF6FM0-TY1845527A6
M6C59."8C>$$[;E=F;#8T=4QI0V4U=7!,:3-T<E-T=TQA<5$R:&Q-4VAO6317
M86YR:U9C<V1H:7))3V)F>4XO=W8Y8U9A1$5Y<E934&A05VYI4$$T<28C>$$[
M=&4W=#!L15132T=)2DY707!3;CEC5F0Y871F.2]*+W=1+W)I<E%V8E5Y36YQ
M<'-!83AH,TI(.$U68BMT5W8X078U4"M#2#EC5F%&-R8C>$$[86U2:SE63F=$
M6&M/-4DO:&ER9C%Q,2\S.&XO0D0K=4MU*W17=BLO:R]W0T-(.6-69#EA=&8Y
M+THO=T%%4#8T<79I:T5K4U-,,&11=R8C>$$[*U)&8U9D2#EK+S9Z9CA33TMR
M<U99;#5'+W=#3VXU;"\W84UV+T4R>E0Y;"\S;6(O04E99C!U-3=6+W4X4"]#
M>"MH;'5B:#!Z<U9D:28C>$$[<G-69&EQ,E@K-F8O0494*W)&5C)+<T5V9B]*
M>C9F.$$Y<V1V*U0P=6$K9BM.1"MR*W0S*U O:DQL+W<W+V5H;F5B0C!$<U9D
M:7)S5B8C>$$[9&EQ,E@K-F8O5E V<U936'EK86588D4P3D%:2S!"4"LW2#A-
M2E9/=E58=V(O9U<O<&=6279/6&Q,4W9.=6M$4SE296%/,S4K<%=*228C>$$[
M,DY41SAD0THT<&LK>DEF,F%G,$EO4FER9FQN>71995@O5BMR,TXS8VUA2T=!
M;35+='AJ='59:E91:V-91D9E;E1E;%1V56Q64%!56"8C>$$[=V(O9U<O<&ER
M45!+445!,$%0545D>#0T<75+075(-W%#0CAJ42]W>%9I9#$K6B]L93 Q1S@P
M*S5A-&IU<E,V:G-U2'!&:$Q*2S!31"8C>$$[,#)4:TMC<#%(>&-4,6]$5$=L
M56)4.#-F>31U;"MS5S)R*W%K:712;'0W:V=R1312>5 S6%)7;$A).7-64F)F
M;6(U3%-E2S-L=FYJ;28C>$$[;G V36)7.7A69U1X56EK6C)*-E9X<%5,8R]M
M>#5!=#$Y9CA!4U)K95)52W=P1DPV:%%M8SAG<DEP,D9T2V9K=G5T5E98+VQA
M;FMO3"8C>$$[0DLY,TEL<&-X=WDR,3(Q=DU)-4)C;$9I02M$:W)-6E8R6E(K
M0F\P<4-0-3 K4E!R:VM);G548GA24$Y,9FDR;4YU:7=M45,X>G@U;R8C>$$[
M56%&9U%Y:79A=3E&5UI71B]A,SEP2&0R<D8W95=V<'5Y<VA)0DLQ-'5&86TR
M,C(O6$969$5#27%$;V]!2'E',DMT4B]:4#A!<DXO>"8C>$$[231Q=7A6:5AK
M8B]J<"M:9BLR:DPO=T%48DY0,E@O95IV*T=(.4QU93%F-W9$+W=S9F]:8FTT
M9$TW1EA9<3=&6%EQ=&PO=6XO04Y5+R8C>$$[<7A69&ER0DPS+WEC*VXO.7-D
M=BM4,'5A*V8X06I1+W$O<F0O:B\T>35F.$%$=CA!96AN96)",$1S5F1I<G-6
M9&EQ,E@K-F8O0494*R8C>$$[<D97338Q-6ET4$QB2G Y<F\R<%AV1T@Q,$9J
M1$I,1GAA64EY97!8:C9N>$8K2B]:0GA61%,O;4AB5SA+=F1A1')K8VAJ85(T
M:W1*2B8C>$$[:7!765$X2WA--$QK;FM&2%9D>&EQ:$(K6F-%.%1&4$QM=7)C
M2VEY9E8U3%(P*S-B>51H95IB9U0K-C1(:512:4)I<7!E9FU46E=S8R8C>$$[
M:VIA2')4>%%S>7EU='$T045C:7AU+WA-<$MJ;'DY,4(W:6U&5W)R.'E)3%-B
M,')N>3=R<6MY>E)+,&1O.'%L64=+*W!73C)O<C K128C>$$[;G)807%L<"\U
M;S)D-V508F8T9#$K,F]E34UT>EI34DI+,W!T2E-0:S-,64DQ86=5-S1Q="]W
M0U9R868Y5FUN4&QZ>D=$0DPV3%)F;R8C>$$[,C1,;&E7-&QE2DE:5'<V9S!'
M,65O<7%V=2]Z4C K,W9'=%(U9CAW>E!(3SEU.&ME;GHK;BLW1&MY0C)+<7E(
M,#EI=E=O>%9K5V@V;B8C>$$[86599$@K=&UY=7)A,VY-:U17=6]23D1)>7%X
M43@T;DY1<F5$9E--5E154DE"459!2"M5,SEC5F0V82M,9CA%,SEC5F0V82M,
M9CA%,R8C>$$[.6-69#9A*TQF.$4S.6-69#9A*TQF.$4S.6-69#9A*TQF.$4S
M.6-68E91;V]/;4MT-'%G3E P3WAS2G)Y83-$:#<V5G U-G-A8S)*2B8C>$$[
M<%-L3W59*TA44GAM4FHO16),:UHY5%!)26E8.$%O23,P,3A7+W=#0V(K=5I$
M:G4Y3F9&=BM#8BMU2W4Y3F9&=BM#8BMU2W4Y3F9&=B8C>$$[*T-B*W5+=3E.
M9D9V*T-B*W5+=$=*0T-$>6]E=GA.+UA&5BM+;TM44F1-:S%:3E=E04A5631V
M<3982$IG=VEQ5S0P0G Q63ES<D]+4"8C>$$[1GA6-FTX86Y)369H6#9,=79.
M1BMM=FDS+T).+UA,1V@S<'(T="]W5&8Q>%8S<'(T="]W5&8Q>%8S<'(T="]W
M5&8Q>%8S<'(T="]W5"8C>$$[9C%X5F]X25)1,6]E=GA.+UA&6&XO=T-92% X
M050T-"]P,VHK:G!05R]29%!Q,W!C6B]5<GDO,V1W<G@W,315,W=Q:U!M:CE+
M9EAB=B8C>$$[.4=F-'DK,T)Y+U)8;V5N5#9R0E-N,7)E;C@Q3BMF2W9F1E50
M-6<K=B]54C8O=T1J<C9V>'5E9C9/.5 Q865O94AQ8U S=E Q9C=R:"8C>$$[
M=%0W9C=U=4MQ,6@K;E P6"]P;BM,9G)N,7$V*V]F,U@Q<C9N-FQL5#%++T(P
M*WHK,50Q2SDX5E10.'50<G8V9'1/6"M+9G$O-DY(<28C>$$[9G V=G X*UHY
M2#%+9D0V+W X*U@K>#5B.&-696]91F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5B8C>$$[9&ER<U9D:7)S5F1I<G-69&ER
M<U9F+R]:/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M
M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D
M9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U
M8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C
M.F9O<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @
M(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y-87)Y($UO>6YI:&%N/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@
M(" @(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/F<R.6LW
M,SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M9&,Z=&ET;&4^"B @(" @(" @(#QD8SID97-C<FEP=&EO;CX*(" @(" @(" @
M(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<]
M(G@M<F5P86ER(CY&:6QE($YA;64Z(" @(" @(" @(" @(" @,# R+F%I)B-X
M03M5<V5R;F%M93H@(" @(" @(" @(" @(%)2,3$W-3<R)B-X03M,;V-A;"!4
M:6UE.B @(" @(" @(" @(" P-"U!=6<M,C R," Q-SHU-#HQ."8C>$$[15-4
M(%1I;64Z(" @(" @(" @(" @(" P-"U!=6<M,C R," P.#HR-#HQ."8C>$$[
M4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!6
M97)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @
M07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O
M;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L
M971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F
M;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @
M(" @07)I86Q-5"8C>$$[(" @(" @(" @($%R:6%L350M0F]L9"8C>$$[(" @
M(" @(" @($%R:6%L)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R
M92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C
M:R8C>$$[(" @(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA
M;64Z(" @(" @(" @(" @(" @,# R+F%I)B-X03M5<V5R;F%M93H@(" @(" @
M(" @(" @(%)2,3$W-3<R)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P
M-"U!=6<M,C R," Q-SHU.#HU,B8C>$$[15-4(%1I;64Z(" @(" @(" @(" @
M(" P-"U!=6<M,C R," P.#HR.#HU,B8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @
M(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F
M(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ
M*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS
M=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ
M*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I
M;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[(" @
M(" @(" @($%R:6%L350M0F]L9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O
M;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @
M(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[
M1FEL92!.86UE.B @(" @(" @(" @(" @(&<R.6LW,RYA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!R<C4P.3 P."8C>$$[3&]C86P@5&EM93H@(" @
M(" @(" @(" @,#<M075G+3(P,C @,#@Z,S0Z,C@F(WA!.T535"!4:6UE.B @
M(" @(" @(" @(" @,#8M075G+3(P,C @,C,Z,#0Z,C@F(WA!.U-C<FEP="!6
M97)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@
M(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF
M(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@
M4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R
M('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L
M350F(WA!.R @(" @(" @("!!<FEA;$U4+4)O;&0F(WA!.R8C>$$[5&AE(&9O
M;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C
M>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X
M03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G,CEK-S,N86DF
M(WA!.U5S97)N86UE.B @(" @(" @(" @(" @<G(U,#DP,#@F(WA!.TQO8V%L
M(%1I;64Z(" @(" @(" @(" @(# W+4%U9RTR,#(P(#$T.C$T.C W)B-X03M%
M4U0@5&EM93H@(" @(" @(" @(" @(# W+4%U9RTR,#(P(# T.C0T.C W)B-X
M03M38W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R
M(%9E<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @
M("!!<G1W;W)K)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@
M8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M
M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG
M(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @
M(" @("!!<FEA;$U4)B-X03L@(" @(" @(" @07)I86Q-5"U";VQD)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D
M;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @(" @(" @($--
M64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @
M9S(Y:S<S+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @(')R-3 Y,# X
M)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P-RU!=6<M,C R," Q-3HP
M,3HP-28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P-RU!=6<M,C R," P
M-3HS,3HP-28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M)
M;&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP
M93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT
M(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C
M:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE
M(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z
M)B-X03L@(" @(" @(" @07)I86Q-5"8C>$$[(" @(" @(" @($%R:6%L350M
M0F]L9"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N
M="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @
M(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%109STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @(" @("!X
M;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E
M+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @(" @(" @
M("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B
M/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@
M(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\
M+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP
M5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB
M;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXU
M-# N,# P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XY-C N
M,# P,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN
M=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE
M/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \<F1F.D)A
M9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y!<FEA
M;$U4/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&86UI;'D^07)I86P\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF;VYT
M1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P96X@
M5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@-RXP,#PO<W1&;G0Z=F5R<VEO;E-T
M<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&86QS
M93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=$9I;&5.86UE/F%R:6%L7S N='1F/"]S=$9N=#IF;VYT1FEL94YA;64^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1.86UE/D%R:6%L350M0F]L9#PO<W1&;G0Z9F]N=$YA
M;64^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L
M($U4/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N
M,# S/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^87)I86)?7RY01D([
M(&%R:6%B7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @
M(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA
M;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @
M(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U
M<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@
M(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U
M<%1Y<&4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \
M+W)D9CI397$^"B @(" @(" @(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS
M=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(^"B @(" @
M(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z1D$W-3 V,S W,$8R14$Q
M,4(V1#)%03<P-T(V.#1#,S(\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @
M(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z1D$W-3 V,S W,$8R14$Q,4(V
M1#)%03<P-T(V.#1#,S(\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I%-S,S13@V-#0P1#9%
M03$Q044S0S@P.#0R,D8U1D1$1#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP
M34TZ4F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O
M;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E
M9CII;G-T86YC94E$/G5U:60Z9F%E-3 Q830M9F(T,BTT.#(P+6$X9F$M-S0R
M9F$P-C@X,S!D/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12
M968Z9&]C=6UE;G1)1#YX;7 N9&ED.D,T0S9$-41&.$-$.$5!,3$Y-S@V04$U
M-C1#0T9$-C@V/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z13<S,T4X-C0T,$0V14$Q
M,4%%,T,X,#@T,C)&-49$1$0\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T
M4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&
M<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z13<S,T4X-C0T,$0V14$Q,4%%,T,X,#@T,C)&
M-49$1$0\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C M,#@M,#14,3<Z-3,Z,34K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T
M179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N
M:6ED.D9!-S4P-C,P-S!&,D5!,3%"-D0R14$W,#="-C@T0S,R/"]S=$5V=#II
M;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P
M+3 Y+3 Y5#$T.C,P.C0U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O
M<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $D EX#
M 1$  A$! Q$!_\0 '@ !  (" P$! 0            8'!0@$"0H# @'_Q !8
M$  !! ("   )!P0.!P<# @<% P0&!P$"  @)$1(3%!465G8VE9:UMM+6%U57
MTR$T-3<X.51WDY>WT=35)C%29G64I1@B(R13IK@E05$RD3-"1&&!DO#_Q  =
M 0$  00# 0               0(%!@@#! <)_\0 4A$   8  @4'!@@*"@("
M @,   $" P0%!A$2(3%1D0<3%$%A<=$(@:&QP? 5-C=28G:BM18B.$)6<G66
MM\47(S)3<W23MM3AM/$SDB0T)2:"_]H # ,!  (1 Q$ /P#W\< ' !P < '
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M9F)69F661D1&+9Y J#@ X . #@ X . #@ X . #@ X . #@ X . #@ X =6
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M,Q.QB>DQ!'IY35'\!K:D4Z;1+C!SG)RW"-4Z*2%*6;22+04:2;,],R6:2QO
MW*U@NFY+YW)=CCD]L<8U<G'?X=L2ZW&2\+NQYR*%BA9CJ2W0VJWD(83*=4HW
MT)6J0A)M$;!+7@;2Z?6=V*A$*K3L1?S>6P<2=D$AGX^!5QK7!"P7>P]5M F>
M[Y"7G40@R%$5MSCAIZ$5UD9%-GLZ]"PQ;;:=>VP5:XE@0*O$N(DS:]F1)DV+
M=?6%5N62S;-%>@UIFR$QVH#BC?4@D/=*=)!KYOFTBXX0Y;L)\F%_?8KY,N3=
MVEQ!,KZVLPY)Q%BA6*(V&F2DH=Q&\4=RDKEV$N^BMIKVWN?AG5Q5/DSSYR'2
M51LFZ^]I0MY]-V8.S<222U145UQHG?1BJ"!2(.-'*<?:1<-8()*8:[[&# =#
M++<FA+F#\F6':G=45=\O&#C'Y6&\6L7^"$1[4I4JGI;V*[B%^G<=A*)11D1&
M+*.4W,WGV$\V;R9C;CKS?2"29Z;:O0:GE*Y(IW)]RY/V&$SJJK&6-,!6L3DZ
M@XRC0[II32[-^VG8:L%TAI*#!G.$^41RDD1XD*4=>:T))B2UF5/!LEFH*HVC
M.W8U*#$,D5JR^P&UKU(UGU=3N:6X^0?EIPTK?,N#B!,CBRB&J<3]9.CS-OY#
M=5QIGR':3_L'R7.HCTR$7,66]!E6\VQ3<4R+&ML)URXEQZ>BKZ:PPS*B:))A
M\ZN2VG\4U%J6ESH)\J>&]8XU>>P5:U$*]J\'TF&GL'8T>PWB?#M#@J.Y&AX?
M>Q25).FS*NW2X:KGHK-<^YI.H:5^,PN-9U =%G-'F>MA3>SD),EUZKZX("FW
MUAVXA25(6C,'4H:DMULR8EH'5 HN-1[AOJB1T*J:;/$U!FN^&FEUPY@!5 _A
MAX[8I18;K;JN)/0C9.8FVG*F(=-72W295')1-J227">,N<(V2/0+$^4CR@VN
M4"#RJ1$X3<J5\IF)<$8C4XJ\3.33N81I&JAZ*2/@F*J:BQ<0J2VX:XRH:5$P
MI,LR-XX(Y\'B>1HJIZ9;616DO85L6M B0%VM1 F90Z3[V/,#DI;D&:*$J$SZ
M%'XQH:RR;$8S8*+,SJWQDF,PDIA).WKY-I!4%11HM*N8W6/VSKK-OA]F=!EG
M:37Y:7$)3+9L8,F(3YMH=BV24/Z)<ZUD>B61->4S7.<H>,\=.X6Q522,50\)
M18LO!W*),HKRI3A>DKZAV,^MVFFX;OJVV5 *0[%M<-./P3</HDO32:U9R(^#
MH" 1-51<_:!F6Q>!=>[GH(^V>!]VQ>2#;G?NG9,B)*J'"&(PQCC=\X%1L+NU
M.;,1J U#)/?9EG=?LPN31B.S41)-L_-BU^&[S#DA+C&B]*:O'%+==9=.0Z41
M$5*U,Q8YHD<VTEI/.GS>:K?=^4]/L9N,+>MPE!IK?$?*7@3E'K769R7855+P
M)':9B19L-%?&^%I%H[':F6L]+U>4B6Y+<*(DGR2WRH-T<G[4O56]M7VUL:-]
M>(#+X'1@876K:'.AVLJA^($G(9Z13DYC,J)A(FF@+8MF: =!9PW3+KK8>*NM
M7,P, V*'Z@[C$2+.+ANMFUU PU5HA+:*9"^#BDV+I2WNF.L0R2RVE"6$J4DG
MC,EFLE\.(/*!PV]"Q@G!G)R]A>TY3,1TF(N4&=,Q4]>,RCI[O\(U5F'(JZF"
M5/$GW*G)<AU]R<ZAIU4)M!L(9-J75]TL7@R?29/:QD2?_9 8V2S7SK%-V?Y0
M/R@Q%Y%M5$L9D;GV8]4Y=>G;:;Y/^FXT]&QLTSMY_7O5N!E5Y8$([,G?P+;M
M&U'T,T?"7PC!<AD9?_E+Z)S.GSAD?2=/+0S1GI%9L2\O#>(%\OBBPNN)_3;(
MPJ^V1W*7_P &_P &KIFW4E9E5M?"_3"9Z.1I*MY@U<Z9/9<V>^'/0!KL*5BG
M8&LYX]?,(.1+RM<:W0=/O5$;/>2V1<;[)I;;^FL&>W_>4TVU_P"[IG]G'^OQ
M?L\JT#Z\B[S%.F75F?<0G7MBA[O3#Z-$/N\:/TD\0TOHJX![8H>[TP^C1#[O
M&C])/$-+Z*N >V*'N],/HT0^[QH_23Q#2^BK@'MBA[O3#Z-$/N\:/TD\0TOH
MJX![8H>[TP^C1#[O&C])/$-+Z*N >V*'N],/HT0^[QH_23Q#2^BK@'MBA[O3
M#Z-$/N\:/TD\0TOHJX![8H>[TP^C1#[O&C])/$-+Z*N >V*'N],/HT0^[QH_
M23Q#2^BK@'MBA[O3#Z-$/N\:/TD\0TOHJX![8H>[TP^C1#[O&C])/$-+Z*N
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M6*!W<2D,XM^0=;7#H5<$=MP^WVKR:32>G%&YEP*(1[8\2+E3NP\BOG&&C-;
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M=0V SL_#Y@]A=<5A#,S2-Q5O"R$L,1*'L@4E-EHT*31C@)B]*,\N(T"CR2;
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MX'_9LG[TGCQ_RA/EEQW^TXOW57C;?GL \:#@ X . #@ X . #@ X . #@ X
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MMS61&3C2FYD5AE]:)=<.#C95K6/33LHI$K#1H;:D2+"-'@QXD4KV+/DGB.)
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M?EJU:_-U";(>$^HUW;#&JF0&3/GZI.O8N44&2&K3<C&S6SZNC-MQ8"PKJ/V
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MK+=EGV]XV:7['JQ/KA2=MR.,DIC-K<%4D%!0J&:BQSF261;[,"DT&CW$D+L
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M . #@ X . #@ X . #@ X 1"8_M<!\7QCZT1Y);?,KU&*5?F_K%[1+^0*@X
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M*?\ $L_]SUP^M_E/_DK\E?\ EL)_PPQ"/5QS; ?) . #@ X . #@ X . #@
MX . #@ X . &M_:'Y "/C ?]2R#E:-I]WM(4+V%W^PQJ'X/CY56-\/A?K%UR
MI>PN_P!ABE&T^[VD.Q]_\N(S\-3'ZQA?./J/O+U*')UEW'ZTB6\@2' !P <
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M $B^:X;^&.,RW%Z?$,CWGZ/ /9T_[_2+YKAOX8XS+<7I\0R/>?H\ ]G3_O\
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M(_Y1Q^ 6!?T+PG^[E/\ \,/Z0,>?IMB[]Y+G_FA^0JD?T.57_5[$?\HX_ +
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MD )+91S#AH1!DDU=N22[C7QO62KC+-5WHST 99$1Y[<_0>7G&Y/ @. #@ X
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M+:DM-NF^P3CLME33?1Y34R/S;J2(M%>:!]LZ8-#SYA0J> !@<-?V(W+R>+'
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M#KV)?_"2YENMXGY#\J(EM<:-'KH"6]%91C>)UQZ'Q7H5!@49F,.)R%F3!2*
MOJ[%N15<0*+2T8+=$FY-N8-S,:+5/2J1,EF Q/#ERX'""&C+58L$?O=M'25F
MJ/)_H:^KNJ658L2J^RP^_AR*Y$PUA^JN(L5V4W*;FSKN+$586UFPN/%23KCD
M:'()@ES($AXTNHO5OY0^(+"UI+R)7/Q+"LQ$QB66U,Q/B*VIY4MJ*[$<A0*.
M5,175%8^B1*4;334F;&4^:(=A'8(V5STYUNG<LC.C&67[(#TM&3VNY]%I$M#
M0+8%&B%;+[.!:36&MWFK9SN8645<R%RL6UP_=ZM5$F[5NWW:KY#/Y-+^WJR8
MM^4&QL+>+B##>(*FQ<IH#<"KDX96;D5+5*V\33RIKBEO63KDPND/$TI#;+3:
MF7,=K^4_#U-:F_3<G=;74TK#N)<.V]8B[L';"UC8H;)J6MV\<9-UHH3:4-5K
M3<,^CLF\E;CSKB7FMM$\;ZIZ:J;X44UTUQNIC7&F-]\:XQMOC3&<XTQMMX]O
M)QG.-?'XL9SXO'SUY)&24DH])1$1*41:)*,BUGHYGEF>O+,\MF9CQQ1D:E&D
MM%)F9I29Z1I(SU$:LBSR+5GD6>W(A^^2(#@ X 5!V!_>-MW^;J7_ %&]YAW*
M'\1,8?5RW_\ !>&:<G'Q_P &?6:E_P#/8$PF/[7 ?%\8^M$>9D6WS*]1C"5?
MF_K%[1+^0*@X . 'E'Z&_P :%9_Q];?]IJ7-3^3+Y3\4_P")9_[GKA];_*?_
M "5^2O\ RV$_X88A'JXYM@/D@' !P QQ<N)CXDF>/$QX0&$'O2YDR6>-QPH2
M*'-E'A F3(/%$6C$>Q:(K.GCQTLDW;-TE%EE-$]-ML %!SKMWUDK&(UO/;!O
M"O8A#[@#HR&KSQT\W9,IT#7$BSR96-Y4QYXBR]3FQ!#==%+.B38DRW5SIEPG
MC8&1[MFWL%]!3(J1AA,A!OFY0(=&,#(<FTWPJT(BBC5)\/?-5,>+"C=VT71<
M(;XQC&Z2FNW_ -^ &3X 0.3VC74-<$6<GFL<#D!#.*DBHMR4;9+C1DYE"D*A
MQ1\(1W5)-1<FEJ#J.A22S71D0*L2#1NONJ.?8;@$\X 860R2/1(4L=E1T/&P
MK=P.9KESQ)F)&I.RY)H'$M%'S]9!MJZ*EW[ 4-;Y4\\_)/6C!KHJZ<HI;@&:
MX . #@ X :W]H?D (^,!_P!2R#E:-I]WM(4+V%W^PQJ'X/CY56-\/A?K%URI
M>PN_V&*4;3[O:0['W_RXC/PU,?K&%\X^H^\O4H<G67<?K2);R!(< ' !P TX
MNVM[Y=WA%;7IR,4M,6+6B;2J \'MVPYC"$6;^<2^MY(*,MQ\7J"ST):';H0T
M@V- GK^)*NM7+9!N2QHNNNT"2RZ\_,7_ &-8ZZZ:7S6%-6QUL;-*LFU>GTJV
M)0.UB-R3:*6=B35)0E UY$B1V%:4%,HT&*;V!2",F]>>VTY&CT'S%\4A4O1;
MD8@2"3,CU]>O,LM6LS/5KSRU^^T;G=5:AFM.5P;%6/),RB=3.S;'LV2OM2[8
MZ@V>3>3.R;8>B78PFMAS]5 9JP4*.!5?PX1N;7*>J(\.&>B(X"#//JRU$7O[
M[!LKP(#@ X . $2A'R?U_P",RG[4&>2>WS)]1""V>=7K,2WD"0X . #@ X .
M #@ X . #@ X . #@ X . #@ X . #@ X . $0G'[A(_$L)^VD?Y);?,KU&(
M/9YT^LA+^0)#@ X . '4SX7;]YFL?YSL_94]S43RP_B3A?ZT_P IL!N+Y&/Q
MXQ7]5"^]ZX6CU\_@.]<?CNF?_D='^95R=?(1R;?M_!/\3*T8GRD?+[RG?5['
M'\,+$;?7SMMK1MS;:YSKMK5%B;:[:YSC;7;$0,9QG&<?LXSC/[.,X_9QG]G'
M/9,?F98$QJ9&9&6$L2&1D>1D94TTR,C+61D>PQXMR>$1X_P,1D1D>,,,D9&6
M9&1W4(C(R/49&6HR/:.LNMB%>P%[U1.]>EAQZPB512(S>,.A$H6-8/,!%/)&
MU?;D2T(DFH4UB?:,F@E9TT8O]S;Q5AHFOMKZ-IJ]AA_#>'G^26?R<*BS\12<
M'V4S'=+16KDTK"/#P8F>KX>B,R934&<6(4L-1%NLL2%3GE1R2X:>:3M3BF-B
M7$;'*_7\I2)5=AN-C.L@X N[^H1!^#I,S&JX"/P?F/18KLZ">'%2'IJ&7I$=
M->PB0I39&3JK*AO:&UG8X:^3LBJ;!>SGKM.+><M4!3< 'HN6 60IR(#2\B/-
M/W&T95(%UHZ^S(<-#&I0*X7V>-F^5TM<GI>53%KT>,^G$V$L1/7O)Q>XQ=:;
MAMU\+ 5O7L1'8<*YDQYTAPZM<B8Y7/\ PES,TI4%UPWVV]- Q:\Y)L(,RI4=
M6%\88;CT'*908+:><F.6,WE!I[&1,:FSJ6-(@1FBMD1H3=FP5:;T$XDYMLF'
M72;6<9:]OK<90"1MGA/=].F\[IR./B3F-UFJPA,?LK!?5U(ATJ!V*G6,I;.W
M ?+2.9D[Z$MA3@@S4/OB+-?S[:UM<L>,&,/633TM4B^;O\%UK\IRLPNJ/1UV
M)RF$[9QK:#B5.%K5IYR$;5:=H_1M1%R6%V+\AA9NM75[D7P9(Q'6.L14Q\/N
M8?QO9L1FK3%29%]986Z$;-9)J)^%UXLJ7F6YW/6A5,:_<F-1GD5K$5]OFW=Q
MZ0MZ6':5E\]G[9L9?0<M8+=-S&'40*/I6"AV%W3-UNQ@TIE\982ARBFH*(!A
MLA=MM3#-11MMHS=-N>SX%QC;6&"+C$&(6FYC]%+Q"VEVK=II<BW@4I+>9=4Q
M0VUS5Q[5U"51)$*-8O-%,94MHTL/-#Q/'N"Z>OQW2X=PX\["CWT/#;BF[9FZ
MB1Z>PN^;:?:2_B"HI+614M.+1,C3I58RZ<)Y*724^RZ8Z]>G5CA8+>X05)"(
MA\7OB+ID(<[BLPC1ADF,EQ636 HE=)A1<:5.V^ >HL(()RH*2=+-'"K$<@KK
MNIS7;D8Q+!H<?08MG)A/S,?U29%*[4W-9,83%MY=IB)3>-IJUQ9<_&5>\B/0
MQ"5$0\MIU<>,VLLQLCRVX8GX@Y/9\RKC38\+D]ME1;MFWI+6%(5+IHE5AM*\
M"P4-RH=?@JQ8<DXAF$B6IE#S29$EQ!DDQL-W,"Q^0VC VI63U4L[&UW*GZ5:
MWZ^DL6K8ZQ7+L4GDBB\U$N6HX?9 K#?5JDV<ZOG+80YT(X19IZ:N^>B\M4*N
ML<54#,NUPDMZ-ARVD(PSR@OV=3AF>PN8PAZRJKR(ZU&C8FBDWS*6G4R'6X;A
M2>;90CGAYMR'S[*MPEB%Z)4XO0S*Q+41UXIY.X]5;XHKI#<.0MFLMJ*8T[)D
MX7F<X;RW6E1VG9K2HIK?4HV1"8IV+D6\2JL& L$30$/8=<W-F,SEO(:V"_E1
M4),BD2]D\&7[D*[,AF(\.D51<@F>986#F@RS%IIX]-%+'4<I-DJGPG K\0Q.
M3VF8Y-W<3L3\8MEB*1:RX-U+J/@<YLER"[-A1X\)$M#L!D[>7#FPEL-%^*E=
M]N.3*M3<XNL+'#<WE&NY'*:UA5ZOP8XK#<:HASZ2'<_#!P8[,]F#.D29RX:V
MK!_X&ASH$UN0\HB4I/Z=6%94'L;L3944E070$WNWK6+.1E>,*NT92SGD/K@
M2V1)$'Z1&/-VS0QJ]%I-FFK[5UA3!)5;7.J*9W$6)J'$O*1B>HMH)0$8YY,H
MD^L<JU.HMF;^FPU7R31*D/IDUS33,PGHJ&V>?)PE%)4LC)"8:PWA>_PQR9X7
MN*B<JP<P'RI2Z^U;M4LKJ'\/76*+**3D6-'7&LG'7H1L2U.OG'-HT]%0V9&X
MJ31SM)<Y2XCPO X2^!,K(MJ"_DY7<5P)*(B8 &,.@Q,+NI82EH&)0^=BF3XP
MS7@&8^X"EEE@BV,-&[E>ZUO*MC65C.?%*-$?@,8EQ=0_@VX[AJ'*1#P]"FNP
MY4(U8B5BJ9;/O1&'YC"\/'7N0IBUP5ES+;CEJL^23 T3!%?+.5+CV#^%\'8@
M_"9#>*)D1R9B.=!9G19Z4X:3A*%41V9<B/"?;Q&5DW.A(;GMF;SC3=/B[JGD
M@DU?VNO9L/FTT3ZD=A+)9QZ-@F336O)'D,"*LXN69-2A#<DB/(#$F#=(PBB7
MW<C3&':SE%RWT;89%QO?V-IA[%R\44U[>)Y'^47$S-=60&&BPY9G!KYC-3+8
M9ER5241I,5$=M$U")BG8LSGEN(=;2UFDO F'JVJQ'@]O"MW14:N67DVPN]96
ME@^\>):PIUC#>M8;[L2,F*N3&EKD.+A+7#2U*A&RAI;3BG<_>_8 O9%7V#%V
MDECYL%MU/IVQC6X#9BNJRL606<(:&VZSUBLKEGG49LPWR%WVTV::N$E=M-?/
MZ^5<,?<H4S$V%<1U3-G73X!\D6#<2SCKSCN+8Q)88HB,SFW'XZU&P:8W1U="
M4:39YQ*S26F0M_)[R<P\+XKPY;/5=E L"Y8<;X8@E8E(;0_AJMPG,>@.-L2$
M()_.44A)3DDHGC;4A*CYL\K8']E+>(]BB,/33"MXN.O92HU8:2<5L(65BB8/
M1Y[9LWA:PV-F$9*XW4Q(6(X; 7D8?QW11FR?."^BGF\NC\IN,9/*1)IDIA-U
M4;'JL'KI9+F&8:EU*8*7OAME^9B-C%$JS=-16+$:+A]ZJD5Q*88?=F$K0Q"3
MR6X+C<F4:Z6J<[;RN3Y.,T7<5K%,Q"+==@ICX#?8AX:?PI%JFTI.MD2I6(V;
M:/9FF0^PW"4DE[>=@?WC;=_FZE_U&]Y['RA_$3&'U<M__!>'BW)Q\?\ !GUF
MI?\ SV!,)C^UP'Q?&/K1'F9%M\RO48PE7YOZQ>T2_D"H. #@!Y1^AO\ &A6?
M\?6W_::ES4_DR^4_%/\ B6?^YZX?6_RG_P E?DK_ ,MA/^&&(1ZN.;8#Y(!P
M < *;O\ JZ%7%4<T@\^A@NP #H0Y*:1(V.]<BBIH&EN5C^KP'OJHU->BFFK)
MXV&OFSQHN];MME&BVZ:>, '3Z1@S:)TIX/0Y8V_?&HYW6O@[,5Q&CO6ZL3$M
MQ'K#/PWKF\D%<SN*Q^M+"GP*T'!BLH]O%Q$P"@:^,Z@)3%9(Z=OE%@C@*\]9
M_P!G+2(]?89^C7KRU[!>W:>:7$&Z&=1S'8 M9L'MB3V7T8!=FV_7@A,A$Y4-
M2Z604?>,2B>*A<>VCA@4?O)$(=B:\4='G0K==M#\.2N!6VSW]\@(BS5EK(B5
MEGZ#ZO?:-0Y22N!9J,A[8#VUVZV26^^PI>AIC,7_ 'J7)A*Q"UOU[8QB-6-$
M*89,.V4O>RBXS_8HOUR%V?8E=PUI7T60<*NR[K-3(#0:MNK/(LR_%RS//7F>
M9;"+/+K/++:*S@\6[+M6<$LJ4 >WC?L=.^@/@V(J5DN['L6F1?S&MNY4B:=C
M ,TP/<OXH%F(NNCD;+RH9*W*9PD D<WE ]0LVD-C&B+M!666K+^VKAJRW:MO
MMZA+(NW[K[V/.G)R5]A&US8D?=W:QXX#KSMF\BKVNL0Z\DZ.9!I7);$0ZK!X
MP@\WI0E1ASK[$WEM.CC-F#>C<OREYDV<=?7[^_OK \LNK876G//5GJ(L]^H^
M_</U=W7VV6%/*QMVV[CSN)23JWT9N>V69.P.T%D2%Q=\"[45^9MLJ$;I2$S*
M05@MJR4DQF25Q6Z(I;#>.@" R%H$HK&E1\B"/KU$99D6HNLC+T'EK/9GK,;"
M4&^N /W[PGHGV3L&$3"RKU;%WMA#^VU<:5'6GLQ(SM=NI8+G9:==2;:JE9Z%
MB,4IPU7KNJKP8*2X.]F\9(RP9>R.H3JT>K,LMVO7U?G%UYYYEJ_5R[QN!0'
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MF,EL/*MSD8/M,>5KYLB$+M6Y!@M^SYIPCIOG7;Q>+@!*N #@ X . #@ X .
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MQ 6XW:$F*1N.N2(Q1X.=Z;M7S;1SE9HXTW1<:)J:YUP 33U&%_,XOYO:?J>
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M"L_X^MO^TU+FIO)E\I^*?\2S_P!SUP^N'E/_ )*_)7_EL)_PPQ"/5QS; ?)
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M?_\ 1'^<C.I>O<8A>PN_V&/.9Y&_^SM__KG^[G:S+>7$AQ"^^M=#'^Q-J@X
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M;3?7.-M=M=I08SKMKMC.<;:YQG&<9QG.,X_9QR3V^9/J(07M/UF)?R!(< '
M!P < *X)T]51F<,;++5U#25@#4VR;&8O8\,<R!OAB@^:#U-22K;9QLX'-"A1
MH-=;[[.1S4F1;,E4$7SK1:XMV]HS"76M6$QN X:C7#1(=3'5IJ0MPN;)1))+
MBVFEN((B2XMMM2R4I"#*VNTU2].19O5L)VP;)!(F+C-*D)YM+B&S)TTFK2:0
MZZAI9F:FD.NI;-*7%DJ#,^J/68>*? V%"5*R$$G !V]'M()'6[==U$\F?9)Q
MG5%AIE-:)8D)K2**)9TVC29%RD#RP3VUUU[J\4XD<=0^Y>VRWFTOI0XN=(4H
MDRB9*4G-3AYE+Z.R<HE9E)-M*G^</,SZ",)X8;:<8;H*A#+JF%K;1 C)2:HG
M/]$5^*V6B<3I+Y1#3ET4G5%'YLLB+&#^J=0(&YN\*1@&<BTLBU2PD36[R,QE
MM!(+&J8(3F00UO%!(\0U6;%$)79$OD:AQR[<$6SQXP2%J#TAB/E\KF*;=3$)
M#4E]B5$E6TUVQ1)DJG3I-RW!CRU2G7'5$IHXE;#C$PE"6U(0X;I.&Z>7$WA.
MG2_.<=C,/Q9<6HA,UJXT5$"OC4KD^1#3#:;90I#I2[.9)-]2U.)6MLFC;)HC
M5-=>O]&Z.H4\3J*N4G-<MA[*"*I0\$EF*-!!'UR(;!<)LM=62 <UXS@A)/7&
M@LYG)EAAN3SEUGI_#]V:9J#MK$TV*G%SB.6^?2UO-\R\I_-9FM3S/]0Z9ZW6
M/ZE>DU^(.]^#]$2H2RIZTE5J6T0#*''(XB&7.>90QDV1-I9?_KV4EJ:?_KFR
M2[^..$,ZV]?PI< >$4S6HPQ%EL.(Z08PX&U<!ETS962-5&&R+/35#8;(3ILV
M'SKK_P#12I<F^$^AN7SE12MS$=^\U(8=N;)QF41ID-KF/J2\DV6HRR<(UGI$
MY'899>(__F::;0[II0DBH:PWA]EZ.^S2UC3T0]*,XB&PE3*B?=DH-LR06B;4
MA]]]G+_X'7G7&=!3BC/B%>N-42*Z'E[2F+B97-MHG6T4";R(0'*-HII5\HL2
M7@C$<W<L-WS(PX-V&X>NU]WBR*+R-Q<B.08DQ>'BM36(K6/3(HXLIV+"Z78R
MWRCNO-+E'9Q:^(^S(T7"0ME+->E"$DA)FB3*;<4XT[H%0]ANIDW2[Z7%9ESN
MB5L1@Y+++J(A5<NQFL/1C4V:VWE/V*EK4:U))<6(XVEMUK3/,,.O]'"RIPX.
MJ.NV1>2$F9@X1;1$(DZ(E!\K9SQJ_75T9XSASI.1[&:;J)^;RO+&C>1N/.F4
MM'N.%=]=NM,,.6U@MF,VMEAM4MXT-M+BK@J;21KRT3@N.0R(\]&*M4=.3)F@
M<R,/T33K[[=17(=DNH>?<3#8)3CK<M$]#BC)']HIS;<TS++2EH3)5F\1+$BG
M]6UO:HYD(LJ#16=#!KS=^/92H(/--V3Q9FY'.5FNCY!;"&7@QX]%O]4_)T?B
MWKT:]U78NW#=3KP+2QJW%O5LZ5!=<03;BXKSC*EH):7$I4:%%I:#B$.MF>9M
MNH0X@TK0E1=FPJJVU;0S9P8L]IM9N-HE,-O)0M2%-J-!.)/1TVEK:<(LB<:6
MMI9*;6I)QUQU_HUT<-R1S45<K'I(%(1T\54AX+9V6"%@2,7+#GRF67_CH%(P
MV:QLEG;&5'\?:,PKO=88T;-4NPF^NT,LQDVUBEB,\W(8:*6_H-/-/G*:<06G
M^*;4I2I+>6IN0M;R")U:E'UE8?HEOOR55%:I^2PY&D.G#8TWF'F$Q7FW#T/Q
MDNQ4HC.YZW(Z$,+,VD)062E-,5+-TGJ4NK>%R+4@L!<N]RL>&.UU7,7:DF,<
M=8<J-\N$G0-@9+L!3E%5-=BQ+$V;=31L_=)*\<6XM81H.)8S(_-D^E!-2'4)
M),E3:Y"=$E:)I?6RRMU)D:5K::6HC4V@RY95+43B64RMA2><..I9NQVEJ-45
M+J(RB6:=)*F&WGFVE),E(0ZZA)DEQ9'^'-)T\[C)6&.*O@6\1.,8P,+1G6*!
M4@3X?"-&6D,9K"TF:;/T>):C1WLRGJCKJ"RP9;"\-=FJ&4Y3=6Z)+4Q-G/*6
MPY)=:D]*?-]#DTUG,6ETUFO2EFXYTD\\W^<63NF2E9PJCIEQ782JNO.&^W%:
M=BE$8)A;<$D%"0;24$C1A\TWT4B271^;0;6@:$Y6?RV"Z!P < ' !P B$X_<
M)'XEA/VTC_)+;YE>HQ![/.GUD)?R!(^>4DLYSG*:><Y_9SG.FOCSG_\ .?V.
M &A$QZMZ6KW18VW+QVBE>UU HAD6S<)8RVD\X0*R)XS:[IYQY*PV.IJM2Q+7
M?Q)N'BHEEMHY:JD4D^0EZ+9I+::C\Q9%Z]?I%&CFHS/867GU>^8W[YQBL=3/
MA=OWF:Q_G.S]E3W-1/+#^).%_K3_ "FP&XOD8_'C%?U4+[WKAM?T1_@D4G\.
M$?M,<YZWR!?(_@?]FR?O2>/'_*$^67'?[3B_=5>/U<_4QI;-M1F[0%[WM1E@
MQNN3M5>LZ=>5+JW-PN0R4-+7P\RRM.HK12POH; C7#9\']4.DM$=DLJ;ZJ;<
M]?,NTR[LO:1CQO/5ED1EGGU^PR%!$?!6T-N+T#Q>P[S@3,I2LQH6PW$<DD$*
MGK3A%A3RP[/G;R4RZ>UM-)=')A,9];%CR62RZJ3M<&3#R4JH/EUF06,-0<B=
M(]N19D>9=FPBU;,BR+49&)^Y\'S61::5[(Y19MTS:(UC(XC-8I44T,5[(X"-
MFL+@3"O19\:7(5KO;$;'NQ@U N:KV'6;&ZH*R-4B2<0+S1@PS?A&>H]1=^O9
MNVY<2,]FO4,<#\'/6 V!/JG.6]V*FU3M*QVJ*M:XD<_C[".4W$&IB,G(PO"G
M$*A$1D4FF$ ?PJ'YKR?W,=M6;PQO'TVP4\V2-2G!\)TMAD1$>>9GUGWYGJVG
MLR]!97E176L=2,HM*>.[5MFXI_<:D)WG$QMA[ =GSC6O@Y !&6X<+6E>UK#X
M\S;"B&Z#IF&C3-L^<I>MG*:AE\7($@@SSZB++/9GU]YF->'/@RZ5)18C71RQ
M+N/5.QKR[:SJ:JR4C@^L2H"/W]#I%7TY7JUX.KIA,2!1A!Y;(HE!W%M2JT6T
M%CA=Z%C;-B-74;;!.D>9&1$1YD>>_+?KRVZ]FLQMO&J0A\5MN0W.-<G5)9)J
M=JFD"#9V]9JA-(?3LFM25Q5RU9ICD7:9UP2N"4IF7JC]9F[:-PR34<Q4:.EG
MP1GJ(NHC,^.7@0UM4Z PL?*7T[@EVWY6,Z_*5>%C1:6P\A43PA!$.R9H)++S
MKR/L)Q3LRCQFO+!G,; SQV-L$+-C\?E086ZA\DCK <S'( SWD1[-1Y]19$>H
MR/TY=@ATC\%OU_,@FT9$2ZX(<"1JBH:M>#@AZ%'$3R]#WJ5[(599$FWL.OIP
MO(K  6](Y?)2_K=9U!IYI,#XVQ(/+&&XU :$Z1YY[=NWM+(]F75EKVZBR,2(
M;X.:I4BQJ222R+JG4IDEA2&SY#(Y.<@+=V3E<EZMG^H#W=,7$ZWB\:"!VM/G
ML(B8_&P08,,D <02;,]6FI(82",^PMF679GGW[>WV"M[RZ NTJ5O&O.OA8Z_
M-]@J^IRI'S>P9T) Q.JR51P\+!(!V;C;R/5F_G1*UJS'Q&$2%G%V<E#QB2GH
MD*<,4HD1W>EUPDE:R,^K,]19YYF9Y'F>66O;Z#&Y9CK)4AOK8VZH.0KUI3S"
MM(]58D8()NA!@''8B+&#8H]"&V&47@R0QM0,)+!3+?.KAD:'-"&NNRB?D[!&
M>O/MSWEP/VBI!'1: ZR#:=3VS[DM^T%I]2$Y>V?8!*NVDG>M>NQ*5&:G@>1=
M=5K 8(.@H S.YN8=L0D-%G39:6G"1>0O'CA%9N SSZB(BSR(L\M?7K//=U]1
M#=O@0(A,?VN ^+XQ]:(\DMOF5ZC%*OS?UB]HEVVNNV/%MKC;'_XVQC./_P!L
M\@5""6>/5?UK8;%BRW=OGL&EC1FU;(96<N73D 01;MVZ2>NRBJZRV^B:2>FN
M=]U-M==<9VSC')+:7>7K$'L/N,:]]+^M#/KA539B20;J6++M6AJ>D4\IJY1>
M82VRPC39?3RL;CXXBNJW\K3?=)T37)OTMO,ND4DJG%FM786>1=F_O,0DLB[]
M?_0Z!^AO\:%9_P ?6W_::ES4SDR^4_%/^)9_[GKA]<?*?_)7Y*_\MA/^&&(1
MZN.;8#Y(!P < ' !P < ' !P < ' !P < ' !P UO[0_( 1\8#_J60<K1M/N
M]I"A>PN_V&-0_!\?*JQOA\+]8NN5+V%W^PQ2C:?=[2'8H;8,2,SC"!!DT?(Z
MQV8*ZHO&Z+E+535_#==5,)KZ;Z8WUUWWUQOC'E8UWVQC/BVSC/&1F1'D>6LO
M:.0R(S+,L]1^LAF_9>,^[H+YH'_X?C,]Y\3#(MQ<"#V7C/NZ"^:!_P#A^,SW
MGQ,,BW%P(/9>,^[H+YH'_P"'XS/>?$PR+<7 @]EXS[N@OF@?_A^,SWGQ,,BW
M%P(5?/[&ZXU.0 B;3GE)5J5E67&(N,G\H@D-(23+1=FV=X LY$^'.3&6KD@P
M;N,#DW'F5WS-)3R5'*.N[,]Y\3#1(]B2/S"5NW=4L!DK-/G->L@\$U?;3@L[
M6C;89#=185K(R>TK?K;:-8[J.CSYD>?9+JL\- KQJ4<>;8N$E]V9[SXF&B6X
MN!#Y0LE4=D1UE,*[?UQ/8D3W=IC91"W49E,=(*,':[!]HR-@U'PQWNR?MG+)
MWJ@Z4V;.VZ[9;&BR2FFK,]Y\3#1+YI<!*O9>,^[H+YH'_P"'XS/>?$PR+<7
M@]EXS[N@OF@?_A^,SWGQ,,BW%P(/9>,^[H+YH'_X?C,]Y\3#(MQ<"#V7C/NZ
M"^:!_P#A^,SWGQ,,BW%P(8R")IHQM%%%/1))(M)TTDD]-=$TT]).8UTT3TUQ
MC73337&-===<8UUQC&,8QC'![?,7J("V>=7K,3#D"0X . #@ X . #@ X .
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MU;-FK;YM0V.C_9SL[#2-O1!&U8?,)U..]O8N#UJ"_P"S[;]P3816E710.3>
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M3,\B(^W4>KOW""FN^M*Q+HK$_" 35K+H[44PIZK[>%1E,2V-V*\Q<(Z,K0&
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M1KIIY.FH!(_/H?\ K)?TFG]_ !Y]#_UDOZ33^_@ \^A_ZR7])I_?P >?0_\
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M1+125AHJQG5YW/-+B:-';_"[@-*'UPJ5;944429Z))6A%@\^'QB0M5]6J,@
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MMH9*2>JV7.I&1Q>&!09M_AQG.<KX=DV+IQA;.<Y5PIY><Y\K@4GM/J%N\ '
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M-=---<:ZZXQKKC&,8QP>WS%ZB MGG/UF)CR!(< ' !P < ' !P < ' !P <
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M7*E["[_88I1M/N]I#L??_+B,_#4Q^L87SCZC[R]2AR=9=Q^M(EO($AP < '
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MDE1AAKKHV+#U-%]=V1)OIJ@_;92=):ZIJZXQ);?,KU&.-7M+UD+*Y D. #@
MX =3/A=OWF:Q_G.S]E3W-1/+#^).%_K3_*; ;B^1C\>,5_50OO>N&U_1'^"1
M2?PX1^TQSGK?(%\C^!_V;)^])X\?\H3Y9<=_M.+]U5XVWY[ /&@X . #@ X
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MMY\"\0U[BXGX!Z9._=V)?3,Q^ ^-6\^!>(:]Q<3\ ],G?N[$OIF8_ ?&K>?
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MF T<R;Z8QH@T8LFZ#9LCIC&J2*6FFN,8UQR2V^97J,4G[2]9"Q.0)#@ X .
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MUP^M_E/_ )*_)7_EL)_PPQ"/5QS; ?) . #@ X . #@ X . #@ X . #@ X
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MI_Q+/_<]</K?Y3_Y*_)7_EL)_P ,,0CU<<VP'R0#@ X . #@ X . #@ X .
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M^]ZX;7]$?X)%)_#A'[3'.>M\@7R/X'_9LG[TGCQ_RA/EEQW^TXOW57C;?GL
M\:#@ X . #@ X . #@ X . #@ X . #@!$)C^UP'Q?&/K1'DEM\RO48I5^;^
ML7M$OY J#@ X >4?H;_&A6?\?6W_ &FI<U/Y,OE/Q3_B6?\ N>N'UO\ *?\
MR5^2O_+83_AAB$>KCFV ^2 < ' !P < ' !P < ' !P < ' !P < -;^T/R
M$?& _P"I9!RM&T^[VD*%["[_ &&-0_!\?*JQOA\+]8NN5+V%W^PQ2C:?=[2'
M8^<9'/7@4R&9C'_H P\.<MB)1R*_=5R!<(K(K-Q);SGF_5*NBB>Z27_\73;7
M?/BVUYQEED9'GM(]F>S/M+>.3K(^PRXY> >GSCW9C7TQ(_@OC5O/@7B)#T^<
M>[,:^F)'\%\:MY\"\0#T^<>[,:^F)'\%\:MY\"\0#T^<>[,:^F)'\%\:MY\"
M\0#T^<>[,:^F)'\%\:MY\"\0#T^<>[,:^F)'\%\:MY\"\0#T^<>[,:^F)'\%
M\:MY\"\0#T^<>[,:^F)'\%\:MY\"\0#T^<>[,:^F)'\%\:MY\"\0#T^<>[,:
M^F)'\%\:MY\"\0#T^<>[,:^F)'\%\:MY\"\0',BHY\+"H-".K;1[EX7>+ILU
MU'39/)(P_(Z)).%6S11;"2;O1/939LCG;?7;.$\8\7!ZS\Q%P+(06SSF?$S,
M2'D"0X . '7*W\)3691V0%1BI;AF)Q H$;"!D7>4D2;20)((!V!L=A*PTGVN
M5O#%@N /6BRT'**DC3,(%\1X;D9LL2>Y%!.B?=WZMWB0LBHNX+&\K=A<5@D#
MDS>JI?6U^2X59\DUC[)O)S](V32E;EA$:##Y42DS%F..6-*1AI:8QB.[/GT=
M9NXPJ4#+;OW(#++;M(R++OS\W5U9BLHQX3RCY1&MY@A [J'1M\$:G(<6)12-
MIM;"T/P6?V' 0D0V;S)QZ3+;' 5G*THO%2>!9EJ7U B92VCCR5QI,H$Z)]G;
MV;,^&>L9@-X16N91)%(I$:AO23F'EAN:XB>6(6OV N:%!I^:QTR1$G#]CAPP
ML8)=00J151E3X ;(@WPH@$#E%?7+,*$9=I>Y9_\ 78>W(29_W;CIFB+%NBL*
M]F<M5KO\F0TM$R^\9C91"9V$E"B!6O7JKN2[L64SK41.PBL\8.7J IB86WCP
MTX2(M"6K &6O+OW["+//N/L$)4\)O0VIN019&*6T[EL8,B(H8BZ &):E6\W(
ML)SZPAN-W,X;C=BL4E<0"UU+R6Q#2*Q^;6C5[1[(M0L@(' H,NTO?(\^!ZN&
MW4+;D/<N P^K'UJ2Z&6*!8@)[.JSF,=491(@?A\P@L;F$@R/*+BIB]C3]&8N
M(L,C$&<Q^0F/7,JG\$#/4A*Q SL!!EF>69=7IR\=?G%-B?"@T"?+19F"B=P%
MPDF900SO+Q\2#N@ 2.6(<]D0<C)HMY0K(%Q+";CIM$)5N'!E'45(UK.7YEJV
M ,PI<Z#(^PMNT\M99^_G(1<-X4:NI+(Z<;#:VL\*#MHHC'@[:5QX,P.&3<OV
MKC2K]P9AG+GD 8C3BLW?LCV95*@[X27$M@B394K((BUE(3H[=9:MNW+K[.SJ
M+K%N+=Y 9BA.S]P0^LIKI(NMD)F$K(UG.GL*B\O+;Q^+G9$+]9@FLN,'86,,
M:@7N$E9D, DG;-J[=@AIK5+3"H1EL[>_PZNO(5ZGX1\#%6CQO:E.V8#D!.S+
MT@U:MH]I "X^RD*>[)$Z((:AE=+'7=!2<<;K1HQ,U9BA&!;I7,B5@RTE;,QR
M#\&7679GM/+5GN_]=8YSKPF%9HB=#3>E^P+IHZET7KX6AN KD83)ST]1(_L4
M6BB8DQ9S BQ>0ZNRH[0\4+MA\;?21VD)BQN1-L[$]09=I<>TB]O?O(1JPO"3
M!7+C:$4G7<N.V$<=5LC$B\C8P=W$M6<RO;KO24D7/1Y&W8K*Q4FAS_L9%7.]
M=3%S7<B>D6;]@7=1A@CDSL BZSV>G61F75UY>D<2/^%3KG$(8R6;4[<@DJPI
MUU;$]91<5$96*AZK>JY9<B$2V)MYHW5?$BT)BS9P++>AMXVF2F,.%'#(1\ZD
M2$9"33D>TMO7JZR+W[CW#LUC90@; B"Y:-EX>2(L&[M]%C[D \- 7*VF-E1A
M-W%3<CCCAXUVSE-94*>+#]]L>4W>KZ9QMP*1F^ #@ X 1"<?N$C\2PG[:1_D
MEM\RO48@]GG3ZR$OY D. #@ X =3/A=OWF:Q_G.S]E3W-1/+#^).%_K3_*;
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MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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M@2,FI"2C@1<PK$(Z]/DQ(IF4D),?ZV-O2!-V^=N09GK[3S/OU^(NO@0' !P
M< ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < '
M!P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
M ' !P UD:=/J"8)#=&$<E[%P#>BWL<+,KBN=I(HIJ%$S$",%P^3-[!3D,0C;
M4/8,S'XBD:)BHRJWD#W5<2KG"&409Y^_OY]XNX;!HR')E3 MF\8D3LG0F1UP
MW-G=,')$U@PFMV[XTA@EZ.612AX$(/U&D$G OTT0-D&669$R;EDP"E,=0.O_
M )IRGF)2#919T]=,7V]H6NH7C/K/:2Y+,8*:WG&Q>O0IE.825H; 09]'@9H<
M7<#"@]V/U0;) S]_?T;NH<9OTQZTM)&E+FM:)MI(B>;R%$NWEDZ0=).&KUF1
M;!M,I2?5/6%(NQHS=.O=4\0/5,8,;8C?HP]FB@$YGO\ ?7Z=>W:)+).L=+3
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M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
)X . #@ X ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g69956g33a91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g33a91.jpg
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M-E-6=I66U-7A\0E2=[8C)#*B)3-"=+,7.$948G+_V@ , P$  A$#$0 _ /\
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MRSQFQSRBBL=[6OT9>[N!!W([]'QQ&Q_,1F' !P < ' !P < ' !P < ' !P
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MIF.1834YXH;"Y25+*0MN+Z%*G34I2S(U+/GFH6?SU(\H' !P < ' !P < '
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M*6N*X[.FPU+)2'&?6H;CC3S?XS3SC2DJ.[.=\/!!P < ' !P < ' !P < '
M!P < ' !P < ' !P < ' #7KR UH>V544J8.&/+(1;;;\EK.S7K]CR%A#8QZ
MU=PQGDPRF[A9[(C+OJ'K/*+'KN?/T(H\Y,<DJM?N\#S+<,%$9V[_ .@I4+I'
M9X\:QW"8J C<:"NLVIT!U#]0?DZ35SC^??5GJ]';QAAPAN- S&OZ]:@&DJX_
M&CZYG6RDSYESBZ#V$9%ELR*WD>NW,3FGTEM,C//;F=_,M-F0D%;2C@4C!UCX
MC+!=KT]URT5:9F]=P586F1;D0EV>S'>ZC)9#IAY"W#E7ENC0UC.'""QUU6J2
M\G.SO?\ RWZ[$9';++P%YIVM;_-8NT[E?//^UQXLM3;7FF"YWA\]]E[!:<@"
MO>;A'A_!O951P>)^IV!_5WJP5D-WJA>QG(,KDJIWLK\@3GA@@PSY;E:W1^-<
MK;=.C+W"<T],[)L=]EMH]0'0Q#WB&TC*97A5Q^R=Q';\_1FEG5+@6RE<Q49<
M:M4CW?\ 0KXRU*,U.U#%+%-7^5FBSAQQGRG.R//.R;9:;?CK#FGD5MG.SOMR
MR/\ H,(.T]N+J]KZ8SB1N6!2QK<9$5K,HK&=*OK16Q.S?*V;5R>Q/&5I]UO6
M)0M SF=K89!B.52MC'9PO.3GLSO?(\]/BY6SRZ2G-5EMRM;,LCZ=W5[AG;VF
M6N)4BJX*=<R8/;&;BC;),<@M7HUZ0HXSIMBA6)G:BW-!5B,U,YZEZ,AT-PM3
MW:P.X9KP]P0E%?,\B(B+<5\RS^-I"\T^;LS,[GG\%XGPKGK7VQB5V=-D"7R#
MR(U'J0?6896V.K$C,M4RSX9,WRW5_P!$IW!6IY^E,-]?*?)814<:V58C<RBI
M&69F>1J4=K;<BX]@ECN96N9$FQWM;+HV"X]9"KA+<KG7J%L"J%K0VRW@$U6S
M-)!@W;$C'RG@4N7?>5?/-.L5&:#&I%)GT/Q98(),898ODNH=N:709D5^PO*^
M6X9%_P!1Z%>W1:_1YC;/F S#@ X . #@ X . #@ X . #@ X . #@ X . #@
M X . #@ X . &$90_;"N'P&-N6AV<"%0_5Z'KXYJ79.C/2ZMQ=>EA\<M?N?Y
M:/KTL?CSPZZ]+K_+U\-3AG4:;4*>3RHYSH,N&3Z"NM@Y3#C'ID%=-U-\_GI+
MG%FDLRVC[Z7-*FU.G5$V42"@3XDTX[F2'RBR&WS96=E?B.^CYBLCR4>1[!IF
MAJ7D73UXL:=R0$I"_@]T^R(-';F;)2.6[S-74.E5,8M>TQ..!I>PMWHJ[ TS
M,@VM9^1QDHU*T]CK&QGI6@4CE)9PY2\&?-^B8?/#N#:GAZ/C!538GNOU1NC%
M2:)4L.L1"*=3DNOH;J-554XS3G,)4=EMQPDN*WAB*L\F3^):MC8L15W$7SDQ
MK3,12,&)I<BGLQZ4[6CJ]<IF)'YAJ@U)3,=;M-I+=+E/-<]29#SK;5VBIH7X
MU[=N4Z5&JD6M>+.5CQ]HN*EWLN U,Y'TW84!G96SX2-(U/C0]>5?E:'67=RF
MT,>?Q2W1L-JM5ZS\5$Y,L8/L,1VJ$]AREF[R>,5NCGB=N<Y6ZA1L1(FXGQ2B
M2Q-63'K%)-<<S-]FJ5,[*?BMO--$?MY?*E@UEY^0]7F<254FN4B11*R6%G(#
M=#IU<PTY!PMA1<5^ V<CU>K\R18F'Z32R+F1Y3C+KII]4_BIL@53/1K"]U4D
M*8>8ZQC#TW095\T%_$&*VCUK""V7DKP!(+D].>H)QPPA7KDUF]>BISS6IL^5
MSDFQ-$9J**73O1*E)Y:*4E'RPV;:L/8AAS&\"4PFWIBFVX+;[C+C,0DI13GE
MNOR$,N+=6KB:Y7L+RWZ<NK5+TR8BN1&K&Y\C.$XG$6')L%W'U44XS"2ZY/<8
M;?;=F&I:ZDPAJ/'6\VVRA/U6O'C<='&MT(2\M?AJ9?Q=Q*J^+]0-QLI[6CQT
M8V7LF&>,I/!6@(KW=4;C7LR5C[)T/ZE("XY^H(Y,Z9R<8S8]#ZE1#P["8F<E
M13*46((\Y-4GX8KOKF)\3(<1+<0VB1339C$VZ;50J91^=(B)<)M*L*IRE8)?
M-TYM=+$DY^'RLG$JQX=D0%4NG8JH'J.%L+.-KB-N/.1JD3LHW&DNTZEG)-$:
M6IOTBD^JGXY;A60X,ZMK=6T^W%KRM$O$9)[OTZ;!&Z--LAIX.1OB&*E>QH8#
M,HI*6(.^-R 6II\I[PBW8GMX\K/)MC.F0H,^FTQEVOOTOE:AUY$JO2&&:BFM
MU5Z3@R%)D0JDP^4<HII4SZA(C*I[SBS<D0WG''D\3W*;@FJS9]/JE4>:P\S5
M>1^9051</QWWZ:JA4EF-C:;%CS:9(CG(.42TOG/CRBJ3+;:6X\UEMMDXXM^,
MFSJ-M8)%=:R70ZWY%IFPA2E88TRA,*3I]6V%IMFH41;'971\M5VKAS=L96*W
M+I"M4BL1W31'*[+9ZRF<EV*6':7)EX96_"IG*31,11*.Y4J)'<B45>%'*96'
M&&(E3=IL9;5<;A3GHC4M]Z0TRAQ#\Z2;ZG>SJG*KA1]FK18>*4,3:IR95S#4
MNLMTRN2$3*VWBYNJ49$A^72VJG)0]079L!F6[$98C.O+:4Q!C$PAOZ$?'+>6
M:>MBRZ=.[7*^L]CJZY2CV55 ]ZKVB?V>UL0#:4MKHK!'?PP7"J]CU<!RE6 5
MT#R'5QG>%Z?'F<GDVQV='ID291G*XZWA?$E*IK",3,T\\)XKJ&*:O48&+%.^
MMH3)+Y-ETXDOP52ZC$]0.,B+:0X181>4W *:U4Y<*MM4%ES%.&*M5)"L+.U'
MYW83IV%*/3:CA)#1PW%1C.IQ*D9L3T0Z;,.H%*=E<Z.T8L6IXZ[1K.<;O?PS
M+N-#R&U<QQ->+-U4RN:T%:U65O85F"E[0ZCHUCQRF5S)A>J>! K''3DDJ6HJ
MU/T/1L\F^*FZVFNR$JF5J/RC84J2*N54)DWL,1,,4NF8C<;8]8YL=JH3V9BI
M4'T!2):4LJ4RZAMCF^:?Y3,).T-5 CJ3"HDCDUQ93%T<Z4;Q,8IEXHJM4PTT
MY(]6-<AVG0'X919QOG&AK4\E#K2W7^=GO%#4&U=7.CCFU )!BH27X:_1,^;
M&VPLR5S]NQ!)F:42<%%Q'="[5J:RWN28JO-FU/4I302U(9^L>PY),&XLPK6Z
MRJK0%1J3)IJ&BE5"=3IU7EU-NHO.MJ5-HTEN/6HQ1'G5N5JM42DUYUU;3"VU
MLH<MUW+!C3".+:'1"I%13*J\6I..'$IT"I0*-#I;M.8;<2F#6HKDBARCELLH
M:HM#KE7P^TTV\^VM#ZT7WOYOT?GP. #@ X . #@ X . %#^3^IRV\_'S;FI
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MX!97^;_M(/9K-\YZ_P"8(/V[C+0]Y< LK_-_VD'LUF^<]?\ ,$'[=QEH>\N
M65_F_P"T@]FLWSGK_F"#]NXRT/>7 +*_S?\ :0>S6;YSU_S!!^W<9:'O+@%E
M?YO^T@]FLWSGK_F"#]NXRT/>7 +*_P W_:0QI7WF$58KW9^K;PQ)!J\M?()%
M#U+#?+T:$^/4N%W+*//J&SGEAGUCEZ.?6/?>.777?7;(^@]A])=!7T"RB_\
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M<@'#ZF,DV6&&5F_?M5J-.#KON6U<L05H,<YI8\,@#T\ ' !P < ' !P < '
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M"[?<8I+P+_HJ;_[33/T<5.%[2[/>8(V'V^XAN_S 9AP < ' !P < ' !P <
M' !P < ' !P < ' "M-L?:L*_M+TO_UB1.4MO<KR,0]G>GS(67R"AP < /$2
MEFA'7YJV%B2Q#2M2P1U(8K%K.:."3.+"M7GE@@GL99]8XPPS3PQ2R=XX22QX
M9=Y]9MD2G&TJ-))-:24:C-*2(U$1FI224I*2+:9)49%<R(SR&#IJ2VXI)*-2
M4+-))22E&HDF9$E)FDE*,]B34DC.Q&9$=QRNU3N':"R9UUDZL&TSBA5V E5]
M@NEH#L4L%.8&=$^3,QG$HJL.J@#EK-B[V$N:TO.FM:!)O240E>0Z0(P*L'"P
MRSM"J4>FR6:@4*/3&9:J?,5 AI?IS3S'H:YAM+)M2H]4?AU*/\GR*DB'4G&H
M<V<VB<M]EY+#3J=4TJLU2,]33FR*H]#148*:C-6Q476'DOT#$YO>FBR:5'FT
MN2=2C4Q<VF-NS(,!URGMQWFE/O-*W%V*S;,-T4DPHU&Q+%4MVZSH7H(J"V8F
MV1KTTW@*! IGE4L&RRLJ=AB%XF3@OT5QHA[J08DY!@N$I1*>1IT:FLN369:X
MLQU=%J;B%&Y)9*G5!B'(<;:_'2RU*E>G;;;;4VN1%5SS]$3KJFEM^RJ4JIOM
MP7H:)<)I%<IC:TI;C/*J5.?F1VW'3YBGWHL3T#CCKJ7&XTI)H3Z4VFDNMNZS
M[ )/B>L[#8OX0-_5<W/<!?7FGUZ.0I>@$>XX9P7IW5W-1IS ;5D*T^Q'G>:R
M.KSU&I24M7 0H9@G9R@)O])3VX,R53X_R?05E#I#50J[YI:;-[UUZ(^4.$UZ
MW'9DSDP5,0B2XI*XDN55'WGF$Q6GXGF:@[/@Q:C(.HX@2<VL/4ZCQR4ZXEGU
M%B9'5-G/^IR'HD!4],B:I;:31*B1*7'99D*E.L3)IM"]NJI>VH.BVPPBP!%3
M\4BH!WKZ_,QA5+VGL;9M39\(NFG#;![')A7U9<Q;+Q IE,K56F&Y,250\8Z>
ME\5,115(I;JJ5'<?;E8I:?A*GLF]+]%3J:NF&ZN8Z3!^KORI'JB&VB*4N,:"
M;E/&XE?W51=;0NK-%5Y#3#D3"CL><FGO$S#]+4JFBJ$TB$TJ1>1'BQO6W''3
M.*F4E:G8C!-J;:2V-Y&-&Y]65GG66RD;5M_QW9>\8S=I1,"2+D/ST5?@<FPQ
M.;J[%H,5F8VXJPE6:4U;.85:EM@NB9;)-CJ(ZM4[#T6C514*I4V=5&\0QLV$
MRV76X;A5QM4.(REE5.<C))F'*=E19DACG+1'0Z26XRYTH=1Q)*K5*1/I=3@T
MI>'9-O3KAO,N3&_D)Q,R6\;Z:BW)4I^;$:BRX49_F(7(6TI3LE,'?WG@QL .
M #@!&@?V6<OO_2^BBWRGL3V>\P$EY #@ X . #@ X . #@!@FC[66+[Q%_U?
M8Y4[2[2\Q%;#[#\AEJO^;5_]1#_R\>044]Y Z:H;^U6P:M)G+:[3/V EB4M1
MJ0WK-;L*:H&8\8ZUB6&+/J>2CC!GWE)CWAA)EGC\>6/77>25<U1*(KVOXD9"
M&5R,M1SI_P#"*2/_ %F:OT6$?O+G+Z<_\I;S&'H^OP_J(WI'X,NI0W.SE-DV
M+1K4Z.;K5U$>2K1TKNR+45*E<ENE:D$LN-16HWIIJF</4GRAZ:ME#_,'8S96
MZI[\4K9*.]^K,_$P)&9WV$>_XXCL[!!!5@AJU88JU:M%'!7KP1X0P000X=1Q
M0PQ1XXQQ111XXX1QX8XX888]8XX]8]==<^<<@^O #3;X03^I_N?[W*OT]5>:
M=Y?_ *GL<>SX?WO3AN?\'GZYL">T9OW/41M(F?:>I_@T"_5=7FSJ']"T?V73
M_LC(U97/IJL>U*A]K>&'VHY7]=:PV-L 4MSN11&1&YP&)]4H/!VFPBM "!FB
MLU31;+ 4(LG[5*(37)DLL:%&:WA:N=]5XI.^=H.L+,R+4^WR'-+QB^$M8]W[
M!U1JMSTZ"2'A\V5LM :Q%1FV>,/ZY[1M$!MUT<V?7FYM'::V4(,$YB=U2SI&
M58:"(0">G-09V@*4BJU R--B,[Y=&S/,RVD9ET=!F-A=H><">L[*TSKW50]=
MW?6=_)?/QFW"W)FS42T*\>'N!=,',U5_##RY5OZV-=R%S84DSI>J04:(\Y=:
M3ZY:B7AC.&-LC/9ID>>?1T97\N[59J^$4\HD;5VX=D,/BOHDG%JG>%[1HBND
M^6#F=J[C=5\'G@<0]/1'/%=3;G#:93:L]+0Z<I5DW$5?V(->;1YF7EA,]K&P
MMBN17//4K6\=G3?3PL/:/P@.Y%$AY3+J1X=NKBX>/[]H9/5EJ9A,E[;XN;?F
M/2%]JGJVC=>[Y8TE#60RT5/CL:JPVLY8;D)C. %(L5R%4 $17*YV(RO??EF9
M::D/?XW?"<ZO\F_)95\>]=]);)2*>+E/>QC9RCL#LRK6'RQ#ILU;U@B"CJRH
MN3.+%)FX@K/9=C:PH2Y]]3K\RO19EYY#J@#29$9GT';S[NC9\'T\X&(C+=]A
M?]L+/TE$<I;>Y7D8A[.]/F0DW(*/)?J8WZ-VCEGW'C<J6*F4F/7666&-B'.'
MO/'KOXNN^\>L^\NNN^^NN^^OB[X <C/_  BDC_UF:OT6$?O+G/Z<_P#*6\QQ
M^CZ_#^HJT]\%:1K[125A<<RY)!NCKIA]<B8FE0D"PU+M:"J%!P0V+,9 X8BS
ML=U^I>O5Q\4.=Z[UG'C#6MWTV1F9$1]!%Y_' CG,.Y%M+I/9Q'9O7>O%#52>
M&144-7!K8*MU!3IP=>E)+)E_.L7KUC+XYKI&]-WE8O7K&6<]F?/+//+_ "==
M<!F9G<SN8Y"(BV":\@H@&V/Z+=E?@ Y?1TESKZM]%5/V?-^S.CT.$?RKPQ^L
M-%^\HPY4? ;?U0W7^\ X?0+5_-0<@7Y&3OUCF_=U)'[&_P 03ZZZ#_IM1/\
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ML);=YRE7?1*ILQ1J02$>KNQD\WGI6M=D\ZX=F(T#^RSE]_Z7T46^4]B>SWF
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M^/+H,]UO>8^S/I(M]_<0\@/[+.7W_I?11;X/8GL]YBB2\@!P < ' !P < '
M!P P31]K+%]XB_ZOL<J=I=I>8BMA]A^0U/U;H[2C]9VLQO>G]6NK#-N9]J3'
MFW7ZFQF9:M&>C7I5I2A@1<O25ZE?#""K#G/W'7AQQBBQPPQZQZ];4:W68#=)
MCP:O4X<=-&@*2Q$GRH[)*6A:EJ)IEU""4M1FI1DFZC,S,S,>-IE#HE0<K$F?
M1Z5-D*KE20J1+I\22\:&W$)0DW7F5N&E"2)*$FJR4D1$1$+6_BM>,?\ HYZ(
M_P!T.O\ ZO<ZWYSXE_2&N?M:?_$#M?FKAC]'*#^QZ?\ PX?Q6O&/_1ST1_NA
MU_\ 5[CYSXE_2&N?M:?_ ! ?-7#'Z.4']CT_^'#^*UXQ_P"CGHC_ '0Z_P#J
M]Q\Y\2_I#7/VM/\ X@/FKAC]'*#^QZ?_  X?Q6O&/_1ST1_NAU_]7N/G/B7]
M(:Y^UI_\0'S5PQ^CE!_8]/\ X</XK7C'_HYZ(_W0Z_\ J]Q\Y\2_I#7/VM/_
M (@/FKAC]'*#^QZ?_#CGWYW:MUEK1:.?P<:Y1-?^V_'?:OMGW)4%]5]K^S=^
M^'?L[VG["'T/7_4/7[_J7K7ROJOKMOY#Y/UF;T]5_A"5.I5+\'KE)^4:C.G^
MAF85]#Z[+D2O1>DD53TGHO3N.>C])Z-'/YMN=S$<Z_-*VV/P=*52Z9^$;R8_
M)M-@4_T\+%OIO48<>)Z;T<>D^C]+Z!MOTGH_2.<SGWYG/7S;<Y5^JR9]IZG^
M#0+]5U>>DH?T+1_9=/\ LC(\S7/IJL>U*A]K>% ["\-M!;/VT,W4UKK/VZT[
M.O+AFN V5L=22WZYJ)BLMNJ;6TM=J[4(1=FV-<LUN<PIS.Z^<D'6.X:^64]"
MI3J0=H.LN=K=&WH[#SVE?IMMZ1KRQ>!W@#H1.O[$=5VVJI6NZL4M(^X[:VD6
M&:[4HM>[KTP UTDX&6\EFM( U6\F]OKJ5K!6@@#0'M@09KX3-@H*N0T%S/+7
M+HSS(_,BS&LSGK7X'YHQICK39B0*O:(TWZZFJ[JW$K%'I..ZBUUH5EUPT4Z#
MBO4^H]C:U\+%S6,VL=@61<[;?UFYP0AIF?WQNY!E==NK:61=%U7V96YU[]?8
M/PEMWP/35K(=N^9G!I@;8[*@;"-"&MX?1+&ON$&VFCX2 3F? CC]W 0)5MC[
MH:-LL+$&EL:RHJY3U"=DGUN+%UZP#YVS;;0K]!)Z.I-L]-1&531GP/578"MX
M@:]]\F-FV#=WCJ"84J[+WT;#U^@.@L](;706UUS:>QU:ECJ.@(5,0]8G:[AO
MC5YAPCJD^\#]D%U6OT;>C6]]=OQ8=")/@Y/$B9I)MUC7YZT0OMM5\HCKFS=F
MVU=3;^MSZW\ACQ]$4;+=*M(]]ZW+J/7KYL.17%C,7@L [C8L;U$N<J$PQN?A
M;86PRMWY';J&T6K]6I.FT^)$UZ)D"*\#"\-48^4B2*YXF]C/#%L9NM^NEK=V
M[WB2;FLX2CK96.ZU".WC0H15J%:M6A"?&X9MN^PO^V%GZ2B.4MO<KR,0]G>G
MS(:T =/ZEV3N#R,*;%U=KI^)C7U)%#B+JDK35?'B^M*ZTO=#:5LZ,OV*M#J]
M=NW.J<$D=?JU;M6.H_EK$N>?K)%6JM.I&'6J?4ZA ;=@377&X4V3%0X[\M5-
MOTBT,.MI6YS$(1SU$:N8A*;V21%Y"/1Z14ZSB1VHTNG5!UJ?!::<FP8TMQMK
MY$ICGHVUOM.*0WSUK7S$F2>>M2K749G8W\5KQC_T<]$?[H=?_5[G7?.?$OZ0
MUS]K3_X@=E\U<,?HY0?V/3_X</XK7C'_ *.>B/\ =#K_ .KW'SGQ+^D-<_:T
M_P#B ^:N&/T<H/['I_\ #A_%:\8_]'/1'^Z'7_U>X^<^)?TAKG[6G_Q ?-7#
M'Z.4']CT_P#AP_BM>,?^CGHC_=#K_P"KW'SGQ+^D-<_:T_\ B ^:N&/T<H/[
M'I_\.'\5KQC_ -'/1'^Z'7_U>X^<^)?TAKG[6G_Q ?-7#'Z.4']CT_\ AQKO
MY!:<U#K?O5QG7>J];H1>^S[7#7BJ6CK"L2NB)O$SR1(2BK=X&+HVK(V6^-'7
MI*,TN=7.X/I6<HNYJL&<=F5BK5'"^-V:A5*C.91A=QY#4R;)E-H=*M45LG4H
M?=6E+A(<<02R(E$A:TD=E*(_OPY1J/3>4#DQ>IU*IL!YS'=.9<=A08L5U;*J
M;5W#:6XPTVM39N--K-M1FDUMH49<Y"3+6CX#;^J&Z_W@'#Z!:OY^<^0+\C)W
MZQS?NZDC][?X@GUUT'_3:B?[CQ<.RW-WC\,!P < ' !P < ' !P < ' !P H
MW?\ ]IHS\)J?ZJ,\S1M/L]Y#!>PNWW&*2\"_Z*F_^TTS]'%3A>TNSWF"-A]O
MN(;);2VZEZ=%@"SIFR9X-+1335T<I)+EL!@,LEX68-P#1ZTB@F(]8RZ$@#!"
M>Q@.[JUJU":2Q/%_,ZRP'(17^+>8\:=O743V.7"*\_ ?3;(FJ0$$.SRJ+?9D
M0RQ( ]TK*0V0A'$651CP8P$=!!4'2**A<41&GZ@^Y2L0QA!G1NT]8FNE3(/L
M9#+8O>13!'[&MZ_?Z<LPGI^VL53NJ1EZ8LA'R<GM3$1ZYV/^3S];ZB]'+X@"
M(3;_ ->Q[0):@KP/Y1P"60-0_.$U1LXXG+MAE&1F@\;#L,2I7$,)\N*FAO3Y
M$V*MC1KS19WLJWRF'78+;.L2L=MC5AB-:E$[+U^4B<[I0:GR#G)<NQM9$)Z7
M9J@M9UB4N)VZ(ZPS[*51?=J>AZ&7K<<7H]_$ 1K/R(T9A/0CZVNAS4B*X\-<
M+#691=I0@!ZW/(:RZV23G7LRJHF<&=V8DCIQY,O4(3SFL?5*MC"D0RJ!;'N_
MKP,?*AY&Z,)G&E?'[14+=Y&I]D7.Q$5A]BJ@_M73G6N0/L67>( 90OJCZK'1
M=ZT2CIE*)"?.A/8S%EL*(3WCTN/D#I9$6&5M8=E*70I3UPQ[=+5PY>JR'I-<
M*:[VV'6P,KKN91D8AE5>[B)0Y !1*6_#:HXT([,MZG',V!M'P2/(+5;Y8:Z
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M G*Z^*383-B%XU5*7@%9=(WHZ_>>44P9M%=&%E@%V>\>JYE<.UL+L(Q@%2W
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M'SAJ/YJC_NYA[^5A\W*=^=K/[R8B_FH?Q<=;?='</_$;Y#_XI<?.&H_FJ/\
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MH%L4%9E6A.34T@%F90*A;E;,M/#(NC36Y=17RA*3\&QMQ:.:O)6-R*\(5";
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MF!-F"_XTX,L]&V,V)[I*837UX=.#J)(@E61X#C(9V U%V.8RN6\'9'%4]D]
M@I<WI,CZL[=&=]NO1P'RCI?">J3$Y"$@?8C#SD_*!F0Q]FGJHXE%S+9LKRL;
MDJ=R+,YS!V7^^[I;2/NH/%M6 0<O$%D=< %*E/97:X#\7+NON*_OOE>]MI7&
MQ6LAOE3"_;M:,R.Z2]8MXX"P^D*V_8])"P=C:RPY[BO=VW$!IL>)JKY&]&TH
M%.M=I#@W9](HY],=>T=7Z4E,(=K=&T]E\R,BUTL>_=0"I0\_ )7810'_  _S
MP.>Q+[*K6-@"_%?,R;:Z6FO#M2 "]N4 -;V$H:0]O+>^8"=G48];<IX@Y4I
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M]L?I:5^3AWD2UZ0FA Z[V<CS+\(#S37O%A?GI[6V1,'TGM5D>QQ$B6HB5%J
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M5_?\;/Q\!@%3P%WA1 :^UT:=-<#=9*%[45\J$6S3QGT:&*0;Q-779$@#] 0
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MJ#D"_(R=^L<W[NI(_8O^()]==!_TVHG^X\7#LMS=X_# < ' !P < ' !P <
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M7$(#9,:B7M7ELU8"A;9$78M"!LU4%Q6Y7PD\83T9FL?UCBP#CMJW:M@S[CL
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MAP < ' !P < ' ",MWV%_P!L+/TE$<I;>Y7D8A[.]/F0DW(*' !P < ' !P
M@&V/Z+=E?@ Y?1TESKZM]%5/V?-^S.CT.$?RKPQ^L-%^\HPY4? ;?U0W7^\
MX?0+5_-0<@7Y&3OUCF_=U)'[&_Q!/KKH/^FU$_W'BX=EN;O'X8#@ X . #@
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M\,>^_1Z"":\ ' !P < (T#^RSE]_Z7T46^4]B>SWF DO( < ' !P < ' !P
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M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
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M,<]KN/*S-'%AA+8RAPZBB[GDQQZSF[BCZZCC[DRR[PPZZPQ^+'KXN 'VX .
M#@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
M . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #
M@ X . #@ X . #@ X . #@ X . #@ X . #@!5FUO\R2/[3T3]<8\ +3X .
M$0;/_FJ?X7C/_P ,EP E_ !P < ' !P < ' !P < ' !P < ' !P < ' !P
M< ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < '
I!P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g69956g35x57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g35x57.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I 4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q 9;P(0         IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M        /X   #A"24T#\@      "@  ________   X0DE-! T       0
M  !X.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             !P    _           0
M                   !              /P   !P
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   !P     !29VAT;&]N9P
M _     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   <      4F=H=&QO;F<   /P     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
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M# P,# P,# P,# P,# S_P  1" !' * # 2(  A$! Q$!_]T !  *_\0!/P
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ME+.SNH5T-OMR\1M-FX-L#+>6ML?I
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6[AP=ND9)11("=\F4Q3'2%0@'3!0@<G()RCU% Q0$Q?4O/&J2X!QW]X[_?\
M1ICZR*ZGG2_^83^']6HYQX'X?.E/.G'U9/Q]VG./ _#YTIYTX^K)^/NTYQX'
MX?.E/.G'U9/Q]VG./ _#YTIYTX^K)^/NTYQX'X?.E/.G'U9/Q]VG./ _#YTI
MYTX^K)^/NTYQX'X?.E/.G'U9/Q]VG./ _#YTIYTX^K)^/NTYQX'X?.E/.G'U
M9/Q]VG./ _#YTIYTX^K)^/NTYQX'X?.E/.G'U9/Q]VG./ _#YTIYTX^K)^/N
MTYQX'X?.E/.G'U9/Q]VG./ _#YTIYTX^K)^/NTYQX'X?.E/.G'U9/Q]VG./
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MTYQX'X?.E/.G'U9/Q]VG./ _#YTIYTX^K)^/NTYQX'X?.E/.G'U9/Q]VG./
M_#YTIYTX^K)^/NTYQX'X?.E/.G'U9/Q]VG./ _#YTIYTX^K)^/NTYQX'X?.E
M=YJ].Y(8XI@ @<2\!S] #S^KGG^/ \:J!R ?&E8TM+*#E+2H@RE5("ZMF""S
M=ZW(5%9\Q .4TG+=T0K2P1B:H=#IL JG:''A)S'+G*OK'E(Y\ X8 ;>/A[._
MK\J@X.V<-U&3ZIZ['Z[Q5/)9GD,H5G=&244(G(FA86ACJ5M\)S=*??+JCWT&
MX/R7EM)&,V$Q@*WD'!@,1,6(P'7E_P!;!P>[N&<GKC'^,<V#AA@GO_-[N_\
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MYTP])/Y)3EL@8).>1CG.00/ CO))]@/AW"J<@Y4,48=Q P<8Z;^W;&>_QVK
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MJ1.\1@(3CE0G_6;"J1C .#DG/7 /</?4 #)PH\.9SD^'O([_  _G=R=%EI@
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M*CEN!>2P5L[V1:_)$1!)I.(AYPR*8/D@=Z$V5(Q2'21*0!3-:[(J#R-MC[+
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M4PY,FN"JB?<P<XY6<(#DY&^-N\YV/LVJ-P1D@#P[\@CO./@._P :Z$2G#J.
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M'(" @(#P(" ^X" @(" ^WJ'MSI2K+?XZJ#YP=\6))&2*AA,>3@EEX&1.82]
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M/Z9QG.=MR3@>T]YZ'.(( .0A;O\ M#K]_?WY[MB,D;W3'QMN0)X>$I=7JS4
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MI,[D81ZU*PUWD/E5NX=2OM2]$6S'4+>TMC";F4"(VB.@;M!#Z_.6<$<B@$
MGJWS/J?$/#'H;AN73[C4;S3I>*[W0=0OI[>&S;39)>QD:>2U,LS2KV,?G$*]
MM'VL"2EVB=>S'M_Q12&N,\88[QPQD%I9C0*/4Z4RE7"2:+B2:5: CX1M(+HI
M&.DDL\18D<*))'.FF902$,8I0$?+YYC<SSW!4*9II92JDD*9'+D L 2 6(W'
M=]U?5-M"MO;P0*Q=888HE9L LL:*@)P2,D 9P2*R!JU5ZFE*:4II2FE*:4II
M2FE*:4K@?8?L'2E1^J%5RQ';ALT6ZQ9%CYO$5CI6(XW&^,T5CGD:)9($;P.0
M)YZB+%$B:-S\SK'A#E?NS'\@6ZD6PD*"RE2"TI32E-*4TI32E-*4TI7YK%ZD
MCEYXZBB7GCGCGTYX#W^SY_;D/?4$9_$'\#FE>4Z"["V]UNU;I'$IN<PZBSO6
M/+K#QX"QETY*NDLUR@;;"2UW8N':"<!%G8P"J+QRD[D 256,JU\6B@)E/79O
M*9;26F@VXTJX#Z/<V5Q(QN8RLRVMK);E4 CRK,S*P))'*& !.,>3+P4(;K7I
M)=;L%%S:W E0@(]FES<"Y26Y#2_DXP%QS-A6 )!&^-L'91;#K9L-P]?:?<,@
M53(4AD6]-KDUD*8VD20K2+2K\=%-")/9(J*S]5T+=1V*J;1%N1$R()J+]9CD
MY+C3B:/BG4H+Z*T>S2"T6U$<LBRNQ$KN6+*J 9#!0,9!!)SD ==PCH+:!ITM
MN]W%>&YN#=K+"I6,H\<:KRY9^8'DY@P8J01CVR7WY;;YO=QM1RUMZKECC:G-
MY!95HD;/S#1T]BV3JLW:M7%)-\@Q,#ON'XUX8\Z[<BRC4'7B@;N>X\.KJ>'M
M531-:T_59(6N$LI7D:%&".X>&6+"L0P!':9W!Z?CM-=TUM7TF]TY)5@>YC15
ME=2R)R31RGF4$$@]GC8Y_';Q4Y-VLUN)VGXZ/7\QL++\";QLO8TOK_X,F(6*
MJ\A?:ABEA&R3@TB^"56C 1Q1*OVZHQ*"KU%TX;F0:.HE5-WZ2GE6MX]:NM43
M2)9(;JTLK$QM>1H\7FCW<COS)#*K\QN0JJ0F.1B6W KY<U;B+1[?ARPFLII[
MV&UXQN]$U.:2V:S%E+-!;XG,;O+(\)6RD>$,L+R@.K")HSGW6[=,;*X;P%A+
M$J\RUL:^,\3X^H*]@8H':LIM:HU2)@E)5FV4574;M9 [$[MNBHLL=-%4A3*'
M,43#Y1J%R+V_O;P(8Q=W=S<B,GF*">9Y0A8 !BH?E) &<9P.E?5^GP"VL+*V
M$@E%O:6T E486010I&) ,M@/R\P',V <9/6LSZQ*RZ:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4J+N]W_$YW2?Z@<L?[D36H;H?<?X5R'E VX&X
MP_\ Y:UK_P##[BO,OM%  SAV,_ZJIF#Z YYO^3O?@-6T_P#)/^JX_</R^-?*
M?!G_ (@\AAWR;36^_P#_ (GJOL]ON]E>PK5VOMNFE*:4II2FE*:4K1YVKF +
M?1YNB]H5@R/!]D?!B:4;EJME;^(:7_#;KOXZ8;2[( .$A'L8R5DHBPMA14%:
MIRSITJ8A(% 0M2 C#CJI]8?I+OD?'W8SL3BO _+%PY>V$VG^4KA^(OJG#_+%
MK-LJ\Z:EH;\\<R3Q $RQ)'++;W:X.;&>5SM;KB'6R+/U6V=[B*Q'UZ76_L&]
M]/1;\6/WBP&9XDRJHL6+F:/-+&,"4;)5^7!&ISXJ\ O!FI\VHH=N@L<A?5)Z
ME78L#X$XV/AOMCX;&N(X!XCL^">);6*VF;_(#R@!;S2)I'S#HNL%EAN-/G)/
MY"6UN7%E/DKSVQL;EB55G'H8?[DL#P^3U,*R^6:'$Y519,'XT>5LD?&SRC:3
M2(O'@@V>JH%<O'C<Y'*$>W45?':J)NO#@W4(H:YD9QD9\,C/X=:^E)>*.'8-
M7;09M:TV'65C24Z=-<QQ7)64*T7*DC*&=U966-2TC*P8)RFLWE-U% P<<"'(
M<#R @/L(#\X"' _?\^IK?USI2FE*:4KX/Z@'/TA_7^/7T^SWTI4.]L5>P1"Y
M-W?O<072:M5NL&?QE<[1<J@[1:4O)XT*J-35R$.Y@89->-^&VT)(]\U=SJ'B
M'BI?-!4 S9%2ICZ4II2FE*:4II2FE*B[O-J2ULVS9K+%UVJ62VP&-+K9J(WN
M%1K]UCV-QA*U*NX:0:0MECI6*/*)J%408++,EN[67 #$43,HD>Y'-/ Q>"62
M&0J5#Q.Z-ANH+(RL5)QD9P<;US?& O?\E]?DTWLAJ,&DWUS8-+#%<*EW;VTD
ML+K%,DD;2!E_)ED8!R#@XQ7FZQ+F-&X9K[*C<!?HJG2E=L\#;]L]PC#TZK-Z
MU"76F75^@RDV<&T@D8>OR2Q+E1K$V-&-F9VJ[91S'E: <YUBWUX ,7=R!*SB
M7%Q,HD9@59I 'Y79QL2P)*A5.PKYET7C+4[O7?))Q'J%ZTEKJD-]PMJL!5$M
M!J-K?/&MQ):PHMO%<2PWNF3LXC!#1J4$?YWKF#T  ^@ U;KZ^KY4#D@^@#](
M"'(<#Z#Z<>OH/MZ:4KQZ;@\**T_*?::;1T&QD&TTP8;S,)-B)$Z0?TYRG>+(
MR@TB%!45"T"SW2"*1M\OJK1$RI+&12YM-MSIC[2EAOURQR1OCQ&#CH#7Q/Q+
MH1L]8\JO!03"3I'QQH"XR1+92#4+J* #&YTN\U" 8Q@VI4Y"''I1V%9K#<'M
M$P7D]9UXN7E*1'0]F4,(=[\557KK5B.L4!'I.YE(IP]*'IU(NDC])0/TA<!R
M >O^&QZ[]?&OJ3R=Z\.)>"^']79^>>;3XH;PYRWGMF/-+HMG?+RPM(/%75N^
MI>ZFNTII2FE*:4II2FE*:4II2FE*X'V'[!TI41<=P.$&F\+<K8:I<)F3SO-8
MSV\L\NTMRD[)"U>H1 Y/'%LI%+J0C5JLZL@OKB$D1O.RYTO*FHKLXKK3\:I4
MN]*4TI32E-*4TI32E-*5\G#DHASQZ<_L]?QP(#^O2H.P)\-Z\BV[5Z]#<SVR
M8 \= ']CWCDHE!PJ!1(%_P!NJ!2  'X A4'"Z!2!Z%1763+P50P#9;K*<G[*
MX [C@C.^=]NOX8KXPXVDD3BKRX$.Q_\ AC3>I.X&J\+HJG?#*J,R ,".1BOV
M2P/HQV#&.?99M@.H<ZAS87HO)U#"<P@$(V* "8PB(@4H 4H"/H4 *'H :N+]
ME?\ 9'\*^F_)PQ;@/A)F)).@Z=N22?\ 1T'4_#P&!W5+K55=K7DDW)X32J^Y
MGM%-IY62:,9GO&S3=;AA@1,0*KD#':C^Z':1)2% $7$@P=Y1AA[L0!1%L#8Q
M5#"FFM9&5>11^<O,N^!GO_$^[IN:^-.)^'Q9\6>4W@\)RQ<1:6G&.A)D '4M
M+,U]RQ C"O(DVK6_JGU@BJP.PK?9V:F:PSULLP1='+P'DY&5!M0[0<3@=?XB
MH!C55XL\$3&.#J1;QK27/U<"<D@DJ'R%$QU<4Y4$> !VQN-CMW9()QW5]%>2
MW7CQ%P)P]?._:7$-DNFWC%LN;K3#YG(TG?SS+$DYYM_R@)W-3OU57H--*4TI
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E?)C=( /TB ?MTI6K#=]O4V_V7
M'&^#;?%6I9;(&-MMV1'UL>"R-\)L7TQ7E8-I6R6(BIVZME"6FXN.5BA3(H#]
MT9@D=5ZV=-T:&9?7!..523[,@X^O;7D'&_'7#EWI7E!X5ANW;4M+X5U22\E[
M+-C'+<6C0):"Z5F4W?;7$,30<H/:.8P6D1T71YMG?-ZCEOL8YRSF&!AEZ[E%
MDA)RA3LV2SN3R/?FD>W3<+E(F91VYEHM)+@P@8T@T'GI73,-"''8YVR'_P#8
M0/QR,5X#PJPL]:\A<]WFV@\VU55FF!CC9I]5U%(0&8!<R/+$JC._:H>C"O3C
MMKW@X7W5I7T,62<L,KC6VOZ?;ZY9(P8.Q1;UFX6;H/U(I5=9;RJ2%NX%DZ,)
M#@HW<-72+9X@L@2XK!LX[B0>[<?RKZPX6XUT/C :D-(EG$VDWLEC?6MW#YO=
M0R([HLAA+,>QF,;=F^0W,K(Z(ZLHE'JJNMII2FE*:4II2L99CNN.\=XQNUSR
MT^8QV-H*NR+BYNI-HJ_8>1.$P9/6SIB@BX6?)OBN@9 S2054='<%0(0PGX$3
M@$GH-S6KUN_TS3-)U"_UF2.+2[>UE:^>9#)'YNX[)T:-0S2"42=GV:JQ<MRX
MWKRXXUVS4+*&?<T=G_4;F28V\9FH['=MMNOS=LHZE,1SCME'.X=XQ8.19*N&
M$I$R(UFR19EHYS)QL;$.@68R"9E L\H8LF<AL.#D$+X;9\=QW8Q[Z^2-*X5T
MS5N(M=\G-G?FXX9US3X^-.%]23+RZ1<211/!)&C+&SQS02-:7<):-YH8+:3G
MCF3GK\=S&S_=Q14"*;H\#,=X].@(]G%1FXC"$F]K6X2OUV%1\-%>:O6\=)^<
M)1C0I"@6ZT:W]TF0B25G;)@98#@Y)9>?8X93AAW_  .^,'/>:CBO@GC/3QS<
M6\.Q\;V%NBPP\2:#++:\16UM I6$S2)',94AB(54U#3K\@J +Q1EC/;L<U,@
MV!S=YNL[F<A9,V]UIL:IIXDS+5'D?D:@7E0S!^S;C,J2,Q&JQC&)*Y;BK#22
M32056#O:_#*-B@>J,@@D.S ;$-U!R>_OP-C[?NKT3R'MJ5R;^>TXJU+5N&;2
M-K$:-K=HT>IZ;J.898U[;M)X3"EN77,$X1RP#6MNR;[Z]7*^B*:4II2ODW''
MK]/^T/7U]!]/3U]!]/F$.0TI43]N=LK5DR+NJCX+"2V)W]3SB:"LMJ5:>&+F
MV8&D5=]^4E%3RJ.\6F+-RWKO?BXEN1ANGQ_IW"2E2RTI32E-*4TI32E-*5^+
MENB[;KM7*1%F[E%5!=%0H'3516(9-5-0@@(&(<AC%,40$!*(@(>NE4LJNK(P
M#*RE64C(96&""#L002".\5XF<@T>2QIB?>7AEB"S>Q;*]X]2S?13"(@Z1I=P
MD'])DW;<HJ$.F@4([&<HHJB  IWB*BG'64Z=KF^V.4^J1@[=Y.#OD;8WQOON
M <Y^#]2L)M*T?CC1$YA=<!\;66O:>2,.+*^EDT^=U  PI[#2K@,!ZW-U.!7J
MHJ>^';U*/L"4^PY'K\!D3/\ C&L9(I%<>J+H)2C*PL4U6[1*4,F>)0?N9 C^
M/CXYQ(%>/7;!PV;)K+ F52YS#(&1DC(&1N/'ZWV/@:^OK/CWAN:3AVRN=3M[
M;4^)-)M-5L+20LHECN8P502E>R65I5ECCB=Q)(T;*JEL REM%FAZ=69ZW3[L
MC&!K4-)3\P]4$ (UC(EFL_?.#=0@'"39!0_'(<\  #Z\ZFNLN[J&QM;B]N7$
M=O:02W,[]R0P1M+(YZ;*BL=\=*\TN=]P.-MRN[_LV]RV$(JP>8Y<LEWPO:*7
M9(M&/F)G&B=C4HMDDWA&CQZT4C%86TW)!)<7"R)D6ZI5RD/'.DD[60S(PWR&
M!!QTWWQ[\C[^ZOE?B#B32N*^-/)7Q5H$-T)=:O+[0KRQN8EBGGTE;T:?=S2!
M'D1HFMKR^"L7Y6165BIB<+@.Z,L^[$:O;=DF1K]<L%8VM677>4=NFZ:E.I<]
M93>%X;?!U^-%=V^;U632)&R,\UC13EZQ/)JR:\38X1V0J<'U $R5!.%8= .;
M(#' &_XC!ZJ*YV^CXD\GEG><!ZGJ-]P_I5WK;:OPSQ;8/+YH&7""RU#L<2"R
MF!BFN8X3V]G=*TSV]W;RE5VA;(NTOL\I=JWM7WF0[6I9SDT8QICK)<*9%]C[
M-[%ZD8(26C)6-.XB/,+"B1-6/E(A8]>L#I84VR<.],2,-4KDGE88;?'@P'@>
M\^[KW>%>L\!>56ZFO[7A'CF%++7YA$FEZM!ROI?$$<@ M9H9HLPF:Z7E[.>$
MFUN9"50028B.[/5RO>::4II2FE*:4II2FE*:4H/' \^W'K]FE*BQ0K37G^ZS
M<+4V>&EJQ9*[CS!4E.9N,T*FCE9C/GR,$-54W?E:'B!QF,8^!1/S61[@;<!0
M;Q_> #E2I3Z4II2FE*:4II2FE*:4K%F5LUXJPA"QMARU>J_0H69G6%8BI&PO
M2LV[^?E!.#"-;?).=198J2JIS 3NFS=%9RZ41;IG5""0.I [MSC?PK4ZQKNC
MZ!;QW.LZC;:;;SSQVD,MU)R+)<39$<2;$EB S$XY5569V51FO*YNT.0^YGMD
MC)'35*.W_'I!,D<JA2G2R/MS(J0QB"( =)1(Z:A>>HBA3$, "4W%MADRC_44
M]1C8$_7X5\A<;8?BKRX8(('#.G*2/6P1K'"X(/+G&"#G?(P<@8-;X=C&=<1P
MNWO9SA:5OU=8Y2N.WVIV"L4M=[T3$U$1T6+=Z[8D[OPZG<K,GI 0,N1RL#)X
M9!%4K1P*5:$<JC._*,#OQ@=U?0OD]X@T2WX9X'T&;4K6/5[[AJRN;2P9\37$
M,<+*[Q;<C8:&4!><.W92<JGD;&P*9EX^ B9*;E7!&D7#Q[V4DG:I@*DT81[9
M1V\<JF,( 5-!NDHJH81]"%$?FU57I,TT=O#+/,ZQPP1O-+(QPJ1QJ7=V/<%1
M68GN KS&[IMS6-MQNX/LZ-T>W^*L1[=(9ON^%%ZQ8HY"/DKC4H2?IS=ZN -'
MKQ$\"NA=9ADBL=806+,2+=9,BL8Z3U:+*2C+N2Q7?(VSOX^S!QMG<;&OE#C#
MBS3.*.)/)?Q=PY;W9O9>(;_03:742QR7ME;W-@KORI)(CVSIJ$\:OS8S<2J0
MKQ.!B+)4%F_L_&.6]I5MM=VPS@/+^7%LC[?]SF/'$DO'U&7;O"&CJI>"QP)/
MR5V0C6D2WML;&+,YJ)?,"3L>A98@SE@X@X3*Y*J<%6 Z'P/X#/0=_><:;5;?
MB#R;QZUP9?7=_H7#>MZRVI\-\5Z8\S16<Z2<T=I>B$B5;::!($O88FCN(98O
M.(5NK<M$^P_97VF5M8W&H[8MZS-E#9*L!(QMB?.%?52?XZS;&21@:0#]*78=
M<8J_FE0!)G.Q9B1,D\,+"090DLBLDYJ5SD(^S=Q[F'B,;?=W_"O3.!/*M>QW
MUCPGQXJ0ZI="%-&XAM^633=>CF81V\G:Q<T7/,P*1W4/Y&9\QRQV\Z,K[T2F
M P<A](A^S5ROH&OK2E-*4TI32E-*5 /M M[#/9IC.N2\'6V^0,M9&M$?3\7X
MY.X<)*3TDNLD,C(.B,>I^,;&(*(MQ*U("SF5DHIB4Z0.S+)4LW*/$D@ 9Z_@
M"?;7G7E(X]3@72;::WM4U+6M4O(K'2-,+,#<3.P[25Q'^4,,0*IA!S//-!&"
MH<L,IX/W8XRS+=[?A^,E4PS-BVNU>1RY4F";Q_$U"?F6;;S:O,[.+=*.FW%?
MF55X>0,T.!DG3<Z9TRJIKIHSD$D#N^'WX ^O'-;?0.,=)UW4+[1(90-<T>UM
M)=:LXEDDM[*ZG1.WM8[SE$5P]K.3!+R$E74J=U8+*D!Y !^D.=3774TI32E-
M*4TI32E-*5#;?KE[+F%MM5RM6"<?63(N591Q&T^H1U9AG,\Z@9*SG5CR6Y[&
M,T7#APQ@ $5R%!!1 TDI'$>]VQ.Y63I<D*2HR>X>\X^'6N(\H>MZUH/"U]=\
M/:;=:GJ\[16%E':0/</:RWA,2WTD489VCMB0V I4RF(2<L9=E\TVWK:G.[B<
MM,-G4-+O92MUNR-,K;_\Q,WAG:]NR(D\7<CBYC8@.H,DUJ;Y5_6F1RJ.FTI>
M%;;=P*Z91\8J2V5YB$SD9RY\3X=,;'((\<[5\L<-\(7/$VM1<$P3R36MK=KK
M/E&UY'[0WNHK*S#2(KH$F9+.1I+6-@TD<NH&[OP&CAA*^AS>OL1HNYG;2WQ!
M5XR)I=FQA'-9# LQ'(@P1I4Y ,"-HN'14:D!9M7I9JV0BI1!+K*F!6<J"2KZ
M+9F)6R!E*C;; (VQX8]E?2W'GD\TWBKA5-#LX8;"ZTB-).'9HD$:V$]O%R10
M*5&1;3(HAE4$8/9S;R0H:\\F!,GY^H.=XW</CNA6F9W#XZLC'#>^G T%&.W,
MYD&--))P+;+;:"CDE3KOIQ=H@E;)1!)=&.R.T:VQR8(NWK<VP6!YN4\PP)%
M&=]E/0>&_3KT KYJX;U;B/3N(H^)].TV[GXETNZ71/*%P[;PM)=:E&THA&LK
M;P*Q:6Y:(+=2H&CCU18[Z5NRO#S>Q1@N=TV1<*(K-SKH(+&;N X6;F53 XHK
M% 3%*JD(B10I3&*!RB &$.-7_KZZU]MHQ958AE+*K%6 #*2 2K8VR,X..\'K
M7=TJJFE*:4II2M;_ &N4CY9V=NY9<!$#+5VI1Q>!XY"5R52XM0.0]?5-X8!
M/<.0'TYU1(<(Q]G_ $KR_P L\IA\F7%3#JUM8P]<9%QJUA V_P#LR'8[5J;[
M,V-5-VAM.*N4PC5NS^Q.T # /YOS&FXV7  _S0$7YA]0X'J'YQX"A,\PW&!$
MHV[^AS_CWY[]Z\;\E,1/E+L,_P#RGDWT>,C<A>TL=*D&-MMISGINVV<$#U!
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MW'XY_&O:_)[Y-8[3AK59>+HO/]?XTADEXA:XY7EBANRTJ6?,% 2>)Y/.)W0
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M;#-8*E<G;P6N(:A/5FW0FX T;G62F%W:K.WY-^ ZFX&?@$W$U*IHQ7PVM"L
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MOS)L<8)YPN!ZPW.,9WJXXS(U"F^ AKI4Y83 ;@L;8XAZ?Y(@4W*;9XH<.D3
M \@''(<\:QY;2[A!,MK<Q#?>2&1!MD9RZKGIW9Z=]7H[FWE_S<\+]/L2(QR=
M\8!.^,;==QM6H_;/M<PW"]JMO:R9#P3EO8:97,.7.M"63=*1C&S;B83(DGE2
M<(U$P@NYL#F**= BJQVL<61E",FZ(.B"EV^J\6:[=\%:%H$]TK:;'+<((A#$
MLACT]XUM(VD4<Y6+M6P&&Y .^*YVRT+38.(=1U:*%ENY(XVYQ)(8PUTK-.P0
MGE+2$;D=,X&.E;I?;7 UU%-*4TI32E-*4TI7R?V#U$/7YO?V'T^_V^_2E1TP
MC4LGUN\;AI*_Y58Y$@+=ED9[&%=9.%%E<5TH*I ,?@=^F=%,K=T$TUDYKNDS
M+$[N33.*O4H)"J5(W2E-*4TI4']V-*RQ/WO;)(8RMV882(7S ]@<ML,=3RT=
M!CCA/$^5K,VDK*W39.?#)GR1!X_AO-B*MU#IR?DG4!)4PBI4*76:NTZB6B5C
M:8PCI>Q2V(:7>)6#<8NN:U99V9I4LK6Z5QI$PR5U3=1-I?2;"CT2:E?'KCYD
M^1>)Q '5:,D%*_:U;G>U BY20@8;;E77OD](O?@;.?'>0%V5YMD'9LE1,3,Q
MS&,EY)I6D1CJQCR3:4^>FFJMKC[Z^>P5@5&*22(I6Y2MIS2%>A4;*]925B0B
M8Y.>D8Q@M%1K^9(S1+)O(^+</9%>.9.GH+K-&"T@^5:(*)MU'CE1,RQU*_61
MG(B*3,M*R4=&HE(<YE7[UJT3!,O](YCN%$R%('SF$>D _I"&JD224A8HGE)V
MQ&I<Y\  ,GZ]N*6=$W=E0>+,%'MZ]U>.SM%Y^M06[W=*PHDA7U:](MZ[."G#
MJ1R\>E*Y#PG P.0'L8=@)TN^EXXQUY19 W>J29EE%1%<IC%^DN!XKB7AC26N
MHY^T0K%B7M4+1VFLRSV:2!P!RHS<JKD QJ <K7E>OR1+K%R(60QN)'YHW5E!
MN+&.&=O4+'U@ 6 &_<,UZH:9E/#=1J-4K58=*-H.%K,,RAHNN5*SO&;>*;-$
M&3)-HG%0:Z7<@5,A2= "*GHIR/5U#X'-INJW$T\\T1:22:1I9)KBW4M(S%V+
MM),N&.<D-@YVQ7HR7UC%'%&DF%$2"-4BF8! .5 O+&?5 &![*N4,\8_$QBE"
MZ',05^03QEDE4>&Q0,L8 3J9A$A $!ZPY*;GY FX'BWZ&O\  )6U ) SY_8X
MRQP!O<#K[JJ])6AZ/*>O2VN>@&2?\UT'?X=^V]<DSOCTX@ +6HA12;K HMCS
M(2*7=N?\$;O5:N5/U] . &$4S?)4 H^FC:-?K^9;G=@0+ZQ)RHR1@7!)/@.I
MZ#?:@U*T._/(-L[V]P-CG?\ S7LKLESGBP.?$VYC&@ +B89EO(PA0!MSX@1-
M+,F9?S/2(J>OR2E,8?DE$=6_16HYPMK))T'Y(I, 3T!,3.!GNSUP<=#4^D++
M&3<(O7':<T6<'!QV@7.#L<=*KL;E+'$RHFE$WRFR*RO0!$&=GA7"YA43[X@
MBD\,H(G2_.$#IY,3Y0!P \6I+"^B'-)97:+OZS6\H78X/K<F!COR:NI=VLF
MEQ Q/0"5"3CKMS9V[]JO5NZ1<D*HBH11,P<E434(H0P<\?),01*;U]/DB/KK
M$.QP=CX'8_A5\$$9!!'B#D5V-*FFE*:4II2FE*:4K@?8?L'2E1[IU6R3'[B<
MTVZ<R@QGL86.DXBC:#BE%=0[_'E@@#7@+K8GC<42IH(WOS.O@T4(JJ9;X<6!
M0J(HDZGU];_*E2%TI32E-*5"_>K@"V;@:KBF,J,'BRUNL>YBC\AR=3S&+_X&
ML<0ECO(])58R"<?7+2JLNU>W9C+MT%(DZ:WEBB97+18R*Y%*A!6.SFW,UV3@
M8PNYRT%I4$KA-BY)4LJ9;QY*62)I$-M7I.1',VVJ#Y@5U)VBA8HS%&0AWTE(
MN8E[>H9ZA(LY!-Q*1ZE=B V,[ZSS\:I>=XUKE:R>EX3J\\TK^6,HUZ2<I4^<
MQ*MDANV\O9-ED)>?BZ=?UF61XR9AKE.N;XZBK-WK  =-5*W1)$*@BDD43F(D
MF1,IE5#JJ"4A *!E5E3'44.)2\G44,8YS<F.81$3:4J,F\G#B.XG;1EW"(V*
M+J;W(-64C(F>F !2.CI=B^93$6X=I%4364:%?QS<CHS83.$D#J+(D.H0A3;[
MA?5VT'B#2M96![H:=>1SO!']J1 &21 <$*S1LP!88SBM7K5BNIZ7?:<TJP^=
MV[Q"1L85MF1B#U =5R-MN\&M7_8C-Z%A?9GYO:<ITA.4RIDZYV<\ >:CVSN
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M&>G3-55AES%\FHFBPR'273A;I!)LE:847*@G.*9"D;B\!8QC*@*8%!,1$_R
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MP(\F+U% I2%X VJ1%IX!!@N\\N PNXQRDLI.!YI@Y *]QP:J,]YD'M+?'>!
MXSZI'43<P]8AL<QW&/;7/>Y01 H&2QY+$,FT371*A-5\BJ9> ?I^J5E$R:W
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MH446[99$J2[GO#&75(F80VGFES&"%L=/L054KVT<(DSW\QNGEG4DG)//ZJ#
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M&+A%TU73. &(=)=!0Z2A#E$#%,0Q@$H\\ZUCJ\;%)%:-QL4D4HX]ZL P\,$
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ML#-J\L[]JFB +.5QG)=Q"QJ0-T1!,X*U9<AE3 <RJ1! ALB.RTQ2%6.]O7V
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M$EP.YB6.3[:W@:\PKKZ:4II2G >_'K].E*>WM]''T>GT?9[>GZ@]/0-*@@>
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MJ!N8IN:2(@]5!!+KW;+MA1X+B@/I* ?2;$+U"O,<7$ADVT+<(N1%%BNY,?\
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MXF=M9+!9;7/.8$SI2%:O;$[34)&QSAZU9.W:3%DV:)JNUFC?Q#L7!TT4T03
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M '[RI'O!'<:Q)N634_MU>S,>[/P;%C0Q1Z#"!BI%SIWIBB <&*D!BBH("($
MQ1,( 8.<O0F4>2OC#<9.JV@ )&?6?3\;==QG'C@^!JUJ8_\ C'0C@X\UN<D
MX]42C&>G5@#[Q6]G7DM=K32E-*4TI32E-*4TI6A?$(?_ "\6Y?\ U.Q__"[
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MD@M37\^:%!07-AK=VYUY\*W,>AYQD%<<V1@*"3C&QQCJ<75G1>0F/F=%0?:
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MS<:1YCVLCR2.P7+RNTCD 84%G+,<#8;X"X &*M+&J H%155CZJ(J(""1D*H
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MJW+J<<B@!&)5E?&%WY6SW/\ '_"KL5@\9<F1#S1NF I'V\ G._3?;O[ZV#_
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M1YHGIE]/733=$Y(MED+Y"D8$S*1$TP/.846'/9C%8/HZR&H'5! GGQMA:F?
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MRPS4PNP8OL:8\>M+O-RDS)PS:59.Q;&0ASLW*Q5*QRMVST$(L[H&*+<UJ+"
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ML>4K.XAWC&"8R=QD$KS8UI*!>WA[.*0L:R:1#/\ ,*R"KY2H\Q?8U8'KL>K
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MSR*GI.Y[,3/(57LT5E2,)7,#_M'\91V6F6-MHG"-I'IEM) K6NGZE$+EYO\
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M$'TO6+.YM[T^BK"W*06CA7GDN6T^'3FGF<1JJL8H@[&-S&Y 588R"[SA3XZ
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2=G7@]-*4TI32E-*4TI32E?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g69956g38l06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g38l06.jpg
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MCA%I%II+(T81;<=C)3'9&;C\G'EPI1\P<!E_J_7]YA1+P!0C\/'F+=_<8*0
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M+^+:V6$WCHNG@O=C8Z.K/ D0CEJV9:UBG9-*W,B]1R3TA"8(RL"<<50&/K!
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MB\9CC!JS28BA8*/B!8T>T:,TT\$9^&Q,F , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M/NO][/AZ?Z^6!RK]./E/^R/Y8M[?YL'W7^]GP]/]?+ Y5^G'RG_9'\L6]O\
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M":?)_1^:FNN0SU]NS\\_>D97@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MIXVX+UK@+B"\X=UVAZJZM99IU8INC=6\F_57%";2YJ=1+.W1]TTW9G+H+2&
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8!QW;CAFU<NU-;VFU;K..]:_IWP@GT
MIUK7^G?/._E_IR)/EBY/HDV_L628IRE&*ZR:2][>$>*#F8E[+(R"UY$MTYD=
ML2(Q8YM?O>^NM.)6[[(L1_/6_P"=]E!!NQD>&I[_ ";C!3-MQ\N$N=:\>_2M
MQ!=\2^D#B?4;NI*;CJEU94(R;<:-O9596].G372,,PE/"_E3D_$]H/1=P[9\
M+\ \+Z39TXPA#2;2ZK2BDG6N+RC"XJUIXZSDZBBV]\1BGT/OF/"_Q@&Z?X-M
MBN_N^^Z.>/-=L(N>C5J0]BHK^;$99"1<;*V ]'?Y<L49=$7,@<Z3^?/!.8.5
M.]<].N?GZ4_15XHK:UP#7TBZKNK7X=OY6E+GDW45G6BJUO'=MN%)2]5%K9**
MCX'F=]+CA6CHO'MEKEK15*EQ)IRKU^2.(2O;6;HUIO"QZRK'EG/.\NINXZZY
MXYZ[ZWKGGGG?776]_+7//.OGO>][_+6M:UO>]_X-9L_TZFJ'7H>,"<3?\4K/
MMZV/K=KHV?:T\F M?KY;Z[BS@ZY%P7G>^>NM;TA!14:;ZWKOKGY)?S=[Y^6>
M1_IPU_\ ?'Z3N*;R,^>A;7KTVW><I4K&*HRBNJVK*KT;SU\<'L5Z$>'OWM>C
M#A+3I0Y*]33:=_<KHW7OO^$2D]D]X2IK=+9$,QSK2%A60T5^6G+A*'ET-[_I
M[&KBW8M'6M[_ *>4GX@CK>M?ESTI\_Z>]Y9>I)SX<X:JPSZJE/6;.?974+NE
M=3S[96]W;?9''\DOBPQ#7-?IRQSSCI5S#NZ$[:K;1]N(U[6X]B<N[)&RVRO#
M .C-V%)Z>V)N2%)<K2RJBR,Q#)=KJ-TU>4VKP.91563UOKA%>/%RZ*N]ZWQ]
M7WU]/6^/GK,H^AOB.IPOZ0=$U"$I*-9W%C447^>KJA.-*&/'FN(T4EUSLC&?
MI?X9I<6< :YI-5)XC;WD&TGR2M+BG4G/?IRT?6MOP67MU/K'Q?(0$&#\J]+Z
M%BV##:_?6^NU^FK9)'M?OK>][Z[7[XZ5[ZWO>^NN][WOY[S'NJWU35-3U'4J
MS;JW][=7DW)Y?-<5IU6G[N?'V%_Z;94]-T^QT^DDJ5C:6UI!16%RV]&%)-+"
MZJ&>GB=OG0.Z, C@)_LFSIV\1Z^;=G'(,#7WK_:_>3=>5&%D]_X-]I#S8SO?
M^'7+CG7]'RRY;[^"X6T"C/:I6U+7;ZFGU_)JD-*LX37^3.XL;F*Z)ND\9W*%
M:?7XAUFK'\RE8:-9SQT=Q">I7<DWTYHT+RW?NJ+NC<G\(.>=@[XN:KG#CGAG
M8%;1^PP[7>^.?I&:\.]1B2+<?/6NNUG(F;Q/GKGGK>]H"_I?1UREUUK='Z'V
MO^NTKB;ANI/,K.[HZG;P;651N8*E44=\X];3E*6%C=/JS1_Z9G#WJ[_A3B>G
M3:C<6]SI-S-+9U*,ORBCS>U4Y.*?V9Z(]"F;I&CAY/\ W)8SFU?8UVFNWOVX
M+7Y(93<.YX4VHV8C86.;+RWAMK>M<<+N;%*2I(BIQK?2VQC%!13OE@AI/S5^
ME3Q16U?C^.A0KN5EP]9TJ:I1E]17MU%5:TI);.<8>KC%O>*E)+\YY]0/HH\*
MT=%]'$-;G04+_B.\KW,ZLH_7E9V\Y4K6,6]U!I2EA-*32DUE)E7\UA-H!@%]
M_A>SLE"_8P^)M%5.05U5S*@)]ESUK2+@]7:/Z91 LIQO_P#?CA2DX&\J<_+O
MM(SSPI]/A%+ZO<SZ(/$5U2UOB'AB=24K.ZLZ>IT:;>8TJ]"3I5I1[>LA*DFE
MXIO&[SI?],?ANTK\.:!Q1&G&-[8ZA+3:M5+ZU2UNH\].F^_)5A*2;[X['IIS
M?P\[Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 5Y]=$'
MXCRAZ>*BGSP84&>>;J(#20]RLR?CW[*MI*Y9OF+QMVDX:/&CA)-PV<MU$UD%
MD^%4N^.^.>M"5U7O7WFMOQ12]EQ>OXI:"/GV)TQ+E_-O!J,7M/O9MW^A8RO,
MC,$%+CS5@4N<6A@S4>*+.5STFZ8R\>_#M6[AB*)M5UTR;43)MMI]$_81-$?<
M?I;UY!O-]J0N1UO0H4S[JHRGB]>M0LXFDL("]U ?FTP?S0LTL6N$'E:VN0?"
M)G2@Y./I<2BFEZ[LLP0>J3=2)QQ^&&E%XP_'KA>+[KJL8?9IHE"-^T/79^K*
M:EI"740RFOI*76@I6U<UUY=O2W9Z#@-/$)%'3RC>/B;R$!)>Y)$M0DW))Y,)
M?3$,K-L>W$DV=AFC8(F@'U?;X9W6,O[-O=NWUV/Q3/O/U#Z/A*!V'EO+E)$J
MQ\C0OTM;IF[P,RZKV:%I39WHFO'(D3(@EKM>:2K*/-?-4E/S6Q"*]X*Q#F<1
M[20V2M(L14EC\9'*D]TWEX23WZ)^*R^JVPNF/=R81\0#T?8EL*+-*U%\T$9]
M273Y;;M^8$Z$/A3"KY%9%;IV6QOLI=? :5R$G,J]7DBM6#J*&O\ F!&.=BY&
M\*QUP]/M_L_'XQ\27%)=5G"?7OAXQC/1XZ]?9N5U\#>EK3BBGD\4]/+S%O=]
M)?"5KJ6.IV5D4@=,$)SX3]&V?)Y.!66.(<-IG)9=7$=V8,D4RG)GAR^V09NR
M:K%^R$R6WM^L_P#]EU^PD>7>X)\A>SJT7DD@L81K>H?BN5=&V3]G9AJM2AZH
M/?7B3S_4!B406 K2F93R=J_>NPK4+#V;8W))/)B,6C'411DRRK(<<>&_6+^#
M?X['?!/=OLF12QS1 U"IP5I._5E.TB,L*T//<^@K<7 +<\S7)=RT@.4*T](R
M"1)2N-%JLYZ"MB5I1U.41PFT9$X_&':_$BZ;_A?M&%UWQCOOG*7BEW]I:/VQ
M#4;'MWX<546"2-/8Q._05GC[&'0J4SFM&,MZC?C+T7+V22JL.E@^1-PS>81X
M2?8AUY(_Y07'LN';E_TATJJ">.9KM[_%%6XY;MD^?_3MF>,_.LR1(P::>A*)
MK2LYE?)V?WM%_.TRF'F*_O0=VU^W<F;!%3N6*)Q>C8,4@M:%+.&H1B1W?R\0
M<MHJR9Q5P)PL9?7#>%MG=)>&%U?18>,9R]NR<>Y/8LGEQRFX8]\W 9U4\%][
MR&R;)-5=8\LA<Z*^.9QYXCT9W (0.NZ+DH@SG#.]>!\X&&YW-G,+DD=.C19<
MUL>GVZ!I)9WQ]7;*\4WUW[=N_LSR&WOOTE'H_ONPS7G]G(+:\\^0+WIGJ/T]
M=I_<.,^F[2,0 E4"\#B4[F4T]#RX.-9,G4$>1WNDV<MDFWO$LU7D2Z<'H\_'
MV_CV[D87MZR3W7@NN_3XD3D?B%7OP)E,AF4+A;NR_.5H>VX8-(F(?857)%NJ
MB^'G'O4\-)22I M\31@+?/GD\:PZ5 9),)=U]VBU389K7DN?<M8V)Y5]W9]9
M8>^%V\/-KK.4K]@>VX$M-8&['T-9=EDZ?\HW97^X' #$87CXF]+:F]?V1!6$
M$L/T:);WO,X7'X8K(J[9C+.I\K8)%5X*3CG#Y(:')",+;JNJ>^=TO8MEYD^1
M?VN>'^"?07J:3,QE@3WS?%_0A*71,57=B44\7D=+CCQ]E$9=7-FN9)*JUD:H
M1L"YEJ29^<1]MMXXD<4D,@CCL9WT]_P7ZMQCZR3VSC?KL_';K^$4G]OV[ZYY
M@\K\P36TZ+?GYP)\9V-^)=1UE:40&-(-:GM*L*$L"K2X5#T8\D3@+)%90/>
MIR*GH!Q-J]967!'$;!%EV4[&CE%+.</"YMLKPBVM\=?LZ[^Q[W8L"0B\8CD9
M:\M>&L= B 3;ADB\;LN$! ]N/1Y:($")A^@UY3;\Z;HOBQ1XFEKCAR1>K<]N
M51\SOL 8 P!@# & ?-5)-=)5%7G7:2R?:2G&_P"CI-3G?'?._P#1USO>M_\
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MBFGNFGX8-Q&;#&M8P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M3R@"&^Z.WW0-#;$[,I(^^\6XQ(LZ^\?LSQ\X9LV+=J)R\8\,Y^TSK! P!@#
M& , P225I"9;,*ZGL@#;?RRIR,C+0 K]XEFF@+^6QE_#I OMBR?-AI3[?'"C
MX=]499D46OU_VMDFW?)(N4Q.7NN_7[#.\$# & , 8 P!@# & , HQ\26 +V%
MXNNUN/9[>FX8#'VD"2XXUVX^WU>;'3A=)K\];WRL^%!20O?T?YW:+Y5+\]*;
MUNR?2/H4>)>!N)M&E!3E=Z3=*EG^35ITW5IR6-\J4-C('HLU^7#'I!X4UE3]
M7"VU>VA6?@Z%Q+U%2,EE9BXU-T\K;HSS!I*<+)IK)]:Z35XX43ZUO6]=<=\Z
MZYZUO7SUO6^=ZWK>M_+Y;SQOG&4)RA)8E"4HR3ZJ46TU]C31[/QDI1C*+3C)
M*46NC364U[&GD_><21@&"A8D?"/Y58>FBJD!(3II6CLGSSK32/2QU&F,_C@U
MSUK7R2YEKF0SUPW7[WRELDR19[Z^U$6G"^<M6T#4^(/0QPMQ12I3N(<*ZAJV
MC7;A%RE3T^XN56MZLNK]70E&-)XRHPS)\L8F%=+X@TO0O3'Q-PI6JTZ%;BG3
M-)UVS4G&*K7MM1G:7-*/3-2K34:J763PES-[9UF#3-0P"-H1WH:?L&+]J<:Z
M:23])AZ'TN?I\B9>VX(=JZXYW\]<=R)&1<Z^>M;^ESOY_/YZWNYM=3N=/X=U
M2,7RU=,_<NXJ8>'=Z/5E;QCE[-K3IZ<\+P?L:5 TAJWO=<TZ4EFGJ'[HT(97
M-^3:K3C7E/"WP]0AJ"RUU6.F&Y)RV2OC (ZD*WVNP*]%(<_35'<R:4/>M:^?
MV=DB&5CB'*F]?[3;QY(>>D==?+ZW3%QOG77U/>^;DTZ'J>'>([N;Q"Y>EZ50
M3Q_"5YWL-2J..=WZFAIS4VOS?7TU)KG6:%?2];K>AVT%F5!:CJ-9K/\ !T86
MDK""EMA>MK7RY,M9]3/"?*\2+EME=(W;]:,VF^7YY^FVA<53%\K:^6T^3,M>
MHD7[;Y_X'#02$#+=<_/6^$2O'S^>E?EJYJB_(N%*$&U&KK>K3NG#=2=EI%&5
MM;U&O_AU;R^O8QZISM'XQ*#!_E?$=::6:>D:;&W4OY*N]4K1KUH?TZ5K96DG
MXJ-TLXRLR1ELE>. 3()#&:KM1%RZ[UTD@U8L4%'9 D_=+<-1XL8R0Y[7?$R;
MU9!B.8M^.W#QXX1;H\=J*<\[J.D:5?:YJ=EI&FT)W-]?W%.VMZ-.+DY3J22Y
MGA/$(+,ZDND81E)[(I^JZI9:+IUYJNHUX6UE86]2YN:U22C&%.G%R>\FES2>
M(P6?K2:2ZF02Z!2BK)\_JZ:I[0E=:PJ A#[32G*J#$_/&1*^I,Q:J<;VFJD+
MD%Q$(_IPE\N'*0)#O7SYYYWF=OI V-7ARZX'X+;?J>&N%+>'93N;RISW,VD\
M-JI3<4_>\O)@WT ZC1XGLN->.()>MXHXLNZBV7-&TL(1MK2+>,KFI?7:]JRL
MHZ[->#8(8!WT+@[BTK)JBJFR7U^[*M"#1(@CK?&M]QER>:/YMW\N]=<[Y;PD
M=(G'>OH=_/A+>OH]?/Y;RMZ$M!_?#Z3>%K*5/UE&A?+4+A8RE2L8NNI/9]*L
M:?AN\+Q,5^FOB#][7HQXLU&-3U5:>FU+&WEXNO?-6\8K&^7"<\8QNLY/:!QQ
MPGQPFGSSPFGSSQQQSK7//''.M<\\\\Z^6N>>>=:UK6M?+6M:UK/7+IT/'/KU
M/U@# & , 8!3VWO3-CUKZD\T^?HYY9MVT('>K:=KS?T1$TOIUM1'<2%[?BT)
MVKR+=M4>Y(OK39O][FXOM32R',<YEA3[4':"4DTWE+&,)]7GM[BX6"#7]\0Z
MT;*@4%H"(4Z/F)NR;G]:49"AD=KV1 8I-9+$((5)^A;=C88_)ST9 "V\FI^E
M)W&#CLL=&L= C9!LHZY5=(\*#E%+?/1)_'9/[&TRD%D?$&NZ&^GIR[,4;;<&
M7AL!H*@X10QLLG9XV379Z=F=FV"0LL]'O+2UZ&#32IZ0\^%Y-T.  RT[Z%$B
M@9DP#,)9]_<">7;JM\O/L6%XXZM]_ ER3_$SF]64H#N&S*3>*,4/4!'S$2'*
M!)[1TDL\I(*]U(*DF=/0/T<#KV5(#3]B$P-8SD7,N&[2$;9V%/-R@I"J_(E'
M@CEWPGX-^7?#?A^I=6?JY_B&W+3DA9QY[ :QE!B#%O.L"N0)!AGH:<L>[IOB
M50L YJ@':49J9Y4U7E(ZTL2$/HFO<$H8R&R>I,'Z6A4#'%@I H'+Y;M=$\+.
M^,^SOX;9,[?_ !$W _J0A%XA$6DKJZ<^N'EWZ-2UR#BU=4;YVG<VA%<3$B<5
M&N^VLO\ 0!/\)AT)C;IIURX5D%DE0WZ0MJT<CRH<O3VXQMWQG[%\NF=JSR'W
MM=UI-9;0A(3NL;"(V!X-%,IW"XMZ#J(E&PWH2[Y>M;$0X#7Y75:3HF6A=$T9
M:,H'6)'!;8#*6!!'6P\6<,%T5Q*CC?JL2?@^BVZ/IG"QGV^PR&(_%HF9R FK
MU*4#+&-+E_.5Y^C(0H[J7TI$"<>BU8PWF>UMN9V+8-1QBGIK^-D:59:8\53)
MS/,5E!F/1H,\LH>8YEC4''#QG?*6%A]<YZ-]-O/PP?:]O7GM7;>7T$/C5/U=
M>LA<>"6$?-Q:22J4(0-?UW<=C0.<0PL^(QYJB4F%=PBI9583B0 6*+9M&72^
MF@_DDR G#8CE3Z-_RL[+PQOU]OXSM;/UW-KVYM_Q/3E%&(X+GDSL.S+1G_)\
M[(0<1)553U.R$0<9FV\>37/G0'%OVQ2S]2.(*-M&NV308_)BFCIP69"$EAM^
MQ+WM_)/Q14$7\2*?3KJ 3F&52U+V)W6GFZ'MZ]2MJ1#:KD-I>O?6I^F76N'2
M$<5:F0\,@OG"?7!%9^1C+Z1!:Y,_0:!$$9L32?#ERXZO;ZWAOLLKS;Q[_<35
M#O:_H>>6,5\X1ROJ86O059U]B'4U=R*;-Z61J;SW&_/SJ93;AEH6I,7DDW9O
MHJ+4LVC/+MHUZ)QR:SWHKP."HQ)^(Y4DFWMA97COG]2SGVI/!4"B?=MX+1.'
M3Q6,$;*M2PQ57S>)0@S<LD;USOGXE/NJ>#Z=@&EVX%V,>BJ'\P4]U*0<UZC;
MLF&AR1!83'V36?DFSP2TL]<+ZRZ;YC'K_P#<]NO4M]"_:_HBP++,>:XU7M,*
MWJ'LF^QCN;NY#-D*62JCS\ \^*RR8H,-#.YD2E"EF^BHW33>,)O&C33^*S:>
MKET& MC$28CE22;;QA/IXMO;MT3>?LQV^LZ]=WE,_A8G/4\%!0^L+VM*':84
MX.3,.)O& <AMRU4JJHTR/+KA6/$K?E&4IA<B$]. +8*8/D&J*X[D(OVAL$ES
M)/IU?N2R_=X^.Q^FWLR[HZP82EW":Y.5! _3U->(Y@35E$IW:MD6G++,KWS[
M8%CU\/5%=B&D4@5Q35XW3C<B6(2::16%2^4=DHMU]T,"#\?CW#E[=F_#HDWO
MOV63^>[?27H6F+>CW=,<1(W#Z8\>^P/8MK0<PL49O9\I3D9CT:KFOW1-@R==
MCFLLD,X(E@BB.^>-OH,6>$>%M#!C1V$4GU\6EYO=K.VVWBNI';OXM(]:QKCB
MX&N6I"(0DK%I17\NT6=KN)IYYAZ%Z+^H[S>AT&O'W?'JX(^:K4A->;0>KCI[
M,"E6\=E6 Z?,5D8S^//RZ>.PY>GC[O!O&.O?*^)9VC?3=W2:XZJK"ZZXKN)J
M7YYRG7I*$CX!*CTD/5>*@$JIF/DH!::Y4..&FS!-O>4;7%R^,I"0BQJ+S0&B
M)>-68PZ_DAK9M/.&EYY]OL9?O! P!@# & , 8 P!@# & , 8 P!@# & , 8
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MO]B2^[!8'! P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M6=EBP!^%QFMI9P3%6HSBC*1L"PFS8A,!&])\1 ;VQ<M&3=TAVHX^:W7/>N=
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M?A8D^,E3@HM&QII,J]D AOK[=W\?QW7?=FQ;! P!@# & , 8 P!@# & , 8
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#J3[00_!&F,@1;.
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MJ[ZWPA:A>$FC8+6N=_)+OH1$F)?C>U/I_0(2L3VESRY;<]IA^/Q\3<S@# &
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M[J0C7%=,&A]Y"X1'I4/@;. Q3K@.9=?:WA;9VVSU7?._B^[-C'LVHK3ED?\
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M\P,=K#BWGIT6RS][]K\?+HD6MP0, 8 P!@# & , 8 P!@# & , 8 P!@# &
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MT('!#$9CDQC@F1E13-4D2:"PYEC']+P[I)8\?#?+Z/",ULWQ[ZMFUN!O2K6
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MT1YG(F2*A^2$Q<CPG#N<KO!"?;,@3>'>6#EH0$M8DX]I-?'!DC/WU4#^R8O
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M,G\#5Y3L[RW;;5&M"<<^"JQEE+V9AGWMGJ9S'I?(P!@# & , 8 P!@# & ,
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MTO)9^TRWP33E'2:DVFE4NZCCGQ484XMKV937V'I%RQB\1@'E#_NA*.O6-_\
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MG;<OM6=S-NB:<M+TZC:O'K,.I6:W3JSWEA^*CM%/Q2-E>40JPP!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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ME?T7^HO?@XC & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P"/K#JZ%6HTBC*;BU2K:%6#"[1CG"1$@.VRFM?&D)
M!%"G?8YRU[=I#RK=%PH.=]+#WO/.T'K9PAUTGL2FUG'BL?82#@@8 P!@# &
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MM5]\"#O, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!6-3Q_1*UKI7&
MX"3!W)FTY_%%I'GEK6H[JIE:'W)W'?Q'9TRXF2M4M9GR+45^K-H0_AP@657D
MJ&DY.X7,J"<[8V\EGSZEG,$# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MMO"*S?C[X?\ ^^W!?WN/?QN8O_W;O13_ #]X>_ZW_P#YF5/]PSTM?\WW$?\
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M7]L'?[3QSR[_  7R')'M\7\Q^%\'_J97]L'?[3QSR[_!?(<D>WQ?S'X7P?\
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M4VN;+2BFUBF];UO>M_EO6]ZWK_3K\MY2&FFT^J>'[T5CJ?S & , RN&PB46
M84 1 5T9+I"31Q1GPZ8L^N14>%NC)AW]<0=-&^],AC)RZZ2Y5VNMI+:39)9;
MKA/JK:+H6J\0WDM/T:TE>WD+.]OY48U:%%JTTZUJWM[6Y[BK1IM4+6C5JN"F
MZDU'EIPG-QBZ1K>O:3PY91U'6KQ6-G.\L=/C7E1N*R=YJ5W2L;&CR6U*M43K
MW5>E24W!4X.?-5G""E)8IE)*N, W%?!__P!V]U?^"L4_Z7*9N;]#?^/N-_\
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M^/N-_P#1&D_Z[<FDWTT_XAX%_P!+ZQ_J5H;WLW[//@8 P!@# & , 8 P!@#
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,..>=?+GG6M20?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g69956g40j56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g40j56.jpg
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M:"/TI_:7 .T<_,7ZROCQ<\SWF&@C]*?VEP#M'/S%^LKX\7/,]YAH(_2G]I<
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M !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
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M4F2"Y)E!&22,R-1J,\=RP,D. #@ X . #@ X . #@ X . #@ X . #@ X .
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M1V-I@UO.$EMEY3?)&T+MN4+>*-T:QX2C YR/$4%+*DSHI"$9(KF1EM07(+;
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M,RV(?*Z$RJ52KO<JLEGYW5YSU0EZ!DE.BUYQ(<Y)!D9H1HI-2K7..\UHV@<
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M_"\XES)LUVHR52)#-/9DM1WI;SCC\*G/0(4ILTQI<>1%;;91H'GGP])#@ X
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MW7/Y.X]4_'6T&$_F*QX.'KA8"V;Q?\"C>,#T2Y]!!\Y X . #@ X . #@ X
M. #@!-=<_P"MZY_U_P#V'N4K_I/W?R0E/.7M+^1=OED7PX ?*W$-(4XXM#:$
MX[JEK5A"$X_YJ4K.,8Q_\\YQP ^N 'YG.,=WNYQCN8[N>[G&.YC[_OS_ ,L?
M=G[\_=]V?^6> '[_ )?Y\ '^?^7 !C.,X[N,XSC/^6<??C/_ /?@ X . #@
MX . #@!\J6A&,96I*,94E.,J5A.,J6K"$)QG.<8[Y:U82G'^:E9PG&,YSC'
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M.EZXC!QB;8IH*3+8:'BH1EZ$V3=@L.16&6@B_/U^[I+^P@9O3WT@%O#+&.;
M+4:95-!0Z>$) =G08[EOWY4:-N:$*VC+P/#+[.LV381G5%@? G6G(Y056VX-
MTKD@4LU5YH-673W';5KRUY:]=QRW3277A&3>0^O=DG\N]A;8>D[25VQ(DCZ:
M$D7K=Q.7!V0++Q)Q>_V.RT&Q:@K-"LI==FFT8K5WBKA"LN!2,C8X-6O/[UZK
M?=M65AM)ZTZA*'U 7MVU6RP6G1DFGMQ:U)N5Y*6L_FQ,1-<L"? FY!QZ#F/A
M<+94HZI='IA4?/(C$OVO:\ O ;UH [6Z^GOZ-V[HZ;K\" X >??5;T[[GV/N
MO4FW]+EQ-=/476FUM4S34PT^(GQ@&]#.OZW9Y<3P>%-5+52! W.Y! Y26D'K
MKJJH5MR6-:,N%(3[XB2.W\^\N;^Y>\58UMTM]=.O8FK=856SQJ%J.A5'3.LY
M$&K[#*-M1-=U:)H>/8HE30Z<DC1QB$S5]QPLS8^O =H2R>"(9V+;11A0.BA-
MRUF>LSO?VZ]>\RW<W->:;,Z>^MF]:XVKHHC8)-BI-U=WV.$6<EM5Z-*5JPWI
MSJ-UOJ/6]BF,1VK@5-.V@YHJVVHS*E26"4: 8E6$X7+LDQQ4!6*QZ^CW&1EO
MOKL.P.TMUPA[;:XZ9Y1&DV;.B.-US2=ND*O:9]-!N[U&TX71+>4LIAFGC!D6
MP]/)&>Z&B:HP6#:[MH(_2;#/4N;LT!&7WK+HZ-^_5F.O!TIUY4^K[#IE(+2H
M<BW6&W6,):)VY4V&-62QC>?4WL<K.C2#86,66FV5':.DJY%AC:X"%QINO+7)
MD!JVS& MVP(,R.V>K^"+^Q[_ &B5/]-_5S7K??R]+VN<@BF[AJ:R4.00NLHJ
M\97!_P!G 'M8MLH4B$RY?9<VE5'<H<6*L4@A&RR5"MAFQ$^!4I]8";EEP_\
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MAU*32:K4Y5/AH<*DU*F3HDDG*Q)*-"K"&7FU.2IBHSROZ'^>T#YDAP \[^9
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M8COC!DJCV-1NO9W9U(:@JA8/-A7!$%Z<1STV6<P=@.R&8PM1,<R)(V"%VI)
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ML;9KJ (LI4I:&XUDC]6UDMB]J/@:N?30;)'J?3A%8'4*17I$6O62873;]B1
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MS*BRF6I$:3'=0_'D1WT)=9?8>:4IMYEYM27&G6U*0XA25H5E.<9S(I'-P <
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M0@OM2H4Z#,91(B3(<IA2V9,65'<;?COLK6T\TM#C:E(5C.0#M\ ' !P < '
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MP$$D5U_4Z+7F@]/>$%F!HN'6HD?."JYJTN%I!8B1!?GU<YD>Z_$6)X$!P <
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M*5_TG[OY(2GG+VE_(NWRR+X< ' !P < ' !P < ' !P < ' !P < ' !P <
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M_P#[#W*5_P!)^[^2$IYR]I?R+M\LB^' !P < ' !P < ' !P < ' !P < '
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M8\S[N >)2OG>=]CJ_P N\7+(N_B%CS/NX!XE*^=YWV.K_+O%RR+OXA8\S[N
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M8\S[N >)2OG>=]CJ_P N\7+(N_B%CS/NX!XE*^=YWV.K_+O%RR+OXA8\S[N
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MZK"Q!DABNGSYBCV*S54^FLU^P)&&[..P9IUE0&-U^ 2"V: )D&:T0+!U,SG
MBW]N_7]D,AJW>^G]U :=8=9;!KEHBWW6E-W%6!C,SQ=:Y6L]@B8!RG7"?2BZ
M(%O!"C8TG"=CY/ QK[3[W@4IEB:V['0"W=J&VN #@ X . #@ X . #@ X .
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M"K2.UNC_ (M_SE?7F(?]BWK6;1UTZQ[ZV?9'F=:CM7"3,VN:]C*&@*SHFMZ
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MO0!A(PU.?F37")NSG,.^"@DB 0H)OS=1WZ?OJ]PAQ?Z-VG&YDN1-V;9'&(>
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M9MLMU*II6PSX;JIB&21ZC69EY(P<3='11^9Y!$:(\RZL!$9^_FZSU<1PV+K
MZ:ZF&BF+'N37@EV4S5Y>0$BY5==IB#+<<$ 1)J;7V##Q&,!;D'($XD<6UD4,
M"YD&9DMH=&>D("!T'^H?I L9]^!.W'I(D2'*U_86)1.\550=Z=;VK/C7I"OE
MII)($J=)1:I9%"G 4N67;@CW<J[.,XSVD6+[^^L38_['[K<_<-\@:/4*N\T_
M7JX)#/,CLB&G1\1N.ML9F:Z25"2I&,9PPN>^]+6C_P!N0XIQ><J[F<+$7-]W
M$"5<D!Y4HV:(6S%>Q7=C)3+DXBH0O6MX0\TO*E([24RL'AR)&[J>[F3(2VQA
M.4JRYWJL9Y?TNI6X^O[]_MM8T>M.\OO_  ?5?Z7LL0A$QS-=V)G$%Q#3B4:V
MNRUO96I*<*AMH!Y7-;QE6,K=BX=0A.%*4K"4YSB-+_ZJW"='_P"R=XY\[$%8
M><8\0W[*FXGAF5XU[<LLJ;Q_[EM_ ;LG)?\ ]FA>9/\ ]/DW+(]Q\!%CS+>7
M$<2=DB59@XQ7]A8\88=RUWVN+JG#'98[N<3LJ"8\ RK_ ";Q+['+N?N1WV<9
MXTNH]Q_?^?:&CUEO+[_Q[!\9V:(PRM[R=V-WJ)?@648UK>,O9<QG&.U0S@%V
MJXGW]WPQ*<Q<X[N>U[F,YXOU'N/@%NLMY<1RKV.)0J8G-?V!G,)M#KF4ZZNB
MTO8<3WV$PU)"Y3-<3C[EMQ<NK;5_A6G"ONXTNH_98_\ '>&CUE[;E_GN'TG8
M@I3L=G &_85(C>%)6K7MR2TVCN9SV4AY07#<>3]W<\%>4A_N]S'9]W..+]1[
MCX!;K+>7$<"-FB'&HKN*[L9*9;^8Z$KUK>&W6E84I/?RFE@L.1&.ZG.<2)"6
MV<IRE6%Y2I.<K]1[CX!;K+>7$?JMEB$-S',U[8F<0G4LN)3K:[J<>4I24X5#
M;2#RN8UC*L94]&2ZVE.%*4K"4JSAI=2MQAH]9;RW_>OJ',K8@I+SS.0-^RIB
M+X6I:=>W)3*T?E,O8"Y;>E?_ &C2E2/_ *?%^H]Q\ L>9;RXB7Z[V6(Q=J?G
MR>V)GPZ:M3>,:VN^<LX0P[G.)N, _P#P*L]W_ F7V2EY[N$XSRE1ZCY^CH//
MV"2([ES<Y=)9^T7-^ML)V'A'DMM/O?#O%_>?51L'M^U[O<[?L/)[MO ?^/A_
M>>"=S[^V[GW\M"\.9>U S:B"<UG9BLCFVG'<HU=?'$R,/)[]*1ZD ,I(N(Q]
MSK</+RVE?X7$I5]W #[3M$.M^.QBM[*PJ3"Q.0M6L;TEAMO.,Y[&0^H%AJ--
M^[N9A/K1*QG.,=EW<\ .LWMH(XS">Q5MI)3/D9C-H<U1L%MYA>%*1VDYE=>P
MY!CYRG.<29:6F,IRE6%]ZK&<@'ZO;(1#4Y[-7VCE,"1B.ZA&JM@+=?7E:$8<
M@M)K^7)\?&5XSF1$2\SA&%KRO"$*S@ ["MH!T/R&,UO9.51H?AJUIUC>EL.-
M]SN]C'?2"RS)F??W/ F%KD]W[NR^[@!Q(VJ&6L>C%8V=C))#JVLKU;?4(CX:
M1A:L$%J 82.6K&>XTB;EA;J^ZAO"EXSC !Q?6V$[##_DMM/O<SO ,(^JC8/;
MX=[O<[?+'D]VN(/_ !\/RG$3N??VW<SC@!SKVH&1F?C-9V8KQ<AI;N4:NOJ\
M2,/)[Y*8&4@,X(+1C[G40^V4RK_"YA*ONX ?>-HA\OLL8K>RL*?AIFI7G6-[
MPPAM6>YAEY_('#3$S'_M0G5HE)Q_FUC@!UF]M!'6H+J:OM)*2#RF&DN:HV"T
MZPI*U(RN<TY7DN0&<Y3G*7Y:66E(RE:5Y0I.<@'TO;(5#$U_-7VCE,&3B*XA
M.JM@+?>7E:4=K"837\NSHW=5C.945#K&$X4O+F$ISG !SKVB';>EL9K>R5*A
MQ,S'%HUC>G&76\)[[L8CZ 66I<ON?=B''6Y)[[_#V?=^[@!Q(VJ&<<'MXK&S
MDY(MNNM*7JV^MMQTLM]HI)!Q8!*!SB\?X6FIJF7'7/\ =MI4O_#P XT[:"*8
M;?Q5MI82Y.\ PA6J-@I?2[W58[=QC->P\W!_PY_\>M"8G<RG/;?XL=T YG-J
M!F_&/=K.S%>+,,Y>[/5U]<\([?&<I\7=X 5XRRCN9[;$'M\LYSC#O>YSCN@'
M[]:0?,AF-Y-;+[]Z#B>ES.L+WB.AO.<X[!Z3D#V#,['<[N8+KB9>,=S.6NYG
M' #A;VT$<;@.XJ^TDX(NK9:2YJG8+;C"D*4C*Y[:Z\E8]K.4YRAZ8EEM:<I6
MA2DJQG(!^KVP%0Q,D9J^T,IA2O!'$(U5L!;[SG?X1VL-A-?R[-B]W/?>%QD.
MQN\[J^T[S&<X .=S:(=MZ8QFM[*4J%%\+<6WK&].,O([WONRB/H!9:F2NY]W
M@D9;LCOO\/9]]]W #B;VL%<7 ;Q6-G)R196\TIS5E^;0PE",+RB>M8!*![RL
M9[U#,S++BU]U"4Y5CN< /A&V0BV&Y&*OM%*79N(.$+U3L!#Z7%*4G#SD=5>P
M\W"QWN<YG+0F(E.<*R[C"L=T Y7-J!FL$,YK.S5>+<M8=[/5U\<S([7_ -7Q
M?A %62.$_P#O<PNW[+_WG>\ /WZT@WA*(WDULOOUPL3L.?5A>_!DMYSW.Q7)
M\0]@B;]_WP5+Q*QC[\M=S&> '"WMD(ZB O%7VBG!%QQMI+FJ=@-+8RVK*<JG
MH77TJ'MJSCNMN3,,H<3G"D95C.,\ /U6V J6),C-7VAE,65X(MM.JK^I]USO
MDI[6-'37\O2HO=5C/A;"'(^$X4K+G<3G. #F=VD':=FM9K6RE*@1TR7%-:PO
M;K3Z%)[_  W"=0!4W.D8Q]RHT13KZ5?X,MX5]W #X;VJ&<<@M8K.S4J(,*D-
M*<U;?6VV$H1AS+<YU8!+<!_.,]ZF/,4R\M?=0E&5X[G #C1MD(N.Q)Q5]HI1
M(F^ I;7JG8")"',JRGMGXZJ_AZ/"[N.[F<\A$7"<X5VO>YQG(!R.;5#-I(JS
M6=FJP-4TE[#>K;ZXJ1E[/<3D<EL K))*?\W50L/X9Q][F4XX ?N-IALR,1O)
MG9G?JA>'X<SJ^^8CX;[O>]AF3D#V*9O=^_P'*\2^Y_B[+N??P XV=L!7DCU)
MK&T$8)*<0UA[55_95'RTKO<Y()<KZ5#DJS][:YN&$NI_Q(RK'W\ "]L!4,R7
M\U?:&4Q9F82T(U5?UO.N85A/;1F$U_+LJ'W<]W$UA#D7*>ZK#O>XSG@!RN[3
M#,O3F%5K9BU0(V)3JVM7WQUE]&49<PU!>; J:GR>YCO<QHBGG\+[C>487G&.
M 'XUM0,Z[!9Q6=FI5/8S(:6[JZ^--,)PG"^SG/+ I;@/YQGN88EJ9>RKNHPC
M*L=S@!\)VN%6Q'?Q6-H83)FX@H0K55_0^VYE64]M(857\/1H6,X[N9KZ$1<8
MSA67>YG&<@![:X5E,]2JQL]>!RD(=PSJN_/*D9<SC&,P$MU]62"4]WNN*AX>
M2WCNY7E.,9SP ^_K4#>$9C^3.S.^Q"\/[3ZK[YX/V??=[V&)'B'L<S>[]_@.
M%^%][_B[+O?OX ?+6U0SJ1RDUC9R,$E.I:P[JV^M*C]EGN*R12X 2H<E7^;2
MIN&,.X^]O*L< /E6V J6'Y&:OM#*8\W,!2$ZKOZGUNXSC';,,)K^7GX6<YQW
M)S*%Q,XQG.'LX3G. #[<VJ&;<G-9K.S59'L)D.J;U;?7&WTJ1E>&X+B "D3W
M\8QWJF(BGG4K[B%(PK[N 'TUM,,\]"936MEH5.C>%-K=U??&664=YVG937G
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MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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M621YE;,OU=75]ESE/1/69UZA]RMZ2%Z\E6$D1O9VV- #?3]O65:[%J2\=?\
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MO5"#+&50&<HM9*B*R,GM16)XX .FC'X@B!.8A0F9D. U'C2FX<5#[3B8[.$
M&"+Z6J3]Z%WX7J[2V+4&G %C;L4I0YZYCQ8H3("YAC2L<6W-@3AXYWP$"1:)
MJ:@BW'A6![<?N.*:_O[_ ,=8#\U9JV51"N2;]9T\$>DU&" (R]<TA%7(S) P
MV4FCHCDM&,+>KD >0SB$+?RO,,J^2EQ\MM3EMIC7GW?\@-Z<D!YW\R!CAP <
M ' !P < ' !P < ' ":ZY_UO7/\ K_\ L/<I7_2?N_DA*><O:7\B[?+(OAP
M< ' !P Z^(<3$M<_$6-B>Y&;AKFX8:Q+7$:==>:BKDX3VRHS3SSSK;&5Y:0Z
MZZXE.%N*SD [' !P < ' !P < ' !P X6XT=EV0\TPRT]+6AR4ZVTA#LEQMI
M##;DAQ*<*>6VPTVRA;F5*2TVAM.<(0E. #FX . #@ X . #@ X . #@ X .
M#@ X 8L:#"AE$5AQ L2LN0?+EEC1\2"HH5E80F23(JBLM9FD)"6V\/S9.79+
MV$(PXZK"4]P RG !P < ' !P < ' !P < ,88"AK".D!SXD8<$S,-8EBS$"*
M3'2L,O-R&<2(4UI^,_AJ0TT^UVK2NS>:;=3W%H2K !SQ!P\>J6N!!APED)7A
MT]42*Q&5-F^#1H7ADM3*$9DRO X<.)X0]E;O@T6,QW_9,-(0 =S@ X . #@
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:?R?'IGC#:S$O;M4^J#T*P;LEAGL&E?2#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g69956g46y71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g46y71.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27(4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M        /X   #A"24T#\@      "@  ________   X0DE-! T       0
M  !X.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      ,U    !@             "1P  !T(          0
M                   !              ="   "1P
M   !                         !     !        ;G5L;     (    &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   "1P    !29VAT;&]N9P
M!T(    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M  =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I
M;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP
M965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   D<     4F=H=&QO;F<   ="     W5R;%1%6%0
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M;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M   *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M    "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M    .$))3001       ! 0 X0DE-!!0       0    *.$))300,     !GW
M     0   *     R   !X   7<   !G; !@  ?_8_^(,6$E#0U]04D]&24Q%
M  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U3
M1E0     245#('-21T(               $  /;6  $     TRU(4" @
M                                                           1
M8W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0
M   4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9
M E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M
M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,
M9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I
M(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-2
M1T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M     %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N
M8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                9&5S8P
M   N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S
M4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO
M=7(@<W!A8V4@+2!S4D="                             &1E<V,
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@
M245#-C$Y-C8M,BXQ                                  !V:65W
M   3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4
M %<?YVUE87,          0                        */     G-I9R
M    0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [
M $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D
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MAG#@<3IQE7'P<DMR
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0'_P  1" "[ E,# 1$  A$! Q$!_\0 '@ !  $$ P$!
M          @%!@<) @,$"@'_Q !B$   !@$# P(# P4)!PT+#0 ! @,$!08'
M  @1"1(3%"$5,4$6(E$7(S)A<0H8&21"@9&Q\"4W4G*AP=$G,SA6=G=XDI>U
MMK?6)BA'4U1869BBU.%#1$5&8F-UAI6EQ-/5_\0 '0$!  $$ P$
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MC9[7HVK01E651</'L@Z%94SI\N D22(4?CY^NGH]5@&G]'O<'4;CB"M([F:
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M$G R6\+2,@- )"D)A/=3-U-TA 9)>O)^K*F!-O85^]U-U\QAX#UQB 9:5B@
M>!4X,]9@ &$RZ7(%OK1_:95VV1EOU%-+6V]Y CN+\OJZ(EV )\#-13[_ %\=
M[$&Y<7MY8RU_V/4-VBDN6E:>&WW=@+Y;7&6Q4-R:,DFF#BUE)6'&1&"V"8\0
M:&/X<[*(:=AK%'MY6#DV4K&NDR*MWK%RDX05(<H&*('3,8 '@0Y*;M,4?80
M0$-; TM72UL,=325$-3!*T/CEAD;(QS2,@AS21UW','8[K5JMH:VVU$E)7TL
M]'4PN<R2"IB?%(QS3@@M> >8YC(/,$A57D/Q#^G50J1?NB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HBA-E#=A=*IG:8P/CG"+;),W7L=UC(DW,2V7:GC-@W8VJ
M9GX9BP9)62,>#(N$E8%15<Z#@HD*X(44 *3R*$686>YC!REZC<3R.3J1&9;>
MORP:^.C6)FYGF=F+",9]S7Q @$36>IQ[]%9H/YH),A5?0$640<)(D6/[-O9V
M]L:[?7])R;CW(-GH<38Y-W4(^\P<.NZ"JNHYG- ::DSA%LF3-U*-6ZDLH=6.
M.X,HW06760<$2(LCQ^Y; DGD-/$K/+-'6R:H^E8O[$)SK4TZ65@VWK):,,V[
M@ '[-J"CGTHG!9PW0<KMDUDFK@R1%38C=AMJGX^]RT/G#&[^,QDCZJ]/T+/'
M>DKK,71F!'SM<ZI$UF"T@48YL_9&<LW4EQ'MUU7@@@)%3UMXFUUO 5>T+YTQ
MTE W5Q*,ZO(*3R!4Y=Y"/HR-FF2"(@#E)[$/)F-)*,W**#F/2=%<NTDFJ:JR
M9%6&>Z3;G(3-[K[/-..EI?&4;)S%\9A9HX@UJ*A52H34@_745(V,UAG)R-)=
M9LLN6,>'(S?"@Z.1(2*CX0W1XWW"7')U=QB_:66 QNTH3D+K%22#V'L*EXCI
M=^+5FW(DFZ8.(,\0JS?I/>%C.%!X12*F J$4D]$31$T1-$31$T1-$31$T1-$
M42[DM1"[S,)HR&6K9#9"/AS+9Z[AIF9Q]C;M7R3%-"=N,T4J)FOQFI.!8,XD
M55R*^&8>^(AR@H($4M-$31%IKRSU.<G8ISKN4AG>":K-;<-J.2,#X\R]D)KD
M-ZSR3'M\[P<#(1MSAJ2XK1X:7A:Q(3S1E,QQ;&WEG#8XNV":IDE$0>OL3Q_)
M9AD.KKL@B9;*$7(Y"GVB&+(BW3+Z<4I=@&OVY&@V&*J5T:X^E"-3I6Q]7+-.
M1<+(H,BD ';KO145:HKN$R*F2O5$PU%3U5L,P]<TG$;G$&9LDV[[?TZ\U[)T
M<[Q/8ZA75&D-7#1"L;*,W[RSH-&0-W[AU/O7<<2O ^(=82D7Z?J\[24F*QE&
M><D[(VM%AICG'I\'7XF0FUCJN/(_*<ZQ<50T8#]%-A1I)K-J/5 *R%$5"%7%
M1,Q=$5RMNK!LG>V_']299*D'1<APV/9EG:DJQ,EI=:'*\0\G<<Q%VL:K=-I6
M)RV1C!VYCXU^ *I F0'PM!70!0GK[5:NW+J4US=#NPM&(,8U2>5P[";;$\VP
MM\L=/M-5G[C(#D=W3 6J+":2;(6&DOV311U$3;!N/KG?W"*"D8G<1690>LWM
MMG\8,<AWNG9AH+]_9<P,_L4ECJSVRR1]#PM9#U^YY:EVD+&"I'8_A%#LTYZ8
M62[(B567A3 Y>,UN"+U[\NIFOM8EMM[7'<9AVS5O<)1LFY#C,@Y4R'.4BEH0
M>/ZU7[3&-8U_7ZI:W3^1N;&<(E"B=FBV(J5,RZ@)G,8A%;<YU@L:)X+):&M6
MFZEFY3;/4MRLK3K36;I8,<4.K6]T1K%&N>1:9!/FB2,DL1RC#(LT/BTBH=J
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M '(B #VP0354T=/3Q23SS/$<4432^21[N36M:"23]PR3L"N$DC(F.DD<UC&
MN<]Q :T#F22H3ONHSMI:29V+:5N,RR35%,U@AJ3./(#@INTRI'HH)**H%$!Y
M52;G()0[B"8H@(WU'V::I?%WCX:*%_"'>SS5T#:C<9X2P%S6N_S2\>>,+PG:
MFM;7\(?.]F<=ZR"1T6W4.(!(\P#\%*+&>8L:9AAQG,<6^(M#!,2E<@Q7['K%
M0P ()2,:X*C(,%??V3=MDA,'N7D! =6I=++=++,(+I134DCMV=X 8Y .9CE:
M71R#S8X^:]:EK:6M87TL[)FCGPGWFGP<P@.;\P%>-DL,34J[/6J><F9P=:AI
M2?F794%W)FL5#LEY"0<%;MDU7*YD6C=50$6Z2BRHE[$DSG,4H^6JI1$C-^>%
MI6@C?T(?)H(/;%4*K4ZVE2'$E9L@SE]CW$K4F5#0A7LG$6%:3CV4@X=HI3*+
MBO?#WB-F1AG"/A,11FR]U")=').-:UCJZ8IPW3+CC&VV^4GMR6.,D*SS"Y5/
M(9Z#(T)>MU^TU5Y#RC)TUDE')G9'S=48]91L[4;*-U%"*:E>W0X]>2$)3I"0
M>O[XYRVI@618Q-?=LT%\B1=!#(<O+L8]T_>O&=%6K)?CL=,.';P"Q[QB1159
M0YE1(HKY?W2;G*WD+=NMC>)PK(8VVC05"M-@K=LB;HG>;O"SV/POMD2A[9%V
MA.!A7[)DVD48L'M4?H'.1L5P)^XYM%/GY_AC^*S0PW^8'>S\/" 2^$CY1Y5Z
M\YO*=+E7&.(:_7"ILKG!8WE+@F'HD;B[A9%B(-$T5&*3UVVCG,@@^6!N!0L?
ML^J'MO=M&DB:#S6SBWE;J5Y+*O<43J,:ACZWS85AID!R\*JHBE46%I$M<?27
M<95>3, PK678@9X!%>F0-]V+JK/WBA)LKM!6J&K^6%JI:K;CZ=0QS9K+B:IR
MUGLL=$ODW3&4G4(A")>*+JM$&+"7!@\:0LRLY% QB+C";^,/J6.L469;WA>Q
M/Y+$%4L5IAJ!-AC>$MV:*97K;1&[Z?7<."Q32T_'T&$6V<J.G[-XFJC)%2;I
MIOW!3CUSQ\3R^Q3HT4)HB:(FB)HB:(FB)HB:(FB*'MV#%0[V\%FF+5>F>7RX
M4S"%,J,?ZG\GTS41FZ2-KEK%V)&:?'XMV$.E!^95-7T[N0%(I@Y$I%,+1$T1
M-$31%JKZBF1+HUROLKP"URY9]O\ B;<+D;)$1E?+U+F8ZIVEB2DXY?VBGTB'
MNTPS?1M5<76<3%([L4 ?O48I1A'J$474 Q% .1ZF><L+V+%&WG!MG@-\:</3
M[1D6P9QLS U>DLH5&+S>XQ:AC^"F4)2NU@EOI[,JQ+%DEP61@YB28L"(PQ32
MBBY"+#U&WF;D:'D(]QB;C/9$DX"G]2":A,:9&R&,/49^>IVX?&];H43/O9>3
M:1)#TV+FGL77D%GK;V[H6+<MAD$Q,4;^6=\?E_-3AM^_7/\ =>E;N9W)X^LV
M,(3/6%7-MKTC(LJK;XZ/K<G4)&&"9935)MQ%WL)<F<?)&*JP4D)ZO)G,W?(R
M;ILL)$2E4JH]3S/),]T6@V> PA8*(;/V)MI-NC*G,3Q\MV#(&0\2L\CNLY5.
M(556C4,0,7*XL4V3MNY>KQ8.)CXLF5(C<2?+/KUU55W/XRN@=3#;[28G<_NG
MJU%S1BW/^8;50:IEHT154+!A<<;*56%KL86!<FB:R^";E"V"**HX-)^H+VN$
M.PP*$6(C]97+4ACV@S%5H>'I&WVS E=R,_BW-FFG3*NW.P[H87 +2#G"QQU9
M)G&IQ<J,ZN"R2<F=Z@HBFEX@T49]>'Q]85,'J[;J\8+S\MF/&&$;97*M<]W^
M&7,=B][=6-BFLD;7:0ED$MH;C/B\:Q],L4<Z1B7,89-U+Q@H.9=1PHEVMBE/
MRRKNA>I_NVEYNJX5BZOMDMF9;?FK!U&C\@U>=N;["+>JYTQ-;\I-VJ[ANJ[E
MSWRBH5<6$G&).S-95NZ82!4V!'@$3)Z"JG65WH9BPG+8-Q!@2X6FO90C(>R;
ME\B%Q[2[3>GDW2\7-B-H/&\O'5B,E7<#6<L6YTXB'%CERMXN-;0JIGC@"G'D
MGKUZ_)>1+JQ9ROV4HP^(ZW@R3P-.YLP+@V$FI.2MCN[OI?<1A(N18&QF-'"$
M$E'4J?\ )&3<<4IWTFW361;F:KI=YB>O7W*,>-^IKN4J>,\59@R7+5/)F3)O
M:WDR>*K'6>8K&)FL^?=#4\0UV7R346J"C)BK4R2RSZR6%NNU<,()N1F1%)1T
MX7*195N_5\W7U4KC&,1CK!-YS''9IRICLEOI;JS2N);3$XBQQ4[RZ;0AGDY%
MNFM@N+NQC&)+NYQ1A66;5W(N6\B1L<A2C/XX60('JR;E)+)[52;P_B:KXM0W
M&TG;/-524LTL&2X^YY"VXDS;'RCZS)K*4-G!UZ61<0,DZ**Z+R-63E4G"2:)
MN\IZX]>O'PV\5,7IL;VLF[LRY7@LQL,=5S(&/ I<N^IE-:V)O)5N*O;"0D8I
M&2>R+N9K=KAED&7?6[Q4+ [C;*T!=PI'19R$34(MI>B)HB:(FB)HBU;Y]ZPF
MR_;)E"Q8?S1.Y"J%XK*J)7C%SCJ?5:/&KE(J[23B)!-,6TI%.TS<MGS4YT5#
M$52[@525(0BI5<ZUO3NLV.[KDIKFP&$11',2TEH>7KLS'VEZO.*.$HPL% J-
MA=3)5U&KDJIV0J$9@B8[XS9(R9SE&1^7Y_/;P6+P_= ?37,)0')=S#N$ $1Q
MW8."\CP(F'Q_(/F/ #[?(!'VT4K;3B?*^/\ ../*KE7%UD9VRB72,3EZ[.L0
M5(B]9J&,F;O0<)I.6KANNFJW=-7**3ALX24153*<@AHBR)HB:(J!:I!Q$5FQ
M2S0O>[C8*5?MB<"8#KLV*[A$HE#Y@*B90$..1 1#5)7S/IJ&MJ(P#)!25$S
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MDFI3G)W_ (>L=.?V+*S+8C6F;&89!?YLY9?)FV+))E!AV)10<;9ZU1JU%Q0
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MJ.-WF'JQBRA06*Y)G(Q\ECV,JT.TJ$DSF"F)*MY""2:%CWQ)(IS%?>J15,Z
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MKI1N=V5UV, <*HJI@4K%0=('J/F, ?O5<D!W& .1;QG "(\<B/Q'V#W]Q'V
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MDQA  #4.<UH]X@ [;]?)<@QTA+61NE< 7%K&ES@UH)<X@ D!HW)Z#==WR]N
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M78'5NK_\K;KE$/\ %EJP?_\ DE'4'L*J>FL;"?C3W ?A"?7P4_WS5)MG06I
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M$T1-$31%CC)&8,78>C64OE*^U:@QDD[%A'OK1+M(EN\>%3\QF[8[I0@+*$2
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M-$5L7&XU^AUZ0L]F?$81,<F!U5!*91590X@5%JU03 RKETX4$$T$$BF.H<0
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M\1C*DW4+I"7UH9LZ:-TI-J*2[F*<E*LF)DC 8CUD)^14334 # (AY$#"7NY
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M^8AKU&-^3IL@Y?;I<I&>N$B+NQ9S"39IZA8H** U;E:E*@W 3<)I   0OW0
M   UC+]8;V[#C=*D$[GWAC?ECW#C;&W0YV6\?]#W9FSW&:(L9:SW 74P<[W=
MO><^3B<=LDDDD\R2O2'42WT@/(;H\M?_ *^3_P!VT_3][!R+K4Y_Z?+;'(,
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M0#AW8SPY'%P_L]W</(>)&,[+9J3LF[*NZE[G2VF^],4G=&6H/=B4L=W1DQ5
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M&9IGPETOMO?NQEKFM$1A (!/%L2 !FZK=>A>+4VDBI'65T%>;K)*7"JBG:V
MT IV@@.8\F<3;$C#.7O9O7N-_A&_I'_3KS,G;<[<E[6!X#[%^=QO\(?Q^8_/
M\=.(^/W#/V\U.!X>7R\%^]YOQ_JTR?$_:HP//[3_ !3N-^/]6F3XGY[_ (\C
MY\TX1X?:2>?Q_%.\WX_Y _T:9/B?M3 \!]@3N$?F//\ ,'^C3)Y9./#*<(\/
MLV_!?G(_J_H+_HTR?$_:5'"T=/O/\5(#9_D#+V,,]6N9PA@-WGVQ3>*VS2P5
M:.R!6L<FCXYO:2&;V!S(64BC*1,1;A@FU2)ZLH+"IW F42CL#]'NIK:;4-Z%
M)1NK0^T-<Z%L[*< ^U0#CS(.%S@&M;CF 00<$K7?Z2%JL-UTMI^*_:BCTW!#
M?)G4]9);*NZ=Z]U"[-,V.D_:Q@C,O&3W>6AI]X[3QSAF_?WDW$64<<M>FU.L
M%;K2+-6&\B;<EB=V5NI+1KEFFY%F5)-1SV"H"@-R*$,J( F!RB(CK:VLK+W4
MTE53BP/:9H)8@[V^E=CC8YN<#&>?+._B.:U0TU8NSBRW^R7A_:E32BVW*CK7
MP#2UZC,@IYF2E@E=Q-9GAQQD$-YX(V/RO-=B^])NW1;O=K.9VCQNF1!TV3I[
MIXFBNB4$U$TG3<3-W*93%$"+(&,BH7@R9C%$!'%HL-YY&V5F6^Z<1.<-ML@C
M(P>?ER6^)[4NSJ3]HW6VF^&3]HWCN4+7 /\ >W:\<33ON" <YR,KTAL=WE?3
M;#FD?_R/(@ ?S@'ZM3^@KS_S96?Z%W\%([4.SS_+;3/RN<!YD>&/FLA8JV,[
MACY&IP9<VU;BV&-_C38UMD*GCX)*>CXXH&,1XPC)5)9C)E;N005>Q[A)0'3(
MKE$A!4,0HU-#9*]E93NKK37OI!(._8V!Q)9OC(Y.:'8+F9RYN0,G9>!JKM*T
MS4Z=NT.FM=Z4I[]+2/;:Y:BZQ,C;4' QQC>)[X^-D<I.(Y'-<< %?5'5=M>;
MJMC..EL&[PKM4643$*/ZU4\EX:Q[$41D1LD=7X99ZM'5NGS<0P,<@D?+-GC1
MTW3\CA(RH@7NS#! 60L--*88PT%D3H&Q-:.>'1EK2WP.PQTV "^==VN?M%TJ
M1?*.*X5CIN&JKH+I+6S3.V'>15@GJ8IR1NP\3@X^&2LZ['-QLMNMVZ57+\_7
M6-:L3F9M=3L#.&=*OZS(3=)LLA5Y"=J4@L0BKVKS3B./(PSE3O.+98$S'5,F
M)S5--*9H6R. #B7 X.6DM<6DM/5I(R/(X7C7FWMM=PEI&2.DC#(98R\!L@9/
M$V5K)6C9LC [A>,#<9P 5,(I>T!Y'D1$1'^<>==Z\I<M$31%'BS?;[]\QBX(
M[*M2A\<?DUR)]I</O"L_MG<[%\3K/P"WPAS_ ,>+#55O\19RP-^$!6F&7GY-
MX^TBD/HB:(FB*$&_" =2.+8"=;$,=.M7!DI(& .2HQTTQ?PHK&^I0+).XQ,3
M>X "H]W <B&0>S>I9%?)Z5YQ[=0311[\YHGQU#6@=261R8'4[+#W;70R5&E:
M:MC!(M=VI:B? R&T\[):1[G<L-:^:+B.< ;G;<:AP^Z8O=[<'+S]>! P>X?K
M*/N'ZPUF@#)('(AP ^(*U9& 02< $;^&XW_@M.^3H=] 9#N$9(D.1R6>?N2F
M/[BLW>K&=-ERF'](BR2I1*8O(<\ASR AK,EHGCJ*"E?&X.:88VC',&-HC<""
M 00YA!!WR,\E@R]4\M/<ZV*0.!$\CP2#[S)'E[2-L$<)!R-O G"L;D ^8\:]
M->3@GD,K*.$XIW,97I#=FDHH+2;;R;LY 'A!A'@9PZ6.< $"% @ F FX 3J%
M#ZZ\>^SQPVRK+^9B+&\LES\,#0,Y))=C',C.V-U[FG8))KO0B/\ =F$KB,^Z
MR++G./( 8;C.>H6Z+:?B7J3RMBR9;L3;@]KU7@2.&D"P;V_ USGWI(U=T\FV
M,>HZC[]#IN'S!JX:%DG9 !)PJJD8K=+@.=5NT"JIHQ;*.N:ZH#O:*R)M*\0N
MC:XLA:92\2<7&(W%F&MY.))R%O3V/4%3*;U<;46TG![);IY:YCJIE1)&U]2X
M4[6.A,7=F4"3+GYXFM_=RIN&Q?U?N?N[K=F !P7GG;3D01[NT.X?[[7R$W(@
M'T 0#6-N]LO^)UW_ (N+_4K-W<:B_P"<+9_X";Y_^M>O-6?8]O?5HL\Q39R2
MW8;.0>4::=3L,5#;5?@14>NXIY#JE> KE50YD0:/EQ(")T3E5[#B<0+QKFVI
ML[!(T4=;B1G"<U4?+B#ND0Z@>/(@\UUOH]0/=$XW"VYB<7M_J$W,M+=P:D]"
M>1!Y;KYV,P[6^J@[RGD-U8JMF^WSCFYV1:1M%,):&M3GU%)AX=*4K+,LV]!C
M .VPHK0\>+M8T?'F;L3F[T#%+L3IZ_\ 9I%8[7#5NLK*F*CA9.RHH&R3MF#0
M'B:0TKC))GFX.(=L5JYJ73/:U/J&\STK-02TLE?.^GDI;DZ&F?"YV8S3PBIQ
M'%P8#68RW&#OSQO^]2ZIH<&B,=[G&RA#=T@9O*69@=6'* FDFYS&FVQG2"R!
M>U5@0RQW@<)$;K&$"#7U6H>RYS80'V @5,)(;;1D-#@7$D4H]W&<@Y'4C. O
M-I=+]L+'3DQZG;_5)VM)NSL<1:0 /ZT/>.<-P"<\O ^3]Z]U+_;C&>YOCCVX
M2N0!Q^P'@:J1J'LL&<S:>/\ V:W\J0^O+"HOU7[8O\7U2<[[W.0G?Q_K1_%;
MD^BWAW>'C[/.19//$?F6HTQ7&ITT8N_,I<\%8IL9^-!D*;J9<*@UDHEJ+U=O
MZ0H*K-UW*:A_$7MUB[M1N>D*^BMC--MM<DS*B8U$U#![,^.,L;PQO8(HA*V1
MQ)RX$L+=L<6^9.QVT:YMUQO$FJC>(J9])3LI8+E4&ICEE[UY?)&72RF)\3?=
M(;PAXDR<ENVW;*N^ND4.Q.ZU5Z\\O3J+<G:2LBA)(1$.@Y1,)'#5D[4;O59%
M9NH!D5E$FY&9%2F(5RJ8AP+\W>TOZ86@M W^HTW;K=<-77"WRF"Z2VV>"FH*
M*=I DIFU<S9/::B(\0D;#'W;' L,A<"!OGH_L&U-JBW1W6KJZ>QTM3&):2.J
MAEGJIXW#+)70QEG<1OV+.\=WCFD.$>""M;>?-^^><CS 15?H\UA+'$8_D4(V
MXB^BI=>[3#-)D<[ DFYC%H]B2/9OTWAV+8OK%!<IBHL9),Q3>%?OI#7K5FG+
M#J+0K[AIRSUT]7!4U@[HUGM](V(R6Z:4QOBB=$V5LIC8,S<;"'<+#G.'9;V"
MZ*IZZ\T6LFV[5EWIH**6.TSQS-IJ2EJ3,!7,IN-DD_>NC[ELKCP0D/:6B1PQ
M'?\ ?)9OY_OPV'Y<#W#4C?K']*!-SS_-S]=66.V;M. VUM>/+,U+CYCN1CX
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M!L,!;[-:U@PT?Q7:'/(<?/D./V\ZX+DM@.TG ]/W"[?,P4#(C!=U3)/)I7D
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MYC@X ^+78PX<B"05072VTMXMU;:ZZ/O*2OII::=G(F.5A:2T_NO;GB8X;M<
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M@@ AP/N Z<T6NO=#M\90;62RC2&Q6K,BPO+C (% C9-%4_"]@C4R@!6YTE#
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M'ZG7GN=N7@MW6_2KT"1Q.M&IFN<>(M$- [A+MRWB-7[V#D<6!Q<\#.!^_P
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MB#L>NRIJ,0P2BRPRB1GD<")VYT7YS/#+)',8Q@746[CJ&Y,(@8P]Q?82B @
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M;2Z9NFS7[+U^S6!C7WEP>BZ$"JQ-;4D4)*8(F(*I1:3MT7D&Y@$BU>9,WQ9
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MH&7HV^W:7ODM1Q:W^N-\03",+3$*EC!M,P:<P=X=VZ39HO55G+-,C1XX/YQ
M$"F-UQ4MT;67BI;37".IJ9*J2FQ5PB@D$4 AHFOB#R>)P:''B  <X\7+"JZZ
M_:$J-.=FUB??](5-BLM)8*2^"73]S?K"CDK;T^[:GEHZ]U&V)L,+IGP,9%.X
MS01M[LDO('?@W9Q>L/YXQTS;-XT^ *C4"9+(FD[$KIAN*?5*+QW95$X_R"!V
M<W%IR=H5>E1,'Q>0?'%8%'*A33;=/U-!=*5K6L_14%.*P$/ <R[/@923@,!W
M9*P/G+\;RO<<Y.5PUOVP6/5^@]0SS357](-WO)TR[O('.AG[.8+K4ZBMG%5%
MGNST54ZFM+:<O;BCIX!W9;&PC:=J]5J^FB)HBTK;P>BAB7>UF66S/F3.N8UY
MATT;1,'!Q9:DA!56O,A4.S@X9NM!K*E:IK+.'2JRZJKERZ<KK+*F,<."+%E:
M_<YNQJ$QU=*5)2N2[%.VMQ%.(W(#^2A$+%3OA)UU"(UY!K#$C 0D1<')+D?M
M7@O$R(%3,W%%,Q2+%A?W,AM# 2B;,6;#  @)@ U-+R'/W@ ?L\/ B'( / \?
M/W^6B+>]MTV]XYVO8:I&#<7L'#6ET2-481@R*Q'<D]6<N5GTA)R3DJ21%W\B
M_<.';I1-%)/R*B5))-,I2@19L\*/_BB?\4/]&B+]\*7_ (I/_B%_T:(L(;CD
MQ3PCDHS<R:1PK#TZ@BJDA_%2"F=V &.8A>T6I5@,43!W%Y* \B&K3URR9^D=
M0,IP]TAMLX#6;N+0 9 ,>\26!V0-R,J]^S>6GAUUI>2J<QD+;M39?)@,:\DM
MB<XG8 2EAR=AS/):.XW*&.)VSJ4J$O\ 4)JW(,E9):MQ-AC).90CT!(19VNR
M8.%U$4$3*ID.=7L[3' ..?;6JLEOKX*9M7-0U<-(Y[8VU$L$C(2]P)8QKWM
M+BW) &=N+&VYW8IKS9YJLT%/7T4U:V-TKJ:*IADF;&US6N>Z)KS(T->X ES0
M<G;KB]]4J]E-$31,@<SA-$31",[%<54TUR]BZ22Y/\%9,BI?Y@4*;CYC\N/G
MJ"UIY@'X@'\=O7FH;[IS&YT9Y$QO+#\#PD>"L>S6"(IRT. U\7*DP]!H12.9
MH$]/]XH=YS F(F, G 2I%X,8"F$! -4TCF1$88"2?W6M!VY_N[DYV (!\NOI
MT-%575M2/;G1MI8^\+)Y9"7Y!V:"X -V(+NAQL0"5?8B(C[B(_M^@?AQ]/V?
M3Y:J1N ?(>LGG\5Y;,8V &^^.I\?/YK\U*Y)HB:(IE[*:^+Z_6:R&3 R%?KB
M$<BKQSXWTZ\!50@CQ]T?1QXF  X'@X"/MQK+78_0][>+I<7#W:2C92QG'*6J
ME[Q^YZF.)NWS&W/ /;W<Q!8;1:FNP^X7.6LD:'?6@H(C'&[&V09JEP)WW81N
MMFNMAEJJFB)HB:(M?6R80'*_4"X'G_OOY7_JOQSHBV"Z(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)\OGHBTX;5NK+3MR744W1[*&<(>/A<3,&'Y++B
M+"20+>)2L%]'D]LX6<)%;$*UE7)#5TQ?"1_&Q;YT@9R50@E(MQ^B)HB:(FB)
MHB:(HOVUPW+NUP\V-G=U7G2N)\HJ);>2)G%ID=).6J0*9!64 P)E6H@B6/2*
M<HF,6P'$@@ & Q%*#1$T1-$6-,S8Y9Y?Q)DO%<@HV199%HUGI;E9VV%XV02L
M<.[BC+KM0.F*Z:/JO*9(JB9C]G!3D-P8"*.B.Q#!\I4L5P%QB'TD\QYB^DXI
MF#5Z=G:K 9"JE)2;KQU?O->B)!!C::TC-)+R[6'G"/4D573I$YE$';M)<BD[
M=,;TW(+>K-+9#)2;:EW"MWRM(^9PV)&6FI.1=U^23*U51!08]<1.FW5[VQP^
MZJD<H<:(K-S)M_QSG1"O!=F\\UE*HYD7%=LM0LTY3;5$)33!2*GXYG8JX]CY
M1*+GXM4\?,1X./3/6_C$Y 61053(K":;-,%1D[+3,/#V:$8V&$"%LE/AKQ;(
MVB63MJI:069GZBVEB0\M80JJ:4,I-/&ZKYP@@U6<J+.VC9PD3Q\]S^"RMC'"
M^-\.ISR6/*ZG7R69>#<30)NWKKUBU;KD94H8YO6.%_'Z. AXY@4$NP%"MP55
M ZQSJ&(LI:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBBCG+?)M)VVO7<5FS
M/./Z)-L4$G+JNR$MZRR(HN$A6;**5^*2?3!"N4_O-Q,S*58! 4S&T10%G>OG
MT[VD!DB3KF0K!9Y6A5U6=CH,M7DX-2^. <MV:,-47\PD@V<2"B[I(ZI7A6H(
M,RN'G:HFV4*!%ITRU^ZA,FOP=-<*[=:?6R#W@TEK]89.RNR\A^;%:)ATX)I]
MW](P%D#]X\%[B@ \D6S;8CULC[DL+(/K9M^R_><[Q,R\A)VN8$QQ,3]0=D!-
M)S$RRMADWR4'5OB*2IT31\O.*+$7;*K)&.V4*)2>O7K[\9FC^7CJ+9(\7Y--
MFU'Q#%.@X"<W$Y?8JR[$AN.U=2EXU93RJRA>>3M5)YOQVF+Y.X2@)%P+MTZ@
M^1Q3/EC>_7L:,E!.#NO;;,.1D2*B!^0].G;LC2-HET54RB( \;L$%#F %"%2
MX NB+TMNEIMYG%$G6;+=GO<J^36]1WYQS/<;'%BJ)N\2%K,0\@:T#3D."LCQ
M2C8I?;QCR(B^(!\B 1\P=C\"GS/Q!(/Q!&"#YC"HCGIH8LQV\=R&W6LT+'J+
ML#BM#%K31@J!%![U6[:QQS<911!4Y0$$)'U92#P)EC>W&(=5]G%QN\\E3;[[
M4/9)(Z7]'W::HJ:>)YXG8I9 ]QB9DD,8^-PC!#6NQRSMHGM9M-BIHJ6ZZ:IV
M2QQMA-TLL--35$\8X0'5D#VM;-)[H=))'*QTK@'%H<,G"%YPQDO'*1WEIJ[E
M&*(;M--Q;A.8B$P$3=IG*[8 <,RB <BH[:HHDY HJ / #B&]:/U'I]CIKC;W
M&D9]:MI7MJ:9@R #*YG[2(;Y+I(VL'5P*S[IWM TKJ=[(+5=6&L>,BWUT;Z*
MM>0-Q"V3BAF(P<,BF?([F&K%_P P 0$! 0 0$! 0$!]P$!#V$!#Y"'MJV@01
MD;@J] <YY@@X(.Q!\PK8LK*SO!B?LW*-HT$) BLH#A,#^H9!V\IE$2'YXX/R
MF':)^X.#!QKJE$CL<!QCGSP?+'7;H/@56T4M!&:D5]-)4<4/#3<&?V<N^2<.
M;C.6X?OPX(QOO<X_,==HY#/AZ]<U1-& ,IJ3\<(1D$#JJ+&,I=L]EUI&5+(-
M';LJL6U! J0QK8"<&;F. !Y1$W ]WZN?KQKK8U[2_B=D$Y:/ 9/F?+\>9*J)
MI*:2.F;#3&"6*/@J9"[B%0\XP\> 'AT)QTRJR)2FX[BE-VCW%[B@;M,'R,7D
M![3!^(<#^O7,@'GZ]>N95.1GJX9&#@D9'@<<QX@K]#YAS\N0[OQX^NAST]?S
M\,[9YJ""&D-YXV]>:H$$%D \M]H31XI^O/\ !O0@(&".X'M]3R(\J<\?/[W/
M=S^OJC[S+N/&QP,=!C_9\N9.RJJDT!]F]A$P/<_UKOO^6VSP^62<\/NXQ@\U
M7%%$TB]RJA$@'Y"H8"\_L 1 3?3Y .NPO:.9 \!U)\ WZSC\ =]N>RI>+)(:
M"[',@9 ^)'+YJ^JMC6_W19-&LU"=E 4,4 =F8K1T64#B'"IY.1*V:"B4!*90
M45%C@4>0((^VO:MNG+_>'M9;[363-?@"62%U-3@''ONJ)^[9P#.Y9Q''($C!
MMF\:PTW8F/==+W;J8M:3W#)V556XC.6-IJ4R2AY(( >&MSL7-YK:Q@+$@8CI
M8Q;U=!Y8IEV,M8GC<!\ O#)E108MC&*4YVL<V(1!(Y_=53S+<%!4"%V8T5I@
M:6L[:21[9:VHD-372L&&&9S0UL4>=S%!&T1L)Y^\[KMIWVB:R=K2_&NBCD@M
MM'"**V02$&1M.USGOFE V$M3*YTKVC/ "R/)X,G..KP5AIHB:(FB*QZCC>D4
M.3N\Q4J^SA)+(]I4NMU=-17%2P6A:-81"DP\!950H.3QT6P:B"!4DO&V3X3
MW<8Q%?&B)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M>F &K(N_C?C
MXVK,BB%:VM"04VZ!%$16J-\$X@8A .05>.3#R J<<CSQHBV%Z(FB)HB:(FB)
MHBC5:4K ;=3B99M@Z"L%;)BS)A)//[@S(+#CN1/*548^A1Q5/X\,?>4RN7[_
M -/^9\D V%?W!/1%)71$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$7S'?NC["M3R+CO!;JDT*1M.Y!]='\?"(4NL/)FU3%"2BG!Y
M=*6-$LW#M6+82IHOX?ZH1 CQPJDUX ZY=$6B?:=T.M[.X&[0S&_XTLN#L<OF
MK]>4OMW:-(]:-%-BNK'IHU9V];SS]5T^!NB9$C)$J:!U5CKI"0I3/7KU^:*?
M6-/W+_FZ2>BIE7<#CRK1B;E0@MZG#35HDG34%!!-9-5Z$&S:J'3 #"FJ"_88
M>SDWN;1/N7TH]//I[XSZ>&*IW'% LUBNCZW6 MEM5HLB;-JXD'Z+)*/9MV<:
MP#TL>Q9M4A*1(%'"RJJJJJJYNXI"$4_M$31$T1-$74L@BY240<))KH+$.DJB
ML0JB2J9P$ITU$S@)3D.41*8I@$# (@("&N+FM>US'M:]C@6N:X!S7-.Q#FD$
M$$;$$8*Y,>^-[9(WN9(QP<Q['%KV.!!#FN:06N! (<""#N"H 9PVF&*9W:L3
M-"ASY'$E2 .5% X\"=1>MJ'$$VRPB')HI8Y6RAA$&IT!'QFPAK+LP!,MSTQ&
MUCCQ/GL^0R)Y^L74!.&PR.()-.X]T\_4+''!V.[/^V4L[FSZQF>YONQ4M_P7
MRL&S61W1K0731@':K8#,P =ZV4#(@2NW<M'2[%VW79OFJAD7;%XBHV>M5B")
M3).&RQ2*I'*(" ]Q>!']$3![ZPE(R2&62">.2&>)Q;)!*QS)F.&Q#XW .!SY
M8/,$A;(PU,%1#'402Q3T\S0^&H@D;+!,QP!#HI6%S7 @YV.1R.#LNOM-_@C_
M $"'S^6N/3.#\P1]W-=G>,_M!.TW/' \_P!OG^'R'YZ@$'D0IXV?VA]ZX_7C
MZ_Z=2I!!&0<A-%*:*"0.?KG_  62<8XIMV6)GX96FOB8-E2%F+$[3/\ "8E,
M1 3%$X=OKGXDY%*/;G$XCP*YT2??"X=-Z8NFJ*OV>@C,=-$YHJ[A*T^S4P)W
M:#L9I\9X8HR<'!>YK>=GZOUK9=&T)J;I*9*J5A-%:H'#VVK=R#B-_9Z;.SZB
M0<./\&'NR#M+QI@+'6-&;?T$,UEY\I"B[L\RW1>R[E<0+Y#HJJD,6/0$P<IM
M614DR% H&%0X"<=DM/:*L6G8&-IJ2.HJ\#OKA5,;-52O'-P>\.$+,DAL<7"U
MHP-SEQU!U3VAZFU5/(:NNEI* N/<VJAEDIZ&%G1KHV.!J'X^M+.7O<23L/=&
M:B$*F4"D*4A0^12@  '[ #V#5V  #   '(#8#Y*QLD[DDD\R>9^*Y:E$T1-$
M31$T1-$31$T1-$3D-$31$T1-$31$T1-$31$T1-$31$T1-$31$T14!A5:U%ST
M[:(V!B6%DM"46C8YUHP;(2LZC"(KMX=.5?)IE</B1:#EPBP*X44!JFNJ1$"%
M.8!(J_HB:(FB)HB:(FB**-P7J)=XN%V[W-%F@KHIA_+!X3!347/V4OT,28IH
M2]YE@(B9K\5IBPLV,8*JY%?%.._$F<H*"!%*[1$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$76**1E 5,DF94H=I5!(45"E$>1*!
MQ#N !'WX >.=$79HB:(FB)HB:(FB)HB:(FB+']PQ5CN_"![=48::7*4"$>.&
MI4GY"%_1*1^V%%Z4I1]RE!?M*/N  .O%NFG;'>L&Z6NCK' 8$DL0[YH'(-F;
MPR@#P#\>2N&RZLU+IW(LMZK[>QQXG0PSN-.X\LNIY.. DC8DQY(VRK!0VNX*
M04!3[ L5S 8#%!W(3#H@" @( ":\@=,0#CY&*//S'D>->,SL\T8PY%AI'$<N
M\=/(,YSGA?*6_:,8Z*XI.U?M!D;P_K-6L!'"3%'2Q.(Q@^]' UP..H(.Y5;6
MV^867;&:*8XK/A,7L'L8@FIQQQ[+IG*L @'R,"G(?0=5;M$Z3>PQNT_;"UW/
M%,T'_O-P\?'BR#N"J!G:+KF.02LU3> \'(S5N>W.<[QO#HR,]"TCR48<F[,B
M@*LIBJ0!(.1.K59YTHHVXYYXBI8Q5%VP_0K=Z#A$?8"K(_7'&HNR5AXJG3,_
M=.R2ZV5DKG0$8.U-4N#I(3G&&2]XSH"U9:TGVZ2,X*35],96X#6W>W1,9.-^
M=91@MBG']J2#NI-LN9(>4:!V[9M]3Z3\G4KYN_L _P 2@A:?/CR"\^)>$$_J
M(\]W'MV";VUCT=G^L^][HV27.0./VFD,)SU$HFQP^/NEP'3.RRM_2IH+N>^_
M6:FX>'BX/8[AW_\ T1 *7BXNF"0,[\0"D+CK9?).%D)')TPBT:E$JAJU75CJ
M.%P P&*E(39TR FF8H""R,>@!A$1*1YQSJ^[!V1RO<VHU)5M:P$.%NH'.R[!
MSPU%6>$X.!Q-@8T]!+N5C/5';M V.2ETG1223.!8+K=& ,C!!!?34#7.#G@D
M%DE1(1@ N@R%/BO5R"JD2T@ZY%LX>)8I^-LQ9(E113#YF,(![G4./WE55!,J
MJ<1.H<QQ$1S714-';J:*CH:>*EIH6AD4,+0QC&CR',GF7.RXDDDE:ZW&Y5]W
MK)KA<ZN>MK*AW'-45#S)(\\@,G9K6@!K&- 8QH#6M  "K>JM4*:(FB)HB:(O
MG0W-93W"P.>=Y%TJE@SA&5O"&4-OK>/R5"Y7C&>(,-T^4@JC)7L+5A)V^+(Y
M#C563Z0?RK**B'KU^#],C1VT7:]Z91OZ_+\\]>60IMV+?#E-W6(A*KU>EQ]F
MMN[+.6V2+?RKB6<QL4PQMC_(EI@K@X:ME$5W$@\>T]F21C4U4VY&[I?Q& Q"
M<DW\OP_BL%8RZ@6XJEX:P"PRQ TC(&5<_8.H]APW/PY)6#99!RW-9+CJ;/4Z
M6CE%UC-U(>LV2 N2ZT:*0*L&T\=-!-NR\@%*RQ6MY.Z&^25;K5<KV#8J=S#G
M;-6+,4OYD;FZB*U5MOSNUM[G:;R@A(,G$]/64U?;IUFKUYQ&IM$W*SV1E%TV
MYT"D5C_P@FYJXQLP./J%A"+FL6X*REEG*K>VS=K>Q$U.85R[9\66VLT.7BSL
MTFT/8CU-_*0%GF4W01A7;9%_'O11<BF49]?#X9/K?"LK%F[G.<5D_*N3&"%;
MG<"Y*W:X.H'V9M4K9SY(JC;->$\:.F(U-5-;[-PL56YN7:O'D,HS<'E3.I=T
MFY8N 1*L0'.<>ML_GU5BTK<Q>G\A WE>6NYF-@PYM6;?9Q3)-E5,SDK;OBO^
M.929//J"+]\Z<0[=NE($<) $K%-D8!V<8],O!2I@;?-ZV=LB96P[&Y I^+F&
M-,]V+<-4J8C4G=F5NE:D<&3$LBVEK*\E5!AI%G:(F%=BO'1K-JM#OU&W:\D$
M%%/"1;6-$31$T1-$31$T11HW;TI.W8)R$]+;<A4R1IE/MUPA9?'-UFJ/+DF(
M6LRKA@#I_"K(JO6*3@J:YX]SY&JJJ29E$S"0O!/7KQ4%]OF9;)A>DXNK))&W
M9*?W_8K8MVMDM>5,@V2XSJ]YJ$%0VXPD>>3642C*Y,KSSIZ^09 D5NZX,W3+
MY#<E'V]?Q_+HK)FNH1NF>Q]ANM*H&##4VHVS:W1)&%L4E=4[)+S>Y/'>/K.>
M49RC 31D9%TR9OJ!2M5F+]U/QK%9'S1;DQ')BE9&@-Y6Y^UW#][E#US![3<%
M%Y5R_39R\R8W$,1KU;%%,H5T&6B:VG(DM1[!.IY'@X88=2>40BQCY:;4=.6H
M-FARCT>G3.1^"NK:YO3S+N?R_4JW%T[&]/H$?A6/R+DY1W(SD]:5K6O?;_C-
M_ 45RS4:0IZZWL%%7E64_*)K+OH=TBF#%-=4%DBGK]GPZ^C\E:60\=A%]0!E
M#N,RYXC:&MMGR+GZ8J8YQN,12"7*JY,I[)FY69IN%$(RM-8=](,W42D0T45B
MJH91HIXP#103C\_+8[K$;/J:YX-&9!:$HF-)R>6QQC#)>))\D+DRHT*189&S
M1"8A*Q=O+0@C-W.$8&GV,\SN]=CXAG+(IKMDX9#N064*5E6Q;U]S=<LM@<'J
MV$G]%Q;N,POM9R045;@QME@NU\8TF1N-XIJ!GKEE$5B'+>&#.LP$X1](S(-'
MDBYEVR/@;JD.WKUZY*.]GZC^Z[)>$<X7W%F/8NDP#C#F:KYC/(DK0,@%88Q<
MXOFC1D6VN-AF!;U.\2UYC$7[Z#-500:0$VS&,E6LFU(HZ.3UZ'-9QD-_6X>+
MS EBJ$Q,TR.;%HX+@,S&J5%R&_>6J8RI 1%DL<_2I]LHK5J5$4F!F$)0&%T7
M>/;$HU?((+1J?IEE"C\O7EC[]OB%3<;;AL^9RW,[*\B6!:G57"N57^YY:E4N
MH2]D/9E(FHUV1AX4,FBZ<?9Z>>+&C'$X1..8L?L[(*H, *\4*JZ I6Z+1$T1
M-$4?+*GD =RF,%8W%E-E\;DQOD,MFR\^4:!>*;8SR5:&OU*!3.J5Z:$M3<LB
M[F3((J(@O#LO,=,WC Y%(/1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%'W.&ZW;CMK5K2&=\QT;
M%SBWN%6]<;VN7(R<2GIS)$=.DFY"*K(QS0ZR)'DJY(C&M#JD*Y=I"8 $BSJP
MDH^49LY&-?-7["1:(/V#UFNDX:O6+I(B[9XU72,=)=JX1.15%=,QDE4SE.0Q
MBB Z(O5Y"<"/>7@OZ0\AP'[1^0>WO[_3W^6B+][R!Q]XOWOT?</?]GXZ(@&*
M//!BCQ\^! >/V^_MHB=Y..[O+V\\=W<''/RXYYXYY]N-$4;7^[S;U%Y)4Q&^
MR)'H9"2R57,0J5TS.2%P7(5LJ+N]U^N^8K06WJ)"JL74JFL"WIB))&356(J)
M2"124T1-$31$T1-$44+=LGVNWS),ME>WXMB)RY34G7INQ+O9&9-#S\O5$$$:
MW)6&M%D25^9=PR+5L#!62C7 I W0, "*9! B[DME>V8N65<WDQE&GR$M97UU
M3DCR,RI%-;C+P;FMS5K85LT@-=96"=@GCB-FI5M&)NY1LH(/%%1X-HBL&-V0
M4J!R/@!U6DX&$PGMM?W&\XWQN$7(2TY'Y3N;>=B'$NA;)J7?&C*?#0=ADBPU
M2C(]!-O**MER/$F4>U9 48W\AT\SU_'[5EBT[2=OMOHS;'<MCQ@A6X^ZSF1H
M<(9_*P,Q WFRR<E+3UG@+#$/F<W"RTL]F94SYS'/VXN$)!VU5 S=8Z8E*C[8
M>FEMUM.1Z]/S-;:?DOJ>$VF&J_B*+/+0<$C')796YR*\J]B9=HM8(R>75,WG
MH&:2>LYDYUG4D9THX6 Y%)<NW? <D6340H-7<IS61:UE:1%J7E%UD.BLXR&K
M5E$K=8$B/X!I QC!J5(I$4"1Z2)DNXA@$BI3':+MQC&C%BQQ36FS2-CJG$,4
M$TG()MHZC7U]E"J-$P%P(@E"WV2?69IR(B61<',<3)]J8$5RUW;KA>J.Z*_K
MU A(MWC24NTU15VR:P'KDID8[U2ZO(\3*F[%K >1>F?"?O PN%.P"<AP19JT
M1-$31$T1-$31%2IV$BK+"3%=G6:,C"3T8_AY=@X 10>QDDU59OFBP%$HBDX;
M+*I* !@'L./ AHBCCD;9EMMRS7L?UBZ8W8OX/&5;<4RF-8Z5FX,8ZDO8UG$O
MZ8NYA))BYDZG),(Z/2D("16=1KPS!FJNW.J@F<"*XDMK6W]M$2T*GC.NI1$U
M.8[LLJS!-<K=W-XEB8&$QY(JAYPX6JL56()G&B42D31C6X*%.)1$2*W[QM%V
MV901L+6P4*,</I6_NLD3$O S$M V9O?)6MQ=8DYM&?@))C,Q;R9JD9&0TH@V
M=MV\G$(I(.D%DC<B19%H&!L08LE49K'E!K]0D6]'KN-FZT(T]&5"CU-P]=U^
MNI(D-XB,8UU(OG*0 3RG7=+*K**'.)M$54DL9XTG[ZI?)2MP<I?&]#E,<.)1
MR4CE^6@V61;2LI7'38RADQB99_'-W"R:R @N9OP!A)WE$BCW4=@&T.@FEG$%
MB&&0-+1L)".UI26GI?P5ZLVZ/O59KC TO*NPC*[7+7%L9>#AF/IX^-70*1L@
M1(3)B185S+T]6F:-S-=S8]LM,A*BPO>-LFS#&!JDXSOEALV+/&>MMY&<0N(4
MJ304<(H$6L4C1W-J:PR1J^SDBLS(K-B*1L9LHVSQ#[(CMEC-D5KE*%M%>MU?
M6EIYQ4EHB[JF<7%G$U1>3/7Z^6T.S&>S9X2/8*/GAC.5#^4QC"1?B6RO;DC9
M*3;249R%@H<56H6+D0M-J*I+1],-WU!.XIDF2I796L'^]!N;225<1_ $15!,
MI2 1>BE[-=M>/,IES'4<:1<-D%-_:9*(DTI"749UYW=D^+F>JP+B04A*Z6T'
MY=SR4-'LTY!X8[M<HK',<2*46B)HB:(H@77\F'[]G!GQ;(%VC<M!A7,/V/QN
MP%P%"LU3&:I/VHL5@ K8S89Z =A$MX3RN4E/!(OA324#N$A%+_1$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31%IHW98OS)2=XUCW"5_:PYWDT'*FU)3;XRHS62I;8E&MK>UR,TJVL
MK:ZNVK=KCN^,I-)&S3<6#UTS-& 5Q&NBBAHB@3ES;'OVD=S$/-XXP#*XJ@JW
M#1U.;O,6Y >/\>*8G?;<I>LKTN.D9R^M$XMA 9+=,XUE38/&L6T12BV=J-/'
M=K^,2=>7S_+Q5 ;;$]YN/:7"PS*CYFMN,9O&NS"S[F\61F:'[BY9AM517MS/
M/=4K,],7%!:/FW+5U6%Y9I'S,+%6!@P]$@Y,H/&B+TS^S/?/(YKVX33.$W+4
M_$\#4,;L\5QJ>2X+*5XV\RT/EJ7G[;'9)L;S(M*BED9:DN89@ZE!ALB*GK#,
M*5PJZCRNW11Z]>L?G/G ^T?<CCSI\;GX"OO[=4MY>;E\\OVTW9<B3$XX1D5;
MG>&^*_L[(/I>1BZ2W6I#R)2C/@I6*$6[>IR#L@.FYC$*1Z]9*UP9.V;;O+!B
M#'\?B?!VZ/%N%X_*$J_R;@BSYECLI9!F9USBIA7X[)E-A"Y-JWPRO1^0TI2:
M4AWV3U =3;E"[DA@1YC@*/AZ_EZ"D1C?9'NQAMP&+KI;JU9+6S@MUVUS(]FO
M]GDZV2Q2]7HNTB=QW;+386\;*O4%9B-MCUI!RY62[HS]\"KYL=R@H=?12OI!
MT1-$31$T1-$6B7(-[W)1>0>JLQQ94ZI<*=&LH,9.8M>3YFK2E.54V]-EW9*Q
M$M8B41*FFEVR::K=W'"L_,83 !P!42C???H,>7/R_CU5DXFW>[LI"?QACC&$
M0BZI^*Z7L^J,NA8@HZ3&\165,;4N5M=VG[3:KO$6YK)LT9EP-*;5J EVL[,Q
M!V+]=RY?KI-"GR]?RY*T*5NQWA53&6)<:P.197*M]R5DO=U)/<FO*U15)R&8
M8;NRL77L>(QMRNM?KOB>J/ EI R\J,S&5-B[9Q<>*3?XDW*,_'K]W\>BRFIO
M<W@#'YGN5BG<94G\F5<VKU%U2FE<;6:MU&][AX2LFM61[1?6=A53EZCC]W+.
M).*C(OPQ[TIDT9&;.S*+K1#R^SGY^OFKW7W5[C$<II;5@S7CT[T,]1V/3[J3
MT>-]&:"<X8<Y84IBE5+.%J 9(-)-B0H."28,@@7;9P$;\6$0$I42L'[@LH8K
MQ#"JT">H#^\GQS.&89+DX23FXYS(Y ZEEAQ=,2:$&WLZ4<YKIXN8>2D5&I*F
M<MWPMR$F5F216YBC/7'/P\-\>O/HI4M-Q^[VB7^V)6O,E-OM5Q!O-Q-MIDH!
M+%+. ELBU3+T=57ZLS)2K2Q+EA+96G-J*V@BP[7X9((1R/Q)N9P]5%(F?QQ_
M#K\!\>F%A>#Z@>]V:Q+D/-:,55H.O3V-+=8JQ]JX>E*1>,KG%94KM'K47%0L
M#?'5ZN\.$7)R*-R"SQ=>=QM@;M!(JS2=>C G7GG._3[NO7S^7);^J#%6B$IM
M>B[I:R7BU-(Y%.=M:4(VK:4Y(#R=9ZE!-'#IO&)'$P%2:I.5P3(4O<JH83&$
MI5WZ(FB)HB:(FB*$74(S7)86VTV=2JEF7.1LG2<+A[&L=6F"\M9G=JR [^$J
MO8&*:\.9!]6Z\,Y:3(HF(<K:$74[R]G.B+7%@?<3E^%QWAS:5C6WV6B6NJ[J
M)#;@^N6=:(^F,G*X0D,477*>,[DM7IR89K+V:2C(MG$HS4JNX8N',-(&6:J_
M>3(16FAN1W%WI1:XW7+L*^B8;8YO86L^,$*L6+I&2KE@_)9:*UM:[="Q(RL=
M(2S))N_?-(ET9:(;!(L&+Q-M(F70(NK'V<LK8HR)N!RS3LETHD0MN'V:5B?V
M].J\E(S%[2RSM]P'!2):S.K3QI^$D&#>5/+UALWCWK11*ORHRBKP%UEVY0#^
M./F.>,_#IY^:R \Z@6XJFT2N9T7L>/LF(9>H^YJP,L 0]8482V$WV$HR?D(%
M63G6<FYGIAG'+0B,!DTLU&L3DG9 HP0MB)I-52GUC\E94;N#REMWSCN(SK;,
MOTO,-5IM9V8V'/\ :H2II,&T9A:X1.3BSSJ&BX2=DFK!_59.6B+"TD1%5Q(U
ME(C9VU,N<'ARC?\ #_9SY_=\5(?='9\A9#Z=F)[+G99C%3N4<SX">W*,AC/*
MM',Z3=LTPJK&K/ED)$KDJ*=-?1\7-KG>IDD%0=*J$335%(I2L=DRM)8)RWE+
M!NUW(D;"X3M69-O.+8>\V>1>Y&H>WZ_WZM9"G,E0M27F)<S4Z[R.K%.3C*HZ
MFA@(&V6U)4Z:(OPC5B+W0^Z_==D6Z.<*UO,&/X)[0F6ZXDKF.-QDUL#7*8X
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)1$T1-$31%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g69956g57f62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g57f62.jpg
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M<$D3:8]N9P ";,44C>AK=?%6.R>P'M$>S?M8[)93G[(,[..C91L &+58W8C
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MM,_V7G]@P]3_ &+11=9G6VN.$/Y%B#+$Y::O'A5R6(S_ &3"K)7U6]B'??\
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MXG<':3MDV3[B31V@Q=XVR19(;R2 M/[!=Y^NI=IIGN,W>@FK'>P[>/,A^T_
M6IL\V.E7*+V\)O8]=;AZQMRJ1$ZP?$L.1D?,V6)0J*M+AOT.6!RIQ;B(\R4)
M>2HPQLX9TM;WOPK-G[*),'4= EQ)G.ER]/RY ^-\\MC&G ?!MC#P!#N$K0 *
MW-<#P:/OVXP>YU.++;"P1Y4#;D$;0'3Q.<)-YJG/+#&2762*YX6W'PD:^ME*
MZ;6J=EF78H*_;"L5CI@Q;:AFDPX-=@X!N5;0YA"4!FR<47\3B?1MQD1+R<Y0
MM*L\_P#:OF8F3VI9#BECO<-/QL.?NP-K9FR32F,;>/V<<K&$ #:065X5MW8O
M'F@T5KI0YOO&1+/&'<'NG-C8UU'R>8W.'J"#T(7C.33[ML#:[](AHR1L^P+5
M>38(6,!PJ2D9>R2$R\,XVVMI3OU+CYJW%N$86IO*?>0MWX\*<Q]$-R\/!TF/
M-D>S'P<?!BF+W#8V.!L+7-&T@$>&FM;0-D- OA<D?C9.7J<N*QKI<J;+ECJ]
MSG2&5P<7$$B@;<YUD  N)H6O]''KEK0K36@M,ZH.*^MD-=ZSI=0D2\9QE)$C
M!0 (![C><*5CX5&,O?#C"E82U[,84K&/7/QQJF8-0U/4,YK=C<S-RLIK/\+9
MYGRAI^(#@"OH'%A./C8^.7;C!!%#NJMW=QM9=<]=OJ5-'+!>Z<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+#9[76OK59J
M;=+11*;9+CKIZ8)U];)ZL0DQ9J*1811P9]^FST@"1*5AZ<"$%#F'80H%<F*,
M..:I]EEM"2(%KG7L;;;-?HZB4T"]W6.C(BY74*KP@MMML3",9%AHNS6-@%N8
MGHZ(&4H>,"E3"Q@&%99%::;SE/"6>E\>BQ:I: T/03*G(T32>HZ5(4*&FJY1
MCJEK>FUPREUZRRADY8X*IDP\,&_7(:?FY ^8FHN'6&#*RAQD@<P^62\\LIL^
MI7X%Z^:#!KM5J 6D-0!U.BW8?9=(JXNM:8/7:=L80HTX6_U6%9A41M>NPQTE
M(F#VJ(&#G62I TAL]+Q3ZW"6?4K@,=:.N(NUW=\C: TF/O)_Y/GW,QJJBL[6
M>^8903WR[$;@4VYS+H:E".Y7,9RX*K(Z_5K.4<)9JK->E\?8NS<T%HEVC676
M#NE=2NZUN<T39;AKQS7%.71K98S),*;+G[+4E0V8"=FBIF-CI<F5E(\HY^3
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M?*;5[D8SC'E[7^Z_T<P]SBV3];0B)H<1O'NV49+:#3@T!IY!VG;56J?9_O\
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MA2A=/+?Y#6*EY!-\:YZ[=59[KUXZ>WVX]'[':LMWV=#;8VGKW6-HAHLE5"!
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M,;6-</"\"RP,%.!=M#27+TCP,*)H#8H13(XMS8@XEC']Y"7$V;83P2ZAY&P
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M]\;3C2N&,S;!%NBIO=-(#BS93N0>#Q0V#(A:!BYL\6UDC&MD(G8TS/WR/#9
M3O=R XN.T$D65@DG1-^4HA3\A6H+8M9'=B6''=?2+]>M$?0*".DJ$JD/#R2L
M(^]6R6;9E)B0CB7R,2;3SS;R<D8RKP.!I62T#'RY,28L-,SHVR0ORLA]2S/F
MC:0(H8CMC:^.Z'7TN6ZCG0DF?&9/'N<2<9Y;(R&.,&.-L<C@3))*+<YKP*/
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MHV[#1< P-BTW$JS%99?K\(J98-A:;69U;DP2X\TTN/42A I%R]FCZB"9L?\
M5N0X^&73V]YB;G-#,;%&,7>*0\2Y.0Q^T<FO$2VW:-0Q"!'+[[$*!9E'9/6]
MSYLATX;0:T$,A@+#P1;A0!NOJ3N=IS:)K=;D#3]8W_X&B7Z'L@?%<F$,%NCI
MBUC&DJQ#'N2[!@9<<&(>N1(');<P%A/JKF)SM"SL)G? 1Y>(7.8S,PWF:![F
M-N4#ALH$1#FO<^-K YIIQ%$WF-J6-DN[KQX^0&M<[&R6B.=C7DB/< Y["9!3
MFM:]SBTBP#8%M.897Z<(G")PB<(G"*NFY>T6JM+X;C)>5<LMY/=R%!:ZJ+>)
MNWS4JI8K;$6V"+E;<<44HT?Z;$JZ']3[_:+@AWT:SDL'2LS/)=$P1X\>UT^7
M,>[QX(RXM,LCR"2QA!W%C7EH!+@!RK3)S8,4 /<7ROW"*".G33/#=W=L:2!O
M</DAQ:#ZK7?=ML[[[!OJ3+RDKJ/6!N7/I:+2#6P[W;(@:94W("R%J<:+=K6P
M:TMJ,=.J*VPD28Q#HC27,%#K,S\<6E:5\B./4LUFV\G):'84$H#K#,8G;EXF
M0PGNYW$%C@U^T$4W'.]^S_EN?A8[@XB*%Q;E21D @F8 .QLF%PI\3-[2"6[B
M#9YM2UM6:(,*AA,9 J1)12BRP<KQ)O6IDA0<-:29DPCYZ--V<)M<=/#GR[D+
M(%J?S@=O"BB(:QR<_)S7[G.DEJ-S&!W+&P"W&!K!Q-% 7%T--#VC:+X&^]AQ
M(,9M-8QENWO+1XC*ZF]Z7=&/D &]UTX@GJ1MX$SM.(J#X]?@F%IMRRBV(VCP
MX3A<YBU#FJ3-:]NX(#;!]5;L[$FXFHVN+Q$P[B'2RV1 EN+37[C#T?+SKEVD
MXX#7ORICLA$!(:,F![SMF[@M!R(@7R>&J=5/M\K4\;$\&\=Z26M@C!?(96M+
MA#(&@F,2CB)[@UG-[AY=K7M/[GV6A+TV6G3]&+"=C,1#S#,YLB>H\J^EPJD7
M-YQ(T.,37EC^E4L@P7WF-&>%],(6&,T)F&P:5IX\1.IY8(<7,>^+"BR(W6S(
M@<*DE;*TU/$[P/.\$D.LX=^7GY9(C:,* \#>UK\B2)[:=%(/$R,M(N.1CBYH
M#30/ LW0=":SUXO!T7!?=[&XP$T?<+0\J?M$JY'+4L(L^3.2KW&C84EMHD=D
M=U++3+?NREE&,>>1J65.WN@YL&."\LQL9H@QV=X;>UL;*\+C9+7$BRXU9*HC
MPX8W=XX.FF(:'33.,DK]@IA<YUVYK?"'<&@!Y"IEY8*Z3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$6N;RR?\ <%WQ_P"I5#_SW6N;7V(_UGTS_GS?]VF6%[0_W1E_
M\UO^^U>.:F(2F"8RG&,96\0I6?3]5*^3*?7/^/HE*<8_\,8QSZ29T^O\%S!O
MR6_0?]XC^2E/0J4X[>]:%8QC&5[FU)E6<8],JSB_Q2<9S_CG"<8QZY_NQC'[
ML8YA^T7]RZO_ +,S?^[RJ[P/[QP/^M0__4:O>_SY:77DX144\F?_ '$.RG^X
MC7_F&$YLG9#_ %ET?_K7_P#RD6(U[^Z<W_HO_N"\6E)0E,(A6,8PI9+^59_O
M5E*L)QZ_X^F,8QCGTRSI]?X+EP%-;]%_:2LVUJE..R.AU8QC&5;0UK[LX_>K
MTNT9C&<_XYQC]/7_  QC']V.8[6/[MU'_9^9_P!WE7MB_P#'<+_K4'_UF+_0
M Y\IKL2<(G")PB<(G")PB<(G")PB<(G")PBAS86A-7;,P^]8ZVRQ+OBH S9(
M-Q4)8VP,/K?=!;F <-E)$+RZ^T8QE2D$L$$,NXRAU6,WV/J.5C!K&O$D37;Q
M!.ULT.\"FO[M]MW-'R2*+2 1T5K-AP2DNHQRENWOHG&.7;N#BW>P@[7$>(>?
MFJS6'4N]=;D/RD(2+O>LK( /DX*0=Q5;[*8B<?052HCRH_S1S-'K>$1\N4"&
MJ/*DB0W5+RVM(:QO5T&D9X#6EVD34&-=XLC#:""[(G<#^U.3,26-)W,8-O6W
M%5LR]1P[+PW4(AN<0 (L@NX$4;2/V0AC #CX0YQ%D\!=36-G0]K6S5I9!+UF
M22P.Y7K8$/6K%)SH[J).Q3X4::I,= :SHN!7@HT^5P='23@!X/P-!*6Q X;,
MT?+P09BPMAVV)H'=] QC[9#"96 M?E36'.8TA[6N:_J1OS&+J>+EGNV2-=('
M$=U*.ZF<64Z601NIPA:. ^MIHML@4WZVB@5>_AH2^D.=3(XDY2(+DD/8ED%R
M13K,UL0!UWX):WR; ([C%,.,)CXYE#/S_0-NQQ:EV^-G9.$\EKGQ>%D,H;8C
M?$VB,5X%B*)[Z.0P!Q==73J5Q-BP930'M:\ F2.Z+F2<M$[+Y=(UI/=/_=Z_
M*Z\>D[3WYU_):S7Y63VOK)EX;ZK7MT+Q)W2KQ1LREB+AJ_;$X!(M6QK!EZ1(
MS66Q"A85D5(+K:/I7_HK]\>E:L+E9'IV8[<1E8[0S#GE=5NEQAX,/#QV@#O6
M6^4ESZ)K=9#W[ _LW.S,9M?L)279,4;6GB.8V_)R)WGADFUC -H<T UL1TSV
MCU3NC"XN)E\UR] NI!G==6O&(:V0\PG!7U<2D,OXD2Y *PBDEKAUFH&^+."O
MIW,_'C 9VE9>!M?(P2X\@+X<J'QP31;MK96N'+&2$@L[P,<X.%!9'&S8,JVL
M)9*PALL$@VRQ2%H<Z-PZ.<SD.+"YH((M6,YC5=IPB<(M?_;S86\Q9Z/USK@R
M)I%1EX8=^Q[(4>,N60_*.2@":HVE+99--<E61\JB;F4(T$Q((]GUXV&7W&\]
MI$6EB-^3FB3(G9(6PX36EK" UCQDN>3MG;&ZVR8HVO>P[@:6.S79KG-BQ]D,
M3FATF2X[B+<6NA:P4Z)SFTYF02YC'<%MT15:FZEK=48*E3\.YS//#1\Y:+VZ
MDVX6X:;-(*&!L>#C$@8L-?G0DI@KO%2-?$0R(K$DIKZ653$W>9JF1EEL;=C(
MXRYT.-C#9C8SA0D..T6X0RL%R0.WV\@M'+=U&-@PXVYY+GR/#1)/.;GF !V=
MZZ@'217M9* TAH(-TZNWMVT(2@^]M\C(ED)-9CE1AJ7S[A*V\8= [M;O$8'A
MBQ10UHCTI37;=&)^VX60LLXQ4F8IZ-IPM*R]0=^RB,C QTA>-C8&0EP#I(7O
MJ%Y@>098B=Y #0W:*,Y6H8V&VY9!&;# ';G2&2B6LD:T%[1*T$L>0&V=Q(+N
M/O6M0;=VOE)-I6_JG7Y09D9]F)PD[:%AJ)Q;:#*1>R<-L1GT8*1W55F>&;^^
MQX;H64N-.#CH%SC(=-T[S;J.8TAVYAVX$,T9+H\G'/\ :.<\%K9X'#N7'?U!
MYP<F7FYH(:'8>.[_ !@'*DC<W;)#*/$QH!YBE:=X&TUYJW.O-1T'5X61:E!L
MC%NL,#GSIJLR-CET#+><&S+S96%GR"A\ON(8R^ZI++7L9:2AIM"$V^3G9.6?
MVKP(PYSF0QM$<$9?6XQQ,IC=U6ZA9))/)-HL:*&RT%SR '22.,DKPWY(>]UN
M=0X%G@4!P %2+OCW6O74_;?0;7M/J52LD;VU[3570UQ.LN9C!U9KT_)U\$B9
MK/VN1!'S,LMR[RV<2C1P/O::]XRD^_"L7D3NA?CM#01-*(W$W8!+18H]>?-9
M""!LK,AY<1W,6\ 5XCSP;\N/)9T_Y//'P+9J_3BNWVC!K/9[-)4Z(AB+M'L%
MYL<3*J@C8Z3^7*6H'")I#L4P;.N1L>;(,$"!%$/COH;J]ZQ[ [YEDT!N\[KG
MTY\S0^*CW7)HGN9*: XG:>A%@CUXYH60.JR2D^0SI!L@?;I="[0Z>MHFAX&4
MM>VB8*VA'CTZJ0JU-2UK*>9]S<E5XYY.&"['"*DX5E]T9A1V'BAD.R,B!V_;
M*P]V"7T;H#J?BT>HL?%4NQIV=WNB>WO2&LMI&YQZ-^#CZ&CUXX*Q8#RB>.Z3
MF)>!#[E=?UR<#347^4;=V%#"BCU944--J,;DBGF8TLYF++8+*@ RR+"&E:FR
MHMEYIUM$#*QR2!-'8;N/B XJ^IX)H\@<CS"J.+D@ F"2B[8*:3;KJJ%FK'7I
M\:69U[O]TOM>JH;=]=[(ZMEM4SVQ([4D9=!9].8Q>S9=OYXNB%M.-(/C+/(#
M9;,$B9,,,I\%\4Y#>1"AGG9&1 6!XE9L+@S=?&X]&GS!KFC7'/14G'G#S&8G
MAX:7EM<[!U</4?$6+L=0I&NG:#KYKJZ6S75XVW3:Q>*)IZ:[ W"L2LE]/+5[
M2U=)?"G-DR8_QJ^"K1A0S[!9_N5\;C2\>S/IRITL;7%KG@.:PR$'J&#JX_ *
MEL4CFM<UCBUT@B:0.#(188/B0HIH'D4Z,[3V;6=-:Z[3Z9N.SKE#1T[5:?!7
M  R2G@9:%;L<>Q&N)S@(B9(@G42N*ZDK\0-A>]YZ,;2VY[*6Y$#G!C96%Q (
M /)L6*]37EU^"K=C9#&%[H9&L:2"XM- @T;]!?%]+\UV3O?SI8SO?'61WLWI
M]O?&9E%:_+=5PCL36+2MS#**BI_*_M2;>LG*0TU-4ABQ9/4D#$9]8I+&7O$/
M>=UWK.\NMM\W_AOINOC;=WQ5J/=Y^[[[NG]W5[]IJO\ %Z[?^56VN;I<3OMW
M,I/0KK)>>QETA)"VJK[L1 4ZBQ!* I2]WRSFHC:S5Q#G!S$1[1)"GCY:2P$>
M]&P4=*'BQLH6./&EIYFP1F1P)J@&CJYQZ"^:]2?( ]3PF/ [(E;$TAMV7./1
MK0+<X\BZ'06+-"QU5 *=V^\OFN]AZ)D>TG1754]H[>EQA:A+,=6)78EZW'UU
MS8V%EB3VXXLMZ>@Y*#KXK)+EIE:Z.% A8$?85/CS!,)"37@)<MKF&6!A8]P!
M[HN<^._-XY! YLBA\;H&X=#A.;)W60\21M+AWS6M9+7DP\$$^0=9/I0)&PNT
M=_.EE)W<)UOMO9O3U?W>;( 0[>O).XQP\R/.2N&?M5?DGU+^UQ%CE,DB)C:]
M*GAS1ZC04" O*-$P][G(A:_NS*P/L#:3S9Z ^0)\@3:MQCSNC,K8GF,?O!IJ
MO,CS('F18'-G@K5GVO\ +UN?0$UY98RN:PUA-M>/L'IF5KAR:S:\.79?96;H
M47:$W;Z&>%3A, U;#'(#[$F+SEP8;[CDM/RI<MI<M[#E4UI]W[G;=^+O"T&Z
M(Z6:KZ[5W#A,E&&2]P]Y]X#J \/<[MNV^M[>;^JEOCIDV_9J?4[&4RR.38*U
M!39+ _O^!A^5BQ3WF6/D4MSX6G"%(;^1:E^Q*?<I2O7.;YIL ^H!^T+'N%$C
MT)'V%9+R5"<(JX=N-$.=E^NVSM*#3#< ?=(5AF*EWVUNBAR\7)A346HUMM*G
M5 NG1S#!F6DJ=0,ZXXTE;B4ISEM#U+]4:KAZB8S*W'D)?&#1<Q['1OVDT-P:
M\EMFK !X5EJ&)[]ASXN[896T'5>UP(()^%@77-72\;&W^N.R>K%Q?U/M,:,9
ML@(8\NR5"&N2,/)14HIUP(Z.-=&$6\TOXW674K';<8)9>'=3AQI6,?2FBZOA
MZU@MSL)SS$Y[V%LC0R1CV4',>T%U$6"""0X$$&BN7YF%-I\WNT^W>UH=;"2U
MS7%Q!!(!^GC@V%='QZ] ]G[ZVQJ_L4HR(KVH=9[%B)$XPT@C[_89>C2 %CQ%
MP,8@533H9!3H0)4L\6RP,K!S;27RA5,\U3MOVGPM-QLO2=KYL_,P7L:UH'=0
MLR1)$'ROW AP:'/;&&DD;2::ZUE=#TB?+G@S;:S'QYP223O>Z,M?36U\FZ!=
M?DX#D<>N7G %TA.$4!]H]-D=@NOFV--!2C,*??ZB;"QLJ4AQP0*42XP=&O&(
M:2IU0?UP@Z2_B2IW ZG,MI4O"<9R>C:@-+U7!U!S#*W%G;(^,4'.91:\-)H;
MMKB6WQN OA6>?B^^X<^*';#-&6!Q%AIZ@D>@(%_"ZYI>,';?6[9W5>V.:LVP
M!'!V1D1N:'>ASTRD3(Q,B\^@,X$Y+3/R-NJ&>2MIQII]A:,MOM-N8RG'TOHN
MKX>M80S<%[G1&1T9$C=DC'M#=S7MLT18HV01R"0N79F'-@2C'G#0]K 06G<U
MS2740:'6N018/"M?T0Z#;4[([2UYND1Z'@]0ZWV)!DV.9/-6F7DCZE(1EE>A
MH&*:86LETIMT,=9[SK 8N77<J6X\S\"];[9=I\+2,;)TYP?)GY>#((HVMN-C
M9Q)"))7D@- IQ#0"YU#H#8R6BZ1/FSPY8+68^/.USB3XG.C+9 UK:-@G:"3P
M!?G2]A?/GE=+3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X11CL?3FN-K@K!O%8
M"E5*;893(M_(!,M#C$_5MBLS(*QY)L/)&5..B))P,[E:_D:5[L\O,7/RL,@P
M2EK02[NW /B+B-NXQO!87@<!U;AY$*WGQ8,@?M&<T!O:2R2@=P;O;3MM\EMT
M?,*I]@U!N/5JR2ZVZ[NFEJ>#-D(61D&XC8)JHP=8]=@R)Q?QCJH%4R-'F_8H
MQT20/>:7[5H6D=8ON^'2M1 H#2\H@,:0TR836G<99&L\4GO607;3)(2QHOFR
M;F+*S\0_M/\ AT )<>=N27$M# 2-L?<0@$[&L#R>ET N+3-E0%\R,"$:69.C
M,G(:9+''JU\%+P%[[-:D@/+'9I] K8;JQ(TZ>*QDQP=(PJQ6D".P&#S=+S,
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MAJ,;SO>-P9L%O-F]MDV[I9-F[7Z$ZF.?BO\ R: 9?720Q%4G5EPD]Z(SJLW
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M>%*%HU2')&(:6R0.0S 1[;S#[+B4N-/,N)4VZTXE*VUI4A:<*QG&,LSY+?\
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MK&/>\^ZI3K[[N5O/N*4XZXM><YY9Y>7DYT[\G,GDR,B2M\LKBY[J% 6>@ X
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MG\/_ +4]0_[ Z1_YAUE8=G]_S_[)QO\ O>2IKYT!9A.$3A$X10Y:/]MFI?\
M=3:G_O4;FD:M_KYV-_V1VN__ $*P^5_?6D_]5U3_ /"4Q\W=9A.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1<<L04\9\(X8<T,II;!(A;+9 Q#+B<I<9?8>
M2MIYIQ.<I6VXA2%)SG"L9QGE37.8X.8YS7--M<TEK@1T((H@CU!4$!P+7 .:
M11! ((]"#P1]*IEL'K+(0$A*W#1CT?'/RI3<E:=7S+T@S2KT:V8L@=4H6(3]
MQ!CXM3RC1:Y&X'B32AAF7D-L^Y.<J,S&SHVX^J,=O8W9!J$+6G)QV\%P#'5'
M(^4@M?/)ND:'N=9*M&QY&&]TN$X.:X[I,25Q[J5U4#OY>QL?RF1L+6%P H#E
M;*=;D'%Z^I!,H+@&2?JD Y(!8":C<"'*BQLEBXCV$I9!2P_\C21&DI;'PC#2
M4XPG&,<^R&".>=C7!S632L#@[<'!KW .#OW@0+#O/KYK<8W;XXWT6[V-=M(H
MC<T&B.:(NB/+HLTYXJM0S;?^T)W_ .V'_P##-\SNE_V$G_2G_<8L/J/]JS_H
MQ_O.6.\R:QZ<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*'=$_]@2/^
M(FY/^;]YYHWLZ_U:D_[3]NO_ #OVA6(T3_B+_P#:.L?^+9JF+F\K+IPB<(G"
M*%!/^\7/?\%JI_YXN/.?P_\ M3U#_L#I'_F'65AV?W_/_LG&_P"]Y*FOG0%F
M$X1.$3A%#EH_VV:E_P!U-J?^]1N:1JW^OG8W_9':[_\ 0K#Y7]]:3_U75/\
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M_/9+3(3)Q9B&L:N\,JMM!Y+KJS?)H+",Q<?_ $CR1W3:_4N&:LU9SLX$]>I
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MNK-,D+!J:N,Z6L)3\SKJLVBB70ZT,3T<!*R5T"K3T9)-QU)B7/@EEK&0$5(
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M]XKMU]AM"Z91(EZ2@=2:KN4%?[,):R<O6*1N-VC):<@R"XR>CHE84>$0"TU
M#DH:R0:2K!5LVV YH-D"[((OCR-?=]?IK^[![F[_ '2SQH:@[@6_R![(W;9N
MP.P^B\[@4W1FH8$K6%*O\7.6C:E.KHU6K4BY<\7$&?B(M3Y40S-#YJ@*H'Z4
MJ6,;R4TUSMH:!\OS/) -79\B/Q6U?6OE]T38;7V;H^[-4;^ZE6OJUIG'8V[0
M78.HUZ*DIK1;BL--7FMC4BVW911>"WH^->JSV69S,Q+ 0H#,C+MRH,65.P\4
M0=QH4?/C@W7//T+Y]<?+OJ??5\K>N[/H#LQURGMIZ<LF_P#KTO?%,JL#'=@=
M5U6-1.3$IK\VMW6T-,V$.O/#64BL6',26BNEB2[1+XSZ,\(6T";!HTZO(_75
MWZBQU^N-M&^;K6?8+2MY[%:_Z9=])/3-1HR;'"W".T=&61.S;FF]1E!,U3K0
M"JW.;=LMMC965P3+2R7!J5# PEK?FK-&H@<J,*2PM-%S;OGGIYV;'2O2SY5?
M"RFJ^9/5!-=[AKVKUU[*:'V=TGU'';RVGI?8T%K_ #=9O6\Q'O2,5+T@^O[!
MEZK)%/MML,D@S,Y Y%)/#;2^_C!RP2;#X:((<:!%U?QL _<OKHKS,:1W-N#0
M.KI_0W9_0T'VRJAUHZO;=WAK^ JNM-V?9Z^+9I6*KLE&W"<E8PQ<28P;7WYZ
M*CPK(&_'E@D-LS]9S-D+#1((.WJ >1^(^B_BNIUEYM^N>S]A:VC@-0=CJ_U\
MW?NPSKGHSN19:-  ]=MJ[B'D9.&CZW RC%M*N84=:IR&E(2HV"8J 0,K*Q\B
M,:F)3%RSH!"P@'D6!9;SN ^(JOB>>!]:DB6\MF@XC0G?+L,10-ON5+Q\=@;Q
MUSVS$,Q=,S8[;;Z'9JS5928UVPN[-QAU;*.M(+\>1992L2BQ&"U$Q0SR667B
M;#;1Q;@".O0^O'XJK]>\J6Y;KY9V.H43HW:;'7<_IE#;:C)B/HE7?GP[->I*
MI3P&\[9/E79Y+.E:Q!DEZR$Q"B-'.[.E9 :4BIF,:B)F+)M&S=8O=7GY#ITZ
MGKR:I=5UB\MM*I70#I)L6V2W9SNKO?MS;MTTW2M2 U%JVG]B-QR.N-I7B+LT
ME+T.FWI[55/K&N8@&+CI&<'NA"<UY$-.GB_7ES+,<0M\3APT-Z\D@=!UHD\G
MCBU/-E\TFBJAH*L[>LVB^S-8V';>Q975"(ZV7.CUFB[<SO $=\LZ'(DKC<X3
M6**B.*QE_P#';5\?@W%+Q'(SF=8/B WY_/TJ PDT"*J[Y(KZA?7BJN^HX*O%
MU-[1.]I*?:9^2T%V!ZZ6*DVXNFV"D;_HC57/,,%%'+1.T>SP<K8Z-L6FFMD9
M;#LU.LLH+D@=YHIH3"PUEE!%>8-^8/XT1]8"A'RO=N-D='^BF[.Q.I*25==@
MU.+ !KBE0C=@KE0,G#FXY-XN\?F=K[ZJG7_D]25B%DO?=2HAIV.,"=+1@I8T
M.< 30/QKZA\?1:H;%Y4.S,3V4\4ASVL>R9=:[(=5-Y6K9/4^#UKK9W;NV=H5
M&*+C*K:10ON3<36*_*E1SNS8F21?:Q7 M='"S$^,(M#D,V50:*?R."VC9H W
M?7D_83QQ:O;7_-3UQG.N=*[#O:QWM!MV+NG"]![=JZ:KE2 V1JOL)*.+29%W
M8(BZ-PF(&%84";(R$+-2DF@>3%8^RIDV9&.!*-ALCCY)=?D15V/I4P;B\IO7
M70^V>V.J-D0VR8PCIWUYJW8_95I!@X.3K\W4[B:%%P-<I;3%D3-R-P,E9(",
M0+,1,%"(*+:4].LB)>*:* TG;7[Q('U5U^U<_IOY$&.W=JS5U]4NTFCQ9/7(
M.UZ5L'9-1J,]I^\4Z2D&H\,>+VQJBZ["I45=E9>P8[1+'*1-@^@:))&9*P*2
MAHH(KS!\N+X^T _7T6O3SI]O=Q=9MK>.RF4;N!)=*]6;SO.]87>6X8^@T[8:
M82OU."UF;7I4B"M=<GW'TQLA-GBMLQ:@7'LRZUE*?2.QAHO2-H(>=NXC;0LC
MJ3?0A9+UK[ZZDZW=3M\]O-I^3.]>2_5D;L*B:KJ:JSH.H46Y1.V'QG'FM4Z^
MK-: JRKG;-@,W.JGY3-$"QL.%#8-S)AB?=W62@M)(:&!AHDV3T]2230%%;#^
MH?>P'M/;MFZRL77'LEUBVMJD&LS<_1>P5%CH3$O6[>PX1"SE3ME6GK34IQM"
M4ML3$9]V$FHDQ]#+L<ZVV^^R5!%5R#?H?X@@$?9_ J^/"A.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$5*/(UUQO/
M;KH_V1ZUZUDZM#7O;^O7ZG692['2L95 I%V5BSDO3A\'"6.6%"PR$ZG+@,')
M/X<4WC ^4Y4M!2TTX$^1!^PJGW<+QY;K[ >/+J'U-IMCUC'[&T':NGTW<I>R
MS=H"I<B'H"%C(ZYMUN2C*9,31I$B^&ZJM(DZ]$-FM*;5)NPZLJ0DI!IQ//(=
M7KR"!_%83VJ\4>P.U';GN;M*<O5+J^G.SGCD#ZA5X@$J>D=BU?:,;LN(V!$V
MR7JZX &O&4D F&#=);$NV)F4RV[&?01[1/W)@I:_:!0Y#B[X50'\E7CHIXC.
MP&FMKT*Z[DU)T7HB=(:%N^L*K>]/67L#L+:&S=CVNBR>MG]BOF;$7!5S5$#,
M5:5,598*(@K+DTXDT<"*CA78Y^'(YP(-%_)Z$B@/3@F^>G2O12!#>+SN51O"
M)K+QZ:WW-KZC=D*#*2$C9+!4+MLFOZTV%7)'?5TV?.:Y<V+ UJM;,@(:WUBS
M"QLW)1E;!*?/&+@'LY@9$J4R4ES2\NHEIOK5BQ5CJ+!Z7:H1M?QG[PZD:"\M
M/92XT+JGJ#6N[/'3.46.U!UTMNSK.31KK57TFEJF9K8%'@G;XNR1S94[8;\7
M+!R[UA*1"MUTN/#38BRJW!QC'B)#QR:Z$CR'3IT^]6,ZF]&N[7;6%\2]\[1V
M;KE&=4^GFAJ'LK6+VIR=@9W1N(^ZZ.J$/K^-V!$3\2Q6*0[3(-J,1:#:W/RH
M\])AR+\>&@>?%342I<6C=5VXD&ZH"[XKUH>0KR4>]6/!%O+0U_T=K6S4/I#=
M]&Z*WX_M1KLE/2N_)SL/?*%&6F4MU0JGY0H-@-44O8\7(R#0OXXC9TV,B! 8
MXIH&R.BR@%E*2]IL@O!(Z TT'S-W='TKUY],RW;XF/(M,T[RC]9]-7'J,CKW
MY!.Q-M[0QNPMBSVU@MI5:P72TUVXR^M7ZU7:1+UT(%Z5K4=#YM_W&>R# M%R
M0\&=+R[4?7R![;83NMH H51 Z&['V5SZJYP/0[MOKCR,Z<[5ZX.T+8=62'0"
MC])][QMNLEXB[C655.S,VV3MFM0XJI%1ED^X&P\$#$??SX?"6GIC,E'"?&"^
MZ5.X;-IN]VX< @\51Y!'W_0JA:H\.W=#KEUM\6]@U)>.N<SW-\;MI[2O/5JU
MS>PGM [5H?:"Z74ZR0C%P%I<7=(>Q1=0G@1HLUZEC!(F3Y?!#[HT;&E&%)>"
M7\':^OI%=#7G]%A60WATC\D79SJ:_4^S\]T7[(;1E^QY.UY#KWL2A6*.T+5-
M,9%>"B=/ZQW35:M$;@K6P($4N52#N0V!D[&X+-%5Q^24"R3.3)0'-!MNYHJK
M!%_21T-^EBNMJ">O?4OOEXJ.GO;"V:78T\[L7:>Y]/'=<^G %D[%]C=+:8KQ
M-B$J5AJM6LLL+";%E[KL=%D^0V2D40='@C:_ 2UHM0T"S*EQA27->1=]#;C0
M)-<7Y<<#UI;D?(QUHM?<7I!V1ZST6;@:[<]N:Z+KU6E[0L]FN#3PTE&S<6W.
M$184G(B19A<4T":<%&R1(+!*RV8\U;.!72H::<"?(@_850;3'1'N,;V=\9?9
MG?3W7BOF]/\ K9NS1FV*QK2X7^;5)E6:$+IVM92C8GZ&"Q))=K8L(=>,S$S"
M8C9E^48@F9<)L92RJMH#@+HEI%UT%]:/Q\NOP58[IX;NU9O5KLS0ZM?-%M;G
MLGF)M?DYT0W)3-W*H$E677H#%8H6RY-%*CYJNV5X8>9?E6:_%66&9+8BPF+"
ML<\N2BRD/%@T:V!AZ7THD#H?K4LU[QV=_;SOWO3V7W58.E<3=.V_4"G:+JM
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M8VJ*!LZPP4KJ,R[4.,OIVO\ 9)4/$W*DA&@MFG1]J&'D"012X+*U#2[XY9
MS[;F/JLIQ[N$/!/G\1T4(=L>[VM^ID=UBEK%!3]\C.U':+4?5BCGT4J!,"B[
M/N)$\Y VV6+.E QR*F B (5(.Q#A\@M+["@@R<>_*2J:TNNJX:7&_0?S6?\
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MM/7FI[=L&<U]!6R"V\18GFK9L<$N$P?*01M?:@S&B,*:$B%OD UXFUME@O<
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MRRP),:2>C%F$0/YG^)_G]WV*HM#I'"B !S1%DW0JQ0'('H/5>@SQ3=RM]]H
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M7J?AZ\**=$]A]V]Q_,!XZ+;L*-ZQ#2=2Z:=DDJ@>L>[HK?3$9#3.NCH=N_[
ML,!' Q-"C;Y8IB*&I6OB'I*1K K;C<Q,EGRR6!R$!K'@7\IO45Z\=3?3_)3=
M2_%CV_A/$AXU>I9M&JS.[^MW?JE[_P!N0;=ZJKD9%:[A=Y;RNI\P!8VS\Q,[
M(M5>[UIU$7'$D2+JWW06VLNAO-H*"\%[W"Z<T@?3M _BH:\@_C=\I_;I_OAK
MNTT67W6+L/<(]OZD;3E^[4IK[1&KM%Q%OKU@K^L(GJ5%%A5F;VXW"1*ZU.7?
M9<+]F>=/D[%'V'[]#P\A.D:YK2TCBAXAM!)//.ZKKI0'W=5;G?\ XZ.U^S-F
M>8*Y5ZBP34;W*Z0=?]-:1'-O-5:*D]BT?7@$':(*;QB14B!'C)5IT1N9D5M1
M9^&_J B7AUI<S \_B?Y ?R1KP P&_"XD_05.G6OHKV%UQY#.H_8:WU>"%UEJ
M#PR:GZ;7"79M$"?(1F_:IL1,]-P(,0.4Y(G13,*IY3=G"97#DY6L9HM2UY1F
M527 L(\R\N^JJ6H"Y]3]S>/KKAXY=A[/LNBM?=C>N_D-[#W[76I=P[)9K.KM
MSUK?$J,\Y6T[FB8V>HNOKHB!B8^1A#KR;#1$6*[/R3YBRH/$6>50-EPY(+&@
MD"R-H )KJ1?XE7Z\+=YOFX_(]YF]T7EO5#TC<9+I &>7HB[HVAJ*.EX?4M]&
M<I-=V:/'Q<?>K!18E,37M@3D8 ($1=!9<D404 P!"B/ #(P+_?Z\'J.:\@>H
M7I8X7DG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PBQ"TZ^H5Y*JYMVI%0N!E'L85PI1=IK4-8
M"JA;8WW?;K35R)8(MVOV./\ >OZ*;B5B28OO5\!3?NSZD67\(G")PB<(G"+K
MIB'B;#%24#/Q<=.0<R"7%S$-, C2<5*QA["QCHZ2CC6GPS@3!G7!RQ"F71R&
M'%M/-K;6I.2*(M3=9NM^@RIH[177[2.ECK&A#=A,U-JFAZY*GFVW?G;1-$4^
M!AGI1#;W]LA)RWTI=_M$XPO]>%))/4D_25-W"A.$3A$X18)L?5NLMQ58JC[=
MUS1-ITHYY@DVG['J%?O%6,(%RK(Q!5?LT?*1)#P^5KRPZ\(MQG*U9;4GW9]2
M+C:PU#J;25812=,:OUWJ.FMEOR#=2UA2JU0:P@\E+2"340-4C(F*260AAE#Y
M*1,/.I9:2XM6&T8P4DDFR23ZGDJ1.%"<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
JB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g69956g66q53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g66q53.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1'B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $<:^15 X0DE-! 0      "L< 5H  QLE1QP"   "   < E  %UEO:V5S
M:"!3:&%R;6$@1W5N87-E:V%R #A"24T$)0      $*:G N'#H6&3<**-8%V5
MW20X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q :T<*0         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M            /X   #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          $$   %8          !                          $
M        !6    $$                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   $$     %)G:'1L;VYG   %8     9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !!
M  !29VAT;&]N9P  !6     #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M       ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M       X0DE-!"@       P    "/_         X0DE-!!$       $! #A"
M24T$%       !     $X0DE-! P     !W     !    H    !X   '@   X
M0   !U0 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$
M  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M             /_A.7AH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_
M>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK
M8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z
M>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q
M,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z
M<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M
M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C M,#DM,#E4,38Z
M,#@Z-#$K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R
M96%T;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@,C Q-CPO>&UP.D-R96%T;W)4
M;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,"TP.2TP.50Q-CHP
M.3HU.2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T
M861A=&%$871E/C(P,C M,#DM,#E4,38Z,#DZ-3DK,#4Z,S \+WAM<#I-971A
M9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP
M9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \
M<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%=O<F0@,C Q-CPO<&1F.E!R;V1U
M8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT
M=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C
M.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/EEO:V5S:"!3:&%R;6$@1W5N87-E:V%R/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@
M(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N
M+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R
M86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M1# U-3(W13,X-$8R14$Q,4)"-41!0C=#.$8U-4-#034\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#DM
M,#E4,38Z,#DZ-3DK,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D
M1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(O/@H@(" @(" @(" \>&UP
M34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D0P-34R-T4S.#1&,D5!,3%"0C5$04(W
M0SA&-35#0T$U/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M26YS=&%N8V5)1#YX;7 N:6ED.D0P-34R-T4S.#1&,D5!,3%"0C5$04(W0SA&
M-35#0T$U/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I
M9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z1# U-3(W13,X-$8R14$Q,4)"-41!
M0C=#.$8U-4-#034\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @(" @(#QP:&]T
M;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@
M96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_\  $0@ <@)= P$1  (1 0,1 ?_$ !X  0 " @,! 0$
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M$]V(GSB1]5^]_B_N8S\<?K?>^'PXYCT[CKNW]_#]M)R#Q/R[M:^_LI[L1/\
M;R/O_P"R^_CMGO\ 8<R7>0'N'AK7[=W=Y)R#Q/R^BY]V8GSB1]7^1_?[_P![
MF-D]^OOW?MW;ZZWU3D'B?O[_ &[O:]V8GQ_3$CX_M?Y'!._8/G^O?^_\G;D'
MB5QBLQ,=OTQ(^&.W?[5W[?\ Z<<Q_GVC]C_KV:3D'B?O[^_;S[LQ/G$CZO\
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M<I1A2\X0G*\XPG"E9PG&<]U9QC&<\'N/3?EX^2]- +FAS@QI< 7$$AH)T7$
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MC#<B+QN4]+?+4M1>AY.L ;--SP[F83IMFL_IV]64@\LC1MCMQR!KQU^@\<<
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M2)I=R-)]'O0MZ>ET7N_OC/?)"3VU=VV2-T XR_&O =*GCH^-^!K=C/?A]D+
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M44@@;V+>[ WL;>=N:;BW.^OM)1'$0FUXE,4*BC5*<35:,%<=QF*+9RF:5?\
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M7*9B_*ZWE\M9 ZV+]V3^I(=D]E P1U:S3V=:"&(!@F'DLK(G"*$+S3]522#
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MHI!ZJTLW+8E1J)1Z%7/>@2X9]W;A&9$2B(*S!2E7.$,&@4\:-(LY^4?6MOH
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M?CJ3_P#@NZQN$5U.$3A$X1.$3A$X1.$3A$X1.$6)4LQ9C@9Z=;*?FCE$&[#
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4A$X1.$3A$X1.$3A$X1.$3A%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g69956g74a56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g74a56.jpg
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MVV'Z@6Z=0E=AQ=E]9*>#$]?NL]P[0]A2PC?[EF?A4RK6W=%4'"M,#!>H\YV
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MHV! QG(&>N^0#MCH1T'YYZ5*]*[R';#V[F]9K/K6LT =)L=OKU)+VZ\V^M;
MV*/JU.7<8.PM>U*S:C":UV=1K3$B%?EVM2;NV%;JJ-@H,VZNC$,VR%2U<<;9
MW_#;\<]>FV/Z9V)<5%.*4XI3BE.*4XI3BE.*4XI6N3U+H&PP&@B^W-:;YW)I
MZR4HOK4'&@ZX*TZ(!-L7O<>OJ>6E6&!9J3:)$N=$"'23(IZ'.'M17GDO/,2L
MH3CBN2=<$ Y]1\#TJ--Y=W/^ .+:M66P#LC>Y>G5K5VQ:A;KSL$$Y==H4*XV
M7<)G?I5]T'KD,-A2>K^JM/7#8T\1!$SU6:MJJ8C) --*2B<13'-OL,YVZ 8
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MG68,+6]?WZTZECW9O6-OOM2#5JLQ1-SM%3+V-#]7JA.01D%:I6YPI3)Z?/J
M3OUW(S^?KZFASI)UU-4_6]'9K5SJH34@&UU.A2=>;EW/K:SAZ?>WALFZU"3=
MJ)?Z]<CM6M,D,%EF0-@.E!T@@$!DT,-$P@F9#8ID_#\!V^ZI4(Z'U(3JNJ*1
M(I<!BHZ./4.RZHKPN86"#*66UB/4*H:QT<,0@)D0*X.5F%##$?G0SL=+;<R!
M)PTU[%177[BZ]:OWHY5)M\@VJ,>HLDS(IUQU[LC8VH[Y7&[+ :%V8<+O>JK5
M3;<P$LD"/$9/@?K*@Q5T<(G3(+I$('F0%2#C_< _S_G_ 'K"8W2WK'!I]QH(
M_50\;3K]J;7.CK8 %G[>-A$]7:GEW0A0JTW\C88[PQP-.V'<YDD^)=@64]*.
M//V,R6=C0515,GU[D_><9/Y"LP-=;=+6(M:SABEXF%+QM34>Z[1*_$5KC_5-
MG:)727-56;X$4ZQ'A9JJ]=4W/T8<S$ &_HWBQBB^"!3$Y3)]>Q'W'K^.:G+B
MHIQ2G%*<4IQ2G%*<4IQ2L"NVL:/L4CKLM<0?U@AJ>^L;.H$CZD7'_0+Q&JMK
MI3!SX0LA!8*>RL7>T#/IIILB(5]4^<6/40A#Y<13^M845ZVZ6-R;M+*4SYJ1
ML7=>J>Q5R<_$5K9^L;CTA&U+#U?<?9'.M('_ (8CZ,U8W^'Q28-6-?A;WV$(
M6<-V)1=4Y/X C[CG^YK#C/33KZ7I>O*+'K%IJHO4Q&SD];&M?[6VQKN_4U^[
M/$7KE&#;,I%V [";$VI967@\#?LSX8EA [YF M08,H>ID[_'KL#6*E?3\ZGE
M8]='_P"'!<,$ 4BHZVE5JJ[0VS4*M>Z#0R<\S4JGMZM5B\"0FYQ <H7-2TM;
M6@W!V?\ 7K'$*O3H%E/Q"2F3_,]!U/<;;?=T[5(N[.O>D^R!&HP-C.V]=HU$
M4?N%3(:PWCM_2%^IDVW CE1>)(LNC=AZ\N<:!9 #EA"YC3RC@DI&02:3&>7'
M>RVH#CZS_.L.K/3;JBJC5,'7:,P<JPFW7C: @^O8VP;6=LMXVAJNZZ3N]]MF
MR"5S*W'9UBLFJMA6JG/6&\V:T3F1TL;('RHI&N5J:(4R?7MC[@01^8!K*2O4
M;KT;#6BOE-?8E"+GI36_7:RQ/Q7=V?J6G-1DKB7U[3_F(]E:E0_P\1O]ND?B
M" ]%M)7ZO\(V;),0!C4)3)V^!R/G]"NBSTFZX*OQ+8JZ;8'"I.R76[N5M>T-
MJ*UA OVQP9FMWS88+4&;K_A;7;_:Q%DLC1>Z J@.L;TZR68VV1:.60\2(J9.
M,9]/GMTWZX^&<;#T%=?=.B?62^A*I6CU+LS-;J6IA&A6Z_7-M;?J :UZ3!,?
M+"]5[/'56]AXVVJ1&CKF1\A-F(M;$B*8LD.3EZ':K-'+J9/YYZ#(/J#V^[';
MT%3]:-742YVG5]TL@%)"RZ9L9NVZT(I(EH*:S8+%1;1K0Q/3!'3X@XMB72;G
M90F(9R(3@1L$OJ$2+'*PX$Z*J,]?CL?QS_,"HWW1U8TOOXH*.[%#6M)T56[!
M2L'J%M#:.I#A:BVMZ!)LM#LQC55QIA&UT@S*%P)<NJV224")F1\38T./,<=?
M<5.2/]P#_.OQ'4_KVR+/@XFMAXX+9MBZ*VL6#B2]E$"LWGK.O5"]'%!@X8:B
M0P(^@_X'ZM:A5H$R-JQ6/56HMA"EXQ4ZT44R?YC\<Y_F:[9GK;I:.:'V%FEX
M08%;R,]DH$S\16M7P-TV"A'=8%[I\NHZJ*[F71K*;!_AUYERJ,?._4HP)DO'
MB$&%1GK\=C^.?Y@5.7%*U^]N?4GZU]0))2IW&QYLFWHH*"?&:E 8?^O$X9&8
MW%C*D%G(CH0-Y9R\24T0E)G+&QW94:#)1E&%UW1^'=2UJ2/V:+DMVD:-[N3:
M&,JI=B0#SM@#'NJ1S$*2":I&J:W8:3&[W4P,JQB1;9"#/*"P1>120!ECU8@
M!CG -6,U'V)UMMS0M3[%0#,2M:\L]839I)&T3H@J/7&F'78A:(:GRG684=8D
ME&E0)$G+J8SSC'Q6%K:=:4JG7=C<6=[/82(6N()FA*Q@N78'W2@ RP<$,HQG
M!&V:]UM=PW5K#>1-B":)959L+RJ1D\V3@%=PV^ 0=ZS_ %YLJ@[:JT*[:TMH
M.[5,@]+CPS]>G-$!K[\%]<68PE]K.<8=COMJ;=;5A*TY\*\>U25*Z9[>>UE:
M&XAD@E7!:.5&1U# ,I*L 1D$$;;@UVQ2Q3HLL,B2QMGEDC971L$J<,I(.""#
M@[$$5F_.FNRG%*<4IQ2O/[IBS=):WJR-J_LS5 -V[Z?\5AL[>M7@XD5CN9;M
M[_\ $>1*T7;-+S&,5?9KNN88#%5M%9V:(L<'68#0 ]H-(/1*2*(U]J-OKZ^'
MY?"N9!Z]L 9[8QC\>N1USG;.:AXIVF[3; /[PI=VVK1FR)MGU Z3M'K._>H)
MZXT75- UYO=C59(=I>J=8H%UU0]&_#>KRT+;VTM_D=<[<#70ED'+*F;_ *F
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M6V@Q!*TK3NS$RJ[LS0M& N/VB/,#DX( 4%<FW=0X8L-3NI[NZEF9IH%@6)0
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M TIE=F;G(82)H;0M#ZZT9%"H""K@Y4]\L0)G9;$XR7)R6V6'9I!^+$@0_B?
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M<+RYE?N1+&5>[M]-XQB6VU0QV&OJG+9:V$"1W;*,):ZFJ@!^; 6.X4!D) 4
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MB6%EQ%INDR06T:22ZC;J(KF))F#233QVEU;QS/(DMTQ*23>ASH?K+?FK=7'
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M>>8? CB9&,L0-?(F2T!/TJ"3NW@R.";64CN+)+Q3&S9=EY;?E(S*4<$2'<(
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M4B9)+>Z__,LX)F)8,S2Q@VEP[$=&DN;::7E.X5U)SD&LH6(Y(YK? 'LUS-$
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MP&00=NE;"7-QZ]TUKV1%T%KVQWL@9GAH, L+&BHL<^=,8'AH!<F4,3P#,QB
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MHK>T2.BN)G(/,H#+(H8D!>0KR^\S5L9]36)F?0NM\-W'F ]VZU-F?GQYQEI
M>[>$+3[T84C*<N+RG.<8RIM&<K1G&,Y\?!S!;K5V'[0T&^Y?GYEMOT.^<#Y$
M]:RYPDP2YU9OWAH=[R_/S+??IU& /D3L>E;*>6?5IU5'N;*'B=(DK+/^2CYK
M1^NDF"I&2W!A"/BDFH$F1,G/*;:BQ94.6^,=<><0SYFM^_/G">*5BG2^Q!<U
MNR4^"VEE]HDFXP5JSG#DX+86F6T^4J_>3D/*BY'Y9QCVQH:QK?[ON]B5/KZ_
M.KL\4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2M9GJC]K=P]1-,478>H!8F9+)[/%
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M/T\Y_+\O]\?GY\8_/[>?' [D'T!.V23UQ_L=\;9J/A\^G0?>,YP.O>GY^/\
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MAR(6;#0I07Y.;(G9"X3X0MM9LY;_ %"2=(FD>&VC@98R3& 'F=F1^90Y**@
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MR]0+:AO.$_/UNT>50D-N9RE2XDU]*XBG6X[TCYI2F$7T=)AU"V;4N'+I=8L
M!YD,>VI61(R([NS)\SF&X#1J5<!F5>3WFL\WDUE,MGK-N=.NB2(Y6)-E<C(
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MA*<9RI6,8YEY59RJ*K.[E55%!9V)("A%&22Q&,#<G&!TSAYBJAF=@JJ&+,Q
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MC3?A7A+B'C"]FT_A&S?4KV.,3W.EO) DBP>8D33$3O'%/!%)(HD<<LL(96*
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M#'GRX8P2V%YB2S,Q+.YW8X&RJJCLTC2+;1K06EMS,"YDEEDQYDLC  LW*
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MTS%[3A:^5?\ 5DLVR(L,]NN\VABO2/5KZOP!]IIJ+B1M15.W2W3Z3O6ZZ-<
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ME*G VZ#? '-GJ-B=\8!QGX=>F\H@ .T]E;OU_KK75T[J(Z0'^T8R&U9K!?\
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M)L@&Z"+J)FE(LJ8'(.#H1(=(&D&8;B)",NQB;K\.0C#B6Y;#2'$);=4\U6]
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M!V'O;].@QC&>G??N>N];..]QU%(V-Z>^SRH"]F*9K/N':[#?"% UML':9*L
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M>\>Y5*"!,]<II@?=K'0Y8ZQK>"4>,+AR#EJLFN53R_+) /?;/+C.V^0>@/\
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M!V+U>T;U.,O12=:1+B:^T">V=8:B<&+>JC[+-R*3-K6!JQSI;$P)*C00Z!@
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MZ<WJ!?VT<4Y3ZK_&G^5/VGG67^5.YO\ 3F]0+^VCBG*?5?XT_P J?M/.LO\
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MV$&#FV\[^&*G#+E8 V59[+]&,6+\/5Z/,?9=-'/P_7CYSZ4.1)G_ $<&7)_
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M,$(TIR1.(07AZ9<5\/7[&47):BB7EY5.#UQTV-=+L3973W>.C+&J\;JTW:=
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M!2D6+9.QZWK$.S;6(]FC1*T@8<LK$\ZT;FP)T,*-+R8T.;+AH@OJ8.<8WK.
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M2],]Q=Y=Q:*=ZM:KKQ6=>H0N9<=&4_J!L:;;RH*O"81@C(UY.M.^;VJ /Q6
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MRU)<HUG'8;F*UP<KFW*W&%*,S@MH:( Y)J1$)@S2F<@ ^@W^6?Z'\?QJ8_\
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M)I0D;XZ8 ^_;L22-@>_X; =UVQZB[RV=9^X(6AT_6%N ]T](:WU#$VG<;?(
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,XI3BE.*4XI3BE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g69956g77h63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g77h63.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1^R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'Y:^@(8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!L$OK@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              I,   /C          $
M                 0             #XP   I,
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   I,     4F=H=&QO;F<   /C
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   *3     %)G:'1L;VYG   #XP    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      5?P
M  $   "@    :@   >   ,;    58P 8  '_V/_M  Q!9&]B95]#30 "_^X
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MMS[2X7G%^S#9M<P6;W:?II8YVRO_ (/WVILMG6!=D.PWMV/KI%#; "UCQ0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M$H9, ,/SA2U=I[-69HZ><J6[;9I&2132N@NO>US@Y[JUP16R7;<>[H^+8@N
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M1.NV/\N@"9%EFZ<V:*V+(#*7?6-8LD@-7K5*^;DFJJBWX*T^XQNP*Q!^XBY
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ML; V-7=O,']D29N*W#*U--RS8V-TQ?-'\0D6?3:*M1,X0.G(@0"& YSE/<]
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MK[$L$99L!.5!!%LBDW;(I-VZ"94D4$$R)(HI$ "D3223 I$TR% "E(0H%*
M   !EP:UK0&M :UH :UH   Y  #D !R '(+1[Y'RO?)*]\DDCB]\CW%[WO<2
M7.>YQ+G.<227$DDDDG=:N2N"81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M%P=AK-<ML8XA;3 0UDB':9DG47.QC*6CW"9P$#$6:/D5T%"F 1 0,F/D,Y1O
M?$]LL3WQ2L.[)8GNCD8>1W9(PM>T[@<VD'D%W0V)Z[N.":2%W>Z-[F$CS'A(
MW',\CN.9Y*OS8OI9<KVR34L^OHFT\]W<5!7;VO1=E?T99!S[@.5485J=2!$
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M[SOSY\U]$9'5<FM^C/\ 1+:ID)X,OKO0L]2,G<08YF0R4&.KM'<V"C%7B:
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MY@Z2RBYBEWE0=IV7"7<A-@"^;&NHP/ R5EHLOL%['RG8#J^;.(-:'#RN$$
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M$PB^%$TUB&353(JF</!TU"E.0P>?/@Q3 )3!Y !\" _4,(OL         \
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M$5U%%%#+G(*9!1$QV;H8['635I7Y;LL,LT-D2537$3XG\&S7%[N/B(=V ;;
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M5L>I#_Q+CW^VQH[_ /-2_P!W_?\ _K+9I3XV>_U=R7T1K8&@?CZH_P!4\O\
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M;N3;%78S6UI2;OZ\XGJBK4-NNV6([K$(SAI)2?>O_":*SSY5LJDJDFDYCO\
M'/T?0?!1<YZ;;6DZDZL[BY52Y4YUY]O^KUM;WB,N'.$,G&5_9>BMAO;J?5:-
MS(HV;/V=[JYHB;;S3%8A&:BC\7D<D""@JJRBNCPB81,(O.GZ[O9,#K*CZ[TY
M*Z/Z0FSQ?2/*&Q V55]42$OJ:1+";6A[$I3HJ[%>(LWUZ?M8MPRC*XFD#AY*
MJMV93@*GO BQMT!V[#])]5\Y6&,T]N6LK:(@IVV5?0^XZ(]H&Q[COJVR2,'K
M2ONJJ\<N'#>-742A[.$JL8"(0#.6? 4"D#W['HX:270C:Y<V"/5>HJS\C9<=
MFU=-:5+LA<G>[8AHERK*=9K-P9>M8WF"0+[T;8N2[E=398R-KU<#IJ3'OR#G
M!K*%C53S0LS[GD98].PYL1!NY$LL>X':+RN3>?7^D:7+3%[E4[=O3:LN:\[J
MO0@)S3%K>I%(C"Q9C  M:M4V)48.O1Z0$02;-CN03*J[5RI9O*-R-B..LPP8
MVE'[FQ];]C@:23(_SS3NWEE<=R7$-WV:%A]39MF7MQ14HS6P^-A%/$U.P1UV
M$[S2#<AUBR[>69Y))):W?9JE7F%5:3"+SO\ 0>UO5_HO=>FN6J7TKR8SK_3+
M'?5WUQ)RG/-C?.*'4M3A%R<? V4WX;%4GI=[&3K)DI)-#MD1=LW+DZ!2+)I
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M$7V72DU2$73*J0JA!F_R%"E, '+Y'VF 0\CXPB^QZ3YV+_"WWI</Z=HT@/\
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MHJJH<QCJ*',8YSF$QA$1$<RK6M8T-8UK6M :UK0&M:UH #6M
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MIC^G<H<RBG$O,)SG,8YSGTS13G.<PB8QCF-#"8QC"(B8QA$1$1$1$1RT!S@
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M13_PB81,(H+>H/Q4MWOHDNA'&[[WI&M/K5#6&UOJ)%P4LXN49"?&7;5"P,;
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MP,'_ "<7Y13W@H?M_1]D7]*3\:?TQ_);])_K]D_N?_-__GG'P?X'_/\ P?\
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MY1<PK]\A'O'C0Y5EHYH(@02*46$3")A$PBA]KSNOF_;/5>R>.=:W0+MM[4-
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9,(F$3")A$PB81,(F$3")A$PB81,(F$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g69956g77v34.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g77v34.jpg
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M P$! 0            8$!0<( @,) 0H+_\0 5Q    8! @ ("P0%!P@(!P$
M @,$!08' 0 ($1(3%1965Y8)%!A5DY25T]35UA<AE](9&E1VT2(V-UBTM;8C
M,30U1W2&QB0F,C,X05%W0DAA=8>WQT/_Q  > 0$  @,! 0$! 0
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M17\KV7^BIXU^%#^(VN?YKOO]=7#&V;;3DP16*%I3)H X$,K%:0K)@0B_[(A
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M#[17\KV7^BIXU^%#^(VN?YKOO]=3R8=MO8!3'X90SY-IXKN#3^'VBOY7LO\
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M<.,XSJ1JG59) U#?B4_W@+G/)&.G.'N;'RU(U9JXD@:CU 2G^\!=;@2,<QR
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M[@^1*?,/3T;3NO[DOD;\6&Y)M&FKX["A,1Y<P&'#Y6U'BJ=DR 68S"GG5$!
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M)*J1VFLD3&UU9"G,O;R4V554P"*SBVXJQ9,Z-\?F3VD3Y8$,&F)),N0G 2C
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M[-HW8M+K0W-;7( _U9)UVVUUWE[:*8O!NOB5.EASYRL%KMFI)M/)DW7%AS@
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M,C>.L4^T"!]=HCWD9OC=,'<>HTR-XZQ3[0('UVB/>1F^-TP=QZC3(WCK%/M
M@?7:(]Y&;XW3!W'J-,C>.L4^T"!]=HCWD9OC=,'<>HTR-XZQ3[0('UVB/>1F
M^-TP=QZC3(WCK%/M @?7:(]Y&;XW3!W'J-,C>.L4^T"!]=HCWD9OC=,'<>HT
MR-XZQ6)VABJ>/W--+G9;$8$#M8\*B$1G+"7(X\)C?5E?N#Z?#I=R>5&%"22H
M&F4/D:=%I1HL/S$3%T:X. 1%IXK!W'J--H;QUC_7^OE-98^T"!]=HCWD9OC=
M,'<>HTR-XZQ5F-?JC/?4\H/>:X.DR-F<(ZDD1KC&3'U+'W98W.+JQ)W<9V7
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ME<,M0KT;U;3+'*W26 [#7 *XYC[*DJ=+('XG)Z9&H4)'-U.)5Y2$!.SG!8!
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M;V!C+VD;B1@$( P5-,!@& 60C ,+4=D(@BQG&0B#G&,A%C.,XSC&<9X=;.R
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M2T3-B%)4I[F88;.@M&8B5(!,"<V1E,8G'@&U\1.)P _FEL8M4G@DU"K38O\
M^VVU:==U8F+X(O!A> VF7)2EKOXA^!T7$V]M=R1 ,DA439;,A-P6F"=NKA?T
MXG4RM/?L=A&I&M(*E>&+,)OAUUYN(E"-/F;X:7;A<746Q<\1<B7M.",JW(5/
M%=1E<,\JK*P)/F#0N<REGL&M8PT(IY9'V;LQ#7)V&R5[IE&N/G<!2.;T>X1I
MC*1MW.2Q:)+E><F0#**4GI\^@M-0KMI?45T-ALE^NL+46E[7#8O^IO8S"1$N
MMOU/(E\3(7?]/,RISDBUP$L1S)?>+7*%M1U)0ZXWY^$#4\VT:JTY:O9!?-/V
MB;IO5-VFOZ>TO[*)SDNTW'2T:)QT=O3^HGHD!N-=;@M^3R5A@/",AV2E:VFW
M)9*-LA,BG$B;84A51TF!1&)'VQ&XVDDUKFPZR'U:XMRB$QH+ F=71_ 4!OYS
M6*U#BI;6;)3P@.D2X]$B*7;>Z\%R+E?KE&L;#MM1I^SV=S5ULMC-UU<NRZEN
M#\J,Y8[6+>U,EW ($;E3[KLER-"V)L==R?<883(T]IX57+98+9*OLAFZ+U%>
MKRWHZZ7-ZU:/3>]+V]B-*;OUU-Q=AQ+<I2I/)&66HK4J:%0I"+9'0_(5'Q\\
M;:7"&KW)%9,[C4!*!+RX3'U[LVR<Y,^.QL:C<PYQ5D%,Y;E&H\BCLRB*YW6/
M: AU;1/Z9,8QFGI'0"'G9O!A(LDB4QJ>_P!LT\@7A-CMTB7%NCC<^6NV6R\\
MI=;1#3)MEN9MMZL\B8_.8;EQ3<6FU0%N-2@QTD+A3CWR/%?TOIZZZB6JRJOU
MRCPY5I0Y;X:+K=++R9EQ<U4:Z7)^Y6.]1X3$!]R'+%N==1<$MO1%2*H6T^?@
MK\4WR)0,[$!4V@% 3%Y8<Q"A:5.<Y&'=/BV@4.P^&,)!DD(9N<L@,:<ED\X!
M?C2V068\$6H1ITWTJ<*_8\[JH1T6J[K@&R,MKDJ7[($PS9>7JM[:[FW"$HI7
M#V4<H$]:8)Q#AATX=1BPX:2@ZB:TF9"[M9T7 7UYQN,EOV.JFB]F FXN)M;D
M[DH4B;M+Y,;>A4\71/MD;DLVZ,++(9'S$7G4%C5EI&%N?$ZQB:YJ^(V5*XM2
MQR;0)'425P6HF1W"4# VEX<T6"279 !6K(]3?!;&:OG@M_4L&>+5?K!;-3LV
M^+/;>@1+Y.9A,R8C\F,&99:D/L09@2 J'-E,[")D=+SS?D=X5I+MA-U8TQ/M
MYNVG]0732KUQE6]QBX3+#;WY[L:8Q%E*>B!Z,P_/A%2BF9!B/EQ<*0IEER@4
M;<$2V3)V-KL%B;EDYF<IB]0,CHW/V5<M&Q/Y\:2\XKR4)J..E.LC*-BK,J<3
M#,K'A$J/7%-;3@#D/SN\&C#]T:@Q-10([U^O5UM>C8$J-<"]># N+EL:$F0A
MA;%M1+N2%VF$])4KCYK#KDA,2&$RE9VN$]]BU.3Y>F[A*8T_8K1=M:SXDFW!
MFS"X6UNZ/<FCKD(?N:X=K6B[SF8R4AB$^RW'7+F%45/!DVQ*GM9'&=+.VQ7)
MWNO4=G*X@S1F5/DG11I>VMZU(C;FQ&WXS))28:OSQX\SFFFD-:92]'J2TI"@
MLB('!8[.>ML)J_Q7KK.TXQJEVS0;7=I]T8M<B+'?99C1F8X\)752I'NK=#6M
M;<1IV<XZEEMP-VG\*[4!FYS7M/2F;3!U*_I1F]3KK9X%JD76-*DQWGY,I^41
M:[0E,?W-RFH0AR6ZU!;:4ZXTIS <WB^89*7B,Y<R'?+4<25S@G0NS9@WETI"
MO!9[:^(6UV;ER7"CQ1Q0+D91J->0I3X$< L!YGSV^6HV2[3+693<SDBT(Y0V
MQ+BA?&--O!+D6>Q&F1GV@YQ,F.^PA;,AMUK*TI#BOHMANPOMHA7417(7+&UK
MY,[(ARRCBWG&2IN5;Y$J')CO%OCHLB.^M#\9QIW#:E*;1%=:FMO32E;D[ __
M !5U=_\ <5/]F'K]$_V6O]KUJ_W1?O\ E[E?F_\ M6_['+M_OBP?\Q;K]3^O
MZ?U_*^M7-[?_ (1=QG_M),O[I/UM+'_ZS:?]Y0?^):K96;_UBT?[TM__ !C-
M?S*M?MROW=32E-*5-(!(HS%9,D>9=7S)9[&00L*41"0O4M8&M<:H3&$IE!SG
M"7V.2$DQ <("LD"9U)).,*"6J+/($,H7FELO/L*;CRW8+I*2)#+<=UQ("@5
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M)@L6I^[ND.2'W)"+<+YR67)!FS+6F\)MDJ4IQ3T13+S[#L'2S5U1P-]KLHA
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M]J__ 'G_ ./7K\Z^#0NR?.;C.FE[B1+5,URN5-I2E68%04@D!YCLC+4!QG&
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ML/H%QI[=+3'Q)O\ ]H6WNI^BCOSS_#/7#/XZ>TXU+\<[#Z!<:>W2TQ\2;_\
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M>.BT_ \_ZYCNIX\;9\ W#TJ-W4_5O=U':S57HW;\VGCHM/P//^N8[J>/&V?
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MJEEMN53 %:1!.[.KV%+W!)A>@12V:1N-JUJ')HR<+4B9Y<D1RE)DXHPK"DD
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MC'2CD^>@L8?%.2Z.\?Q;F5D9^'QCE \MXSXS_P!R5R/(_P"5Y7(CR\P'1O\
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MD>N@/,SRU.WBW2KQGFQQ2+_%^6Z.<CR_BIQO)<KR1O)<IQ>4Y(SB\/$%P9$
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MII2FE*:4JSOTA8(JTK'Z4/C/&V)O $Q>]/SFB9VE"6,P!0!K'%P/3HTP!FF
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3*<3DO\GQ..9QI  Z!4$D])K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g69956g80c20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g80c20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2!:4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (#Z^@E0X0DE-! 0      "L< 5H  QLE1QP"   "   < E  %UEO:V5S
M:"!3:&%R;6$@1W5N87-E:V%R #A"24T$)0      $*:G N'#H6&3<**-8%V5
MW20X0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0
M  !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R
M:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $
M  ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U
M '        IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN
M4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2
M<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O
M;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP
M $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B
M;V]L      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U
M8D!OX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M          !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M              !2<VQT56YT1B-0>&Q 8Z>IH         IV96-T;W)$871A
M8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&
M(U)L=                %1O<"!5;G1&(U)L=                %-C;"!5
M;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC
M<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M    #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M     #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M            /X   #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _0      !( -0    $ +0    8       $X0DE- _<      !P  /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      (%   "6P         !                          $
M     EL   (%                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   (%     %)G:'1L;VYG   "6P    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "!0    !2
M9VAT;&]N9P   EL    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     (X0DE-! P     %G$    !    H    (D   '@  $ X
M%E4 &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( (D
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MO+8V?8YT[6DD;7?0?]!75F],ZKTW-ZAU/%Q*WUY&#<QF8]U1K
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! ?_   L( 3P!< $!$0#_Q  ?  $  @(#  ,!
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M# [[@IK8B/8%CH%+MM4I59C9\51:@R;D  %@ 66 )9980@++ '0   #6@A
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MKEM?V'4<VCT)V1)2(RWHF(#O&SV)HT4G3%MC4A<1*%*I#C.8>,W>')[95P>
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M"<HL1@M!W+EPG_)#QO\ I5YY_:.(9M5C&,8QC&,8QC&,8QC&0:\5_GD>WO\
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M);';[#Z#S:CMN713$^L$N&L*DKRD@[_-XJ64"-SB2P8D\+*\2AG$E;E!"TT
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MA-8%*FC4&ERA*YF*&4]Y.2EA6$+S3T]D'&,C_P#5FV+ HOS4[IMVJG1<PV-
M.7;CD$-D37LT+G&7Y-"W4M%*&TPG0AD.$9&;]^H5.];*3*F\I0?K9)1F05>4
M->$\B^DG-U&U#/+6DU7=<>,<'[!O9BGUI3&RT2[HDBR8.TCM=-^*79Y P+Y
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M#K6N5C/P5*4R),H6+#R4J1(0:I5*E!@"4Z9,06(T\\\XS82RB22@",-,&((
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M8QC&,8QF)+NH:F.DZ^<JHORLH;;E;NZUJ<G&&3MD2/["J<&->2YM"X2)8 8
M*V]<06>F4%; :#X#+^;91II8\I(T:1N2)6]O2IT*!"F(1HD20DM,D1I$I02$
MR5*G)" E.G3D@ 4024 !910 @ $(0ZUKDXSXWO0=;$+>@A#K>Q"WO6M:UK7Q
MWO>]_P -:UK^.][_ (:UD-OMUS)U/U1RY 8-S-$V.WT$<OVMY[>_-3_8>ZJ;
M^FJ:C"I6K>:B73DT]&@0M#D\B975Z:G9P;VYY;FLT@Q08I*2HU5<*(?\0C7/
M>:N.)3+_ #9E5/=E=2.M&W]XO<5UG!93#*,I%8O7$7I;LZLZ'GGR.,VQ21J(
MJ2+)*>[(B$\L:$FXNM/*;RVMMM)><OE#SOYN-<M45V]V%;=F3$M+&UMT78_A
MF5E-M31A0:36E+Q]Y,3D@8:ZKYC"A;D#(TDHTSHO2[>%Y/SA;T;9)]C&,8QC
M&,8QC&83KCFZA*AL&W+6J^HX'!+(OI\;I)<<TC,?0M<@L5\:4>T+>XR9P3EA
M-6G$$C/.V'XEE'."QP=5!9KFXKUBC-F,9\?'6][UK>M[U\-[U\=?'6M_'X;W
MK_'7Q^&_A\?\?AOX?X91OGW)'>_/_4=E3R\)#YQ\KSJQ.F[3LZ->Q'4\R@5F
M7BY5X<T*MP>J>9:WGR\@V .-=5JG^Y#V5S;FQE3!2F'M:O2L2%:LV)X$\RX#
MZX5O7G>G9CK+E,[5659%969**M;SZ5K3U"YOJV: -H^Q[]K)$F0?;$3D]LK8
MX%G)T[7N3L47;TCBF/3&-RY';W9V=ICS2V,+"V(&5C96]&U,[.U)$[>V-36W
MIRTB!N;D*4LI,C0HDI12=*E3E%D)R"P%% " (0Z['&,8QC&,8QC&,8QC(X/0
MGIWG>&1 _C^RI991-G]?P"<UM$HQ2,4ETOL>.Q66-IL&?;=>U$01*=5K74,5
MR%,-ZLF5+65@:S-&:+6GG)E!140/FOUUTYP3)XIPEW4\7AWD_P!_6''%_(G;
M]'K7+H2H+6A[D1&(3+HHZO\ I5\M5I*)TTG268FOSF>2O:5#[*![,7J@GOE@
M^J>/>4**GTUM2E>:Z+J:R[',.,GL^KJK(5#I?+A*56UZK3_(6!E0.CD6K<!#
M<%92E2,I4X&&+CP&*S!G"V.QC&,8QC&,8QC&,8SS\MED9@<6DDXFCZUQ>'PY
MA=Y1*I*^+"6YEC\=84"AT>GIV7J1EIT3:UMR52M6JCQ@*(3$F&F"T$.]Y4NZ
MBN[H"[NG*X]1_-BV[PFE/U@UQ8V[> ) ]3V@+#[9J>G'9[?5EH\ZUA/&QN6V
M# T46GPG%,L*8BDEB*2_NQ$%4L$F1+9O:B>N*O8V@HA<]C\AEV!6;-,WH%;-
M?8W/4?+>=+VC2),Y2Z(1N=(GI6C8URW1[-IT !&!X.9UQ R5*(HHPV21J:6M
MA;&]D8VU S,S0B3-K4TM2-.WMC8W(B0)T:!O0)"R4J-&D3EED)DJ<HL@@D "
MR@! '0==AC&,8QC&,8QC&,8SB+UZ%J0K'-T6I&UM;TQZU>X+U)*-"A1IBQ'*
M5:Q6H&60F3)R0#-//., 446$0S!A"'>]1E=L>FM6\_<=NG3'/+_573SE(+2K
MF@*J*A]J1EPK!PN.UYFU0>.I9U8\96/K3%XU'53J)\EBLTT*E.VH!) B2'KD
MZDNO%TCS;U1W3W/9%#]C4Q#$O;T>Y)@4IK%DHKJNVJGX.[(Y4;;Y5;=H-T4V
M-\5D5LI7&JIG*).]HF=O=8^3.ENT29R*0-25J7.=D#RQX4%Y[<K$TDM<(BHD
M4HLZR+JES%6K:[,E1P*2VD]!>5E<4^R/J]S>FVM(,E)0Q^-_>ZTQS= HU+\X
M%)5KL>D(D=QC&,8QC&,8QC&,8S%LDO*E8;/HI5,OM^KXK:,[+-.A%;R.?11D
MGDQ*)%\AQD6B#F[)9 _@+'K81B:F]7H(@B#O?Q"+6JSOHCWGUATI3OJ$P5#S
M12UI^?G)"NQN:^O&)\MJ2P?JVPXRR0-*\7W-Z=,;T*F'P,B L#JX*(F"7H)(
MME@V0YU3,[D0/\/'</S_ /&,[_BRY_[G XDJ:?A9<<Z!J#H&S+BLB[^Y^DFN
M>TD3'X3$;K?9 TQ.O*JK6+M$R=W$^ P./+C7 QNB+.M<3@M*]S6VP,8QC&,8
MQC&,8QC&,9 G[_T;V%<?,\!<.>FQ[N&C*UL5KG/8_'D%>G2"V9U72+(J0N#I
M!8I8#*::ZA2H2DBU6]5\@;Q*YTF.+ C/6N#2AC[S'IXO\7<D=_U#Z+WH"GJZ
MK?A'NN;12MH3PC#7Y(,JH$] E;0!LJ9MT47D(:GO26R$2*7IF5@3(7:+)D$>
M=R'9>2O0JC)[>*_,_GOAMZE$S@4DO2W[2ED68:^77%TU<4HO*T&RKXJK4KXO
M547DDH$$$4KAA6JSEB*+1Y W(CU>DZEQVN/1(C$\A6,8QC&,8QC&,8QC&<!T
M)<%#8XIVE:0VNIZ!82V.*E'MQ3(' U.8!$M4-^E"/:XA*I$6>:CTK2[5%EB(
M^T$?/]:'^=K;7*EP/_6H//+MZLF$OTJZI[*BMSUC[ 6#/OLD<7<\UT^$RI$R
M\UH%AR)7$IRRH&Q/!8WS[$'9"G)<'IO"X"3C;&)4"V]>'B-Q1?MVRF\Y8??$
M7=;70QM#TA7557C-*RICJT$53)4C6/HRMHNI2M5A[,3I DNI8SFTI^ :HV_
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@$ =?QW\ AUK0=?'?QW_#6M:_CO>\^V,8QC&,8QC/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g69956g92v31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g92v31.jpg
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M_P"=]B"Z:LX49ZUU1?+LOK^'<YXS0YFYTM?UVPM(J/3YJY.RQZ0G%V=V$9&
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MZ(1LK2]IB+^TAO(0:^U$.@?9_OTW]/VJ#GM5Y\C^L9VK59L(F?+^NF9(VI/
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M8L]@-QG?W-+<7X6+W.(T)K#J*:VQ@-GL:O-VT3'6&)?)HQQ'TTDI**5[L[[
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M6^*4N]5]R_7_ (?V GFU_3;BPU[:C 7G3=5@>6WVMS?+L_T;1V>.YM;]AUU
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M(=+>DU/.OT^M=Z(G@U]FFZ,6M(T3=;-U>$N:"Q'IBA&X^:NNT(?JHXQ]/O\
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M;1N^?E^F?[TIK8+])CC/-^7>L>.S=Y)+T#A6E]6;[<=9TX6OW5SUD#UDK"X
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M,LQV51DL=@":O;#3K_5;I++3;.XOKN0,R6]K$\TI5!S.Y5 2$1?B=VPB+NQ
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MF>S/AK3>(K_5AJ0YTLM-+01Y/*EQ=S+:)>2*".=+(2&1$.4-RUOSADRC8Q<
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MR:=J$(;(BNK*Y<2* SQ02$Q+J#PH3M&0]7[Z&RJ#_P#/*:FW1/+,YI%=/=1
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M#(0ORMC/;X3DX&V<C*:);:?>:OIUIJU])IFFW%Y!#>:A% +J2S@D<*\ZP--
M'$>06S*O*N7P_+R-BCZZ]_QG4>=X6]PF+]<?2#>W]Y<VFL#NX;?%9??B175M
M2751=\ON.99FMV-7:@TYSC0K/>4^BPY3%,HKJ2J)?86V5X2MXY=%?4/X5,$F
M,OC6>FVX7W2]4@>\-<*T,UO,I$1$@LYX)QS0EY"@*[#[2(KNTXJGTN?B6_XI
M@L([:#3M5U*Y:XEGT]HA+%%"&NKY8X09) D0F1AD2-%&SE!&OZG>J@YMZ\44
MK\#P;,%]JWL(#.K>O&EGL:;1 9P5="8^YQY&4J:V:SN#5#CCL%LMNHXT14<]
MD+/*#+-8\2KK5Q8FWT2PBU^=)8EGTKB:*'W>.W(D+.OBW2K(T4R0\J$P?B9P
MC%.4_._MBUEM+X7BMHG='U&_@MR[1QN8H8$>ZD(5UE'Q&**/)C"A'?+*>4->
MK]*5F@WOJ56;/3_X."W2Z;0"T5ES/)Y+!F7F8IG U"2[JLR-)4U+=8-H@=&%
M,2"$ 252QU#[-"#XVDMQ6@PZE8V;0ZKHNE:+>BXD=K/2PGNO*0OAS<L<DB>(
MZ[,#+*,(I!3F9!D?9A<7-[PI;7ERNG9N9YVBDT^VM[42Q1%8.>[BM8H(!="6
M.5'*1+_+6/F'-DFL%7U3V5YU[-==W&P[O>6?**CL5KG:SG%>)&/F:7FN3U+L
MK?RQT9KS0ZZTAI*RR+C(!DF*,L((=(0<IYY]<^TU_C/2GETJ*PTRYLY=*GN8
M-7GDN05O>2XEMI@T:#DFA"HM[#,ZQ7,+?\HG\A<O]>Z![-H[GAR<3^Y75WK6
MC6E]I,@@87-M>W%C%?VH%R"DBL\LHT^6WS):R1GQG7Q0A3?)CVR-:]CD>Q[6
MO8YJHK7-<B*US53^E1R*BHJ?TJ+\IYL'7I7!2""0000<$'8@CJ".Q%,OI6NA
MP'/-SN)P5M(LAD=#I'5;9&Q+9K35)9[*Y)GM>R']\^!HOYI&.CB_+^21%8UW
MEM>W(LK.ZO"I<6MO-<<@."YBC9P@/8L5"@G8$Y.PK):+IK:QK&E:2LH@.IZA
M9V'C,I80BZN(X#*4!!<1!RY4$%N7E&Y%?.;GNM>SUYW+I=GI>^;8P$%P[\QA
M<C=:'GN+R8Y<@YX#6#4)8P=PRNAF*J(V:6HU9]L/$ 58VA2M+5FHZOQAIVL:
M;I5E;6]]I6L:>JR:IJ-K<SK'>RR(R/'%:BX"2Q<RPS)[Q)$D1,R)%(#EOI72
M?9U9:&U[++9Z3JNE:AS164&I65I>7L*1L")9+V:V::VE8>*C&R"%CR',0 5=
M6\5[H0YWC^6.WPA^YZ4;::FB%#S<597NOJ[*6:5ZZV](G>#4T43G3#U-L\,=
M4.TXMNW/T2!"E#5E=KQ0L&EVTM\KW-[(]Q$JP!$,R6\G)[Q*25CB&ZQR%0>:
M<2>%%RJRIS_5/9;+?<4ZE:Z+)#INB00V-U)->M/*MG+J$'CC3[9566XNW'*\
MT D8&.R>W-W<^(Z231UV#NV+]CL/6Y98CN8="SVE!U.7K]R;50XK864(%K23
M9D?:AFS5-;96==>%Q44FG@S[Y+]H,$,<P;R9O+#4M7L]?LUM1SV%[#.D]NEV
MT8MKF0+)$8%N5<QJ\B2L(O'$)\7E !7F-9OASA'6. =8DU1A#KVBW5G-8:A/
MI,<\FHZ=!))#<+?/ILL27$L<$MJC7(LFNU%H969ED"+5+;&T_P %T@LUF=:\
MNZ$!*Q*V4V23(;40EKF+%'7_ +C\,]R'.]T;/VPR6^?OH)&P/BM:\K\<^IL\
MMC<*7,VGWB$!"Q-O<!MB A./%0Y'PKXD,H."'1L'K4<=KKFGR"-+37M'E0F8
M)R7VGLA#!FEY2?=)4 8^(_N]W:NO.&@E3*ZXZ[L71\EZG4W5K&B@K.EF97 I
M:A6U=..'1WVLLJ*B/N+"EDE'*%AKY;:2V6C*FAF%D;'5G2,6.=Z=-NM3O;;A
MV/47A"7S6UH9(Y$(6*:X>&)Y'BR&41F0R&)B"I C<C!(^9=,X9T74O:'/P[!
M>-/H::EJJV\\$R-)=6=A%=7,,$-R%>.1YEMUMQ=(K)("9XE(9 <V:3W'[J'O
MC,S#U6[N[FK"9:$U^JQ&%(R)<$ZP3?@?_CM'F;UJ1L*B8W]I;U_PG^U"IY62
M([1(N*=92Y:/WYY60<Q2XM;4P$'!QF&*"78,!\,J_,X-=TNO9CP9/8+(-#CL
MTD8QK<6.IZHMZC*"O,/?;J]M68E26#VT@.Y"J&!&C?#?;;.]-L0L9LJR+"]
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MZ3)TSN2NWS8#[WZ54VG7J];:4_\ PCF^OPD[>O2G%33YDN0P_/S4I,I\C)[
MJJD"EE*E:U&LD+E%5SY)&M5$1TRJY/M_YN7Y]$,3%FC,9+'+,G*23_YB._SK
MPE%PO*DPE 0859 X"@[D*&V )ZX_I4@XVXRM#IGS;YIR<^T^3UG.M\;5L=+9
MTN7UT )*Z&OBB&,GDGHM!09ZQD_ ,3(.)"4<P0V02,.>_L9K:&Y/O@?W*YMK
MBQO&0$O'!<!&\9 %8EHIH87R%8JH9PK<O*<!K]GJ-[IJ'1O".LZ9J6GZWI,<
MY58;B]TYID-K*SR1H%N;2ZNH@&=%=V2(R1B0R+=[G_1N#>L/-=#)ENKUW;-'
ML[F32U%1G3:2:VMS/X:GI*X%XM&\L;.4XHU9 5;7MXL,<,DYCHF23/K*5VXV
M=YH_#UA-X&H)J<MQ(9XXX7B:25_"BB1.6(LL,85%:260J 68@9*15Q_6-'XP
M]H6OV@ON'IN&K;3;9+&YN+N"ZCMK6+WFXN9IB]T(WN[AWG=(+6VYF8+&I(43
M7 IWJ.L]#VFUK^B7J\^32U,J3U W^E>!NJVM6)7J#"ZVT5#9;DO]BBQHA(^N
MJGOEA0@**K618FZK<:O?7-VE[(MD)XSF)386DJQX_ /%FB>[;DV^(7$9R.9!
M'T'5-/X/T/3-*FT:W?6S:7*!;F1=>U2TEF) \5A:V=S%I:"0\V4>PN!RMR2-
M,!DZG^N/;U[9CCC;2O%J-AEK-M'JZT&1[ZZ4B02 ZOO*A)WR%15%T'-^6$<I
M\TU>>-9U+BS_ .._D"NB:'JW\6M&D=%BN8)/!N(T)*<W*KI+'GXA'*K9 8DH
MX>/F?DYV^=^..$SPGJL=O#,]SIU[![WI\\B@3>&)'BEMKCD 0W%M(O*[(%66
M)X;@)%XWA)83S-5IE'BE'BE'BE'BE'BE'BE'BE'BE'BE'BE'BE'BE'BE'BE8
M>]U--LN\=@,LY)9#H=;#31QS*]7 T]/0TX]($.QZK^W#F >R[CAB1D,I-T98
MHQ9[">67D>MN\FLZDTA)99UB .<)''#&(E4'HI4^+@;%Y'?JY)^N."(88.#>
M'$MU41R6,ER[* /%N;B\N6N9'(_'(LB^[%VRRQVT<.RQ*HAZ5\H91M@:< /3
MQA0K\2PH-(++"^=Y115C*2D*BNB="C(W01)"L;WNF<C_ (3$$E2S,RB,*#N,
M8(SS,S$XQC'4#&,YK;0/$5(T21Y2Y "DMS @!56, GFSG<9SD#&V_J..H&BA
M6EB94($V>":NL#)POVR$S,>P>8(J9WXDGEB?(V&2"3\CXWO1CE:YWR9H\*[,
MG+D%'8KC)V!5CMD@X!!R<[46.?F>-4E#@,)$57# +NP=0,X!&X8;$;[U#_L/
M9& X.* 1[XXK6Z#!->Q53["H,:9^%7)\*C99A8?O_?P]C'QN16O5/+/479(
M%Z,X5O\ X0K-CZE1GT!&#FLGHJ(UX6<9,<3N@/9LJN?F Q[;=>H%47\P>^XV
MVQC&,]1OL=NGF-OTVW?<;;8QC&>HWV.W3S&WZ'@#JO;MMO\ GMGR/;H,C<4
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MY]3@=AGKGN>V#7GOTSD[?/J<#L,]<]SVP;!8+)ZN#!S:W#M5^HLKQE6V2/\
M:_N Z&!'M*49QG_18\FQ_;?NW_'Y&"#I]'-C<1\Y""&80&:#>1I.3; *Q#KR
M\PP"7Y>?;8#L.:L->W%N;P6UV?\ EXXC)@\W*TI'PAN49VCYL# !<^?+B_\
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M<4Y)W;.09'L?.\GTG-"6,=N'4:ZG%MQ0K6$8D.*R!0ACI CXQ#2QF%BOAG;
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M4ZD@^SUVB@Z 12U4#+5@E@,/=K YL0%=-9HT5A/)I]!]G?&-_<:H-7DNM7A
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M+%$)'"JF<O(57<XR<D 9)ZG8=2>YKI)>:<Q1%V?EPD2LP 4'  !8@#H!DD;
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ML@5;7G&FS?4MGR[G?:N?";PTL=N IND4VIVN5WB5M376]O10:J//7 BZV$*
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MS&-)#:Q_P]Y0OXEC0ZI(%ZGE)&2!B*B_:/V$VX@]PWJ)V2$MQ4*=0X[-8P,
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M##((-=EMKB6ZL8DLC'>V5Z5FM[FTQ<Q7(R-X)HN9' 8 ,!\<;J4<*P91?3U
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M6?=R(OXV?6-OQ_L8WY7YI50N<#',Q8[DY)ZG?]AM5;.S\O,<\BA%V PJ[ ;
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MR9?E8<VVK\3<*6/%4=I!?W6H006DDDAALIUACN?$5!RW"O'*'"<@,9 5TYG
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MQ^E.K;^_U-WJ650MA;W[:B"2&LHWV4M97!BTU;6C111SV]B23-*R8@F<A/\
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M>)[[4)-4,YT_3+>%W@MY1#)<W5U(Z6\3RE7:. )#<2RF-1(QC2-7C\3G#/\
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MXLXFCNKEO%9[N)(XTA)""/<MXDTAEBYV9UY).3)?KO#7M/FL9;V7B,ZGJK7
M1HO EME"RAF,KNLR J9%Y #&_("&)B/,.6^W#?4K/\NMQMGK+IF]W8<<C*<M
M:M*G-Y5T\<D!)6=HY3+0A+DD65X4U_9V1IT0;R1:AE.+96HYV)TCAJWTV074
M\GOEXHQ&YC$<-OD$,T$1:0B1@2K2O([A25C\-7=6QG%_M(O^)+=],LK;^$:1
M(P:>!9S<7E]R,&C2]NA' K6Z.HE6UAABA,BI)/[Q)#"\>>7LOIM!INR=%BW,
MS9B\3I"Z?%9FU)>^FS]2P2*?-V-37N9)%!8ZZMF%O;*Z'&GMBG'_ ,7^ZE"I
MP0 ],UU[R]U:\BG5W-K,R6UN<F*"$*IBF53\"&=&666<CF^/PV?DB55[3P#9
MZ7IG"NCW&G<B?Q2T6?4KZ-5%U=W9D=+JUEE&)'BL9D>V@M"PB7PC.(_%N))9
M*6Z+5:FXU%,+3_P169HTKI=D=7$BV ])<1_B-.@2W@>EG4VU8/((72?LT N/
MW4HI(S7RK&C-?O;?4K66T-Q:RV\,T:7"/+"\8D02NC2P2,JN0LD;+%)$0WB+
MA<MC'0;"73)X+P17*7$XDDMO"619-FC4B*XART3))&_\])N:,PL1(O(37TI\
M=?JY>3<TDW7[G_,I,)E7Z=3D5MBMVZD"6P6S;\-1MHI"O6S:QJ1-/4A(D2-&
M)YVO33<'3[$W>3=&TMS<%AA_&,2\_./_ ,SFSXF-N?FQMBOB7B,:>O$&MKI/
M)_#!JNH"P\/>+W074H@\$Y),'A\O@%CS&+D+?%FI(\O:PM'BE'BE'BE'BE'B
ME'BE'BE'BE'BE'BE'BE'BE(6GS-!LZ"URVHJA+O/W8D@-I5FL5XY0\BH[X56
MJV2*:*1K)QB8)(B1"8H2A9H2(8I6>4\$-S#)!/&LL,JE)(W&593^H(."K AE
M8!E(8 BZL;Z[TV[M[^PN)+6\M9%EM[B)N62-U[CJ&5@2KHP9)$9HY%9&93"?
M._5KC_,])%K:*IM[&^!9-'2F:?06NA3/LGAD'F?3CV$\@\!\HTLPCKHB(J]4
M.<H-+-!2RHIL38\/:7I\XN8(I&F7(B>>:2;P0P(/A*[%58J2OB$-+RDKS\K,
M#M>M^T#B?7[$Z=?7D,=G(5:YBLK2WL_>V5@Z^\O"BN\:N%<6RLEKSJDG@>(B
M,KZZ1VKDO'X8)^H=$R6%:75W5T''H[D2O*.JLXT)]\> '+)^[.'J&V(#CWB0
M3?MD+'61$_(WYS?2N::GKNC:*%.JZE9Z?SPSW""YG2)Y(;7P_>)(T)YY%@\6
M/Q2BMR<ZYQS"J8>_/K!J/92'E!7-^M/Y#L<M:6,XE^)6.N8M73V< \CZ,Z 2
M[!E> $\7]^(\FJM@7V!HL"2"N)D87?Z?!HS/=SZKH]OJKFREM83<%@MNLCI)
MS'"Y^*6*(\\4T-Q&B2B-^2656W?0N)]2T16BL[N>*RN+BVNYX[=T5G>!9$21
M'='7)AGE0HZO#)F-I(W:&(HCY;T,UQ!L,?0>EU$%#%]&%"X6H/CO[2-GU^S6
MWUV0HU(A"-<R=P])8F-9(K@CPB&1D-YG!P=,TO->7L2PYR8[.)UD89SRB65B
M(EQE3B.1\'X75@&KK.H>V2T2 C1M#G:[*D)/JUS$]O"<$!C:6L:M=,IPRE[F
M&+F'\R&1"4,F^V[[#DG#<;C^802XK%F:NLQ^@,SDQ-:539HFIO#!A8K8:9AU
M=)IM*-55%C=*2EA83VTPCS5LKII"Y#B4R:;H\%OIX-K;&XCMI6@+(T4#)*P5
M9 >=#-.(XWEYN=C(5YN>3FK7_9JEOQ)Q??W_ ! ZZIJ26%QJ5I'?*LZ7=_'/
M;1LSP.IBF%G9O/<PVO)X,2VZN(_!MB@R U&D'RE;:@9M,J$7*(*-F0(B@QC+
M/2'ED0N!&JW-&'.G^B-E'B@FG)*,5X[AWR.:R30/X?J)MYY;33YI(X8'G9HH
M)'$:Q_%+)*$7"1HA5S(Y ())R 37T6E[9/<6ZWM^JO+,L1$LJKS CEBCC9GR
MSL04"*OPCE &^UZOTQB.DNMMZ/?QO&H_X0<W2A10L%KQ]B;9C29V=0A6LK1-
M,=GDNY=*T6.(Z6MCQ\EJS[?L578^!#>>+>A\BW\)6E3'*BW3.#$>4? )GA\0
MS<H#%!;E_P#17)_;FFD^ZZ+)'R'46N94M9#O</I:0L+A7=B97M(KPP+9\Y,:
MRF_6 [2BM?O.DU\Y4V-GF&;3*WN5DN]#FV7M?-7NOLI8,J=)4_F^/@VELI1C
M(PCX51'0$/%G:QW]K&[_ (\5:WUK[]:7%H;BYM?>(FB]YLY!#=0\W_B02LDB
MI(O56*, >QJI7%.($>N.UZUJ-4:S>5-V/0MR/8-MI;K8]TL*]E5"V[QNPOKV
M/]I'2 E4(1P#JB>EJE'A ?8BES",DIW*Y#E%,C*C/R@HI/*,\H9V1 2< %V5
M<D<S ;C4^&>&+G0]4U>67_UJMTML+#6+Z[N+_B*9/#1)K"[GN 5,*RPQM"MN
M\,;?R@\<C*I@R6XUL*?JM[JLO7B_L+^X-!_TAJ2;2M!B?4G7$+74Q-K8/!'L
M[Z&L4 :IA>X:*T4FQ(6.8P6O&?\ *O!_%4^MZ_KW#NJVG\/U9+V=-(LI9(XF
MMQ!<F&YTR>1RHFO;94 C.5$Q]X8@F.)&[1[+_;UKG$/$^J<-\96L&FO92:GJ
M >&RG-REK80NDVGW5O%XQYK5@U[/=Q(7,<<N?#@1F,!]WQQAM57ZZ)"Y9:0>
M&FL%+D'F+-JDE>\*\D01K(XG/*)DC*C_  Q.:L['K%$R-R>;)?P-RK,"Q,8$
M;\V"60$\LAY<#))(.<=>@Q7VCH]VJR/!\(67,R<H9463E'-$ QRV% Y26(^$
M]2:[_4WG=GK-0PP NNK7$%D5,IUVA$-=!4P5)EQ<F-*@;*]CP(P8"IE8,7(X
M>&4:*%9B6N9ZZ)9/<W"*CQIDLC22\P14"-+*V1DY14!.Q) Y0,FK/BW5H=*T
MZ66:*:X6%$D$-J$::6>6>*W@A"N54^(\H0$NH4D.QPF*T?RU?ZZYFU'/VNWT
MW0!Q"F3K59W&&YVC?%'&R7XM2=#8#VEH$QWV?+'715SY6Q_A*A6%TD$NX6L6
M@P3(US=W%_AQB*"T>&$],"0RL)9!S;X3DYL892"5/+-3N./-1M9H=,T>PT+Q
M(BIN;W5H+R\',2#X"VD36]M(5& TQE"<W,D@8*ZZ-V7L5SH6KYC>TTESK\YU
M769'(Y[09.H)M:H,C<UI=GFK6VD:D4H]"9$(Z&:S'@*'KR7L@L%%D7Z^=4>.
M2+E\6-XBP_!*ICD4]U>-P'C<9W1U5@=B!7R5K.HQZ'/9V]W!<2->:K'HX>T1
M;F*"ZE,JH\\D3D"V+Q,GO$?B1Y*GFPRDSQY161H\4H\4H\4H\4J'NT\6S7;<
MR)17A=A3V%18LM\]HZA1_P"2IK!(919T2(N&<0^NL YY@[.L+A?"1$Z(F!XE
MF%76 6,U72K?5K=8)F>-HW$L,T?+SQ/@J=F!5T=6*NC A@0P*NJ.NR\+<4W_
M  IJ#WMDD-Q'/"UM>6=R',%S"65UR8V22*6*1%DAFC8,C HPD@DFADCSA_JS
MF^.WQ6P*T5EM-=-6D4P5@:"'4U='6&3CSG14U0*\J2(RQ<&&P^P/LK$E8A_V
MX"UXI)HY-EI'#UOI4K7/C27-RT9B5W58TBC9E9A%&O,0S\J\[L[L0N%Y%9E.
M;XN]H6H<56L6GBS@TS3HYEN7MX)99YKFXC1TB>YN).0,D(DD\*&*&% S\\HE
MD2-TM)YL%<_K'KV[]:?8G4>T.:Z#PFMQ9V&UE6"/U>COCF5&C/O*<5:^>_I)
MC1@0R&R9:DRU*(_^8)''/AC0V 5I**^VO= T*\T?6KJ9;V379?!DL$BFC2U\
M2*);>(.7#!>923.LGA\Z0IX3A@W-T_@[C^?2%TO2;^6*'2;26X1IO=I)Y4MK
MJ8W4B$1/XA\.X,C0E(V*FXDYTD 4*Y<'Z7]3U-E"G1) >>91DC%L8*VZ%NMM
M9P?"+*#6R532:*@2?^XWW3K6U-'C^_[.KB(?$<+H-EPG?SR W[):6X(YUBE6
M6YD'=$* Q0AMP9>>1P/PH&(==_UKVLZ%96[C08YM6U!E(AEN;9[73;9SLLLJ
M3,MU=E-R+;P8(F8 R3,@:)Y+]KMS><DKN=<2Y0Z7G&8.S-L<199OYK;-M/1%
MU59!G<U9QN<362.DLG&Z.Z$=%?1*15/#LX";,LI,AQ)>S:9%9:7IV;*!X)&,
MD'P.(HF2,0P./BC.7YII5(E'-&5<,[,-=]F^B6?$]UK?$W$6-:O(+RW1;>\)
MFA:ZO$N)FO;Z(@).H$(BM+:3-JW+.)(62".,Y0](TS\U7%ZMF<(N-*/=CU06
MDO"R+:[)=,.Z=]O_ )&AIFD^\4RRAQS$V0QS2_[;(U?JCN=W<TD0,Y21YPZJ
M)IF>24AEYA+XO,TQ\@S.K9P0>F?H2PM(9@MDCP06;1,[V=O###:*%8*8O<UC
M2UQC#,BPE.4$$;&M@O0'I?0.A<PO1MW/;6+LM;U-?56EZ6597,<5GGJ^X+SE
MG;G.?8W!5#(7#(RPM)2+7]E:A!V11)8<L[^F\'7]Y?6$PNVDD-O,D<<LK%Y,
M/"DK1/(WQRM$6'QN6?E=5=F923\T>U[0](T;7K.32HH+7^(V<ES<VEJB16RR
M1W4MNEU!!'B*VCNUC;^1"J0"2&22%$20(M\?-NKDU'BE0GV/V#YCPEV/;T2Z
M?6.VMXE+5M@@4I\$;&L4V[L(VO;(/1U;Y@XK UC97PO-&1D$J+(L>I\4<:\/
M\'G3!K=TT!U6[%K;B-/$9% 'BW<X!!2TMRT2S2@,RF5.5''.5PNL<0:7H7NG
M\2N/!]]G\"+ YB,#+S. 05@B)022;\I==CDXFF.2.:..6*1DL4K&R12QN:^.
M2-[4<R2-[55KV/:J.:YJJUS514545%\VM65E5E8,K ,K*0592,AE(R"""""#
M@C<5F000"""" 00<@@[@@C8@CH:\_)J:/%*/%*/%*/%*/%*/%*/%*/%*/%*/
M%*/%*/%*/%*/%*/%*/%*:L,=%37(0GY"XS2AIQ*J$AQ1 T0ZM&E(#!ED21(8
MO@""7]N^;\,/XE0=L2.<QQ[C+")CAG/,/A(YV ;<D#!8!FR>N^Y)JZCLYY;:
M:ZC4-#;E?&(=.:,,RJK%"P8JS,%! ._;&].KQ5K49;[C/+.HRB%;W#T.CL !
MI@@+@D5PUZ &0KEG$!O@)!+D,69SG/D'&.BA=(JR*Q7_ .[RRN]-L;XJUW:Q
M3.@Y4D9>65%R3RI*A651DDX5P,[XSO6;TCB37M"$B:3JEW913.))K>.3FM9I
M%'*'EM90]O(X7X0SQ,W+\.<;55#COHKZ_>LV@+M>6\M E+L;BTTL)=^Z^VQP
MEI^X,FHPZ4FT8359MU:TM0:ZR:E1/5U\$+#;&^(GG/$SVIW":[)97&II#<7&
MFQ+#9RR)&&MU/)XLJ<Y>1Y6,89F7GD9R2@B'PO0G$&M1VUY9PZE=6]KJ&!?6
M]L_NT5VJ@@).D C$D>&(,39C/=3@5?IJJK6JYJL<K45S%5%5JJGRK55JJU5:
MO]*J*J+\?**J>8ZL/2/?6ZT=?+9*&0;"/_O(8,GVDCA1/E\J-1%548G]K\HC
M$1%5[V-^7)Y2R>$A?E9@/Q!>H'<_3\NY(&]7EA:>_7"6PFCA>3X8VE.%:0D!
M4SD8YCL.K$[*K'"E2#):8*,6R*>%I,$4[828G0$1)*Q'I'/"_P#W12M1WU?&
M[^VN147_ (\K5N958 CF .&&&&1G!!W!'<>=6\T9AEDB9D<Q2/&7C<21L48J
M6C==G0XRK#8@@UT>55YT>*4>*4>*4>*4>*4>*4>*4>*4>*4>*4>*4>*5DG^K
MCPRPZ/QVFZD'99VGJ^+93V!EVMCH[*6N@AQ_0>&;'+,>#$,-.5<W$>T3&K34
M4+V.L;)X\;62R(SZ4L,CMT/7R((_M7'?;)H$NIZ)!JR2VT,.AVG$37\ES*8E
M6RU'0+VT!C"*7GF%][EX%LO^;*RCE8@"H<Z)^IY28;B^#RF4R$][V.MYW@LI
MTS2[XBWR7)N>;ZRQU"7<XB\GJH"=-U'?@RGLG-Y=RVCO](-%*6TLRD_9V3Q:
MUE9,8 )R&^( X8 $$'&>;ILN,]ZQ-[[7(]+T33K2PLO>-:AT[3;?4[K5/%M=
M(TS4Y+*W>6RF>)6O-4U*-I TFE:1#/<@%@[P^'*4U;]:>BZGJW#><[K;8[18
M;5W&>$;?T>FRQ6(-DM 44 RZ!R5E<WUSG\_H)QI+K-UE]92WHU$< RV9$;^5
MB1G.YZGZ?IVKK/"^IWFL:#INHZA97-A>SVZ^\P75H]A(TR?RY+B.SEFN)K:V
MN74SVL5Q*9UMY(Q,%DYA4R6M35WM:=37=:!<5%F-*%955J&/85U@'.Q8YQ#0
M2XYABAIF*K)8)XI(I&JK7M5%^/*)(XY4>*5$DCD4J\<BJZ.K#!5T8%64C8@@
M@C8BME@N)[6:*YM9YK:X@=989X)'AFAD0Y22*6-E>-U.ZNC!E.X(-49ZI^G5
MZJ[^_P EMC.6PP6_/T/,I@*30:>HJ)')^W,#@=05!T<$W[,P)KZP8!];"-.3
M-/)!8*D(R7>CR1Z-:ZE86,45O:ZN$CO8@O-&R<LL3!5=C'"KQS.DO)&/$0*K
M$!01G+OBSB*_EM)KW5)[F>Q8M;3S+"]Q&Q9'YC.8O%E(:-60S/)R'F*8YGYI
M+TW3^?>J7.,6IV'(J,I=="YIR^F"P68#J!UU?4+Z'/1V9=,?-13#B1W$[;&\
MLIAF%SH8B006)K)5DM5M;2RC6&SBBMX%9N6"%4"("W7,?P$MDEFYF9B"SG+5
MIO%W&#V7@:SK]QJ.ISZCJFF:3[PTGO5QX^HW"6ELTCW$R<MM"64%48^'$H2*
M,@*M2;P/M&7]B..<^[9C!+4#,]%H(K^J O8A8+@&)Y! DP=E$"6<&PL4L6>"
M7]L83 KH_M',]JHOE0W /G5KP[KEIQ+HFG:[8I-':ZG;BXACG"+-&.=D9)1&
M\B!T=&4\KL,C8FI>\5FJ])(\!@\XA4,1(I4,HY(\[&RPSP3L=%-#-&]%9)%+
M&YS)&.16O8Y6N1454\@@,"K %6!!!&001@@CN"-B*J1VC=9$9D=&5T=25964
MAE92-PRD @C<$9%?.K[%X$3UW]G\1;\PTL6A@LYJVXJ38W59Y-/>QW1^>-HB
M)V2E"$7%6/#7DN,)@%G:4=#/,+'/$LLGQK[0+!>#O:EH>J:1*)$O7L+T/S1E
M4N/>I=.N[9G!93(($C>1W52#<!B"P)KG_'.HO:>V3ACBG4M/?35UB30[C68T
M\>TAOH6D&DZI<1J51HH-1TP!9A&9(W,TS<S*Y6E&:*1I\HJSQMD%%_;F4Y4+
M6DQ.<4L2S%MD1#87,08P7]O-&UCIV2MD1)(7HWK1!#E2<%=F1A\0/-@\P/Q
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MB02+&Q>VJA+#D@F=1U-0(YZQB1(V0,8\QOGU[GTK;>$^$++0]$TBUO[:UO\
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MIR02;?>36Z4>*5\^'Z@'+<CQCJ?-Y<^?;O&N CM%8MMB@R5K(1M#'^$<*04
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MHXK9K?5O>;RSF5I)<WKZA>R3HKY13XR%Y+=I)4-N/A!@TE %K(! FU@P,(,
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M^H*Y72:^]'DN=38X\:#84,55TRWE*C,"BDLGS45-<: 6P)90P'EV]S734F:
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M9CD2RMY9^2<J0RFZG2.&0<LR,JDG2I_M#Z\P7T.:.[!A*>V*SM-JP&7UX-0
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M"HA822&P6<LKM6L]*EU2ZLEU&Z-Q!I$"@0,N5NV]ZO(8YW.=D86@5D<,[+&
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MH]1Z:?\ $]>NZ-P#8:?''=<3%KFZ8!TTBVE*QQ @%??)XRKEAWCB=4!R.:4
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M6=UX5[28H_\ P35T>OJKJF*"TN2)FB&T=<!8P."/ T.;(>VR!8]I#Q'$.A<
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MQ,CI)GK)/)(Z.-\C_P :.5SG23/FFDWNYN7N7!($<2 )#"FT<,:@*J(HP
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M(9M*TXF*6\.!\,TDEM9D[+<LRLH^<=!X%U?6W\9T.GV)=O\ F[A&#RKDX-M
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MBE_?V"E32N:K],O5BD?Q>:IX7SZO*]>CJNSX_8"TS([3'GTF5M<54$LM4?\
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M/Q 0DD+2S-YD*U*CQ2CQ2CQ2CQ2CQ2CQ2L2O>+V@V/3.A:'UGY%HB\QA\BC
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MLW0G-:VIZ@'/??Y@>G;]LXWQ7TC>?/M5U$?9^Y<UX#E(=ETZ^6DIRK02F!;
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M5[B$=,C([,Z&.NCD9%^^*"V[A#AF3B"^\2<-%I%DRRZC<G(!0?$+:)O]4TV
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M7R9K>@:WPW?-INO:7?:1?*@D]VOK>2WD>(LRK-%S@+-"S(ZK-$SQ,R,JN2K
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MMKZYLKX@H(T=(^3AFN\0:CQ!=M=7TS% S>[VJL1;6L9)Q'#'LH(& TA'B2$
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MPEW/"[_W%GY:F&1IBV<U3UC@OA5+=(>(]:B!3:32=/D'Q7+@92\F0[B%#RO
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MSJ45QJIM!(_B-'::=J5U<:#;8D+R&:/21=-)(S-<'"<DC>LG81?2SK4YY5?
M[@O5#*^MV<L0OY['G]\COPU^D'*^KS):21\BMM@W23?E@57Q-_= @0EUZCP;
MI6J:28M(L;6PUFQ626$PQQQ-JD9^*2&ZE(\2>Y.,QS32._, &;D=RN)U/7M:
MUIU?5]2O;\Q "%+B>1XH%Z<MM;Y$%O&,X$<$<2*,X7K6VNV]6_6OL15?K-1R
M[&Z XB0*Z&T=7$^J(MVN?&>,4999TFO=>B&-5DCDL)#1S!Y/J])(9%1> 7NA
M:9<S,UYI\)N(Y/C8HT,PDC;=93&4=B&!#+)GNK#M6TZ#[3>/N&K62QT;BG5;
M6RDA> 6CS+>6T4;H8S[M#>I<1VC*I^"2V6)XVPR,K &K'>9.M$H\4H\4H\4H
M\4JD/N1[AU?K?2UV6R0(FQ[CMH7LQ.,<]SQJX57/BEUNK2"6&46@!?'+^"#\
MPT]N3#+!!- (+9'@[APGPK+Q!-)<7+O:Z/:'_F[L##2/@$6MMD$-.^1S'#")
M"&8%F1'@G'_8G[_2L7PJC2W>JMNG=1TI6ZZEI$1;70F_5!JT;X5&4V>#:R*"
MLJA6.6&&$:$>/\:?6* >)SHE[ 7MX+6+3M.MUL].@_RX$_%(V<F6=R2TDK'=
MF8LQ.Y9B,UYDY[D ^??;TZ]/4#.,#&[N\MZ@GO\ D1MG&1_;;Z# H\5&!],#
M?YCYC)SZ]CMY'BGGG.=_Z8ZX/GU_*D4^>^CMJ6&O !(IYW&I>F$%OA+!:P='
M *$.V-S25F(^63(YR?1B(J?7Y5R>J"$QREW=91R>"JJ"KY;X^9L_#A=QYG\J
MG ZX]0,]M^Y\L;G<=CC>EKSRJ>WJ".VP_<[8._H.H PS]$S6T=WCNG<X(C$Z
M/S"\BTN7=,GR-9-:B1VE :W[Q_D"N@ON&3"LL32(7R"NEA82^:.XB%M/!=Z=
M?*6L-1A-O<@?BCR<QS(=\/$WQJV#RD!@"5 )2 23Y_7'7<'Z>IR>M;E>L_N1
MR?V2HQXJNU&RO20H6PZKE^@*B"TU/91(UA?\>.2L+[RI_-\J-8@,D5(G1L/@
M!+^XS.+<0\*:GP_,QEB:YT]R3;:E I>VEC.2G.RY$,O+^*-R-P2C.F&/H#G[
MV_/O4X_Z7YB*NU8 :&A3;"Z*T5E9?D%LBQ;H@V2PA/JA;P.UI09 "9%D"8RI
M?"V5/W)$9!DDQ,FL=<9WQTSOC((VSZ$CY$^=6<%BEJMZ+.>ZM);Z2:6:XAFS
M*KS.SL8EF66!%!8XC\$QL26D5W9F-=^V>X''/5S*UV<TFPEZ+TT&E!K*C#4,
MX]IN=19C"M"',NX1'30T#+$J!9CK"R_#]GN)?7AGSL:([:-!X1U?7I%:&$VM
M@"/&U&Z4QVT:#=C&6P9W"[A(LC)'.T:GFKVMXVM[>"%Y7G:&&*)IY,>),R(J
M&60C;GD(YW(V+$D #:L7+&[Z!UWH]UW/L,T*[2\&;6Y[-!O>ZGY]E(W2/#SU
M6Q[G_$R-E>\XC[OE((F*(GD>284Y>R0V]EI6GQ:/I8(M(6\2>X8#QKZY..>>
M4CJ,@!% "JJJJ@*B 5$YVZY.WSS], CIOMG<]PX//.HV_;?&>F1MGSV.,],C
MTIH;O'5^\R]EF;)[X83FQ/B*B8.^<0H>5DXY$/[F$B)KT>S\;W?C5_X9)6QO
MC>YLC;.^LH=0@-O,>5>>.19!;V-R\3QN&$D<6HVE]9F0 ,JO+:R^'S<Z!9%1
MUR^B:S<Z!J,>H6@\1XTFB> W.H6D=Q#-&R/#/-I=[87W@DE79(KR(2>&(YN>
M%GC;27].\?F':.603](H8MKW#D-R1CM;+T&SL]K+7(%)*F6O,U3Z8ZTJ<X ;
M1L@"BFS]=6126579OC:C58Y_).,>#K'0=626&.6[LKZ%+JQN;UO>'#%0+B,
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M3017)0'.=I99"!T P!Z8UMSC]<C8';Y]>OY=Z@.0.]71#G1V\#,ZRKE'(HW
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M-,#RJ:LC[';J@EBBNY(M36HY$EC.1H]BV/\ [_M[*"/Y5_\ W^3("T7X^O\
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M5'5UCN;CPRRN'"^'';111F,%"P8U8ZQ>Z?=31'3+,VD, 8!N5(S("P(YHT#
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MT]O':/=7#VL#,\-JTLAMHF<EG:. OX<;2$EG*("S$DDYS5MOTP1""^V>UM[
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MP.N"KQS#G#*1L5R2!CMBO%NI\CC'R.^V=_RVI]R5-7+8P6\M:!):C0O&&LY
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ML/GMUVW/ZCOGOVJL )HED&+8 $1E!&CQ%"DPN1\4X\[&R12L<G]*U['(J?\
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M4=SCIYD#R/G\CG]N@IX>LA4X'OAZ]J(YS5N,YU2JL6-5?^N!!B+RRB8_^O\
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MR!C8AZZNBD>Z6*L!#;,YY'YI7\,XDUV;B'59M0E3PHRJP6MN#D6]K%D11 C
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MN>W3?;ML=\9W[$39Z#Y2?H'N%?[N&%TN<XASDVE6Q:W[CKN-K/\ LV@Q2_\
M@_+%GWW;"TC59891FQ2M1LR+Y@^.;H6/"T%B3B?5[])?#)PWN=FO.7(ZX,X@
MY<[$-D'(Q5:[[_+'R (&1DXZG\OSWD\XG5='BE'BE'BE'BE<=B ):UYU6?$T
M@&R#* ,@=\HV80R!XY$3OC^_K)#(]B_']_#OZ\KC=HG21#AXW5T/DR$,I^A
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MK"L[*Z 5A4Y1+9B95*?_ (I1XI1XI1XI1XI1XI3:V..R_0,S<XW:4==I,QH
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M(YK7(B_#D1?E//%E*,RL,,I*L/(@X(VVV([4Z[CS..@V&.W3;J?F>V<='D4
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M5\KRL,7,+;F,)Q5KU_,4&$)MLJXNY=R*E!FG1RE)F@Q/MCRC-]3Q=;J=49F
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M>?I_OU%8NX+5,V66K+Q8_P!N9+&\6U#5KF/!MPGJ/8BOC?\ [X_H0QSXVO\
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MKK^YPC[,S5U-"5%H"*5U')'8R*@'/Y9_.E[ >W?*=A9BYFVL'Y?:V'2.M<^
MS+A;J^1K.:]YZAP2FO[V^JJ1U%D1.D:/E=\_&#ZDZI6YLHS<U2$WEI4&*JIS
M^FU33B.5<RYG+H9N=<^Q>%FUMI_-:B7(YFGSTNAMOB1$L;J2J#%?9%L_-/\
MCF+65\:SSJQ6K-*KE*?WBE'BE'BE'BE'BE9(>R?Z>6K,V]_UWU?O<_0V^I*?
M:;3E.I287(W]O*Y\A=U060J2+1V1\KEE) EA@!E*EG(BL@H7*"_J'#W'=O'9
MP:7Q%#//%;J([34[;E:Z@B  2&>-_P#.C0#"R*3(%"J8W;+U!&?U^>^?/Y[>
M7RJEUEQ_W)SSGQW/JIICV12?A<9E-?F]#&0_Y5/R#A 23EM@=\*J/D7X:BI]
MU3Y1?-QCUCA.< Q<26\9(SR75M<0%1C."SA5)[8'K5')]],;]>I_H?4;Y8]Q
M)V'(M67<^M7>,T&CFM6S9@[6VJ6N<COJV2S$@8(R1WU7ZQ)*]ZHBJC?A/+V)
MM)NCBSX@T6X<Y_E^^Q1RD#J1&S%R!GKC'3>HY3GKZ=]\= ,XR3Z''Z4U(NJ#
M$R?@$P?4S"?M]/VHN#MY2/O_ -F?C1/G[?\ \OS\_P#IY=-IY4<SWNG(N,\S
M7L07'GDG&/6IY=QCMOMC(/4 @G^I_+%/VHHO8G6)&[&^JO;+"(CZ(,7IL]-B
M*\C\B_[9(["\@051E1%7]RV1T351$<K?GY2QENM M21=\2:0A7/,MO.MY(N.
MH,<#%@V?].,_EBG*<=?([;DGSSMCY_F< 8<Q?'?<^LA4NQ]3M%**SX=*E-O,
MC<'1L541?QUH,LY14B*J?[(6I_2*Y51J*J6R:SPE(P2/B6W#'IXMG=1)GUD<
M*JCU)Q4\FP&>GD,?GY]OR^M1O:Z/=Y>5!MMP3N^1*^'?[;3F]VT:7Z.5KGB%
MNBAC+A^6K\3PM6)R?VURI\*N1BBL;D<UGK6C72Y_\+4("PV!^)>8E3O^$[^8
M%1R_F?(CY[ @>0SO\O*D.'JPQDB#UV#ZG9F*[Z-"!PEM.2Z7Y^J1)&GPOY%=
M_M1J?*_*_'_/GLVGE!S27NG1IU+O>1!0/,DGIC>HP<XR/7! ^?KC&,Y'7-3/
MC>'>W_7YXQ<7P^RYG4DK]7[/M3ILK&'"Y53]Q'EY1G7Y#T:J2PO' LH)/Z^T
M:QJCW8>\USA;2E+76L1ZA*!D6FD@718C_2;E6\!1G8\TD9&^-ZD*<=?7Y]QU
M'8]=CY#O6G_K%Z!8/A=S!TC<WA/7^S_C58MA>"-%ILNLK%;)!C,\Z8F"M?&U
MSH$MB))CU8LC@65,1) CN;<1<;WVM1-86D*Z7I.=[6%BTUP =C=SX4R [,8E
M C!V<RE585@8^_W\S_38>M_O-(J:/%*/%*/%*/%*/%*/%*/%*/%*/%*/%*^=
MWVLYC)ZU^RNB*<,X+D??;&?7Y2T5OXZJAWLWU?J\V1,B,'$4XV5UD"U?QM0,
MNO'C:]HI<T?>>%]2&O\ #]NG-SZIHJ+:7,?62:R48M;A1^)N5 (W.Y+HYVYE
M4T,OD/IV_MU[8Z[G:FBBHJ?*+\HO]HJ?\*G_ )^7]4;9R<D=CCKYG!SMU).#
MCTZ4>*G/H-\]=^HV&,[=OBV)V/G1XJGJ/7;OMC/0Y\MNF1CY$T>*D]L9[;[9
MWW\^O< 8/7;<FCQ3;.P)'UR.NXV '8[Y_?!XIVV\L_/MYX[X^1.=Q1XIL3C!
M'4]_IG()).W0]]MZ/%,[;_ML>O4Y[[CT.^<YRQ]+M8JHT'-4%<9K]_>SQ 9K
M$T,,MA=VEB4Y(Q6.%$9-...Z145TKXT<YC7K"R16/5MW!:F1'N)Y$M;*!2]Q
M=SL(X8XU&6/,Q 9L= #@$C)&14@$XZG?<[]^HS\L?L/79GT8]4R_7['VVQZ"
MHMEW#IZC66X/B5A$6<KF?]6KP]22BO:@=4US7V;Q7_MC+)K(XWDAUE;/YR#C
M+B9=<NX[6QYDT?3N:.S0Y4W$AVDO95V^.7&(PPYDC))"-+(H] , "KW^:74T
M>*4>*4>*4>*4>*4>*4>*4>*4EWE+5:2EM\[>!06=+?5A]-;UQ3$D&/K+,64(
M\,AB_P#CA)%GEAD;_P!V/5//2&:2WFBGA<QS02)-%(NS))$P>-U/8JRAAZBE
M?-]U[CFW]-M)89C65-Y><-(LB)N<]4  *L@*FM.F?./E=BX6.5]7:5ZND@AE
MF_VV#8W$ LD%^T8'T#I&L6?%=O'/;2PPZPL:B_TUW6-Y)$ 5KFUYB/%B?9B%
MW0L$?#;OYLOK\L_MY=>@[[G/DS!.F<\-8DD&WR_P[^T;/=UXDO\ ?_G 7/#,
MW_Z.C1?G^O+YK"]0X:TN/F(G8?FJD?K4 '?;RW.V?/&1W&?IUR:<@-W2V:*M
M;;U=@B)\JH)XA:(BK\(JJ/+)\)\_U\_^?G@\4L?^9%(G_P :,O\ ]P%4_MO@
M;_GTWZ;GH>@QC925[&I\N<UJ?^:N1$__ %JOQYYX)Z#-23L,D8'0#;/YCYY[
MY/3!!IOV&OR=2JI::;/USD^?EAMQ7C2?+?\ E$CF(8]SD_\ T4:KOG^OCY\]
MX[6YE_R[>9_5(G8?F%P*;^6XQTQT)SU'?IC';MUI)$Z9SPY_XQMKF72*OU:R
M2Y!'>]R_TB,:1-$Z15_[?1'>>C6%ZF[6EP!YB)R//<J#CZU."0?Q#N<Y[?D#
MG;'RQCO3O',$+8DHI0Q,;D^6R#SQ3,<G_FCXW.:J?_1?+9E920RLI'4,""/F
M"*C.^1CS^O7?Y#J!G?I@G;W/DCB:KY)&1L1%57O>UC41/^55SE1$1/\ NJK\
M>0 2< $GR R:G;8C]<=NF//&V=\DYP>IJ/[/IV6$.'I*B<K8:<Z9HE;EL8++
MI+RP-D7ZQ!P"UJ3HA$C_ (:V&21DJJJ?6-R_UY>)87#(990MK;H"TES=L+>&
M-!^)V>3E^$#<D @=R*C!.3\NH./,>GR&_7:KU^L_HCO>A:C/]8]H*@?-9+/D
MPW&-X8Z5#33K2)5>#<]&F;\0-8(OQ+%G$:^0B16PVD0(\9@%KI'$7&ME96\^
MF<.2M<7,ZM%=ZR!R(D9V>*P!RQ+C(-QL%&\1=BKQUA?3_<?+L/GN3UQT.T[6
MM:U&M1&M:B-:UJ(C6M1/A$1$_I$1/Z1$_I$_I/.0]>M5U^^*4>*5 _5N)F=!
MU&9W65Z9L.3[?-Y;:8--%DPLM;+88S?EY:QOJ\FJU]'?5+;BOM,;07&2T#1'
M$Y^R'+9*/:4UO<TUBI4:B^F^8CUI5W9=1ZS?98O=9OIY/.[BTRI%(=T3(<SR
M',,UK+;4,R,72[>PJ0,53ZB&$[;R!$;=JZ \<M8 Q1E*8.5_3FX968;08':?
MFZ-3W:<=&@2XRG/*:.J"X8>XW%$C5V=R-?4S:JVC>\#H6Q(!=<[2M6.JG>!3
MAUM:"I5M]ERO+['+YC'/CESU!D-=S/7T8&:AKZP8*;E6OS^RS5- (H,X0M$I
MF; KB@@QAWLJ72C@3@RI#/"I33ZMQ2?H.ERF[R_0]-RSH&2H-AC0]9F*W+7,
MY6*W\^:+U5"56ZZDO*U)7V>/R]]1VL$$)=3?4(,I#;2EGMZ&U4^_O[^55NO_
M -.CDVBL^E%V&HTY _4Z,@/1G6%'SN]WL6B.Y11\9LM;6=/T&+M-J$?:8ZA@
MFL!([']J7>V5\5,KZBX*HE4IVP>D60 W6.VM1T#:UC\GTC==-_;C5^'AN3;3
MH'=.A=^O\_#N0LH%M0,1;:CH]IF]!D/YLNCT&*K*BN,$CNUM]#;J5=GQ2CQ2
MCQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2CQ2
MCQ2CQ2CQ2CQ2CQ2H\ZCRGG_:,;9X'I>9 U.7M48Z< U)&2C%0_;]M85IH[XC
M:RS%5SE&L )QRHD?(QLGXI96/OM-U*^TF[COM/N'MKF+(5TP0RG'-'(C I)&
MV!S(ZLI(!QD A686B_2MLZJ>5./^R6PS5/\ D50L]N\Y5[>*OB57J@XUJPBH
ME_;0HK(H(75RR-C9\RD32?+EZ-;^TM) O\4T"UN)<?'/97$EF7.WQ-$5E',3
MEF(D ). H'2,>7IW(SCY?V_VCX_]-WVM :Z6E[_RW12-:Y6"Z#&6-##(YJ?+
M&.GJ!;*5J2.1&/=_\C7*Y/LY$3S()[0>&WVFT34H 3^*"[BF(!V)Q*T8.!N!
MW.QVZTE!^VV?(8'8GY[TPBO3+WQ!E>,W*</N?JJ-;8UFSM10G)\?^/\ !:Q!
MG*G_ )HL,:_/_#?CX\OEXOX,=0QN=7AR-XY+.-G!\N:-G3_]QZ=:%>@!.,CZ
M8S^^?S].CDJOT_\ W3O4:MYN.#82%Z-55J6ZS2V4*.5$>CH3*EM<^:-/E6HP
MQT+W)\+(B+\I;R\=<)0Y\&SUJ](S_F>[6\;>6"LQD /J@('8FIY1V[8(^GT[
M]_TJ1&?I?=;> LT_MB]EVJ_*0C\JJDIT_P"_Q_NOFD?'S_\ V$^4_P"W_;S'
MGVD:;XA"\-?R>Q;4I/%_(0<O3_SX_>G*-OUZ_+;?RSYTQ;3]/+W&HWK_ ([U
M/B&Z@15^JZBLT^4+<Q$14_Z5'5'CH]5^6M12E;\(CGO3Y^$OH^/N%9O\_3=8
MLV[^[O;7* _.66-O+_2.IP-MXY!G;(^1W_;/Z_2F<GIM[X_E_;+C>**JN1$L
M4VU@@+45?C[.'5JGJUO_ "Y&Q?94_P#"U5_KRZ_XOX,Y>;WO5O\ _7[FG.?0
M-GP]^@RV/,T(W[_/;H1N#N#Z]-N@&-JDG+_IM>QNK(C3JW;L3@Z5Z_!E9R6G
MM+FWGA7_ ,44%WI1ZE]=*YJ?5I$2&)&Y[GN@F1C6/Q]S[0M!ME_]6:1>7DP'
MPR:G+'#$&\VAMVE\0#KRDIG &1G(GE'TSG^P^7YYR3M6C?K_ .H/#O6Z&4G
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MSO(]!8;RPGYAG\)@C3L Q3/ED=.A]""?KGIY;9[UUXS]/#O&6LW6FGU>![$
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MZ+^J1NZB+_%Z_+\]K-2T7:8+525>IDFO,MT>L-[ID:W69ZKV=?2Q7F;30<E
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M->!KK:G;<YZ+HW/<?7Z/$KK1Z( ?\M1O''%U<%UN=5%H*1M1!CYJ.ZAU5>J
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MS_"]?Z/';=HK,N^MI^67MQF> <XTU[66$M&)SW6;<'/3MJ&U&K"JI5-L]-@
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M&3#F"N(4((ZTF\<]H^9]3QSNB6V:L^(UEA2DZBL;V*]XY476@QF:LQJ"PV<
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9'BE'BE'BE'BE'BE'BE'BE'BE'BE'BE?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g69956g97x73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g97x73.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1B@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &(2^8G8X0DE-! 0      %T< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<<
M 5H  QLE1QP!6@ #&R5'' (   (  !P"4  -36%R>2!-;WEN:6AA;AP"!0 7
M4&]W97)0;VEN="!0<F5S96YT871I;VX .$))300E       0W]G\S.ZD#3;D
MLH/G^K#ZS3A"24T$.@     !"P   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M         #^    X0DE-! T       0   !X.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         !.$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       "O@  !V0          0                         !
M      =D   "O@                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   "O@    !29VAT;&]N9P  !V0    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   KX
M4F=H=&QO;F<   =D     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    1.$))300,      W>     0   *     [   !X   ;J
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M$;2RS\W57DQ (@B1X%%;;F,Q,\FN>I/=M?N>!54-S00?3,-]GT<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MH;'P&"5"P1DF,T/1"C0U1%)B<N$H*39C>'F3H[6W\?_$ !T! 0  !P$!
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M^?7K\?RZ4[IK["?E3WS?K'_Q+TP?M*\^O'.?#&/R^5.Z:^PGY4]\WZQ_\2]
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M=:P_=NL^OI1'(]TZ(!DRO&]BJ1'7%=7,:C2#]Q7B<O4<XX(QX\#(\\\<].G
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M!45%3_A^Y45/THOE/ITR#4@(/3^A']?A3J-1IT/Z_7]?Y\4ITI7WPOY*^/\
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M)^7J\-"^;'(&^/!GSYEQ'FC8-SS*H?;>-XV^JPES#%>+3:=Z&(;LAW<,J4H
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MTC&3P3C&?+/XF5NH<%T[1[.GS%<-C'2!444**/T>'2&$O+Y3C<Q7O8!IAU,
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MNRV1O+)4^3SM501E\*Z5H;5DN:UK6*KU;5TJ&B$7W'#"U/MYB_0Y7-](QM-
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M1)/S-5'J-2TZ4ITI3I2G2E.E*=*4Z4ITI4=N<EF-"J/NJ&KL3-:YHY9X85G
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MZ#)"02"JLQ^"A4E_Q!Q5?5G$LVYEVW&V.M%MY=/GXK)9[*@JWF.RQOK"))(
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MT1$1$1/PZC5K7ZZ4ITI3I2G2E.E*=*4Z4ITI3I2J9:TE->1UB7556VT5?/\
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M9$6$ <L_C_Q29GH67)>JJJN)(,1[G.<YSE<YRK4QBK5Q]YXY==6OW*42!SG
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MFLXZX^';W>@'A,:R^TL*36Z.[9F*1MOH*Z:@6S(%W9-@I,M84ML>.V3%GFD
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M@D@I ^0\.E87MW[.8\1J)VHZ<$5.FM5.1W'H<)"C&MMPE,!XHC/H!8=CNGJ
MI+B'204J"B4['NZWN3Q7:SP[?\E[":\<ES24F.J8T=DR??[&=#E$IZZ-$)(B
ML($;XY)UF8L@(HU9$E%5ZD00B['=;DQ:X;LI]81@*2T,9+CQ2HH0!XYVDG)
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MD;D*4,C.:M-VH=KN-[1^+B\68B\T6BJY.INM7)M-,6&2P+.N!P8JA8.!&B1
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MT$?+\IYP&$GP8U]HG[2HAQZC,C'8PY,:0MZRZAQ5+YKB5ZH^>2SK8<>:=GT
MU;>]+Q]''5U]D.)T_#B1;TEU@A3CZ)3;8AMLH_ZKLI4EIEA *=SCJ<J2,J'S
M^[*)W:%IC7TS2^B68B=47@SM+24SF2IN*F+(4Y.?4YD*C(A^A.//.@**6VE
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MWGVY+ZD1XJWGW&VU5'=\HX3C0-6;9WS:IUV:4&HB1ZZVN[.Q6#'278&AU%#
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M^$]$O<N.M*DI,=UN-*:0XIKNS9W7=GUMJY-G:EV=)!U]K-K&'WU7F 4V@CU
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MNT#23XN/?7N!;C:YL^%*3<YD.&I(MUR;M#LU/>2"!;WK@ZU%C2G"VAYYUMH
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M=<XX^8 =NP,;EO.)J,UH\E,]0H6ASMO9QP4Q#YFPD$4K/_M[[O\ 4=YW&/+
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MHUM=4WJY6E4R5;51[C'N,VX09$*=#^E9]&]93HJVU-K;?BRG$$-N!MQ$"O\
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M17D*_>2II025#(WI4,G%>N.S[536M-(6:_H* _*C):GM(Q]!<8WT,QHI!44
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M-B(\TMM([QXN,30XHE"7$IW'B>H^S76E@,>U76UK[3](%Y#$&0PC9JJRH<4
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M"GGE[-C3:2M:@.N<LFF[WJ-R0U9;>]/<B-)>D)9V#NVU+#:22M21E2C@ $G
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MTE0)1%2Z5+4IB)N6 =Z@Z^M]_/TH"<BN[+MFP/=SP7M.$N0@,9 T4+YBCOF
M$:PR.K@(XU!J*MQ/"LDULSPDD+"";8UAI]5(?\K..UV#TOJ2=I.]PKW 5])%
M<^F94<-28ZN'H[R?JJ0M/*=P4$.I;< W(36T:STG;M:Z>G6"Y) 1*051I(0E
M;T&:A*O1YC&X<.-*44J *>\96ZR2$N*K4;V=?# Y?'<<'<J=SNAF\?<R]I_(
M,K,X748*YI+8_-'!U%" _(T^QL(LN26+"K9DZ\SU7*E-#?2N/3,RES51P1:L
M\3IFJNT>T"->+5I:.E^P:FA,RY<"?&[E-CO+JE"2+<G<ZG80EIY0;6&C+4MY
MI?M$'CNA^R.[-2=/W?54I^)J#1DYVW6V?"?;<<OFFXZ!Z''N!;=60EMQQ]MI
MUY2Y2X12P^VC:WW?H"ZXE7HNN,RD0)5#[:&0;_:]U507N^E?;]Q6HKD9Z_'K
M5$54;Y\(J_3H" 05?5!&><<>/)XJ!W8.W&[!VYZ;L<9]V:\BV@^&!WC1N,,5
M@-?QV*^T'./?=,Y,YDN,M=T=Y SO']741*S.7^@L RFC%72B:_E>U8K_ 'B1
MA$KH\N+#M+-L!WJ)CM*TD9TV?#EJ8CVG0OJNUM2VUL.R+A)D!UYB.V$N)/HZ
M&(;&_.7>Z*T)[L$H\8N=CVMV[5:K/<(B9KM][1E7O43T1QI]IBW1(A9CR7WM
MR5XD.2+@\EO:=G>H2ONW/97ZZ !%' &.!C!  (80C&U&L&(3$8-C&I]&L8QJ
M-:U/HB(B)].O+RE%:E*4<J42I1/4DG))^)->S4I2A*4) "4I"4@= E(P /<
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M"I1>J0%" &\K?+W[-,65)A:R4RRE:&YEA1E"VP58M:P2&RH*VY(VJ2DI6"%
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M9("'%8Y QG: <$]>AQD$@YKAYN*NHB/$8!R5M#@C=G&X^'\^.O%=)O,?(JB
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M*=ZEEQ1"QE+J2,%655Q=R0EM^_O6R4OTF;*1':WK4EQ33CA[Q:"25!*<)Z$
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MH/U1@\FO6#P-/XS[:^,,5PG4<8;#BW$X> RFIC?+$VU*YL@IILJVM]%G6S+
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M2R"XM)^C.4!*5*4O( "4#=OP$]$CF,RW_P#JKL>"-[JU^SL^HG'))7D[0 %
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M#D8,0$_&<M4G(%4H!N"'7T]/9)(&-Q'L1FAQY<R6*^5'82*>3+A7BQYL=3J
MOB3%ZQ;T2+A7>1W(Z\@9;*BE/M *&U>X'_+RD>T!Y%60:?D)4"AY,E)2LAL[
M=Q*4*7PM !SA*LC"B2G:.3QBSQQR7,WG<7H.5MIE+J11Y$A(%<3'@+K8<4XH
M4BAS165[0P[\L C":FV&2'329++*V@*8 V.CR"^1>S^)_P#$SMFU%JQ"R;9I
MLRS;''I"$1)3$(2K%I]M&X]VI)C/Z@U($#/T]YAN)<)CH*N[:FD)TGV>VBR=
MPXW-O<@)F+9*E+6@*]/DK>922ML+6+?"7O'LB#W:@?:K,GE',\+]X/"_)/!5
MAK63,KR3EY>7UD+/38-?K:^KL_0\[7U-W7RI-9*>@E&\=O1O;]#"+'5[7M;Z
MA?A/QDA+S#C2%#V3MPVH'G*%IRA0.<Y23UKCK4EMW:XVXE9/(R3NXR.4G"AC
M!'('3W5:;D[X>' /(UAF1UH+?B;"T^.T7'NDXIX<KL)@^/\ D3$:O:8S?Z'-
MZR!#Q<BVB0[G18.A=;RL=<96VLZU;&KFV)HEC(8ZC52KXS^VGB8MGQE94.=B
MXAG%O,5USI4UN+A55%5W?(&BPFXX^NK/2Q0U[_M'[2J=];S9A@OB3Y%K&KI)
MIKP@-&D*5?WI2G2E.E*=*4Z4J-Z?89?%U_VIJKZLHH2O]H1;"4,+Y1U:Y[8L
M&.JK)GS"-:Y10X03RC>E4$%ZIXZK,L/2%]VPTMU?7"!G \U'HE/FI1 'B:IN
M.MLI*W%I0D=2HX^X>9]PYJR<[EG;ZM4#QYE64%694]O8<A D1BE$Y$]LM;B
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M(D-/DM][Z5P8/UD%:0EKGC@(.?'J1C9$A6 7Y002?^2@!(P<#!(7N7USRE0
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MC<J;1HZ2Q$U!#=D.I9;]M/>+("0I2<)!)X&3P,XYQ6*O:'%V]X-(WJR#MZG
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MNE4CWD(9U<J9? 3*220,)>0!W@.#@KZ=X <9Y"O$*R!B 7(CG='6"#RI"E<
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MQ&*I%98-FRKD'J3U5MHD!4]2>6^:RMG*GI1$5%3YWSZE3S]41WCZIU(A845
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MW1(=2&A@D[2,E:^0E.XJX!*E^83G??3Y#H=;;9 2DLH6'%#:!N!QMSC/ '7
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M'C?(Q<Y,OJ^(>!#LS DRI#I,:))*<X!.^81J#*5[D5JJJ^%3JY\ !G  '/N
M']JLU'<HJQ@JYZ8\_#YUD'TJ'Z'Z_P#%1'D.2>'A];*BF+&DQZ&P,"0 C@F
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M]6R?X?A^\1\1@)I]T+W]E'_,Q_ZG3UE%\U_@/YU#U9)_A_C/^FGW0O?V4?\
M,Q_ZG3UE%\U_@/YT]6R?X?XS_II]T+W]E'_,Q_ZG3UE%\U_@/YT-MD_PQ\%'
M_33[H7O[*/\ F8_]3IZRB^:_P'\Z>K9/\//_ '?U]GG]?>^Z%[^RC_F8_P#4
MZ>LHOFO\!_.GJR3_  _QG_33[H7O[*/^9C_U.GK*+YK_  '\Z>K9/\/\1_TU
M^"9"]]LG^%'_ +#O_K,?_P"RO_[SIZRB^:_P'\Z>K9/'_+_%_P#CS]]:Z?A+
M9BXE?#\X".&.QPR#Y,1JJ<+%7T<Q<@,=^2]Z.3ZL7QY3ZIX7\_5)F?'0TA"B
ML%*EDX3D>THD#K[\U7?@/N/.+3LVJ0TD95@Y0#NR,'SXK8S]T+W]E'_,Q_ZG
M57UE%\U_@/YU0]6R?X?XS_II]T+W]E'_ #,?^IT]91?-?X#^=/5DG^'^,_Z:
MUS_#US5O)M._=H8['+&^(?S_ !R^3A;X*RAXW5R)ZGIY3PY%1R?145%153J5
M%QC#=DKY4HCV/ DX\:J+M\A6,=W]5(/M'J-V?W??6QC[H7O[*/\ F8_]3J;U
ME%\U_@/YU3]6R?X?XS_IK[]T+WPO^%%_K)!]/_[B_P"7^OXHGGIZRB^:_P !
M_.AMLG:!]']8'Z_&./=GPK6Y\-[-6TJ+WRJ&.QWL?$=[JHY$4XFJA16N8];4
M]3D]2)ZD\.1?2OXIY^G4J;C&&25+Y_R>\^1('P_VS6>@2%ELIV>R "2K!R!C
M..0<']> V1?="]_91_S,?^IU-ZRB^:_P'\ZI&VR,G'=@'/[_ ,OW?A3[H7O[
M*/\ F8_]3IZRB^:_P'\ZAZMD_P /\1_TT^Z%[^RC_F8_]3IZRB^:_P !_.GJ
MV3_#_$?]/]*?="]_91_S,?\ J=/647S7^ _G3U;)_A_C/^FGW0O?V4?\S'_J
M=/647S7^ _G3U9)_A_C/^FGW0O?V4?\ ,Q_ZG3UE%\U_@/YT]6R<?]/\1]_N
M_7W<ONA>_LH_YF/_ %.GK*+YK_ ?SIZMD_P_QG_31,A>^4_PH_YF/_YDZ>LH
MOFO\!_.GJV3_  _QG_355#F;4=/-B+''\P:9%*-/?"JN&)#^I5?Z_">GW?HU
M53_:=X3ZKU;+FL*E-.@JV(;6E7L8.5=  .OGX#[ZNT0WDQ7&3MWJ[O'M<>SU
MR?R'W>-4K[H7O[*/^9C_ -3JY]91?-?X#^=6GJV3_#_&?]-/NA>_LH_YF/\
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ME/P5?'T7PGAZRB^:_P !_.H^K9&#_P O/&/;/WY]FJM=9JUERQ$C1QN$R%$
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M<O!Z>P?M+.?O"A[_ # J[%MDX'_+_P"4RGZ_12-VX=/#(Y&0?.GW0O?V4?\
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M5^(/_P#S(>XC_P#P7&WX?]?CYZ4K9;TI3I2M9'PRU18O?IX7S_\ K+>[-/\
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M_E'E'AR582ZV4S=\.7=-GMW7-KIHICXE=:7^>U-8&)9-$L.R&6F.\T,I1A(
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MEQ/V&\:\3]V7+?='4'4\WD*O N=RSXZ,@8B^N72'\@V]:[UN&K]*4<0D1!"
MZM%/OX3%=%FB:/6X&FXT&^W.]H==6Y<$MA+"EN%J.K'TZD(*RC+B@%)(2"@*
M<2/94,=PU7VY:AU7V2Z+[*I<=AN)I.4^M^Z(2UZ3=H;"0W8H;V&@MM%K9<DM
MK*7"99$9U_<XR",[>MDKA].E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I2G2E.E*=
M*4Z4ITI6/W<OP'3=Q?&%A@[&9]D63)<6VSE^T;BDI[:*]6J11L>-YHLR$65
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M88 ?>D,(0I;KB2ASO(KHVK"<X24E63B2!K73-QC.36+O"1 :9CO+G294:+%
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MU:M8N<I2MLO6UJUJ+0HE@*7$9E6M,-*U*RII];Q;"TA"H^?X8U$:TFR$YFT
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MI;@*3WC:Y++JG4N1E)2V9GM^U&NVW,\KEV;K6C;*6@<N9/F03X[7T/&/,''
MGK8%MQH]Q4Y9?=M5:Y% 6@'":K_M%9D&\FZ:1-NIN:Y0 )9)C*CAQ)[FW76
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MY ]T:O5^SUJJ/='+7(TG#GW'M([1)S6G?64;3]J5<;?98MLT]MO[98=@:#U
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..I3I2G2E.E*=*4Z4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g69956g98y91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69956g98y91.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2<X4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )QR^$ $CA"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M   !#-S_I]J,>^"05P=JZO!<-..$))300Z      #E    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4
M!R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0F
MQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M   BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W
M!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;V
MP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $
M5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D
M="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M       $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M      0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&R;$F
M         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M  4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'
M0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E
M!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F
M]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  Y-B3  $  0#DV)
M,  0 !.$))300F       .             #^    X0DE-! T       0
M >.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "
MT    &       !.$))30/X      !P  #___________________________
M__ ^@     _____________________________P/H     /____________
M________________\#Z     #_____________________________ ^@  #
MA"24T$"       $     $   )    "0      X0DE-!!X       0     .$
M))300:      ,U    !@             "9@  !:,          0
M                 !              6C   "9@
M !                         !     !        ;G5L;     (    &8F
M]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M  3&5F=&QO;F<          $)T;VUL;VYG   "9@    !29VAT;&]N9P  !:
M,    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M=S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F
M5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP96
M5N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M      4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M    !"=&]M;&]N9P   F8     4F=H=&QO;F<   6C     W5R;%1%6%0
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MEC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M  "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M  .$))3001       ! 0 X0DE-!!0       0    #.$))300,     !T%
M   0   *    !$   !X   ?X   !SI !@  ?_8_^(,6$E#0U]04D]&24Q%
M$!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E
M0     245#('-21T(               $  /;6  $     TRU(4" @
M                                                         18W
M!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0
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M(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M   %A96B        #S40 !     1;,6%E:(                     !865
MH@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M   "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V
M@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                              9&5S8P
M N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D
M="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7
M(@<W!A8V4@+2!S4D="                             &1E<V,
M  +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C
M$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@24
M5#-C$Y-C8M,BXQ                                  !V:65W
M 3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %
M<?YVUE87,          0                        */     G-I9R
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M$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-=
MV.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^
MP0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!
M*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7
M@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BA
MBO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'
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M:+IOVG;J?@J%*HQ*DWJ:F@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                    _^%"1VAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP
M37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A
M9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P
M,3$@-C8N,30U-C8Q+" R,#$R+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@
M(" \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO
M,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B/@H@(" @(" @(" \>&UP.DUO9&EF>41A
M=&4^,C R,"TP."TP-%0Q-SHS,CHQ.2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^
M"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(P+3 X+3 T5#$W.C,P.C0X
M*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C R,"TP."TP-%0Q-SHS,CHQ.2LP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y4;W5C:%5P(#<N,#PO
M>&UP.D-R96%T;W)4;V]L/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*
M(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z
M<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @
M(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C P,D5&039%-#9$-D5!
M,3$X-$0S.$8S,C=$-C!%-D5%/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D,P1C0V,#4W-$%$-D5!,3$X
M-$0S.$8S,C=$-C!%-D5%/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \
M>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z96$U93 X.60M.&5C92TT
M,#AE+3AD,3$M,F$R-F5C-V9E.64R/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#I&1C)$1D$V130V1#9%03$Q.#1$,SA&,S(W1#8P
M139%13PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,"TP."TP-%0Q-SHS,CHQ,2LP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O
M;2!A<'!L:6-A=&EO;B]P9&8@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H
M;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E
M<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO<&1F('1O
M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M
M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C P
M,D5&039%-#9$-D5!,3$X-$0S.$8S,C=$-C!%-D5%/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 X+3 T
M5#$W.C,R.C$Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z0D9&-#8P-3<T040V14$Q,3@T
M1#,X1C,R-T0V,$4V144\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,#@M,#14,3<Z,S(Z,3DK,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E
M9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A
M;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T
M;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M
M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D,P
M1C0V,#4W-$%$-D5!,3$X-$0S.$8S,C=$-C!%-D5%/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3 X+3 T
M5#$W.C,R.C$Y*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R
M;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12
M968Z:6YS=&%N8V5)1#YX;7 N:6ED.D)&1C0V,#4W-$%$-D5!,3$X-$0S.$8S
M,C=$-C!%-D5%/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \<W12
M968Z9&]C=6UE;G1)1#YX;7 N9&ED.C P,D5&039%-#9$-D5!,3$X-$0S.$8S
M,C=$-C!%-D5%/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12
M968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z96$U93 X.60M.&5C92TT,#AE
M+3AD,3$M,F$R-F5C-V9E.64R/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/E1O=6-H57 @-RXP
M/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P
M+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T
M;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 0("70,!
M$0 "$0$#$0'_Q  >  $  00# 0$             "04&!P@"! H# ?_$ %(0
M  $$ @(! P,!! 8&! H'"00" P4& 0< "!$)$A,4(3$5%D%181<B(S)Q@7F1
MH;'!\!@9);4*)"<S0EFSM-'A*30W0V*6U_$Y15-89'B#N/_$ !P! 0 " P$!
M 0             ! P($!08'"/_$ $$1  $$ 0(#!08%! (! P,% 0$  @,1
M!!(A!3%!$U%A<? &(H&1H;$4,L'1X0<5(_%"4B0S8I((4W(60T14@K+_V@ ,
M P$  A$#$0 _ /?QPB<(G"*DR$]!Q*TM2<Q&1[J\8RAHPX89Q>,Y\8REMYU"
MLXSG[85C'C^?">O7DN\,4,:RD@0A@H=SS\;X[K;[2\8^V?:XTI2%>,^<9\*S
M]\<(K/,V50H^_0^JSK=7A-D6"N2UP@J.1+!M6B8JT$:#&S5AC(5;N#S8B*/D
MXX21.886P(^:,V\M.74^2+[TC8-(V3%&SE!M4!<(:.L%AJATI7)4.8 %LM2F
M#*]9X)XL%UYE$I 3L>=$2P>5_,%("$"OI0\TM*2+Z3E\IU:F8FO3UDAXJ=GA
M7386'./''D941FQ5.HOE !N+P^2.Q9[W38)]YI"FV9.SP@CBDNR Z5E%_>OI
M:NSSCQ[OW>//^7CSPI6$:/V4T%LJ[SFM:%M_7UMOM;5)IF*G 6F)DYL7]#.3
M%SJD!"DN.%H@95:(N<<"P0W#R*VP9)0I3B6<D63S;57(VP0M4/FHT.R602:/
MK\&08PU*305<3&JGBXT%:\$%CP^)B+_4764+0)F0#P]E'U#7N)Z]>OLK@X1.
M$3A$X1.$3A$X1.$3A$X1.$7R?7EMI:TXRK*<><)Q^<Y\X^V/QS%Y<UCW-&IS
M6/<UO_8M:2&_$BOBH/3I9:+[K(%_"[_0\E#CLGO'OF(NLQ$!0D-3!H:2,%:@
MY6'>,DGF1W_8VJ4(+*3A[+J$9RAZ,0$.M#BLLN.XPV0K\#>VG_U+?U)X+[1Y
M_#\7@_"^$8V#EOA9A\3QGS964UDCV![9#(S_ !R 6W0W3^4V>2_8GLK_ $$]
MAN+\ P^(3\=XCQ'(R\9DTF9PZ:&/!Q2YK'.A,9AD<9VN<03))8#'VP7M(CUM
MVE:]NZU8MMPK.:Q*+.)$;2TE]L&8$9:96U,Q;!CCA3 ;SKKPF$$.O>YX-YQH
MAYA;3F?U;_2;VRXS[<>R6-QKCG!W\)S9)'-/YACY;;)$^*UY+FQ50TDFB=B=
MU^=/ZA^S7"_9/VGS.#<(XH.*X>.R,B8Z3+&\Z@^&8Q^XZ1E#46@#?E=K!%TW
M-NVB=MM2U8R=JTSHC;%WFM;N! T$W#%')C-.VFZQ"9O:#5T-(7MRR;"KS<8#
M4"J/'4MS6QV'\S@=X#CV+7].7AOE7?\ ;Z=5A/LQZA%SH%.[*)I6K3Z_G7@G
M975VO=MS4]79D KL%IGJW=>RT6@K7#6,GOT$BLU"5;5-'2PIS]AB%P;U?;C9
M 6><)OZY58^M<OU5*USW+WA==W](=9+?J[04XYL;77;K*856"#MSUF@]DQ@H
MZCO9*7^ST5%;#ZH[+EI09])!!5?L=);8<2PX0X1)JCW@\]^7ER^MJ?X]>N2E
MZY"+5#IW<+3=M=[,D[;.R%@/B^UW<FGQI<D^HA\*KT?M)MFHU&"86K&/9'5Z
MM0T5"QC&/.!P 1V4Y]J,<)Z]>@MK^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1=8HP0)#3A9+ R'B&!&5$/-LI=**<2R..WEQ2<+??=4E
MMEE.<N.N9PA"5*SC'"+L8SYQC/\ 'A%C?9NUZCJ6,A).VJG5ILMFBZ;7X^N5
MBQ6V8E[+--&O1L6)$UJ,E#_+[,<:\\:^PS' L#N$'F"CIR[@BQ]0.U&G-KV6
M+JFLYF9O,D97Z[:9DF!JUC5"T>$M]5'N537?IN0C (RI35C@3HPR*J$J2U<W
M&9,,M^O,1_U)HY/AZ]?[6H]L]1B1KL.])HT7*Y5.EU28UB\;;)F0AK1JZVD;
M89"V%;W-;:VV5;*&H=G4<@:7!#TJW(&8NE!:-G!"3[2Q42>O7JU(]3K$-;JG
M6K4&1$F!V2!AYX0N!EDST$4-,1HTBP1"SB!043,2\T2ER.E4@A)D U,EX$'P
M]\22>O7\JY.$6@^U_40T_IHF^&W&D;<S0-?SMYI4EMF*@Z<=1)796NM73FWK
M-K:"'7>Q[Z586*I6IX,2:-H\=K\NVQCU.;NN+"X. \3UZ]?98RO7JT=>-89D
M8O8]0V10+S%66;@B]=7FP=>*98?TR!UMK;:Y=M$G[1ON(UI)1)-2VW0UQE=C
M;\9LF1E98F($H;AD--HCB++5Q]1OJS58!JS1=X:V1%/:_LM\RG5YE<N$L(_!
MU0*ZPE E:^/8!IV$V3L6NOR)>O*O,QP'ZZ[6[&*4=%D1R4$$5D["]4;KIKIV
M.*D8R[RE5E)IB)!O(INIH"MRHSD;09$B8J0U_P!J4RU;';C7+ZB+E:WK&M72
M_P ?*5:TM$4Y C=?,L)%L;JCM-KG<5OQ1JI'VIJQA5JX6*U!R@$4RBB/TO:,
MSIX^M6UT*;/P)8Y*ZU6Z#00\9B5C9$"EV*0S*L,MQV)(H!O]/'8;J.0CU5).
MQUCN2_JD?2=UNNG1FK%H*O#WS]13<*H/NJ;Z^RJMJ,0IYDE5)-%UKC%L%6.*
M,VG7VS=<DY#+DT2Z72GZ6KR&]2.U;$V;5=1ZJI]>@+;L832U7B&]EB3)!>JM
ML6B4[8*W76=I0,--Q#LFYJR'ZL6,**A827@W+79S VV+,/7Y@"8:*/CM\/5?
M7Q62H_N%M'7>_P".T+O5K6Y[,;=JA3K5M6CPUAJ->*9W5KN\7#1\^W5IZXWD
MFD?5VW4&S=96F#E;7:LE2Q^M9V&FA6+(=$ D!O[_  Z?-8@V%ZI@VKH[K-.7
M!&JX&+WI+3FU9P6S7!FKS,#U&DMMUW66LKM AS<P*38-CSL!L6H;9EZ^&$0E
M-1IFUH8"%Q,QD42LI]>OY^]+?G>7:W6O7LIT._ 6Q;[VM;ALBNH@HZ,D,W/]
MB[%1ZH;0ZO@B: R5L27G=CTL&MP)^(T*:7-86/,81'RR@"CO]?/N_;Y*V.L_
M=/6?:BP;/KE#KES@)#5,TJ#L#5Q+UL@]TM$]9:^YA^M5#8MQN-,)216"#T0>
MTJY0+,_#R<-)CP;HY;ZA"7Z^7[K<#A2G")PB<(G")PB<(G")PB<@D#FBUON.
MCI&>L$E-1\ZQA,D2LIQB2;?RZPXO.,Y;:?:^9+C*/[K*<MM?"TE#6,+QCSR5
M&^WJAUZ=-@._G6Q62-;T)=$CC!GY1<B0<0V0[A"%-!CY;:RWA S2U+7[EY5G
M+SZLI4]A#*<MHPUCR3]/7V^6X[U'-W0T!V4L_8^D=C^N=3B9J\Z=U"]"T%Z<
ML,#"Q<M9[?>7ZK<Z](YD#V3&!0M5W"SW8$EP5,878ZK 1N3$G/L,\*5I+)]&
M.[&K4UW7VFP[CG6$#)[(B]:$5JY0HDKKJTE[?,EH7>%Y(_Z2FFPSAK31'JL;
ME3]%[&S,:35[-#RNFW0KC+Q5D)Z] _7JLIQG6;MZQM6 N#.M=JB;#JAID9L#
M<DWV"KQU'V\'->H#U*VZ2;K2LM[7G[%0*@3UZUIL$"UUXK7NNUE0L:'K=%9L
MXP56%DIO8^)NN@Y_>_HGK[^OJLH]"=(]Q8"1[(1^]X"_ZLKVQM&:FK=.S8[W
M'7-N$W''/[M$V=:8)+/:;LS.G/D 6K7"_P!NCI[7I-]171"Y#7E/D8[(:H45
M][]??S5HWC2?:6]=;]":&HN@K;J#975K4^QX]G:+%XU=%U^9NL/U(VOU\I4-
MI&;KUX*L^6MGW*_PMO%G;;"4%BI5F"(>MBX*ZMQ48DGK;Q[QX?'96/OCK9N+
M3EXV7M"-N%@UGH_5%8V->]5[)V!O,^;8K=_.U[U3DZ_"&R5MN\W?<UC9&ZM4
MV* L]7SA\:PJF)UC]-(9N8^)8I'KIZ]<E+;U.B-B@:1J\YMQV73LS8A$WM2Y
M0LR:2:_29/94W(7(;6HWSN.,C@ZPB)B-UZ*R#AD)Q-:R6RSC)2W72@>CWCS6
MR'"E.$3A$X1.$3A$X1.$3A$X1<5*PE.5*SC&,8^^59\8Q^[[Y_AR'<CR^/+X
MIZ]>2UJO/8CK56+%B$NFQM?C6.-*^%X0IYF4*B"TK]JF"UB"FHB24*QX=P8X
M,ZSG'ES"?SS?A]A^)<7;%G-]G),RB70RNQRYIK?7$YS1J=OMI!V)W( *TW\:
MQ<;6P<09" =,A;*!I-_D> =KWL7M7>-LO-VVC3]'DK8/:H4RANP,F>;:8^=:
M'AAX,40K,M(9GPB6$Q[( [)2RCVC&'(Y0[KF71G1U*1K3XL^',_&R87X\\--
MD@E:6/C(L %CJ+>5#8 U86Q%+'.P2Q2"5CMVR V'7O=C8^/CMSM:IZ/I'2_;
M5S=WSJ( 6Q7:H2$8"=+2Q>Q@9.)LB=>Q=;@;C,T6^D@HS=IC51\3&PVVI.L.
M6ZUZ_D!&@K=*5PWVO5+/GZ^7EW@_JN]N:B],HR1J.J]R1M9&D>RFT=COU*MR
MA=J;7L/:-TTI;-;;#R*3%E?")(S6F)ZU5LEH@N, ^AD'/TM#,XL)[!3]?7P5
M8U+4^HUPV?M:;U1%U64V;JSL"=:-JG0R)X8NO=@)+3(^M9&1D5$*'BS)ES4,
M_BO&-1V#H5E<C(ONLLVG,D0@H]<CR^?UZK;_ (4K2WHI_P#9;MK_ /S2[Y__
M /8V[./7KUNG?ZK8?[^*W2X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A%A#=77[5/8 >D [2A7)MC7=^K^S*NVQ*'Q*Q+76<D+B'RG(X@5
MR2BTND?,;!'J)AI1; V)((MMA",%&UGR'W->OX6;$93[<82K"L8QC[X\>,X_
M=G[><??^./MG/GA3]5K[V'UU5MAP]$5<;Z_KJ%H>R('8CDX'8GJF:2] 15B$
M;C&K(-+PI,,V]B54460V4\T2$&3'' EQYA;>2+J"Z=ZYU96GHH./J$!8JY6_
MV"TK-IFF ]A.5R,K;SY5;J=K<.3;[$)BLBE2LP W)2B3!&'IZ4:?=84>@BTT
M^B]/:&A-PV5.UKU28FH25?S<;&O;W86@JAHA^T;@@ZQ7M929D]#*DM<35OF]
MQPE;A-5JE:;-33,B!"-$F5N";B7)1OZZ?/G^WUDYJ-7@:15J[3:M%LPE8J<)
M%5NN0PWOP-$P4& /&1,:/AQQUS# ( K K/R.+7\;2?>M:O*U%*N+A%%KOC7?
MIUR&[4ZQVS9(R1V?O"<NBIK48FZ[&.!#3=JZX['B[9M^RZGC+R'$T B4T34+
MM XVN[6XU>'BOE&E43LPJ2<*/C=7\?7<.O*ALKT$U5T WW*V#:5$VQ3['-V'
M-JF9K8FE.S<G'2#\56M=ZSU3L 7]J-:;"%='JD72ZSJD*[Q3!C4&#*!U"R3#
M UC>C95TGH;<CZ^O7DLU[I:ZE(K6E@=Y7C5U9KE5O-$O6E2;QLN(J(YMUIV!
MXNF'UN5E;#&*M+WQ6(>)4"DJ4&G6+ U''CG-RJ&2"E:<RVC/2E"UG3GD[BU=
M4=3I$DM"0$C7NWA]-IEQQ'WR3V&=JF1FX;:<9&7:4@[K-RLE^R1YLE)1?U[T
M0Z"W$*3'8*._Y^7D-_YWV5R=?KAU!J=D[8668[*Z.;NV^.T%AU7<RXV[Q^L<
M1]XJM:AJ=":6J*;%="9DJY1J7YBU2CU>,8+F=DWBZ3U?CPF#!665'N4^NGSV
M[_0"0@OII[WU)5/I[QK2,H74VAD4)483MX6E2NE=;MR%;@DP.U!Q[@%(UNOR
M4AJFHR0'](#K;,D7682<8<=+:P_PGKUZ"X;;JWIMQ%K-W)+7FA@[0[BV#KFS
M6+/K;<30E[V;9:E> ]?:8V)J$.N7!AXPVKRVQFQ+'=: (XV=47"A+F_+5L4@
M%:O#UT_5/T]>@N=DI?2<RS[LZ.[6=O%OM=NUG7NV>Y;3L"Q6MV;M==IMEBH.
M"MB]J 'Q94/+THVB0JXZL55RO1M?A0_FAHI@$B9QPHW^OT_G]?@LAZQOO1G=
MM>CIL.?I<.9W0U")K2'UCL:S!TR_;"U)KK.P*DW3:YJN=F@YP2+K_P"TU^8.
M!K,0TXR[*G%2.?G2A3)2N@=9>C6[+IK+4+%LJNVYSJ/;]8VRK2\3M .R#Z^O
MT7';/BZJQ;K8-<7'I^WP+>H[3*66I6EZ:FF).-@;9-0SI B):/(KDTO3NED6
M%>NQ^FMPQ][@J^)(!6_9T'V0L>WJQ3:]2966V5-TA$VN]6N(K%4A2ITN7EJ<
M.Z($/$N1H106(@*)%'(KUI?<_7UAF8./NE.V3HZ&NM;DKCK*Z;KBJQ3ZCLNK
M0\?%2LG*0L@';YPVHGBQTR)(YINW(S6VP'HUF2DQ:F1'1,D6*4?+Y^?AZW[M
M[YKW:[KW<+;0*E3=L42YKVA7;]8Z+9:?;:W9J586]:V>@U"TPL=:X66-B"[.
M-.;(K@P]?%(?D2<)E%)92J-?1@E[D>7U_P!'N5_6S<NH*%3Y/8=YVKK>ET"%
MES*_,7FV7BL5VGQ,]'3S]6D(22LTQ*!PH,N#9Q2JX9&E&M&C3PS\0\PB09<'
M24JDJ[":#39#J:K=^H4V^,IS6PY*JJV33<62/U^^,P:S>3H/,UB3$ISH9(Q;
M=F(%;A%C$,/I.RTZVI1/7R6.W.['4K,[2Z^%V-TO+%W].R,U@N&V14I>$.<U
M$!%R>QQEV".EB800VH S$>3-1Y<@R>&PZZ^L;X S7!B;]/CY>O71?LUW4ZJ1
ME9MUEB=_Z@NZJ;J:U;PD*YK[9%)NUPD-74R)D9J=M\#5X">,EYF&8#BCD,R(
M0[@#Y;/TB2OFS[<$6T",J4G&58\9S]\X_A]_M^_/[O'G[YX1<N$3A$S^,_OX
M18>L.P)F-E"0A@A661W,H2HMEYQQ].,^W#J?:\SC"%YQE3?C"L*2I.?.<\XV
M7Q*:!X:V&Q;AU>2!IW-57,]_F2O5\.X!A9F'%D2YFE[R[4P&,!E&@-P3= EV
M]<J"O&GV(NP!//&"8'<9=PVEUK"L#D>4>[.6O>I2L*1G'A>,*7C'G'];SYQC
M<P,IV5 97L+'![FD$%NP#2#OY]ZY'%L&' R1%!-VT;HVOU$@D.)<'-H ;; @
M];\KC6[I]X-E];MZP.LJM7F9.#NVE69QJX2U8EI'7VEYR4W)4]<D;HW78H?P
M5#ZFH47942,X TX*Y*D8923,5F!9L%OK6ZN5?\>NO(GR5[C=A=O06@_47LLE
M8X>RW+J:;L6#UY9'*Y'Q[$H12NH.H]NART]#1V6XTM1][ML[(O#C99&Q&$C1
M;24,B(<64JNZ9[77[:O9>KZPE-8;(UA4B^L]HV?(#;1J==@9*?ML9?=:5\,^
MMF05ILF7(82-L\LV>,3]'A1!<:XA.<MJPHBQRQZBQ\IO*N:-B=;A,2NT*KJ6
M^:GLTY-RD=42:5L?8_:.#(F+O8/V>7'U^7<UQUVC[=0J8(Z?8KW9KPFI@M#Q
M57LEP )ZY5_OS5^4;U,^NEZ@9*Q LWZ/B!XUR8A9$V$KYPUN )IEOO\ 6FJZ
MNLVJPI;L%RK% N1L!1K$J"OPKD+]-9ZQ7G9:!3*D5JZ^]2."M]>KC<]H;<@^
MQK)$.VFOT*M,ZUFOVPIH1>QV9:\5&8E-DP8*:_ CZQL*I,&Y.TZYE$/1 ]<J
M4^J<AE'$\]^:J.HO4QTYM'8,-K-B,L'ZY9;M8ZS"2\*B'-KXT5C8-\IFN).<
M$DYF)NZ"[V!1GIDA$#3)Z&J'ZD$W;)J&9*#((*/F/E_/+U:_);U%*]3I[<D3
M:]>6Z;=U9/VB.;A]<-1$S/&0-/([!R,];)%5MF*37PP J=U[M$[] +.&RY)V
M/T.-CY*3.A!Y AOIZ]'R55*]2?4,0;:A;3K[<]/9UO*5B/V])3L#0U1VI!;Y
M/Q]=H$W<%PNQ9HH^,MYDU!/Q[-$%N<S& S#!=IB:ZB/GD1)-_7^OC_"N'1'?
M6C=BMA5:DZ]HUY:"GJOL>S2<_8'Z,T/!B4K&I2(0CVUNX6@&7#MX6U@5,LQ4
MH38*V<%F+ME?AC<R"(PF_</KS\ZV'P^77#H'JLZLA:I6S-H:UV=3[Q8JQ6;C
M&4X;&N3?VHI]A:O67+Q3).0V+$"FUJ-?US:1LQ=B56MARKC$6FOT685.Q&#2
M;^N[]Z^W(*^S/4OTV!((^JH&ZF:<Y/N0R=F$5ZC"TWZ 3>077"8M+@IFPA;R
M-7H'<4M"562052F;$XS*HGXR D:[%6*6A2;]_P!OCW\N@^9*N&*]0&CS5J@:
M#'Z<W\[L2>J*=G_L"BKT)^S1.F7CZ?&B;@E!@]E&!?LL8=>8$5JN1DA)[18?
M_5VCM>"O0$TT"0?'X_Z'T74L_J1]?ZY$5>?:'N<W"V% !!4D$W181JO"E4W7
M-^D?U(2[WNJ2DU+5JL[7I)D_4*(!<+RTLZ19C:O)NP$XB/*519+U)=6 R5:$
M=IVRHU%A519&)$EX&"S,W.I;5B-H*UM9:0-"6F8#2Q8;-JFTP3H-Y+I<J"U%
MO29,<U''P9DH4#KX'^1]"L^ZJ[,Q.T;O!5)%6L%2?LU.VG/1D79\16;%&V'0
MNWDZ7W75;$BN25AK+#]4MTU4&H:2@;388JT#2<J;&'+ BQRY$E\O'[U?Z%;0
M\*5\W<94VM.,^,YQX\Y_=]\>?]G,7WI-.T$4=5!U41=@[$$;'SM/7JE$1?\
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MLHUEVK$2\?==(D]=M<%"4E,03KB@MD[*)BR+,ZY:Y9%SNHZ-BHC#I@5-3!/
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M)PB<(G")PB<(M'.U?J/]->ET[7Z=V W+'UO85KCFI>LZPK=<M^QMG3L0^68
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M[W'/=;'T343VL-93M*H]CR)8I(.9)CK1-1^)@./M)\7]%'S#T @L!HJ-CB6
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MMM"RY"0*% !'2K+Q9A+ K"''WFT*(NFFQ5];S8R)V&60[+/P#3"9,)3SDZ*
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MT.H6TZA#C;B5(<;<3A:%H5C.%(6A6,I4E6,YPI*L9QG&<XSCQQ=$$&CT/(_
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M604XR.VAE#Q+CKV4(QA;BL^?,N+G==[/@!>YH#8;]PI922/E.I]6.0'Y6_\
MXCI9L[=ZJV/QC_A^/\N0.0ON6"<E$X1.$3A$X1.$72D)("*&R9)FB@"X=99R
M280R*QAXAU+ [67B'&V\./ON-L,HROW.O.(;1C*U8QDB\;6D.GL_4-TRQF^_
M2'3V8V21VJN]R$[?77U$-1Q-V+K$YN&0L-(M,]K$?;TKA$O0J^3'"YKD8U[I
MEN &RY%C2LB8$AZ_9%ZE^Q7577':,#7P.QY.^1C&LKP)L>I*HMTDZBZ+<XP
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MVE*&VT(QA*$(0G&$I0E.,)2E.,83C&,8QC&.9,8R-K6,:UC&-:QC&-#6L8T
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MR_C:2E'O==6MUQ7CW..+4M6<J5G.1)/,WYJ7$N)<XESC5N<22:  LG?8  >
M Y!??A0G")PB<(G")PB<(G"+QA4-WJ=KO7'_ $DM=]QN[6M[C9>_AM3G.BU"
M]1.&I\V58K-VS_HNL4Z=H6LZKA<%S4WAS&QI_5KT$,B8IKA 1VQR%*<FEE'R
M^73NY^NY>SEKS[?ZV<YSYS^?W?PQ_'[?S^_GSYX4KZ<(G_/_ #XX0\CZ^^WS
M43OI1_W/4C_TL7<K_P!XH'"#D+YT+\^JEBX1.$41_K>&C->GCL\<D9YQO.U>
MI+BW/I5/L.(QVVTJMT?RG"O<M3([B5MY3A*DN(1YSEU*<UEX!((/RV[[_4=^
MW>LVM<18< #L=Z/A8[K^7-2RA?-\.<O-LM_VCGPI92M*?I_>KZ?W)6E.4.?#
M[/D1XQA#GN2G^KC')HD@@T!W<B+.U;41R/\ %+$U>U^-D'?K1',7R*^S[#!3
M+PQ++1 Y#:V7QWVT/,O,NIRAQIYIS"FW&W$9RA;:TJ2M.<I5C.,YQS(@.!:X
M @BB" 00>8(.Q![BC7.:X.:XM<T@M<TD.:1R((H@CH0;1EA@9IM@=EIAEEM#
M3+++:&FFFF\82VTVVC"4(;0G&$H0G&$IQC&$XQC@ "J %"A0J@.0'<!W(YSG
MN+G.+G.)+G.)<YQ/,DFR2>I)M?7DJ$X1<5^?8KQ^?:KQ_CXSX_?C]_\ /'^.
M/SPBL&H-;$7(2Y=U+JV(]><M0D77&Y9;PB6)BPI;*DI&1(^,M9]?<K:WAF !
MD!R[$KAM\D9P7*+93C4P8Y>Y]?Y2]P(O2T^ZT?EI^H>+=/<JV=I;M>FC^6N8
MWZ_"C\PL@9\?O\?Y\J5BQ\D2N 6P^5S'O1Q@T6J2.G%9<$AB6S\-"D8>)^9(
M;Y@@M<"45EYK"@A,#+^7"27/.BQL+<I[@ USFV2WW6N))&Y;0)H59WK;E059
M#0X$-:+W)Y W0\ 7  43O0\ KR-<)R 0Y&_3K-^![(/U+CF!%E?&OZ?!"V<*
M<^GR]A'S*;2I:6_=E&,JQC&=UN]\R+\S6U[^=[GIX*UN@N8'DAA<++>>GK70
MFN5[75J&G;GK%=;-';HG=17O4_:AS=P*KC38:/KW7+=$W5]A&:Z2*?,G:[,'
MK:\V^ML2,LVXJTUN)EQAXDH"46:[#R$:45F*L"Z:2-Z!(!V-^0OXB^MJ\B$.
M,8E<([UZJIVAPL@T=B&[$<M5BM@%+O1Y.4FZW'3<K[4+FT9F0!U1TE$%A0\K
MX.B8^3CI?#<B-+  /L"RC98P+R36GL. !+PH9O%VG4 "?B>9HV:!(H\Q]U4_
ML]51%Q8 !;MR3U/EW<O)7=PL%J=VQUC.;*A=6%1-,KNTXS76UX_8%LU!:CP(
M^#VC7AZ3?*HB$<=FQC*N3+U:QVRO;.JP-L81 %VNAPC;\G7#<@VB$?[^O/Y_
M5.[O.P\ST\;[AS4?VRNN7=:3U]<XW1L8%H6>F-?&JTG":?[ 6JKZLT?(OVW;
ML]:J].T4!4)5;I<=D5FW52-CKD' F5VB7=TV8K2JJ#KNKS%T?#S_ )]=$(+2
M6N#@X&B"""#UL'E5;@T;Z61?.U=*^QCW9'7UOB+EN$S6$1/S-9DIC/:G;;-N
MBM46(OK#;K'%$2SE^1;C@)NTT7;PJ!@I8F:"0?"C!.A0B(I,24>?VZ]?7WWK
M(>C^N':B*["Z'V'M28F)FN:XJDS%;!.L^WIS8F;;MF4IU\B+=MJ@0LZ<>C7U
M&O3\Y4V(O7D&B !K[<42)^R$*+$B2$^4J6SA%H!ZI-KUE2>A78NQ[BU5G>&O
MA*K"C2NI?VND*"S>Y:5NE9B:?!&W:+-CSJI%O7(Z =EI]DI&(R,9+)<;(:0L
M5XG=_/U_E14^F/I2N=,^[;&E=I= ^N?67=V[NO5ROVM=LZ WUM+>K<I1:+<:
M./=M769K;9<C/TPU)]@KD_F6@7VJG:E0RPL/E&QX2,%'QZ]_S^7Z>)7I5X4I
MPB<(G"*(OTDO[OJ7_P"EM[I?]YTGA%+IPB<(G"+I&AK,^D]IA8?TQC):_I%M
MH^K0UA>%!E?(VY[Q'O?C+R$?&XK*$>UQ.,9QDB[:O/M5[<_?VY\9S_'Q]LY_
MS_/(=>EU&C1H]QK8H.8OEU6/AK Q)20L46^V<I#Z/:X",:-\4@$[G*UOX^;/
M_BBLK;2U_56UEQ+F'_&,(YIX^2R5YB#NTD9>IS0:80/^1-5?(5U.X%KJR\.E
MAQCED=BRFZ6/<"7MD]SW*NW"[(-4*(OI:'8O<.="ZHL&U54#:NSQJLY&OFTK
M2E$>V5LF8$,DQ(]Y->IXYT>1)?2X+P9(N,DIS'Q8YLBM*VQ5ISLR; 'EN 3T
MH]_F0!YTN?"UKG$.%VTZ0"02[I7>1N:-7R6LW0WU *+WVK$S<];ZBWUKJF12
M U0]@W+JLJ@05YR1)SL9(/:\F6YB<AK2-7Y"$(CK(H(Q#L1*.LAOMY<>\(P:
M:D#-FD-!+0.AOJ-NX[\_!62Q,,7:MUT7:/>(WVV-$ZNA VZ*0K[8QGS]L>?W
M_P \_P#S^W^K\\O6LOWA$X1.$3A$X1?F?QG_  SR"+!!ZBOFBM8JMH+LD+9,
MR$VP[#AR("8H:3?8@S&Y+(JE%2<8G&63RP\BX3'O.YPH-+Y7QYS\RO'-DX9'
M)Q'&XC^(R8GXT#L=N/$^L:5CB7?Y64+J]CT('<MEF4Z/%EQ!!CO;-*V0S/9<
M\>FS_C?N6W9!'4'FKF==;81EQU>&T)QG.5*_&,8QE6<Y_P $XSG/\L9SSH/>
MR-KGO<&M:'.<X\@&M+W';N:TD^2UVM+B&M!+B: ',E6Q6[U3K@TA^KV2'G6W
M AY)/Z<:T0OZ MTAD4M325?*@<AT0EMEQ:$I6MAU*<YRA7CG<.XWPKBP:[AV
M;#E!T$62WL]8)@G=*V*2GM:=+W02@6+MCK VO:RL#,PJ_%8\L +G-!>WW2YH
M:YP#A8) <TFB=B.]77C.,_CG3!!NNAKXK43DHK8EZL-,3M6GG92?#>JI$D0/
M'QLN2##2^9(!8"VK%&,YP/,LB)7@N.;*QG 1R$$M>%85A6;'N8QS!5/ !L6=
MNH/2^JP<P.<UQ)MIL#I\>_PODKFRK"<9SG/C&/SGF %[!9$@<U9M:V+1+B[D
M>K6ZOSQ.&Y)[(D;)BDEX8AY9^!DR/I$.?4_3!3(S\:\3\7P8+;RUAS*LI\W2
M8\\+ ^2)[&$@!Y:=));J OE>G>N?>%6R:)[BUCPYP%D"[ NKY<O]\E>/N3XS
MGS]L9\9S_#/\_P#7]_X?OY2K5RX14.6B!Y0F'?>-D!%Q,DU(LMA&.BM&K0VX
MU@600WGVF!*R[AU0SGEM3S3+F?NWRIS&R!CCMH>UPHUN"-N>X) V[Z&UK!S6
MES"200=J)%GN-<QOR/-5SEMU]EFK=9MM9(E$0H\Y'/RKBSFT ,D(=)RY&*:1
M(-90CW>UT);S226U9PMK*TX6G'-9N9C/D,3)FND#G,+19(<S\S>56.JK[6/6
M(];2\W30;.W/EL".X[JX,JPG\^?\L9S_ +L9YLJQ?N%8S^/\?QG'^_'^S\\C
M4+J]_1\D6-]A@'NMQ9T.7:Q95+S\,&Y6\L$C!.6)"(W]?F8<TAB.E!*_YQ(I
MP7A[Z7XUNLLN+SE.<VUO^6JO>_I0.Y6QCNC#G-ETZ*UTZZ<6;Z 6@D%_Y1X]
MP-J_1FWQPV&GWLE$M-,MODY;2VHEU"4I<(RTWA*$9=5C*\H1X2GS[4?;&.8F
MCTZGX7?^E0ZG.<6-[,.<2!>K2#]Z&WU5GBW^#9$:>L;C50D''FF7(2=-CT2C
M&#)=R'BWW61"RTI8EBD(R$Y\F4JPZE+F6W4/(;R$1;LSWA5VWEWD=-QRH;K8
M.+*7?XO\[*V>P$"VMU.'O5NT78\!2OG.<*2KQ]_SC[>?/G_Y9YA1U7TT_6['
MT6KL>ECN[Z\U28$>:%C\,ST@))R'U1SGU00"XYCZ1TQYP%CZ991BOE&#4PP\
M]E[_ ,8=;6[\;?NRGDGPV5DA8YY,;2QE-II-D$- <2?_ '.!/A=*L\+!.$3A
M$X1.$3A$X1.$7B1KO=>@M]SMH[9M^L^B+_<"=VEK6$TUJ..ZPQ#?8VB;):[K
M(TG;:':KB2RG8UKV_/Z%#)OZ]CI9CXZMM241)0Z"HICZ.4>O7KYJ.[S[_/U7
M[+VUH5E2<9SX^_G\8^WC^7W5Y_Q\_G^'"E<^$3.?'WSPH/([7MR[_!1+>E04
M,PGU(4O$,M*7ZK_<IQ"7'$HRI&"=?)RK&%9QGQA:T(S_ /B4E/YSC&1VW(-<
MK )^UK)C2\$L:YP! .EI-'?8[>!\-ME*[^H ^<8^K'\YSC&,8=1G[Y<RUC]_
M[W4J;Q^[*TJ3_>3G&(L>/R/[++LI-_<=MSV/G\ZZ<^7>F)$#.,*P8-G&<)5C
M.'F\X]JD*<2KS[O'M4VA;F,_C*$J7Y]N,YXL>/R/[(8Y!_P=_P#$]X'W->:A
M]]:B]5AWH-M*%_5X_$DWM[J>KZ3ZT1QSXP^V^E7GGE88?7AM#38KSKJ7<H=:
M2CRZE&%?:&/!>6O8\-!K40*<.\;W1Z @$GIWYN@<UG::@X4-3!LYANJ<"!O\
MP.O<)886\U6PN/MPT[&R61TM+=6,6.ZW\;SJF6G6UMN*2XVXZG"$*3G.%96C
M&,^58]V,9:\7&;%F]C5<NOSN_P!@DQY8R YH+B+TM(>1YZ;H^NY7%]>#GQX+
M'SY\>,X=1G&?/N\>,XSXSY]B_'C\Y0O&/.4*\6+#LW_]'_\ Q/[+C^HQ^,><
MFBXQX\^<OM8QXPWAWSYRKQX^+.'?/_\ +SA?]W.,YB_/Y$?<)V<G_1__ ,3^
MRY?7A><X^K'\X\^<?*C]V4IS^_\ <I:$Y_@I:4_E6,9GU^OV"C0_;W';[#W3
MN>X;)@\+.<)P6/[LY3C"?F1[O*E*0G'CW>?*EH6A./']925)QYSC..18\?D?
MV4]F^KT.JKO2>0Y].G5?GZB#X]WU8^4Y3A6,X=3G&4Y3E>%8SC.?*<H2I>,X
M^WL2I?\ =3G.%CQ^1_9.SD_Z._\ B?V\OB0.9"Y9."QC.<EC8QCW9SY>;QXP
MG"5*SGRKSC"<+1E6<_C"DYSX]V/,IV;_ /H__P")Z\NBHED>:+@)@47/UA!$
M:>.R*+(HCB27G&7&$#CR.%IR"^Z_E([9>%8R,^I"_.%HQC-,^MT3@QI<2#L-
MC7Q]?,+%\;RQU,>?=-  @G:P+K:^\[5:PZP90&U_#+6R0=&1(-B/U,XTTYM4
MW)F6&)*#>:6TLB7#+??D DBO9,ADHAVS14-MCY?QQ''#8]HFR9HRVK@8)*+R
M7#WM+3J/0]* Y6"M4M#=I-31>GLGM=N7$]"VSS(L"MK/.QEYF5"EZ\R_$FYB
ME2,;A^.=+$^(D#)0WRC/D1I>&UMK'PZV^L4E*,XQC#;N$X5GG<@>)&!P#P#N
M&O!:^N0L$6+JQX$+;8S28RZ%[F:@[0&N;8W)%@;;7O6W/HH2^U-KF!/5:]*-
M^0LH,@Y7JKZC(N0@ZT^#-2>!M:Z;;)#'CRSE)D'[%],R+!E )8%).%.P(Z\G
M"FV-P,8ZAIW+;LFPW< NL EH%DD"SIYC;?>_#M<\-$$D?: O:#J--NR[51K0
M++MB:W+=PIN:\>3F'C/UHP)V6<%'R<L=GZ%M93B<I7[ ED%.#KRZA2%LJ?<4
ME[#B?=Y3[<5. !('*Z[_ *T+[]AR(6FZ)P>\,:XL:3I<&FB!9)W VK?< ]5;
M^T]ET[4-'F]C7^<%KE1K(V39B7,2\MD9IQ21AVTM#MO$OD%EO,"!C#-.DE%O
ML#L-...I1G**)\SVQL!+B1L*!.XV!) ZV;(V!6_P7@O$O:/BF%P3@^/^+XEQ
M"4PXF/;&->\,=(XOD>6LBC9&Q[Y)7$-8UI+B 25KD('?^S;+$E)IG]9Z#,2,
M3%Q 9941LK;L04RVX,;.%ADL2&N*46E?SMP@CS=VG0UM9F":LQDR!-V28L5Q
M:VI,EFSGBM,1ZLL@A[A0LM):#M;CNO3N=P[V+?+'$S&XQ[4,[7'DFR(X\SA/
ML_D,=H?)@1NU1<2XBWWFLR9V.Q,-X[6%D\K&21[;UV%C:Y!Q4##1PL/#PP(T
M;%1(+#(H49&A-)'" #&82AD<409MMAAAI"6VFD)0C&$IQCFFYSG.<YQU%SB2
M:J[/,[G?O*\3---D2R3Y#WRSRO=)+)(\R/DD<;>][SNYSG6YQV!)- "@*UR%
M6G")PBBM[U=@JE"]BNJW2S=T)J;/6?N=5.Q-?VU.;A24U#V NEUJJ8I^J:S*
M*L-?A(:SW&2M+Y[!DOB6+(1!L@UT$>>)"/9(M,.GNINE?3_U6F^N/3RBT*R/
MWKIM=[YLV]"[(O\ MW:^FTU?:6NP:Y1I:S6[8MNAZSK"[B3 )8%.BX2&G4V"
MOP,H>?)PY$:V$4?OZY_+]NGHAX4IPB<(G"*(OTD_QZEW^EL[I?\ >5)X12Z<
M(NE(F#@!$%%&#Q[#3>?<84MML<=2\X;;6XIU2&_'RK1C"5*3A><X3Y^_"+C&
M8(2",V6<U)%LMI:+-99;'000C&,.N8':6XACW*\YRTE:L(\^/.?SPH'KPV'@
M/7R5'L<H6$D5B)<'?EU.?6HAEJ'P9,1PF4I/&!420.TP[CYF5?5+RXAE.%8R
MVM2L8P0^MB?LKB<<2VPMYU6&T(:4XXI:L)2VE*,J6I2O.<8PC&,Y4KSG&,8S
MGSR":!/<+^6ZR +B&B[<:%<[.PKQ5O-RT4.M920GQVR'<X<D<"H^G?SC [;#
MV2&U*6ZT5\[:!G,)SAS*%^?;AO[T,=$'%S6:3(;<\- #CTNN?Z=W.MGL9WM#
M#('=F#IC=)N!N2&@B@6@$D6#MU)H\;5AEV.::686$X^_AH5T3WY7]2XVXEM+
MK*<9^9G[JRZA6/;A.,J5G&,><3.T21AFLL<]S=)!WL$'F#RH<]QR'5,-SV2E
M[8V2-9&XR->-M)H;;$ W5'ISY J*3T/AGAO3JZXJ>/'4T:%MT@4!I&1UJ6C?
M&R&R"WF<H\NN^YM"/F]^?*58QA/MQ[N8-CT9;W:M371MH&[!%-- ]#5W=<Q7
M563/C?BQAC'!S9"'N(%$&W- W) WZ@;W1(I7?ZGW<#LKTQJ>OMCZ>TAK+;-(
ML-TJ&L[ ;<=RSVN;!"7K:-Q@J#1&XNNQ>N+@+/PJY&=P7-2;\F._$M#_ "-1
M97M\/6O:-WZG"KY> (/VVWY^:UHG4[3H:X&B=0[CWT:Z#;G?+:Q(;J&1V3+Z
MTI,GN"O5NI[,.KT<1=*W4+(9;ZU#SKC/DP.'LDA7JJ9+!IS[%()(K\8YA:EM
M?"O#>'G;!N =^0Y\^77Q6#OS.H #4:KES.P\ LC\E8IPB<(G")PB<(NN2A"D
MH]^,J2ES&?&,_;.<H6CPK'XRGPK/G&?MG'\_'*I=(;J>-0:?RU8)>#%1%&P0
M\]/'D%(!L42"""*VW!OG\/TY%4F/@8./-(D (>/".)'&"(+&#&8)?$$6^L09
MU]MM#KK V27U,-+6I#.7G/C2G*U9SK8^'AX\ADQ\9L+FQ18ON,:P=ECF0Q-;
MRMC3,^CXFZI623Y$K6LEE=(QMEK7.)#2:Z&P"2W?>S>_55S*L8S^,_?[^<8^
MW\/X_P#/^KF[R- '>S>U7X[W?P5-@=>7Q/K_ 'WKE^?QR5*_//\ +S_/[>/]
M_,=6XV)OJ*(^=HOQ>,93GW>?'\O^?]_VX=0 N^?3X^72T5%9KT"-*YFF(6*'
MF,!.QWZJT$*U(JCWS,R#P/UJ&_J?HW3U*-<'^3X5EJ40I&7LJ7FPS/+.S,A,
M9-Z"XD6!5T=@:-;;@;'HL QNK4&@$"KH"P3WCGUY]Z[DH$N1C9 !LHH!9H9
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M3:!$-Y9D'4-):]R,IK<^R7/-N-DGO//OYU]_%:KGRRO=(XZM1+I2:!<3M=
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M71,)B#F->6R&)I+Q(/\ D2:+F]'$'>]K<2)PJLN/<KT0N) )C(U0(_T0!@A
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MEQ#[2\.!?(M"'%,YQ\SS"E9P0RVZQEMW#OPK\YQ34,"<CMG.:-0&,=,KBTV
MVP;W%N%#85Y[DQN-U!_Y;IF[P?#EOSY<]QMU@(H\Y9G/63WN7%D2#UD*Z":,
M")>!I)#=ORVC=FSDX;/ ,);A8F0<$8!^HD25Y"> Q%K&90XHI".!/D9TG"X7
ML<]TTTNASNRN>)E-J(AQ#6/!MQ<;&X-60%S1).Z-C8^U!,CA[L?^1P 'YF.<
M&-):?SWRK8^\%Z!88B7'I\<40,>?,LPC3[P9V !9,T]L3"U#E9'<Q&C&$$8^
M-W+3F!&75J\+^)'OYZC%U]A$)"XN$; YSZUDU9+@T 7N.0H]%UX@7=F'.T7I
M#G/Z#D2ZNX;]>[=03=G):I2?JO>F.X=('55)51]1)%UCYOY8VSHDY+5^GPU0
MRI$A;:50TE'MA"U(B'(PXTAHAP$E'RLH9Z18]@!IKK;3"RB-M-N-6=0_Y ]>
M879=CY=XQ;"QXF8YN-)$X:2V"@^1[1O;=.I]US)-FRZ=FF2_ZU BFXAIJ":]
MSC P,^R@>4^D'S\0Q)#"7GW&L$LH0ZELE>#$85["FVW\+1C7>W0XMU-=7,L-
MMOK7D?AW;+F3QF.5S2]KR3J<YAMMGF!Y']^>RNKF*I3A$X1.$3A$X109>M-M
MOT]Z! :3K7<735GW#MBV'78KK4'KV:_HXV'79F#;K.;7-PF\W+GKL;4\>RL^
MLKE),NWCLF? ,YF)E$QRTL$]=/7^_E@+T9+QV]L&Y+Y&;<[BZAOVA'*7*26K
MNKM@[0:@[A]LJ(\U,UAL:>N6Z]75V!_5JU$COR,88W(2=K6P3+PPCQKA+"I8
MXHVL?3S_ 'H=>G+JO23G&,_;/"E?GL1GSCVX\9QG&<?N\9_/V_'^SA%^X2G'
MXQC'^&/]?C'[O/[_ !^?W\(GMQC.58Q]\_G/_/\ ACS_ !\<(H8O2SNU:K#G
MJ4#S<FP \]ZL/=,Q"7&WU>1$S^OX]9"E-M*2E*2S16595G&<9=PK./C2M:<Q
M'(\ M8:Y;"KH%U^-AI/D#U"VL?"R<EI=!&9 V[-@;AKG=39V:X]3LI6&]IT9
M\AD<:=&>>)6TAO#0YRT94\89'M9<<0-\:$N%QY0[3CJD(=4TGV*RAQI2Y[&3
M<EA %W== "?H1Y7NLG\/S8QJ=CN U!MDMZU7_+_W _>K7!&UZ*ZC#B)\?*,M
M-/XS].=_YIZ/*E6U_9CSX5'A%$X\XPKV,YQX]ZD)7/83 D%ANR +%[$-/7G;
M@/CYJX\(XB':1C.)'.G,H6X,W.K_ +$-VO<KFYM6C-)=4Y/#IPTE]2_[ W.<
M)%8 *?SX^G]V?C8E ',^,9\X(3A/G*'<(=A,3LP].[J2!O?>"/"N?10.$\0)
M _#.%D 6YO4EH_Y=2UW*^6]6%]E;.I:7<LJFV,.((R-E.1R_ZI&)7$'\7G+'
MCW?JJDA9SC/M]ZO?[OB\N<Q[*:KT=+&_AJ[O^NZ?VG/YC'<018-MW ;K)_-R
MT[@]1X[+Y,;1I)BV&1YX5QPI3+8Z<,'^7<DHD5CX3C(^/NXF*D<^%>/'TJ_=
ME.5M87)BD;9<T@ $NY; 5?7I8^8[T/".) ./X5]-NSJ;0#=-WN.6INPOF HF
M=,6:O1'J^]XYLPQ3F,=1NFSI! OUWTZ%+M789R0>0P0I2\M#C?3K4S[,K2K"
MT,-_)EQ.>:R6-S8WM=VDAG>P<]P&N#NZJ;O7@.Y;#,#B&3+-BLA#.S@CME <
MG LW;U<=0UF^MFKK=+L[WOZY]7*] 3FV-A%UD.R3TC78MR.UWLF^_52$6'@F
M0')$H%6L9\<T.A\5>3BQVAG,N(986\[E;2=C(;/'H<U@.K:CN*(/*CUY<CY!
M4MX>^&W9L,HC<UP88W-!UT7 \G @AI Y7SV%%15^AAWNZTS?5?K_ -: =FF/
M[=BXK:QA-.QJS:$9%CL$;?N\^RK-]D:<-2C2EQDR$1],'8%K]Q*AE-I/%*8;
MR8)7/K2 W220.\;W9KIS'H4QX[\J)@QHWOD]]SG22 D@./(&@&@<S9)._+99
M>]:J?C)/JWKF5@Y%!K$AVRZ7$8^F^H&<\([#Z_-")=<6VA3R7!_&6$.(2X*O
M*74XPOW8YISES<PM)+7#%FV[B-5&Q=]_4@V*W75BQ<EF&(,C'T"/+B:US])K
M4\:V@ NT^\=ZV-@$W2ERA[M4ZY%LC'6!C)2T%G&K<')]^76_HG2\*]C*LY4R
MF0#3E:U*6[\F%84KPO*;N'L[3&:827F_>(J@\[N&]61N.6]>"IS.&\0R<E[X
ML33$"(VZ2T!S1K#7[N_Y!I=0\:!I5S&T*2I[ ^)P?YLN_!\?PD^[Y?U7$)[/
M_->WS^J9^C\^[QES^LG*F_Z_-[L9>>@UY>&KO_Z[_7P6I_:<_G^'=RO\S?\
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M=BQXSVR9 AE>>R;/,X]I,16AKY!=@AO+2-D[5?IYFQ9*J5_HR(=+,0 Y7+'
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MP'$:FFP>_20=V_\ 7PI0RTF:%@/6[VR.)(T'-MM?1#4@LL6&F7DZYF>8['[
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MGUQ$PB+DCXY!PI*1#"&$H>7A)?9OK<Z'4/'2:^JLB#3+&UY+6&1@<X"W!I<
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M,)%5\(C)@XDO@<^6FV"8\TB1&:<2 BSA4\TV=F]J^-S!(6L#3ID:&N>*>RZ
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M>UR#KICGUL *%A;\08<(_P"KP#_X^(7ZI':&.<2_M'.<[WB-5-U47:6G;W0
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M8HFC-";!9ES(34KL/4X>,LELK E:D;*4*[/0I<L?]*(5!FM-8L:#=WMRKO\
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MWE8,4<N8(R-30QQ%EH)/O :K(:0T$$@6=C0YKQ_ (8\CB<(DC;-$72.9%(+
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M3D/QF.9"[2TEH<*Z@V10()Z@7=+U(4UJKIK$&_3&P6ZL=& R,%^FCH%!>C)
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M?-E!*76V\_Z-^Q/M+[)87M,_VEFB<>+\?S>+8?#XYS,<>.2=\D3WDBF2.:6
MQ-<6- ;8V"Q_JI[5\%]I^(\&_L\4E<+X+@\+GRPPL9D.Q8FLID8(8V..M+-+
M&62Z@!1,#_J ]>MYF>I1U<%>J1\U([9V-V'DJ"7%."%@3$8SK@A3#3A@HT:(
M"_#0K RYE$BT&H1AE1IC[C#N#R/V=PGVDX#%%[)$3.CCX-P^?'S =6K4Z(V6
M[N+VO>2YI:3^;2*TZ1^>9N'9P?QQO9A\N=,R7'Y;P]I180:  Z]>H-$+TR#Z
MPV!8^K2=56J>$BMBR>LGJG)3L8ZC]/%F'8IX%IS"XX$%*@O.66#<"B-J6/E]
M+:W7,X?<^=_W'#Q_:2+BD,!FPL?B;,T0O<X.=$V0OH:G$AU;MU&@0"O1-QII
M.'?AI7:9G0&)Q%$"Q6D[41M1(%D<CU7GA]-#JAN*+]1_NRY*DC5D;0NZ]'.6
M^08,P\F97(:$J!H4/"?&PM1HUCK931!#A30B6(:2Q\OTTB^TQCUO%/:KAF1B
M>T89$Y\O'9\:2 .U7"R&(D.?[P%M>^A1=;AL*W'*Q>%Y4;N&.<0W\&,@2.-'
M6'R@L:*')K018H[[V=C)CZR^KMD[!ZQV>4I$,5.P5)U_MNPVX8(X)!(C#=)?
M;"DDQ+XV39- (F)=3BX\]M8C*GLO1DCAYLB,YOL;Q?!X7%QV/*D,<W$.&'%Q
M#H+M+CK+QJLM9JMFK4QQ<6,TN;1#]CC6+/D'#,+-38\F-\E'DT/83;>NP(V(
MH$GO*Q7Z#&J]E4?J#JBVVF*>B:;L30>C9BHX(D@5N2S+5)#4W,)BF1W#1&2P
M21U#%EGL?5#99=9CU-N)*S5[3<4X;F<-X!BX;C)/@8+8<F]9#9"02T.<2#1-
MTT5;M]Q2SX=AY$&=Q&:2/1%/.7QG47:M@-5$FKHV!0%>0&(/5<UA>U]E/3YE
M!@D'"6[O-6X^N9"/=5G]0>U5LM]L)QD]_P#[/?RR&\^XX.I$?C#*G4?3YQEO
M'Q+,X'Q!^7QW)8T.&=PO(QL=H?52O:TM%7L20=P=/CW:^7@93\G/E8T/;/AR
M1Q-#SL]U4*<?=).Y+:;SJCL)T*A39\+4"J;/* (G"8>7!4DDN2."<<D,%9;:
M.*6^D]U.,$809D5YA&,^](.&&,,MI[O#^'SP\#.#.&]N_'DC>"YQ:2]I: 38
M=R.]$>&U+K01S##9!*&F;LBUWO.<RS?-UAQW.Y%7N1LH/>KVC+[GU1>[\42)
M$M)J5%Z=RTVZ:9(*C"@2P=LD1^ \C.-21?U.07W1FGW&486(K!Z_=C+3_G(?
M9KB BX/$[L2W R\N6;M7O#71RF$PAFDAQTEA(!-V!9YWR(.%Y#78>LM:W&R,
MF22BXAXD,>@-!]XC8D$GD/>L@W,IV5H=GO-2"&KPV9#,:^2:=&CGN!E%LY']
MC.1D+2H(M;*\+<R.5A+BO"/I'FGLYP[U?:GA.7Q3$QHX "Z+);+(UKG %H#:
M(U W5<NX"MUO<8PI,V!C(P7-9*'N;J+"X#<<K#B#O1%G>JM15^@%3[,!T-Z[
MVMT,L.MRVO+"TP^6<MMJ0*_I L*FR HA"/9EEE#3["Y(MW#B\^$AH0VZ0C#A
M?#<R#CO%LR5FC&R7QN821[^G'A98;YM(LDGF!M86.'CY$6=ER/CTPRENDEUZ
MG!D8#FM -"@0YSB=[TT+"L;UT]16"0A>LEZAEMG"S_=_IU4G8]93ZR!YXS:8
MHD:MAE[R,T"8E 8[K;"L8P;[GUMJ42XYSW^-FM9!% \;,RHY[  MK39!(WOF
M1=&G =%[S XK#%PZ#$D;[^-Q3%R]54#$R9KY&DWN:OI8!VY*;_6>OY"E:ICZ
M1*2RY:31'DC&/NFED!M.F(6C( +RDBE#Q8K:TCC(92,ZVA.5M?"ZKPC5R<AL
MV3).QNEID!#:Y#4+N[!)W)Y[G>[WYO$LQF;Q&3,C:8HW2M<&@ '2'"R1RL^(
MZ]Z\V-/CY4[UEMAZZ?V/K0N35TVUU2WGU[$AG@I+(&\KDZJBMF#R:;1(332T
MY8>IC&<6@9AMEHP(6-9:(:Z,F9B&5\C(:#X&L:VO>$H=9-?E!-DV-C?(\EWI
M.*\)=DY&5&.S<,*..'W7?^L76\Z3J8+&Y)MIZ;G?T9[^UY.WO7J*[5A(@DE@
MX,M0\H<<%X'"$-;3^E%#?*A$CAUUA#6)!D@!;'SH?;PI3;B-+!R&8V1VDA>/
M=<TZ +LT?>!_X\[TC4#5<J7&X+FPX.?^)F+]!:[3I H/>=R15@4>GT40OH;:
MYN06ATW:1AXP.*;W1VR@5ER!3Z);#S'8O9:2QH:+!9' 8;1,-O,21LFHMYS
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MWW_PX1?O"+\\X_CC_7PB_>$3A$SG&/SGQ_CPB<(N#K:76W&EX\I<0MM6/O\
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MPGKYK+VP/3F[7QE%N9]&]5SOS/7<*JV$RFP4E)==A(^:M0T26_7HDXI>FXY
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M]#T]ZF/?VW4Z?VTN)[ 2\YL30T<?0]3_ +"W Y%JK0ZM70F9::S>@Z?"*CT
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M1Q3JNU R;;T:8])QD^9'IPZ00]:^E7?QVY=_Z[7GV1]075?7^6A:E%LC;*O
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MG%WC97<ST_>T\V%0Z?<8BL143TOAU0$K3(IB=FIN4)D;5&#QZXV;,-;&^O\
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E<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
